<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=us-ascii">
<meta name=Generator content="Microsoft Word 15 (filtered)">
<title>Rasitrio-II-WS374+WS375-PO-EN-final-clean</title>

<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Helvetica;
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:Courier;
	panose-1:2 7 4 9 2 2 5 2 4 4;}
@font-face
	{font-family:"Tms Rmn";
	panose-1:2 2 6 3 4 5 5 2 3 4;}
@font-face
	{font-family:Helv;
	panose-1:2 11 6 4 2 2 2 3 2 4;}
@font-face
	{font-family:"New York";
	panose-1:2 4 5 3 6 5 6 2 3 4;}
@font-face
	{font-family:System;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:Batang;
	panose-1:2 3 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:SimSun;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:PMingLiU;
	panose-1:2 1 6 1 0 1 1 1 1 1;}
@font-face
	{font-family:"MS Gothic";
	panose-1:2 11 6 9 7 2 5 8 2 4;}
@font-face
	{font-family:Dotum;
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:SimHei;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:MingLiU;
	panose-1:2 1 6 9 0 1 1 1 1 1;}
@font-face
	{font-family:Mincho;
	panose-1:2 2 6 9 4 3 5 8 3 5;}
@font-face
	{font-family:Gulim;
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:Century;
	panose-1:2 4 6 4 5 5 5 2 3 4;}
@font-face
	{font-family:"Angsana New";
	panose-1:2 2 6 3 5 4 5 2 3 4;}
@font-face
	{font-family:"Cordia New";
	panose-1:2 11 3 4 2 2 2 2 2 4;}
@font-face
	{font-family:Mangal;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Latha;
	panose-1:2 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Sylfaen;
	panose-1:1 10 5 2 5 3 6 3 3 3;}
@font-face
	{font-family:Vrinda;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Raavi;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Shruti;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Sendnya;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Gautami;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Tunga;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Estrangelo Edessa";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:"Yu Gothic";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:DengXian;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
	{font-family:"Calibri Light";
	panose-1:2 15 3 2 2 2 4 3 2 4;}
@font-face
	{font-family:"Palatino Linotype";
	panose-1:2 4 5 2 5 5 5 3 3 4;}
@font-face
	{font-family:Verdana;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"Arial Unicode MS";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:"Segoe UI Emoji";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Cambria;
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:"Segoe UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"Segoe UI Symbol";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:BISansCond;}
@font-face
	{font-family:Marlett;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial Black";
	panose-1:2 11 10 4 2 1 2 2 2 4;}
@font-face
	{font-family:"Bahnschrift Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Bahnschrift;
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Light SemiCondensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight SemiConde";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiCondensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold SemiConden";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Light Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Candara;
	panose-1:2 14 5 2 3 3 3 2 2 4;}
@font-face
	{font-family:"Candara Light";
	panose-1:2 14 5 2 3 3 3 2 2 4;}
@font-face
	{font-family:"Comic Sans MS";
	panose-1:3 15 7 2 3 3 2 2 2 4;}
@font-face
	{font-family:Consolas;
	panose-1:2 11 6 9 2 2 4 3 2 4;}
@font-face
	{font-family:Constantia;
	panose-1:2 3 6 2 5 3 6 3 3 3;}
@font-face
	{font-family:Corbel;
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"Corbel Light";
	panose-1:2 11 3 3 2 2 4 2 2 4;}
@font-face
	{font-family:Ebrima;
	panose-1:2 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Franklin Gothic Medium";
	panose-1:2 11 6 3 2 1 2 2 2 4;}
@font-face
	{font-family:Gabriola;
	panose-1:4 4 6 5 5 16 2 2 13 2;}
@font-face
	{font-family:Gadugi;
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Georgia;
	panose-1:2 4 5 2 5 4 5 2 3 3;}
@font-face
	{font-family:Impact;
	panose-1:2 11 8 6 3 9 2 5 2 4;}
@font-face
	{font-family:"Ink Free";
	panose-1:3 8 4 2 0 5 0 0 0 0;}
@font-face
	{font-family:"Javanese Text";
	panose-1:2 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Leelawadee UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Leelawadee UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Lucida Console";
	panose-1:2 11 6 9 4 5 4 2 2 4;}
@font-face
	{font-family:"Lucida Sans Unicode";
	panose-1:2 11 6 2 3 5 4 2 2 4;}
@font-face
	{font-family:"Malgun Gothic";
	panose-1:2 11 5 3 2 0 0 2 0 4;}
@font-face
	{font-family:"\@Malgun Gothic";}
@font-face
	{font-family:"Malgun Gothic Semilight";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Malgun Gothic Semilight";}
@font-face
	{font-family:"Microsoft Himalaya";
	panose-1:1 1 1 0 1 1 1 1 1 1;}
@font-face
	{font-family:"Microsoft JhengHei";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei";}
@font-face
	{font-family:"Microsoft JhengHei UI";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei UI";}
@font-face
	{font-family:"Microsoft JhengHei Light";
	panose-1:2 11 3 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei Light";}
@font-face
	{font-family:"Microsoft JhengHei UI Light";
	panose-1:2 11 3 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei UI Light";}
@font-face
	{font-family:"Microsoft New Tai Lue";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft PhagsPa";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft Sans Serif";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:"Microsoft Tai Le";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft YaHei";
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"\@Microsoft YaHei";}
@font-face
	{font-family:"Microsoft YaHei UI";
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"\@Microsoft YaHei UI";}
@font-face
	{font-family:"Microsoft YaHei Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Microsoft YaHei Light";}
@font-face
	{font-family:"Microsoft YaHei UI Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Microsoft YaHei UI Light";}
@font-face
	{font-family:"Microsoft Yi Baiti";
	panose-1:3 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:MingLiU-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MingLiU-ExtB";}
@font-face
	{font-family:PMingLiU-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@PMingLiU-ExtB";}
@font-face
	{font-family:MingLiU_HKSCS-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MingLiU_HKSCS-ExtB";}
@font-face
	{font-family:"Mongolian Baiti";
	panose-1:3 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MS Gothic";
	panose-1:2 11 6 9 7 2 5 8 2 4;}
@font-face
	{font-family:"MS UI Gothic";
	panose-1:2 11 6 0 7 2 5 8 2 4;}
@font-face
	{font-family:"\@MS UI Gothic";}
@font-face
	{font-family:"MS PGothic";
	panose-1:2 11 6 0 7 2 5 8 2 4;}
@font-face
	{font-family:"\@MS PGothic";}
@font-face
	{font-family:"MV Boli";
	panose-1:2 0 5 0 3 2 0 9 0 0;}
@font-face
	{font-family:"Myanmar Text";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Nirmala UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Nirmala UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe MDL2 Assets";
	panose-1:5 10 1 2 1 1 1 1 1 1;}
@font-face
	{font-family:"Segoe Print";
	panose-1:2 0 6 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Segoe Script";
	panose-1:3 11 5 4 2 0 0 0 0 3;}
@font-face
	{font-family:"Segoe UI Black";
	panose-1:2 11 10 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Historic";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Semibold";
	panose-1:2 11 7 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@SimSun";
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:NSimSun;
	panose-1:2 1 6 9 3 1 1 1 1 1;}
@font-face
	{font-family:"\@NSimSun";}
@font-face
	{font-family:SimSun-ExtB;
	panose-1:2 1 6 9 6 1 1 1 1 1;}
@font-face
	{font-family:"\@SimSun-ExtB";}
@font-face
	{font-family:"Sitka Small";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Text";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Subheading";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Heading";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Display";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Banner";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Trebuchet MS";
	panose-1:2 11 6 3 2 2 2 2 2 4;}
@font-face
	{font-family:Webdings;
	panose-1:5 3 1 2 1 5 9 6 7 3;}
@font-face
	{font-family:"\@Yu Gothic";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Yu Gothic UI";
	panose-1:2 11 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI";}
@font-face
	{font-family:"Yu Gothic UI Semibold";
	panose-1:2 11 7 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Semibold";}
@font-face
	{font-family:"Yu Gothic Light";
	panose-1:2 11 3 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic Light";}
@font-face
	{font-family:"Yu Gothic UI Light";
	panose-1:2 11 3 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Light";}
@font-face
	{font-family:"Yu Gothic Medium";
	panose-1:2 11 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic Medium";}
@font-face
	{font-family:"Yu Gothic UI Semilight";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Semilight";}
@font-face
	{font-family:"HoloLens MDL2 Assets";
	panose-1:5 10 1 2 1 1 1 1 1 1;}
@font-face
	{font-family:"Agency FB";
	panose-1:2 11 5 3 2 2 2 2 2 4;}
@font-face
	{font-family:Algerian;
	panose-1:4 2 7 5 4 10 2 6 7 2;}
@font-face
	{font-family:"Book Antiqua";
	panose-1:2 4 6 2 5 3 5 3 3 4;}
@font-face
	{font-family:"Arial Narrow";
	panose-1:2 11 6 6 2 2 2 3 2 4;}
@font-face
	{font-family:"Arial Rounded MT Bold";
	panose-1:2 15 7 4 3 5 4 3 2 4;}
@font-face
	{font-family:"Baskerville Old Face";
	panose-1:2 2 6 2 8 5 5 2 3 3;}
@font-face
	{font-family:"Bauhaus 93";
	panose-1:4 3 9 5 2 11 2 2 12 2;}
@font-face
	{font-family:"Bell MT";
	panose-1:2 2 5 3 6 3 5 2 3 3;}
@font-face
	{font-family:"Bernard MT Condensed";
	panose-1:2 5 8 6 6 9 5 2 4 4;}
@font-face
	{font-family:"Bodoni MT";
	panose-1:2 7 6 3 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Black";
	panose-1:2 7 10 3 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Condensed";
	panose-1:2 7 6 6 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Poster Compressed";
	panose-1:2 7 7 6 8 6 1 5 2 4;}
@font-face
	{font-family:"Bookman Old Style";
	panose-1:2 5 6 4 5 5 5 2 2 4;}
@font-face
	{font-family:"Bradley Hand ITC";
	panose-1:3 7 4 2 5 3 2 3 2 3;}
@font-face
	{font-family:"Britannic Bold";
	panose-1:2 11 9 3 6 7 3 2 2 4;}
@font-face
	{font-family:"Berlin Sans FB";
	panose-1:2 14 6 2 2 5 2 2 3 6;}
@font-face
	{font-family:"Berlin Sans FB Demi";
	panose-1:2 14 8 2 2 5 2 2 3 6;}
@font-face
	{font-family:Broadway;
	panose-1:4 4 9 5 8 11 2 2 5 2;}
@font-face
	{font-family:"Brush Script MT";
	panose-1:3 6 8 2 4 4 6 7 3 4;}
@font-face
	{font-family:"Bookshelf Symbol 7";
	panose-1:5 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Californian FB";
	panose-1:2 7 4 3 6 8 11 3 2 4;}
@font-face
	{font-family:"Calisto MT";
	panose-1:2 4 6 3 5 5 5 3 3 4;}
@font-face
	{font-family:Castellar;
	panose-1:2 10 4 2 6 4 6 1 3 1;}
@font-face
	{font-family:"Century Schoolbook";
	panose-1:2 4 6 4 5 5 5 2 3 4;}
@font-face
	{font-family:Centaur;
	panose-1:2 3 5 4 5 2 5 2 3 4;}
@font-face
	{font-family:Chiller;
	panose-1:4 2 4 4 3 16 7 2 6 2;}
@font-face
	{font-family:"Colonna MT";
	panose-1:4 2 8 5 6 2 2 3 2 3;}
@font-face
	{font-family:"Cooper Black";
	panose-1:2 8 9 4 4 3 11 2 4 4;}
@font-face
	{font-family:"Copperplate Gothic Bold";
	panose-1:2 14 7 5 2 2 6 2 4 4;}
@font-face
	{font-family:"Copperplate Gothic Light";
	panose-1:2 14 5 7 2 2 6 2 4 4;}
@font-face
	{font-family:"Curlz MT";
	panose-1:4 4 4 4 5 7 2 2 2 2;}
@font-face
	{font-family:Dubai;
	panose-1:2 11 5 3 3 4 3 3 2 4;}
@font-face
	{font-family:"Dubai Light";
	panose-1:2 11 3 3 3 4 3 3 2 4;}
@font-face
	{font-family:"Dubai Medium";
	panose-1:2 11 6 3 3 4 3 3 2 4;}
@font-face
	{font-family:Elephant;
	panose-1:2 2 9 4 9 5 5 2 3 3;}
@font-face
	{font-family:"Engravers MT";
	panose-1:2 9 7 7 8 5 5 2 3 4;}
@font-face
	{font-family:"Eras Bold ITC";
	panose-1:2 11 9 7 3 5 4 2 2 4;}
@font-face
	{font-family:"Eras Demi ITC";
	panose-1:2 11 8 5 3 5 4 2 8 4;}
@font-face
	{font-family:"Eras Light ITC";
	panose-1:2 11 4 2 3 5 4 2 8 4;}
@font-face
	{font-family:"Eras Medium ITC";
	panose-1:2 11 6 2 3 5 4 2 8 4;}
@font-face
	{font-family:"Felix Titling";
	panose-1:4 6 5 5 6 2 2 2 10 4;}
@font-face
	{font-family:Forte;
	panose-1:3 6 9 2 4 5 2 7 2 3;}
@font-face
	{font-family:"Franklin Gothic Book";
	panose-1:2 11 5 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Demi";
	panose-1:2 11 7 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Demi Cond";
	panose-1:2 11 7 6 3 4 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Heavy";
	panose-1:2 11 9 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Medium Cond";
	panose-1:2 11 6 6 3 4 2 2 2 4;}
@font-face
	{font-family:"Freestyle Script";
	panose-1:3 8 4 2 3 2 5 11 4 4;}
@font-face
	{font-family:"French Script MT";
	panose-1:3 2 4 2 4 6 7 4 6 5;}
@font-face
	{font-family:"Footlight MT Light";
	panose-1:2 4 6 2 6 3 10 2 3 4;}
@font-face
	{font-family:Garamond;
	panose-1:2 2 4 4 3 3 1 1 8 3;}
@font-face
	{font-family:Gigi;
	panose-1:4 4 5 4 6 16 7 2 13 2;}
@font-face
	{font-family:"Gill Sans MT";
	panose-1:2 11 5 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans MT Condensed";
	panose-1:2 11 5 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans Ultra Bold Condensed";
	panose-1:2 11 10 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans Ultra Bold";
	panose-1:2 11 10 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Gloucester MT Extra Condensed";
	panose-1:2 3 8 8 2 6 1 1 1 1;}
@font-face
	{font-family:"Gill Sans MT Ext Condensed Bold";
	panose-1:2 11 9 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Century Gothic";
	panose-1:2 11 5 2 2 2 2 2 2 4;}
@font-face
	{font-family:"Goudy Old Style";
	panose-1:2 2 5 2 5 3 5 2 3 3;}
@font-face
	{font-family:"Goudy Stout";
	panose-1:2 2 9 4 7 3 11 2 4 1;}
@font-face
	{font-family:"Harlow Solid Italic";
	panose-1:4 3 6 4 2 15 2 2 13 2;}
@font-face
	{font-family:Harrington;
	panose-1:4 4 5 5 5 10 2 2 7 2;}
@font-face
	{font-family:Haettenschweiler;
	panose-1:2 11 7 6 4 9 2 6 2 4;}
@font-face
	{font-family:"High Tower Text";
	panose-1:2 4 5 2 5 5 6 3 3 3;}
@font-face
	{font-family:"Imprint MT Shadow";
	panose-1:4 2 6 5 6 3 3 3 2 2;}
@font-face
	{font-family:"Informal Roman";
	panose-1:3 6 4 2 3 4 6 11 2 4;}
@font-face
	{font-family:"Blackadder ITC";
	panose-1:4 2 5 5 5 16 7 2 13 2;}
@font-face
	{font-family:"Edwardian Script ITC";
	panose-1:3 3 3 2 4 7 7 13 8 4;}
@font-face
	{font-family:"Kristen ITC";
	panose-1:3 5 5 2 4 2 2 3 2 2;}
@font-face
	{font-family:Jokerman;
	panose-1:4 9 6 5 6 13 6 2 7 2;}
@font-face
	{font-family:"Juice ITC";
	panose-1:4 4 4 3 4 10 2 2 2 2;}
@font-face
	{font-family:"Kunstler Script";
	panose-1:3 3 4 2 2 6 7 13 13 6;}
@font-face
	{font-family:"Wide Latin";
	panose-1:2 10 10 7 5 5 5 2 4 4;}
@font-face
	{font-family:"Lucida Bright";
	panose-1:2 4 6 2 5 5 5 2 3 4;}
@font-face
	{font-family:"Lucida Calligraphy";
	panose-1:3 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Lucida Fax";
	panose-1:2 6 6 2 5 5 5 2 2 4;}
@font-face
	{font-family:"Lucida Handwriting";
	panose-1:3 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Lucida Sans";
	panose-1:2 11 6 2 3 5 4 2 2 4;}
@font-face
	{font-family:"Lucida Sans Typewriter";
	panose-1:2 11 5 9 3 5 4 3 2 4;}
@font-face
	{font-family:Magneto;
	panose-1:4 3 8 5 5 8 2 2 13 2;}
@font-face
	{font-family:"Maiandra GD";
	panose-1:2 14 5 2 3 3 8 2 2 4;}
@font-face
	{font-family:"Matura MT Script Capitals";
	panose-1:3 2 8 2 6 6 2 7 2 2;}
@font-face
	{font-family:Mistral;
	panose-1:3 9 7 2 3 4 7 2 4 3;}
@font-face
	{font-family:"Modern No\. 20";
	panose-1:2 7 7 4 7 5 5 2 3 3;}
@font-face
	{font-family:"Monotype Corsiva";
	panose-1:3 1 1 1 1 2 1 1 1 1;}
@font-face
	{font-family:"Niagara Engraved";
	panose-1:4 2 5 2 7 7 3 3 2 2;}
@font-face
	{font-family:"Niagara Solid";
	panose-1:4 2 5 2 7 7 2 2 2 2;}
@font-face
	{font-family:"OCR A Extended";
	panose-1:2 1 5 9 2 1 2 1 3 3;}
@font-face
	{font-family:"Old English Text MT";
	panose-1:3 4 9 2 4 5 8 3 8 6;}
@font-face
	{font-family:Onyx;
	panose-1:4 5 6 2 8 7 2 2 2 3;}
@font-face
	{font-family:"MS Outlook";
	panose-1:5 1 1 0 1 0 0 0 0 0;}
@font-face
	{font-family:"Palace Script MT";
	panose-1:3 3 3 2 2 6 7 12 11 5;}
@font-face
	{font-family:Papyrus;
	panose-1:3 7 5 2 6 5 2 3 2 5;}
@font-face
	{font-family:Parchment;
	panose-1:3 4 6 2 4 7 8 4 8 4;}
@font-face
	{font-family:Perpetua;
	panose-1:2 2 5 2 6 4 1 2 3 3;}
@font-face
	{font-family:"Perpetua Titling MT";
	panose-1:2 2 5 2 6 5 5 2 8 4;}
@font-face
	{font-family:Playbill;
	panose-1:4 5 6 3 10 6 2 2 2 2;}
@font-face
	{font-family:"Poor Richard";
	panose-1:2 8 5 2 5 5 5 2 7 2;}
@font-face
	{font-family:Pristina;
	panose-1:3 6 4 2 4 4 6 8 2 4;}
@font-face
	{font-family:"Rage Italic";
	panose-1:3 7 5 2 4 5 7 7 3 4;}
@font-face
	{font-family:Ravie;
	panose-1:4 4 8 5 5 8 9 2 6 2;}
@font-face
	{font-family:"MS Reference Sans Serif";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"MS Reference Specialty";
	panose-1:5 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Rockwell Condensed";
	panose-1:2 6 6 3 5 4 5 2 1 4;}
@font-face
	{font-family:Rockwell;
	panose-1:2 6 6 3 2 2 5 2 4 3;}
@font-face
	{font-family:"Rockwell Extra Bold";
	panose-1:2 6 9 3 4 5 5 2 4 3;}
@font-face
	{font-family:"Script MT Bold";
	panose-1:3 4 6 2 4 6 7 8 9 4;}
@font-face
	{font-family:"Showcard Gothic";
	panose-1:4 2 9 4 2 1 2 2 6 4;}
@font-face
	{font-family:"Snap ITC";
	panose-1:4 4 10 7 6 10 2 2 2 2;}
@font-face
	{font-family:Stencil;
	panose-1:4 4 9 5 13 8 2 2 4 4;}
@font-face
	{font-family:"Tw Cen MT";
	panose-1:2 11 6 2 2 1 4 2 6 3;}
@font-face
	{font-family:"Tw Cen MT Condensed";
	panose-1:2 11 6 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Tw Cen MT Condensed Extra Bold";
	panose-1:2 11 8 3 2 2 2 2 2 4;}
@font-face
	{font-family:"Tempus Sans ITC";
	panose-1:4 2 4 4 3 13 7 2 2 2;}
@font-face
	{font-family:"Viner Hand ITC";
	panose-1:3 7 5 2 3 5 2 2 2 3;}
@font-face
	{font-family:Vivaldi;
	panose-1:3 2 6 2 5 5 6 9 8 4;}
@font-face
	{font-family:"Vladimir Script";
	panose-1:3 5 4 2 4 4 7 7 3 5;}
@font-face
	{font-family:"Wingdings 2";
	panose-1:5 2 1 2 1 5 7 7 7 7;}
@font-face
	{font-family:"Wingdings 3";
	panose-1:5 4 1 2 1 8 7 7 7 7;}
@font-face
	{font-family:AngsanaUPC;}
@font-face
	{font-family:CordiaUPC;}
@font-face
	{font-family:Abadi;}
@font-face
	{font-family:"Abadi Extra Light";}
@font-face
	{font-family:Aharoni;}
@font-face
	{font-family:Aldhabi;}
@font-face
	{font-family:Aparajita;}
@font-face
	{font-family:"Arabic Typesetting";}
@font-face
	{font-family:"Arial Nova";}
@font-face
	{font-family:"Arial Nova Cond";}
@font-face
	{font-family:"Arial Nova Cond Light";}
@font-face
	{font-family:"Arial Nova Light";}
@font-face
	{font-family:"Avenir Next LT Pro";}
@font-face
	{font-family:"Avenir Next LT Pro Light";}
@font-face
	{font-family:BatangChe;}
@font-face
	{font-family:Bembo;}
@font-face
	{font-family:Biome;}
@font-face
	{font-family:"Biome Light";}
@font-face
	{font-family:"Browallia New";}
@font-face
	{font-family:BrowalliaUPC;}
@font-face
	{font-family:Cavolini;}
@font-face
	{font-family:Dante;}
@font-face
	{font-family:DaunPenh;}
@font-face
	{font-family:David;}
@font-face
	{font-family:Daytona;}
@font-face
	{font-family:"Daytona Condensed";}
@font-face
	{font-family:"Daytona Condensed Light";}
@font-face
	{font-family:"Daytona Light";}
@font-face
	{font-family:"DengXian Light";}
@font-face
	{font-family:DilleniaUPC;}
@font-face
	{font-family:DokChampa;}
@font-face
	{font-family:DotumChe;}
@font-face
	{font-family:"Elephant Pro";}
@font-face
	{font-family:EucrosiaUPC;}
@font-face
	{font-family:Euphemia;}
@font-face
	{font-family:FangSong;}
@font-face
	{font-family:FrankRuehl;}
@font-face
	{font-family:FreesiaUPC;}
@font-face
	{font-family:"Georgia Pro";}
@font-face
	{font-family:"Georgia Pro Black";}
@font-face
	{font-family:"Georgia Pro Cond";}
@font-face
	{font-family:"Georgia Pro Cond Black";}
@font-face
	{font-family:"Georgia Pro Cond Light";}
@font-face
	{font-family:"Georgia Pro Cond Semibold";}
@font-face
	{font-family:"Georgia Pro Light";}
@font-face
	{font-family:"Georgia Pro Semibold";}
@font-face
	{font-family:"Gill Sans Nova";}
@font-face
	{font-family:"Gill Sans Nova Cond";}
@font-face
	{font-family:"Gill Sans Nova Cond Lt";}
@font-face
	{font-family:"Gill Sans Nova Cond Ultra Bold";}
@font-face
	{font-family:"Gill Sans Nova Cond XBd";}
@font-face
	{font-family:"Gill Sans Nova Light";}
@font-face
	{font-family:"Gill Sans Nova Ultra Bold";}
@font-face
	{font-family:Gisha;}
@font-face
	{font-family:Grotesque;}
@font-face
	{font-family:"Grotesque Light";}
@font-face
	{font-family:GulimChe;}
@font-face
	{font-family:Gungsuh;}
@font-face
	{font-family:GungsuhChe;}
@font-face
	{font-family:"Hadassah Friedlaender";}
@font-face
	{font-family:HGGothicE;}
@font-face
	{font-family:HGMaruGothicMPRO;}
@font-face
	{font-family:HGMinchoE;}
@font-face
	{font-family:HGPGothicE;}
@font-face
	{font-family:HGPMinchoE;}
@font-face
	{font-family:HGPSoeiKakugothicUB;}
@font-face
	{font-family:HGSGothicE;}
@font-face
	{font-family:HGSMinchoE;}
@font-face
	{font-family:HGSoeiKakugothicUB;}
@font-face
	{font-family:HGSSoeiKakugothicUB;}
@font-face
	{font-family:IrisUPC;}
@font-face
	{font-family:"Iskoola Pota";}
@font-face
	{font-family:JasmineUPC;}
@font-face
	{font-family:KaiTi;}
@font-face
	{font-family:Kalinga;}
@font-face
	{font-family:Kartika;}
@font-face
	{font-family:"Khmer UI";}
@font-face
	{font-family:Kigelia;}
@font-face
	{font-family:"Kigelia Arabic";}
@font-face
	{font-family:"Kigelia Arabic Light";}
@font-face
	{font-family:"Kigelia Light";}
@font-face
	{font-family:KodchiangUPC;}
@font-face
	{font-family:Kokila;}
@font-face
	{font-family:"Lao UI";}
@font-face
	{font-family:Leelawadee;}
@font-face
	{font-family:"Levenim MT";}
@font-face
	{font-family:LilyUPC;}
@font-face
	{font-family:"Mangal Pro";}
@font-face
	{font-family:Meiryo;}
@font-face
	{font-family:"Meiryo UI";}
@font-face
	{font-family:"Microsoft GothicNeo";}
@font-face
	{font-family:"Microsoft GothicNeo Light";}
@font-face
	{font-family:"Microsoft Uighur";}
@font-face
	{font-family:MingLiU_HKSCS;}
@font-face
	{font-family:Miriam;}
@font-face
	{font-family:"Miriam Fixed";}
@font-face
	{font-family:"Modern Love";}
@font-face
	{font-family:"Modern Love Caps";}
@font-face
	{font-family:"Modern Love Grunge";}
@font-face
	{font-family:MoolBoran;}
@font-face
	{font-family:"MS PMincho";}
@font-face
	{font-family:"MT Extra";}
@font-face
	{font-family:Narkisim;}
@font-face
	{font-family:"Neue Haas Grotesk Text Pro";}
@font-face
	{font-family:"News Gothic MT";}
@font-face
	{font-family:Nyala;}
@font-face
	{font-family:OCRB;}
@font-face
	{font-family:"Plantagenet Cherokee";}
@font-face
	{font-family:Posterama;}
@font-face
	{font-family:"Quire Sans";}
@font-face
	{font-family:"Quire Sans Light";}
@font-face
	{font-family:"Quire Sans Pro Light";}
@font-face
	{font-family:"Rockwell Light";}
@font-face
	{font-family:"Rockwell Nova";}
@font-face
	{font-family:"Rockwell Nova Cond";}
@font-face
	{font-family:"Rockwell Nova Cond Light";}
@font-face
	{font-family:"Rockwell Nova Extra Bold";}
@font-face
	{font-family:"Rockwell Nova Light";}
@font-face
	{font-family:Rod;}
@font-face
	{font-family:"Sabon Next LT";}
@font-face
	{font-family:"Sagona Book";}
@font-face
	{font-family:"Sagona ExtraLight";}
@font-face
	{font-family:"Sakkal Majalla";}
@font-face
	{font-family:"Sanskrit Text";}
@font-face
	{font-family:Selawik;}
@font-face
	{font-family:"Selawik Light";}
@font-face
	{font-family:"Selawik Semibold";}
@font-face
	{font-family:"Shonar Bangla";}
@font-face
	{font-family:"Simplified Arabic";}
@font-face
	{font-family:"Simplified Arabic Fixed";}
@font-face
	{font-family:"Sitka Banner Semibold";}
@font-face
	{font-family:"Sitka Display Semibold";}
@font-face
	{font-family:"Sitka Heading Semibold";}
@font-face
	{font-family:"Sitka Small Semibold";}
@font-face
	{font-family:"Sitka Subheading Semibold";}
@font-face
	{font-family:"Sitka Text Semibold";}
@font-face
	{font-family:"Source Sans Pro";}
@font-face
	{font-family:"Source Sans Pro Black";}
@font-face
	{font-family:"Source Sans Pro ExtraLight";}
@font-face
	{font-family:"Source Sans Pro Light";}
@font-face
	{font-family:"Source Sans Pro SemiBold";}
@font-face
	{font-family:"Speak Pro";}
@font-face
	{font-family:"Speak Pro Light";}
@font-face
	{font-family:STCaiyun;}
@font-face
	{font-family:STFangsong;}
@font-face
	{font-family:STHupo;}
@font-face
	{font-family:STKaiti;}
@font-face
	{font-family:STXihei;}
@font-face
	{font-family:STXingkai;}
@font-face
	{font-family:STXinwei;}
@font-face
	{font-family:STZhongsong;}
@font-face
	{font-family:"TH SarabunPSK";}
@font-face
	{font-family:"The Hand";}
@font-face
	{font-family:"The Hand Black";}
@font-face
	{font-family:"The Hand Extrablack";}
@font-face
	{font-family:"The Hand Light";}
@font-face
	{font-family:"The Serif Hand";}
@font-face
	{font-family:"The Serif Hand Black";}
@font-face
	{font-family:"The Serif Hand Extrablack";}
@font-face
	{font-family:"The Serif Hand Light";}
@font-face
	{font-family:"Tisa Offc Serif Pro";}
@font-face
	{font-family:"Tisa Offc Serif Pro Thin";}
@font-face
	{font-family:"Trade Gothic Next";}
@font-face
	{font-family:"Trade Gothic Next Cond";}
@font-face
	{font-family:"Trade Gothic Next Cond Hv";}
@font-face
	{font-family:"Trade Gothic Next Heavy";}
@font-face
	{font-family:"Trade Gothic Next Light";}
@font-face
	{font-family:"Traditional Arabic";}
@font-face
	{font-family:"UD Digi Kyokasho N-B";}
@font-face
	{font-family:"UD Digi Kyokasho N-R";}
@font-face
	{font-family:"UD Digi Kyokasho NK-B";}
@font-face
	{font-family:"UD Digi Kyokasho NK-R";}
@font-face
	{font-family:"UD Digi Kyokasho NP-B";}
@font-face
	{font-family:"UD Digi Kyokasho NP-R";}
@font-face
	{font-family:Univers;}
@font-face
	{font-family:"Univers Condensed";}
@font-face
	{font-family:"Univers Condensed Light";}
@font-face
	{font-family:"Univers Light";}
@font-face
	{font-family:"Urdu Typesetting";}
@font-face
	{font-family:Utsaah;}
@font-face
	{font-family:Vani;}
@font-face
	{font-family:"Verdana Pro";}
@font-face
	{font-family:"Verdana Pro Black";}
@font-face
	{font-family:"Verdana Pro Cond";}
@font-face
	{font-family:"Verdana Pro Cond Black";}
@font-face
	{font-family:"Verdana Pro Cond Light";}
@font-face
	{font-family:"Verdana Pro Cond SemiBold";}
@font-face
	{font-family:"Verdana Pro Light";}
@font-face
	{font-family:"Verdana Pro SemiBold";}
@font-face
	{font-family:Vijaya;}
@font-face
	{font-family:"Walbaum Display";}
@font-face
	{font-family:"Walbaum Display Heavy";}
@font-face
	{font-family:"Walbaum Display Light";}
@font-face
	{font-family:"Walbaum Display SemiBold";}
@font-face
	{font-family:"Walbaum Heading";}
@font-face
	{font-family:"Walbaum Text";}
@font-face
	{font-family:"Yu Mincho";}
@font-face
	{font-family:"Yu Mincho Demibold";}
@font-face
	{font-family:"Yu Mincho Light";}
@font-face
	{font-family:"TimesNewRoman\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:TimesNewRoman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:TimesNewRomanPSMT;}
@font-face
	{font-family:"Times New Roman Bold";
	panose-1:2 2 8 3 7 5 5 2 3 4;}
@font-face
	{font-family:PraxisCom-Regular;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial Bold";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:EUAlbertina;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Times;
	panose-1:2 2 6 3 5 4 5 2 3 4;}
@font-face
	{font-family:"\@TimesNewRoman\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Arial\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:"\@Batang";
	panose-1:2 3 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:"\@BatangChe";}
@font-face
	{font-family:"\@Gungsuh";}
@font-face
	{font-family:"\@GungsuhChe";}
@font-face
	{font-family:"\@DengXian Light";}
@font-face
	{font-family:"\@Gulim";
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:"\@GulimChe";}
@font-face
	{font-family:"\@Dotum";
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:"\@DotumChe";}
@font-face
	{font-family:"\@Meiryo";}
@font-face
	{font-family:"\@Meiryo UI";}
@font-face
	{font-family:"\@MingLiU";
	panose-1:2 1 6 9 0 1 1 1 1 1;}
@font-face
	{font-family:"\@PMingLiU";
	panose-1:2 1 6 1 0 1 1 1 1 1;}
@font-face
	{font-family:"\@MingLiU_HKSCS";}
@font-face
	{font-family:"\@MS PMincho";}
@font-face
	{font-family:"\@STXingkai";}
@font-face
	{font-family:"\@STZhongsong";}
@font-face
	{font-family:"\@Yu Mincho";}
@font-face
	{font-family:"\@Arial Unicode MS";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:Times-Roman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:CourierNewPSMT;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"SAS Monospace";}
@font-face
	{font-family:"Bookshelf Symbol 3";}
@font-face
	{font-family:Goudy;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Garamond-Italic;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial\,Bold";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:DIN-Bold;}
@font-face
	{font-family:"CG Times \(W1\)";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"HelveticaNeue Condensed";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@HGMaruGothicMPRO";}
@font-face
	{font-family:CourierStd;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Roman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:EFPPNA+TimesNewRoman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@TimesNewRoman";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"TimesNewRomanPSMT\,Times New Rom";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"TimesNewRoman\,Times New Roman";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"TimesNewRoman\,Bold";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"CG Times";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Minion;}
@font-face
	{font-family:CourierNew;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Noto Sans Symbols";}
@font-face
	{font-family:LZLLQG+TimesNewRoman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:TimesNewRomanPS;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:HelveticaNeueLTStd-Cn;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Wingdings-Regular;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@HelveticaNeueLTStd-Cn";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Wingdings-Regular";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Geneva;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"TimesNewRoman\,BoldItalic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:ArialMT;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
h1
	{margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:17.85pt;
	text-indent:-17.85pt;
	line-height:13.0pt;
	font-size:13.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
h2
	{margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Helvetica",sans-serif;
	font-weight:bold;
	font-style:italic;}
h3
	{margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:4.0pt;
	margin-left:0in;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
h4
	{margin:0in;
	text-align:justify;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
h5
	{margin:0in;
	text-align:justify;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:normal;}
h6
	{margin:0in;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:normal;
	font-style:italic;}
p.MsoHeading7, li.MsoHeading7, div.MsoHeading7
	{mso-style-link:" Char Char1";
	margin:0in;
	text-align:justify;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-style:italic;}
p.MsoHeading8, li.MsoHeading8, div.MsoHeading8
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-align:justify;
	text-indent:-28.35pt;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;
	font-style:italic;}
p.MsoHeading9, li.MsoHeading9, div.MsoHeading9
	{margin:0in;
	text-align:justify;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;
	font-style:italic;}
p.MsoCommentText, li.MsoCommentText, div.MsoCommentText
	{mso-style-name:"Comment Text\,Comment Text Char Char Char\,Comment Text Char1\,Comment Text Char1 Char";
	mso-style-link:"Comment Text Char1 Char Char\,Comment Text Char Char Char Char\,Comment Text Char1 Char Char1";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{margin:0in;
	font-size:10.0pt;
	font-family:"Helvetica",sans-serif;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{margin:0in;
	font-size:8.0pt;
	font-family:"Helvetica",sans-serif;}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:green;
	font-style:italic;}
p.MsoBodyTextIndent, li.MsoBodyTextIndent, div.MsoBodyTextIndent
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-align:justify;
	text-autospace:none;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoDate, li.MsoDate, div.MsoDate
	{mso-style-link:" Char Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyText2, li.MsoBodyText2, div.MsoBodyText2
	{margin:0in;
	text-align:justify;
	line-height:13.0pt;
	text-autospace:none;
	border:none;
	padding:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:blue;
	font-weight:bold;
	text-decoration:underline;}
p.MsoBodyText3, li.MsoBodyText3, div.MsoBodyText3
	{margin:0in;
	text-align:justify;
	text-autospace:none;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:blue;}
p.MsoBodyTextIndent2, li.MsoBodyTextIndent2, div.MsoBodyTextIndent2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.7pt;
	text-align:justify;
	line-height:13.0pt;
	text-autospace:none;
	border:none;
	padding:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:blue;
	font-weight:bold;}
p.MsoBodyTextIndent3, li.MsoBodyTextIndent3, div.MsoBodyTextIndent3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:31.65pt;
	text-align:justify;
	line-height:13.0pt;
	text-autospace:none;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBlockText, li.MsoBlockText, div.MsoBlockText
	{margin-top:0in;
	margin-right:70.8pt;
	margin-bottom:0in;
	margin-left:85.05pt;
	text-indent:-28.35pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
a:link, span.MsoHyperlink
	{color:blue;
	text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
	{color:purple;
	text-decoration:underline;}
p.MsoDocumentMap, li.MsoDocumentMap, div.MsoDocumentMap
	{margin:0in;
	line-height:13.0pt;
	background:navy;
	font-size:11.0pt;
	font-family:"Tahoma",sans-serif;}
p
	{margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Arial Unicode MS",serif;}
p.MsoCommentSubject, li.MsoCommentSubject, div.MsoCommentSubject
	{margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{margin:0in;
	line-height:13.0pt;
	font-size:8.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoRMPane, li.MsoRMPane, div.MsoRMPane
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraphCxSpFirst, li.MsoListParagraphCxSpFirst, div.MsoListParagraphCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraphCxSpMiddle, li.MsoListParagraphCxSpMiddle, div.MsoListParagraphCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraphCxSpLast, li.MsoListParagraphCxSpLast, div.MsoListParagraphCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.EMEAEnBodyText, li.EMEAEnBodyText, div.EMEAEnBodyText
	{mso-style-name:"EMEA En Body Text";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-align:justify;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.AHeader1, li.AHeader1, div.AHeader1
	{mso-style-name:"AHeader 1";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.2pt;
	text-indent:-14.2pt;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.AHeader2, li.AHeader2, div.AHeader2
	{mso-style-name:"AHeader 2";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:35.45pt;
	text-indent:-21.25pt;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.AHeader3, li.AHeader3, div.AHeader3
	{mso-style-name:"AHeader 3";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:63.8pt;
	text-indent:-28.35pt;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.AHeader2abc, li.AHeader2abc, div.AHeader2abc
	{mso-style-name:"AHeader 2 abc";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:63.8pt;
	text-align:justify;
	text-indent:-28.35pt;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;}
p.AHeader3abc, li.AHeader3abc, div.AHeader3abc
	{mso-style-name:"AHeader 3 abc";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:85.05pt;
	text-align:justify;
	text-indent:-21.25pt;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;}
p.CharCharCharCharChar1CharCharCharCharCharChar, li.CharCharCharCharChar1CharCharCharCharCharChar, div.CharCharCharCharChar1CharCharCharCharCharChar
	{mso-style-name:"Char Char Char Char Char1 Char Char Char Char Char Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:0in;
	line-height:12.0pt;
	font-size:10.0pt;
	font-family:"Tahoma",sans-serif;}
p.Default, li.Default, div.Default
	{mso-style-name:Default;
	margin:0in;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.Text, li.Text, div.Text
	{mso-style-name:"Text\,Graphic";
	mso-style-link:"Text Char1";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:12.0pt;
	margin-left:0in;
	line-height:15.6pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.Nottoc-headings, li.Nottoc-headings, div.Nottoc-headings
	{mso-style-name:"Not toc-headings";
	mso-style-link:"Not toc-headings Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:85.05pt;
	text-align:justify;
	text-indent:-85.05pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.Smalltext120, li.Smalltext120, div.Smalltext120
	{mso-style-name:"Smalltext12\:0";
	mso-style-link:"Smalltext12\:0 Char";
	margin:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
span.Smalltext120Char
	{mso-style-name:"Smalltext12\:0 Char";
	mso-style-link:"Smalltext12\:0";}
p.CharCharCharCharCharCharCharCharChar, li.CharCharCharCharCharCharCharCharChar, div.CharCharCharCharCharCharCharCharChar
	{mso-style-name:"Char Char Char Char Char Char Char Char Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:0in;
	line-height:12.0pt;
	font-size:10.0pt;
	font-family:"Verdana",sans-serif;}
span.TextChar1
	{mso-style-name:"Text Char1";
	mso-style-link:"Text\,Graphic";}
p.Char1CharChar, li.Char1CharChar, div.Char1CharChar
	{mso-style-name:"Char1 Char Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:0in;
	text-align:justify;
	line-height:12.0pt;
	font-size:10.0pt;
	font-family:"Tahoma",sans-serif;}
p.Table, li.Table, div.Table
	{mso-style-name:"Table\,9 pt";
	mso-style-link:"Table Char\,9 pt Char";
	margin-top:2.0pt;
	margin-right:0in;
	margin-bottom:1.0pt;
	margin-left:0in;
	text-align:justify;
	font-size:10.0pt;
	font-family:"Arial",sans-serif;}
span.TextChar
	{mso-style-name:"Text Char";
	font-family:"MS Mincho";}
span.Nottoc-headingsChar
	{mso-style-name:"Not toc-headings Char";
	mso-style-link:"Not toc-headings";
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.CharCharCharCharChar, li.CharCharCharCharChar, div.CharCharCharCharChar
	{mso-style-name:"Char Char Char Char Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:0in;
	text-align:justify;
	line-height:12.0pt;
	font-size:10.0pt;
	font-family:"Verdana",sans-serif;}
p.Comment, li.Comment, div.Comment
	{mso-style-name:Comment;
	mso-style-link:"Comment Char";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	text-align:justify;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:#BF30B5;
	font-style:italic;}
span.CommentChar
	{mso-style-name:"Comment Char";
	mso-style-link:Comment;
	font-family:"MS Mincho";
	color:#BF30B5;
	font-style:italic;}
p.Legend, li.Legend, div.Legend
	{mso-style-name:Legend;
	mso-style-link:"Legend Char";
	margin-top:2.0pt;
	margin-right:0in;
	margin-bottom:1.0pt;
	margin-left:0in;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;}
span.LegendChar
	{mso-style-name:"Legend Char";
	mso-style-link:Legend;
	font-family:"Arial",sans-serif;}
p.Style, li.Style, div.Style
	{mso-style-name:Style;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:0in;
	line-height:12.0pt;
	font-size:10.0pt;
	font-family:"Verdana",sans-serif;}
p.CharChar, li.CharChar, div.CharChar
	{mso-style-name:"Char Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:0in;
	line-height:12.0pt;
	font-size:10.0pt;
	font-family:"Verdana",sans-serif;}
span.CharChar1
	{mso-style-name:" Char Char1";
	mso-style-link:"Heading 7";
	font-style:italic;}
span.CharChar0
	{mso-style-name:" Char Char";
	mso-style-link:Date;}
p.Listlevel1, li.Listlevel1, div.Listlevel1
	{mso-style-name:"List level 1";
	margin-top:2.0pt;
	margin-right:0in;
	margin-bottom:1.0pt;
	margin-left:21.25pt;
	text-indent:-21.25pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.CharCharCharCharCharCharCharCharChar0, li.CharCharCharCharCharCharCharCharChar0, div.CharCharCharCharCharCharCharCharChar0
	{mso-style-name:"Char Char Char Char Char Char Char Char Char_0";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:0in;
	line-height:12.0pt;
	font-size:10.0pt;
	font-family:"Verdana",sans-serif;}
span.TableChar
	{mso-style-name:"Table Char\,9 pt Char";
	mso-style-link:"Table\,9 pt";
	font-family:"Arial",sans-serif;}
span.CommentTextChar1CharChar
	{mso-style-name:"Comment Text Char1 Char Char\,Comment Text Char Char Char Char\,Comment Text Char1 Char Char1";
	mso-style-link:"Comment Text\,Comment Text Char Char Char\,Comment Text Char1\,Comment Text Char1 Char";}
p.No-numheading5Agency, li.No-numheading5Agency, div.No-numheading5Agency
	{mso-style-name:"No-num heading 5 \(Agency\)";
	mso-style-link:"No-num heading 5 \(Agency\) Char";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
span.No-numheading5AgencyChar
	{mso-style-name:"No-num heading 5 \(Agency\) Char";
	mso-style-link:"No-num heading 5 \(Agency\)";
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.BodytextAgency, li.BodytextAgency, div.BodytextAgency
	{mso-style-name:"Body text \(Agency\)";
	mso-style-link:"Body text \(Agency\) Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
p.No-numheading3Agency, li.No-numheading3Agency, div.No-numheading3Agency
	{mso-style-name:"No-num heading 3 \(Agency\)";
	mso-style-link:"No-num heading 3 \(Agency\) Char";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.NormalAgency, li.NormalAgency, div.NormalAgency
	{mso-style-name:"Normal \(Agency\)";
	mso-style-link:"Normal \(Agency\) Char";
	margin:0in;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
span.NormalAgencyChar
	{mso-style-name:"Normal \(Agency\) Char";
	mso-style-link:"Normal \(Agency\)";
	font-family:"Verdana",sans-serif;}
span.BodytextAgencyChar
	{mso-style-name:"Body text \(Agency\) Char";
	mso-style-link:"Body text \(Agency\)";
	font-family:"Verdana",sans-serif;}
span.No-numheading3AgencyChar
	{mso-style-name:"No-num heading 3 \(Agency\) Char";
	mso-style-link:"No-num heading 3 \(Agency\)";
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.TabletextrowsAgency, li.TabletextrowsAgency, div.TabletextrowsAgency
	{mso-style-name:"Table text rows \(Agency\)";
	mso-style-link:"Table text rows \(Agency\) Char";
	margin:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
p.Proc1, li.Proc1, div.Proc1
	{mso-style-name:"Proc 1";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:12.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.msoins0
	{mso-style-name:msoins;}
span.TabletextrowsAgencyChar
	{mso-style-name:"Table text rows \(Agency\) Char";
	mso-style-link:"Table text rows \(Agency\)";
	font-family:"Verdana",sans-serif;}
span.msoIns
	{mso-style-name:"";
	text-decoration:underline;
	color:teal;}
span.msoDel
	{mso-style-name:"";
	text-decoration:line-through;
	color:red;}
 /* Page Definitions */
 @page WordSection1
	{size:595.35pt 842.0pt;
	margin:56.7pt 70.9pt 56.7pt 70.9pt;}
div.WordSection1
	{page:WordSection1;}
 /* List Definitions */
 ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>

</head>

<body lang=EN-US link=blue vlink=purple style='word-wrap:break-word'>

<div class=WordSection1>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>ANNEX I</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>SUMMARY OF PRODUCT CHARACTERISTICS</span></b></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Rasitrio 150&nbsp;mg/5&nbsp;mg/12.5&nbsp;mg film-coated tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; QUALITATIVE
 AND QUANTITATIVE COMPOSITION</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each film-coated
tablet contains 150&nbsp;mg aliskiren (as hemifumarate), 5&nbsp;mg amlodipine
(as besylate) and 12.5&nbsp;mg hydrochlorothiazide.</span></p>

<p class=MsoDate><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For the full list
of excipients, see section&nbsp;6.1.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
<span style='text-transform:uppercase'>form</span></span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Film-coated tablet.</span></p>

<p class=MsoDate style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Violet white, ovaloid convex film-coated tablet with bevelled edges,
with &#8220;YIY&#8221; debossed on one side and &#8220;NVR&#8221; on the other.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB style='text-transform:uppercase'>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Clinical
particulars</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.1&nbsp;&nbsp;&nbsp;&nbsp; Therapeutic
indications</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Rasitrio is
indicated for the treatment of essential hypertension as substitution therapy
in adult patients whose blood pressure is adequately controlled on the
combination of aliskiren, amlodipine and hydrochlorothiazide given concurrently
at the same dose level as in the combination.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.2&nbsp;&nbsp;&nbsp;&nbsp; Posology
and method of administration</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><u><span lang=EN-GB>Posology</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The recommended dose of Rasitrio is one tablet per day.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Patients
receiving aliskiren, amlodipine and hydrochlorothiazide from separate tablets given
concurrently at the same time of the day may be switched to a fixed combination
tablet of Rasitrio containing the same component doses.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The fixed dose
combination should only be used after a stable effect on the monocomponents, </span><span
lang=HU>given concurrently,<b> </b></span><span lang=EN-GB>has been established
after dose titration. Dose should be individualised and adjusted according to
the patient&#8217;s clinical response.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><u><span lang=EN-GB>Special populations</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Elderly patients aged 65&nbsp;years and over</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>There is
evidence of an increased risk of adverse events related to hypotension in
patients aged 65&nbsp;years or older treated with Rasitrio. Therefore,
particular caution should be exercised when administering Rasitrio in patients aged
65&nbsp;years or over.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The recommended
starting dose of aliskiren in this group of patients is 150&nbsp;mg. No
clinically meaningful additional blood pressure reduction is observed by
increasing the dose to 300&nbsp;mg in the majority of elderly patients.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Elderly patients aged 75&nbsp;years and over</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Very limited data are available on the use of Rasitrio in patients
aged 75&nbsp;years or older (see section&nbsp;5.2). The use of Rasitrio in
patients aged 75&nbsp;years or older should be restricted to patients for whom
blood pressure control has been established for the free combination of
aliskiren, amlodipine and hydrochlorothiazide </span><span lang=EN-GB>given
concurrently</span><span lang=EN-GB> without accompanying safety concerns, in
particular hypotension. Extreme caution, including more frequent monitoring of
blood pressure, is recommended (see sections&nbsp;4.4, 4.8, 5.1 and 5.2)</span><span
style='font-family:"TimesNewRomanPSMT",serif'>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Renal impairment</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No adjustment of
the initial dose is required for patients with mild to moderate renal
impairment (</span><span lang=EN-GB>estimated </span><span lang=EN-GB>glomerular
filtration rate</span><span lang=EN-GB> (GFR) 89&#8209;60&nbsp;ml/min/1.73&nbsp;m<sup>2</sup>
and 59&#8209;30&nbsp;ml/min/1.73&nbsp;m<sup>2</sup>, respectively) (see sections&nbsp;4.4
and 5.2). Due to the hydrochlorothiazide component, </span><span lang=EN-GB>Rasitrio
is contraindicated for use in patients with anuria and in patients with severe
renal impairment (GFR &lt;30&nbsp;ml/min/1.73&nbsp;m<sup>2</sup>). The </span><span
lang=EN-GB>c</span><span lang=EN-GB>oncomitant use of Rasitrio with angiotensin
II receptor blockers (ARB) or angiotensin converting enzyme inhibitors (ACEI)
is contraindicated in patients with renal impairment (GFR &lt;60&nbsp;ml/min/</span><span
lang=EN-GB>1.73&nbsp;m<sup>2</sup></span><span lang=EN-GB>) (see sections&nbsp;4.3,
4.4 and 5.2).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Hepatic impairment</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Rasitrio is
contraindicated in patients with severe hepatic impairment. Caution</span>
should be exercised when administering Rasitrio i<span lang=EN-GB>n </span>patients
with mild to moderate hepatic impairment or patients with progressive liver
disease. No dosage recommendations have been established for amlodipine in
patients with mild to moderate hepatic impairment <span lang=EN-GB>(see
sections&nbsp;4.3 and 4.4).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Paediatric population</span></i></p>

<p class=MsoNormal style='line-height:normal'>The safety and efficacy of Rasitrio
in children and adolescents below age&nbsp;18 have not been established. No
data are available.</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><u><span lang=EN-GB>Method of administration</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Oral use. The
tablets should be swallowed whole with some water. Rasitrio should be taken
with a light meal once a day, preferably at the same time each day. Grapefruit
juice should not be taken together with Rasitrio (see section&nbsp;4.5).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b>4.3&nbsp;&nbsp;&nbsp;&nbsp; Contraindications</b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Hypersensitivity to the active substances or to
any of the excipients listed in section&nbsp;6.1, to other dihydropyridine
derivatives, or to other sulphonamide-derived substances.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>History of angioedema with aliskiren.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Hereditary or idiopathic angioedema.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Second and third trimesters of pregnancy (see
section&nbsp;4.6).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Anuria.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Severe renal impairment (GFR &lt;30&nbsp;ml/min/1.73&nbsp;m<sup>2</sup>).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Hyponatraemia, hypercalcaemia, symptomatic
hyperuricaemia and refractory hypokalaemia.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Severe hepatic impairment.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The concomitant use of aliskiren with
ciclosporin and itraconazole, two highly potent P-glycoprotein (P-gp) inhibitors,
and other potent P-gp inhibitors (e.g. quinidine), is contraindicated (see section&nbsp;4.5).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The concomitant use of aliskiren with ARBs or
ACEIs is contraindicated in patients with diabetes mellitus or renal impairment
(GFR &lt;60&nbsp;ml/min/</span><span lang=EN-GB>1.73&nbsp;m<sup>2</sup></span><span
lang=EN-GB>) (see sections&nbsp;4.2, 4.4, 4.5 and 5.1).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Severe hypotension.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Shock (including cardiogenic shock).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Obstruction of the outflow tract of the left
ventricle (e.g. high grade aortic stenosis).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Haemodynamically unstable heart failure after
acute myocardial infarction.</span></p>

<p class=MsoNormal style='line-height:normal;vertical-align:baseline'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.4&nbsp;&nbsp;&nbsp;&nbsp; Special
warnings and precautions for use</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>General</span></u></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>In the event
of severe and persistent diarrhoea, Rasitrio therapy should be stopped (see
section&nbsp;4.8).</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>As with any
antihypertensive medicinal product, excessive reduction of blood pressure in
patients with ischaemic cardiopathy or ischaemic cardiovascular disease could
result in a myocardial infarction or stroke.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Symptomatic
hypotension occurred with higher frequency in patients with non-complicated
hypertension treated with Rasitrio than in patients treated with dual
combinations of aliskiren/amlodipine, aliskiren/hydrochlorothiazide or
amlodipine/hydrochlorothiazide.</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Hypersensitivity
reactions to hydrochlorothiazide may occur in patients, but are more likely in
patients with allergy and asthma.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Systemic
lupus erythematosus</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Thiazide
diuretics, including hydrochlorothiazide, have been reported to exacerbate or
activate systemic lupus erythematosus.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The safety and
efficacy of amlodipine in hypertensive crisis have not been established.</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Dual blockade
of the renin-angiotensin-aldosterone system (RAAS)</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Hypotension,
syncope, stroke, hyperkalaemia, and changes in renal function (including acute
renal failure) have been reported in susceptible individuals, especially if
combining medicinal products that affect this system (see section</span><span
lang=EN-GB>&nbsp;</span><span lang=EN-GB>5.1). Dual blockade of the
renin-angiotensin-aldosterone system by combining aliskiren with an angiotensin
converting enzyme inhibitor (ACEI) or an angiotensin II receptor blocker (ARB)
is therefore not recommended. Close monitoring of blood pressure, renal
function and electrolytes should be exercised if co-administration is
considered absolutely necessary.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>T</span><span
lang=EN-GB>he use of</span><span lang=EN-GB> aliskiren in combination with ARBs
or ACEIs is contraindicated in patients with diabetes mellitus or renal
impairment (GFR &lt;60&nbsp;ml/min</span><span lang=EN-GB>/1.73&nbsp;m<sup>2</sup></span><span
lang=EN-GB>) (see section&nbsp;4.3)</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Geriatric patients
aged 65&nbsp;years and over</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Particular caution should be exercised when administering Rasitrio
in patients aged 65&nbsp;years or older. Symptomatic hypotension occurred with
higher frequency in patients with non-complicated hypertension treated with
Rasitrio than in patients treated with dual combinations of
aliskiren/amlodipine, aliskiren/hydrochlorothiazide or
amlodipine/hydrochlorothiazide. Patients aged 65&nbsp;years old or over, are
more susceptible to hypotension-related adverse reactions following treatment
with Rasitrio (see sections&nbsp;4.2, 4.8, 5.1 and 5.2).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Geriatric patients aged 75&nbsp;years and over</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Very limited efficacy and safety data are available on the use of
Rasitrio in patients aged 75&nbsp;years or older. Extreme caution, </span>including
more frequent monitoring of blood pressure, is recommended<span lang=EN-GB>
(see sections&nbsp;4.2, 4.8, 5.1 and 5.2).</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Heart failure</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Calcium channel
blockers, including amlodipine, should be used with caution in patients with
congestive heart failure, as they may increase the risk of future
cardiovascular events and mortality.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>No data on
cardiovascular mortality and morbidity are available for Rasitrio in patients
with heart failure (see section&nbsp;5.1).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Aliskiren should
be used with caution in patients with heart failure treated with furosemide
(see section&nbsp;4.5).</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Risk of symptomatic hypotension</span></u></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Symptomatic
hypotension could occur after initiation of treatment with Rasitrio Rasitrio in
the following cases:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>Patients with marked volume depletion or patients with salt
depletion <span lang=EN-GB>(e.g. those receiving high doses of diuretics) </span>or</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>Combined use of aliskiren with other agents acting on the RAAS.</p>

<p class=Default><span style='font-size:11.0pt'>The volume or salt depletion
should be corrected prior to administration of Rasitrio, or the treatment
should start under close medical supervision.</span></p>

<p style='margin:0in'><u><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Electrolyte imbalance</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Treatment with
Rasitrio should only start after correction of hypokalaemia and any coexisting
hypomagnesaemia. Thiazide diuretics can precipitate new onset hypokalaemia or
exacerbate pre-existing hypokalaemia. Thiazide diuretics should be administered
with caution in patients with conditions involving enhanced potassium loss, for
example salt-losing nephropathies and prerenal (cardiogenic) impairment of
kidney function. </span><span lang=EN-GB>If hypokalaemia develops during
hydrochlorothiazide therapy Rasitrio should be discontinued until stable
correction of the potassium balance.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'>Hypokalaemia may develop with the
use of thiazide diuretics. The risk of hypokalaemia is greater in patients with
cirrhosis of the liver, patients experiencing brisk diuresis, patients with
inadequate oral electrolyte intake and patients receiving concomitant therapy
with corticosteroids or adrenocorticotropic hormone (ACTH) (see sections&nbsp;4.5
and 4.8).</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal><span lang=EN-GB>Conversely, </span><span lang=EN-GB>increases
in serum potassium have been observed with aliskiren in post-marketing
experience and these may be exacerbated by concomitant use of other agents
acting on the RAAS or by non-steroidal anti-inflammatory drugs (NSAIDs).
Consistent with standard medical practice, periodic determination of renal
function including serum electrolytes is advised if co-administration is
considered necessary. The concomitant use of aliskiren and ACEIs or ARBs is
contraindicated in patients with diabetes mellitus or renal impairment (GFR
&lt;60&nbsp;ml/min</span><span lang=EN-GB>/1.73&nbsp;m<sup>2</sup></span><span
lang=EN-GB>) (see section</span><span lang=EN-GB>&nbsp;</span><span lang=EN-GB>4.3,
4.5 and 4.8).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoDate><span lang=EN-GB>Thiazide diuretics can precipitate new onset
hyponatraemia and hypochloroaemic alkalosis or exacerbate pre-existing
hyponatraemia. Hyponatraemia, accompanied by neurological symptoms (nausea,
progressive disorientation, apathy) has been observed. Treatment with
hydrochlorothiazide should only be started after correction of pre-existing
hyponatraemia. In case severe or rapid hyponatraemia develops during Rasitrio
therapy, the treatment should be discontinued until normalisation of natraemia.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>All patients receiving thiazide diuretics
should be periodically monitored for imbalances in electrolytes, particularly
potassium, sodium and magnesium.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Thiazides
reduce urinary calcium excretion and may cause an intermittent and slight
elevation of serum calcium in the absence of known disorders of calcium
metabolism. Rasitrio is contraindicated in patients with hypercalcaemia and
should only be used after correction of any pre-existing hypercalcaemia.
Rasitrio should be discontinued if hypercalcaemia develops during treatment.
Serum levels of calcium should be periodically monitored during treatment with
thiazides. Marked hypercalcaemia may be evidence of hidden hyperparathyroidism.
Thiazides should be discontinued before carrying out tests for parathyroid
function.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>There is no
evidence that Rasitrio would reduce or prevent diuretic-induced hyponatraemia.
Chloride deficit is generally mild and usually does not require treatment.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Renal impairment and kidney transplantation</span></u></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Thiazide
diuretics may precipitate azotaemia in patients with chronic kidney disease. When
Rasitrio is used in patients with renal impairment, periodic monitoring of serum
electrolytes including potassium, creatinine and uric acid serum levels is
recommended. No data is available in hypertensive patients with severe renal
impairment (serum creatinine &#8805;150&nbsp;&#956;mol/l or 1.70&nbsp;mg/dl in
women and &#8805;177&nbsp;&#956;mol/l or 2.00&nbsp;mg/dl in men and/or
estimated glomerular filtration rate (GFR) &lt;30&nbsp;ml/min/</span><span
style='font-size:11.0pt;color:windowtext'>1.73&nbsp;m<sup>2</sup></span><span
style='font-size:11.0pt;color:windowtext'>), history of dialysis, nephrotic
syndrome or renovascular hypertension. Rasitrio is contraindicated in
hypertensive patients with severe renal impairment (GFR &lt;30&nbsp;ml/min/</span><span
style='font-size:11.0pt;color:windowtext'>1.73&nbsp;m<sup>2</sup></span><span
style='font-size:11.0pt;color:windowtext'>) or anuria (see sections&nbsp;4.2.
and 4.3). No dose adjustment is necessary in patients with mild to moderate
renal impairment.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>As for other medicinal
products acting on the RAAS, caution should be exercised when Rasitrio is given
in the presence of conditions pre-disposing to kidney dysfunction such as
hypovolaemia (e.g. due to blood loss, severe or prolonged diarrhoea, prolonged
vomiting, etc.), heart disease, liver disease, diabetes mellitus or kidney
disease. The concomitant use of aliskiren and ACEIs or ARBs is contraindicated
in patients with renal impairment (GFR &lt;&nbsp;60&nbsp;ml/min/</span><span
style='font-size:11.0pt;color:windowtext'>1.73&nbsp;m<sup>2</sup></span><span
style='font-size:11.0pt;color:windowtext'>). Acute renal failure, reversible
upon discontinuation of treatment, has been reported in at-risk patients
receiving aliskiren in post-marketing experience. In the event that any signs
of renal failure occur, aliskiren should be promptly discontinued.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>There is no
experience regarding the administration of Rasitrio in patients who have
recently undergone kidney transplantation, therefore caution should be
exercised in these patients.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Hepatic impairment</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Rasitrio is
contraindicated in hypertensive patients with severe hepatic impairment (see
sections&nbsp;4.3 and 5.2). Caution should be exercised when administering
Rasitrio to patients with mild to moderate hepatic impairment or progressive
liver disease (see sections&nbsp;4.2 and 5.2).</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The half life of
amlodipine is prolonged and AUC values are higher in patients with impaired
liver function; dosage recommendations have not been established.</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Aortic and mitral valve stenosis, obstructive hypertrophic
cardiomyopathy</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>As with all
other vasodilators, special caution is indicated when using amlodipine in
patients suffering from aortic or mitral stenosis, or obstructive hypertrophic
cardiomyopathy.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Metabolic and endocrine effects</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Thiazide diuretics,
including hydrochlorothiazide, may alter glucose tolerance and raise serum
levels of cholesterol and triglycerides, and uric acid. In diabetic patients
dose adjustments of insulin or oral hypoglycaemic medicinal products may be
required during Rasitrio therapy. </span><span lang=EN-GB>C</span><span
lang=EN-GB>oncomitant use of Rasitrio with ARBs or ACEIs is contraindicated in
patients with diabetes mellitus (see section&nbsp;4.3).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Due to the hydrochlorothiazide component,
Rasitrio is contraindicated in symptomatic hyperuricaemia (see
section&nbsp;4.3). </span><span lang=EN-GB>Hydrochlorothiazide may raise the
serum uric acid level due to reduced clearance of uric acid and may cause or
exacerbate hyperuricaemia as well as precipitate gout in susceptible patients.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Thiazides reduce
urinary calcium excretion and may cause an intermittent and slight elevation of
serum calcium in the absence of known disorders of calcium metabolism. Rasitrio
is contraindicated in patients with hypercalcaemia and should only be used
after correction of any pre-existing hypercalcaemia. Rasitrio should be
discontinued if hypercalcaemia develops during treatment. Serum levels of
calcium should be periodically monitored during treatment with thiazides.
Marked hypercalcaemia may be evidence of hidden hyperparathyroidism. Thiazides
should be discontinued before carrying out tests for parathyroid function.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Renal artery stenosis</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No controlled
clinical data are available on the use of Rasitrio in patients with unilateral
or bilateral renal artery stenosis, or stenosis to a solitary kidney. However,
as with other medicinal products acting on the renin-angiotensin-aldosterone
system, there is an increased risk of renal insufficiency, including acute
renal failure, when patients with renal artery stenosis are treated with
aliskiren. Therefore caution should be exercised in these patients. If renal
failure occurs, treatment should be discontinued.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Anaphylactic reactions and angioedema</span></u></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Anaphylactic
reactions have been observed during treatment with aliskiren from
post-marketing experience (see section&nbsp;4.8). As with other medicinal
products acting on the renin-angiotensin-aldosterone system (RAAS), angioedema
or symptoms suggestive of angioedema (swelling of the face, lips, throat and/or
tongue) have been reported in patients treated with aliskiren.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>A number of
these patients had a history of angioedema or symptoms suggestive of
angioedema, which in some cases followed use of other medicinal products that
can cause angioedema, including RAAS blockers (angiotensin converting enzyme
inhibitors or angiotensin receptor blockers) (see section&nbsp;4.8).</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In post-marketing
experience, angioedema or angioedema-like reactions have been reported when
aliskiren was co-administered with ACEIs and/or ARBs (see section&nbsp;4.8).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Special caution
is necessary in patients with a hypersensitivity predisposition.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Patients with
history of angioedema may be at increased risk of experiencing angioedema
during treatment with aliskiren (see sections&nbsp;4.3 and 4.8). Caution should
therefore be exercised when prescribing aliskiren to patients with a history of
angioedema, and such patients should be closely monitored during treatment (see
section&nbsp;4.8) especially at the beginning of the treatment.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>If anaphylactic reactions or</span><span
lang=EN-GB> </span><span lang=EN-GB>angioedema occur, Rasitrio should be
promptly discontinued and appropriate therapy and monitoring provided until
complete and sustained resolution of signs and symptoms has occurred. Patients
should be informed to report to the physician any signs suggestive of allergic
reactions, in particular difficulties in breathing or swallowing, swelling of
face, extremities, eyes, lips or tongue. Where there is involvement of the
tongue, glottis or larynx adrenaline should be administered. In addition,
measures necessary to maintain patent airways should be provided.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u>Photosensitivity</u></p>

<p class=MsoNormal>Cases of photosensitivity reactions have been reported with
thiazide diuretics (see section&nbsp;4.8). If photosensitivity reaction occurs
during treatment with <span lang=EN-GB>Rasitrio</span>, it is recommended to
stop the treatment. If a re-administration of the diuretic is deemed necessary,
it is recommended to protect exposed areas to the sun or to artificial UVA.</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Acute angle-closure glaucoma</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Hydrochlorothiazide, a sulphonamide, has
been associated with an idiosyncratic reaction resulting in acute transient
myopia and acute angle-closure glaucoma. Symptoms include acute onset of
decreased visual acuity or ocular pain and typically occur within hours to
weeks of treatment initiation. Untreated acute angle-closure glaucoma can lead
to permanent vision loss. The primary treatment is to discontinue
hydrochlorothiazide as rapidly as possible. Prompt medical or surgical
treatment may need to be considered if the intraocular pressure remains
uncontrolled. Risk factors for developing acute angle-closure glaucoma may
include a history of sulphonamide or penicillin allergy.</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.5&nbsp;&nbsp;&nbsp;&nbsp; Interaction
with other medicinal products and other forms of interaction</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Information on Rasitrio interactions</span></u></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>A
population pharmacokinetic analysis in patients with hypertension did not
indicate any clinically relevant changes in the </span><span lang=EN-GB>steady-state
exposure (AUC) and C<sub>max</sub> of aliskiren, amlodipine and hydrochlorothiazide
compared to the corresponding dual therapies.</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Medicinal
products affecting serum potassium levels</span></i><span lang=EN-GB>: </span><span
lang=EN-GB>The potassium-depleting effect of hydrochlorothiazide is attenuated
by the potassium-sparing effect of aliskiren. However, this effect of
hydrochlorothiazide on serum potassium would be expected to be potentiated by
other medicinal products associated with potassium loss and hypokalaemia (e.g.
other kaliuretic diuretics, corticosteroids, laxatives, adrenocoricotropic
hormone (ACTH), amphotericin, carbenoxolone, penicillin G, salicylic acid
derivatives). Conversely,</span><span lang=EN-GB> concomitant use of other
agents affecting the RAAS, of NSAIDs or of agents that increase serum potassium
levels (e.g. potassium-sparing diuretics, potassium supplements, salt
substitutes containing potassium, heparin) may lead to increases in serum
potassium. If co-medication with an agent affecting the level of serum
potassium is considered necessary, caution is advisable. The combination of aliskiren
with </span><span lang=EN-GB>ARBs or ACEIs </span><span lang=EN-GB>is
contraindicated in patients with diabetes mellitus or renal impairment (GFR
&lt;60&nbsp;ml/min/</span><span lang=EN-GB>1.73&nbsp;m<sup>2</sup></span><span
lang=EN-GB>) and is not recommended in other patients (see sections</span><span
lang=EN-GB>&nbsp;</span><span lang=EN-GB>4.3, 4.4 and 5.1)</span><span
lang=EN-GB>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Medicinal
products affected by serum potassium disturbances</span></i><span lang=EN-GB>: </span><span
lang=EN-GB>Periodic monitoring of serum potassium is recommended when Rasitrio
is administered with medicinal products affected by serum potassium
disturbances (e.g. digitalis glycosides, antiarrhythmics).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default><i><span style='font-size:11.0pt;color:windowtext'>Non-steroidal
anti-inflammatory drugs (NSAIDs), including selective cyclooxygenase-2
inhibitors (COX-2 inhibitors)</span></i><span class=msoins0><i><span
style='font-size:11.0pt;color:windowtext'>, acetylsalicylic acid and
non-selective NSAIDs</span></i></span><i><span style='font-size:11.0pt;
color:windowtext'>:</span></i><span style='font-size:11.0pt;color:windowtext'>
As with other agents acting on the renin-angiotensin system, NSAIDs may reduce
the anti-hypertensive effect of aliskiren. NSAIDs may also weaken the diuretic
and antihypertensive activity of hydrochlorothiazide.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In some patients
with compromised renal function (dehydrated patients or elderly patients)
aliskiren and hydrochlorothiazide given concomitantly with NSAIDs may result in
further deterioration of renal function, including possible acute renal
failure, which is usually reversible. Therefore the use of Rasitrio with an
NSAID requires caution, especially in elderly patients.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Information on aliskiren interactions</span></u></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Contraindicated (see section&nbsp;4.3)</span></i></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span style='font-size:11.0pt;color:windowtext'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span style='font-size:11.0pt;color:windowtext'>Dual RAAS
blockade</span></i></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>The
combination of aliskiren with ARBs or ACEIs is contraindicated in patients with
diabetes mellitus or renal impairment (GFR &lt;60&nbsp;ml/min/</span><span
style='font-size:11.0pt;color:windowtext'>1.73&nbsp;m<sup>2</sup></span><span
style='font-size:11.0pt;color:windowtext'>) and is not recommended in other
patients (see sections&nbsp;4.3, 4.4 and 5.1).</span></p>

<p class=Default><i><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></i></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span style='font-size:11.0pt;color:windowtext'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span style='font-size:11.0pt;color:windowtext'>P-glycoprotein
(P-gp) potent inhibitors</span></i></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>A single dose drug
interaction study in healthy subjects has shown that ciclosporin (200 and
600&nbsp;mg) increases C<sub>max</sub> of aliskiren 75&nbsp;mg approximately
2.5-fold and AUC approximately 5-fold. The increase may be higher with higher
aliskiren doses. </span><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>In
healthy subjects, itraconazole (100&nbsp;mg) increases AUC and C<sub>max</sub>
of aliskiren (150&nbsp;mg) by 6.5-fold and 5.8-fold, respectively. </span><span
style='font-size:11.0pt;color:windowtext'>Therefore, concomitant use of
aliskiren and P-gp potent inhibitors is contraindicated (see section&nbsp;4.3).</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i>Not recommended
(see section&nbsp;4.2)</i></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span style='font-size:11.0pt;color:windowtext'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span style='font-size:11.0pt;color:windowtext'>Grapefruit
juice</span></i></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Administration
of grapefruit juice with aliskiren resulted in a decrease in AUC and C<sub>max</sub>
of aliskiren. Co-administration with aliskiren 150&nbsp;mg resulted in a 61%
decrease in aliskiren AUC and co-administration with aliskiren 300&nbsp;mg
resulted in a 38% decrease in aliskiren AUC. This decrease is likely due to an
inhibition of </span><span style='font-size:11.0pt;color:windowtext'>organic
anion transporting polypeptide-mediated uptake of aliskiren by grapefruit juice
in the gastrointestinal tract. Therefore, because of the risk of therapeutic
failure, grapefruit juice should not be taken together with Rasitrio.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i>Caution
required with concomitant use</i></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span style='font-size:11.0pt;color:windowtext'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span style='font-size:11.0pt;color:windowtext'>P-gp interactions</span></i></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>MDR</span><span
style='font-size:11.0pt;color:windowtext'>1/Mdr1a/1b (P-gp) was found to be the
major efflux system involved in intestinal absorption and biliary excretion of
aliskiren in preclinical studies. Rifampicin, which is an inducer of P-gp,
reduced aliskiren bioavailability by approximately 50% in a clinical study.
Other inducers of P-gp (St. John&#8217;s wort) might decrease the
bioavailability of aliskiren. Although this has not been investigated for
aliskiren, it is known that P-gp also controls tissue uptake of a variety of
substrates and P-gp inhibitors can increase the tissue-to-plasma concentration
ratios. Therefore, P-gp inhibitors may increase tissue levels more than plasma
levels. The potential for drug interactions at the P-gp site will likely depend
on the degree of inhibition of this transporter.</span></p>

<p class=Default><i><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></i></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span style='font-size:11.0pt;color:windowtext'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span style='font-size:11.0pt;color:windowtext'>Moderate P-gp inhibitors</span></i></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Co-administration
of ketoconazole (200&nbsp;mg) or verapamil (240&nbsp;mg) with aliskiren (300&nbsp;mg)
resulted in a 76% or 97% increase in aliskiren AUC, respectively. The change in
plasma levels of aliskiren in the presence of ketoconazole or verapamil is
expected to be within the range that would be achieved if the dose of aliskiren
were doubled; aliskiren doses of up to 600&nbsp;mg, or twice the highest
recommended therapeutic dose, have been found to be well tolerated in
controlled clinical trials. Preclinical studies indicate that aliskiren and
ketoconazole co-administration enhances aliskiren gastrointestinal absorption
and decreases biliary excretion. Therefore, caution should be exercised when
aliskiren is administered with ketoconazole, verapamil or other moderate P-gp
inhibitors (clarithromycin, telithromycin, erythromycin, amiodarone).</span></p>

<p class=Default><i><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></i></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span style='font-size:11.0pt;color:windowtext'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span style='font-size:11.0pt;color:windowtext'>Medicinal
products affecting serum potassium levels</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Concomitant use
of other agents affecting the RAAS, of NSAIDs or of agents that increase serum
potassium levels (e.g. potassium-sparing diuretics, potassium supplements, salt
substitutes containing potassium, heparin) may lead to increases in serum
potassium. If co-administration with an agent affecting the level of serum
potassium is considered necessary, caution is advisable. The combination of
aliskiren with ARBs or ACEIs is contraindicated in patients with diabetes
mellitus or renal impairment (GFR &lt;60&nbsp;ml/min/</span><span lang=EN-GB>1.73&nbsp;m<sup>2</sup></span><span
lang=EN-GB>) and is not recommended in other patients (see sections&nbsp;4.3,
4.4 and 5.1).</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span style='font-size:11.0pt;color:windowtext'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span style='font-size:11.0pt;color:windowtext'>Furosemide</span></i></p>

<p class=Default><span lang=EN style='font-size:11.0pt;color:windowtext'>Oral
co-administration of aliskiren and furosemide had no effect on the
pharmacokinetics of aliskiren but reduced exposure to furosemide by 20&#8209;30%
(the </span><span style='font-size:11.0pt;color:windowtext'>effect of aliskiren
on furosemide administered intramuscularly or intravenously has not been
investigated)</span><span lang=EN style='font-size:11.0pt;color:windowtext'>.
After </span><span style='font-size:11.0pt;color:windowtext'>multiple doses of </span><span
lang=EN style='font-size:11.0pt;color:windowtext'>furosemide (60</span><span
style='font-size:11.0pt;color:windowtext'>&nbsp;</span><span lang=EN
style='font-size:11.0pt;color:windowtext'>mg/day) co-administered with
aliskiren (300&nbsp;mg/day) </span><span style='font-size:11.0pt;color:windowtext'>to
patients with heart failure</span><span lang=EN style='font-size:11.0pt;
color:windowtext'> the urinary sodium excretion and the urine volume were
reduced during the first 4&nbsp;hours by 31% and 24%, respectively, as compared
to furosemide alone. </span><span style='font-size:11.0pt;color:windowtext'>The
mean weight of patients concomitantly treated with furosemide and 300&nbsp;mg
aliskiren (84.6&nbsp;kg) was higher than the weight of patients treated with
furosemide alone (83.4&nbsp;kg)</span><span lang=EN style='font-size:11.0pt;
color:windowtext'>. Smaller changes in furosemide pharmacokinetics and efficacy
were observed with aliskiren 150</span><span style='font-size:11.0pt;
color:windowtext'>&nbsp;</span><span lang=EN style='font-size:11.0pt;
color:windowtext'>mg/day. In patients treated with both aliskiren and oral
furosemide,</span><span style='font-size:11.0pt;color:windowtext'> it is
therefore recommended that the effects of furosemide be monitored when
initiating and adjusting furosemide or aliskiren therapy to avoid changes in
extracellular fluid volume and possible situations of volume overload (see
section&nbsp;4.4).</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span style='font-size:11.0pt;color:windowtext'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span style='font-size:11.0pt;color:windowtext'>Warfarin</span></i></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>The effects of
aliskiren on warfarin pharmacokinetics have not been evaluated.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span style='font-size:11.0pt;color:windowtext'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span style='font-size:11.0pt;color:windowtext'>Food
interactions</span></i></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Meals (low or
high fat content) have been shown to reduce the absorption of aliskiren
substantially (see section&nbsp;4.2).</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i>No
interactions</i></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt'><span
style='font-size:11.0pt;color:windowtext'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt;color:windowtext'>Compounds that
have been investigated in aliskiren clinical pharmacokinetic studies include
acenocoumarol, atenolol, celecoxib, pioglitazone, allopurinol,
isosorbide-5-mononitrate and hydrochlorothiazide. No interactions have been
identified.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>Co-administration of aliskiren with either metformin
(&#8595;28%), amlodipine (&#8593;29%) or cimetidine (&#8593;19%) resulted in
between 20% and 30%<span lang=EN-GB> change in C</span><sub><span lang=EN-GB>max</span></sub><span
lang=EN-GB> or AUC of aliskiren. When administered with atorvastatin,
steady-state aliskiren AUC and C</span><sub><span lang=EN-GB>max</span></sub><span
lang=EN-GB> increased by 50%. Co-administration of aliskiren had no significant
impact on atorvastatin, metformin or amlodipine pharmacokinetics. As a result
no dose adjustment for aliskiren or these co-administered medicinal products is
necessary.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Digoxin
and verapamil bioavailability may be slightly decreased by aliskiren.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span style='font-size:11.0pt;color:windowtext'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span style='font-size:11.0pt;color:windowtext'>CYP450
interactions</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Aliskiren does
not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1 and 3A).
Aliskiren does not induce CYP3A4. Therefore aliskiren is not expected to affect
the systemic exposure of substances that inhibit, induce or are metabolised by
these enzymes. </span><span lang=EN-GB>Aliskiren is metabolised minimally by
the cytochrome P450 enzymes. Hence, interactions due to inhibition or induction
of CYP450 isoenzymes are not expected. However, CYP3A4 inhibitors often also
affect P-gp. Increased aliskiren exposure during co-administration of CYP3A4
inhibitors that also inhibit P-gp can therefore be expected (see other P-gp
references in section&nbsp;4.5).</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span style='font-size:11.0pt;color:windowtext'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span style='font-size:11.0pt;color:windowtext'>P-gp
substrates or weak inhibitors</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No relevant
interactions with atenolol, digoxin, amlodipine or cimetidine have been
observed. When administered with atorvastatin (80&nbsp;mg), steady-state
aliskiren (300&nbsp;mg) AUC and C<sub>max</sub> increased by 50%. </span><span
lang=EN-GB>In experimental animals, it has been shown that P-gp is a major
determinant of aliskiren bioavailability. Inducers of P-gp (St. John&#8217;s
wort, rifampicin) might therefore decrease the bioavailability of aliskiren.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span style='font-size:11.0pt;color:windowtext'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span style='font-size:11.0pt;color:windowtext'>Organic anion
transporting polypeptide (OATP) inhibitors</span></i></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Preclinical
studies indicate that aliskiren might be a substrate of organic anion
transporting polypeptides. Therefore, the potential exists for interactions
between OATP inhibitors and aliskiren when administered concomitantly (see
interaction with Grapefruit juice).</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Information on amlodipine interactions</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Effects of other medicinal products on amlodipine</span></u></i></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Caution required with concomitant use</span></i></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span style='font-size:11.0pt;color:windowtext'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span style='font-size:11.0pt;color:windowtext'>CYP3A4
inhibitors</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Concomitant use
of amlodipine with strong or moderate CYP3A4 inhibitors (protease inhibitors,
azole antifungals, macrolides like erythromycin or clarithromycin, verapamil or
diltiazem) may give rise to significant increase in amlodipine exposure. The
clinical translation of these pharmacokinetic variations may be more pronounced
in the elderly. Clinical monitoring and dose adjustment may thus be required.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span style='font-size:11.0pt;color:windowtext'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span style='font-size:11.0pt;color:windowtext'>CYP3A4
inducers</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>There is no data
available regarding the effect of CYP3A4 inducers on amlodipine. The
concomitant use of CYP3A4 inducers (e.g. rifampicin, <i>hypericum perforatum</i>)
may give a lower plasma concentration of amlodipine. Amlodipine should be used
with caution together with CYP3A4 inducers.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:1.5in;text-indent:-1.5in;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Grapefruit juice</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Administration
of amlodipine with grapefruit or grapefruit juice is not recommended as
bioavailability may be increased in some patients, resulting in increased blood
pressure lowering effects.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Dantrolene (infusion)</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In animals,
lethal ventricular fibrillation and cardiovascular collapse are observed in
association with hyperkalaemia after administration of verapamil and
intravenous dantrolene. Due to risk of hyperkalaemia, it is recommended that
the co-administration of calcium channel blockers such as amlodipine be avoided
in patients susceptible to malignant hyperthermia and in the management of
malignant hyperthermia.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Effects of amlodipine on other medicinal products</span></u></i></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The blood pressure lowering effects of
amlodipine add to the blood pressure lowering effects of other antihypertensive
medicinal products.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Co-administration of multiple doses of
10&nbsp;mg of amlodipine with 80&nbsp;mg simvastatin resulted in a 77% increase
in exposure to simvastatin compared to simvastatin alone. It is recommended to limit
the dose of simvastatin to 20&nbsp;mg daily in patients on amlodipine.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>No interactions</span></i></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>In clinical interaction studies, amlodipine did
not affect the pharmacokinetics of atorvastatin, digoxin, warfarin or
ciclosporin.</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Information on hydrochlorothiazide interactions</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>When
administered concurrently, the following medicinal products may interact with
thiazide diuretics:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i>Not recommended</i></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span style='font-size:11.0pt;color:windowtext'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span style='font-size:11.0pt;color:windowtext'>Lithium</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>R</span>enal
clearance of lithium is reduced by thiazides, therefore the risk of lithium
toxicity<span lang=EN-GB> may be increased with hydrochlorothiazide</span>.
Co-administration of lithium and <span lang=EN-GB>hydrochlorothiazide</span> is
not recommended. If this combination proves essential, careful monitoring of
serum lithium level is recommended during concomitant use.</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i>Caution
required with concomitant use</i></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span style='font-size:11.0pt;color:windowtext'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span style='font-size:11.0pt;color:windowtext'>Alcohol</span></i><i><span
style='color:windowtext'>, barbiturates or narcotics</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Concomitant
administration of thiazide diuretics with subtances that also have a blood
pressure lowering effect (e.g. by reducing sympathetic central nervous system
activity or direct vasodilatation) may potentiate orthostatic hypotension.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Amantadine</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Thiazides,
including hydrochlorothiazide, may increase the risk of adverse reactions
caused by amantadine.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Antidiabetic agents (e.g. insulin and oral
antidiabetic agents)</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Thiazides may
alter glucose tolerance. Dose adjustment of the antidiabetic medicinal product
may be necessary (see section&nbsp;4.4). Metformin should be used with caution
because of the risk of lactic acidosis induced by possible functional renal
failure linked to hydrochlorothiazide.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Anticholinergic agents and other medicinal
products affecting gastric motility</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The
bioavailability of thiazide-type diuretics may be increased by anticholinergic
agents (e.g. atropine, biperiden), apparently due to a decrease in
gastrointestinal motility and the stomach emptying rate. Conversely, it is
anticipated that prokinetic substances such as cisapride may decrease the
bioavailability of thiazide-type diuretics.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Medicinal products used in the treatment of
gout</span></i></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Dose
adjustment of uricosuric </span>medicinal products<i> </i><span lang=EN-GB>may
be necessary as hydrochlorothiazide may raise the level of serum uric acid.
Increase of dose of probenecid or sulfinpyrazone may be necessary. Co<b>-</b>administration
of thiazide diuretics, including hydrochlorothiazide, may increase the
incidence of hypersensitivity reactions to allopurinol.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicinal
products that could induce torsades de pointes</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Due to the risk of hypokalaemia,
hydrochlorothiazide should be administered with caution when associated with
medicinal products that could induce <i>torsades de pointes</i>, in particular
Class Ia and Class III </span><span lang=EN-GB>antiarrhythmics</span><span
lang=EN-GB> </span><span lang=EN-GB>and some </span><span lang=EN-GB>antipsychotics.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><i><span lang=EN-GB>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicinal
products affecting serum sodium level</span></i></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>The
hyponatraemic effect of diuretics may be intensified by concomitant
administration of medicinal products such as antidepressants, antipsychotics,
antiepileptics, etc. Caution is indicated in long-term administration of these
medicinal products.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Beta blockers and diazoxide</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Concomitant use
of thiazide diuretics, including hydrochlorothiazide, with beta blockers may
increase the risk of hyperglycaemia. Thiazide diuretics, including
hydrochlorothiazide, may enhance the hyperglycaemic effect of diazoxide.</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Ion exchange resins</span></i></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Absorption
of thiazide diuretics, including hydrochlorothiazide, is decreased by
cholestyramine or colestipol. This could result in sub-therapeutic effects of
thiazide diuretics. However, staggering the dosage of hydrochlorothiazide and
resin such that hydrochlorothiazide is administered at least 4&nbsp;hours
before or 4&#8209;6&nbsp;hours after the administration of resins would
potentially minimise the interaction.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Vitamin D and calcium salts</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Administration
of thiazide diuretics, including hydrochlorothiazide, with vitamin D or with
calcium salts may potentiate the rise in serum calcium. Concomitant use of
thiazide type diuretics may lead to hypercalcaemia in patients pre-disposed for
hypercalcaemia (e.g. hyperparathyroidism, malignancy, or vitamin-D-mediated
conditions) by increasing tubular calcium reabsorption.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Non-depolarising skeletal muscle relaxants</span></i></p>

<p class=MsoNormal style='line-height:normal'>Thiazides, including hydrochlorothiazide,
potentiate the action of skeletal muscle relaxants such as curare derivatives.</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Cytotoxic agents</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Thiazides,
including hydrochlorothiazide, may reduce the renal excretion of cytotoxic
agents (e.g. cyclophosphamide, methotrexate) and potentiate their
myelosuppressive effects.</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Digoxine or digitalis glycosides</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Thiazide-induced
hypokalaemia or hypomagnesaemia favour the onset of digitalis-induced cardiac
arrhythmias (see section&nbsp;4.4).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoDate style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Methyldopa</span></i></p>

<p class=MsoDate><span lang=EN-GB>There have been isolated reports of
haemolytic anaemia occurring with concomitant use of hydrochlorothiazide and
methyldopa.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Iodine
contrasting agents</span></i></p>

<p class=MsoNormal><span lang=EN-GB>In case of diuretic-induced dehydration,
there is an increased risk of acute renal failure, especially with high doses
of iodine products. Patients should be rehydrated before administration.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Pressor amines (e.g. noradrenaline,
adrenaline)</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Hydrochlorothiazide
may reduce the response to pressor amines such as noradrenaline. The clinical
significance of this effect is uncertain and not sufficient to preclude their
use.</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.6&nbsp;&nbsp;&nbsp;&nbsp; Fertility,
pregnancy and lactation</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Women of childbearing potential/contraception in males and
females</span></u></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Healthcare
professionals prescribing Rasitrio should counsel women of childbearing
potential about the potential risk during pregnancy. A switch to a suitable
alternative antihypertensive treatment should be carried out in advance of a
planned pregnancy since Rasitrio should not be used in women planning to become
pregnant.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Pregnancy</span></u></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>There are no
data on the use of aliskiren in pregnant women. Aliskiren was not teratogenic in
rats or rabbits (see section&nbsp;5.3). Other substances that act directly on
the renin-angiotensin-aldosterone system have been associated with serious
foetal malformations and neonatal death. As for any medicinal product that acts
directly on the renin-angiotensin-aldosterone system, aliskiren should not be
used during the first trimester of pregnancy and is contraindicated during the
second and third trimesters (see section&nbsp;4.3).</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The safety of
amlodipine in human pregnancy has not been established. Reproductive studies in
rats have shown no toxicity except for delayed date of delivery and prolonged
duration of labour at dosages 50&nbsp;times greater than the maximum
recommended dosage for humans (see section&nbsp;5.3). Use in pregnancy is only
recommended when there is no safer alternative and when the disease itself
carries greater risk for the mother and foetus.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>There is limited experience with
hydrochlorothiazide during pregnancy, especially during the first trimester.
Animal studies are insufficient.</span></p>

<p class=MsoDate><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoDate><span lang=EN-GB>Hydrochlorothiazide crosses the placenta.
Based on the pharmacological mechanism of action of hydrochlorothiazide, its
use during the second and third trimester may compromise foeto-placental
perfusion and may cause foetal and neonatal effects like icterus, disturbance
of electrolyte balance and thrombocytopenia.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Hydrochlorothiazide should not be used for
gestational oedema, gestational hypertension or pre&#8209;eclampsia due to the
risk of decreased plasma volume and placental hypoperfusion, without a
beneficial effect on the course of the disease.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Hydrochlorothiazide should not be used for
essential hypertension in pregnant women except in rare situations where no
other treatment could be used.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Rasitrio
should not be used during the first trimester of pregnancy. Rasitrio is
contraindicated during the second and third trimesters (see section&nbsp;4.3).</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>If pregnancy
is detected during therapy, Rasitrio should be discontinued accordingly as soon
as possible.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Breast-feeding</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>It is not known
whether aliskiren and/or amlodipine are excreted in human milk. Aliskiren was
secreted in the milk of lactating rats.</span></p>

<p class=MsoDate><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoDate><span lang=EN-GB>Hydrochlorothiazide is excreted in human milk
in small amounts. Thiazides in high doses causing intense diuresis can inhibit
milk production.</span></p>

<p class=MsoDate><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The use of
Rasitrio during breast-feeding is not recommended. If Rasitrio is used during
breast-feeding, doses should be kept as low as possible.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Fertility</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>There are no
clinical data on fertility with the use of Rasitrio.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Reversible
biochemical changes in the head of spermatozoa have been reported in some
patients treated by calcium channel blockers. Clinical data are insufficient
regarding the potential effect of amlodipine on fertility. In one rat study,
adverse effects were found on male fertility (see section&nbsp;5.3). The
fertility of rats was unaffected at doses of up to aliskiren 250&nbsp;mg/kg/day
and hydrochlorothiazide 4&nbsp;mg/kg/day (see section&nbsp;5.3).</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.7&nbsp;&nbsp;&nbsp;&nbsp; Effects
on ability to drive and use machines</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>No studies on the effect on the ability to drive and use machines
have been performed</span>. However, when driving vehicles or using machines it
must be borne in mind that dizziness or drowsiness may occasionally occur when
taking Rasitrio.</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Amlodipine can
have minor or moderate influence on the ability to drive and use machines. If
patients taking amlodipine suffer from dizziness, drowsiness, headache, fatigue
or nausea, the ability to react may be impaired.</span></p>

<p class=MsoDate><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.8&nbsp;&nbsp;&nbsp;&nbsp; Undesirable
effects</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Summary of the safety profile</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Aliskiren/amlodipine/hydrochlorothiazide combination</span></u></i></p>

<p style='margin:0in'><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>The safety profile of Rasitrio presented below is
based on clinical studies performed with Rasitrio and the known safety profile
of the individual components aliskiren, amlodipine and hydrochlorothiazide.
Safety information for Rasitrio in patients aged 75&nbsp;years and older is
limited.</span></p>

<p style='margin:0in'><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoCommentText style='line-height:normal'><span lang=EN-GB
style='font-size:11.0pt'>The most frequent adverse reactions observed with
Rasitrio are hypotension and dizziness. The adverse reactions previously
reported with one of the individual components of Rasitrio (aliskiren,
amlodipine and hydrochlorothiazide) and listed in the respective paragraphs on
the individual components may occur with Rasitrio.</span></p>

<p class=Default><u><span lang=EN-GB style='font-size:11.0pt;color:windowtext'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Tabulated
list of adverse reactions:</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>The adverse
reactions for aliskiren, amlodipine and hydrochlorothiazide are ranked under
heading of frequency, the most frequent first, using the following convention:
very common (&#8805;1/10); common (&#8805;1/100 to &lt;1/10); uncommon
(&#8805;1/1,000 to &lt;1/100); rare (&#8805;1/10,000 to &lt;1/1,000); very rare
(&lt;1/10,000), not known (cannot be estimated from the available data). Within
each frequency grouping, adverse reactions are presented in order of decreasing
seriousness.</span></p>

<p style='margin:0in'><u><span style='font-size:11.0pt;font-family:"Times New Roman",serif'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p style='margin:0in;page-break-after:avoid'><i><u><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Information on
Rasitrio</span></u></i></p>

<p class=CharCharCharCharChar align=left style='margin-bottom:0in;text-align:
left;line-height:normal;page-break-after:avoid'><span style='font-size:11.0pt;
font-family:"Times New Roman",serif'>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='margin-left:5.4pt;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-bottom:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
  layout-grid-mode:line'>Nervous system disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Common</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Dizziness</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
  layout-grid-mode:line'>Vascular disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Common</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Hypotension</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><b><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>General
  disorders and administration site conditions</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Common</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Peripheral
  oedema</span></p>
  </td>
 </tr>
</table>

<p class=CharCharCharCharChar align=left style='margin-bottom:0in;text-align:
left;line-height:normal'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'>Peripheral oedema is
a known, dose-dependent adverse reaction of amlodipine and has also been
reported with aliskiren therapy in post-marketing experience. The incidence of peripheral
oedema for Rasitrio in a short-term double active-controlled study was 7.1%
compared to 8.0% for aliskiren/amlodipine, 4.1% for
amlodipine/hydrochlorothiazide and 2.0% for aliskiren/hydrochlorothiazide dual
combinations.</p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>The
incidence of any adverse reactions potentially related to hypotension in a
short-term active controlled study was 4.9% with Rasitrio versus up to 3.7%
with dual combinations. In patients &#8805;65&nbsp;years the incidence was 10.2%
with Rasitrio versus up to 5.4% with dual combinations.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'>&nbsp;</p>

<p style='margin:0in;page-break-after:avoid'><i><u><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Additional
information on individual components</span></u></i></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Other
adverse reactions previously reported with one of the individual components may
occur with Rasitrio even if not observed in clinical trials.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p style='margin:0in;page-break-after:avoid'><i><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Aliskiren</span></i></p>

<p style='margin:0in;page-break-after:avoid'><span lang=EN-GB style='font-size:
11.0pt;font-family:"Times New Roman",serif'>Serious adverse reactions include
anaphylactic reaction and angioedema which have been reported in post-marketing
experience and may occur rarely (less than 1&nbsp;case per
1,000&nbsp;patients). The most common adverse reaction is diarrhoea.</span></p>

<p style='margin:0in'><u><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoDate style='page-break-after:avoid'><span lang=EN-GB>Tabulated list
of adverse reactions:</span></p>

<p class=MsoNormal><span lang=EN-GB>The known aliskiren adverse reactions are
presented in the table below using the same convention as described previously
for the fixed combination.</span></p>

<p style='margin:0in;page-break-after:avoid'><u><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='margin-left:5.4pt;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-bottom:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
  layout-grid-mode:line'>Immune system disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Anaphylactic
  reactions, h</span><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
  layout-grid-mode:line'>ypersensitivity reactions</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><b><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Cardiac
  </span></b><b><span lang=DE-CH style='font-size:11.0pt;font-family:"Times New Roman",serif'>d</span></b><b><span
  lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>isorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Common</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Dizziness</span></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Uncommon</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Palpitations</span><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>, oedema
  peripheral</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><b><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Vascular
  disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Uncommon</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Hypotension</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
  layout-grid-mode:line'>Respiratory, thoracic and mediastinal disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
  layout-grid-mode:line'>Uncommon</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
  layout-grid-mode:line'>Cough</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
  layout-grid-mode:line'>Gastrointestinal disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Common</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Diarrhoea</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><b><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Hepatobiliary
  disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Not
  known</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Liver
  disorder*</span><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>,
  j</span><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>aundice</span><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>,</span><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'> </span><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>h</span><span
  lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>epatitis</span><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>, l</span><span
  lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>iver
  failure**</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
  layout-grid-mode:line'>Skin and subcutaneous tissue disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Uncommon</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Severe
  cutaneous adverse reactions (SCARs) including Stevens Johnson syndrome, toxic
  epidermal necrolysis (TEN), oral mucosal reactions, rash, pruritus, urticaria</span></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Angioedema,
  erythema</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
  layout-grid-mode:line'>Musculoskeletal and connective tissue disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Common</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Arthralgia</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
  layout-grid-mode:line'>Renal and urinary disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Uncommon</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=FR style='font-size:11.0pt;font-family:"Times New Roman",serif'>Acute
  renal failure, renal impairment</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
  layout-grid-mode:line'>Investigations</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Common</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Hyperkalaemia</span></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Uncommon</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Liver
  enzyme increased</span></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Haemoglobin
  decreased, haematocrit decreased, blood creatinine increased</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>*Isolated cases
of liver disorder with clinical symptoms and laboratory evidence of more marked
hepatic dysfunction.</span></p>

<p style='margin:0in'><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>**Including one case of &#8216;liver failure
fulminant&#8217; reported in the post-marketing experience, for which a causal
relationship with aliskiren cannot be excluded.</span></p>

<p style='margin:0in'><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Description of
selected adverse events:</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Hypersensitivity
reactions including anaphylactic reactions and angioedema have occurred during
treatment with aliskiren.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>In controlled
clinical trials, angioedema and hypersensitivity reactions occurred rarely during
treatment with aliskiren with rates comparable to treatment with placebo or comparators.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Cases of
angioedema or symptoms suggestive of angioedema (swelling of the face, lips,
throat and/or tongue) have also been reported in post-marketing experience. A
number of these patients had a history of angioedema or symptoms suggestive of
angioedema which in some cases was associated with the administration of other medicinal
products known to cause angioedema, including RAAS blockers (ACEIs or ARBs).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'>In post-marketing experience,
cases of angioedema or angioedema-like reactions have been reported when
aliskiren was co-administered with ACEIs and/or ARBs.</p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Hypersensitivity
reactions including anaphylactic reactions have also been reported in
post-marketing experience (see section&nbsp;4.4).</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>In the event
of any signs suggesting a hypersensitivity reaction/angioedema (in particular
difficulties in breathing, or swallowing, rash, itching, hives or swelling of
the face, extremities, eyes, lips and/or tongue, dizziness) patients should
discontinue treatment and contact the physician (see section&nbsp;4.4).</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Arthralgia has
been reported in post-marketing experience. In some cases this occurred as part
of a hypersensitivity reaction.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In
post-marketing experience, renal dysfunction and cases of acute renal failure
have been reported in patients at risk (see section&nbsp;4.4).</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><i><span style='font-size:11.0pt;color:windowtext'>Investigations:
</span></i><span style='font-size:11.0pt;color:windowtext'>In controlled
clinical trials, clinically relevant changes in standard laboratory parameters
were uncommonly associated with the administration of aliskiren. In clinical
studies in hypertensive patients, aliskiren had no clinically important effects
on total cholesterol, high density lipoprotein cholesterol (HDL-C),
fasting triglycerides, fasting glucose or uric acid.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><i><span style='font-size:11.0pt;color:windowtext'>Haemoglobin
and haematocrit</span></i><span style='font-size:11.0pt;color:windowtext'>:
Small decreases in haemoglobin and haematocrit (mean decreases of approximately
0.05&nbsp;mmol/l and 0.16&nbsp;volume percent, respectively) were observed. No
patients discontinued therapy due to anaemia. This effect is also seen with
other medicinal products acting on the RAAS, such as ACEIs and ARBs.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><i><span style='font-size:11.0pt;color:windowtext'>Serum
potassium</span></i><span style='font-size:11.0pt;color:windowtext'>: Increases
in serum potassium have been observed with aliskiren and these may be
exacerbated by concomitant use of other agents acting on the RAAS or by NSAIDs.
Consistent with standard medical practice, periodic determination of renal
function including serum electrolytes is advised if co-administration is
considered necessary. The combination of aliskiren with ARBs or ACEIs is
contraindicated in patients with diabetes mellitus or renal impairment (GFR
&lt;60&nbsp;ml/min/</span><span style='font-size:11.0pt;color:windowtext'>1.73&nbsp;m<sup>2</sup></span><span
style='font-size:11.0pt;color:windowtext'>) and is not recommended in other
patients (see sections&nbsp;4.3, 4.4 and 5.1).</span></p>

<p style='margin:0in'><u><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><i><span lang=EN-GB>Paediatric population: </span></i><span
lang=EN-GB>Based on the limited amount of safety data available from a
pharmacokinetic study of aliskiren treatment in 39 hypertensive children 6&#8209;17&nbsp;years
of age, the frequency, type and severity of adverse reactions in children are
expected to be similar to that seen in hypertensive adults. As for other RAAS
blockers, headache is a common adverse event in children treated with
aliskiren.</span></p>

<p style='margin:0in'><u><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Amlodipine</span></i></p>

<p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
color:windowtext'>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><b><span style='font-size:
  11.0pt;color:windowtext'>Blood and lymphatic system disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Very
  rare</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Leukopenia,
  thrombocytopenia</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><b><span style='font-size:
  11.0pt;color:windowtext'>Immune system disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Very rare</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Allergic
  reactions</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><b><span style='font-size:
  11.0pt;color:windowtext'>Metabolism and nutrition disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Very rare</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Hyperglycaemia</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><b><span style='font-size:
  11.0pt;color:windowtext'>Psychiatric disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Uncommon</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Insomnia, mood changes (including anxiety), depression</span></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Rare</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Confusion</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><b><span style='font-size:
  11.0pt;color:windowtext'>Nervous system disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Common</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Somnolence, headache (especially at the beginning of
  treatment)</span></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Uncommon</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Tremor, dysgeusia, syncope, hypoesthesia, paraesthesia</span></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Very rare</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Hypertonia,
  peripheral neuropathy</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><b><span style='font-size:
  11.0pt;color:windowtext'>Eye disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Uncommon</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Visual
  disturbance (including diplopia)</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><b><span style='font-size:
  11.0pt;color:windowtext'>Ear and labyrinth disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Uncommon</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Tinnitus</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><b><span style='font-size:
  11.0pt;color:windowtext'>Cardiac disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Common</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Palpitations</span></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Very rare</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Myocardial
  infarction, arrhythmia (including bradycardia, ventricular tachycardia and
  atrial fibrillation)</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><b><span style='font-size:
  11.0pt;color:windowtext'>Vascular disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Common</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Flushing</span></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Very rare</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Vasculitis</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><b><span style='font-size:
  11.0pt;color:windowtext'>Respiratory, thoracic and mediastinal disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Uncommon</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Dyspnoea, rhinitis</span></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Very rare</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Cough</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><b><span style='font-size:
  11.0pt;color:windowtext'>Gastrointestinal disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Common</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Abdominal pain, nausea</span></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Uncommon</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Vomiting, dyspepsia, altered bowel habits (including
  diarrhoea and constipation), dry mouth</span></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Very rare</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Pancreatitis,
  gastritis, gingival hyperplasia</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><b><span style='font-size:
  11.0pt;color:windowtext'>Hepatobiliary disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Very rare</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Hepatitis,
  jaundice, hepatic enzymes increased (mostly consistent with cholestasis)</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><b><span style='font-size:
  11.0pt;color:windowtext'>Skin and subcutaneous tissue disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Uncommon</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Alopecia, purpura, skin decolouration, hyperhidrosis,
  pruritus, rash, exanthema</span></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Very rare</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Angioedema,
  erythema multiforme, urticaria, exfoliative dermatitis, Stevens-Johnson
  syndrome, Quincke oedema, photosensitivity</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><b><span style='font-size:
  11.0pt;color:windowtext'>Musculoskeletal and connective tissue disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;color:windowtext'>Common</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Ankle swelling</span></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Uncommon</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Arthralgia,
  myalgia, muscle cramps, back pain</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><b><span style='font-size:
  11.0pt;color:windowtext'>Renal and urinary disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Uncommon</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Micturition
  disorder, nocturia, increased urinary frequency</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><b><span style='font-size:
  11.0pt;color:windowtext'>Reproductive system and breast disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Uncommon</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Impotence,
  gynaecomastia</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><b><span style='font-size:
  11.0pt;color:windowtext'>General disorders and administration site conditions</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Common</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Oedema, fatigue</span></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Uncommon</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span lang=FR style='font-size:11.0pt;color:windowtext'>Chest
  pain, asthenia, pain, malaise</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><b><span style='font-size:
  11.0pt;color:windowtext'>Investigations</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Uncommon</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Weight
  increase, weight decrease</span></p>
  </td>
 </tr>
</table>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Exceptional
cases of extrapyramidal syndrome have been reported.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Hydrochlorothiazide</span></i></p>

<p style='margin:0in;page-break-after:avoid'><span lang=EN-GB style='font-size:
11.0pt;font-family:"Times New Roman",serif'>Hydrochlorothiazide has been
extensively prescribed for many years, frequently in higher doses than those
contained in </span><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Rasitrio</span><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>. </span><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>The
following adverse reactions have been reported in patients treated with
thiazide diuretics alone, including hydrochlorothiazide:</span></p>

<p style='margin:0in;page-break-after:avoid'><i><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></i></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='margin-left:5.4pt;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-bottom:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:
  line'>Blood and lymphatic system disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Thrombocytopenia</span><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>
  sometimes with purpura</span></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Very rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Agranulocytosis,
  bone marrow depression, haemolytic anaemia, leucopenia</span></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Not known</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Aplastic
  anaemia</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:
  line'>Immune system disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=X-NONE style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Very rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Hypersensitivity</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:
  line'>Metabolism and nutrition disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Very common</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Hypokalaemia</span></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Common</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Hyperuricaemia,
  hypomagnesaemia, hyponatraemia</span></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Hypercalcaemia,
  hyperglycaemia, worsening of diabetic metabolic state</span></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=X-NONE style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Very rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Hypochloraemic
  alkalosis</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:
  line'>Psychiatric disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=X-NONE style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Depression,
  sleep disturbances</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:
  line'>Nervous system disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=X-NONE style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Dizziness,
  headache, paraesthesia</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:
  line'>Eye disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Visual
  impairment</span></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=X-NONE style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Not known</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Acute
  angle-closure glaucoma</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:
  line'>Cardiac disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=X-NONE style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Cardiac
  arrhythmias</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:
  line'>Vascular disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=X-NONE style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Common</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Orthostatic
  hypotension</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:
  line'>Respiratory, thoracic and mediastinal disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=X-NONE style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Very rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Respiratory
  distress (including pneumonitis and pulmonary oedema)</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:
  line'>Gastrointestinal disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Common</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Decreased
  appetite, mild nausea and vomiting</span></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Abdominal
  discomfort, constipation, diarrhoea</span></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=X-NONE style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Very rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Pancreatitis</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:
  line'>Hepatobiliary disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Intrahepatic
  cholestasis, jaundice</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:
  line'>Skin and subcutaneous tissue disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Common</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Urticaria
  and other forms of rash</span></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Photosensitivity
  reactions</span></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Very rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Cutaneous
  lupus erythematosus-like reactions, reactivation of cutaneous lupus
  erythematosus, vasculitis necrotising and toxic epidermal necrolysis</span></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Not known</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Erythema
  multiforme</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:
  line'>Musculoskeletal and connective tissue disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=X-NONE style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Not known</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Muscle
  spasm</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:
  line'>Renal and urinary disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=X-NONE style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Not known</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=FR style='font-size:11.0pt;font-family:"Times New Roman",serif'>Renal
  dysfunction, acute renal failure</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:
  line'>Reproductive system and breast disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=X-NONE style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Common</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Impotence</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:
  line'>General disorders and administration site conditions</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=X-NONE style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Not known</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Asthenia,
  pyrexia</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:
  line'>Investigations</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Very common</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Increases
  in cholesterol and triglycerides</span></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Glycosuria</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.9&nbsp;&nbsp;&nbsp;&nbsp; Overdose</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Symptoms</span></u></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>The most
likely manifestation of overdose for Rasitrio would be hypotension, related to
the antihypertensive effect of the combination of aliskiren, amlodipine and
hydrochlorothiazide.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>With
aliskiren, the most likely manifestation of overdose would be hypotension,
related to the antihypertensive effect of aliskiren.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>With
amlodipine, available data suggest that gross overdose could result in
excessive peripheral vasodilatation and possibly reflex tachycardia. </span><span
style='font-size:11.0pt;color:windowtext'>Marked and </span><span lang=EN-GB
style='font-size:11.0pt;color:windowtext'>probably </span><span
style='font-size:11.0pt;color:windowtext'>prolonged systemic hypotension</span><span
lang=EN-GB style='font-size:11.0pt;color:windowtext'> up to and</span><span
lang=EN-GB style='font-size:11.0pt;color:windowtext'> </span><span
style='font-size:11.0pt;color:windowtext'>including shock with fatal outcome,
have been reported with amlodipine.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Overdose with
hydrochlorothiazide is associated with electrolyte depletion (hypokalaemia,
hypochloraemia, hyponatraemia) and dehydration resulting from excessive
diuresis. The most common signs and symptoms of overdose are nausea and
somnolence. Hypokalaemia may result in muscle spasms and/or accentuate cardiac
arrhythmias associated with the concomitant use of digitalis glycosides or
certain antiarrhythmic medicinal products.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Treatment</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If symptomatic
hypotension should occur with Rasitrio, supportive treatment should be initiated.</span></p>

<p class=MsoNormal style='line-height:normal'><i>&nbsp;</i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Clinically
significant hypotension due to amlodipine overdose calls for active
cardiovascular support including frequent monitoring of cardiac and respiratory
function, elevation of extremities and attention to circulating fluid volume
and urine output.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>A
vasoconstrictor may be helpful in restoring vascular tone and blood pressure,
provided that there is no contraindication to its use. Intravenous calcium
gluconate may be beneficial in reversing the effects of calcium channel
blockade.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Gastric lavage
may be worthwhile in some cases. In healthy volunteers the use of charcoal up
to 2&nbsp;hours after administration of amlodipine 10&nbsp;mg has been shown to
reduce the absorption rate of amlodipine.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Since amlodipine
is highly protein-bound, dialysis is not likely to be of benefit.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In a study
conducted in patients with end stage renal disease (ESRD) receiving
haemodialysis, dialysis clearance of aliskiren was low (&lt;2% of oral
clearance). Therefore dialysis is not adequate to treat aliskiren
over-exposure.</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACOLOGICAL
PROPERTIES</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5.1&nbsp;&nbsp;&nbsp;&nbsp; Pharmacodynamic
properties</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>Pharmacotherapeutic group</span><span lang=EN-GB>: Agents
acting on the renin-angiotensin system, renin-inhibitors; ATC code C09XA54</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Rasitrio
combines three antihypertensive active substances with complementary mechanisms
to control blood pressure in patients with essential hypertension: aliskiren
belongs to the direct renin inhibitor class, amlodipine to the calcium channel
blocker class and hydrochlorothiazide to the thiazide diuretics class. When
combined, the consolidated effects of inhibition of the renin-angiotensin-aldosterone
system, calcium channel-mediated vasodilatation and sodium chloride excretion
result in a reduction of blood pressure to a greater degree than the
corresponding dual combinations.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Aliskiren/amlodipine/hydrochlorothiazide combination</span></u></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>In
hypertensive patients, once-daily administration of Rasitrio provided
clinically meaningful reductions in both systolic and diastolic blood pressure
that were maintained over the entire 24-hour dose interval. The greater blood
pressure reduction for Rasitrio over each dual combination was seen at every
hour including the early morning hours with the 24-hour ambulatory blood
pressure monitoring.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Rasitrio
was studied in a double-blind, randomised, active-controlled study in 1,181&nbsp;patients
of which 773 were classified as moderately hypertensive (msSBP 160&#8209;180&nbsp;mmHg)
and 408 as severely hypertensive (msSBP &gt;180&nbsp;mmHg) at baseline. A large
number of patients were obese (49%) and over 14% of the total population had diabetes.
During the first 4&nbsp;weeks of double-blind treatment, patients received
triple combination aliskiren/amlodipine/hydrochlorothiazide (HCTZ) 150/5/12.5&nbsp;mg
(N=308), or dual combinations of aliskiren/HCTZ 150/12.5&nbsp;mg (N=295), aliskiren/amlodipine
150/5&nbsp;mg (N=282) and amlodipine/HCTZ 5/12.5&nbsp;mg (N=295). Patients were
force-titrated to higher doses after 4&nbsp;weeks for an additional 4&nbsp;weeks
of double-blind treatment to aliskiren/amlodipine/HCTZ 300/10/25&nbsp;mg,
aliskiren/HCTZ 300/25&nbsp;mg, aliskiren/amlodipine 300/10&nbsp;mg and
amlodipine/HCTZ 10/25&nbsp;mg.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>In
this study, Rasitrio at a dose of 300/10/25&nbsp;mg produced statistically
significant mean blood pressure reductions (systolic/diastolic) from baseline
of 37.9/20.6&nbsp;mmHg compared to 31.4/18.0&nbsp;mmHg with aliskiren/amlodipine
combination (300/10&nbsp;mg), 28.0/14.3&nbsp;mmHg with aliskiren/hydrochlorothiazide
(300/25&nbsp;mg) and 30.8/17.0&nbsp;mmHg with amlodipine/hydrochlorothiazide
(10/25&nbsp;mg) in patients with moderate to severe hypertension. In patients
with severe hypertension (SBP &#8805;180&nbsp;mmHg), the reduction in blood
pressure from baseline for Rasitrio and the dual combinations respectively was
49.5/22.5&nbsp;mmHg compared to 38.1/17.6&nbsp;mmHg with aliskiren/amlodipine
combination (300/10&nbsp;mg), 33.2/14.3&nbsp;mmHg with aliskiren/hydrochlorothiazide
(300/25&nbsp;mg) and 39.9/17.8&nbsp;mmHg with amlodipine/hydrochlorothiazide
(10/25&nbsp;mg). In a subset of 588&nbsp;patients</span><span lang=EN-GB> in
which patients &gt;65&nbsp;years were scarcely represented and those aged
&gt;75&nbsp;years were very scarcely represented</span><span lang=EN-GB>, the
combination of aliskiren/amlodipine/hydrochlorothiazide (300/10/25&nbsp;mg) produced
a systolic/diastolic mean blood pressure reduction of 39.7/21.1&nbsp;mmHg from
baseline, compared to 31.3/18.74&nbsp;mmHg for aliskiren/amlodipine (300/10&nbsp;mg),
25.5/12.5&nbsp;mmHg for aliskiren/hydrochlorothiazide (300/25&nbsp;mg) and 29.2/16.4&nbsp;mmHg
for amlodipine/hydrochlorothiazide (10/25&nbsp;mg) (the subset constitutes patients
without aberrant readings, defined as a difference between systolic blood
pressure (SBP) readings &#8805;10&nbsp;mmHg at baseline or endpoint). The
effect of Rasitrio was observed as early as one week after initiation of
therapy. The blood-pressure-lowering effect in patients with moderate to severe
hypertension was independent of age, gender, race, body mass index and
overweight-associated disorders (metabolic syndrome and diabetes).</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Rasitrio
was associated with a significant reduction in plasma renin activity (PRA) (&#8209;34%)
from baseline while the dual combination of amlodipine with hydrochlorothiazide
increased PRA (+170%). The clinical implications of the differences in effect
on PRA are not known at the present time.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>In
a 28 to 54&nbsp;week open label safety study, efficacy was measured as
secondary endpoint and Rasitrio at a dose of 300/10/25&nbsp;mg produced mean
blood pressure reductions (systolic/diastolic) of 37.3/21.8&nbsp;mmHg over 28
to 54&nbsp;weeks of treatment. Efficacy of Rasitrio was maintained over one
year of treatment, with no evidence of loss of effect.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>In
a randomised, double blind, active controlled, 36-week study in elderly patients
whose blood pressure was not controlled with aliskiren/HCTZ 300/25&nbsp;mg (SBP
&#8805;140&nbsp;mmHg), clinically meaningful further BP reduction was seen at week&nbsp;36
endpoint for patients who received Rasitrio at a dose of 300/10/25&nbsp;mg
(from reductions in msSBP/msDBP of 15.0/8.6&nbsp;mmHg at week&nbsp;22 to reductions
of 30.8/14.1&nbsp;mmHg at week&nbsp;36 endpoint).</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Rasitrio
has been administered to more than 1,155&nbsp;patients in completed clinical
trials, including 182&nbsp;patients for one year or more. Treatment with
Rasitrio was well tolerated at doses up to 300&nbsp;mg/10&nbsp;mg/25&nbsp;mg
with an overall incidence of adverse events similar to the corresponding dual
combinations, except for symptomatic hypotension. </span><span lang=EN-GB>The
incidence of any adverse reactions potentially related to hypotension in a
short-term controlled study was 4.9% with Rasitrio versus up to 3.7% with dual
combinations. In patients &#8805;65&nbsp;years the incidence was 10.2% with
Rasitrio versus up to 5.4% with dual combinations.</span></p>

<p class=CharCharCharCharChar align=left style='margin-bottom:0in;text-align:
left;line-height:normal'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=CharCharCharCharChar align=left style='margin-bottom:0in;text-align:
left;line-height:normal'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>The
incidence of adverse events did not show any association with gender, age (with
the exception of symptomatic hypotension), body mass index, race or ethnicity.
Adverse events have generally been mild and transient in nature. Very limited
safety data are available for patients aged &gt;75&nbsp;years or patients with
major cardiovascular co-morbidities. Discontinuation of therapy due to a
clinical adverse event occurred in 3.6% of patients treated with Rasitrio
versus 2.4% in aliskiren/amlodipine, 0.7% in aliskiren/hydrochlorothiazide and
2.7% in amlodipine/hydrochlorothiazide.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Aliskiren</span></u></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Aliskiren is
an orally active, non-peptide, potent and selective direct inhibitor of human
renin.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>By inhibiting
the enzyme renin, aliskiren inhibits the RAAS at the point of activation,
blocking the conversion of angiotensinogen to angiotensin&nbsp;I and decreasing
levels of angiotensin&nbsp;I and angiotensin&nbsp;II. Whereas other medicinal
products that inhibit the RAAS (ACEI and angiotensin&nbsp;II receptor blockers
(ARB)) cause a compensatory rise in plasma renin activity (PRA), treatment with
aliskiren decreases PRA in hypertensive patients by approximately 50 to 80%.
Similar reductions were found when aliskiren was combined with other
antihypertensive medicinal products. The clinical implications of the
differences in effect on PRA are not known at the present time.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Hypertension</span></i></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>In
hypertensive patients, once-daily administration of aliskiren at doses of
150&nbsp;mg and 300&nbsp;mg provided dose-dependent reductions in both systolic
and diastolic blood pressure that were maintained over the entire 24-hour dose
interval (maintaining benefit in the early morning) with a mean peak to trough
ratio for diastolic response of up to 98% for the 300&nbsp;mg dose. 85 to 90%
of the maximal blood-pressure-lowering effect was observed after 2&nbsp;weeks.
The blood-pressure-lowering effect was sustained during long-term treatment,
and was independent of age, gender, body mass index and ethnicity. Aliskiren has
been studied in 1,864&nbsp;patients aged 65&nbsp;years or older, and in
426&nbsp;patients aged 75&nbsp;years or older.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Aliskiren
monotherapy studies have shown blood-pressure-lowering effects comparable to other
classes of antihypertensive medicinal products including selected ACEI
and ARB. Compared to a diuretic (hydrochlorothiazide, HCTZ), aliskiren
300&nbsp;mg lowered systolic/diastolic blood pressure by 17.0/12.3&nbsp;mmHg,
compared to 14.4/10.5&nbsp;mmHg for HCTZ 25&nbsp;mg after 12&nbsp;weeks of
treatment.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Combination
therapy studies are available for aliskiren added to the diuretic
hydrochlorothiazide, the calcium channel blocker amlodipine and the beta
blocker atenolol. These combinations were well tolerated. Aliskiren induced an
additive blood-pressure-lowering effect when added to hydrochlorothiazide.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>&nbsp;</p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>The
efficacy and safety of aliskiren-based therapy were compared to ramipril-based
therapy in a 9-month non-inferiority study in 901&nbsp;elderly patients
(&#8805;65&nbsp;years) with essential systolic hypertension. Aliskiren
150&nbsp;mg or 300&nbsp;mg per day or ramipril 5&nbsp;mg or 10&nbsp;mg per day
were administered for 36&nbsp;weeks with optional add-on therapy of
hydrochlorothiazide (12.5&nbsp;mg or 25&nbsp;mg) at week&nbsp;12, and amlodipine
(5&nbsp;mg or 10&nbsp;mg) at week&nbsp;22. Over the 12-week period, aliskiren
monotherapy lowered systolic/diastolic blood pressure by 14.0/5.1&nbsp;mmHg,
compared to 11.6/3.6&nbsp;mmHg for ramipril, consistent with aliskiren being
non-inferior to ramipril at the dosages chosen and the differences in systolic
and diastolic blood pressure were statistically significant. Tolerability was
comparable in both treatment arms, however cough was more often reported with
the ramipril regimen than the aliskiren regimen (14.2% vs. 4.4%), whilst
diarrhoea was more common with the aliskiren regimen than for the ramipril
regimen (6.6% vs. 5.0%).</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>In an 8-week study in 754&nbsp;hypertensive geriatric patients aged 65&nbsp;years
or older and geriatric patients aged 75&nbsp;years or older (30%) aliskiren at
doses of 75&nbsp;mg, 150&nbsp;mg and 300&nbsp;mg provided statistically
significant superior reduction in blood pressure (both systolic and diastolic)
when compared to placebo. No additional blood pressure lowering effect was
detected with 300&nbsp;mg aliskiren compared to 150&nbsp;mg aliskiren. All
three doses were well tolerated in both elderly and very elderly patients.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>There has been
no evidence of first-dose hypotension and no effect on pulse rate in patients
treated in controlled clinical studies. Excessive hypotension was uncommonly
(0.1%) seen in patients with uncomplicated hypertension treated with aliskiren
alone. Hypotension was also uncommon (&lt;1%) during combination therapy with
other antihypertensive medicinal products. With cessation of treatment, blood
pressure gradually returned towards baseline levels over a period of several
weeks, with no evidence of a rebound effect for blood pressure or PRA.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>I</span>n a 36-week study involving 820&nbsp;patients with ischaemic
left ventricular dysfunction, no changes in ventricular remodelling as assessed
by left ventricular end systolic volume were detected with aliskiren compared
to placebo on top of background therapy.</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>&nbsp;</p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>The combined
rates of cardiovascular death, hospitalisation for heart failure, recurrent
heart attack, stroke and resuscitated sudden death were similar in the
aliskiren group and the placebo group. However, in patients receiving aliskiren
there was a significantly higher rate of hyperkalaemia, hypotension and kidney
dysfunction when compared to the placebo group.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Aliskiren was evaluated for cardiovascular
and/or renal benefit in a double blind placebo controlled randomised trial in
8,606&nbsp;patients with type 2 diabetes and chronic kidney disease (evidenced
by proteinuria and/or GFR &lt;60&nbsp;ml/min/</span><span lang=EN-GB>1.73&nbsp;m<sup>2</sup></span><span
lang=EN-GB>) with or without cardiovascular disease. In most patients arterial
blood pressure was well controlled at baseline. The primary endpoint was a
composite of cardiovascular and renal complications.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>In this study,
aliskiren 300&nbsp;mg was compared to placebo when added to standard of care
which included either an angiotensin converting enzyme inhibitor or an
angiotensin receptor blocker. The study was discontinued prematurely because
the participants were unlikely to benefit from aliskiren. Study results
indicated a hazard ratio for the primary endpoint of 1.11 in favour of placebo
(95% Confidence Interval: 1.00, 1.23, 2-sided p=0.05). In addition, an
increased incidence of </span><span lang=EN-GB>adverse events</span><span
lang=EN-GB> was observed with aliskiren compared to placebo </span><span
lang=EN-GB>(37.9% versus 30.2%). In particular there was an increased incidence
of</span><span lang=EN-GB> renal </span><span lang=EN-GB>dysfunction</span><span
lang=EN-GB> (14.0% versus 12.1%), hyperkalaemia (38.9% versus 28.8%),
hypotension</span><span lang=EN-GB>-related events</span><span lang=EN-GB>
(19.7% versus 16.2%) </span><span lang=EN-GB>and adjudicated stroke endpoints
(3.4% versus 2.6%). The increased incidence of stroke was greater in patients
with renal insufficiency.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Effects of aliskiren
on mortality and cardiovascular morbidity are currently unknown.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>No long-term
efficacy data for aliskiren in patients with heart failure are currently
available (see section&nbsp;4.4).</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Cardiac electrophysiology</span></i></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>No effect on
QT interval was reported in a randomised, double-blind, placebo, and
active-controlled study using standard and Holter electrocardiography.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Amlodipine</span></u></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>The
amlodipine component of Rasitrio inhibits the transmembrane entry of calcium
ions </span><span lang=EN-GB>into cardiac and vascular smooth muscle. The mechanism
of the antihypertensive action of amlodipine is due to a direct relaxant effect
on vascular smooth muscle, causing reductions in peripheral vascular resistance
and in blood pressure. Experimental data suggest that amlodipine binds to both
dihydropyridine and non-dihydropyridine binding sites.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>The
contractile processes of cardiac muscle and vascular smooth muscle are
dependent upon the movement of extracellular calcium ions into these cells
through specific ion channels.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Following
administration of therapeutic doses to patients with hypertension, amlodipine
produces vasodilatation resulting in a reduction of supine and standing blood
pressures. These decreases in blood pressure are not accompanied by a
significant change in heart rate or plasma catecholamine levels with chronic
dosing.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Plasma
concentrations correlate with effect in both young and elderly patients.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>In
hypertensive patients with normal renal function, therapeutic doses of
amlodipine resulted in a decrease in renal vascular resistance and an increase
in glomerular filtration rate and effective renal plasma flow without change in
filtration fraction or proteinuria.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>As
with other calcium channel blockers, haemodynamic measurements of cardiac
function at rest and during exercise (or pacing) in patients with normal
ventricular function treated with amlodipine have generally demonstrated a
small increase in cardiac index without significant influence on dP/dt or on
left ventricular end diastolic pressure or volume. In haemodynamic studies,
amlodipine has not been associated with a negative inotropic effect when
administered in the therapeutic dose range to intact animals and humans, even
when co-administered with beta blockers to humans.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Amlodipine does
not change sinoatrial nodal function or atrioventricular conduction in intact
animals or humans. In clinical studies in which amlodipine was administered in
combination with beta blockers to patients with either hypertension or angina, no
adverse effects on electrocardiographic parameters were observed.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoDate><span lang=EN-GB>Amlodipine has demonstrated beneficial
clinical effects in patients with chronic stable angina, vasospastic angina and
angiographically documented coronary artery disease.</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><i><span lang=EN-GB>Use in patients with heart failure</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Calcium channel blockers, including amlodipine, should be used with
caution in patients with congestive heart failure, as they may increase the
risk of future cardiovascular events and mortality.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><i><span lang=EN-GB>Use in patients with hypertension</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>A randomised
double-blind morbidity-mortality study called the Antihypertensive and
Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT) was performed
to compare newer therapies: amlodipine 2.5&#8209;10&nbsp;mg/day (calcium
channel blocker) or lisinopril 10&#8209;40&nbsp;mg/day (ACE-inhibitor) as
first-line therapies to that of the thiazide-diuretic, chlorthalidone 12.5&#8209;25&nbsp;mg/day
in mild to moderate hypertension.</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>A total of
33,357&nbsp;hypertensive patients aged 55 or older were randomised and followed
for a mean of 4.9&nbsp;years. The patients had at least one additional coronary
heart disease risk factor, including: previous myocardial infarction or stroke
(&gt;6&nbsp;months prior to enrollment) or documentation of other
atherosclerotic cardiovascular disease (overall 51.5%), type 2 diabetes
(36.1%), high density lipoprotein - cholesterol &lt;35&nbsp;mg/dl or
&lt;0.906&nbsp;mmol/l (11.6%), left ventricular hypertrophy diagnosed by
electrocardiogram or echocardiography (20.9%), current cigarette smoking
(21.9%).</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>The primary
endpoint was a composite of fatal coronary heart disease or non-fatal
myocardial infarction. There was no significant difference in the primary
endpoint between amlodipine-based therapy and chlorthalidone-based therapy:
risk ratio (RR) 0.98 95% CI (0.90&#8209;1.07) p=0.65. Among secondary
endpoints, the incidence of heart failure (component of a composite combined
cardiovascular endpoint) was significantly higher in the amlodipine group as
compared to the chlorthalidone group (10.2% vs. 7.7%, RR 1.38, 95% CI [1.25&#8209;1.52]
p&lt;0.001). However, there was no significant difference in all-cause
mortality between amlodipine-based therapy and chlorthalidone-based therapy RR
0.96 95% CI [0.89&#8209;1.02] p=0.20.</p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Hydrochlorothiazide</span></u></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>The
site of action of thiazide diuretics is primarily in the renal distal
convoluted tubule. It has been shown that there is a high-affinity receptor in
the renal cortex as the primary binding site for the thiazide diuretic action
and inhibition of NaCl transport in the distal convoluted tubule. The mode of
action of thiazides is through inhibition of the Na+Cl- symporter by competing
for the Cl- site, thereby affecting electrolyte reabsorption mechanisms:
directly increasing sodium and chloride excretion to an approximately equal
extent, and indirectly by this diuretic action reducing plasma volume, with
consequent increases in plasma renin activity, aldosterone secretion and
urinary potassium loss, and a decrease in serum potassium.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Paediatric population</span></u></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>The
European Medicines Agency has waived the obligation to submit the results of
studies with Rasitrio in all subsets of the paediatric population in essential
hypertension (see section&nbsp;4.2 for information on paediatric use).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5.2&nbsp;&nbsp;&nbsp;&nbsp; Pharmacokinetic
properties</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Aliskiren/amlodipine/hydrochlorothiazide combination</span></u></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Following
oral administration of a fixed combination tablet of aliskiren, amlodipine and
hydrochlorothiazide, peak concentrations were achieved for aliskiren within 1&#8209;2&nbsp;hours,
for amlodipine within 8&nbsp;hours and for hydrochlorothiazide within 2&#8209;3&nbsp;hours.
The rate and extent of absorption of aliskiren, amlodipine and
hydrochlorothiazide following administration of a fixed combination tablet are
similar to when administered as individual dosage forms.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>The
results from a food effect study using a </span><span lang=EN-GB>standard </span><span
lang=EN-GB>high-fat meal</span><span lang=EN-GB> with the 300/10/25&nbsp;mg
fixed combination tablet showed that food </span><span lang=EN-GB>reduced the
rate and extent of absorption of aliskiren in the fixed combination tablet with
a similar magnitude of effect as for aliskiren monotherapy. Food had no effect </span><span
lang=EN-GB>on the pharmacokinetics of amlodipine or hydrochlorothiazide in the
fixed combination tablet.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Aliskiren</span></u></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Absorption</span></i></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Following oral
absorption, peak plasma concentrations of aliskiren are reached after 1&#8209;3&nbsp;hours.
The absolute bioavailability of aliskiren is approximately 2&#8209;3%. Meals
with a high fat content reduce C<sub>max</sub> by 85% and AUC by 70%. At steady
state meals with low fat content reduce C<sub>max</sub> by 76% and AUC <sub>0-tau</sub>
by 67% in hypertensive patients. Steady-state plasma concentrations are reached
within 5&#8209;7&nbsp;days following once-daily administration and steady-state
levels are approximately 2-fold greater than with the initial dose.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Distribution</span></i></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Following
intravenous administration, the mean volume of distribution at steady state is
approximately 135&nbsp;litres, indicating that aliskiren distributes
extensively into the extravascular space. Aliskiren plasma protein binding is
moderate (47&#8209;51%) and independent of the concentration.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Biotransformation and elimination</span></i></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>The mean
half-life is about 40&nbsp;hours (range 34&#8209;41&nbsp;hours). Aliskiren is
mainly eliminated as unchanged compound in the faeces (78%). Approximately 1.4%
of the total oral dose is metabolised. The enzyme responsible for this
metabolism is CYP3A4. Approximately 0.6% of the dose is recovered in urine
following oral administration. Following intravenous administration, mean
plasma clearance is approximately 9&nbsp;l/h.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Linearity</span></i></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Exposure to
aliskiren increased more than in proportion to the increase in dose. After
single dose administration in the dose range of 75 to 600&nbsp;mg, a 2-fold
increase in dose results in a ~2.3 and 2.6-fold increase in AUC and C<sub>max</sub>,
respectively. At steady state the non-linearity may be more pronounced.
Mechanisms responsible for deviation from linearity have not been identified. A
possible mechanism is saturation of transporters at the absorption site or at
the hepatobiliary clearance route.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><i><span lang=EN-GB>Paediatric
population</span></i></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>In
a pharmacokinetic study of aliskiren treatment in 39 paediatric hypertensive
patients (aged 6&#8209;17&nbsp;years) given daily doses of 2&nbsp;mg/kg or
6&nbsp;mg/kg aliskiren administered as granules (3.125&nbsp;mg/tablet),
pharmacokinetic parameters were similar to those in adults. The available data
did not suggest that age, body weight or gender have any significant effect on
aliskiren systemic exposure (see section 4.2).</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Amlodipine</span></u></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Absorption</span></i></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>After oral
administration of therapeutic doses of amlodipine alone, peak plasma
concentrations of amlodipine are reached in 6&#8209;12&nbsp;hours. Absolute
bioavailability has been </span><span style='font-size:11.0pt;color:windowtext'>estima</span><span
style='font-size:11.0pt;color:windowtext'>ted as between 64% and 80%.
Amlodipine bioavailability is unaffected by food ingestion.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Distribution</span></i></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>The volume of
distribution is approximately 21&nbsp;l/kg. <i>In vitro </i>studies with
amlodipine have shown that approximately 97.5% of circulating amlodipine is
bound to plasma proteins.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Biotransformation and elimination</span></i></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Amlodipine
is extensively (approximately 90%) metabolised in the liver to inactive
metabolites, with 10% of the parent compound and 60% of the metabolites
excreted in the urine.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Amlodipine
elimination from plasma is biphasic with a terminal elimination half-life of
approximately 30 to 50&nbsp;hours. Steady-state plasma levels are reached after
continuous administration for 7&#8209;8&nbsp;days.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Linearity</span></i></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Amlodipine
exhibits linear pharmacokinetics between </span><span lang=EN-GB>the
therapeutic dose range of </span><span lang=EN-GB>5&nbsp;mg and 10&nbsp;mg</span><span
lang=EN-GB>.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Hydrochlorothiazide</span></u></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Absorption</span></i></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>The absorption of hydrochlorothiazide, after an oral dose, is rapid
(T<sub>max</sub> about 2&nbsp;h.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>The effect of food on hydrochlorothiazide absorption, if any, has
little clinical significance. Absolute bioavailability of hydrochlorothiazide
is 70% after oral administration.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Distribution</span></i></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>The apparent volume of distribution is 4&#8209;8&nbsp;l/kg.
Circulating hydrochlorothiazide is bound to serum proteins (40&#8209;70%),
mainly serum albumin. Hydrochlorothiazide also accumulates in erythrocytes at
approximately 3&nbsp;times the level in plasma.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Biotransformation and elimination</span></i></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Hydrochlorothiazide is eliminated predominantly as unchanged
compound. Hydrochlorothiazide is eliminated from plasma with a half-life
averaging 6 to 15&nbsp;hours in the terminal elimination phase. There is no
change in the kinetics of hydrochlorothiazide on repeated dosing, and accumulation
is minimal when dosed once daily. There is more than 95% of the absorbed dose
being excreted as unchanged compound in the urine. The renal clearance is
composed of passive filtration and active secretion into the renal tubule.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Linearity</span></i></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>The increase in mean AUC is linear and dose proportional in the
therapeutic range.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Special populations</span></u></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Rasitrio is an
effective once-a-day antihypertensive treatment in adult patients, regardless
of gender, age, body mass index and ethnicity.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Renal impairment</span></i></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Due
to its hydrochlorothiazide component, Rasitrio is contraindicated in patients
with anuria or severe renal impairment (GFR &lt;30&nbsp;ml/min/1.73&nbsp;m<sup>2</sup>)
(see section&nbsp;4.3). No adjustment of the initial dose is required in
patients with mild to moderate renal impairment (see sections&nbsp;4.4 and
4.2).</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>The
pharmacokinetics of aliskiren were evaluated in patients with varying degrees
of renal insufficiency. Relative AUC and C<sub>max</sub> of aliskiren in
subjects with renal impairment ranged between 0.8 to 2&nbsp;times the levels in
healthy subjects following single dose administration and at steady state.
These observed changes, however, did not correlate with the severity of renal
impairment. No adjustment of the initial dose of aliskiren is required in
patients with mild to moderate renal impairment (see sections&nbsp;4.2 and
4.4). Aliskiren is not recommended in patients with severe renal impairment
(glomerular filtration rate (GFR) &lt;30&nbsp;ml/min/</span><span
style='font-size:11.0pt;color:windowtext'>1.73&nbsp;m<sup>2</sup></span><span
style='font-size:11.0pt;color:windowtext'>). Concomitant use of aliskiren with
ARBs or ACEIs is contraindicated in patients with renal impairment (GFR
&lt;60&nbsp;ml/min/</span><span style='font-size:11.0pt;color:windowtext'>1.73&nbsp;m<sup>2</sup></span><span
style='font-size:11.0pt;color:windowtext'>) (see section&nbsp;4.3).</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>The
pharmacokinetics of aliskiren were evaluated</span><span lang=EN-GB> in
patients with end stage renal disease receiving haemodialysis. Administration
of a single oral dose of 300&nbsp;mg aliskiren was associated with very minor
changes in the pharmacokinetics of aliskiren (change in C<sub>max</sub> of less
than 1.2&nbsp;fold; increase in AUC of up to 1.6&nbsp;fold) compared to matched
healthy subjects. Timing of haemodialysis did not significantly alter the
pharmacokinetics of aliskiren in ESRD patients. Therefore,<b><i> </i></b>if
administration of aliskiren in ESRD patients receiving haemodialysis is
considered necessary, no dose adjustment is warranted in these patients.
However, the use of aliskiren is not recommended in patients with severe renal
impairment (see section&nbsp;4.4).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The pharmacokinetics of amlodipine are not significantly influenced
by renal impairment.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>As
expected for a compound which is cleared almost exclusively via the kidneys,
renal function has a marked effect on the kinetics of hydrochlorothiazide. In
the presence of renal impairment, mean peak plasma levels and AUC values of
hydrochlorothiazide are increased and the urinary excretion rate is reduced. In
patients with mild to moderate renal impairment, a 3-fold increase in
hydrochlorothiazide AUC has been observed. In patients with severe renal
impairment an 8-fold increase in AUC has been observed.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Hepatic impairment</span></i></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Rasitrio is
contraindicated in patients with severe hepatic impairment (see section&nbsp;4.3).</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>The
pharmacokinetics of aliskiren were not significantly affected in patients with
mild to severe liver disease. Consequently, no adjustment of the initial dose
of aliskiren is required in patients with mild to moderate hepatic impairment.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Very limited clinical data are available regarding amlodipine
administration in patients with hepatic impairment. Patients with hepatic
insufficiency have decreased clearance of amlodipine with resulting increase in
AUC of approximately 40&#8209;60%. Therefore caution should be exercised</span><span
lang=EN-GB> in patients with hepatic impairment.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Geriatric patients</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No data are
available on systemic exposure after administration of Rasitrio in geriatric
patients. When administered alone, the AUC of aliskiren in geriatric subjects
(&gt;65&nbsp;years) is 50% higher than in young subjects. The time to reach
peak plasma concentrations of amlodipine is similar in elderly and younger
subjects. Amlodipine clearance tends to be decreased with resulting increases
in AUC and elimination half-life in geriatric patients. </span><span
lang=EN-GB>Therefore particular caution is recommended when administering
Rasitrio to patients aged 65&nbsp;years and over, and extreme caution in
patients aged 75&nbsp;years or older (see sections&nbsp;4.2, 4.4, 4.8 and 5.1).</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Limited
data suggest that the systemic clearance of hydrochlorothiazide is reduced in
both healthy and hypertensive elderly subjects compared to young healthy
volunteers. There are no specific data regarding the effect of
hydrochlorothiazide in elderly patients.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Paediatric </span></i><i><span style='font-size:11.0pt;
color:windowtext'>population (age below 18&nbsp;years)</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The pharmacokinetics of Rasitrio have not been investigated. A
population pharmacokinetic study has been conducted in 74 hypertensive children
aged from 1 to 17&nbsp;years (with 34&nbsp;patients aged 6 to 12&nbsp;years and
28&nbsp;patients aged 13 to 17&nbsp;years) receiving amlodipine between 1.25
and 20&nbsp;mg given either once or twice daily. In children 6 to 12&nbsp;years
and in adolescents 13&#8209;17&nbsp;years of age the typical oral clearance
(CL/F) was 22.5 and 27.4&nbsp;l/hr respectively in males and 16.4 and
21.3&nbsp;l/hr respectively in females. Large variability in exposure between
individuals was observed. Data reported in children below 6&nbsp;years are
limited.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5.3&nbsp;&nbsp;&nbsp;&nbsp; Preclinical
safety data</span></b></p>

<p class=Text style='margin-bottom:0in;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Aliskiren/hydrochlorothiazide and aliskiren/amlodipine</span></u></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Non-clinical
studies of the toxicology of Rasitrio alone have not been conducted as these
studies have been conducted for the individual components.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>The
toxicity profiles of the combination of aliskiren/hydrochlorothiazide and
aliskiren/amlodipine have been well characterised in preclinical studies. Both
combinations were generally well tolerated by rats. The findings from 2- and
13-week oral toxicity studies were consistent with those for the individual
components.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Aliskiren</span></u></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Carcinogenic
potential was assessed in a 2-year rat study and a 6-month transgenic mouse
study. No carcinogenic potential was detected. One colonic adenoma and one
caecal adenocarcinoma recorded in rats at the dose of 1,500&nbsp;mg/kg/day were
not statistically significant. Although aliskiren has known irritation
potential, safety margins obtained in humans at the dose of 300&nbsp;mg during
a study in healthy volunteers were considered to be appropriate at 9&#8209;11-fold
based on faecal concentrations or 6-fold based on mucosa concentrations in
comparison with 250&nbsp;mg/kg/day in the rat carcinogenicity study.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Aliskiren was
devoid of any mutagenic potential in the <i>in vitro </i>and <i>in vivo </i>mutagenicity
studies. The assays included <i>in vitro </i>assays in bacterial and mammalian
cells and <i>in vivo </i>assessments in rats.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Reproductive
toxicity studies with aliskiren did not reveal any evidence of embryofoetal
toxicity or teratogenicity at doses up to 600&nbsp;mg/kg/day in rats or
100&nbsp;mg/kg/day in rabbits. Fertility, pre-natal development and post-natal
development were unaffected in rats at doses up to 250&nbsp;mg/kg/day. The
doses in rats and rabbits provided systemic exposures of 1 to 4 and
5&nbsp;times higher, respectively, than the maximum recommended human dose
(300&nbsp;mg).</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Safety
pharmacology studies did not reveal any adverse effects on central nervous,
respiratory or cardiovascular function. Findings during repeat-dose toxicity
studies in animals were consistent with the known local irritation potential or
the expected pharmacological effects of aliskiren.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Amlodipine</span></u></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Safety
data for amlodipine are well established both clinically and non-clinically.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Reproductive
toxicology</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Reproductive
studies in rats and mice have shown delayed date of delivery, prolonged
duration of labour and decreased pup survival at dosages approximately
50&nbsp;times greater than the maximum recommended dosage for humans based on
mg/kg.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Impairment of
fertility</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>There was no
effect on the fertility of rats treated with amlodipine (males for 64&nbsp;days
and females 14&nbsp;days prior to mating) at doses up to 10&nbsp;mg/kg/day
(8&nbsp;times* the maximum recommended human dose of 10&nbsp;mg on a mg/m<sup>2</sup>
basis). In another rat study in which male rats were treated with amlodipine
besilate for 30&nbsp;days at a dose comparable with the human dose based on
mg/kg, decreased plasma follicle-stimulating hormone and testosterone were
found as well as decreases in sperm density and in the number of mature
spermatids and Sertoli cells.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Carcinogenesis,
mutagenesis</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Rats and mice
treated with amlodipine in the diet for two years, at concentrations calculated
to provide daily dosage levels of 0.5, 1.25 and 2.5&nbsp;mg/kg/day showed no
evidence of carcinogenicity. The highest dose (for mice, similar to, and for
rats twice* the maximum recommended clinical dose of 10&nbsp;mg on a mg/m<sup>2</sup>
basis) was close to the maximum tolerated dose for mice but not for rats.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Mutagenicity
studies revealed no effects related to the medicinal product at either the gene
or chromosome levels.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>*Based on
patient weight of 50&nbsp;kg</span></p>

<p class=Default><u><span lang=EN-GB style='font-size:11.0pt;color:windowtext'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Hydrochlorothiazide</span></u></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Preclinical
evaluations to support the administration of hydrochlorothiazide in humans
included <i>in vitro</i> genotoxicity assays and reproductive toxicity and
carcinogenicity studies in rodents. Extensive clinical data are available for
hydrochlorothiazide and these are reflected in the relevant sections.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Hydrochlorothiazide
had no adverse effects on the fertility of mice and rats of either sex in
studies wherein these species were exposed, via their diet, to doses of up to
100 and 4&nbsp;mg/kg,/day respectively, prior to mating and throughout
gestation. These doses of hydrochlorothiazide in mice and rats represent 19 and
1.5&nbsp;times, respectively, the maximum recommended human dose on a mg/m<sup>2</sup>
basis. (Calculations assume an oral dose of 25&nbsp;mg/day and a 60-kg
patient.)</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
PARTICULARS</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.1&nbsp;&nbsp;&nbsp;&nbsp; List
of excipients</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Tablet core</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=IT>Cellulose microcrystalline</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=IT>Crospovidone</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=IT>Povidone</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=IT>Magnesium stearate</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=IT>Silica colloidal anhydrous</span></p>

<p class=MsoDate><span lang=IT>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><u><span lang=IT
style='font-size:11.0pt;color:windowtext'>Coating</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=IT>Hypromellose</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=IT>Titanium dioxide (E171)</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=ES>Macrogol</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=ES>Talc</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=ES>Iron oxide red (E172)</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Iron oxide black (E172)</span></p>

<p class=MsoDate><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b>6.2&nbsp;&nbsp;&nbsp;&nbsp; Incompatibilities</b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Not applicable.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.3&nbsp;&nbsp;&nbsp;&nbsp; Shelf
life</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>PVC/polychlorotrifluoroethylene (PCTFE) </span>&#8211;<span
lang=EN-GB> Alu calendar blisters:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>2&nbsp;years</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>PVC/polychlorotrifluoroethylene (PCTFE) </span>&#8211; <span
lang=EN-GB>Alu blisters:</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>2&nbsp;years</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'>PA/Alu/PVC
&#8211; Alu calendar blisters:</p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>18&nbsp;months</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.4&nbsp;&nbsp;&nbsp;&nbsp; Special
precautions for storage</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'>Do not store above 30&deg;C.</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'>Store in the original package in order to protect from moisture and light.</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.5&nbsp;&nbsp;&nbsp;&nbsp; Nature
and contents of container</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>PVC/polychlorotrifluoroethylene (PCTFE) - Alu calendar blisters:</span></p>

<p class=MsoDate>Single pack containing 14, 28, 56, 98&nbsp;tablets</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>PVC/polychlorotrifluoroethylene (PCTFE) - Alu blisters:</span></p>

<p class=MsoDate style='page-break-after:avoid'>Single pack containing 30,
90&nbsp;tablets</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'>Unit dose
pack (perforated unit dose blister) containing 56x1&nbsp;tablet</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>Multipacks of
unit dose (perforated unit dose blister) containing 98x1&nbsp;tablet (2&nbsp;packs
of 49x1)</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=ES>PA/Alu/PVC &#8211; Alu calendar blisters:</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'>Single pack containing 14, 28, 56&nbsp;tablets</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>Multipacks
containing 98&nbsp;tablets (2&nbsp;packs of 49)</p>

<p class=MsoDate>&nbsp;</p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Not
all pack sizes may be marketed.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.6&nbsp;&nbsp;&nbsp;&nbsp; Special
precautions for disposal</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Any unused medicinal product or waste material should be disposed of
in accordance with local requirements.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION HOLDER</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'>Novartis Europharm Limited</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'>Wimblehurst Road</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'>Horsham</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'>West Sussex, RH12 5AB</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>United
Kingdom</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'>EU/1/11/730/001&#8209;012</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; DATE
OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Date of first
authorisation: </span><span lang=EN-GB>22 November 2011</span></p>

<p class=MsoDate><span lang=EN-GB>Date of latest renewal:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>10.&nbsp;&nbsp;&nbsp;&nbsp; DATE
OF REVISION OF THE TEXT</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:28.3pt;line-height:normal'><span
lang=EN-GB>Detailed information on this medicinal product is available on the
website of the European Medicines Agency http://www.ema.europa.eu</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Rasitrio
300&nbsp;mg/5&nbsp;mg/12.5&nbsp;mg film-coated tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; QUALITATIVE
 AND QUANTITATIVE COMPOSITION</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each film-coated
tablet contains 300&nbsp;mg aliskiren (as hemifumarate), 5&nbsp;mg amlodipine
(as besylate) and 12.5&nbsp;mg hydrochlorothiazide.</span></p>

<p class=MsoDate><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For the full
list of excipients, see section&nbsp;6.1.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
<span style='text-transform:uppercase'>form</span></span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Film-coated tablet.</span></p>

<p class=MsoDate style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Light pink,
ovaloid convex film-coated tablet with bevelled edges, with &#8220;LIL&#8221;
debossed on one side and &#8220;NVR&#8221; on the other.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB style='text-transform:uppercase'>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Clinical
particulars</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.1&nbsp;&nbsp;&nbsp;&nbsp; Therapeutic
indications</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Rasitrio is
indicated for the treatment of essential hypertension as substitution therapy
in adult patients whose blood pressure is adequately controlled on the
combination of aliskiren, amlodipine and hydrochlorothiazide given concurrently
at the same dose level as in the combination.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.2&nbsp;&nbsp;&nbsp;&nbsp; Posology
and method of administration</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><u><span lang=EN-GB>Posology</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The recommended dose of Rasitrio is one tablet per day.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Patients
receiving aliskiren, amlodipine and hydrochlorothiazide from separate tablets
given concurrently at the same time of the day may be switched to a fixed
combination tablet of Rasitrio containing the same component doses.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The fixed dose
combination should only be used after a stable effect on the monocomponents, </span><span
lang=HU>given concurrently,<b> </b></span><span lang=EN-GB>has been established
after dose titration. Dose should be individualised and adjusted according to
the patient&#8217;s clinical response.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><u><span lang=EN-GB>Special populations</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Elderly patients aged 65&nbsp;years and over</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>There is
evidence of an increased risk of adverse events related to hypotension in
patients aged 65&nbsp;years or older treated with Rasitrio. Therefore,
particular caution should be exercised when administering Rasitrio in patients
aged 65&nbsp;years or over.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The recommended
starting dose of aliskiren in this group of patients is 150&nbsp;mg. No
clinically meaningful additional blood pressure reduction is observed by
increasing the dose to 300&nbsp;mg in the majority of elderly patients.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Elderly patients aged 75&nbsp;years and over</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Very limited data are available on the use of Rasitrio in patients
aged 75&nbsp;years or older (see section&nbsp;5.2). The use of Rasitrio in
patients aged 75&nbsp;years or older should be restricted to patients for whom
blood pressure control has been established for the free combination of
aliskiren, amlodipine and hydrochlorothiazide </span><span lang=EN-GB>given
concurrently</span><span lang=EN-GB> without accompanying safety concerns, in
particular hypotension. Extreme caution, including more frequent monitoring of
blood pressure, is recommended (see sections&nbsp;4.4, 4.8, 5.1 and 5.2)</span><span
style='font-family:"TimesNewRomanPSMT",serif'>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Renal impairment</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No adjustment of
the initial dose is required for patients with mild to moderate renal impairment
(</span><span lang=EN-GB>estimated </span><span lang=EN-GB>glomerular
filtration rate</span><span lang=EN-GB> (GFR) 89&#8209;60&nbsp;ml/min/1.73&nbsp;m<sup>2</sup>
and 59&#8209;30&nbsp;ml/min/1.73&nbsp;m<sup>2</sup>, respectively) (see
sections&nbsp;4.4 and 5.2). Due to the hydrochlorothiazide component, </span><span
lang=EN-GB>Rasitrio is contraindicated for use in patients with anuria and in
patients with severe renal impairment (GFR &lt;30&nbsp;ml/min/1.73&nbsp;m<sup>2</sup>).
The </span><span lang=EN-GB>c</span><span lang=EN-GB>oncomitant use of Rasitrio
with angiotensin II receptor blockers (ARB) or angiotensin converting enzyme
inhibitors (ACEI) is contraindicated in patients with renal impairment (GFR
&lt;60&nbsp;ml/min/</span><span lang=EN-GB>1.73&nbsp;m<sup>2</sup></span><span
lang=EN-GB>) (see sections&nbsp;4.3, 4.4 and 5.2).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Hepatic impairment</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Rasitrio is
contraindicated in patients with severe hepatic impairment. Caution</span>
should be exercised when administering Rasitrio i<span lang=EN-GB>n </span>patients
with mild to moderate hepatic impairment or patients with progressive liver
disease. No dosage recommendations have been established for amlodipine in
patients with mild to moderate hepatic impairment <span lang=EN-GB>(see
sections&nbsp;4.3 and 4.4).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Paediatric population</span></i></p>

<p class=MsoNormal style='line-height:normal'>The safety and efficacy of
Rasitrio in children and adolescents below age&nbsp;18 have not been
established. No data are available.</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><u><span lang=EN-GB>Method of administration</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Oral use. The
tablets should be swallowed whole with some water. Rasitrio should be taken
with a light meal once a day, preferably at the same time each day. Grapefruit
juice should not be taken together with Rasitrio (see section&nbsp;4.5).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b>4.3&nbsp;&nbsp;&nbsp;&nbsp; Contraindications</b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Hypersensitivity to the active substances or to
any of the excipients listed in section&nbsp;6.1, to other dihydropyridine
derivatives, or to other sulphonamide-derived substances.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>History of angioedema with aliskiren.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Hereditary or idiopathic angioedema.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Second and third trimesters of pregnancy (see
section&nbsp;4.6).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Anuria.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Severe renal impairment (GFR
&lt;30&nbsp;ml/min/1.73&nbsp;m<sup>2</sup>).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Hyponatraemia, hypercalcaemia, symptomatic
hyperuricaemia and refractory hypokalaemia.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Severe hepatic impairment.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The concomitant use of aliskiren with
ciclosporin and itraconazole, two highly potent P-glycoprotein (P-gp)
inhibitors, and other potent P-gp inhibitors (e.g. quinidine), is contraindicated
(see section&nbsp;4.5).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The concomitant use of aliskiren with ARBs or
ACEIs is contraindicated in patients with diabetes mellitus or renal impairment
(GFR &lt;60&nbsp;ml/min/</span><span lang=EN-GB>1.73&nbsp;m<sup>2</sup></span><span
lang=EN-GB>) (see sections&nbsp;4.2, 4.4, 4.5 and 5.1).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Severe hypotension.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Shock (including cardiogenic shock).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Obstruction of the outflow tract of the left
ventricle (e.g. high grade aortic stenosis).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Haemodynamically unstable heart failure after
acute myocardial infarction.</span></p>

<p class=MsoNormal style='line-height:normal;vertical-align:baseline'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.4&nbsp;&nbsp;&nbsp;&nbsp; Special
warnings and precautions for use</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>General</span></u></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>In the event
of severe and persistent diarrhoea, Rasitrio therapy should be stopped (see
section&nbsp;4.8).</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>As with any
antihypertensive medicinal product, excessive reduction of blood pressure in
patients with ischaemic cardiopathy or ischaemic cardiovascular disease could
result in a myocardial infarction or stroke.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Symptomatic
hypotension occurred with higher frequency in patients with non-complicated
hypertension treated with Rasitrio than in patients treated with dual
combinations of aliskiren/amlodipine, aliskiren/hydrochlorothiazide or
amlodipine/hydrochlorothiazide.</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Hypersensitivity
reactions to hydrochlorothiazide may occur in patients, but are more likely in
patients with allergy and asthma.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Systemic
lupus erythematosus</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Thiazide
diuretics, including hydrochlorothiazide, have been reported to exacerbate or
activate systemic lupus erythematosus.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The safety and
efficacy of amlodipine in hypertensive crisis have not been established.</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Dual blockade
of the renin-angiotensin-aldosterone system (RAAS)</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Hypotension,
syncope, stroke, hyperkalaemia, and changes in renal function (including acute
renal failure) have been reported in susceptible individuals, especially if
combining medicinal products that affect this system (see section</span><span
lang=EN-GB>&nbsp;</span><span lang=EN-GB>5.1). Dual blockade of the
renin-angiotensin-aldosterone system by combining aliskiren with an angiotensin
converting enzyme inhibitor (ACEI) or an angiotensin II receptor blocker (ARB)
is therefore not recommended. Close monitoring of blood pressure, renal
function and electrolytes should be exercised if co-administration is
considered absolutely necessary.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>T</span><span
lang=EN-GB>he use of</span><span lang=EN-GB> aliskiren in combination with ARBs
or ACEIs is contraindicated in patients with diabetes mellitus or renal
impairment (GFR &lt;60&nbsp;ml/min</span><span lang=EN-GB>/1.73&nbsp;m<sup>2</sup></span><span
lang=EN-GB>) (see section&nbsp;4.3)</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Geriatric
patients aged 65&nbsp;years and over</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Particular caution should be exercised when administering Rasitrio
in patients aged 65&nbsp;years or older. Symptomatic hypotension occurred with
higher frequency in patients with non-complicated hypertension treated with
Rasitrio than in patients treated with dual combinations of
aliskiren/amlodipine, aliskiren/hydrochlorothiazide or
amlodipine/hydrochlorothiazide. Patients aged 65&nbsp;years old or over, are
more susceptible to hypotension-related adverse reactions following treatment
with Rasitrio (see sections&nbsp;4.2, 4.8, 5.1 and 5.2).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Geriatric patients aged 75&nbsp;years and over</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Very limited efficacy and safety data are available on the use of
Rasitrio in patients aged 75&nbsp;years or older. Extreme caution, </span>including
more frequent monitoring of blood pressure, is recommended<span lang=EN-GB>
(see sections&nbsp;4.2, 4.8, 5.1 and 5.2).</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Heart failure</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Calcium channel
blockers, including amlodipine, should be used with caution in patients with
congestive heart failure, as they may increase the risk of future
cardiovascular events and mortality.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>No data on
cardiovascular mortality and morbidity are available for Rasitrio in patients
with heart failure (see section&nbsp;5.1).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Aliskiren should
be used with caution in patients with heart failure treated with furosemide
(see section&nbsp;4.5).</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Risk of symptomatic hypotension</span></u></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Symptomatic
hypotension could occur after initiation of treatment with Rasitrio Rasitrio in
the following cases:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>Patients with marked volume depletion or patients with salt
depletion <span lang=EN-GB>(e.g. those receiving high doses of diuretics) </span>or</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>Combined use of aliskiren with other agents acting on the RAAS.</p>

<p class=Default><span style='font-size:11.0pt'>The volume or salt depletion
should be corrected prior to administration of Rasitrio, or the treatment
should start under close medical supervision.</span></p>

<p style='margin:0in'><u><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Electrolyte imbalance</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Treatment with
Rasitrio should only start after correction of hypokalaemia and any coexisting
hypomagnesaemia. Thiazide diuretics can precipitate new onset hypokalaemia or
exacerbate pre-existing hypokalaemia. Thiazide diuretics should be administered
with caution in patients with conditions involving enhanced potassium loss, for
example salt-losing nephropathies and prerenal (cardiogenic) impairment of
kidney function. </span><span lang=EN-GB>If hypokalaemia develops during
hydrochlorothiazide therapy Rasitrio should be discontinued until stable
correction of the potassium balance.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'>Hypokalaemia may develop with the
use of thiazide diuretics. The risk of hypokalaemia is greater in patients with
cirrhosis of the liver, patients experiencing brisk diuresis, patients with
inadequate oral electrolyte intake and patients receiving concomitant therapy
with corticosteroids or adrenocorticotropic hormone (ACTH) (see
sections&nbsp;4.5 and 4.8).</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal><span lang=EN-GB>Conversely, </span><span lang=EN-GB>increases
in serum potassium have been observed with aliskiren in post-marketing
experience and these may be exacerbated by concomitant use of other agents
acting on the RAAS or by non-steroidal anti-inflammatory drugs (NSAIDs).
Consistent with standard medical practice, periodic determination of renal
function including serum electrolytes is advised if co-administration is
considered necessary. The concomitant use of aliskiren and ACEIs or ARBs is
contraindicated in patients with diabetes mellitus or renal impairment (GFR
&lt;60&nbsp;ml/min</span><span lang=EN-GB>/1.73&nbsp;m<sup>2</sup></span><span
lang=EN-GB>) (see section</span><span lang=EN-GB>&nbsp;</span><span lang=EN-GB>4.3,
4.5 and 4.8).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoDate><span lang=EN-GB>Thiazide diuretics can precipitate new onset
hyponatraemia and hypochloroaemic alkalosis or exacerbate pre-existing
hyponatraemia. Hyponatraemia, accompanied by neurological symptoms (nausea,
progressive disorientation, apathy) has been observed. Treatment with
hydrochlorothiazide should only be started after correction of pre-existing
hyponatraemia. In case severe or rapid hyponatraemia develops during Rasitrio
therapy, the treatment should be discontinued until normalisation of natraemia.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>All patients receiving thiazide diuretics
should be periodically monitored for imbalances in electrolytes, particularly
potassium, sodium and magnesium.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Thiazides
reduce urinary calcium excretion and may cause an intermittent and slight
elevation of serum calcium in the absence of known disorders of calcium
metabolism. Rasitrio is contraindicated in patients with hypercalcaemia and
should only be used after correction of any pre-existing hypercalcaemia.
Rasitrio should be discontinued if hypercalcaemia develops during treatment.
Serum levels of calcium should be periodically monitored during treatment with
thiazides. Marked hypercalcaemia may be evidence of hidden hyperparathyroidism.
Thiazides should be discontinued before carrying out tests for parathyroid
function.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>There is no
evidence that Rasitrio would reduce or prevent diuretic-induced hyponatraemia.
Chloride deficit is generally mild and usually does not require treatment.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Renal impairment and kidney transplantation</span></u></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Thiazide
diuretics may precipitate azotaemia in patients with chronic kidney disease.
When Rasitrio is used in patients with renal impairment, periodic monitoring of
serum electrolytes including potassium, creatinine and uric acid serum levels
is recommended. No data is available in hypertensive patients with severe renal
impairment (serum creatinine &#8805;150&nbsp;&#956;mol/l or 1.70&nbsp;mg/dl in
women and &#8805;177&nbsp;&#956;mol/l or 2.00&nbsp;mg/dl in men and/or
estimated glomerular filtration rate (GFR) &lt;30&nbsp;ml/min/</span><span
style='font-size:11.0pt;color:windowtext'>1.73&nbsp;m<sup>2</sup></span><span
style='font-size:11.0pt;color:windowtext'>), history of dialysis, nephrotic
syndrome or renovascular hypertension. Rasitrio is contraindicated in
hypertensive patients with severe renal impairment (GFR &lt;30&nbsp;ml/min/</span><span
style='font-size:11.0pt;color:windowtext'>1.73&nbsp;m<sup>2</sup></span><span
style='font-size:11.0pt;color:windowtext'>) or anuria (see sections&nbsp;4.2.
and 4.3). No dose adjustment is necessary in patients with mild to moderate
renal impairment.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>As for other
medicinal products acting on the RAAS, caution should be exercised when
Rasitrio is given in the presence of conditions pre-disposing to kidney
dysfunction such as hypovolaemia (e.g. due to blood loss, severe or prolonged
diarrhoea, prolonged vomiting, etc.), heart disease, liver disease, diabetes
mellitus or kidney disease. The concomitant use of aliskiren and ACEIs or ARBs
is contraindicated in patients with renal impairment (GFR
&lt;&nbsp;60&nbsp;ml/min/</span><span style='font-size:11.0pt;color:windowtext'>1.73&nbsp;m<sup>2</sup></span><span
style='font-size:11.0pt;color:windowtext'>). Acute renal failure, reversible
upon discontinuation of treatment, has been reported in at-risk patients
receiving aliskiren in post-marketing experience. In the event that any signs
of renal failure occur, aliskiren should be promptly discontinued.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>There is no
experience regarding the administration of Rasitrio in patients who have recently
undergone kidney transplantation, therefore caution should be exercised in
these patients.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Hepatic impairment</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Rasitrio is
contraindicated in hypertensive patients with severe hepatic impairment (see
sections&nbsp;4.3 and 5.2). Caution should be exercised when administering
Rasitrio to patients with mild to moderate hepatic impairment or progressive
liver disease (see sections&nbsp;4.2 and 5.2).</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The half life of
amlodipine is prolonged and AUC values are higher in patients with impaired
liver function; dosage recommendations have not been established.</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Aortic and mitral valve stenosis, obstructive hypertrophic
cardiomyopathy</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>As with all
other vasodilators, special caution is indicated when using amlodipine in
patients suffering from aortic or mitral stenosis, or obstructive hypertrophic
cardiomyopathy.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Metabolic and endocrine effects</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Thiazide
diuretics, including hydrochlorothiazide, may alter glucose tolerance and raise
serum levels of cholesterol and triglycerides, and uric acid. In diabetic
patients dose adjustments of insulin or oral hypoglycaemic medicinal products
may be required during Rasitrio therapy. </span><span lang=EN-GB>C</span><span
lang=EN-GB>oncomitant use of Rasitrio with ARBs or ACEIs is contraindicated in
patients with diabetes mellitus (see section&nbsp;4.3).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Due to the hydrochlorothiazide component,
Rasitrio is contraindicated in symptomatic hyperuricaemia (see
section&nbsp;4.3). </span><span lang=EN-GB>Hydrochlorothiazide may raise the
serum uric acid level due to reduced clearance of uric acid and may cause or
exacerbate hyperuricaemia as well as precipitate gout in susceptible patients.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Thiazides reduce
urinary calcium excretion and may cause an intermittent and slight elevation of
serum calcium in the absence of known disorders of calcium metabolism. Rasitrio
is contraindicated in patients with hypercalcaemia and should only be used
after correction of any pre-existing hypercalcaemia. Rasitrio should be
discontinued if hypercalcaemia develops during treatment. Serum levels of
calcium should be periodically monitored during treatment with thiazides.
Marked hypercalcaemia may be evidence of hidden hyperparathyroidism. Thiazides
should be discontinued before carrying out tests for parathyroid function.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Renal artery stenosis</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No controlled
clinical data are available on the use of Rasitrio in patients with unilateral
or bilateral renal artery stenosis, or stenosis to a solitary kidney. However,
as with other medicinal products acting on the renin-angiotensin-aldosterone
system, there is an increased risk of renal insufficiency, including acute
renal failure, when patients with renal artery stenosis are treated with
aliskiren. Therefore caution should be exercised in these patients. If renal
failure occurs, treatment should be discontinued.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Anaphylactic reactions and angioedema</span></u></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Anaphylactic
reactions have been observed during treatment with aliskiren from
post-marketing experience (see section&nbsp;4.8). As with other medicinal
products acting on the renin-angiotensin-aldosterone system (RAAS), angioedema
or symptoms suggestive of angioedema (swelling of the face, lips, throat and/or
tongue) have been reported in patients treated with aliskiren.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>A number of
these patients had a history of angioedema or symptoms suggestive of
angioedema, which in some cases followed use of other medicinal products that
can cause angioedema, including RAAS blockers (angiotensin converting enzyme
inhibitors or angiotensin receptor blockers) (see section&nbsp;4.8).</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In
post-marketing experience, angioedema or angioedema-like reactions have been
reported when aliskiren was co-administered with ACEIs and/or ARBs (see
section&nbsp;4.8).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Special caution
is necessary in patients with a hypersensitivity predisposition.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Patients with
history of angioedema may be at increased risk of experiencing angioedema
during treatment with aliskiren (see sections&nbsp;4.3 and 4.8). Caution should
therefore be exercised when prescribing aliskiren to patients with a history of
angioedema, and such patients should be closely monitored during treatment (see
section&nbsp;4.8) especially at the beginning of the treatment.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>If anaphylactic reactions or</span><span
lang=EN-GB> </span><span lang=EN-GB>angioedema occur, Rasitrio should be
promptly discontinued and appropriate therapy and monitoring provided until
complete and sustained resolution of signs and symptoms has occurred. Patients
should be informed to report to the physician any signs suggestive of allergic
reactions, in particular difficulties in breathing or swallowing, swelling of
face, extremities, eyes, lips or tongue. Where there is involvement of the
tongue, glottis or larynx adrenaline should be administered. In addition,
measures necessary to maintain patent airways should be provided.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u>Photosensitivity</u></p>

<p class=MsoNormal>Cases of photosensitivity reactions have been reported with
thiazide diuretics (see section&nbsp;4.8). If photosensitivity reaction occurs
during treatment with <span lang=EN-GB>Rasitrio</span>, it is recommended to
stop the treatment. If a re-administration of the diuretic is deemed necessary,
it is recommended to protect exposed areas to the sun or to artificial UVA.</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Acute angle-closure glaucoma</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Hydrochlorothiazide, a sulphonamide, has
been associated with an idiosyncratic reaction resulting in acute transient
myopia and acute angle-closure glaucoma. Symptoms include acute onset of
decreased visual acuity or ocular pain and typically occur within hours to
weeks of treatment initiation. Untreated acute angle-closure glaucoma can lead
to permanent vision loss. The primary treatment is to discontinue
hydrochlorothiazide as rapidly as possible. Prompt medical or surgical
treatment may need to be considered if the intraocular pressure remains
uncontrolled. Risk factors for developing acute angle-closure glaucoma may
include a history of sulphonamide or penicillin allergy.</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.5&nbsp;&nbsp;&nbsp;&nbsp; Interaction
with other medicinal products and other forms of interaction</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Information on Rasitrio interactions</span></u></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>A
population pharmacokinetic analysis in patients with hypertension did not
indicate any clinically relevant changes in the </span><span lang=EN-GB>steady-state
exposure (AUC) and C<sub>max</sub> of aliskiren, amlodipine and
hydrochlorothiazide compared to the corresponding dual therapies.</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Medicinal
products affecting serum potassium levels</span></i><span lang=EN-GB>: </span><span
lang=EN-GB>The potassium-depleting effect of hydrochlorothiazide is attenuated
by the potassium-sparing effect of aliskiren. However, this effect of
hydrochlorothiazide on serum potassium would be expected to be potentiated by
other medicinal products associated with potassium loss and hypokalaemia (e.g.
other kaliuretic diuretics, corticosteroids, laxatives, adrenocoricotropic
hormone (ACTH), amphotericin, carbenoxolone, penicillin G, salicylic acid
derivatives). Conversely,</span><span lang=EN-GB> concomitant use of other
agents affecting the RAAS, of NSAIDs or of agents that increase serum potassium
levels (e.g. potassium-sparing diuretics, potassium supplements, salt
substitutes containing potassium, heparin) may lead to increases in serum
potassium. If co-medication with an agent affecting the level of serum
potassium is considered necessary, caution is advisable. The combination of
aliskiren with </span><span lang=EN-GB>ARBs or ACEIs </span><span lang=EN-GB>is
contraindicated in patients with diabetes mellitus or renal impairment (GFR
&lt;60&nbsp;ml/min/</span><span lang=EN-GB>1.73&nbsp;m<sup>2</sup></span><span
lang=EN-GB>) and is not recommended in other patients (see sections</span><span
lang=EN-GB>&nbsp;</span><span lang=EN-GB>4.3, 4.4 and 5.1)</span><span
lang=EN-GB>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Medicinal
products affected by serum potassium disturbances</span></i><span lang=EN-GB>: </span><span
lang=EN-GB>Periodic monitoring of serum potassium is recommended when Rasitrio
is administered with medicinal products affected by serum potassium
disturbances (e.g. digitalis glycosides, antiarrhythmics).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default><i><span style='font-size:11.0pt;color:windowtext'>Non-steroidal
anti-inflammatory drugs (NSAIDs), including selective cyclooxygenase-2
inhibitors (COX-2 inhibitors)</span></i><span class=msoins0><i><span
style='font-size:11.0pt;color:windowtext'>, acetylsalicylic acid and
non-selective NSAIDs</span></i></span><i><span style='font-size:11.0pt;
color:windowtext'>:</span></i><span style='font-size:11.0pt;color:windowtext'>
As with other agents acting on the renin-angiotensin system, NSAIDs may reduce
the anti-hypertensive effect of aliskiren. NSAIDs may also weaken the diuretic
and antihypertensive activity of hydrochlorothiazide.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In some patients
with compromised renal function (dehydrated patients or elderly patients)
aliskiren and hydrochlorothiazide given concomitantly with NSAIDs may result in
further deterioration of renal function, including possible acute renal
failure, which is usually reversible. Therefore the use of Rasitrio with an NSAID
requires caution, especially in elderly patients.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Information on aliskiren interactions</span></u></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Contraindicated (see section&nbsp;4.3)</span></i></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span style='font-size:11.0pt;color:windowtext'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span style='font-size:11.0pt;color:windowtext'>Dual RAAS
blockade</span></i></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>The
combination of aliskiren with ARBs or ACEIs is contraindicated in patients with
diabetes mellitus or renal impairment (GFR &lt;60&nbsp;ml/min/</span><span
style='font-size:11.0pt;color:windowtext'>1.73&nbsp;m<sup>2</sup></span><span
style='font-size:11.0pt;color:windowtext'>) and is not recommended in other
patients (see sections&nbsp;4.3, 4.4 and 5.1).</span></p>

<p class=Default><i><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></i></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span style='font-size:11.0pt;color:windowtext'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span style='font-size:11.0pt;color:windowtext'>P-glycoprotein
(P-gp) potent inhibitors</span></i></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>A single dose
drug interaction study in healthy subjects has shown that ciclosporin (200 and
600&nbsp;mg) increases C<sub>max</sub> of aliskiren 75&nbsp;mg approximately
2.5-fold and AUC approximately 5-fold. The increase may be higher with higher
aliskiren doses. </span><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>In
healthy subjects, itraconazole (100&nbsp;mg) increases AUC and C<sub>max</sub>
of aliskiren (150&nbsp;mg) by 6.5-fold and 5.8-fold, respectively. </span><span
style='font-size:11.0pt;color:windowtext'>Therefore, concomitant use of
aliskiren and P-gp potent inhibitors is contraindicated (see section&nbsp;4.3).</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i>Not
recommended (see section&nbsp;4.2)</i></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span style='font-size:11.0pt;color:windowtext'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span style='font-size:11.0pt;color:windowtext'>Grapefruit
juice</span></i></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Administration
of grapefruit juice with aliskiren resulted in a decrease in AUC and C<sub>max</sub>
of aliskiren. Co-administration with aliskiren 150&nbsp;mg resulted in a 61%
decrease in aliskiren AUC and co-administration with aliskiren 300&nbsp;mg
resulted in a 38% decrease in aliskiren AUC. This decrease is likely due to an
inhibition of </span><span style='font-size:11.0pt;color:windowtext'>organic
anion transporting polypeptide-mediated uptake of aliskiren by grapefruit juice
in the gastrointestinal tract. Therefore, because of the risk of therapeutic
failure, grapefruit juice should not be taken together with Rasitrio.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i>Caution
required with concomitant use</i></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span style='font-size:11.0pt;color:windowtext'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span style='font-size:11.0pt;color:windowtext'>P-gp
interactions</span></i></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>MDR</span><span
style='font-size:11.0pt;color:windowtext'>1/Mdr1a/1b (P-gp) was found to be the
major efflux system involved in intestinal absorption and biliary excretion of
aliskiren in preclinical studies. Rifampicin, which is an inducer of P-gp,
reduced aliskiren bioavailability by approximately 50% in a clinical study.
Other inducers of P-gp (St. John&#8217;s wort) might decrease the
bioavailability of aliskiren. Although this has not been investigated for
aliskiren, it is known that P-gp also controls tissue uptake of a variety of
substrates and P-gp inhibitors can increase the tissue-to-plasma concentration
ratios. Therefore, P-gp inhibitors may increase tissue levels more than plasma
levels. The potential for drug interactions at the P-gp site will likely depend
on the degree of inhibition of this transporter.</span></p>

<p class=Default><i><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></i></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span style='font-size:11.0pt;color:windowtext'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span style='font-size:11.0pt;color:windowtext'>Moderate P-gp
inhibitors</span></i></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Co-administration
of ketoconazole (200&nbsp;mg) or verapamil (240&nbsp;mg) with aliskiren
(300&nbsp;mg) resulted in a 76% or 97% increase in aliskiren AUC, respectively.
The change in plasma levels of aliskiren in the presence of ketoconazole or
verapamil is expected to be within the range that would be achieved if the dose
of aliskiren were doubled; aliskiren doses of up to 600&nbsp;mg, or twice the
highest recommended therapeutic dose, have been found to be well tolerated in
controlled clinical trials. Preclinical studies indicate that aliskiren and
ketoconazole co-administration enhances aliskiren gastrointestinal absorption
and decreases biliary excretion. Therefore, caution should be exercised when
aliskiren is administered with ketoconazole, verapamil or other moderate P-gp
inhibitors (clarithromycin, telithromycin, erythromycin, amiodarone).</span></p>

<p class=Default><i><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></i></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span style='font-size:11.0pt;color:windowtext'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span style='font-size:11.0pt;color:windowtext'>Medicinal
products affecting serum potassium levels</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Concomitant use
of other agents affecting the RAAS, of NSAIDs or of agents that increase serum
potassium levels (e.g. potassium-sparing diuretics, potassium supplements, salt
substitutes containing potassium, heparin) may lead to increases in serum
potassium. If co-administration with an agent affecting the level of serum
potassium is considered necessary, caution is advisable. The combination of
aliskiren with ARBs or ACEIs is contraindicated in patients with diabetes
mellitus or renal impairment (GFR &lt;60&nbsp;ml/min/</span><span lang=EN-GB>1.73&nbsp;m<sup>2</sup></span><span
lang=EN-GB>) and is not recommended in other patients (see sections&nbsp;4.3,
4.4 and 5.1).</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span style='font-size:11.0pt;color:windowtext'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span style='font-size:11.0pt;color:windowtext'>Furosemide</span></i></p>

<p class=Default><span lang=EN style='font-size:11.0pt;color:windowtext'>Oral
co-administration of aliskiren and furosemide had no effect on the
pharmacokinetics of aliskiren but reduced exposure to furosemide by 20&#8209;30%
(the </span><span style='font-size:11.0pt;color:windowtext'>effect of aliskiren
on furosemide administered intramuscularly or intravenously has not been
investigated)</span><span lang=EN style='font-size:11.0pt;color:windowtext'>.
After </span><span style='font-size:11.0pt;color:windowtext'>multiple doses of </span><span
lang=EN style='font-size:11.0pt;color:windowtext'>furosemide (60</span><span
style='font-size:11.0pt;color:windowtext'>&nbsp;</span><span lang=EN
style='font-size:11.0pt;color:windowtext'>mg/day) co-administered with
aliskiren (300&nbsp;mg/day) </span><span style='font-size:11.0pt;color:windowtext'>to
patients with heart failure</span><span lang=EN style='font-size:11.0pt;
color:windowtext'> the urinary sodium excretion and the urine volume were
reduced during the first 4&nbsp;hours by 31% and 24%, respectively, as compared
to furosemide alone. </span><span style='font-size:11.0pt;color:windowtext'>The
mean weight of patients concomitantly treated with furosemide and 300&nbsp;mg
aliskiren (84.6&nbsp;kg) was higher than the weight of patients treated with
furosemide alone (83.4&nbsp;kg)</span><span lang=EN style='font-size:11.0pt;
color:windowtext'>. Smaller changes in furosemide pharmacokinetics and efficacy
were observed with aliskiren 150</span><span style='font-size:11.0pt;
color:windowtext'>&nbsp;</span><span lang=EN style='font-size:11.0pt;
color:windowtext'>mg/day. In patients treated with both aliskiren and oral
furosemide,</span><span style='font-size:11.0pt;color:windowtext'> it is
therefore recommended that the effects of furosemide be monitored when
initiating and adjusting furosemide or aliskiren therapy to avoid changes in
extracellular fluid volume and possible situations of volume overload (see
section&nbsp;4.4).</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span style='font-size:11.0pt;color:windowtext'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span style='font-size:11.0pt;color:windowtext'>Warfarin</span></i></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>The effects of
aliskiren on warfarin pharmacokinetics have not been evaluated.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span style='font-size:11.0pt;color:windowtext'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span style='font-size:11.0pt;color:windowtext'>Food
interactions</span></i></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Meals (low or
high fat content) have been shown to reduce the absorption of aliskiren
substantially (see section&nbsp;4.2).</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i>No
interactions</i></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt'><span
style='font-size:11.0pt;color:windowtext'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt;color:windowtext'>Compounds that
have been investigated in aliskiren clinical pharmacokinetic studies include
acenocoumarol, atenolol, celecoxib, pioglitazone, allopurinol, isosorbide-5-mononitrate
and hydrochlorothiazide. No interactions have been identified.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>Co-administration of aliskiren with either metformin
(&#8595;28%), amlodipine (&#8593;29%) or cimetidine (&#8593;19%) resulted in
between 20% and 30%<span lang=EN-GB> change in C</span><sub><span lang=EN-GB>max</span></sub><span
lang=EN-GB> or AUC of aliskiren. When administered with atorvastatin,
steady-state aliskiren AUC and C</span><sub><span lang=EN-GB>max</span></sub><span
lang=EN-GB> increased by 50%. Co-administration of aliskiren had no significant
impact on atorvastatin, metformin or amlodipine pharmacokinetics. As a result
no dose adjustment for aliskiren or these co-administered medicinal products is
necessary.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Digoxin
and verapamil bioavailability may be slightly decreased by aliskiren.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span style='font-size:11.0pt;color:windowtext'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span style='font-size:11.0pt;color:windowtext'>CYP450
interactions</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Aliskiren does
not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1 and 3A).
Aliskiren does not induce CYP3A4. Therefore aliskiren is not expected to affect
the systemic exposure of substances that inhibit, induce or are metabolised by
these enzymes. </span><span lang=EN-GB>Aliskiren is metabolised minimally by
the cytochrome P450 enzymes. Hence, interactions due to inhibition or induction
of CYP450 isoenzymes are not expected. However, CYP3A4 inhibitors often also
affect P-gp. Increased aliskiren exposure during co-administration of CYP3A4
inhibitors that also inhibit P-gp can therefore be expected (see other P-gp
references in section&nbsp;4.5).</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span style='font-size:11.0pt;color:windowtext'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span style='font-size:11.0pt;color:windowtext'>P-gp
substrates or weak inhibitors</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No relevant
interactions with atenolol, digoxin, amlodipine or cimetidine have been
observed. When administered with atorvastatin (80&nbsp;mg), steady-state
aliskiren (300&nbsp;mg) AUC and C<sub>max</sub> increased by 50%. </span><span
lang=EN-GB>In experimental animals, it has been shown that P-gp is a major
determinant of aliskiren bioavailability. Inducers of P-gp (St. John&#8217;s
wort, rifampicin) might therefore decrease the bioavailability of aliskiren.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span style='font-size:11.0pt;color:windowtext'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span style='font-size:11.0pt;color:windowtext'>Organic anion
transporting polypeptide (OATP) inhibitors</span></i></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Preclinical
studies indicate that aliskiren might be a substrate of organic anion
transporting polypeptides. Therefore, the potential exists for interactions
between OATP inhibitors and aliskiren when administered concomitantly (see
interaction with Grapefruit juice).</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Information on amlodipine interactions</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Effects of other medicinal products on amlodipine</span></u></i></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Caution required with concomitant use</span></i></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span style='font-size:11.0pt;color:windowtext'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span style='font-size:11.0pt;color:windowtext'>CYP3A4
inhibitors</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Concomitant use
of amlodipine with strong or moderate CYP3A4 inhibitors (protease inhibitors,
azole antifungals, macrolides like erythromycin or clarithromycin, verapamil or
diltiazem) may give rise to significant increase in amlodipine exposure. The
clinical translation of these pharmacokinetic variations may be more pronounced
in the elderly. Clinical monitoring and dose adjustment may thus be required.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span style='font-size:11.0pt;color:windowtext'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span style='font-size:11.0pt;color:windowtext'>CYP3A4
inducers</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>There is no data
available regarding the effect of CYP3A4 inducers on amlodipine. The
concomitant use of CYP3A4 inducers (e.g. rifampicin, <i>hypericum perforatum</i>)
may give a lower plasma concentration of amlodipine. Amlodipine should be used
with caution together with CYP3A4 inducers.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:1.5in;text-indent:-1.5in;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Grapefruit juice</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Administration
of amlodipine with grapefruit or grapefruit juice is not recommended as
bioavailability may be increased in some patients, resulting in increased blood
pressure lowering effects.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Dantrolene (infusion)</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In animals,
lethal ventricular fibrillation and cardiovascular collapse are observed in
association with hyperkalaemia after administration of verapamil and intravenous
dantrolene. Due to risk of hyperkalaemia, it is recommended that the
co-administration of calcium channel blockers such as amlodipine be avoided in
patients susceptible to malignant hyperthermia and in the management of
malignant hyperthermia.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Effects of amlodipine on other medicinal products</span></u></i></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The blood pressure lowering effects of
amlodipine add to the blood pressure lowering effects of other antihypertensive
medicinal products.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Co-administration of multiple doses of
10&nbsp;mg of amlodipine with 80&nbsp;mg simvastatin resulted in a 77% increase
in exposure to simvastatin compared to simvastatin alone. It is recommended to
limit the dose of simvastatin to 20&nbsp;mg daily in patients on amlodipine.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>No interactions</span></i></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>In clinical interaction studies, amlodipine did
not affect the pharmacokinetics of atorvastatin, digoxin, warfarin or
ciclosporin.</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Information on hydrochlorothiazide interactions</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>When
administered concurrently, the following medicinal products may interact with
thiazide diuretics:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i>Not recommended</i></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span style='font-size:11.0pt;color:windowtext'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span style='font-size:11.0pt;color:windowtext'>Lithium</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>R</span>enal
clearance of lithium is reduced by thiazides, therefore the risk of lithium
toxicity<span lang=EN-GB> may be increased with hydrochlorothiazide</span>.
Co-administration of lithium and <span lang=EN-GB>hydrochlorothiazide</span> is
not recommended. If this combination proves essential, careful monitoring of
serum lithium level is recommended during concomitant use.</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i>Caution
required with concomitant use</i></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span style='font-size:11.0pt;color:windowtext'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span style='font-size:11.0pt;color:windowtext'>Alcohol</span></i><i><span
style='color:windowtext'>, barbiturates or narcotics</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Concomitant
administration of thiazide diuretics with subtances that also have a blood
pressure lowering effect (e.g. by reducing sympathetic central nervous system
activity or direct vasodilatation) may potentiate orthostatic hypotension.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Amantadine</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Thiazides,
including hydrochlorothiazide, may increase the risk of adverse reactions
caused by amantadine.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Antidiabetic agents (e.g. insulin and oral
antidiabetic agents)</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Thiazides may
alter glucose tolerance. Dose adjustment of the antidiabetic medicinal product
may be necessary (see section&nbsp;4.4). Metformin should be used with caution
because of the risk of lactic acidosis induced by possible functional renal
failure linked to hydrochlorothiazide.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Anticholinergic agents and other medicinal
products affecting gastric motility</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The
bioavailability of thiazide-type diuretics may be increased by anticholinergic
agents (e.g. atropine, biperiden), apparently due to a decrease in
gastrointestinal motility and the stomach emptying rate. Conversely, it is
anticipated that prokinetic substances such as cisapride may decrease the
bioavailability of thiazide-type diuretics.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Medicinal products used in the treatment of
gout</span></i></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Dose
adjustment of uricosuric </span>medicinal products<i> </i><span lang=EN-GB>may
be necessary as hydrochlorothiazide may raise the level of serum uric acid.
Increase of dose of probenecid or sulfinpyrazone may be necessary. Co<b>-</b>administration
of thiazide diuretics, including hydrochlorothiazide, may increase the
incidence of hypersensitivity reactions to allopurinol.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicinal
products that could induce torsades de pointes</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Due to the risk of hypokalaemia,
hydrochlorothiazide should be administered with caution when associated with
medicinal products that could induce <i>torsades de pointes</i>, in particular
Class Ia and Class III </span><span lang=EN-GB>antiarrhythmics</span><span
lang=EN-GB> </span><span lang=EN-GB>and some </span><span lang=EN-GB>antipsychotics.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><i><span lang=EN-GB>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicinal
products affecting serum sodium level</span></i></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>The
hyponatraemic effect of diuretics may be intensified by concomitant
administration of medicinal products such as antidepressants, antipsychotics,
antiepileptics, etc. Caution is indicated in long-term administration of these
medicinal products.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Beta blockers and diazoxide</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Concomitant use
of thiazide diuretics, including hydrochlorothiazide, with beta blockers may
increase the risk of hyperglycaemia. Thiazide diuretics, including
hydrochlorothiazide, may enhance the hyperglycaemic effect of diazoxide.</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Ion exchange resins</span></i></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Absorption
of thiazide diuretics, including hydrochlorothiazide, is decreased by
cholestyramine or colestipol. This could result in sub-therapeutic effects of
thiazide diuretics. However, staggering the dosage of hydrochlorothiazide and
resin such that hydrochlorothiazide is administered at least 4&nbsp;hours
before or 4&#8209;6&nbsp;hours after the administration of resins would
potentially minimise the interaction.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Vitamin D and calcium salts</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Administration
of thiazide diuretics, including hydrochlorothiazide, with vitamin D or with
calcium salts may potentiate the rise in serum calcium. Concomitant use of
thiazide type diuretics may lead to hypercalcaemia in patients pre-disposed for
hypercalcaemia (e.g. hyperparathyroidism, malignancy, or vitamin-D-mediated
conditions) by increasing tubular calcium reabsorption.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Non-depolarising skeletal muscle relaxants</span></i></p>

<p class=MsoNormal style='line-height:normal'>Thiazides, including
hydrochlorothiazide, potentiate the action of skeletal muscle relaxants such as
curare derivatives.</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Cytotoxic agents</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Thiazides,
including hydrochlorothiazide, may reduce the renal excretion of cytotoxic
agents (e.g. cyclophosphamide, methotrexate) and potentiate their
myelosuppressive effects.</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Digoxine or digitalis glycosides</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Thiazide-induced
hypokalaemia or hypomagnesaemia favour the onset of digitalis-induced cardiac
arrhythmias (see section&nbsp;4.4).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoDate style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Methyldopa</span></i></p>

<p class=MsoDate><span lang=EN-GB>There have been isolated reports of
haemolytic anaemia occurring with concomitant use of hydrochlorothiazide and
methyldopa.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Iodine
contrasting agents</span></i></p>

<p class=MsoNormal><span lang=EN-GB>In case of diuretic-induced dehydration,
there is an increased risk of acute renal failure, especially with high doses
of iodine products. Patients should be rehydrated before administration.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Pressor amines (e.g. noradrenaline,
adrenaline)</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Hydrochlorothiazide
may reduce the response to pressor amines such as noradrenaline. The clinical
significance of this effect is uncertain and not sufficient to preclude their
use.</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.6&nbsp;&nbsp;&nbsp;&nbsp; Fertility,
pregnancy and lactation</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Women of childbearing potential/contraception in males and
females</span></u></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Healthcare
professionals prescribing Rasitrio should counsel women of childbearing
potential about the potential risk during pregnancy. A switch to a suitable
alternative antihypertensive treatment should be carried out in advance of a
planned pregnancy since Rasitrio should not be used in women planning to become
pregnant.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Pregnancy</span></u></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>There are no
data on the use of aliskiren in pregnant women. Aliskiren was not teratogenic
in rats or rabbits (see section&nbsp;5.3). Other substances that act directly
on the renin-angiotensin-aldosterone system have been associated with serious
foetal malformations and neonatal death. As for any medicinal product that acts
directly on the renin-angiotensin-aldosterone system, aliskiren should not be
used during the first trimester of pregnancy and is contraindicated during the
second and third trimesters (see section&nbsp;4.3).</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The safety of
amlodipine in human pregnancy has not been established. Reproductive studies in
rats have shown no toxicity except for delayed date of delivery and prolonged
duration of labour at dosages 50&nbsp;times greater than the maximum
recommended dosage for humans (see section&nbsp;5.3). Use in pregnancy is only
recommended when there is no safer alternative and when the disease itself
carries greater risk for the mother and foetus.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>There is limited experience with
hydrochlorothiazide during pregnancy, especially during the first trimester.
Animal studies are insufficient.</span></p>

<p class=MsoDate><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoDate><span lang=EN-GB>Hydrochlorothiazide crosses the placenta.
Based on the pharmacological mechanism of action of hydrochlorothiazide, its
use during the second and third trimester may compromise foeto-placental
perfusion and may cause foetal and neonatal effects like icterus, disturbance
of electrolyte balance and thrombocytopenia.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Hydrochlorothiazide should not be used for
gestational oedema, gestational hypertension or pre&#8209;eclampsia due to the
risk of decreased plasma volume and placental hypoperfusion, without a
beneficial effect on the course of the disease.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Hydrochlorothiazide should not be used for
essential hypertension in pregnant women except in rare situations where no
other treatment could be used.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Rasitrio
should not be used during the first trimester of pregnancy. Rasitrio is
contraindicated during the second and third trimesters (see section&nbsp;4.3).</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>If pregnancy
is detected during therapy, Rasitrio should be discontinued accordingly as soon
as possible.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Breast-feeding</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>It is not known
whether aliskiren and/or amlodipine are excreted in human milk. Aliskiren was
secreted in the milk of lactating rats.</span></p>

<p class=MsoDate><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoDate><span lang=EN-GB>Hydrochlorothiazide is excreted in human milk
in small amounts. Thiazides in high doses causing intense diuresis can inhibit
milk production.</span></p>

<p class=MsoDate><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The use of
Rasitrio during breast-feeding is not recommended. If Rasitrio is used during
breast-feeding, doses should be kept as low as possible.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Fertility</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>There are no
clinical data on fertility with the use of Rasitrio.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Reversible
biochemical changes in the head of spermatozoa have been reported in some
patients treated by calcium channel blockers. Clinical data are insufficient
regarding the potential effect of amlodipine on fertility. In one rat study,
adverse effects were found on male fertility (see section&nbsp;5.3). The
fertility of rats was unaffected at doses of up to aliskiren 250&nbsp;mg/kg/day
and hydrochlorothiazide 4&nbsp;mg/kg/day (see section&nbsp;5.3).</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.7&nbsp;&nbsp;&nbsp;&nbsp; Effects
on ability to drive and use machines</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>No studies on the effect on the ability to drive and use machines
have been performed</span>. However, when driving vehicles or using machines it
must be borne in mind that dizziness or drowsiness may occasionally occur when
taking Rasitrio.</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Amlodipine can
have minor or moderate influence on the ability to drive and use machines. If
patients taking amlodipine suffer from dizziness, drowsiness, headache, fatigue
or nausea, the ability to react may be impaired.</span></p>

<p class=MsoDate><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.8&nbsp;&nbsp;&nbsp;&nbsp; Undesirable
effects</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Summary of the safety profile</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Aliskiren/amlodipine/hydrochlorothiazide combination</span></u></i></p>

<p style='margin:0in'><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>The safety profile of Rasitrio presented below is
based on clinical studies performed with Rasitrio and the known safety profile
of the individual components aliskiren, amlodipine and hydrochlorothiazide.
Safety information for Rasitrio in patients aged 75&nbsp;years and older is
limited.</span></p>

<p style='margin:0in'><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoCommentText style='line-height:normal'><span lang=EN-GB
style='font-size:11.0pt'>The most frequent adverse reactions observed with
Rasitrio are hypotension and dizziness. The adverse reactions previously
reported with one of the individual components of Rasitrio (aliskiren,
amlodipine and hydrochlorothiazide) and listed in the respective paragraphs on
the individual components may occur with Rasitrio.</span></p>

<p class=Default><u><span lang=EN-GB style='font-size:11.0pt;color:windowtext'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Tabulated
list of adverse reactions:</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>The adverse
reactions for aliskiren, amlodipine and hydrochlorothiazide are ranked under
heading of frequency, the most frequent first, using the following convention:
very common (&#8805;1/10); common (&#8805;1/100 to &lt;1/10); uncommon
(&#8805;1/1,000 to &lt;1/100); rare (&#8805;1/10,000 to &lt;1/1,000); very rare
(&lt;1/10,000), not known (cannot be estimated from the available data). Within
each frequency grouping, adverse reactions are presented in order of decreasing
seriousness.</span></p>

<p style='margin:0in'><u><span style='font-size:11.0pt;font-family:"Times New Roman",serif'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p style='margin:0in;page-break-after:avoid'><i><u><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Information on
Rasitrio</span></u></i></p>

<p class=CharCharCharCharChar align=left style='margin-bottom:0in;text-align:
left;line-height:normal;page-break-after:avoid'><span style='font-size:11.0pt;
font-family:"Times New Roman",serif'>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='margin-left:5.4pt;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-bottom:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
  layout-grid-mode:line'>Nervous system disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Common</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Dizziness</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
  layout-grid-mode:line'>Vascular disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Common</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Hypotension</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><b><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>General
  disorders and administration site conditions</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Common</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Peripheral
  oedema</span></p>
  </td>
 </tr>
</table>

<p class=CharCharCharCharChar align=left style='margin-bottom:0in;text-align:
left;line-height:normal'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'>Peripheral oedema is
a known, dose-dependent adverse reaction of amlodipine and has also been
reported with aliskiren therapy in post-marketing experience. The incidence of
peripheral oedema for Rasitrio in a short-term double active-controlled study
was 7.1% compared to 8.0% for aliskiren/amlodipine, 4.1% for
amlodipine/hydrochlorothiazide and 2.0% for aliskiren/hydrochlorothiazide dual
combinations.</p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>The
incidence of any adverse reactions potentially related to hypotension in a
short-term active controlled study was 4.9% with Rasitrio versus up to 3.7%
with dual combinations. In patients &#8805;65&nbsp;years the incidence was 10.2%
with Rasitrio versus up to 5.4% with dual combinations.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'>&nbsp;</p>

<p style='margin:0in;page-break-after:avoid'><i><u><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Additional
information on individual components</span></u></i></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Other
adverse reactions previously reported with one of the individual components may
occur with Rasitrio even if not observed in clinical trials.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p style='margin:0in;page-break-after:avoid'><i><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Aliskiren</span></i></p>

<p style='margin:0in;page-break-after:avoid'><span lang=EN-GB style='font-size:
11.0pt;font-family:"Times New Roman",serif'>Serious adverse reactions include
anaphylactic reaction and angioedema which have been reported in post-marketing
experience and may occur rarely (less than 1&nbsp;case per
1,000&nbsp;patients). The most common adverse reaction is diarrhoea.</span></p>

<p style='margin:0in'><u><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoDate style='page-break-after:avoid'><span lang=EN-GB>Tabulated list
of adverse reactions:</span></p>

<p class=MsoNormal><span lang=EN-GB>The known aliskiren adverse reactions are
presented in the table below using the same convention as described previously
for the fixed combination.</span></p>

<p style='margin:0in;page-break-after:avoid'><u><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='margin-left:5.4pt;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-bottom:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
  layout-grid-mode:line'>Immune system disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Anaphylactic
  reactions, h</span><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
  layout-grid-mode:line'>ypersensitivity reactions</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><b><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Cardiac
  </span></b><b><span lang=DE-CH style='font-size:11.0pt;font-family:"Times New Roman",serif'>d</span></b><b><span
  lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>isorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Common</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Dizziness</span></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Uncommon</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Palpitations</span><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>, oedema
  peripheral</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><b><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Vascular
  disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Uncommon</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Hypotension</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
  layout-grid-mode:line'>Respiratory, thoracic and mediastinal disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
  layout-grid-mode:line'>Uncommon</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
  layout-grid-mode:line'>Cough</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
  layout-grid-mode:line'>Gastrointestinal disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Common</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Diarrhoea</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><b><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Hepatobiliary
  disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Not
  known</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Liver
  disorder*</span><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>,
  j</span><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>aundice</span><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>,</span><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'> </span><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>h</span><span
  lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>epatitis</span><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>, l</span><span
  lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>iver
  failure</span><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>**</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
  layout-grid-mode:line'>Skin and subcutaneous tissue disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Uncommon</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Severe
  cutaneous adverse reactions (SCARs) including Stevens Johnson syndrome, toxic
  epidermal necrolysis (TEN), oral mucosal reactions, rash, pruritus, urticaria</span></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Angioedema,
  erythema</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
  layout-grid-mode:line'>Musculoskeletal and connective tissue disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Common</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Arthralgia</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
  layout-grid-mode:line'>Renal and urinary disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Uncommon</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=FR style='font-size:11.0pt;font-family:"Times New Roman",serif'>Acute
  renal failure, renal impairment</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
  layout-grid-mode:line'>Investigations</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Common</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Hyperkalaemia</span></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Uncommon</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Liver
  enzyme increased</span></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Haemoglobin
  decreased, haematocrit decreased, blood creatinine increased</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>*Isolated cases
of liver disorder with clinical symptoms and laboratory evidence of more marked
hepatic dysfunction.</span></p>

<p style='margin:0in'><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>**Including one case of &#8216;liver failure
fulminant&#8217; reported in the post-marketing experience, for which a causal
relationship with aliskiren cannot be excluded.</span></p>

<p style='margin:0in'><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Description of
selected adverse events:</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Hypersensitivity
reactions including anaphylactic reactions and angioedema have occurred during
treatment with aliskiren.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>In controlled
clinical trials, angioedema and hypersensitivity reactions occurred rarely
during treatment with aliskiren with rates comparable to treatment with placebo
or comparators.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Cases of
angioedema or symptoms suggestive of angioedema (swelling of the face, lips,
throat and/or tongue) have also been reported in post-marketing experience. A
number of these patients had a history of angioedema or symptoms suggestive of
angioedema which in some cases was associated with the administration of other
medicinal products known to cause angioedema, including RAAS blockers (ACEIs or
ARBs).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'>In post-marketing experience,
cases of angioedema or angioedema-like reactions have been reported when
aliskiren was co-administered with ACEIs and/or ARBs.</p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Hypersensitivity
reactions including anaphylactic reactions have also been reported in
post-marketing experience (see section&nbsp;4.4).</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>In the event
of any signs suggesting a hypersensitivity reaction/angioedema (in particular
difficulties in breathing, or swallowing, rash, itching, hives or swelling of
the face, extremities, eyes, lips and/or tongue, dizziness) patients should
discontinue treatment and contact the physician (see section&nbsp;4.4).</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Arthralgia has
been reported in post-marketing experience. In some cases this occurred as part
of a hypersensitivity reaction.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In
post-marketing experience, renal dysfunction and cases of acute renal failure
have been reported in patients at risk (see section&nbsp;4.4).</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><i><span style='font-size:11.0pt;color:windowtext'>Investigations:
</span></i><span style='font-size:11.0pt;color:windowtext'>In controlled clinical
trials, clinically relevant changes in standard laboratory parameters were
uncommonly associated with the administration of aliskiren. In clinical studies
in hypertensive patients, aliskiren had no clinically important effects on
total cholesterol, high density lipoprotein cholesterol (HDL-C),
fasting triglycerides, fasting glucose or uric acid.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><i><span style='font-size:11.0pt;color:windowtext'>Haemoglobin
and haematocrit</span></i><span style='font-size:11.0pt;color:windowtext'>:
Small decreases in haemoglobin and haematocrit (mean decreases of approximately
0.05&nbsp;mmol/l and 0.16&nbsp;volume percent, respectively) were observed. No
patients discontinued therapy due to anaemia. This effect is also seen with
other medicinal products acting on the RAAS, such as ACEIs and ARBs.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><i><span style='font-size:11.0pt;color:windowtext'>Serum
potassium</span></i><span style='font-size:11.0pt;color:windowtext'>: Increases
in serum potassium have been observed with aliskiren and these may be
exacerbated by concomitant use of other agents acting on the RAAS or by NSAIDs.
Consistent with standard medical practice, periodic determination of renal
function including serum electrolytes is advised if co-administration is
considered necessary. The combination of aliskiren with ARBs or ACEIs is
contraindicated in patients with diabetes mellitus or renal impairment (GFR
&lt;60&nbsp;ml/min/</span><span style='font-size:11.0pt;color:windowtext'>1.73&nbsp;m<sup>2</sup></span><span
style='font-size:11.0pt;color:windowtext'>) and is not recommended in other
patients (see sections&nbsp;4.3, 4.4 and 5.1).</span></p>

<p style='margin:0in'><u><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><i><span lang=EN-GB>Paediatric population: </span></i><span
lang=EN-GB>Based on the limited amount of safety data available from a
pharmacokinetic study of aliskiren treatment in 39 hypertensive children 6&#8209;17&nbsp;years
of age, the frequency, type and severity of adverse reactions in children are
expected to be similar to that seen in hypertensive adults. As for other RAAS
blockers, headache is a common adverse event in children treated with
aliskiren.</span></p>

<p style='margin:0in'><u><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Amlodipine</span></i></p>

<p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
color:windowtext'>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><b><span style='font-size:
  11.0pt;color:windowtext'>Blood and lymphatic system disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Very
  rare</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Leukopenia,
  thrombocytopenia</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><b><span style='font-size:
  11.0pt;color:windowtext'>Immune system disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Very rare</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Allergic
  reactions</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><b><span style='font-size:
  11.0pt;color:windowtext'>Metabolism and nutrition disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Very rare</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Hyperglycaemia</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><b><span style='font-size:
  11.0pt;color:windowtext'>Psychiatric disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Uncommon</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Insomnia, mood changes (including anxiety), depression</span></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Rare</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Confusion</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><b><span style='font-size:
  11.0pt;color:windowtext'>Nervous system disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Common</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Somnolence, headache (especially at the beginning of treatment)</span></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Uncommon</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Tremor, dysgeusia, syncope, hypoesthesia, paraesthesia</span></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Very rare</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Hypertonia,
  peripheral neuropathy</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><b><span style='font-size:
  11.0pt;color:windowtext'>Eye disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Uncommon</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Visual
  disturbance (including diplopia)</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><b><span style='font-size:
  11.0pt;color:windowtext'>Ear and labyrinth disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Uncommon</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Tinnitus</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><b><span style='font-size:
  11.0pt;color:windowtext'>Cardiac disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Common</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Palpitations</span></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Very rare</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Myocardial
  infarction, arrhythmia (including bradycardia, ventricular tachycardia and
  atrial fibrillation)</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><b><span style='font-size:
  11.0pt;color:windowtext'>Vascular disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Common</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Flushing</span></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Very rare</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Vasculitis</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><b><span style='font-size:
  11.0pt;color:windowtext'>Respiratory, thoracic and mediastinal disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Uncommon</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Dyspnoea, rhinitis</span></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Very rare</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Cough</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><b><span style='font-size:
  11.0pt;color:windowtext'>Gastrointestinal disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Common</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Abdominal pain, nausea</span></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Uncommon</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Vomiting, dyspepsia, altered bowel habits (including
  diarrhoea and constipation), dry mouth</span></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Very rare</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Pancreatitis,
  gastritis, gingival hyperplasia</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><b><span style='font-size:
  11.0pt;color:windowtext'>Hepatobiliary disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Very rare</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Hepatitis,
  jaundice, hepatic enzymes increased (mostly consistent with cholestasis)</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><b><span style='font-size:
  11.0pt;color:windowtext'>Skin and subcutaneous tissue disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Uncommon</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Alopecia, purpura, skin decolouration, hyperhidrosis,
  pruritus, rash, exanthema</span></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Very rare</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Angioedema,
  erythema multiforme, urticaria, exfoliative dermatitis, Stevens-Johnson
  syndrome, Quincke oedema, photosensitivity</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><b><span style='font-size:
  11.0pt;color:windowtext'>Musculoskeletal and connective tissue disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;color:windowtext'>Common</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Ankle swelling</span></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Uncommon</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Arthralgia,
  myalgia, muscle cramps, back pain</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><b><span style='font-size:
  11.0pt;color:windowtext'>Renal and urinary disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Uncommon</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Micturition
  disorder, nocturia, increased urinary frequency</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><b><span style='font-size:
  11.0pt;color:windowtext'>Reproductive system and breast disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Uncommon</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Impotence,
  gynaecomastia</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><b><span style='font-size:
  11.0pt;color:windowtext'>General disorders and administration site conditions</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Common</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Oedema, fatigue</span></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Uncommon</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span lang=FR style='font-size:11.0pt;color:windowtext'>Chest
  pain, asthenia, pain, malaise</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><b><span style='font-size:
  11.0pt;color:windowtext'>Investigations</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Uncommon</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Weight
  increase, weight decrease</span></p>
  </td>
 </tr>
</table>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Exceptional
cases of extrapyramidal syndrome have been reported.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Hydrochlorothiazide</span></i></p>

<p style='margin:0in;page-break-after:avoid'><span lang=EN-GB style='font-size:
11.0pt;font-family:"Times New Roman",serif'>Hydrochlorothiazide has been
extensively prescribed for many years, frequently in higher doses than those
contained in </span><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Rasitrio</span><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>. </span><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>The
following adverse reactions have been reported in patients treated with
thiazide diuretics alone, including hydrochlorothiazide:</span></p>

<p style='margin:0in;page-break-after:avoid'><i><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></i></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='margin-left:5.4pt;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-bottom:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:
  line'>Blood and lymphatic system disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Thrombocytopenia</span><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>
  sometimes with purpura</span></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Very rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Agranulocytosis,
  bone marrow depression, haemolytic anaemia, leucopenia</span></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Not known</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Aplastic
  anaemia</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:
  line'>Immune system disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=X-NONE style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Very rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Hypersensitivity</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:
  line'>Metabolism and nutrition disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Very common</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Hypokalaemia</span></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Common</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Hyperuricaemia,
  hypomagnesaemia, hyponatraemia</span></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Hypercalcaemia,
  hyperglycaemia, worsening of diabetic metabolic state</span></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=X-NONE style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Very rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Hypochloraemic
  alkalosis</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:
  line'>Psychiatric disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=X-NONE style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Depression,
  sleep disturbances</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:
  line'>Nervous system disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=X-NONE style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Dizziness,
  headache, paraesthesia</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:
  line'>Eye disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Visual
  impairment</span></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=X-NONE style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Not known</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Acute
  angle-closure glaucoma</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:
  line'>Cardiac disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=X-NONE style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Cardiac
  arrhythmias</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:
  line'>Vascular disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=X-NONE style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Common</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Orthostatic
  hypotension</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:
  line'>Respiratory, thoracic and mediastinal disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=X-NONE style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Very rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Respiratory
  distress (including pneumonitis and pulmonary oedema)</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:
  line'>Gastrointestinal disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Common</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Decreased
  appetite, mild nausea and vomiting</span></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Abdominal
  discomfort, constipation, diarrhoea</span></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=X-NONE style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Very rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Pancreatitis</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:
  line'>Hepatobiliary disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Intrahepatic
  cholestasis, jaundice</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:
  line'>Skin and subcutaneous tissue disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Common</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Urticaria
  and other forms of rash</span></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Photosensitivity
  reactions</span></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Very rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Cutaneous
  lupus erythematosus-like reactions, reactivation of cutaneous lupus
  erythematosus, vasculitis necrotising and toxic epidermal necrolysis</span></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Not known</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Erythema
  multiforme</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:
  line'>Musculoskeletal and connective tissue disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=X-NONE style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Not known</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Muscle
  spasm</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:
  line'>Renal and urinary disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=X-NONE style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Not known</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=FR style='font-size:11.0pt;font-family:"Times New Roman",serif'>Renal
  dysfunction, acute renal failure</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:
  line'>Reproductive system and breast disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=X-NONE style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Common</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Impotence</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:
  line'>General disorders and administration site conditions</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=X-NONE style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Not known</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Asthenia,
  pyrexia</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:
  line'>Investigations</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Very common</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Increases
  in cholesterol and triglycerides</span></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Glycosuria</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.9&nbsp;&nbsp;&nbsp;&nbsp; Overdose</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Symptoms</span></u></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>The most
likely manifestation of overdose for Rasitrio would be hypotension, related to
the antihypertensive effect of the combination of aliskiren, amlodipine and
hydrochlorothiazide.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>With
aliskiren, the most likely manifestation of overdose would be hypotension,
related to the antihypertensive effect of aliskiren.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>With
amlodipine, available data suggest that gross overdose could result in
excessive peripheral vasodilatation and possibly reflex tachycardia. </span><span
style='font-size:11.0pt;color:windowtext'>Marked and </span><span lang=EN-GB
style='font-size:11.0pt;color:windowtext'>probably </span><span
style='font-size:11.0pt;color:windowtext'>prolonged systemic hypotension</span><span
lang=EN-GB style='font-size:11.0pt;color:windowtext'> up to and</span><span
style='font-size:11.0pt;color:windowtext'> including shock with fatal outcome,
have been reported with amlodipine.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Overdose with
hydrochlorothiazide is associated with electrolyte depletion (hypokalaemia,
hypochloraemia, hyponatraemia) and dehydration resulting from excessive
diuresis. The most common signs and symptoms of overdose are nausea and
somnolence. Hypokalaemia may result in muscle spasms and/or accentuate cardiac
arrhythmias associated with the concomitant use of digitalis glycosides or
certain antiarrhythmic medicinal products.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Treatment</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If symptomatic
hypotension should occur with Rasitrio, supportive treatment should be
initiated.</span></p>

<p class=MsoNormal style='line-height:normal'><i>&nbsp;</i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Clinically
significant hypotension due to amlodipine overdose calls for active
cardiovascular support including frequent monitoring of cardiac and respiratory
function, elevation of extremities and attention to circulating fluid volume
and urine output.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>A
vasoconstrictor may be helpful in restoring vascular tone and blood pressure,
provided that there is no contraindication to its use. Intravenous calcium
gluconate may be beneficial in reversing the effects of calcium channel
blockade.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Gastric lavage
may be worthwhile in some cases. In healthy volunteers the use of charcoal up
to 2&nbsp;hours after administration of amlodipine 10&nbsp;mg has been shown to
reduce the absorption rate of amlodipine.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Since amlodipine
is highly protein-bound, dialysis is not likely to be of benefit.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In a study
conducted in patients with end stage renal disease (ESRD) receiving
haemodialysis, dialysis clearance of aliskiren was low (&lt;2% of oral
clearance). Therefore dialysis is not adequate to treat aliskiren
over-exposure.</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACOLOGICAL
PROPERTIES</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5.1&nbsp;&nbsp;&nbsp;&nbsp; Pharmacodynamic
properties</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>Pharmacotherapeutic group</span><span lang=EN-GB>:
Agents acting on the renin-angiotensin system, renin-inhibitors; ATC code
C09XA54</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Rasitrio
combines three antihypertensive active substances with complementary mechanisms
to control blood pressure in patients with essential hypertension: aliskiren
belongs to the direct renin inhibitor class, amlodipine to the calcium channel
blocker class and hydrochlorothiazide to the thiazide diuretics class. When
combined, the consolidated effects of inhibition of the renin-angiotensin-aldosterone
system, calcium channel-mediated vasodilatation and sodium chloride excretion
result in a reduction of blood pressure to a greater degree than the
corresponding dual combinations.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Aliskiren/amlodipine/hydrochlorothiazide combination</span></u></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>In
hypertensive patients, once-daily administration of Rasitrio provided
clinically meaningful reductions in both systolic and diastolic blood pressure
that were maintained over the entire 24-hour dose interval. The greater blood
pressure reduction for Rasitrio over each dual combination was seen at every
hour including the early morning hours with the 24-hour ambulatory blood
pressure monitoring.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Rasitrio
was studied in a double-blind, randomised, active-controlled study in
1,181&nbsp;patients of which 773 were classified as moderately hypertensive
(msSBP 160&#8209;180&nbsp;mmHg) and 408 as severely hypertensive (msSBP
&gt;180&nbsp;mmHg) at baseline. A large number of patients were obese (49%) and
over 14% of the total population had diabetes. During the first 4&nbsp;weeks of
double-blind treatment, patients received triple combination
aliskiren/amlodipine/hydrochlorothiazide (HCTZ) 150/5/12.5&nbsp;mg (N=308), or
dual combinations of aliskiren/HCTZ 150/12.5&nbsp;mg (N=295),
aliskiren/amlodipine 150/5&nbsp;mg (N=282) and amlodipine/HCTZ 5/12.5&nbsp;mg
(N=295). Patients were force-titrated to higher doses after 4&nbsp;weeks for an
additional 4&nbsp;weeks of double-blind treatment to aliskiren/amlodipine/HCTZ
300/10/25&nbsp;mg, aliskiren/HCTZ 300/25&nbsp;mg, aliskiren/amlodipine
300/10&nbsp;mg and amlodipine/HCTZ 10/25&nbsp;mg.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>In
this study, Rasitrio at a dose of 300/10/25&nbsp;mg produced statistically
significant mean blood pressure reductions (systolic/diastolic) from baseline
of 37.9/20.6&nbsp;mmHg compared to 31.4/18.0&nbsp;mmHg with
aliskiren/amlodipine combination (300/10&nbsp;mg), 28.0/14.3&nbsp;mmHg with
aliskiren/hydrochlorothiazide (300/25&nbsp;mg) and 30.8/17.0&nbsp;mmHg with
amlodipine/hydrochlorothiazide (10/25&nbsp;mg) in patients with moderate to
severe hypertension. In patients with severe hypertension (SBP &#8805;180&nbsp;mmHg), the reduction in blood pressure from baseline for Rasitrio and the
dual combinations respectively was 49.5/22.5&nbsp;mmHg compared to 38.1/17.6&nbsp;mmHg
with aliskiren/amlodipine combination (300/10&nbsp;mg), 33.2/14.3&nbsp;mmHg
with aliskiren/hydrochlorothiazide (300/25&nbsp;mg) and 39.9/17.8&nbsp;mmHg
with amlodipine/hydrochlorothiazide (10/25&nbsp;mg). In a subset of
588&nbsp;patients</span><span lang=EN-GB> in which patients &gt;65&nbsp;years
were scarcely represented and those aged &gt;75&nbsp;years were very scarcely
represented</span><span lang=EN-GB>, the combination of
aliskiren/amlodipine/hydrochlorothiazide (300/10/25&nbsp;mg) produced a
systolic/diastolic mean blood pressure reduction of 39.7/21.1&nbsp;mmHg from
baseline, compared to 31.3/18.74&nbsp;mmHg for aliskiren/amlodipine
(300/10&nbsp;mg), 25.5/12.5&nbsp;mmHg for aliskiren/hydrochlorothiazide
(300/25&nbsp;mg) and 29.2/16.4&nbsp;mmHg for amlodipine/hydrochlorothiazide
(10/25&nbsp;mg) (the subset constitutes patients without aberrant readings,
defined as a difference between systolic blood pressure (SBP) readings
&#8805;10&nbsp;mmHg at baseline or endpoint). The effect of Rasitrio was
observed as early as one week after initiation of therapy. The
blood-pressure-lowering effect in patients with moderate to severe hypertension
was independent of age, gender, race, body mass index and overweight-associated
disorders (metabolic syndrome and diabetes).</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Rasitrio
was associated with a significant reduction in plasma renin activity (PRA) (&#8209;34%)
from baseline while the dual combination of amlodipine with hydrochlorothiazide
increased PRA (+170%). The clinical implications of the differences in effect
on PRA are not known at the present time.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>In
a 28 to 54&nbsp;week open label safety study, efficacy was measured as
secondary endpoint and Rasitrio at a dose of 300/10/25&nbsp;mg produced mean
blood pressure reductions (systolic/diastolic) of 37.3/21.8&nbsp;mmHg over 28
to 54&nbsp;weeks of treatment. Efficacy of Rasitrio was maintained over one
year of treatment, with no evidence of loss of effect.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>In
a randomised, double blind, active controlled, 36-week study in elderly
patients whose blood pressure was not controlled with aliskiren/HCTZ
300/25&nbsp;mg (SBP &#8805;140&nbsp;mmHg), clinically meaningful further BP
reduction was seen at week&nbsp;36 endpoint for patients who received Rasitrio
at a dose of 300/10/25&nbsp;mg (from reductions in msSBP/msDBP of
15.0/8.6&nbsp;mmHg at week&nbsp;22 to reductions of 30.8/14.1&nbsp;mmHg at
week&nbsp;36 endpoint).</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Rasitrio
has been administered to more than 1,155&nbsp;patients in completed clinical
trials, including 182&nbsp;patients for one year or more. Treatment with
Rasitrio was well tolerated at doses up to 300&nbsp;mg/10&nbsp;mg/25&nbsp;mg
with an overall incidence of adverse events similar to the corresponding dual
combinations, except for symptomatic hypotension. </span><span lang=EN-GB>The
incidence of any adverse reactions potentially related to hypotension in a
short-term controlled study was 4.9% with Rasitrio versus up to 3.7% with dual
combinations. In patients &#8805;65&nbsp;years the incidence was 10.2% with
Rasitrio versus up to 5.4% with dual combinations.</span></p>

<p class=CharCharCharCharChar align=left style='margin-bottom:0in;text-align:
left;line-height:normal'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=CharCharCharCharChar align=left style='margin-bottom:0in;text-align:
left;line-height:normal'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>The
incidence of adverse events did not show any association with gender, age (with
the exception of symptomatic hypotension), body mass index, race or ethnicity.
Adverse events have generally been mild and transient in nature. Very limited
safety data are available for patients aged &gt;75&nbsp;years or patients with
major cardiovascular co-morbidities. Discontinuation of therapy due to a
clinical adverse event occurred in 3.6% of patients treated with Rasitrio
versus 2.4% in aliskiren/amlodipine, 0.7% in aliskiren/hydrochlorothiazide and
2.7% in amlodipine/hydrochlorothiazide.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Aliskiren</span></u></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Aliskiren is
an orally active, non-peptide, potent and selective direct inhibitor of human
renin.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>By inhibiting
the enzyme renin, aliskiren inhibits the RAAS at the point of activation,
blocking the conversion of angiotensinogen to angiotensin&nbsp;I and decreasing
levels of angiotensin&nbsp;I and angiotensin&nbsp;II. Whereas other medicinal
products that inhibit the RAAS (ACEI and angiotensin&nbsp;II receptor blockers
(ARB)) cause a compensatory rise in plasma renin activity (PRA), treatment with
aliskiren decreases PRA in hypertensive patients by approximately 50 to 80%.
Similar reductions were found when aliskiren was combined with other
antihypertensive medicinal products. The clinical implications of the
differences in effect on PRA are not known at the present time.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Hypertension</span></i></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>In
hypertensive patients, once-daily administration of aliskiren at doses of
150&nbsp;mg and 300&nbsp;mg provided dose-dependent reductions in both systolic
and diastolic blood pressure that were maintained over the entire 24-hour dose
interval (maintaining benefit in the early morning) with a mean peak to trough
ratio for diastolic response of up to 98% for the 300&nbsp;mg dose. 85 to 90%
of the maximal blood-pressure-lowering effect was observed after 2&nbsp;weeks.
The blood-pressure-lowering effect was sustained during long-term treatment,
and was independent of age, gender, body mass index and ethnicity. Aliskiren
has been studied in 1,864&nbsp;patients aged 65&nbsp;years or older, and in
426&nbsp;patients aged 75&nbsp;years or older.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Aliskiren
monotherapy studies have shown blood-pressure-lowering effects comparable to
other classes of antihypertensive medicinal products including selected ACEI
and ARB. Compared to a diuretic (hydrochlorothiazide, HCTZ), aliskiren
300&nbsp;mg lowered systolic/diastolic blood pressure by 17.0/12.3&nbsp;mmHg,
compared to 14.4/10.5&nbsp;mmHg for HCTZ 25&nbsp;mg after 12&nbsp;weeks of
treatment.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Combination
therapy studies are available for aliskiren added to the diuretic
hydrochlorothiazide, the calcium channel blocker amlodipine and the beta
blocker atenolol. These combinations were well tolerated. Aliskiren induced an
additive blood-pressure-lowering effect when added to hydrochlorothiazide.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>&nbsp;</p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>The
efficacy and safety of aliskiren-based therapy were compared to ramipril-based
therapy in a 9-month non-inferiority study in 901&nbsp;elderly patients
(&#8805;65&nbsp;years) with essential systolic hypertension. Aliskiren
150&nbsp;mg or 300&nbsp;mg per day or ramipril 5&nbsp;mg or 10&nbsp;mg per day
were administered for 36&nbsp;weeks with optional add-on therapy of
hydrochlorothiazide (12.5&nbsp;mg or 25&nbsp;mg) at week&nbsp;12, and
amlodipine (5&nbsp;mg or 10&nbsp;mg) at week&nbsp;22. Over the 12-week period,
aliskiren monotherapy lowered systolic/diastolic blood pressure by
14.0/5.1&nbsp;mmHg, compared to 11.6/3.6&nbsp;mmHg for ramipril, consistent
with aliskiren being non-inferior to ramipril at the dosages chosen and the
differences in systolic and diastolic blood pressure were statistically
significant. Tolerability was comparable in both treatment arms, however cough
was more often reported with the ramipril regimen than the aliskiren regimen
(14.2% vs. 4.4%), whilst diarrhoea was more common with the aliskiren regimen
than for the ramipril regimen (6.6% vs. 5.0%).</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>In an 8-week study in 754&nbsp;hypertensive geriatric patients aged 65&nbsp;years
or older and geriatric patients aged 75&nbsp;years or older (30%) aliskiren at
doses of 75&nbsp;mg, 150&nbsp;mg and 300&nbsp;mg provided statistically
significant superior reduction in blood pressure (both systolic and diastolic)
when compared to placebo. No additional blood pressure lowering effect was
detected with 300&nbsp;mg aliskiren compared to 150&nbsp;mg aliskiren. All
three doses were well tolerated in both elderly and very elderly patients.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>There has been
no evidence of first-dose hypotension and no effect on pulse rate in patients
treated in controlled clinical studies. Excessive hypotension was uncommonly
(0.1%) seen in patients with uncomplicated hypertension treated with aliskiren
alone. Hypotension was also uncommon (&lt;1%) during combination therapy with
other antihypertensive medicinal products. With cessation of treatment, blood
pressure gradually returned towards baseline levels over a period of several
weeks, with no evidence of a rebound effect for blood pressure or PRA.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>I</span>n a 36-week study involving 820&nbsp;patients with ischaemic
left ventricular dysfunction, no changes in ventricular remodelling as assessed
by left ventricular end systolic volume were detected with aliskiren compared
to placebo on top of background therapy.</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>&nbsp;</p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>The combined
rates of cardiovascular death, hospitalisation for heart failure, recurrent
heart attack, stroke and resuscitated sudden death were similar in the
aliskiren group and the placebo group. However, in patients receiving aliskiren
there was a significantly higher rate of hyperkalaemia, hypotension and kidney
dysfunction when compared to the placebo group.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Aliskiren was evaluated for cardiovascular
and/or renal benefit in a double blind placebo controlled randomised trial in
8,606&nbsp;patients with type 2 diabetes and chronic kidney disease (evidenced
by proteinuria and/or GFR &lt;60&nbsp;ml/min/</span><span lang=EN-GB>1.73&nbsp;m<sup>2</sup></span><span
lang=EN-GB>) with or without cardiovascular disease. In most patients arterial
blood pressure was well controlled at baseline. The primary endpoint was a
composite of cardiovascular and renal complications.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>In this study,
aliskiren 300&nbsp;mg was compared to placebo when added to standard of care
which included either an angiotensin converting enzyme inhibitor or an
angiotensin receptor blocker. The study was discontinued prematurely because
the participants were unlikely to benefit from aliskiren. Study results
indicated a hazard ratio for the primary endpoint of 1.11 in favour of placebo
(95% Confidence Interval: 1.00, 1.23, 2-sided p=0.05). In addition, an
increased incidence of </span><span lang=EN-GB>adverse events</span><span
lang=EN-GB> was observed with aliskiren compared to placebo </span><span
lang=EN-GB>(37.9% versus 30.2%). In particular there was an increased incidence
of</span><span lang=EN-GB> renal </span><span lang=EN-GB>dysfunction</span><span
lang=EN-GB> (14.0% versus 12.1%), hyperkalaemia (38.9% versus 28.8%),
hypotension</span><span lang=EN-GB>-related events</span><span lang=EN-GB>
(19.7% versus 16.2%) </span><span lang=EN-GB>and adjudicated stroke endpoints
(3.4% versus 2.6%). The increased incidence of stroke was greater in patients
with renal insufficiency.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Effects of
aliskiren on mortality and cardiovascular morbidity are currently unknown.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>No long-term
efficacy data for aliskiren in patients with heart failure are currently
available (see section&nbsp;4.4).</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Cardiac electrophysiology</span></i></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>No effect on
QT interval was reported in a randomised, double-blind, placebo, and
active-controlled study using standard and Holter electrocardiography.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Amlodipine</span></u></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>The
amlodipine component of Rasitrio inhibits the transmembrane entry of calcium
ions </span><span lang=EN-GB>into cardiac and vascular smooth muscle. The
mechanism of the antihypertensive action of amlodipine is due to a direct
relaxant effect on vascular smooth muscle, causing reductions in peripheral
vascular resistance and in blood pressure. Experimental data suggest that
amlodipine binds to both dihydropyridine and non-dihydropyridine binding sites.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>The
contractile processes of cardiac muscle and vascular smooth muscle are
dependent upon the movement of extracellular calcium ions into these cells
through specific ion channels.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Following
administration of therapeutic doses to patients with hypertension, amlodipine
produces vasodilatation resulting in a reduction of supine and standing blood
pressures. These decreases in blood pressure are not accompanied by a
significant change in heart rate or plasma catecholamine levels with chronic
dosing.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Plasma
concentrations correlate with effect in both young and elderly patients.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>In
hypertensive patients with normal renal function, therapeutic doses of
amlodipine resulted in a decrease in renal vascular resistance and an increase
in glomerular filtration rate and effective renal plasma flow without change in
filtration fraction or proteinuria.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>As
with other calcium channel blockers, haemodynamic measurements of cardiac
function at rest and during exercise (or pacing) in patients with normal
ventricular function treated with amlodipine have generally demonstrated a
small increase in cardiac index without significant influence on dP/dt or on
left ventricular end diastolic pressure or volume. In haemodynamic studies,
amlodipine has not been associated with a negative inotropic effect when
administered in the therapeutic dose range to intact animals and humans, even
when co-administered with beta blockers to humans.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Amlodipine does
not change sinoatrial nodal function or atrioventricular conduction in intact
animals or humans. In clinical studies in which amlodipine was administered in
combination with beta blockers to patients with either hypertension or angina,
no adverse effects on electrocardiographic parameters were observed.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoDate><span lang=EN-GB>Amlodipine has demonstrated beneficial
clinical effects in patients with chronic stable angina, vasospastic angina and
angiographically documented coronary artery disease.</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><i><span lang=EN-GB>Use in patients with heart failure</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Calcium channel blockers, including amlodipine, should be used with
caution in patients with congestive heart failure, as they may increase the
risk of future cardiovascular events and mortality.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><i><span lang=EN-GB>Use in patients with hypertension</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>A randomised
double-blind morbidity-mortality study called the Antihypertensive and
Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT) was performed
to compare newer therapies: amlodipine 2.5&#8209;10&nbsp;mg/day (calcium
channel blocker) or lisinopril 10&#8209;40&nbsp;mg/day (ACE-inhibitor) as
first-line therapies to that of the thiazide-diuretic, chlorthalidone 12.5&#8209;25&nbsp;mg/day
in mild to moderate hypertension.</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>A total of
33,357&nbsp;hypertensive patients aged 55 or older were randomised and followed
for a mean of 4.9&nbsp;years. The patients had at least one additional coronary
heart disease risk factor, including: previous myocardial infarction or stroke
(&gt;6&nbsp;months prior to enrollment) or documentation of other atherosclerotic
cardiovascular disease (overall 51.5%), type 2 diabetes (36.1%), high density
lipoprotein - cholesterol &lt;35&nbsp;mg/dl or &lt;0.906&nbsp;mmol/l (11.6%),
left ventricular hypertrophy diagnosed by electrocardiogram or echocardiography
(20.9%), current cigarette smoking (21.9%).</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>The primary
endpoint was a composite of fatal coronary heart disease or non-fatal
myocardial infarction. There was no significant difference in the primary
endpoint between amlodipine-based therapy and chlorthalidone-based therapy:
risk ratio (RR) 0.98 95% CI (0.90&#8209;1.07) p=0.65. Among secondary
endpoints, the incidence of heart failure (component of a composite combined
cardiovascular endpoint) was significantly higher in the amlodipine group as
compared to the chlorthalidone group (10.2% vs. 7.7%, RR 1.38, 95% CI [1.25&#8209;1.52]
p&lt;0.001). However, there was no significant difference in all-cause
mortality between amlodipine-based therapy and chlorthalidone-based therapy RR
0.96 95% CI [0.89&#8209;1.02] p=0.20.</p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Hydrochlorothiazide</span></u></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>The
site of action of thiazide diuretics is primarily in the renal distal
convoluted tubule. It has been shown that there is a high-affinity receptor in
the renal cortex as the primary binding site for the thiazide diuretic action
and inhibition of NaCl transport in the distal convoluted tubule. The mode of
action of thiazides is through inhibition of the Na+Cl- symporter by competing
for the Cl- site, thereby affecting electrolyte reabsorption mechanisms:
directly increasing sodium and chloride excretion to an approximately equal
extent, and indirectly by this diuretic action reducing plasma volume, with
consequent increases in plasma renin activity, aldosterone secretion and
urinary potassium loss, and a decrease in serum potassium.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Paediatric population</span></u></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>The
European Medicines Agency has waived the obligation to submit the results of
studies with Rasitrio in all subsets of the paediatric population in essential
hypertension (see section&nbsp;4.2 for information on paediatric use).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5.2&nbsp;&nbsp;&nbsp;&nbsp; Pharmacokinetic
properties</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Aliskiren/amlodipine/hydrochlorothiazide combination</span></u></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Following
oral administration of a fixed combination tablet of aliskiren, amlodipine and
hydrochlorothiazide, peak concentrations were achieved for aliskiren within 1&#8209;2&nbsp;hours,
for amlodipine within 8&nbsp;hours and for hydrochlorothiazide within 2&#8209;3&nbsp;hours.
The rate and extent of absorption of aliskiren, amlodipine and
hydrochlorothiazide following administration of a fixed combination tablet are
similar to when administered as individual dosage forms.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>The
results from a food effect study using a </span><span lang=EN-GB>standard </span><span
lang=EN-GB>high-fat meal</span><span lang=EN-GB> with the 300/10/25&nbsp;mg
fixed combination tablet showed that food </span><span lang=EN-GB>reduced the
rate and extent of absorption of aliskiren in the fixed combination tablet with
a similar magnitude of effect as for aliskiren monotherapy. Food had no effect </span><span
lang=EN-GB>on the pharmacokinetics of amlodipine or hydrochlorothiazide in the
fixed combination tablet.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Aliskiren</span></u></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Absorption</span></i></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Following oral
absorption, peak plasma concentrations of aliskiren are reached after 1&#8209;3&nbsp;hours.
The absolute bioavailability of aliskiren is approximately 2&#8209;3%. Meals
with a high fat content reduce C<sub>max</sub> by 85% and AUC by 70%. At steady
state meals with low fat content reduce C<sub>max</sub> by 76% and AUC <sub>0-tau</sub>
by 67% in hypertensive patients. Steady-state plasma concentrations are reached
within 5&#8209;7&nbsp;days following once-daily administration and steady-state
levels are approximately 2-fold greater than with the initial dose.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Distribution</span></i></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Following
intravenous administration, the mean volume of distribution at steady state is
approximately 135&nbsp;litres, indicating that aliskiren distributes
extensively into the extravascular space. Aliskiren plasma protein binding is
moderate (47&#8209;51%) and independent of the concentration.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Biotransformation and elimination</span></i></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>The mean
half-life is about 40&nbsp;hours (range 34&#8209;41&nbsp;hours). Aliskiren is
mainly eliminated as unchanged compound in the faeces (78%). Approximately 1.4%
of the total oral dose is metabolised. The enzyme responsible for this
metabolism is CYP3A4. Approximately 0.6% of the dose is recovered in urine
following oral administration. Following intravenous administration, mean
plasma clearance is approximately 9&nbsp;l/h.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Linearity</span></i></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Exposure to
aliskiren increased more than in proportion to the increase in dose. After
single dose administration in the dose range of 75 to 600&nbsp;mg, a 2-fold
increase in dose results in a ~2.3 and 2.6-fold increase in AUC and C<sub>max</sub>,
respectively. At steady state the non-linearity may be more pronounced.
Mechanisms responsible for deviation from linearity have not been identified. A
possible mechanism is saturation of transporters at the absorption site or at
the hepatobiliary clearance route.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><i><span lang=EN-GB>Paediatric
population</span></i></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>In
a pharmacokinetic study of aliskiren treatment in 39 paediatric hypertensive
patients (aged 6&#8209;17&nbsp;years) given daily doses of 2&nbsp;mg/kg or
6&nbsp;mg/kg aliskiren administered as granules (3.125&nbsp;mg/tablet),
pharmacokinetic parameters were similar to those in adults. The available data
did not suggest that age, body weight or gender have any significant effect on
aliskiren systemic exposure (see section 4.2).</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Amlodipine</span></u></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Absorption</span></i></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>After oral
administration of therapeutic doses of amlodipine alone, peak plasma
concentrations of amlodipine are reached in 6&#8209;12&nbsp;hours. Absolute
bioavailability has been </span><span style='font-size:11.0pt;color:windowtext'>estima</span><span
style='font-size:11.0pt;color:windowtext'>ted as between 64% and 80%.
Amlodipine bioavailability is unaffected by food ingestion.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Distribution</span></i></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>The volume of
distribution is approximately 21&nbsp;l/kg. <i>In vitro </i>studies with
amlodipine have shown that approximately 97.5% of circulating amlodipine is
bound to plasma proteins.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Biotransformation and elimination</span></i></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Amlodipine
is extensively (approximately 90%) metabolised in the liver to inactive
metabolites, with 10% of the parent compound and 60% of the metabolites
excreted in the urine.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Amlodipine
elimination from plasma is biphasic with a terminal elimination half-life of
approximately 30 to 50&nbsp;hours. Steady-state plasma levels are reached after
continuous administration for 7&#8209;8&nbsp;days.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Linearity</span></i></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Amlodipine
exhibits linear pharmacokinetics between </span><span lang=EN-GB>the
therapeutic dose range of </span><span lang=EN-GB>5&nbsp;mg and 10&nbsp;mg</span><span
lang=EN-GB>.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Hydrochlorothiazide</span></u></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Absorption</span></i></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>The absorption of hydrochlorothiazide, after an oral dose, is rapid
(T<sub>max</sub> about 2&nbsp;h.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>The effect of food on hydrochlorothiazide absorption, if any, has
little clinical significance. Absolute bioavailability of hydrochlorothiazide
is 70% after oral administration.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Distribution</span></i></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>The apparent volume of distribution is 4&#8209;8&nbsp;l/kg.
Circulating hydrochlorothiazide is bound to serum proteins (40&#8209;70%),
mainly serum albumin. Hydrochlorothiazide also accumulates in erythrocytes at
approximately 3&nbsp;times the level in plasma.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Biotransformation and elimination</span></i></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Hydrochlorothiazide is eliminated predominantly as unchanged
compound. Hydrochlorothiazide is eliminated from plasma with a half-life
averaging 6 to 15&nbsp;hours in the terminal elimination phase. There is no
change in the kinetics of hydrochlorothiazide on repeated dosing, and
accumulation is minimal when dosed once daily. There is more than 95% of the
absorbed dose being excreted as unchanged compound in the urine. The renal
clearance is composed of passive filtration and active secretion into the renal
tubule.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Linearity</span></i></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>The increase in mean AUC is linear and dose proportional in the
therapeutic range.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Special populations</span></u></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Rasitrio is an
effective once-a-day antihypertensive treatment in adult patients, regardless
of gender, age, body mass index and ethnicity.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Renal impairment</span></i></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Due
to its hydrochlorothiazide component, Rasitrio is contraindicated in patients
with anuria or severe renal impairment (GFR &lt;30&nbsp;ml/min/1.73&nbsp;m<sup>2</sup>)
(see section&nbsp;4.3). No adjustment of the initial dose is required in
patients with mild to moderate renal impairment (see sections&nbsp;4.4 and
4.2).</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>The
pharmacokinetics of aliskiren were evaluated in patients with varying degrees
of renal insufficiency. Relative AUC and C<sub>max</sub> of aliskiren in
subjects with renal impairment ranged between 0.8 to 2&nbsp;times the levels in
healthy subjects following single dose administration and at steady state.
These observed changes, however, did not correlate with the severity of renal
impairment. No adjustment of the initial dose of aliskiren is required in
patients with mild to moderate renal impairment (see sections&nbsp;4.2 and
4.4). Aliskiren is not recommended in patients with severe renal impairment
(glomerular filtration rate (GFR) &lt;30&nbsp;ml/min/</span><span
style='font-size:11.0pt;color:windowtext'>1.73&nbsp;m<sup>2</sup></span><span
style='font-size:11.0pt;color:windowtext'>). Concomitant use of aliskiren with
ARBs or ACEIs is contraindicated in patients with renal impairment (GFR
&lt;60&nbsp;ml/min/</span><span style='font-size:11.0pt;color:windowtext'>1.73&nbsp;m<sup>2</sup></span><span
style='font-size:11.0pt;color:windowtext'>) (see section&nbsp;4.3).</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>The
pharmacokinetics of aliskiren were evaluated</span><span lang=EN-GB> in
patients with end stage renal disease receiving haemodialysis. Administration
of a single oral dose of 300&nbsp;mg aliskiren was associated with very minor
changes in the pharmacokinetics of aliskiren (change in C<sub>max</sub> of less
than 1.2&nbsp;fold; increase in AUC of up to 1.6&nbsp;fold) compared to matched
healthy subjects. Timing of haemodialysis did not significantly alter the
pharmacokinetics of aliskiren in ESRD patients. Therefore,<b><i> </i></b>if
administration of aliskiren in ESRD patients receiving haemodialysis is
considered necessary, no dose adjustment is warranted in these patients.
However, the use of aliskiren is not recommended in patients with severe renal
impairment (see section&nbsp;4.4).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The pharmacokinetics of amlodipine are not significantly influenced
by renal impairment.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>As
expected for a compound which is cleared almost exclusively via the kidneys,
renal function has a marked effect on the kinetics of hydrochlorothiazide. In
the presence of renal impairment, mean peak plasma levels and AUC values of
hydrochlorothiazide are increased and the urinary excretion rate is reduced. In
patients with mild to moderate renal impairment, a 3-fold increase in
hydrochlorothiazide AUC has been observed. In patients with severe renal
impairment an 8-fold increase in AUC has been observed.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Hepatic impairment</span></i></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Rasitrio is
contraindicated in patients with severe hepatic impairment (see
section&nbsp;4.3).</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>The
pharmacokinetics of aliskiren were not significantly affected in patients with
mild to severe liver disease. Consequently, no adjustment of the initial dose
of aliskiren is required in patients with mild to moderate hepatic impairment.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Very limited clinical data are available regarding amlodipine
administration in patients with hepatic impairment. Patients with hepatic
insufficiency have decreased clearance of amlodipine with resulting increase in
AUC of approximately 40&#8209;60%. Therefore caution should be exercised</span><span
lang=EN-GB> in patients with hepatic impairment.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Geriatric patients</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No data are
available on systemic exposure after administration of Rasitrio in geriatric
patients. When administered alone, the AUC of aliskiren in geriatric subjects
(&gt;65&nbsp;years) is 50% higher than in young subjects. The time to reach
peak plasma concentrations of amlodipine is similar in elderly and younger
subjects. Amlodipine clearance tends to be decreased with resulting increases
in AUC and elimination half-life in geriatric patients. </span><span
lang=EN-GB>Therefore particular caution is recommended when administering
Rasitrio to patients aged 65&nbsp;years and over, and extreme caution in
patients aged 75&nbsp;years or older (see sections&nbsp;4.2, 4.4, 4.8 and 5.1).</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Limited
data suggest that the systemic clearance of hydrochlorothiazide is reduced in
both healthy and hypertensive elderly subjects compared to young healthy
volunteers. There are no specific data regarding the effect of
hydrochlorothiazide in elderly patients.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Paediatric </span></i><i><span style='font-size:11.0pt;
color:windowtext'>population (age below 18&nbsp;years)</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The pharmacokinetics of Rasitrio have not been investigated. A
population pharmacokinetic study has been conducted in 74 hypertensive children
aged from 1 to 17&nbsp;years (with 34&nbsp;patients aged 6 to 12&nbsp;years and
28&nbsp;patients aged 13 to 17&nbsp;years) receiving amlodipine between 1.25
and 20&nbsp;mg given either once or twice daily. In children 6 to 12&nbsp;years
and in adolescents 13&#8209;17&nbsp;years of age the typical oral clearance
(CL/F) was 22.5 and 27.4&nbsp;l/hr respectively in males and 16.4 and
21.3&nbsp;l/hr respectively in females. Large variability in exposure between
individuals was observed. Data reported in children below 6&nbsp;years are
limited.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5.3&nbsp;&nbsp;&nbsp;&nbsp; Preclinical
safety data</span></b></p>

<p class=Text style='margin-bottom:0in;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Aliskiren/hydrochlorothiazide and aliskiren/amlodipine</span></u></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Non-clinical
studies of the toxicology of Rasitrio alone have not been conducted as these
studies have been conducted for the individual components.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>The
toxicity profiles of the combination of aliskiren/hydrochlorothiazide and
aliskiren/amlodipine have been well characterised in preclinical studies. Both
combinations were generally well tolerated by rats. The findings from 2- and
13-week oral toxicity studies were consistent with those for the individual
components.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Aliskiren</span></u></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Carcinogenic
potential was assessed in a 2-year rat study and a 6-month transgenic mouse
study. No carcinogenic potential was detected. One colonic adenoma and one
caecal adenocarcinoma recorded in rats at the dose of 1,500&nbsp;mg/kg/day were
not statistically significant. Although aliskiren has known irritation
potential, safety margins obtained in humans at the dose of 300&nbsp;mg during
a study in healthy volunteers were considered to be appropriate at 9&#8209;11-fold
based on faecal concentrations or 6-fold based on mucosa concentrations in
comparison with 250&nbsp;mg/kg/day in the rat carcinogenicity study.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Aliskiren was
devoid of any mutagenic potential in the <i>in vitro </i>and <i>in vivo </i>mutagenicity
studies. The assays included <i>in vitro </i>assays in bacterial and mammalian
cells and <i>in vivo </i>assessments in rats.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Reproductive
toxicity studies with aliskiren did not reveal any evidence of embryofoetal
toxicity or teratogenicity at doses up to 600&nbsp;mg/kg/day in rats or
100&nbsp;mg/kg/day in rabbits. Fertility, pre-natal development and post-natal
development were unaffected in rats at doses up to 250&nbsp;mg/kg/day. The
doses in rats and rabbits provided systemic exposures of 1 to 4 and
5&nbsp;times higher, respectively, than the maximum recommended human dose
(300&nbsp;mg).</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Safety
pharmacology studies did not reveal any adverse effects on central nervous,
respiratory or cardiovascular function. Findings during repeat-dose toxicity
studies in animals were consistent with the known local irritation potential or
the expected pharmacological effects of aliskiren.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Amlodipine</span></u></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Safety
data for amlodipine are well established both clinically and non-clinically.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Reproductive
toxicology</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Reproductive
studies in rats and mice have shown delayed date of delivery, prolonged
duration of labour and decreased pup survival at dosages approximately
50&nbsp;times greater than the maximum recommended dosage for humans based on
mg/kg.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Impairment of
fertility</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>There was no
effect on the fertility of rats treated with amlodipine (males for 64&nbsp;days
and females 14&nbsp;days prior to mating) at doses up to 10&nbsp;mg/kg/day
(8&nbsp;times* the maximum recommended human dose of 10&nbsp;mg on a mg/m<sup>2</sup>
basis). In another rat study in which male rats were treated with amlodipine
besilate for 30&nbsp;days at a dose comparable with the human dose based on
mg/kg, decreased plasma follicle-stimulating hormone and testosterone were
found as well as decreases in sperm density and in the number of mature
spermatids and Sertoli cells.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Carcinogenesis,
mutagenesis</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Rats and mice
treated with amlodipine in the diet for two years, at concentrations calculated
to provide daily dosage levels of 0.5, 1.25 and 2.5&nbsp;mg/kg/day showed no
evidence of carcinogenicity. The highest dose (for mice, similar to, and for
rats twice* the maximum recommended clinical dose of 10&nbsp;mg on a mg/m<sup>2</sup>
basis) was close to the maximum tolerated dose for mice but not for rats.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Mutagenicity
studies revealed no effects related to the medicinal product at either the gene
or chromosome levels.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>*Based on
patient weight of 50&nbsp;kg</span></p>

<p class=Default><u><span lang=EN-GB style='font-size:11.0pt;color:windowtext'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Hydrochlorothiazide</span></u></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Preclinical
evaluations to support the administration of hydrochlorothiazide in humans
included <i>in vitro</i> genotoxicity assays and reproductive toxicity and
carcinogenicity studies in rodents. Extensive clinical data are available for
hydrochlorothiazide and these are reflected in the relevant sections.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Hydrochlorothiazide
had no adverse effects on the fertility of mice and rats of either sex in
studies wherein these species were exposed, via their diet, to doses of up to
100 and 4&nbsp;mg/kg,/day respectively, prior to mating and throughout
gestation. These doses of hydrochlorothiazide in mice and rats represent 19 and
1.5&nbsp;times, respectively, the maximum recommended human dose on a mg/m<sup>2</sup>
basis. (Calculations assume an oral dose of 25&nbsp;mg/day and a 60-kg
patient.)</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
PARTICULARS</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.1&nbsp;&nbsp;&nbsp;&nbsp; List
of excipients</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Tablet core</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=IT>Cellulose
microcrystalline</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=IT>Crospovidone</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=IT>Povidone</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=IT>Magnesium stearate</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=IT>Silica colloidal
anhydrous</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=IT><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=IT>Coating</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=IT>Hypromellose</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=IT>Titanium dioxide
(E171)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=ES>Macrogol</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=ES>Talc</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=ES>Iron oxide red
(E172)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Iron oxide black
(E172)</span></p>

<p class=MsoDate><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b>6.2&nbsp;&nbsp;&nbsp;&nbsp; Incompatibilities</b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Not applicable.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.3&nbsp;&nbsp;&nbsp;&nbsp; Shelf
life</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>PVC/polychlorotrifluoroethylene (PCTFE) </span>&#8211;<span
lang=EN-GB> Alu calendar blisters:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>2&nbsp;years</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>PVC/polychlorotrifluoroethylene (PCTFE) </span>&#8211; <span
lang=EN-GB>Alu blisters:</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>2&nbsp;years</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'>PA/Alu/PVC
&#8211; Alu calendar blisters:</p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>18&nbsp;months</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.4&nbsp;&nbsp;&nbsp;&nbsp; Special
precautions for storage</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'>Do not store above 30&deg;C.</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>Store in the
original package in order to protect from moisture.</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.5&nbsp;&nbsp;&nbsp;&nbsp; Nature
and contents of container</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>PVC/polychlorotrifluoroethylene (PCTFE) - Alu calendar blisters:</span></p>

<p class=MsoDate>Single pack containing 14, 28, 56, 98&nbsp;tablets</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>PVC/polychlorotrifluoroethylene (PCTFE) - Alu blisters:</span></p>

<p class=MsoDate style='page-break-after:avoid'>Single pack containing 30,
90&nbsp;tablets</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'>Unit dose
pack (perforated unit dose blister) containing 56x1&nbsp;tablet</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>Multipacks of
unit dose (perforated unit dose blister) containing 98x1&nbsp;tablet (2&nbsp;packs
of 49x1)</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=ES>PA/Alu/PVC &#8211; Alu calendar blisters:</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'>Single pack containing 14, 28, 56&nbsp;tablets</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>Multipacks
containing 98&nbsp;tablets (2&nbsp;packs of 49)</p>

<p class=MsoDate>&nbsp;</p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Not
all pack sizes may be marketed.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.6&nbsp;&nbsp;&nbsp;&nbsp; Special
precautions for disposal</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Any unused medicinal product or waste material should be disposed of
in accordance with local requirements.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION HOLDER</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'>Novartis Europharm Limited</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'>Wimblehurst Road</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'>Horsham</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'>West Sussex, RH12 5AB</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>United
Kingdom</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'>EU/1/11/730/013&#8209;024</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; DATE
OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Date of first
authorisation: </span><span lang=EN-GB>22 November 2011</span></p>

<p class=MsoDate><span lang=EN-GB>Date of latest renewal:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>10.&nbsp;&nbsp;&nbsp;&nbsp; DATE
OF REVISION OF THE TEXT</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:28.3pt;line-height:normal'><span
lang=EN-GB>Detailed information on this medicinal product is available on the
website of the European Medicines Agency http://www.ema.europa.eu</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Rasitrio 300&nbsp;mg/5&nbsp;mg/25&nbsp;mg film-coated tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; QUALITATIVE
 AND QUANTITATIVE COMPOSITION</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each film-coated
tablet contains 300&nbsp;mg aliskiren (as hemifumarate), 5&nbsp;mg amlodipine
(as besylate) and 25&nbsp;mg hydrochlorothiazide.</span></p>

<p class=MsoDate><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For the full
list of excipients, see section&nbsp;6.1.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
<span style='text-transform:uppercase'>form</span></span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Film-coated tablet.</span></p>

<p class=MsoDate style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pale
orange-brown, ovaloid convex film-coated tablet with bevelled edges, with
&#8220;OIO&#8221; debossed on one side and &#8220;NVR&#8221; on the other.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB style='text-transform:uppercase'>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Clinical
particulars</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.1&nbsp;&nbsp;&nbsp;&nbsp; Therapeutic
indications</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Rasitrio is
indicated for the treatment of essential hypertension as substitution therapy
in adult patients whose blood pressure is adequately controlled on the
combination of aliskiren, amlodipine and hydrochlorothiazide given concurrently
at the same dose level as in the combination.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.2&nbsp;&nbsp;&nbsp;&nbsp; Posology
and method of administration</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><u><span lang=EN-GB>Posology</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The recommended dose of Rasitrio is one tablet per day.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Patients
receiving aliskiren, amlodipine and hydrochlorothiazide from separate tablets
given concurrently at the same time of the day may be switched to a fixed
combination tablet of Rasitrio containing the same component doses.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The fixed dose
combination should only be used after a stable effect on the monocomponents, </span><span
lang=HU>given concurrently,<b> </b></span><span lang=EN-GB>has been established
after dose titration. Dose should be individualised and adjusted according to
the patient&#8217;s clinical response.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><u><span lang=EN-GB>Special populations</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Elderly patients aged 65&nbsp;years and over</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>There is evidence
of an increased risk of adverse events related to hypotension in patients aged
65&nbsp;years or older treated with Rasitrio. Therefore, particular caution
should be exercised when administering Rasitrio in patients aged 65&nbsp;years
or over.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The recommended
starting dose of aliskiren in this group of patients is 150&nbsp;mg. No
clinically meaningful additional blood pressure reduction is observed by
increasing the dose to 300&nbsp;mg in the majority of elderly patients.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Elderly patients aged 75&nbsp;years and over</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Very limited data are available on the use of Rasitrio in patients
aged 75&nbsp;years or older (see section&nbsp;5.2). The use of Rasitrio in
patients aged 75&nbsp;years or older should be restricted to patients for whom
blood pressure control has been established for the free combination of
aliskiren, amlodipine and hydrochlorothiazide </span><span lang=EN-GB>given
concurrently</span><span lang=EN-GB> without accompanying safety concerns, in
particular hypotension. Extreme caution, including more frequent monitoring of
blood pressure, is recommended (see sections&nbsp;4.4, 4.8, 5.1 and 5.2)</span><span
style='font-family:"TimesNewRomanPSMT",serif'>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Renal impairment</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No adjustment of
the initial dose is required for patients with mild to moderate renal
impairment (</span><span lang=EN-GB>estimated </span><span lang=EN-GB>glomerular
filtration rate</span><span lang=EN-GB> (GFR) 89&#8209;60&nbsp;ml/min/1.73&nbsp;m<sup>2</sup>
and 59&#8209;30&nbsp;ml/min/1.73&nbsp;m<sup>2</sup>, respectively) (see
sections&nbsp;4.4 and 5.2). Due to the hydrochlorothiazide component, </span><span
lang=EN-GB>Rasitrio is contraindicated for use in patients with anuria and in
patients with severe renal impairment (GFR &lt;30&nbsp;ml/min/1.73&nbsp;m<sup>2</sup>).
The </span><span lang=EN-GB>c</span><span lang=EN-GB>oncomitant use of Rasitrio
with angiotensin II receptor blockers (ARB) or angiotensin converting enzyme
inhibitors (ACEI) is contraindicated in patients with renal impairment (GFR
&lt;60&nbsp;ml/min/</span><span lang=EN-GB>1.73&nbsp;m<sup>2</sup></span><span
lang=EN-GB>) (see sections&nbsp;4.3, 4.4 and 5.2).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Hepatic impairment</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Rasitrio is
contraindicated in patients with severe hepatic impairment. Caution</span>
should be exercised when administering Rasitrio i<span lang=EN-GB>n </span>patients
with mild to moderate hepatic impairment or patients with progressive liver
disease. No dosage recommendations have been established for amlodipine in
patients with mild to moderate hepatic impairment <span lang=EN-GB>(see
sections&nbsp;4.3 and 4.4).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Paediatric population</span></i></p>

<p class=MsoNormal style='line-height:normal'>The safety and efficacy of
Rasitrio in children and adolescents below age&nbsp;18 have not been
established. No data are available.</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><u><span lang=EN-GB>Method of administration</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Oral use. The
tablets should be swallowed whole with some water. Rasitrio should be taken
with a light meal once a day, preferably at the same time each day. Grapefruit
juice should not be taken together with Rasitrio (see section&nbsp;4.5).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b>4.3&nbsp;&nbsp;&nbsp;&nbsp; Contraindications</b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Hypersensitivity to the active substances or to
any of the excipients listed in section&nbsp;6.1, to other dihydropyridine
derivatives, or to other sulphonamide-derived substances.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>History of angioedema with aliskiren.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Hereditary or idiopathic angioedema.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Second and third trimesters of pregnancy (see
section&nbsp;4.6).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Anuria.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Severe renal impairment (GFR
&lt;30&nbsp;ml/min/1.73&nbsp;m<sup>2</sup>).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Hyponatraemia, hypercalcaemia, symptomatic
hyperuricaemia and refractory hypokalaemia.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Severe hepatic impairment.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The concomitant use of aliskiren with
ciclosporin and itraconazole, two highly potent P-glycoprotein (P-gp)
inhibitors, and other potent P-gp inhibitors (e.g. quinidine), is
contraindicated (see section&nbsp;4.5).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The concomitant use of aliskiren with ARBs or
ACEIs is contraindicated in patients with diabetes mellitus or renal impairment
(GFR &lt;60&nbsp;ml/min/</span><span lang=EN-GB>1.73&nbsp;m<sup>2</sup></span><span
lang=EN-GB>) (see sections&nbsp;4.2, 4.4, 4.5 and 5.1).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Severe hypotension.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Shock (including cardiogenic shock).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Obstruction of the outflow tract of the left
ventricle (e.g. high grade aortic stenosis).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Haemodynamically unstable heart failure after
acute myocardial infarction.</span></p>

<p class=MsoNormal style='line-height:normal;vertical-align:baseline'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.4&nbsp;&nbsp;&nbsp;&nbsp; Special
warnings and precautions for use</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>General</span></u></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>In the event
of severe and persistent diarrhoea, Rasitrio therapy should be stopped (see
section&nbsp;4.8).</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>As with any
antihypertensive medicinal product, excessive reduction of blood pressure in
patients with ischaemic cardiopathy or ischaemic cardiovascular disease could
result in a myocardial infarction or stroke.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Symptomatic
hypotension occurred with higher frequency in patients with non-complicated
hypertension treated with Rasitrio than in patients treated with dual
combinations of aliskiren/amlodipine, aliskiren/hydrochlorothiazide or
amlodipine/hydrochlorothiazide.</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Hypersensitivity
reactions to hydrochlorothiazide may occur in patients, but are more likely in
patients with allergy and asthma.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Systemic
lupus erythematosus</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Thiazide
diuretics, including hydrochlorothiazide, have been reported to exacerbate or
activate systemic lupus erythematosus.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The safety and
efficacy of amlodipine in hypertensive crisis have not been established.</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Dual blockade
of the renin-angiotensin-aldosterone system (RAAS)</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Hypotension,
syncope, stroke, hyperkalaemia, and changes in renal function (including acute
renal failure) have been reported in susceptible individuals, especially if
combining medicinal products that affect this system (see section</span><span
lang=EN-GB>&nbsp;</span><span lang=EN-GB>5.1). Dual blockade of the
renin-angiotensin-aldosterone system by combining aliskiren with an angiotensin
converting enzyme inhibitor (ACEI) or an angiotensin II receptor blocker (ARB)
is therefore not recommended. Close monitoring of blood pressure, renal
function and electrolytes should be exercised if co-administration is
considered absolutely necessary.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>T</span><span
lang=EN-GB>he use of</span><span lang=EN-GB> aliskiren in combination with ARBs
or ACEIs is contraindicated in patients with diabetes mellitus or renal
impairment (GFR &lt;60&nbsp;ml/min</span><span lang=EN-GB>/1.73&nbsp;m<sup>2</sup></span><span
lang=EN-GB>) (see section&nbsp;4.3)</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Geriatric
patients aged 65&nbsp;years and over</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Particular caution should be exercised when administering Rasitrio
in patients aged 65&nbsp;years or older. Symptomatic hypotension occurred with
higher frequency in patients with non-complicated hypertension treated with
Rasitrio than in patients treated with dual combinations of
aliskiren/amlodipine, aliskiren/hydrochlorothiazide or
amlodipine/hydrochlorothiazide. Patients aged 65&nbsp;years old or over, are
more susceptible to hypotension-related adverse reactions following treatment
with Rasitrio (see sections&nbsp;4.2, 4.8, 5.1 and 5.2).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Geriatric patients aged 75&nbsp;years and over</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Very limited efficacy and safety data are available on the use of
Rasitrio in patients aged 75&nbsp;years or older. Extreme caution, </span>including
more frequent monitoring of blood pressure, is recommended<span lang=EN-GB>
(see sections&nbsp;4.2, 4.8, 5.1 and 5.2).</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Heart failure</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Calcium channel
blockers, including amlodipine, should be used with caution in patients with
congestive heart failure, as they may increase the risk of future
cardiovascular events and mortality.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>No data on
cardiovascular mortality and morbidity are available for Rasitrio in patients
with heart failure (see section&nbsp;5.1).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Aliskiren should
be used with caution in patients with heart failure treated with furosemide
(see section&nbsp;4.5).</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Risk of symptomatic hypotension</span></u></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Symptomatic
hypotension could occur after initiation of treatment with Rasitrio Rasitrio in
the following cases:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>Patients with marked volume depletion or patients with salt
depletion <span lang=EN-GB>(e.g. those receiving high doses of diuretics) </span>or</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>Combined use of aliskiren with other agents acting on the RAAS.</p>

<p class=Default><span style='font-size:11.0pt'>The volume or salt depletion
should be corrected prior to administration of Rasitrio, or the treatment
should start under close medical supervision.</span></p>

<p style='margin:0in'><u><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Electrolyte imbalance</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Treatment with
Rasitrio should only start after correction of hypokalaemia and any coexisting
hypomagnesaemia. Thiazide diuretics can precipitate new onset hypokalaemia or
exacerbate pre-existing hypokalaemia. Thiazide diuretics should be administered
with caution in patients with conditions involving enhanced potassium loss, for
example salt-losing nephropathies and prerenal (cardiogenic) impairment of
kidney function. </span><span lang=EN-GB>If hypokalaemia develops during
hydrochlorothiazide therapy Rasitrio should be discontinued until stable
correction of the potassium balance.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'>Hypokalaemia may develop with the
use of thiazide diuretics. The risk of hypokalaemia is greater in patients with
cirrhosis of the liver, patients experiencing brisk diuresis, patients with
inadequate oral electrolyte intake and patients receiving concomitant therapy
with corticosteroids or adrenocorticotropic hormone (ACTH) (see sections&nbsp;4.5
and 4.8).</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal><span lang=EN-GB>Conversely, </span><span lang=EN-GB>increases
in serum potassium have been observed with aliskiren in post-marketing
experience and these may be exacerbated by concomitant use of other agents
acting on the RAAS or by non-steroidal anti-inflammatory drugs (NSAIDs).
Consistent with standard medical practice, periodic determination of renal
function including serum electrolytes is advised if co-administration is
considered necessary. The concomitant use of aliskiren and ACEIs or ARBs is
contraindicated in patients with diabetes mellitus or renal impairment (GFR
&lt;60&nbsp;ml/min</span><span lang=EN-GB>/1.73&nbsp;m<sup>2</sup></span><span
lang=EN-GB>) (see section</span><span lang=EN-GB>&nbsp;</span><span lang=EN-GB>4.3,
4.5 and 4.8).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoDate><span lang=EN-GB>Thiazide diuretics can precipitate new onset
hyponatraemia and hypochloroaemic alkalosis or exacerbate pre-existing
hyponatraemia. Hyponatraemia, accompanied by neurological symptoms (nausea,
progressive disorientation, apathy) has been observed. Treatment with
hydrochlorothiazide should only be started after correction of pre-existing
hyponatraemia. In case severe or rapid hyponatraemia develops during Rasitrio
therapy, the treatment should be discontinued until normalisation of natraemia.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>All patients receiving thiazide diuretics
should be periodically monitored for imbalances in electrolytes, particularly
potassium, sodium and magnesium.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Thiazides
reduce urinary calcium excretion and may cause an intermittent and slight
elevation of serum calcium in the absence of known disorders of calcium
metabolism. Rasitrio is contraindicated in patients with hypercalcaemia and
should only be used after correction of any pre-existing hypercalcaemia.
Rasitrio should be discontinued if hypercalcaemia develops during treatment.
Serum levels of calcium should be periodically monitored during treatment with
thiazides. Marked hypercalcaemia may be evidence of hidden hyperparathyroidism.
Thiazides should be discontinued before carrying out tests for parathyroid
function.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>There is no
evidence that Rasitrio would reduce or prevent diuretic-induced hyponatraemia.
Chloride deficit is generally mild and usually does not require treatment.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Renal impairment and kidney transplantation</span></u></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Thiazide
diuretics may precipitate azotaemia in patients with chronic kidney disease.
When Rasitrio is used in patients with renal impairment, periodic monitoring of
serum electrolytes including potassium, creatinine and uric acid serum levels
is recommended. No data is available in hypertensive patients with severe renal
impairment (serum creatinine &#8805;150&nbsp;&#956;mol/l or 1.70&nbsp;mg/dl in
women and &#8805;177&nbsp;&#956;mol/l or 2.00&nbsp;mg/dl in men and/or
estimated glomerular filtration rate (GFR) &lt;30&nbsp;ml/min/</span><span
style='font-size:11.0pt;color:windowtext'>1.73&nbsp;m<sup>2</sup></span><span
style='font-size:11.0pt;color:windowtext'>), history of dialysis, nephrotic
syndrome or renovascular hypertension. Rasitrio is contraindicated in
hypertensive patients with severe renal impairment (GFR &lt;30&nbsp;ml/min/</span><span
style='font-size:11.0pt;color:windowtext'>1.73&nbsp;m<sup>2</sup></span><span
style='font-size:11.0pt;color:windowtext'>) or anuria (see sections&nbsp;4.2.
and 4.3). No dose adjustment is necessary in patients with mild to moderate
renal impairment.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>As for other
medicinal products acting on the RAAS, caution should be exercised when
Rasitrio is given in the presence of conditions pre-disposing to kidney
dysfunction such as hypovolaemia (e.g. due to blood loss, severe or prolonged
diarrhoea, prolonged vomiting, etc.), heart disease, liver disease, diabetes
mellitus or kidney disease. The concomitant use of aliskiren and ACEIs or ARBs
is contraindicated in patients with renal impairment (GFR
&lt;&nbsp;60&nbsp;ml/min/</span><span style='font-size:11.0pt;color:windowtext'>1.73&nbsp;m<sup>2</sup></span><span
style='font-size:11.0pt;color:windowtext'>). Acute renal failure, reversible
upon discontinuation of treatment, has been reported in at-risk patients
receiving aliskiren in post-marketing experience. In the event that any signs
of renal failure occur, aliskiren should be promptly discontinued.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>There is no
experience regarding the administration of Rasitrio in patients who have
recently undergone kidney transplantation, therefore caution should be
exercised in these patients.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Hepatic impairment</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Rasitrio is
contraindicated in hypertensive patients with severe hepatic impairment (see
sections&nbsp;4.3 and 5.2). Caution should be exercised when administering
Rasitrio to patients with mild to moderate hepatic impairment or progressive
liver disease (see sections&nbsp;4.2 and 5.2).</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The half life of
amlodipine is prolonged and AUC values are higher in patients with impaired
liver function; dosage recommendations have not been established.</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Aortic and mitral valve stenosis, obstructive hypertrophic
cardiomyopathy</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>As with all
other vasodilators, special caution is indicated when using amlodipine in
patients suffering from aortic or mitral stenosis, or obstructive hypertrophic
cardiomyopathy.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Metabolic and endocrine effects</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Thiazide
diuretics, including hydrochlorothiazide, may alter glucose tolerance and raise
serum levels of cholesterol and triglycerides, and uric acid. In diabetic
patients dose adjustments of insulin or oral hypoglycaemic medicinal products
may be required during Rasitrio therapy. </span><span lang=EN-GB>C</span><span
lang=EN-GB>oncomitant use of Rasitrio with ARBs or ACEIs is contraindicated in
patients with diabetes mellitus (see section&nbsp;4.3).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Due to the hydrochlorothiazide component,
Rasitrio is contraindicated in symptomatic hyperuricaemia (see
section&nbsp;4.3). </span><span lang=EN-GB>Hydrochlorothiazide may raise the
serum uric acid level due to reduced clearance of uric acid and may cause or
exacerbate hyperuricaemia as well as precipitate gout in susceptible patients.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Thiazides reduce
urinary calcium excretion and may cause an intermittent and slight elevation of
serum calcium in the absence of known disorders of calcium metabolism. Rasitrio
is contraindicated in patients with hypercalcaemia and should only be used
after correction of any pre-existing hypercalcaemia. Rasitrio should be
discontinued if hypercalcaemia develops during treatment. Serum levels of
calcium should be periodically monitored during treatment with thiazides.
Marked hypercalcaemia may be evidence of hidden hyperparathyroidism. Thiazides
should be discontinued before carrying out tests for parathyroid function.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Renal artery stenosis</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No controlled
clinical data are available on the use of Rasitrio in patients with unilateral
or bilateral renal artery stenosis, or stenosis to a solitary kidney. However,
as with other medicinal products acting on the renin-angiotensin-aldosterone
system, there is an increased risk of renal insufficiency, including acute
renal failure, when patients with renal artery stenosis are treated with
aliskiren. Therefore caution should be exercised in these patients. If renal
failure occurs, treatment should be discontinued.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Anaphylactic reactions and angioedema</span></u></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Anaphylactic
reactions have been observed during treatment with aliskiren from
post-marketing experience (see section&nbsp;4.8). As with other medicinal
products acting on the renin-angiotensin-aldosterone system (RAAS), angioedema
or symptoms suggestive of angioedema (swelling of the face, lips, throat and/or
tongue) have been reported in patients treated with aliskiren.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>A number of
these patients had a history of angioedema or symptoms suggestive of
angioedema, which in some cases followed use of other medicinal products that
can cause angioedema, including RAAS blockers (angiotensin converting enzyme
inhibitors or angiotensin receptor blockers) (see section&nbsp;4.8).</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In
post-marketing experience, angioedema or angioedema-like reactions have been
reported when aliskiren was co-administered with ACEIs and/or ARBs (see
section&nbsp;4.8).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Special caution
is necessary in patients with a hypersensitivity predisposition.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Patients with
history of angioedema may be at increased risk of experiencing angioedema
during treatment with aliskiren (see sections&nbsp;4.3 and 4.8). Caution should
therefore be exercised when prescribing aliskiren to patients with a history of
angioedema, and such patients should be closely monitored during treatment (see
section&nbsp;4.8) especially at the beginning of the treatment.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>If anaphylactic reactions or</span><span
lang=EN-GB> </span><span lang=EN-GB>angioedema occur, Rasitrio should be
promptly discontinued and appropriate therapy and monitoring provided until
complete and sustained resolution of signs and symptoms has occurred. Patients
should be informed to report to the physician any signs suggestive of allergic
reactions, in particular difficulties in breathing or swallowing, swelling of
face, extremities, eyes, lips or tongue. Where there is involvement of the
tongue, glottis or larynx adrenaline should be administered. In addition,
measures necessary to maintain patent airways should be provided.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u>Photosensitivity</u></p>

<p class=MsoNormal>Cases of photosensitivity reactions have been reported with
thiazide diuretics (see section&nbsp;4.8). If photosensitivity reaction occurs
during treatment with <span lang=EN-GB>Rasitrio</span>, it is recommended to
stop the treatment. If a re-administration of the diuretic is deemed necessary,
it is recommended to protect exposed areas to the sun or to artificial UVA.</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Acute angle-closure glaucoma</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Hydrochlorothiazide, a sulphonamide, has
been associated with an idiosyncratic reaction resulting in acute transient
myopia and acute angle-closure glaucoma. Symptoms include acute onset of
decreased visual acuity or ocular pain and typically occur within hours to
weeks of treatment initiation. Untreated acute angle-closure glaucoma can lead
to permanent vision loss. The primary treatment is to discontinue
hydrochlorothiazide as rapidly as possible. Prompt medical or surgical
treatment may need to be considered if the intraocular pressure remains
uncontrolled. Risk factors for developing acute angle-closure glaucoma may
include a history of sulphonamide or penicillin allergy.</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.5&nbsp;&nbsp;&nbsp;&nbsp; Interaction
with other medicinal products and other forms of interaction</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Information on Rasitrio interactions</span></u></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>A
population pharmacokinetic analysis in patients with hypertension did not
indicate any clinically relevant changes in the </span><span lang=EN-GB>steady-state
exposure (AUC) and C<sub>max</sub> of aliskiren, amlodipine and
hydrochlorothiazide compared to the corresponding dual therapies.</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Medicinal
products affecting serum potassium levels</span></i><span lang=EN-GB>: </span><span
lang=EN-GB>The potassium-depleting effect of hydrochlorothiazide is attenuated
by the potassium-sparing effect of aliskiren. However, this effect of
hydrochlorothiazide on serum potassium would be expected to be potentiated by
other medicinal products associated with potassium loss and hypokalaemia (e.g.
other kaliuretic diuretics, corticosteroids, laxatives, adrenocoricotropic hormone
(ACTH), amphotericin, carbenoxolone, penicillin G, salicylic acid derivatives).
Conversely,</span><span lang=EN-GB> concomitant use of other agents affecting
the RAAS, of NSAIDs or of agents that increase serum potassium levels (e.g.
potassium-sparing diuretics, potassium supplements, salt substitutes containing
potassium, heparin) may lead to increases in serum potassium. If co-medication
with an agent affecting the level of serum potassium is considered necessary,
caution is advisable. The combination of aliskiren with </span><span
lang=EN-GB>ARBs or ACEIs </span><span lang=EN-GB>is contraindicated in patients
with diabetes mellitus or renal impairment (GFR &lt;60&nbsp;ml/min/</span><span
lang=EN-GB>1.73&nbsp;m<sup>2</sup></span><span lang=EN-GB>) and is not
recommended in other patients (see sections</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>4.3, 4.4 and 5.1)</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Medicinal
products affected by serum potassium disturbances</span></i><span lang=EN-GB>: </span><span
lang=EN-GB>Periodic monitoring of serum potassium is recommended when Rasitrio
is administered with medicinal products affected by serum potassium
disturbances (e.g. digitalis glycosides, antiarrhythmics).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default><i><span style='font-size:11.0pt;color:windowtext'>Non-steroidal
anti-inflammatory drugs (NSAIDs), including selective cyclooxygenase-2
inhibitors (COX-2 inhibitors)</span></i><span class=msoins0><i><span
style='font-size:11.0pt;color:windowtext'>, acetylsalicylic acid and
non-selective NSAIDs</span></i></span><i><span style='font-size:11.0pt;
color:windowtext'>:</span></i><span style='font-size:11.0pt;color:windowtext'>
As with other agents acting on the renin-angiotensin system, NSAIDs may reduce
the anti-hypertensive effect of aliskiren. NSAIDs may also weaken the diuretic
and antihypertensive activity of hydrochlorothiazide.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In some patients
with compromised renal function (dehydrated patients or elderly patients)
aliskiren and hydrochlorothiazide given concomitantly with NSAIDs may result in
further deterioration of renal function, including possible acute renal
failure, which is usually reversible. Therefore the use of Rasitrio with an
NSAID requires caution, especially in elderly patients.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Information on aliskiren interactions</span></u></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Contraindicated (see section&nbsp;4.3)</span></i></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span style='font-size:11.0pt;color:windowtext'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span style='font-size:11.0pt;color:windowtext'>Dual RAAS
blockade</span></i></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>The
combination of aliskiren with ARBs or ACEIs is contraindicated in patients with
diabetes mellitus or renal impairment (GFR &lt;60&nbsp;ml/min/</span><span
style='font-size:11.0pt;color:windowtext'>1.73&nbsp;m<sup>2</sup></span><span
style='font-size:11.0pt;color:windowtext'>) and is not recommended in other
patients (see sections&nbsp;4.3, 4.4 and 5.1).</span></p>

<p class=Default><i><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></i></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span style='font-size:11.0pt;color:windowtext'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span style='font-size:11.0pt;color:windowtext'>P-glycoprotein
(P-gp) potent inhibitors</span></i></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>A single dose
drug interaction study in healthy subjects has shown that ciclosporin (200 and
600&nbsp;mg) increases C<sub>max</sub> of aliskiren 75&nbsp;mg approximately
2.5-fold and AUC approximately 5-fold. The increase may be higher with higher
aliskiren doses. </span><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>In
healthy subjects, itraconazole (100&nbsp;mg) increases AUC and C<sub>max</sub>
of aliskiren (150&nbsp;mg) by 6.5-fold and 5.8-fold, respectively. </span><span
style='font-size:11.0pt;color:windowtext'>Therefore, concomitant use of
aliskiren and P-gp potent inhibitors is contraindicated (see section&nbsp;4.3).</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i>Not
recommended (see section&nbsp;4.2)</i></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span style='font-size:11.0pt;color:windowtext'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span style='font-size:11.0pt;color:windowtext'>Grapefruit
juice</span></i></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Administration
of grapefruit juice with aliskiren resulted in a decrease in AUC and C<sub>max</sub>
of aliskiren. Co-administration with aliskiren 150&nbsp;mg resulted in a 61%
decrease in aliskiren AUC and co-administration with aliskiren 300&nbsp;mg resulted
in a 38% decrease in aliskiren AUC. This decrease is likely due to an
inhibition of </span><span style='font-size:11.0pt;color:windowtext'>organic
anion transporting polypeptide-mediated uptake of aliskiren by grapefruit juice
in the gastrointestinal tract. Therefore, because of the risk of therapeutic
failure, grapefruit juice should not be taken together with Rasitrio.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i>Caution
required with concomitant use</i></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span style='font-size:11.0pt;color:windowtext'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span style='font-size:11.0pt;color:windowtext'>P-gp
interactions</span></i></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>MDR</span><span
style='font-size:11.0pt;color:windowtext'>1/Mdr1a/1b (P-gp) was found to be the
major efflux system involved in intestinal absorption and biliary excretion of
aliskiren in preclinical studies. Rifampicin, which is an inducer of P-gp,
reduced aliskiren bioavailability by approximately 50% in a clinical study.
Other inducers of P-gp (St. John&#8217;s wort) might decrease the
bioavailability of aliskiren. Although this has not been investigated for
aliskiren, it is known that P-gp also controls tissue uptake of a variety of
substrates and P-gp inhibitors can increase the tissue-to-plasma concentration
ratios. Therefore, P-gp inhibitors may increase tissue levels more than plasma
levels. The potential for drug interactions at the P-gp site will likely depend
on the degree of inhibition of this transporter.</span></p>

<p class=Default><i><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></i></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span style='font-size:11.0pt;color:windowtext'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span style='font-size:11.0pt;color:windowtext'>Moderate P-gp
inhibitors</span></i></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Co-administration
of ketoconazole (200&nbsp;mg) or verapamil (240&nbsp;mg) with aliskiren
(300&nbsp;mg) resulted in a 76% or 97% increase in aliskiren AUC, respectively.
The change in plasma levels of aliskiren in the presence of ketoconazole or
verapamil is expected to be within the range that would be achieved if the dose
of aliskiren were doubled; aliskiren doses of up to 600&nbsp;mg, or twice the
highest recommended therapeutic dose, have been found to be well tolerated in
controlled clinical trials. Preclinical studies indicate that aliskiren and
ketoconazole co-administration enhances aliskiren gastrointestinal absorption
and decreases biliary excretion. Therefore, caution should be exercised when
aliskiren is administered with ketoconazole, verapamil or other moderate P-gp
inhibitors (clarithromycin, telithromycin, erythromycin, amiodarone).</span></p>

<p class=Default><i><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></i></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span style='font-size:11.0pt;color:windowtext'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span style='font-size:11.0pt;color:windowtext'>Medicinal
products affecting serum potassium levels</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Concomitant use
of other agents affecting the RAAS, of NSAIDs or of agents that increase serum
potassium levels (e.g. potassium-sparing diuretics, potassium supplements, salt
substitutes containing potassium, heparin) may lead to increases in serum
potassium. If co-administration with an agent affecting the level of serum
potassium is considered necessary, caution is advisable. The combination of
aliskiren with ARBs or ACEIs is contraindicated in patients with diabetes
mellitus or renal impairment (GFR &lt;60&nbsp;ml/min/</span><span lang=EN-GB>1.73&nbsp;m<sup>2</sup></span><span
lang=EN-GB>) and is not recommended in other patients (see sections&nbsp;4.3,
4.4 and 5.1).</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span style='font-size:11.0pt;color:windowtext'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span style='font-size:11.0pt;color:windowtext'>Furosemide</span></i></p>

<p class=Default><span lang=EN style='font-size:11.0pt;color:windowtext'>Oral
co-administration of aliskiren and furosemide had no effect on the
pharmacokinetics of aliskiren but reduced exposure to furosemide by 20&#8209;30%
(the </span><span style='font-size:11.0pt;color:windowtext'>effect of aliskiren
on furosemide administered intramuscularly or intravenously has not been
investigated)</span><span lang=EN style='font-size:11.0pt;color:windowtext'>.
After </span><span style='font-size:11.0pt;color:windowtext'>multiple doses of </span><span
lang=EN style='font-size:11.0pt;color:windowtext'>furosemide (60</span><span
style='font-size:11.0pt;color:windowtext'>&nbsp;</span><span lang=EN
style='font-size:11.0pt;color:windowtext'>mg/day) co-administered with
aliskiren (300&nbsp;mg/day) </span><span style='font-size:11.0pt;color:windowtext'>to
patients with heart failure</span><span lang=EN style='font-size:11.0pt;
color:windowtext'> the urinary sodium excretion and the urine volume were
reduced during the first 4&nbsp;hours by 31% and 24%, respectively, as compared
to furosemide alone. </span><span style='font-size:11.0pt;color:windowtext'>The
mean weight of patients concomitantly treated with furosemide and 300&nbsp;mg
aliskiren (84.6&nbsp;kg) was higher than the weight of patients treated with
furosemide alone (83.4&nbsp;kg)</span><span lang=EN style='font-size:11.0pt;
color:windowtext'>. Smaller changes in furosemide pharmacokinetics and efficacy
were observed with aliskiren 150</span><span style='font-size:11.0pt;
color:windowtext'>&nbsp;</span><span lang=EN style='font-size:11.0pt;
color:windowtext'>mg/day. In patients treated with both aliskiren and oral
furosemide,</span><span style='font-size:11.0pt;color:windowtext'> it is
therefore recommended that the effects of furosemide be monitored when
initiating and adjusting furosemide or aliskiren therapy to avoid changes in
extracellular fluid volume and possible situations of volume overload (see
section&nbsp;4.4).</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span style='font-size:11.0pt;color:windowtext'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span style='font-size:11.0pt;color:windowtext'>Warfarin</span></i></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>The effects of
aliskiren on warfarin pharmacokinetics have not been evaluated.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span style='font-size:11.0pt;color:windowtext'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span style='font-size:11.0pt;color:windowtext'>Food
interactions</span></i></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Meals (low or
high fat content) have been shown to reduce the absorption of aliskiren
substantially (see section&nbsp;4.2).</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i>No
interactions</i></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt'><span
style='font-size:11.0pt;color:windowtext'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt;color:windowtext'>Compounds that
have been investigated in aliskiren clinical pharmacokinetic studies include
acenocoumarol, atenolol, celecoxib, pioglitazone, allopurinol,
isosorbide-5-mononitrate and hydrochlorothiazide. No interactions have been
identified.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>Co-administration of aliskiren with either metformin
(&#8595;28%), amlodipine (&#8593;29%) or cimetidine (&#8593;19%) resulted in
between 20% and 30%<span lang=EN-GB> change in C</span><sub><span lang=EN-GB>max</span></sub><span
lang=EN-GB> or AUC of aliskiren. When administered with atorvastatin,
steady-state aliskiren AUC and C</span><sub><span lang=EN-GB>max</span></sub><span
lang=EN-GB> increased by 50%. Co-administration of aliskiren had no significant
impact on atorvastatin, metformin or amlodipine pharmacokinetics. As a result
no dose adjustment for aliskiren or these co-administered medicinal products is
necessary.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Digoxin
and verapamil bioavailability may be slightly decreased by aliskiren.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span style='font-size:11.0pt;color:windowtext'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span style='font-size:11.0pt;color:windowtext'>CYP450 interactions</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Aliskiren does
not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1 and 3A).
Aliskiren does not induce CYP3A4. Therefore aliskiren is not expected to affect
the systemic exposure of substances that inhibit, induce or are metabolised by
these enzymes. </span><span lang=EN-GB>Aliskiren is metabolised minimally by
the cytochrome P450 enzymes. Hence, interactions due to inhibition or induction
of CYP450 isoenzymes are not expected. However, CYP3A4 inhibitors often also
affect P-gp. Increased aliskiren exposure during co-administration of CYP3A4
inhibitors that also inhibit P-gp can therefore be expected (see other P-gp
references in section&nbsp;4.5).</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span style='font-size:11.0pt;color:windowtext'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span style='font-size:11.0pt;color:windowtext'>P-gp
substrates or weak inhibitors</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No relevant
interactions with atenolol, digoxin, amlodipine or cimetidine have been
observed. When administered with atorvastatin (80&nbsp;mg), steady-state
aliskiren (300&nbsp;mg) AUC and C<sub>max</sub> increased by 50%. </span><span
lang=EN-GB>In experimental animals, it has been shown that P-gp is a major
determinant of aliskiren bioavailability. Inducers of P-gp (St. John&#8217;s wort,
rifampicin) might therefore decrease the bioavailability of aliskiren.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span style='font-size:11.0pt;color:windowtext'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span style='font-size:11.0pt;color:windowtext'>Organic anion
transporting polypeptide (OATP) inhibitors</span></i></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Preclinical
studies indicate that aliskiren might be a substrate of organic anion
transporting polypeptides. Therefore, the potential exists for interactions
between OATP inhibitors and aliskiren when administered concomitantly (see
interaction with Grapefruit juice).</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Information on amlodipine interactions</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Effects of other medicinal products on amlodipine</span></u></i></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Caution required with concomitant use</span></i></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span style='font-size:11.0pt;color:windowtext'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span style='font-size:11.0pt;color:windowtext'>CYP3A4
inhibitors</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Concomitant use
of amlodipine with strong or moderate CYP3A4 inhibitors (protease inhibitors,
azole antifungals, macrolides like erythromycin or clarithromycin, verapamil or
diltiazem) may give rise to significant increase in amlodipine exposure. The
clinical translation of these pharmacokinetic variations may be more pronounced
in the elderly. Clinical monitoring and dose adjustment may thus be required.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span style='font-size:11.0pt;color:windowtext'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span style='font-size:11.0pt;color:windowtext'>CYP3A4
inducers</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>There is no data
available regarding the effect of CYP3A4 inducers on amlodipine. The
concomitant use of CYP3A4 inducers (e.g. rifampicin, <i>hypericum perforatum</i>)
may give a lower plasma concentration of amlodipine. Amlodipine should be used
with caution together with CYP3A4 inducers.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:1.5in;text-indent:-1.5in;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Grapefruit juice</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Administration
of amlodipine with grapefruit or grapefruit juice is not recommended as
bioavailability may be increased in some patients, resulting in increased blood
pressure lowering effects.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Dantrolene (infusion)</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In animals,
lethal ventricular fibrillation and cardiovascular collapse are observed in
association with hyperkalaemia after administration of verapamil and
intravenous dantrolene. Due to risk of hyperkalaemia, it is recommended that
the co-administration of calcium channel blockers such as amlodipine be avoided
in patients susceptible to malignant hyperthermia and in the management of
malignant hyperthermia.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Effects of amlodipine on other medicinal products</span></u></i></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The blood pressure lowering effects of
amlodipine add to the blood pressure lowering effects of other antihypertensive
medicinal products.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Co-administration of multiple doses of
10&nbsp;mg of amlodipine with 80&nbsp;mg simvastatin resulted in a 77% increase
in exposure to simvastatin compared to simvastatin alone. It is recommended to
limit the dose of simvastatin to 20&nbsp;mg daily in patients on amlodipine.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>No interactions</span></i></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>In clinical interaction studies, amlodipine did
not affect the pharmacokinetics of atorvastatin, digoxin, warfarin or
ciclosporin.</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Information on hydrochlorothiazide interactions</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>When administered
concurrently, the following medicinal products may interact with thiazide
diuretics:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i>Not recommended</i></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span style='font-size:11.0pt;color:windowtext'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span style='font-size:11.0pt;color:windowtext'>Lithium</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>R</span>enal
clearance of lithium is reduced by thiazides, therefore the risk of lithium
toxicity<span lang=EN-GB> may be increased with hydrochlorothiazide</span>. Co-administration
of lithium and <span lang=EN-GB>hydrochlorothiazide</span> is not recommended.
If this combination proves essential, careful monitoring of serum lithium level
is recommended during concomitant use.</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i>Caution
required with concomitant use</i></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span style='font-size:11.0pt;color:windowtext'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span style='font-size:11.0pt;color:windowtext'>Alcohol</span></i><i><span
style='color:windowtext'>, barbiturates or narcotics</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Concomitant
administration of thiazide diuretics with subtances that also have a blood
pressure lowering effect (e.g. by reducing sympathetic central nervous system
activity or direct vasodilatation) may potentiate orthostatic hypotension.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Amantadine</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Thiazides,
including hydrochlorothiazide, may increase the risk of adverse reactions
caused by amantadine.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Antidiabetic agents (e.g. insulin and oral
antidiabetic agents)</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Thiazides may
alter glucose tolerance. Dose adjustment of the antidiabetic medicinal product
may be necessary (see section&nbsp;4.4). Metformin should be used with caution
because of the risk of lactic acidosis induced by possible functional renal
failure linked to hydrochlorothiazide.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Anticholinergic agents and other medicinal
products affecting gastric motility</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The
bioavailability of thiazide-type diuretics may be increased by anticholinergic
agents (e.g. atropine, biperiden), apparently due to a decrease in
gastrointestinal motility and the stomach emptying rate. Conversely, it is anticipated
that prokinetic substances such as cisapride may decrease the bioavailability
of thiazide-type diuretics.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Medicinal products used in the treatment of
gout</span></i></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Dose
adjustment of uricosuric </span>medicinal products<i> </i><span lang=EN-GB>may
be necessary as hydrochlorothiazide may raise the level of serum uric acid.
Increase of dose of probenecid or sulfinpyrazone may be necessary. Co<b>-</b>administration
of thiazide diuretics, including hydrochlorothiazide, may increase the
incidence of hypersensitivity reactions to allopurinol.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicinal
products that could induce torsades de pointes</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Due to the risk of hypokalaemia,
hydrochlorothiazide should be administered with caution when associated with
medicinal products that could induce <i>torsades de pointes</i>, in particular
Class Ia and Class III </span><span lang=EN-GB>antiarrhythmics</span><span
lang=EN-GB> </span><span lang=EN-GB>and some </span><span lang=EN-GB>antipsychotics.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><i><span lang=EN-GB>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicinal
products affecting serum sodium level</span></i></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>The
hyponatraemic effect of diuretics may be intensified by concomitant
administration of medicinal products such as antidepressants, antipsychotics,
antiepileptics, etc. Caution is indicated in long-term administration of these
medicinal products.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Beta blockers and diazoxide</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Concomitant use
of thiazide diuretics, including hydrochlorothiazide, with beta blockers may
increase the risk of hyperglycaemia. Thiazide diuretics, including
hydrochlorothiazide, may enhance the hyperglycaemic effect of diazoxide.</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Ion exchange resins</span></i></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Absorption
of thiazide diuretics, including hydrochlorothiazide, is decreased by
cholestyramine or colestipol. This could result in sub-therapeutic effects of
thiazide diuretics. However, staggering the dosage of hydrochlorothiazide and
resin such that hydrochlorothiazide is administered at least 4&nbsp;hours
before or 4&#8209;6&nbsp;hours after the administration of resins would
potentially minimise the interaction.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Vitamin D and calcium salts</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Administration
of thiazide diuretics, including hydrochlorothiazide, with vitamin D or with
calcium salts may potentiate the rise in serum calcium. Concomitant use of
thiazide type diuretics may lead to hypercalcaemia in patients pre-disposed for
hypercalcaemia (e.g. hyperparathyroidism, malignancy, or vitamin-D-mediated
conditions) by increasing tubular calcium reabsorption.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Non-depolarising skeletal muscle relaxants</span></i></p>

<p class=MsoNormal style='line-height:normal'>Thiazides, including
hydrochlorothiazide, potentiate the action of skeletal muscle relaxants such as
curare derivatives.</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Cytotoxic agents</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Thiazides,
including hydrochlorothiazide, may reduce the renal excretion of cytotoxic
agents (e.g. cyclophosphamide, methotrexate) and potentiate their
myelosuppressive effects.</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Digoxine or digitalis glycosides</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Thiazide-induced
hypokalaemia or hypomagnesaemia favour the onset of digitalis-induced cardiac
arrhythmias (see section&nbsp;4.4).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoDate style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Methyldopa</span></i></p>

<p class=MsoDate><span lang=EN-GB>There have been isolated reports of
haemolytic anaemia occurring with concomitant use of hydrochlorothiazide and
methyldopa.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Iodine
contrasting agents</span></i></p>

<p class=MsoNormal><span lang=EN-GB>In case of diuretic-induced dehydration,
there is an increased risk of acute renal failure, especially with high doses
of iodine products. Patients should be rehydrated before administration.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Pressor amines (e.g. noradrenaline,
adrenaline)</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Hydrochlorothiazide
may reduce the response to pressor amines such as noradrenaline. The clinical
significance of this effect is uncertain and not sufficient to preclude their
use.</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.6&nbsp;&nbsp;&nbsp;&nbsp; Fertility,
pregnancy and lactation</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Women of childbearing potential/contraception in males and
females</span></u></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Healthcare
professionals prescribing Rasitrio should counsel women of childbearing
potential about the potential risk during pregnancy. A switch to a suitable alternative
antihypertensive treatment should be carried out in advance of a planned
pregnancy since Rasitrio should not be used in women planning to become
pregnant.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Pregnancy</span></u></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>There are no
data on the use of aliskiren in pregnant women. Aliskiren was not teratogenic
in rats or rabbits (see section&nbsp;5.3). Other substances that act directly
on the renin-angiotensin-aldosterone system have been associated with serious
foetal malformations and neonatal death. As for any medicinal product that acts
directly on the renin-angiotensin-aldosterone system, aliskiren should not be
used during the first trimester of pregnancy and is contraindicated during the
second and third trimesters (see section&nbsp;4.3).</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The safety of
amlodipine in human pregnancy has not been established. Reproductive studies in
rats have shown no toxicity except for delayed date of delivery and prolonged
duration of labour at dosages 50&nbsp;times greater than the maximum
recommended dosage for humans (see section&nbsp;5.3). Use in pregnancy is only
recommended when there is no safer alternative and when the disease itself
carries greater risk for the mother and foetus.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>There is limited experience with
hydrochlorothiazide during pregnancy, especially during the first trimester.
Animal studies are insufficient.</span></p>

<p class=MsoDate><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoDate><span lang=EN-GB>Hydrochlorothiazide crosses the placenta.
Based on the pharmacological mechanism of action of hydrochlorothiazide, its
use during the second and third trimester may compromise foeto-placental
perfusion and may cause foetal and neonatal effects like icterus, disturbance
of electrolyte balance and thrombocytopenia.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Hydrochlorothiazide should not be used for
gestational oedema, gestational hypertension or pre&#8209;eclampsia due to the
risk of decreased plasma volume and placental hypoperfusion, without a beneficial
effect on the course of the disease.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Hydrochlorothiazide should not be used for
essential hypertension in pregnant women except in rare situations where no
other treatment could be used.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Rasitrio
should not be used during the first trimester of pregnancy. Rasitrio is
contraindicated during the second and third trimesters (see section&nbsp;4.3).</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>If pregnancy
is detected during therapy, Rasitrio should be discontinued accordingly as soon
as possible.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Breast-feeding</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>It is not known
whether aliskiren and/or amlodipine are excreted in human milk. Aliskiren was
secreted in the milk of lactating rats.</span></p>

<p class=MsoDate><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoDate><span lang=EN-GB>Hydrochlorothiazide is excreted in human milk
in small amounts. Thiazides in high doses causing intense diuresis can inhibit
milk production.</span></p>

<p class=MsoDate><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The use of
Rasitrio during breast-feeding is not recommended. If Rasitrio is used during
breast-feeding, doses should be kept as low as possible.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Fertility</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>There are no
clinical data on fertility with the use of Rasitrio.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Reversible
biochemical changes in the head of spermatozoa have been reported in some
patients treated by calcium channel blockers. Clinical data are insufficient
regarding the potential effect of amlodipine on fertility. In one rat study,
adverse effects were found on male fertility (see section&nbsp;5.3). The
fertility of rats was unaffected at doses of up to aliskiren 250&nbsp;mg/kg/day
and hydrochlorothiazide 4&nbsp;mg/kg/day (see section&nbsp;5.3).</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.7&nbsp;&nbsp;&nbsp;&nbsp; Effects
on ability to drive and use machines</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>No studies on the effect on the ability to drive and use machines
have been performed</span>. However, when driving vehicles or using machines it
must be borne in mind that dizziness or drowsiness may occasionally occur when
taking Rasitrio.</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Amlodipine can
have minor or moderate influence on the ability to drive and use machines. If patients
taking amlodipine suffer from dizziness, drowsiness, headache, fatigue or
nausea, the ability to react may be impaired.</span></p>

<p class=MsoDate><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.8&nbsp;&nbsp;&nbsp;&nbsp; Undesirable
effects</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Summary of the safety profile</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Aliskiren/amlodipine/hydrochlorothiazide combination</span></u></i></p>

<p style='margin:0in'><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>The safety profile of Rasitrio presented below is
based on clinical studies performed with Rasitrio and the known safety profile
of the individual components aliskiren, amlodipine and hydrochlorothiazide.
Safety information for Rasitrio in patients aged 75&nbsp;years and older is
limited.</span></p>

<p style='margin:0in'><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoCommentText style='line-height:normal'><span lang=EN-GB
style='font-size:11.0pt'>The most frequent adverse reactions observed with
Rasitrio are hypotension and dizziness. The adverse reactions previously
reported with one of the individual components of Rasitrio (aliskiren,
amlodipine and hydrochlorothiazide) and listed in the respective paragraphs on
the individual components may occur with Rasitrio.</span></p>

<p class=Default><u><span lang=EN-GB style='font-size:11.0pt;color:windowtext'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Tabulated
list of adverse reactions:</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>The adverse
reactions for aliskiren, amlodipine and hydrochlorothiazide are ranked under
heading of frequency, the most frequent first, using the following convention:
very common (&#8805;1/10); common (&#8805;1/100 to &lt;1/10); uncommon
(&#8805;1/1,000 to &lt;1/100); rare (&#8805;1/10,000 to &lt;1/1,000); very rare
(&lt;1/10,000), not known (cannot be estimated from the available data). Within
each frequency grouping, adverse reactions are presented in order of decreasing
seriousness.</span></p>

<p style='margin:0in'><u><span style='font-size:11.0pt;font-family:"Times New Roman",serif'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p style='margin:0in;page-break-after:avoid'><i><u><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Information on
Rasitrio</span></u></i></p>

<p class=CharCharCharCharChar align=left style='margin-bottom:0in;text-align:
left;line-height:normal;page-break-after:avoid'><span style='font-size:11.0pt;
font-family:"Times New Roman",serif'>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='margin-left:5.4pt;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-bottom:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
  layout-grid-mode:line'>Nervous system disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Common</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Dizziness</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
  layout-grid-mode:line'>Vascular disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Common</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Hypotension</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><b><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>General
  disorders and administration site conditions</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Common</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Peripheral
  oedema</span></p>
  </td>
 </tr>
</table>

<p class=CharCharCharCharChar align=left style='margin-bottom:0in;text-align:
left;line-height:normal'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'>Peripheral oedema is
a known, dose-dependent adverse reaction of amlodipine and has also been
reported with aliskiren therapy in post-marketing experience. The incidence of
peripheral oedema for Rasitrio in a short-term double active-controlled study
was 7.1% compared to 8.0% for aliskiren/amlodipine, 4.1% for
amlodipine/hydrochlorothiazide and 2.0% for aliskiren/hydrochlorothiazide dual
combinations.</p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>The
incidence of any adverse reactions potentially related to hypotension in a
short-term active controlled study was 4.9% with Rasitrio versus up to 3.7%
with dual combinations. In patients &#8805;65&nbsp;years the incidence was
10.2% with Rasitrio versus up to 5.4% with dual combinations.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'>&nbsp;</p>

<p style='margin:0in;page-break-after:avoid'><i><u><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Additional
information on individual components</span></u></i></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Other
adverse reactions previously reported with one of the individual components may
occur with Rasitrio even if not observed in clinical trials.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p style='margin:0in;page-break-after:avoid'><i><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Aliskiren</span></i></p>

<p style='margin:0in;page-break-after:avoid'><span lang=EN-GB style='font-size:
11.0pt;font-family:"Times New Roman",serif'>Serious adverse reactions include
anaphylactic reaction and angioedema which have been reported in post-marketing
experience and may occur rarely (less than 1&nbsp;case per
1,000&nbsp;patients). The most common adverse reaction is diarrhoea.</span></p>

<p style='margin:0in'><u><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoDate style='page-break-after:avoid'><span lang=EN-GB>Tabulated list
of adverse reactions:</span></p>

<p class=MsoNormal><span lang=EN-GB>The known aliskiren adverse reactions are
presented in the table below using the same convention as described previously
for the fixed combination.</span></p>

<p style='margin:0in;page-break-after:avoid'><u><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='margin-left:5.4pt;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-bottom:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
  layout-grid-mode:line'>Immune system disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Anaphylactic
  reactions, h</span><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
  layout-grid-mode:line'>ypersensitivity reactions</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><b><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Cardiac
  </span></b><b><span lang=DE-CH style='font-size:11.0pt;font-family:"Times New Roman",serif'>d</span></b><b><span
  lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>isorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Common</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Dizziness</span></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Uncommon</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Palpitations</span><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>, oedema
  peripheral</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><b><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Vascular
  disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Uncommon</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Hypotension</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
  layout-grid-mode:line'>Respiratory, thoracic and mediastinal disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
  layout-grid-mode:line'>Uncommon</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
  layout-grid-mode:line'>Cough</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
  layout-grid-mode:line'>Gastrointestinal disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Common</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Diarrhoea</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><b><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Hepatobiliary
  disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Not
  known</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Liver
  disorder*</span><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>,
  j</span><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>aundice</span><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>,</span><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'> </span><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>h</span><span
  lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>epatitis</span><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>, l</span><span
  lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>iver
  failure</span><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>**</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
  layout-grid-mode:line'>Skin and subcutaneous tissue disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Uncommon</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Severe
  cutaneous adverse reactions (SCARs) including Stevens Johnson syndrome, toxic
  epidermal necrolysis (TEN), oral mucosal reactions, rash, pruritus, urticaria</span></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Angioedema,
  erythema</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
  layout-grid-mode:line'>Musculoskeletal and connective tissue disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Common</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Arthralgia</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
  layout-grid-mode:line'>Renal and urinary disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Uncommon</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=FR style='font-size:11.0pt;font-family:"Times New Roman",serif'>Acute
  renal failure, renal impairment</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
  layout-grid-mode:line'>Investigations</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Common</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Hyperkalaemia</span></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Uncommon</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Liver
  enzyme increased</span></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Haemoglobin
  decreased, haematocrit decreased, blood creatinine increased</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>*Isolated cases
of liver disorder with clinical symptoms and laboratory evidence of more marked
hepatic dysfunction.</span></p>

<p style='margin:0in'><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>**Including one case of &#8216;liver failure
fulminant&#8217; reported in the post-marketing experience, for which a causal
relationship with aliskiren cannot be excluded.</span></p>

<p style='margin:0in'><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Description of
selected adverse events:</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Hypersensitivity
reactions including anaphylactic reactions and angioedema have occurred during
treatment with aliskiren.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>In controlled
clinical trials, angioedema and hypersensitivity reactions occurred rarely
during treatment with aliskiren with rates comparable to treatment with placebo
or comparators.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Cases of
angioedema or symptoms suggestive of angioedema (swelling of the face, lips,
throat and/or tongue) have also been reported in post-marketing experience. A
number of these patients had a history of angioedema or symptoms suggestive of
angioedema which in some cases was associated with the administration of other
medicinal products known to cause angioedema, including RAAS blockers (ACEIs or
ARBs).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'>In post-marketing experience,
cases of angioedema or angioedema-like reactions have been reported when
aliskiren was co-administered with ACEIs and/or ARBs.</p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Hypersensitivity
reactions including anaphylactic reactions have also been reported in
post-marketing experience (see section&nbsp;4.4).</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>In the event
of any signs suggesting a hypersensitivity reaction/angioedema (in particular
difficulties in breathing, or swallowing, rash, itching, hives or swelling of
the face, extremities, eyes, lips and/or tongue, dizziness) patients should discontinue
treatment and contact the physician (see section&nbsp;4.4).</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Arthralgia has
been reported in post-marketing experience. In some cases this occurred as part
of a hypersensitivity reaction.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In
post-marketing experience, renal dysfunction and cases of acute renal failure
have been reported in patients at risk (see section&nbsp;4.4).</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><i><span style='font-size:11.0pt;color:windowtext'>Investigations:
</span></i><span style='font-size:11.0pt;color:windowtext'>In controlled
clinical trials, clinically relevant changes in standard laboratory parameters
were uncommonly associated with the administration of aliskiren. In clinical
studies in hypertensive patients, aliskiren had no clinically important effects
on total cholesterol, high density lipoprotein cholesterol (HDL-C),
fasting triglycerides, fasting glucose or uric acid.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><i><span style='font-size:11.0pt;color:windowtext'>Haemoglobin
and haematocrit</span></i><span style='font-size:11.0pt;color:windowtext'>:
Small decreases in haemoglobin and haematocrit (mean decreases of approximately
0.05&nbsp;mmol/l and 0.16&nbsp;volume percent, respectively) were observed. No
patients discontinued therapy due to anaemia. This effect is also seen with
other medicinal products acting on the RAAS, such as ACEIs and ARBs.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><i><span style='font-size:11.0pt;color:windowtext'>Serum
potassium</span></i><span style='font-size:11.0pt;color:windowtext'>: Increases
in serum potassium have been observed with aliskiren and these may be
exacerbated by concomitant use of other agents acting on the RAAS or by NSAIDs.
Consistent with standard medical practice, periodic determination of renal
function including serum electrolytes is advised if co-administration is
considered necessary. The combination of aliskiren with ARBs or ACEIs is
contraindicated in patients with diabetes mellitus or renal impairment (GFR
&lt;60&nbsp;ml/min/</span><span style='font-size:11.0pt;color:windowtext'>1.73&nbsp;m<sup>2</sup></span><span
style='font-size:11.0pt;color:windowtext'>) and is not recommended in other
patients (see sections&nbsp;4.3, 4.4 and 5.1).</span></p>

<p style='margin:0in'><u><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><i><span lang=EN-GB>Paediatric population: </span></i><span
lang=EN-GB>Based on the limited amount of safety data available from a
pharmacokinetic study of aliskiren treatment in 39 hypertensive children 6&#8209;17&nbsp;years
of age, the frequency, type and severity of adverse reactions in children are
expected to be similar to that seen in hypertensive adults. As for other RAAS
blockers, headache is a common adverse event in children treated with
aliskiren.</span></p>

<p style='margin:0in'><u><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Amlodipine</span></i></p>

<p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
color:windowtext'>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><b><span style='font-size:
  11.0pt;color:windowtext'>Blood and lymphatic system disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Very
  rare</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Leukopenia,
  thrombocytopenia</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><b><span style='font-size:
  11.0pt;color:windowtext'>Immune system disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Very rare</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Allergic
  reactions</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><b><span style='font-size:
  11.0pt;color:windowtext'>Metabolism and nutrition disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Very rare</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Hyperglycaemia</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><b><span style='font-size:
  11.0pt;color:windowtext'>Psychiatric disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Uncommon</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Insomnia, mood changes (including anxiety), depression</span></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Rare</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Confusion</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><b><span style='font-size:
  11.0pt;color:windowtext'>Nervous system disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Common</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Somnolence, headache (especially at the beginning of
  treatment)</span></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Uncommon</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Tremor, dysgeusia, syncope, hypoesthesia, paraesthesia</span></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Very rare</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Hypertonia,
  peripheral neuropathy</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><b><span style='font-size:
  11.0pt;color:windowtext'>Eye disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Uncommon</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Visual
  disturbance (including diplopia)</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><b><span style='font-size:
  11.0pt;color:windowtext'>Ear and labyrinth disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Uncommon</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Tinnitus</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><b><span style='font-size:
  11.0pt;color:windowtext'>Cardiac disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Common</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Palpitations</span></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Very rare</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Myocardial
  infarction, arrhythmia (including bradycardia, ventricular tachycardia and
  atrial fibrillation)</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><b><span style='font-size:
  11.0pt;color:windowtext'>Vascular disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Common</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Flushing</span></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Very rare</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Vasculitis</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><b><span style='font-size:
  11.0pt;color:windowtext'>Respiratory, thoracic and mediastinal disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Uncommon</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Dyspnoea, rhinitis</span></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Very rare</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Cough</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><b><span style='font-size:
  11.0pt;color:windowtext'>Gastrointestinal disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Common</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Abdominal pain, nausea</span></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Uncommon</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Vomiting, dyspepsia, altered bowel habits (including
  diarrhoea and constipation), dry mouth</span></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Very rare</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Pancreatitis,
  gastritis, gingival hyperplasia</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><b><span style='font-size:
  11.0pt;color:windowtext'>Hepatobiliary disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Very rare</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Hepatitis,
  jaundice, hepatic enzymes increased (mostly consistent with cholestasis)</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><b><span style='font-size:
  11.0pt;color:windowtext'>Skin and subcutaneous tissue disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Uncommon</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Alopecia, purpura, skin decolouration, hyperhidrosis,
  pruritus, rash, exanthema</span></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Very rare</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Angioedema,
  erythema multiforme, urticaria, exfoliative dermatitis, Stevens-Johnson
  syndrome, Quincke oedema, photosensitivity</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><b><span style='font-size:
  11.0pt;color:windowtext'>Musculoskeletal and connective tissue disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;color:windowtext'>Common</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Ankle swelling</span></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Uncommon</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Arthralgia,
  myalgia, muscle cramps, back pain</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><b><span style='font-size:
  11.0pt;color:windowtext'>Renal and urinary disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Uncommon</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Micturition
  disorder, nocturia, increased urinary frequency</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><b><span style='font-size:
  11.0pt;color:windowtext'>Reproductive system and breast disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Uncommon</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Impotence,
  gynaecomastia</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><b><span style='font-size:
  11.0pt;color:windowtext'>General disorders and administration site conditions</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Common</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Oedema, fatigue</span></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Uncommon</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span lang=FR style='font-size:11.0pt;color:windowtext'>Chest
  pain, asthenia, pain, malaise</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><b><span style='font-size:
  11.0pt;color:windowtext'>Investigations</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Uncommon</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Weight
  increase, weight decrease</span></p>
  </td>
 </tr>
</table>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Exceptional
cases of extrapyramidal syndrome have been reported.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Hydrochlorothiazide</span></i></p>

<p style='margin:0in;page-break-after:avoid'><span lang=EN-GB style='font-size:
11.0pt;font-family:"Times New Roman",serif'>Hydrochlorothiazide has been
extensively prescribed for many years, frequently in higher doses than those
contained in </span><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Rasitrio</span><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>. </span><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>The
following adverse reactions have been reported in patients treated with thiazide
diuretics alone, including hydrochlorothiazide:</span></p>

<p style='margin:0in;page-break-after:avoid'><i><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></i></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='margin-left:5.4pt;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-bottom:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:
  line'>Blood and lymphatic system disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Thrombocytopenia</span><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>
  sometimes with purpura</span></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Very rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Agranulocytosis,
  bone marrow depression, haemolytic anaemia, leucopenia</span></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Not known</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Aplastic
  anaemia</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:
  line'>Immune system disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=X-NONE style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Very rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Hypersensitivity</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:
  line'>Metabolism and nutrition disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Very common</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Hypokalaemia</span></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Common</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Hyperuricaemia,
  hypomagnesaemia, hyponatraemia</span></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Hypercalcaemia,
  hyperglycaemia, worsening of diabetic metabolic state</span></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=X-NONE style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Very rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Hypochloraemic
  alkalosis</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:
  line'>Psychiatric disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=X-NONE style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Depression,
  sleep disturbances</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:
  line'>Nervous system disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=X-NONE style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Dizziness,
  headache, paraesthesia</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:
  line'>Eye disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Visual
  impairment</span></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=X-NONE style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Not known</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Acute
  angle-closure glaucoma</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:
  line'>Cardiac disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=X-NONE style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Cardiac
  arrhythmias</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:
  line'>Vascular disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=X-NONE style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Common</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Orthostatic
  hypotension</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:
  line'>Respiratory, thoracic and mediastinal disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=X-NONE style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Very rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Respiratory
  distress (including pneumonitis and pulmonary oedema)</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:
  line'>Gastrointestinal disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Common</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Decreased
  appetite, mild nausea and vomiting</span></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Abdominal
  discomfort, constipation, diarrhoea</span></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=X-NONE style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Very rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Pancreatitis</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:
  line'>Hepatobiliary disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Intrahepatic
  cholestasis, jaundice</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:
  line'>Skin and subcutaneous tissue disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Common</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Urticaria
  and other forms of rash</span></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Photosensitivity
  reactions</span></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Very rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Cutaneous
  lupus erythematosus-like reactions, reactivation of cutaneous lupus
  erythematosus, vasculitis necrotising and toxic epidermal necrolysis</span></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Not known</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Erythema
  multiforme</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:
  line'>Musculoskeletal and connective tissue disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=X-NONE style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Not known</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Muscle
  spasm</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:
  line'>Renal and urinary disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=X-NONE style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Not known</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=FR style='font-size:11.0pt;font-family:"Times New Roman",serif'>Renal
  dysfunction, acute renal failure</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:
  line'>Reproductive system and breast disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=X-NONE style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Common</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Impotence</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:
  line'>General disorders and administration site conditions</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=X-NONE style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Not known</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Asthenia,
  pyrexia</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:
  line'>Investigations</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Very common</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Increases
  in cholesterol and triglycerides</span></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Glycosuria</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.9&nbsp;&nbsp;&nbsp;&nbsp; Overdose</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Symptoms</span></u></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>The most
likely manifestation of overdose for Rasitrio would be hypotension, related to
the antihypertensive effect of the combination of aliskiren, amlodipine and
hydrochlorothiazide.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>With
aliskiren, the most likely manifestation of overdose would be hypotension,
related to the antihypertensive effect of aliskiren.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>With
amlodipine, available data suggest that gross overdose could result in
excessive peripheral vasodilatation and possibly reflex tachycardia. </span><span
style='font-size:11.0pt;color:windowtext'>Marked and </span><span lang=EN-GB
style='font-size:11.0pt;color:windowtext'>probably </span><span
style='font-size:11.0pt;color:windowtext'>prolonged systemic hypotension</span><span
lang=EN-GB style='font-size:11.0pt;color:windowtext'> up to and</span><span
style='font-size:11.0pt;color:windowtext'> including shock with fatal outcome,
have been reported with amlodipine.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Overdose with
hydrochlorothiazide is associated with electrolyte depletion (hypokalaemia,
hypochloraemia, hyponatraemia) and dehydration resulting from excessive
diuresis. The most common signs and symptoms of overdose are nausea and
somnolence. Hypokalaemia may result in muscle spasms and/or accentuate cardiac
arrhythmias associated with the concomitant use of digitalis glycosides or
certain antiarrhythmic medicinal products.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Treatment</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If symptomatic
hypotension should occur with Rasitrio, supportive treatment should be
initiated.</span></p>

<p class=MsoNormal style='line-height:normal'><i>&nbsp;</i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Clinically
significant hypotension due to amlodipine overdose calls for active
cardiovascular support including frequent monitoring of cardiac and respiratory
function, elevation of extremities and attention to circulating fluid volume
and urine output.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>A vasoconstrictor
may be helpful in restoring vascular tone and blood pressure, provided that
there is no contraindication to its use. Intravenous calcium gluconate may be
beneficial in reversing the effects of calcium channel blockade.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Gastric lavage
may be worthwhile in some cases. In healthy volunteers the use of charcoal up
to 2&nbsp;hours after administration of amlodipine 10&nbsp;mg has been shown to
reduce the absorption rate of amlodipine.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Since amlodipine
is highly protein-bound, dialysis is not likely to be of benefit.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In a study
conducted in patients with end stage renal disease (ESRD) receiving
haemodialysis, dialysis clearance of aliskiren was low (&lt;2% of oral
clearance). Therefore dialysis is not adequate to treat aliskiren
over-exposure.</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACOLOGICAL
PROPERTIES</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5.1&nbsp;&nbsp;&nbsp;&nbsp; Pharmacodynamic
properties</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>Pharmacotherapeutic group</span><span lang=EN-GB>:
Agents acting on the renin-angiotensin system, renin-inhibitors; ATC code
C09XA54</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Rasitrio
combines three antihypertensive active substances with complementary mechanisms
to control blood pressure in patients with essential hypertension: aliskiren
belongs to the direct renin inhibitor class, amlodipine to the calcium channel
blocker class and hydrochlorothiazide to the thiazide diuretics class. When
combined, the consolidated effects of inhibition of the renin-angiotensin-aldosterone
system, calcium channel-mediated vasodilatation and sodium chloride excretion
result in a reduction of blood pressure to a greater degree than the
corresponding dual combinations.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Aliskiren/amlodipine/hydrochlorothiazide combination</span></u></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>In
hypertensive patients, once-daily administration of Rasitrio provided
clinically meaningful reductions in both systolic and diastolic blood pressure
that were maintained over the entire 24-hour dose interval. The greater blood
pressure reduction for Rasitrio over each dual combination was seen at every
hour including the early morning hours with the 24-hour ambulatory blood
pressure monitoring.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Rasitrio
was studied in a double-blind, randomised, active-controlled study in 1,181&nbsp;patients
of which 773 were classified as moderately hypertensive (msSBP 160&#8209;180&nbsp;mmHg)
and 408 as severely hypertensive (msSBP &gt;180&nbsp;mmHg) at baseline. A large
number of patients were obese (49%) and over 14% of the total population had
diabetes. During the first 4&nbsp;weeks of double-blind treatment, patients
received triple combination aliskiren/amlodipine/hydrochlorothiazide (HCTZ)
150/5/12.5&nbsp;mg (N=308), or dual combinations of aliskiren/HCTZ
150/12.5&nbsp;mg (N=295), aliskiren/amlodipine 150/5&nbsp;mg (N=282) and amlodipine/HCTZ
5/12.5&nbsp;mg (N=295). Patients were force-titrated to higher doses after
4&nbsp;weeks for an additional 4&nbsp;weeks of double-blind treatment to
aliskiren/amlodipine/HCTZ 300/10/25&nbsp;mg, aliskiren/HCTZ 300/25&nbsp;mg,
aliskiren/amlodipine 300/10&nbsp;mg and amlodipine/HCTZ 10/25&nbsp;mg.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>In
this study, Rasitrio at a dose of 300/10/25&nbsp;mg produced statistically
significant mean blood pressure reductions (systolic/diastolic) from baseline
of 37.9/20.6&nbsp;mmHg compared to 31.4/18.0&nbsp;mmHg with
aliskiren/amlodipine combination (300/10&nbsp;mg), 28.0/14.3&nbsp;mmHg with
aliskiren/hydrochlorothiazide (300/25&nbsp;mg) and 30.8/17.0&nbsp;mmHg with
amlodipine/hydrochlorothiazide (10/25&nbsp;mg) in patients with moderate to
severe hypertension. In patients with severe hypertension (SBP &#8805;180&nbsp;mmHg), the reduction in blood pressure from baseline for Rasitrio and the
dual combinations respectively was 49.5/22.5&nbsp;mmHg compared to
38.1/17.6&nbsp;mmHg with aliskiren/amlodipine combination (300/10&nbsp;mg),
33.2/14.3&nbsp;mmHg with aliskiren/hydrochlorothiazide (300/25&nbsp;mg) and
39.9/17.8&nbsp;mmHg with amlodipine/hydrochlorothiazide (10/25&nbsp;mg). In a
subset of 588&nbsp;patients</span><span lang=EN-GB> in which patients
&gt;65&nbsp;years were scarcely represented and those aged &gt;75&nbsp;years
were very scarcely represented</span><span lang=EN-GB>, the combination of
aliskiren/amlodipine/hydrochlorothiazide (300/10/25&nbsp;mg) produced a
systolic/diastolic mean blood pressure reduction of 39.7/21.1&nbsp;mmHg from
baseline, compared to 31.3/18.74&nbsp;mmHg for aliskiren/amlodipine
(300/10&nbsp;mg), 25.5/12.5&nbsp;mmHg for aliskiren/hydrochlorothiazide (300/25&nbsp;mg)
and 29.2/16.4&nbsp;mmHg for amlodipine/hydrochlorothiazide (10/25&nbsp;mg) (the
subset constitutes patients without aberrant readings, defined as a difference
between systolic blood pressure (SBP) readings &#8805;10&nbsp;mmHg at baseline
or endpoint). The effect of Rasitrio was observed as early as one week after
initiation of therapy. The blood-pressure-lowering effect in patients with
moderate to severe hypertension was independent of age, gender, race, body mass
index and overweight-associated disorders (metabolic syndrome and diabetes).</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Rasitrio
was associated with a significant reduction in plasma renin activity (PRA) (&#8209;34%)
from baseline while the dual combination of amlodipine with hydrochlorothiazide
increased PRA (+170%). The clinical implications of the differences in effect
on PRA are not known at the present time.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>In
a 28 to 54&nbsp;week open label safety study, efficacy was measured as
secondary endpoint and Rasitrio at a dose of 300/10/25&nbsp;mg produced mean
blood pressure reductions (systolic/diastolic) of 37.3/21.8&nbsp;mmHg over 28
to 54&nbsp;weeks of treatment. Efficacy of Rasitrio was maintained over one
year of treatment, with no evidence of loss of effect.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>In
a randomised, double blind, active controlled, 36-week study in elderly
patients whose blood pressure was not controlled with aliskiren/HCTZ 300/25&nbsp;mg
(SBP &#8805;140&nbsp;mmHg), clinically meaningful further BP reduction was seen
at week&nbsp;36 endpoint for patients who received Rasitrio at a dose of
300/10/25&nbsp;mg (from reductions in msSBP/msDBP of 15.0/8.6&nbsp;mmHg at
week&nbsp;22 to reductions of 30.8/14.1&nbsp;mmHg at week&nbsp;36 endpoint).</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Rasitrio
has been administered to more than 1,155&nbsp;patients in completed clinical
trials, including 182&nbsp;patients for one year or more. Treatment with
Rasitrio was well tolerated at doses up to 300&nbsp;mg/10&nbsp;mg/25&nbsp;mg
with an overall incidence of adverse events similar to the corresponding dual
combinations, except for symptomatic hypotension. </span><span lang=EN-GB>The
incidence of any adverse reactions potentially related to hypotension in a
short-term controlled study was 4.9% with Rasitrio versus up to 3.7% with dual
combinations. In patients &#8805;65&nbsp;years the incidence was 10.2% with
Rasitrio versus up to 5.4% with dual combinations.</span></p>

<p class=CharCharCharCharChar align=left style='margin-bottom:0in;text-align:
left;line-height:normal'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=CharCharCharCharChar align=left style='margin-bottom:0in;text-align:
left;line-height:normal'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>The
incidence of adverse events did not show any association with gender, age (with
the exception of symptomatic hypotension), body mass index, race or ethnicity.
Adverse events have generally been mild and transient in nature. Very limited
safety data are available for patients aged &gt;75&nbsp;years or patients with
major cardiovascular co-morbidities. Discontinuation of therapy due to a
clinical adverse event occurred in 3.6% of patients treated with Rasitrio
versus 2.4% in aliskiren/amlodipine, 0.7% in aliskiren/hydrochlorothiazide and
2.7% in amlodipine/hydrochlorothiazide.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Aliskiren</span></u></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Aliskiren is
an orally active, non-peptide, potent and selective direct inhibitor of human
renin.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>By inhibiting
the enzyme renin, aliskiren inhibits the RAAS at the point of activation,
blocking the conversion of angiotensinogen to angiotensin&nbsp;I and decreasing
levels of angiotensin&nbsp;I and angiotensin&nbsp;II. Whereas other medicinal
products that inhibit the RAAS (ACEI and angiotensin&nbsp;II receptor blockers
(ARB)) cause a compensatory rise in plasma renin activity (PRA), treatment with
aliskiren decreases PRA in hypertensive patients by approximately 50 to 80%.
Similar reductions were found when aliskiren was combined with other
antihypertensive medicinal products. The clinical implications of the
differences in effect on PRA are not known at the present time.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Hypertension</span></i></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>In
hypertensive patients, once-daily administration of aliskiren at doses of
150&nbsp;mg and 300&nbsp;mg provided dose-dependent reductions in both systolic
and diastolic blood pressure that were maintained over the entire 24-hour dose
interval (maintaining benefit in the early morning) with a mean peak to trough ratio
for diastolic response of up to 98% for the 300&nbsp;mg dose. 85 to 90% of the
maximal blood-pressure-lowering effect was observed after 2&nbsp;weeks. The
blood-pressure-lowering effect was sustained during long-term treatment, and
was independent of age, gender, body mass index and ethnicity. Aliskiren has
been studied in 1,864&nbsp;patients aged 65&nbsp;years or older, and in
426&nbsp;patients aged 75&nbsp;years or older.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Aliskiren
monotherapy studies have shown blood-pressure-lowering effects comparable to
other classes of antihypertensive medicinal products including selected ACEI
and ARB. Compared to a diuretic (hydrochlorothiazide, HCTZ), aliskiren
300&nbsp;mg lowered systolic/diastolic blood pressure by 17.0/12.3&nbsp;mmHg,
compared to 14.4/10.5&nbsp;mmHg for HCTZ 25&nbsp;mg after 12&nbsp;weeks of treatment.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Combination
therapy studies are available for aliskiren added to the diuretic
hydrochlorothiazide, the calcium channel blocker amlodipine and the beta
blocker atenolol. These combinations were well tolerated. Aliskiren induced an
additive blood-pressure-lowering effect when added to hydrochlorothiazide.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>&nbsp;</p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>The
efficacy and safety of aliskiren-based therapy were compared to ramipril-based
therapy in a 9-month non-inferiority study in 901&nbsp;elderly patients
(&#8805;65&nbsp;years) with essential systolic hypertension. Aliskiren
150&nbsp;mg or 300&nbsp;mg per day or ramipril 5&nbsp;mg or 10&nbsp;mg per day
were administered for 36&nbsp;weeks with optional add-on therapy of
hydrochlorothiazide (12.5&nbsp;mg or 25&nbsp;mg) at week&nbsp;12, and
amlodipine (5&nbsp;mg or 10&nbsp;mg) at week&nbsp;22. Over the 12-week period,
aliskiren monotherapy lowered systolic/diastolic blood pressure by
14.0/5.1&nbsp;mmHg, compared to 11.6/3.6&nbsp;mmHg for ramipril, consistent
with aliskiren being non-inferior to ramipril at the dosages chosen and the
differences in systolic and diastolic blood pressure were statistically
significant. Tolerability was comparable in both treatment arms, however cough
was more often reported with the ramipril regimen than the aliskiren regimen
(14.2% vs. 4.4%), whilst diarrhoea was more common with the aliskiren regimen
than for the ramipril regimen (6.6% vs. 5.0%).</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>In an 8-week study in 754&nbsp;hypertensive geriatric patients aged
65&nbsp;years or older and geriatric patients aged 75&nbsp;years or older (30%)
aliskiren at doses of 75&nbsp;mg, 150&nbsp;mg and 300&nbsp;mg provided
statistically significant superior reduction in blood pressure (both systolic
and diastolic) when compared to placebo. No additional blood pressure lowering
effect was detected with 300&nbsp;mg aliskiren compared to 150&nbsp;mg
aliskiren. All three doses were well tolerated in both elderly and very elderly
patients.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>There has been
no evidence of first-dose hypotension and no effect on pulse rate in patients
treated in controlled clinical studies. Excessive hypotension was uncommonly
(0.1%) seen in patients with uncomplicated hypertension treated with aliskiren
alone. Hypotension was also uncommon (&lt;1%) during combination therapy with
other antihypertensive medicinal products. With cessation of treatment, blood
pressure gradually returned towards baseline levels over a period of several
weeks, with no evidence of a rebound effect for blood pressure or PRA.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>I</span>n a 36-week study involving 820&nbsp;patients with ischaemic
left ventricular dysfunction, no changes in ventricular remodelling as assessed
by left ventricular end systolic volume were detected with aliskiren compared
to placebo on top of background therapy.</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>&nbsp;</p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>The combined
rates of cardiovascular death, hospitalisation for heart failure, recurrent
heart attack, stroke and resuscitated sudden death were similar in the
aliskiren group and the placebo group. However, in patients receiving aliskiren
there was a significantly higher rate of hyperkalaemia, hypotension and kidney
dysfunction when compared to the placebo group.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Aliskiren was evaluated for cardiovascular
and/or renal benefit in a double blind placebo controlled randomised trial in
8,606&nbsp;patients with type 2 diabetes and chronic kidney disease (evidenced
by proteinuria and/or GFR &lt;60&nbsp;ml/min/</span><span lang=EN-GB>1.73&nbsp;m<sup>2</sup></span><span
lang=EN-GB>) with or without cardiovascular disease. In most patients arterial
blood pressure was well controlled at baseline. The primary endpoint was a
composite of cardiovascular and renal complications.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>In this study,
aliskiren 300&nbsp;mg was compared to placebo when added to standard of care
which included either an angiotensin converting enzyme inhibitor or an
angiotensin receptor blocker. The study was discontinued prematurely because
the participants were unlikely to benefit from aliskiren. Study results
indicated a hazard ratio for the primary endpoint of 1.11 in favour of placebo
(95% Confidence Interval: 1.00, 1.23, 2-sided p=0.05). In addition, an
increased incidence of </span><span lang=EN-GB>adverse events</span><span
lang=EN-GB> was observed with aliskiren compared to placebo </span><span
lang=EN-GB>(37.9% versus 30.2%). In particular there was an increased incidence
of</span><span lang=EN-GB> renal </span><span lang=EN-GB>dysfunction</span><span
lang=EN-GB> (14.0% versus 12.1%), hyperkalaemia (38.9% versus 28.8%),
hypotension</span><span lang=EN-GB>-related events</span><span lang=EN-GB>
(19.7% versus 16.2%) </span><span lang=EN-GB>and adjudicated stroke endpoints
(3.4% versus 2.6%). The increased incidence of stroke was greater in patients
with renal insufficiency.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Effects of
aliskiren on mortality and cardiovascular morbidity are currently unknown.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>No long-term
efficacy data for aliskiren in patients with heart failure are currently
available (see section&nbsp;4.4).</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Cardiac electrophysiology</span></i></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>No effect on
QT interval was reported in a randomised, double-blind, placebo, and
active-controlled study using standard and Holter electrocardiography.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Amlodipine</span></u></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>The
amlodipine component of Rasitrio inhibits the transmembrane entry of calcium
ions </span><span lang=EN-GB>into cardiac and vascular smooth muscle. The
mechanism of the antihypertensive action of amlodipine is due to a direct
relaxant effect on vascular smooth muscle, causing reductions in peripheral
vascular resistance and in blood pressure. Experimental data suggest that
amlodipine binds to both dihydropyridine and non-dihydropyridine binding sites.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>The
contractile processes of cardiac muscle and vascular smooth muscle are
dependent upon the movement of extracellular calcium ions into these cells
through specific ion channels.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Following
administration of therapeutic doses to patients with hypertension, amlodipine
produces vasodilatation resulting in a reduction of supine and standing blood
pressures. These decreases in blood pressure are not accompanied by a
significant change in heart rate or plasma catecholamine levels with chronic
dosing.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Plasma
concentrations correlate with effect in both young and elderly patients.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>In
hypertensive patients with normal renal function, therapeutic doses of
amlodipine resulted in a decrease in renal vascular resistance and an increase
in glomerular filtration rate and effective renal plasma flow without change in
filtration fraction or proteinuria.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>As
with other calcium channel blockers, haemodynamic measurements of cardiac
function at rest and during exercise (or pacing) in patients with normal
ventricular function treated with amlodipine have generally demonstrated a
small increase in cardiac index without significant influence on dP/dt or on
left ventricular end diastolic pressure or volume. In haemodynamic studies,
amlodipine has not been associated with a negative inotropic effect when
administered in the therapeutic dose range to intact animals and humans, even
when co-administered with beta blockers to humans.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Amlodipine does
not change sinoatrial nodal function or atrioventricular conduction in intact
animals or humans. In clinical studies in which amlodipine was administered in
combination with beta blockers to patients with either hypertension or angina,
no adverse effects on electrocardiographic parameters were observed.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoDate><span lang=EN-GB>Amlodipine has demonstrated beneficial
clinical effects in patients with chronic stable angina, vasospastic angina and
angiographically documented coronary artery disease.</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><i><span lang=EN-GB>Use in patients with heart failure</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Calcium channel blockers, including amlodipine, should be used with
caution in patients with congestive heart failure, as they may increase the
risk of future cardiovascular events and mortality.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><i><span lang=EN-GB>Use in patients with hypertension</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>A randomised
double-blind morbidity-mortality study called the Antihypertensive and
Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT) was performed
to compare newer therapies: amlodipine 2.5&#8209;10&nbsp;mg/day (calcium
channel blocker) or lisinopril 10&#8209;40&nbsp;mg/day (ACE-inhibitor) as
first-line therapies to that of the thiazide-diuretic, chlorthalidone 12.5&#8209;25&nbsp;mg/day
in mild to moderate hypertension.</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>A total of
33,357&nbsp;hypertensive patients aged 55 or older were randomised and followed
for a mean of 4.9&nbsp;years. The patients had at least one additional coronary
heart disease risk factor, including: previous myocardial infarction or stroke
(&gt;6&nbsp;months prior to enrollment) or documentation of other
atherosclerotic cardiovascular disease (overall 51.5%), type 2 diabetes
(36.1%), high density lipoprotein - cholesterol &lt;35&nbsp;mg/dl or
&lt;0.906&nbsp;mmol/l (11.6%), left ventricular hypertrophy diagnosed by
electrocardiogram or echocardiography (20.9%), current cigarette smoking
(21.9%).</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>The primary
endpoint was a composite of fatal coronary heart disease or non-fatal
myocardial infarction. There was no significant difference in the primary
endpoint between amlodipine-based therapy and chlorthalidone-based therapy:
risk ratio (RR) 0.98 95% CI (0.90&#8209;1.07) p=0.65. Among secondary
endpoints, the incidence of heart failure (component of a composite combined
cardiovascular endpoint) was significantly higher in the amlodipine group as
compared to the chlorthalidone group (10.2% vs. 7.7%, RR 1.38, 95% CI [1.25&#8209;1.52]
p&lt;0.001). However, there was no significant difference in all-cause
mortality between amlodipine-based therapy and chlorthalidone-based therapy RR
0.96 95% CI [0.89&#8209;1.02] p=0.20.</p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Hydrochlorothiazide</span></u></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>The
site of action of thiazide diuretics is primarily in the renal distal
convoluted tubule. It has been shown that there is a high-affinity receptor in
the renal cortex as the primary binding site for the thiazide diuretic action
and inhibition of NaCl transport in the distal convoluted tubule. The mode of
action of thiazides is through inhibition of the Na+Cl- symporter by competing
for the Cl- site, thereby affecting electrolyte reabsorption mechanisms:
directly increasing sodium and chloride excretion to an approximately equal
extent, and indirectly by this diuretic action reducing plasma volume, with
consequent increases in plasma renin activity, aldosterone secretion and
urinary potassium loss, and a decrease in serum potassium.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Paediatric population</span></u></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>The
European Medicines Agency has waived the obligation to submit the results of
studies with Rasitrio in all subsets of the paediatric population in essential
hypertension (see section&nbsp;4.2 for information on paediatric use).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5.2&nbsp;&nbsp;&nbsp;&nbsp; Pharmacokinetic
properties</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Aliskiren/amlodipine/hydrochlorothiazide combination</span></u></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Following
oral administration of a fixed combination tablet of aliskiren, amlodipine and
hydrochlorothiazide, peak concentrations were achieved for aliskiren within 1&#8209;2&nbsp;hours,
for amlodipine within 8&nbsp;hours and for hydrochlorothiazide within 2&#8209;3&nbsp;hours.
The rate and extent of absorption of aliskiren, amlodipine and
hydrochlorothiazide following administration of a fixed combination tablet are
similar to when administered as individual dosage forms.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>The
results from a food effect study using a </span><span lang=EN-GB>standard </span><span
lang=EN-GB>high-fat meal</span><span lang=EN-GB> with the 300/10/25&nbsp;mg
fixed combination tablet showed that food </span><span lang=EN-GB>reduced the
rate and extent of absorption of aliskiren in the fixed combination tablet with
a similar magnitude of effect as for aliskiren monotherapy. Food had no effect </span><span
lang=EN-GB>on the pharmacokinetics of amlodipine or hydrochlorothiazide in the
fixed combination tablet.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Aliskiren</span></u></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Absorption</span></i></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Following oral
absorption, peak plasma concentrations of aliskiren are reached after 1&#8209;3&nbsp;hours.
The absolute bioavailability of aliskiren is approximately 2&#8209;3%. Meals
with a high fat content reduce C<sub>max</sub> by 85% and AUC by 70%. At steady
state meals with low fat content reduce C<sub>max</sub> by 76% and AUC <sub>0-tau</sub>
by 67% in hypertensive patients. Steady-state plasma concentrations are reached
within 5&#8209;7&nbsp;days following once-daily administration and steady-state
levels are approximately 2-fold greater than with the initial dose.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Distribution</span></i></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Following
intravenous administration, the mean volume of distribution at steady state is
approximately 135&nbsp;litres, indicating that aliskiren distributes
extensively into the extravascular space. Aliskiren plasma protein binding is
moderate (47&#8209;51%) and independent of the concentration.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Biotransformation and elimination</span></i></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>The mean
half-life is about 40&nbsp;hours (range 34&#8209;41&nbsp;hours). Aliskiren is
mainly eliminated as unchanged compound in the faeces (78%). Approximately 1.4%
of the total oral dose is metabolised. The enzyme responsible for this
metabolism is CYP3A4. Approximately 0.6% of the dose is recovered in urine
following oral administration. Following intravenous administration, mean
plasma clearance is approximately 9&nbsp;l/h.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Linearity</span></i></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Exposure to
aliskiren increased more than in proportion to the increase in dose. After
single dose administration in the dose range of 75 to 600&nbsp;mg, a 2-fold
increase in dose results in a ~2.3 and 2.6-fold increase in AUC and C<sub>max</sub>,
respectively. At steady state the non-linearity may be more pronounced.
Mechanisms responsible for deviation from linearity have not been identified. A
possible mechanism is saturation of transporters at the absorption site or at
the hepatobiliary clearance route.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><i><span lang=EN-GB>Paediatric
population</span></i></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>In
a pharmacokinetic study of aliskiren treatment in 39 paediatric hypertensive
patients (aged 6&#8209;17&nbsp;years) given daily doses of 2&nbsp;mg/kg or
6&nbsp;mg/kg aliskiren administered as granules (3.125&nbsp;mg/tablet),
pharmacokinetic parameters were similar to those in adults. The available data
did not suggest that age, body weight or gender have any significant effect on
aliskiren systemic exposure (see section 4.2).</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Amlodipine</span></u></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Absorption</span></i></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>After oral
administration of therapeutic doses of amlodipine alone, peak plasma
concentrations of amlodipine are reached in 6&#8209;12&nbsp;hours. Absolute
bioavailability has been </span><span style='font-size:11.0pt;color:windowtext'>estima</span><span
style='font-size:11.0pt;color:windowtext'>ted as between 64% and 80%.
Amlodipine bioavailability is unaffected by food ingestion.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Distribution</span></i></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>The volume of
distribution is approximately 21&nbsp;l/kg. <i>In vitro </i>studies with
amlodipine have shown that approximately 97.5% of circulating amlodipine is
bound to plasma proteins.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Biotransformation and elimination</span></i></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Amlodipine
is extensively (approximately 90%) metabolised in the liver to inactive
metabolites, with 10% of the parent compound and 60% of the metabolites
excreted in the urine.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Amlodipine
elimination from plasma is biphasic with a terminal elimination half-life of
approximately 30 to 50&nbsp;hours. Steady-state plasma levels are reached after
continuous administration for 7&#8209;8&nbsp;days.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Linearity</span></i></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Amlodipine
exhibits linear pharmacokinetics between </span><span lang=EN-GB>the
therapeutic dose range of </span><span lang=EN-GB>5&nbsp;mg and 10&nbsp;mg</span><span
lang=EN-GB>.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Hydrochlorothiazide</span></u></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Absorption</span></i></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>The absorption of hydrochlorothiazide, after an oral dose, is rapid
(T<sub>max</sub> about 2&nbsp;h.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>The effect of food on hydrochlorothiazide absorption, if any, has
little clinical significance. Absolute bioavailability of hydrochlorothiazide
is 70% after oral administration.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Distribution</span></i></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>The apparent volume of distribution is 4&#8209;8&nbsp;l/kg.
Circulating hydrochlorothiazide is bound to serum proteins (40&#8209;70%),
mainly serum albumin. Hydrochlorothiazide also accumulates in erythrocytes at
approximately 3&nbsp;times the level in plasma.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Biotransformation and elimination</span></i></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Hydrochlorothiazide is eliminated predominantly as unchanged
compound. Hydrochlorothiazide is eliminated from plasma with a half-life
averaging 6 to 15&nbsp;hours in the terminal elimination phase. There is no
change in the kinetics of hydrochlorothiazide on repeated dosing, and
accumulation is minimal when dosed once daily. There is more than 95% of the
absorbed dose being excreted as unchanged compound in the urine. The renal
clearance is composed of passive filtration and active secretion into the renal
tubule.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Linearity</span></i></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>The increase in mean AUC is linear and dose proportional in the
therapeutic range.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Special populations</span></u></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Rasitrio is an
effective once-a-day antihypertensive treatment in adult patients, regardless
of gender, age, body mass index and ethnicity.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Renal impairment</span></i></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Due
to its hydrochlorothiazide component, Rasitrio is contraindicated in patients
with anuria or severe renal impairment (GFR &lt;30&nbsp;ml/min/1.73&nbsp;m<sup>2</sup>)
(see section&nbsp;4.3). No adjustment of the initial dose is required in
patients with mild to moderate renal impairment (see sections&nbsp;4.4 and
4.2).</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>The
pharmacokinetics of aliskiren were evaluated in patients with varying degrees
of renal insufficiency. Relative AUC and C<sub>max</sub> of aliskiren in
subjects with renal impairment ranged between 0.8 to 2&nbsp;times the levels in
healthy subjects following single dose administration and at steady state.
These observed changes, however, did not correlate with the severity of renal
impairment. No adjustment of the initial dose of aliskiren is required in
patients with mild to moderate renal impairment (see sections&nbsp;4.2 and
4.4). Aliskiren is not recommended in patients with severe renal impairment
(glomerular filtration rate (GFR) &lt;30&nbsp;ml/min/</span><span
style='font-size:11.0pt;color:windowtext'>1.73&nbsp;m<sup>2</sup></span><span
style='font-size:11.0pt;color:windowtext'>). Concomitant use of aliskiren with
ARBs or ACEIs is contraindicated in patients with renal impairment (GFR &lt;60&nbsp;ml/min/</span><span
style='font-size:11.0pt;color:windowtext'>1.73&nbsp;m<sup>2</sup></span><span
style='font-size:11.0pt;color:windowtext'>) (see section&nbsp;4.3).</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>The
pharmacokinetics of aliskiren were evaluated</span><span lang=EN-GB> in
patients with end stage renal disease receiving haemodialysis. Administration
of a single oral dose of 300&nbsp;mg aliskiren was associated with very minor
changes in the pharmacokinetics of aliskiren (change in C<sub>max</sub> of less
than 1.2&nbsp;fold; increase in AUC of up to 1.6&nbsp;fold) compared to matched
healthy subjects. Timing of haemodialysis did not significantly alter the
pharmacokinetics of aliskiren in ESRD patients. Therefore,<b><i> </i></b>if
administration of aliskiren in ESRD patients receiving haemodialysis is
considered necessary, no dose adjustment is warranted in these patients.
However, the use of aliskiren is not recommended in patients with severe renal
impairment (see section&nbsp;4.4).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The pharmacokinetics of amlodipine are not significantly influenced
by renal impairment.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>As
expected for a compound which is cleared almost exclusively via the kidneys,
renal function has a marked effect on the kinetics of hydrochlorothiazide. In
the presence of renal impairment, mean peak plasma levels and AUC values of
hydrochlorothiazide are increased and the urinary excretion rate is reduced. In
patients with mild to moderate renal impairment, a 3-fold increase in
hydrochlorothiazide AUC has been observed. In patients with severe renal
impairment an 8-fold increase in AUC has been observed.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Hepatic impairment</span></i></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Rasitrio is
contraindicated in patients with severe hepatic impairment (see
section&nbsp;4.3).</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>The
pharmacokinetics of aliskiren were not significantly affected in patients with
mild to severe liver disease. Consequently, no adjustment of the initial dose
of aliskiren is required in patients with mild to moderate hepatic impairment.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Very limited clinical data are available regarding amlodipine administration
in patients with hepatic impairment. Patients with hepatic insufficiency have
decreased clearance of amlodipine with resulting increase in AUC of
approximately 40&#8209;60%. Therefore caution should be exercised</span><span
lang=EN-GB> in patients with hepatic impairment.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Geriatric patients</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No data are
available on systemic exposure after administration of Rasitrio in geriatric
patients. When administered alone, the AUC of aliskiren in geriatric subjects
(&gt;65&nbsp;years) is 50% higher than in young subjects. The time to reach peak
plasma concentrations of amlodipine is similar in elderly and younger subjects.
Amlodipine clearance tends to be decreased with resulting increases in AUC and
elimination half-life in geriatric patients. </span><span lang=EN-GB>Therefore
particular caution is recommended when administering Rasitrio to patients aged
65&nbsp;years and over, and extreme caution in patients aged 75&nbsp;years or
older (see sections&nbsp;4.2, 4.4, 4.8 and 5.1).</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Limited
data suggest that the systemic clearance of hydrochlorothiazide is reduced in
both healthy and hypertensive elderly subjects compared to young healthy
volunteers. There are no specific data regarding the effect of
hydrochlorothiazide in elderly patients.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Paediatric </span></i><i><span style='font-size:11.0pt;
color:windowtext'>population (age below 18&nbsp;years)</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The pharmacokinetics of Rasitrio have not been investigated. A
population pharmacokinetic study has been conducted in 74 hypertensive children
aged from 1 to 17&nbsp;years (with 34&nbsp;patients aged 6 to 12&nbsp;years and
28&nbsp;patients aged 13 to 17&nbsp;years) receiving amlodipine between 1.25
and 20&nbsp;mg given either once or twice daily. In children 6 to 12&nbsp;years
and in adolescents 13&#8209;17&nbsp;years of age the typical oral clearance
(CL/F) was 22.5 and 27.4&nbsp;l/hr respectively in males and 16.4 and
21.3&nbsp;l/hr respectively in females. Large variability in exposure between
individuals was observed. Data reported in children below 6&nbsp;years are
limited.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5.3&nbsp;&nbsp;&nbsp;&nbsp; Preclinical
safety data</span></b></p>

<p class=Text style='margin-bottom:0in;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Aliskiren/hydrochlorothiazide and aliskiren/amlodipine</span></u></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Non-clinical
studies of the toxicology of Rasitrio alone have not been conducted as these
studies have been conducted for the individual components.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>The
toxicity profiles of the combination of aliskiren/hydrochlorothiazide and
aliskiren/amlodipine have been well characterised in preclinical studies. Both
combinations were generally well tolerated by rats. The findings from 2- and
13-week oral toxicity studies were consistent with those for the individual
components.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Aliskiren</span></u></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Carcinogenic
potential was assessed in a 2-year rat study and a 6-month transgenic mouse
study. No carcinogenic potential was detected. One colonic adenoma and one
caecal adenocarcinoma recorded in rats at the dose of 1,500&nbsp;mg/kg/day were
not statistically significant. Although aliskiren has known irritation
potential, safety margins obtained in humans at the dose of 300&nbsp;mg during
a study in healthy volunteers were considered to be appropriate at 9&#8209;11-fold
based on faecal concentrations or 6-fold based on mucosa concentrations in
comparison with 250&nbsp;mg/kg/day in the rat carcinogenicity study.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Aliskiren was
devoid of any mutagenic potential in the <i>in vitro </i>and <i>in vivo </i>mutagenicity
studies. The assays included <i>in vitro </i>assays in bacterial and mammalian
cells and <i>in vivo </i>assessments in rats.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Reproductive
toxicity studies with aliskiren did not reveal any evidence of embryofoetal
toxicity or teratogenicity at doses up to 600&nbsp;mg/kg/day in rats or
100&nbsp;mg/kg/day in rabbits. Fertility, pre-natal development and post-natal
development were unaffected in rats at doses up to 250&nbsp;mg/kg/day. The
doses in rats and rabbits provided systemic exposures of 1 to 4 and
5&nbsp;times higher, respectively, than the maximum recommended human dose
(300&nbsp;mg).</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Safety
pharmacology studies did not reveal any adverse effects on central nervous,
respiratory or cardiovascular function. Findings during repeat-dose toxicity
studies in animals were consistent with the known local irritation potential or
the expected pharmacological effects of aliskiren.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Amlodipine</span></u></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Safety
data for amlodipine are well established both clinically and non-clinically.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Reproductive
toxicology</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Reproductive
studies in rats and mice have shown delayed date of delivery, prolonged
duration of labour and decreased pup survival at dosages approximately
50&nbsp;times greater than the maximum recommended dosage for humans based on
mg/kg.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Impairment of
fertility</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>There was no
effect on the fertility of rats treated with amlodipine (males for 64&nbsp;days
and females 14&nbsp;days prior to mating) at doses up to 10&nbsp;mg/kg/day
(8&nbsp;times* the maximum recommended human dose of 10&nbsp;mg on a mg/m<sup>2</sup>
basis). In another rat study in which male rats were treated with amlodipine
besilate for 30&nbsp;days at a dose comparable with the human dose based on
mg/kg, decreased plasma follicle-stimulating hormone and testosterone were
found as well as decreases in sperm density and in the number of mature spermatids
and Sertoli cells.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Carcinogenesis,
mutagenesis</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Rats and mice
treated with amlodipine in the diet for two years, at concentrations calculated
to provide daily dosage levels of 0.5, 1.25 and 2.5&nbsp;mg/kg/day showed no
evidence of carcinogenicity. The highest dose (for mice, similar to, and for
rats twice* the maximum recommended clinical dose of 10&nbsp;mg on a mg/m<sup>2</sup>
basis) was close to the maximum tolerated dose for mice but not for rats.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Mutagenicity
studies revealed no effects related to the medicinal product at either the gene
or chromosome levels.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>*Based on
patient weight of 50&nbsp;kg</span></p>

<p class=Default><u><span lang=EN-GB style='font-size:11.0pt;color:windowtext'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Hydrochlorothiazide</span></u></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Preclinical
evaluations to support the administration of hydrochlorothiazide in humans
included <i>in vitro</i> genotoxicity assays and reproductive toxicity and
carcinogenicity studies in rodents. Extensive clinical data are available for
hydrochlorothiazide and these are reflected in the relevant sections.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Hydrochlorothiazide
had no adverse effects on the fertility of mice and rats of either sex in
studies wherein these species were exposed, via their diet, to doses of up to
100 and 4&nbsp;mg/kg,/day respectively, prior to mating and throughout
gestation. These doses of hydrochlorothiazide in mice and rats represent 19 and
1.5&nbsp;times, respectively, the maximum recommended human dose on a mg/m<sup>2</sup>
basis. (Calculations assume an oral dose of 25&nbsp;mg/day and a 60-kg
patient.)</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
PARTICULARS</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.1&nbsp;&nbsp;&nbsp;&nbsp; List
of excipients</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><u><span lang=EN-GB>Tablet core</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=IT>Cellulose microcrystalline</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=IT>Crospovidone</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=IT>Povidone</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=IT>Magnesium stearate</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=IT>Silica colloidal anhydrous</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=IT>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><u><span lang=IT>Coating</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=IT>Hypromellose</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=IT>Titanium dioxide (E171)</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=ES>Macrogol</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=ES>Talc</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=ES>Iron oxide red (E172)</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Iron oxide black (E172)</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>Iron oxide
yellow (E172)</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b>6.2&nbsp;&nbsp;&nbsp;&nbsp; Incompatibilities</b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Not applicable.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.3&nbsp;&nbsp;&nbsp;&nbsp; Shelf
life</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>PVC/polychlorotrifluoroethylene (PCTFE) </span>&#8211;<span
lang=EN-GB> Alu calendar blisters:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>2&nbsp;years</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>PVC/polychlorotrifluoroethylene (PCTFE) </span>&#8211; <span
lang=EN-GB>Alu blisters:</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>2&nbsp;years</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'>PA/Alu/PVC
&#8211; Alu calendar blisters:</p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>18&nbsp;months</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.4&nbsp;&nbsp;&nbsp;&nbsp; Special
precautions for storage</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'>Do not store above 30&deg;C.</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>Store in the
original package in order to protect from moisture.</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.5&nbsp;&nbsp;&nbsp;&nbsp; Nature
and contents of container</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>PVC/polychlorotrifluoroethylene (PCTFE) - Alu calendar blisters:</span></p>

<p class=MsoDate>Single pack containing 14, 28, 56, 98&nbsp;tablets</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>PVC/polychlorotrifluoroethylene (PCTFE) - Alu blisters:</span></p>

<p class=MsoDate style='page-break-after:avoid'>Single pack containing 30,
90&nbsp;tablets</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'>Unit dose
pack (perforated unit dose blister) containing 56x1&nbsp;tablet</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>Multipacks of
unit dose (perforated unit dose blister) containing 98x1&nbsp;tablet
(2&nbsp;packs of 49x1)</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=ES>PA/Alu/PVC &#8211; Alu calendar blisters:</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'>Single pack containing 14, 28, 56&nbsp;tablets</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>Multipacks
containing 98&nbsp;tablets (2&nbsp;packs of 49)</p>

<p class=MsoDate>&nbsp;</p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Not
all pack sizes may be marketed.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.6&nbsp;&nbsp;&nbsp;&nbsp; Special
precautions for disposal</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Any unused medicinal product or waste material should be disposed of
in accordance with local requirements.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION HOLDER</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'>Novartis Europharm Limited</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'>Wimblehurst Road</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'>Horsham</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'>West Sussex, RH12 5AB</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>United
Kingdom</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'>EU/1/11/730/025&#8209;036</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; DATE
OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Date of first
authorisation: </span><span lang=EN-GB>22 November 2011</span></p>

<p class=MsoDate><span lang=EN-GB>Date of latest renewal:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>10.&nbsp;&nbsp;&nbsp;&nbsp; DATE
OF REVISION OF THE TEXT</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:28.3pt;line-height:normal'><span
lang=EN-GB>Detailed information on this medicinal product is available on the
website of the European Medicines Agency http://www.ema.europa.eu</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Rasitrio 300&nbsp;mg/10&nbsp;mg/12.5&nbsp;mg film-coated tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; QUALITATIVE
 AND QUANTITATIVE COMPOSITION</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each film-coated
tablet contains 300&nbsp;mg aliskiren (as hemifumarate), 10&nbsp;mg amlodipine
(as besylate) and 12.5&nbsp;mg hydrochlorothiazide.</span></p>

<p class=MsoDate><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For the full
list of excipients, see section&nbsp;6.1.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
<span style='text-transform:uppercase'>form</span></span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Film-coated tablet.</span></p>

<p class=MsoDate style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Light red,
ovaloid convex film-coated tablet with bevelled edges, with &#8220;UIU&#8221;
debossed on one side and &#8220;NVR&#8221; on the other.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB style='text-transform:uppercase'>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Clinical
particulars</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.1&nbsp;&nbsp;&nbsp;&nbsp; Therapeutic
indications</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Rasitrio is
indicated for the treatment of essential hypertension as substitution therapy
in adult patients whose blood pressure is adequately controlled on the
combination of aliskiren, amlodipine and hydrochlorothiazide given concurrently
at the same dose level as in the combination.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.2&nbsp;&nbsp;&nbsp;&nbsp; Posology
and method of administration</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><u><span lang=EN-GB>Posology</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The recommended dose of Rasitrio is one tablet per day.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Patients
receiving aliskiren, amlodipine and hydrochlorothiazide from separate tablets
given concurrently at the same time of the day may be switched to a fixed
combination tablet of Rasitrio containing the same component doses.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The fixed dose
combination should only be used after a stable effect on the monocomponents, </span><span
lang=HU>given concurrently,<b> </b></span><span lang=EN-GB>has been established
after dose titration. Dose should be individualised and adjusted according to
the patient&#8217;s clinical response.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><u><span lang=EN-GB>Special populations</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Elderly patients aged 65&nbsp;years and over</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>There is
evidence of an increased risk of adverse events related to hypotension in
patients aged 65&nbsp;years or older treated with Rasitrio. Therefore,
particular caution should be exercised when administering Rasitrio in patients
aged 65&nbsp;years or over.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The recommended
starting dose of aliskiren in this group of patients is 150&nbsp;mg. No
clinically meaningful additional blood pressure reduction is observed by
increasing the dose to 300&nbsp;mg in the majority of elderly patients.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Elderly patients aged 75&nbsp;years and over</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Very limited data are available on the use of Rasitrio in patients
aged 75&nbsp;years or older (see section&nbsp;5.2). The use of Rasitrio in
patients aged 75&nbsp;years or older should be restricted to patients for whom
blood pressure control has been established for the free combination of
aliskiren, amlodipine and hydrochlorothiazide </span><span lang=EN-GB>given
concurrently</span><span lang=EN-GB> without accompanying safety concerns, in particular
hypotension. Extreme caution, including more frequent monitoring of blood
pressure, is recommended (see sections&nbsp;4.4, 4.8, 5.1 and 5.2)</span><span
style='font-family:"TimesNewRomanPSMT",serif'>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Renal impairment</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No adjustment of
the initial dose is required for patients with mild to moderate renal impairment
(</span><span lang=EN-GB>estimated </span><span lang=EN-GB>glomerular
filtration rate</span><span lang=EN-GB> (GFR) 89&#8209;60&nbsp;ml/min/1.73&nbsp;m<sup>2</sup>
and 59&#8209;30&nbsp;ml/min/1.73&nbsp;m<sup>2</sup>, respectively) (see
sections&nbsp;4.4 and 5.2). Due to the hydrochlorothiazide component, </span><span
lang=EN-GB>Rasitrio is contraindicated for use in patients with anuria and in
patients with severe renal impairment (GFR &lt;30&nbsp;ml/min/1.73&nbsp;m<sup>2</sup>).
The </span><span lang=EN-GB>c</span><span lang=EN-GB>oncomitant use of Rasitrio
with angiotensin II receptor blockers (ARB) or angiotensin converting enzyme
inhibitors (ACEI) is contraindicated in patients with renal impairment (GFR
&lt;60&nbsp;ml/min/</span><span lang=EN-GB>1.73&nbsp;m<sup>2</sup></span><span
lang=EN-GB>) (see sections&nbsp;4.3, 4.4 and 5.2).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Hepatic impairment</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Rasitrio is
contraindicated in patients with severe hepatic impairment. Caution</span>
should be exercised when administering Rasitrio i<span lang=EN-GB>n </span>patients
with mild to moderate hepatic impairment or patients with progressive liver
disease. No dosage recommendations have been established for amlodipine in
patients with mild to moderate hepatic impairment <span lang=EN-GB>(see
sections&nbsp;4.3 and 4.4).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Paediatric population</span></i></p>

<p class=MsoNormal style='line-height:normal'>The safety and efficacy of
Rasitrio in children and adolescents below age&nbsp;18 have not been
established. No data are available.</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><u><span lang=EN-GB>Method of administration</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Oral use. The
tablets should be swallowed whole with some water. Rasitrio should be taken
with a light meal once a day, preferably at the same time each day. Grapefruit
juice should not be taken together with Rasitrio (see section&nbsp;4.5).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b>4.3&nbsp;&nbsp;&nbsp;&nbsp; Contraindications</b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Hypersensitivity to the active substances or to
any of the excipients listed in section&nbsp;6.1, to other dihydropyridine
derivatives, or to other sulphonamide-derived substances.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>History of angioedema with aliskiren.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Hereditary or idiopathic angioedema.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Second and third trimesters of pregnancy (see
section&nbsp;4.6).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Anuria.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Severe renal impairment (GFR
&lt;30&nbsp;ml/min/1.73&nbsp;m<sup>2</sup>).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Hyponatraemia, hypercalcaemia, symptomatic hyperuricaemia
and refractory hypokalaemia.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Severe hepatic impairment.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The concomitant use of aliskiren with
ciclosporin and itraconazole, two highly potent P-glycoprotein (P-gp)
inhibitors, and other potent P-gp inhibitors (e.g. quinidine), is contraindicated
(see section&nbsp;4.5).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The concomitant use of aliskiren with ARBs or
ACEIs is contraindicated in patients with diabetes mellitus or renal impairment
(GFR &lt;60&nbsp;ml/min/</span><span lang=EN-GB>1.73&nbsp;m<sup>2</sup></span><span
lang=EN-GB>) (see sections&nbsp;4.2, 4.4, 4.5 and 5.1).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Severe hypotension.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Shock (including cardiogenic shock).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Obstruction of the outflow tract of the left
ventricle (e.g. high grade aortic stenosis).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Haemodynamically unstable heart failure after
acute myocardial infarction.</span></p>

<p class=MsoNormal style='line-height:normal;vertical-align:baseline'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.4&nbsp;&nbsp;&nbsp;&nbsp; Special
warnings and precautions for use</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>General</span></u></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>In the event
of severe and persistent diarrhoea, Rasitrio therapy should be stopped (see
section&nbsp;4.8).</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>As with any
antihypertensive medicinal product, excessive reduction of blood pressure in
patients with ischaemic cardiopathy or ischaemic cardiovascular disease could
result in a myocardial infarction or stroke.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Symptomatic
hypotension occurred with higher frequency in patients with non-complicated
hypertension treated with Rasitrio than in patients treated with dual
combinations of aliskiren/amlodipine, aliskiren/hydrochlorothiazide or
amlodipine/hydrochlorothiazide.</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Hypersensitivity
reactions to hydrochlorothiazide may occur in patients, but are more likely in
patients with allergy and asthma.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Systemic
lupus erythematosus</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Thiazide
diuretics, including hydrochlorothiazide, have been reported to exacerbate or
activate systemic lupus erythematosus.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The safety and
efficacy of amlodipine in hypertensive crisis have not been established.</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Dual blockade
of the renin-angiotensin-aldosterone system (RAAS)</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Hypotension,
syncope, stroke, hyperkalaemia, and changes in renal function (including acute
renal failure) have been reported in susceptible individuals, especially if
combining medicinal products that affect this system (see section</span><span
lang=EN-GB>&nbsp;</span><span lang=EN-GB>5.1). Dual blockade of the
renin-angiotensin-aldosterone system by combining aliskiren with an angiotensin
converting enzyme inhibitor (ACEI) or an angiotensin II receptor blocker (ARB)
is therefore not recommended. Close monitoring of blood pressure, renal
function and electrolytes should be exercised if co-administration is
considered absolutely necessary.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>T</span><span
lang=EN-GB>he use of</span><span lang=EN-GB> aliskiren in combination with ARBs
or ACEIs is contraindicated in patients with diabetes mellitus or renal
impairment (GFR &lt;60&nbsp;ml/min</span><span lang=EN-GB>/1.73&nbsp;m<sup>2</sup></span><span
lang=EN-GB>) (see section&nbsp;4.3)</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Geriatric
patients aged 65&nbsp;years and over</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Particular caution should be exercised when administering Rasitrio
in patients aged 65&nbsp;years or older. Symptomatic hypotension occurred with
higher frequency in patients with non-complicated hypertension treated with
Rasitrio than in patients treated with dual combinations of
aliskiren/amlodipine, aliskiren/hydrochlorothiazide or
amlodipine/hydrochlorothiazide. Patients aged 65&nbsp;years old or over, are
more susceptible to hypotension-related adverse reactions following treatment
with Rasitrio (see sections&nbsp;4.2, 4.8, 5.1 and 5.2).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Geriatric patients aged 75&nbsp;years and over</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Very limited efficacy and safety data are available on the use of
Rasitrio in patients aged 75&nbsp;years or older. Extreme caution, </span>including
more frequent monitoring of blood pressure, is recommended<span lang=EN-GB>
(see sections&nbsp;4.2, 4.8, 5.1 and 5.2).</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Heart failure</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Calcium channel
blockers, including amlodipine, should be used with caution in patients with
congestive heart failure, as they may increase the risk of future
cardiovascular events and mortality.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>No data on
cardiovascular mortality and morbidity are available for Rasitrio in patients
with heart failure (see section&nbsp;5.1).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Aliskiren should
be used with caution in patients with heart failure treated with furosemide
(see section&nbsp;4.5).</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Risk of symptomatic hypotension</span></u></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Symptomatic
hypotension could occur after initiation of treatment with Rasitrio Rasitrio in
the following cases:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>Patients with marked volume depletion or patients with salt
depletion <span lang=EN-GB>(e.g. those receiving high doses of diuretics) </span>or</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>Combined use of aliskiren with other agents acting on the RAAS.</p>

<p class=Default><span style='font-size:11.0pt'>The volume or salt depletion
should be corrected prior to administration of Rasitrio, or the treatment
should start under close medical supervision.</span></p>

<p style='margin:0in'><u><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Electrolyte imbalance</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Treatment with
Rasitrio should only start after correction of hypokalaemia and any coexisting
hypomagnesaemia. Thiazide diuretics can precipitate new onset hypokalaemia or
exacerbate pre-existing hypokalaemia. Thiazide diuretics should be administered
with caution in patients with conditions involving enhanced potassium loss, for
example salt-losing nephropathies and prerenal (cardiogenic) impairment of
kidney function. </span><span lang=EN-GB>If hypokalaemia develops during
hydrochlorothiazide therapy Rasitrio should be discontinued until stable
correction of the potassium balance.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'>Hypokalaemia may develop with the
use of thiazide diuretics. The risk of hypokalaemia is greater in patients with
cirrhosis of the liver, patients experiencing brisk diuresis, patients with
inadequate oral electrolyte intake and patients receiving concomitant therapy
with corticosteroids or adrenocorticotropic hormone (ACTH) (see
sections&nbsp;4.5 and 4.8).</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal><span lang=EN-GB>Conversely, </span><span lang=EN-GB>increases
in serum potassium have been observed with aliskiren in post-marketing
experience and these may be exacerbated by concomitant use of other agents
acting on the RAAS or by non-steroidal anti-inflammatory drugs (NSAIDs).
Consistent with standard medical practice, periodic determination of renal
function including serum electrolytes is advised if co-administration is
considered necessary. The concomitant use of aliskiren and ACEIs or ARBs is
contraindicated in patients with diabetes mellitus or renal impairment (GFR
&lt;60&nbsp;ml/min</span><span lang=EN-GB>/1.73&nbsp;m<sup>2</sup></span><span
lang=EN-GB>) (see section</span><span lang=EN-GB>&nbsp;</span><span lang=EN-GB>4.3,
4.5 and 4.8).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoDate><span lang=EN-GB>Thiazide diuretics can precipitate new onset
hyponatraemia and hypochloroaemic alkalosis or exacerbate pre-existing
hyponatraemia. Hyponatraemia, accompanied by neurological symptoms (nausea,
progressive disorientation, apathy) has been observed. Treatment with
hydrochlorothiazide should only be started after correction of pre-existing
hyponatraemia. In case severe or rapid hyponatraemia develops during Rasitrio
therapy, the treatment should be discontinued until normalisation of natraemia.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>All patients receiving thiazide diuretics
should be periodically monitored for imbalances in electrolytes, particularly
potassium, sodium and magnesium.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Thiazides
reduce urinary calcium excretion and may cause an intermittent and slight
elevation of serum calcium in the absence of known disorders of calcium
metabolism. Rasitrio is contraindicated in patients with hypercalcaemia and
should only be used after correction of any pre-existing hypercalcaemia.
Rasitrio should be discontinued if hypercalcaemia develops during treatment.
Serum levels of calcium should be periodically monitored during treatment with
thiazides. Marked hypercalcaemia may be evidence of hidden hyperparathyroidism.
Thiazides should be discontinued before carrying out tests for parathyroid
function.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>There is no
evidence that Rasitrio would reduce or prevent diuretic-induced hyponatraemia.
Chloride deficit is generally mild and usually does not require treatment.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Renal impairment and kidney transplantation</span></u></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Thiazide
diuretics may precipitate azotaemia in patients with chronic kidney disease.
When Rasitrio is used in patients with renal impairment, periodic monitoring of
serum electrolytes including potassium, creatinine and uric acid serum levels
is recommended. No data is available in hypertensive patients with severe renal
impairment (serum creatinine &#8805;150&nbsp;&#956;mol/l or 1.70&nbsp;mg/dl in
women and &#8805;177&nbsp;&#956;mol/l or 2.00&nbsp;mg/dl in men and/or
estimated glomerular filtration rate (GFR) &lt;30&nbsp;ml/min/</span><span
style='font-size:11.0pt;color:windowtext'>1.73&nbsp;m<sup>2</sup></span><span
style='font-size:11.0pt;color:windowtext'>), history of dialysis, nephrotic
syndrome or renovascular hypertension. Rasitrio is contraindicated in
hypertensive patients with severe renal impairment (GFR &lt;30&nbsp;ml/min/</span><span
style='font-size:11.0pt;color:windowtext'>1.73&nbsp;m<sup>2</sup></span><span
style='font-size:11.0pt;color:windowtext'>) or anuria (see sections&nbsp;4.2.
and 4.3). No dose adjustment is necessary in patients with mild to moderate
renal impairment.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>As for other
medicinal products acting on the RAAS, caution should be exercised when
Rasitrio is given in the presence of conditions pre-disposing to kidney
dysfunction such as hypovolaemia (e.g. due to blood loss, severe or prolonged
diarrhoea, prolonged vomiting, etc.), heart disease, liver disease, diabetes
mellitus or kidney disease. The concomitant use of aliskiren and ACEIs or ARBs
is contraindicated in patients with renal impairment (GFR
&lt;&nbsp;60&nbsp;ml/min/</span><span style='font-size:11.0pt;color:windowtext'>1.73&nbsp;m<sup>2</sup></span><span
style='font-size:11.0pt;color:windowtext'>). Acute renal failure, reversible
upon discontinuation of treatment, has been reported in at-risk patients
receiving aliskiren in post-marketing experience. In the event that any signs
of renal failure occur, aliskiren should be promptly discontinued.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>There is no
experience regarding the administration of Rasitrio in patients who have
recently undergone kidney transplantation, therefore caution should be
exercised in these patients.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Hepatic impairment</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Rasitrio is
contraindicated in hypertensive patients with severe hepatic impairment (see
sections&nbsp;4.3 and 5.2). Caution should be exercised when administering
Rasitrio to patients with mild to moderate hepatic impairment or progressive
liver disease (see sections&nbsp;4.2 and 5.2).</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The half life of
amlodipine is prolonged and AUC values are higher in patients with impaired
liver function; dosage recommendations have not been established.</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Aortic and mitral valve stenosis, obstructive hypertrophic
cardiomyopathy</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>As with all
other vasodilators, special caution is indicated when using amlodipine in
patients suffering from aortic or mitral stenosis, or obstructive hypertrophic
cardiomyopathy.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Metabolic and endocrine effects</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Thiazide
diuretics, including hydrochlorothiazide, may alter glucose tolerance and raise
serum levels of cholesterol and triglycerides, and uric acid. In diabetic
patients dose adjustments of insulin or oral hypoglycaemic medicinal products
may be required during Rasitrio therapy. </span><span lang=EN-GB>C</span><span
lang=EN-GB>oncomitant use of Rasitrio with ARBs or ACEIs is contraindicated in
patients with diabetes mellitus (see section&nbsp;4.3).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Due to the hydrochlorothiazide component,
Rasitrio is contraindicated in symptomatic hyperuricaemia (see
section&nbsp;4.3). </span><span lang=EN-GB>Hydrochlorothiazide may raise the
serum uric acid level due to reduced clearance of uric acid and may cause or
exacerbate hyperuricaemia as well as precipitate gout in susceptible patients.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Thiazides reduce
urinary calcium excretion and may cause an intermittent and slight elevation of
serum calcium in the absence of known disorders of calcium metabolism. Rasitrio
is contraindicated in patients with hypercalcaemia and should only be used
after correction of any pre-existing hypercalcaemia. Rasitrio should be
discontinued if hypercalcaemia develops during treatment. Serum levels of
calcium should be periodically monitored during treatment with thiazides.
Marked hypercalcaemia may be evidence of hidden hyperparathyroidism. Thiazides
should be discontinued before carrying out tests for parathyroid function.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Renal artery stenosis</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No controlled
clinical data are available on the use of Rasitrio in patients with unilateral
or bilateral renal artery stenosis, or stenosis to a solitary kidney. However,
as with other medicinal products acting on the renin-angiotensin-aldosterone
system, there is an increased risk of renal insufficiency, including acute
renal failure, when patients with renal artery stenosis are treated with
aliskiren. Therefore caution should be exercised in these patients. If renal
failure occurs, treatment should be discontinued.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Anaphylactic reactions and angioedema</span></u></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Anaphylactic
reactions have been observed during treatment with aliskiren from
post-marketing experience (see section&nbsp;4.8). As with other medicinal
products acting on the renin-angiotensin-aldosterone system (RAAS), angioedema
or symptoms suggestive of angioedema (swelling of the face, lips, throat and/or
tongue) have been reported in patients treated with aliskiren.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>A number of
these patients had a history of angioedema or symptoms suggestive of
angioedema, which in some cases followed use of other medicinal products that
can cause angioedema, including RAAS blockers (angiotensin converting enzyme
inhibitors or angiotensin receptor blockers) (see section&nbsp;4.8).</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In
post-marketing experience, angioedema or angioedema-like reactions have been
reported when aliskiren was co-administered with ACEIs and/or ARBs (see
section&nbsp;4.8).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Special caution
is necessary in patients with a hypersensitivity predisposition.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Patients with
history of angioedema may be at increased risk of experiencing angioedema
during treatment with aliskiren (see sections&nbsp;4.3 and 4.8). Caution should
therefore be exercised when prescribing aliskiren to patients with a history of
angioedema, and such patients should be closely monitored during treatment (see
section&nbsp;4.8) especially at the beginning of the treatment.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>If anaphylactic reactions or</span><span
lang=EN-GB> </span><span lang=EN-GB>angioedema occur, Rasitrio should be
promptly discontinued and appropriate therapy and monitoring provided until
complete and sustained resolution of signs and symptoms has occurred. Patients
should be informed to report to the physician any signs suggestive of allergic
reactions, in particular difficulties in breathing or swallowing, swelling of
face, extremities, eyes, lips or tongue. Where there is involvement of the
tongue, glottis or larynx adrenaline should be administered. In addition,
measures necessary to maintain patent airways should be provided.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u>Photosensitivity</u></p>

<p class=MsoNormal>Cases of photosensitivity reactions have been reported with
thiazide diuretics (see section&nbsp;4.8). If photosensitivity reaction occurs
during treatment with <span lang=EN-GB>Rasitrio</span>, it is recommended to
stop the treatment. If a re-administration of the diuretic is deemed necessary,
it is recommended to protect exposed areas to the sun or to artificial UVA.</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Acute angle-closure glaucoma</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Hydrochlorothiazide, a sulphonamide, has
been associated with an idiosyncratic reaction resulting in acute transient
myopia and acute angle-closure glaucoma. Symptoms include acute onset of
decreased visual acuity or ocular pain and typically occur within hours to
weeks of treatment initiation. Untreated acute angle-closure glaucoma can lead
to permanent vision loss. The primary treatment is to discontinue
hydrochlorothiazide as rapidly as possible. Prompt medical or surgical
treatment may need to be considered if the intraocular pressure remains
uncontrolled. Risk factors for developing acute angle-closure glaucoma may
include a history of sulphonamide or penicillin allergy.</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.5&nbsp;&nbsp;&nbsp;&nbsp; Interaction
with other medicinal products and other forms of interaction</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Information on Rasitrio interactions</span></u></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>A
population pharmacokinetic analysis in patients with hypertension did not
indicate any clinically relevant changes in the </span><span lang=EN-GB>steady-state
exposure (AUC) and C<sub>max</sub> of aliskiren, amlodipine and
hydrochlorothiazide compared to the corresponding dual therapies.</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Medicinal
products affecting serum potassium levels</span></i><span lang=EN-GB>: </span><span
lang=EN-GB>The potassium-depleting effect of hydrochlorothiazide is attenuated
by the potassium-sparing effect of aliskiren. However, this effect of
hydrochlorothiazide on serum potassium would be expected to be potentiated by
other medicinal products associated with potassium loss and hypokalaemia (e.g.
other kaliuretic diuretics, corticosteroids, laxatives, adrenocoricotropic
hormone (ACTH), amphotericin, carbenoxolone, penicillin G, salicylic acid
derivatives). Conversely,</span><span lang=EN-GB> concomitant use of other
agents affecting the RAAS, of NSAIDs or of agents that increase serum potassium
levels (e.g. potassium-sparing diuretics, potassium supplements, salt
substitutes containing potassium, heparin) may lead to increases in serum
potassium. If co-medication with an agent affecting the level of serum
potassium is considered necessary, caution is advisable. The combination of
aliskiren with </span><span lang=EN-GB>ARBs or ACEIs </span><span lang=EN-GB>is
contraindicated in patients with diabetes mellitus or renal impairment (GFR
&lt;60&nbsp;ml/min/</span><span lang=EN-GB>1.73&nbsp;m<sup>2</sup></span><span
lang=EN-GB>) and is not recommended in other patients (see sections</span><span
lang=EN-GB>&nbsp;</span><span lang=EN-GB>4.3, 4.4 and 5.1)</span><span
lang=EN-GB>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Medicinal
products affected by serum potassium disturbances</span></i><span lang=EN-GB>: </span><span
lang=EN-GB>Periodic monitoring of serum potassium is recommended when Rasitrio
is administered with medicinal products affected by serum potassium
disturbances (e.g. digitalis glycosides, antiarrhythmics).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default><i><span style='font-size:11.0pt;color:windowtext'>Non-steroidal
anti-inflammatory drugs (NSAIDs), including selective cyclooxygenase-2
inhibitors (COX-2 inhibitors)</span></i><span class=msoins0><i><span
style='font-size:11.0pt;color:windowtext'>, acetylsalicylic acid and
non-selective NSAIDs</span></i></span><i><span style='font-size:11.0pt;
color:windowtext'>:</span></i><span style='font-size:11.0pt;color:windowtext'>
As with other agents acting on the renin-angiotensin system, NSAIDs may reduce
the anti-hypertensive effect of aliskiren. NSAIDs may also weaken the diuretic
and antihypertensive activity of hydrochlorothiazide.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In some patients
with compromised renal function (dehydrated patients or elderly patients)
aliskiren and hydrochlorothiazide given concomitantly with NSAIDs may result in
further deterioration of renal function, including possible acute renal
failure, which is usually reversible. Therefore the use of Rasitrio with an
NSAID requires caution, especially in elderly patients.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Information on aliskiren interactions</span></u></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Contraindicated (see section&nbsp;4.3)</span></i></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span style='font-size:11.0pt;color:windowtext'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span style='font-size:11.0pt;color:windowtext'>Dual RAAS
blockade</span></i></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>The
combination of aliskiren with ARBs or ACEIs is contraindicated in patients with
diabetes mellitus or renal impairment (GFR &lt;60&nbsp;ml/min/</span><span
style='font-size:11.0pt;color:windowtext'>1.73&nbsp;m<sup>2</sup></span><span
style='font-size:11.0pt;color:windowtext'>) and is not recommended in other
patients (see sections&nbsp;4.3, 4.4 and 5.1).</span></p>

<p class=Default><i><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></i></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span style='font-size:11.0pt;color:windowtext'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span style='font-size:11.0pt;color:windowtext'>P-glycoprotein
(P-gp) potent inhibitors</span></i></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>A single dose
drug interaction study in healthy subjects has shown that ciclosporin (200 and
600&nbsp;mg) increases C<sub>max</sub> of aliskiren 75&nbsp;mg approximately
2.5-fold and AUC approximately 5-fold. The increase may be higher with higher
aliskiren doses. </span><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>In
healthy subjects, itraconazole (100&nbsp;mg) increases AUC and C<sub>max</sub>
of aliskiren (150&nbsp;mg) by 6.5-fold and 5.8-fold, respectively. </span><span
style='font-size:11.0pt;color:windowtext'>Therefore, concomitant use of
aliskiren and P-gp potent inhibitors is contraindicated (see section&nbsp;4.3).</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i>Not
recommended (see section&nbsp;4.2)</i></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span style='font-size:11.0pt;color:windowtext'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span style='font-size:11.0pt;color:windowtext'>Grapefruit
juice</span></i></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Administration
of grapefruit juice with aliskiren resulted in a decrease in AUC and C<sub>max</sub>
of aliskiren. Co-administration with aliskiren 150&nbsp;mg resulted in a 61%
decrease in aliskiren AUC and co-administration with aliskiren 300&nbsp;mg
resulted in a 38% decrease in aliskiren AUC. This decrease is likely due to an
inhibition of </span><span style='font-size:11.0pt;color:windowtext'>organic
anion transporting polypeptide-mediated uptake of aliskiren by grapefruit juice
in the gastrointestinal tract. Therefore, because of the risk of therapeutic
failure, grapefruit juice should not be taken together with Rasitrio.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i>Caution
required with concomitant use</i></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span style='font-size:11.0pt;color:windowtext'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span style='font-size:11.0pt;color:windowtext'>P-gp interactions</span></i></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>MDR</span><span
style='font-size:11.0pt;color:windowtext'>1/Mdr1a/1b (P-gp) was found to be the
major efflux system involved in intestinal absorption and biliary excretion of
aliskiren in preclinical studies. Rifampicin, which is an inducer of P-gp,
reduced aliskiren bioavailability by approximately 50% in a clinical study.
Other inducers of P-gp (St. John&#8217;s wort) might decrease the
bioavailability of aliskiren. Although this has not been investigated for
aliskiren, it is known that P-gp also controls tissue uptake of a variety of
substrates and P-gp inhibitors can increase the tissue-to-plasma concentration
ratios. Therefore, P-gp inhibitors may increase tissue levels more than plasma
levels. The potential for drug interactions at the P-gp site will likely depend
on the degree of inhibition of this transporter.</span></p>

<p class=Default><i><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></i></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span style='font-size:11.0pt;color:windowtext'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span style='font-size:11.0pt;color:windowtext'>Moderate P-gp
inhibitors</span></i></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Co-administration
of ketoconazole (200&nbsp;mg) or verapamil (240&nbsp;mg) with aliskiren
(300&nbsp;mg) resulted in a 76% or 97% increase in aliskiren AUC, respectively.
The change in plasma levels of aliskiren in the presence of ketoconazole or
verapamil is expected to be within the range that would be achieved if the dose
of aliskiren were doubled; aliskiren doses of up to 600&nbsp;mg, or twice the
highest recommended therapeutic dose, have been found to be well tolerated in
controlled clinical trials. Preclinical studies indicate that aliskiren and
ketoconazole co-administration enhances aliskiren gastrointestinal absorption
and decreases biliary excretion. Therefore, caution should be exercised when
aliskiren is administered with ketoconazole, verapamil or other moderate P-gp
inhibitors (clarithromycin, telithromycin, erythromycin, amiodarone).</span></p>

<p class=Default><i><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></i></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span style='font-size:11.0pt;color:windowtext'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span style='font-size:11.0pt;color:windowtext'>Medicinal
products affecting serum potassium levels</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Concomitant use
of other agents affecting the RAAS, of NSAIDs or of agents that increase serum
potassium levels (e.g. potassium-sparing diuretics, potassium supplements, salt
substitutes containing potassium, heparin) may lead to increases in serum
potassium. If co-administration with an agent affecting the level of serum
potassium is considered necessary, caution is advisable. The combination of
aliskiren with ARBs or ACEIs is contraindicated in patients with diabetes
mellitus or renal impairment (GFR &lt;60&nbsp;ml/min/</span><span lang=EN-GB>1.73&nbsp;m<sup>2</sup></span><span
lang=EN-GB>) and is not recommended in other patients (see sections&nbsp;4.3,
4.4 and 5.1).</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span style='font-size:11.0pt;color:windowtext'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span style='font-size:11.0pt;color:windowtext'>Furosemide</span></i></p>

<p class=Default><span lang=EN style='font-size:11.0pt;color:windowtext'>Oral
co-administration of aliskiren and furosemide had no effect on the
pharmacokinetics of aliskiren but reduced exposure to furosemide by 20&#8209;30%
(the </span><span style='font-size:11.0pt;color:windowtext'>effect of aliskiren
on furosemide administered intramuscularly or intravenously has not been investigated)</span><span
lang=EN style='font-size:11.0pt;color:windowtext'>. After </span><span
style='font-size:11.0pt;color:windowtext'>multiple doses of </span><span
lang=EN style='font-size:11.0pt;color:windowtext'>furosemide (60</span><span
style='font-size:11.0pt;color:windowtext'>&nbsp;</span><span lang=EN
style='font-size:11.0pt;color:windowtext'>mg/day) co-administered with
aliskiren (300&nbsp;mg/day) </span><span style='font-size:11.0pt;color:windowtext'>to
patients with heart failure</span><span lang=EN style='font-size:11.0pt;
color:windowtext'> the urinary sodium excretion and the urine volume were
reduced during the first 4&nbsp;hours by 31% and 24%, respectively, as compared
to furosemide alone. </span><span style='font-size:11.0pt;color:windowtext'>The
mean weight of patients concomitantly treated with furosemide and 300&nbsp;mg
aliskiren (84.6&nbsp;kg) was higher than the weight of patients treated with
furosemide alone (83.4&nbsp;kg)</span><span lang=EN style='font-size:11.0pt;
color:windowtext'>. Smaller changes in furosemide pharmacokinetics and efficacy
were observed with aliskiren 150</span><span style='font-size:11.0pt;
color:windowtext'>&nbsp;</span><span lang=EN style='font-size:11.0pt;
color:windowtext'>mg/day. In patients treated with both aliskiren and oral
furosemide,</span><span style='font-size:11.0pt;color:windowtext'> it is
therefore recommended that the effects of furosemide be monitored when
initiating and adjusting furosemide or aliskiren therapy to avoid changes in
extracellular fluid volume and possible situations of volume overload (see
section&nbsp;4.4).</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span style='font-size:11.0pt;color:windowtext'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span style='font-size:11.0pt;color:windowtext'>Warfarin</span></i></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>The effects of
aliskiren on warfarin pharmacokinetics have not been evaluated.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span style='font-size:11.0pt;color:windowtext'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span style='font-size:11.0pt;color:windowtext'>Food
interactions</span></i></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Meals (low or
high fat content) have been shown to reduce the absorption of aliskiren
substantially (see section&nbsp;4.2).</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i>No
interactions</i></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt'><span
style='font-size:11.0pt;color:windowtext'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt;color:windowtext'>Compounds that
have been investigated in aliskiren clinical pharmacokinetic studies include
acenocoumarol, atenolol, celecoxib, pioglitazone, allopurinol, isosorbide-5-mononitrate
and hydrochlorothiazide. No interactions have been identified.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>Co-administration of aliskiren with either metformin
(&#8595;28%), amlodipine (&#8593;29%) or cimetidine (&#8593;19%) resulted in
between 20% and 30%<span lang=EN-GB> change in C</span><sub><span lang=EN-GB>max</span></sub><span
lang=EN-GB> or AUC of aliskiren. When administered with atorvastatin,
steady-state aliskiren AUC and C</span><sub><span lang=EN-GB>max</span></sub><span
lang=EN-GB> increased by 50%. Co-administration of aliskiren had no significant
impact on atorvastatin, metformin or amlodipine pharmacokinetics. As a result
no dose adjustment for aliskiren or these co-administered medicinal products is
necessary.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Digoxin
and verapamil bioavailability may be slightly decreased by aliskiren.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span style='font-size:11.0pt;color:windowtext'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span style='font-size:11.0pt;color:windowtext'>CYP450
interactions</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Aliskiren does
not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1 and 3A).
Aliskiren does not induce CYP3A4. Therefore aliskiren is not expected to affect
the systemic exposure of substances that inhibit, induce or are metabolised by
these enzymes. </span><span lang=EN-GB>Aliskiren is metabolised minimally by
the cytochrome P450 enzymes. Hence, interactions due to inhibition or induction
of CYP450 isoenzymes are not expected. However, CYP3A4 inhibitors often also
affect P-gp. Increased aliskiren exposure during co-administration of CYP3A4
inhibitors that also inhibit P-gp can therefore be expected (see other P-gp
references in section&nbsp;4.5).</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span style='font-size:11.0pt;color:windowtext'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span style='font-size:11.0pt;color:windowtext'>P-gp
substrates or weak inhibitors</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No relevant
interactions with atenolol, digoxin, amlodipine or cimetidine have been
observed. When administered with atorvastatin (80&nbsp;mg), steady-state
aliskiren (300&nbsp;mg) AUC and C<sub>max</sub> increased by 50%. </span><span
lang=EN-GB>In experimental animals, it has been shown that P-gp is a major
determinant of aliskiren bioavailability. Inducers of P-gp (St. John&#8217;s
wort, rifampicin) might therefore decrease the bioavailability of aliskiren.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span style='font-size:11.0pt;color:windowtext'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span style='font-size:11.0pt;color:windowtext'>Organic anion
transporting polypeptide (OATP) inhibitors</span></i></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Preclinical
studies indicate that aliskiren might be a substrate of organic anion
transporting polypeptides. Therefore, the potential exists for interactions
between OATP inhibitors and aliskiren when administered concomitantly (see
interaction with Grapefruit juice).</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Information on amlodipine interactions</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Effects of other medicinal products on amlodipine</span></u></i></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Caution required with concomitant use</span></i></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span style='font-size:11.0pt;color:windowtext'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span style='font-size:11.0pt;color:windowtext'>CYP3A4
inhibitors</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Concomitant use
of amlodipine with strong or moderate CYP3A4 inhibitors (protease inhibitors,
azole antifungals, macrolides like erythromycin or clarithromycin, verapamil or
diltiazem) may give rise to significant increase in amlodipine exposure. The
clinical translation of these pharmacokinetic variations may be more pronounced
in the elderly. Clinical monitoring and dose adjustment may thus be required.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span style='font-size:11.0pt;color:windowtext'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span style='font-size:11.0pt;color:windowtext'>CYP3A4
inducers</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>There is no data
available regarding the effect of CYP3A4 inducers on amlodipine. The
concomitant use of CYP3A4 inducers (e.g. rifampicin, <i>hypericum perforatum</i>)
may give a lower plasma concentration of amlodipine. Amlodipine should be used
with caution together with CYP3A4 inducers.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:1.5in;text-indent:-1.5in;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Grapefruit juice</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Administration
of amlodipine with grapefruit or grapefruit juice is not recommended as
bioavailability may be increased in some patients, resulting in increased blood
pressure lowering effects.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Dantrolene (infusion)</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In animals,
lethal ventricular fibrillation and cardiovascular collapse are observed in
association with hyperkalaemia after administration of verapamil and intravenous
dantrolene. Due to risk of hyperkalaemia, it is recommended that the
co-administration of calcium channel blockers such as amlodipine be avoided in
patients susceptible to malignant hyperthermia and in the management of
malignant hyperthermia.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Effects of amlodipine on other medicinal products</span></u></i></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The blood pressure lowering effects of
amlodipine add to the blood pressure lowering effects of other antihypertensive
medicinal products.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Co-administration of multiple doses of
10&nbsp;mg of amlodipine with 80&nbsp;mg simvastatin resulted in a 77% increase
in exposure to simvastatin compared to simvastatin alone. It is recommended to
limit the dose of simvastatin to 20&nbsp;mg daily in patients on amlodipine.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>No interactions</span></i></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>In clinical interaction studies, amlodipine did not
affect the pharmacokinetics of atorvastatin, digoxin, warfarin or ciclosporin.</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Information on hydrochlorothiazide interactions</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>When
administered concurrently, the following medicinal products may interact with
thiazide diuretics:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i>Not recommended</i></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span style='font-size:11.0pt;color:windowtext'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span style='font-size:11.0pt;color:windowtext'>Lithium</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>R</span>enal
clearance of lithium is reduced by thiazides, therefore the risk of lithium
toxicity<span lang=EN-GB> may be increased with hydrochlorothiazide</span>.
Co-administration of lithium and <span lang=EN-GB>hydrochlorothiazide</span> is
not recommended. If this combination proves essential, careful monitoring of
serum lithium level is recommended during concomitant use.</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i>Caution
required with concomitant use</i></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span style='font-size:11.0pt;color:windowtext'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span style='font-size:11.0pt;color:windowtext'>Alcohol</span></i><i><span
style='color:windowtext'>, barbiturates or narcotics</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Concomitant
administration of thiazide diuretics with subtances that also have a blood
pressure lowering effect (e.g. by reducing sympathetic central nervous system
activity or direct vasodilatation) may potentiate orthostatic hypotension.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Amantadine</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Thiazides,
including hydrochlorothiazide, may increase the risk of adverse reactions
caused by amantadine.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Antidiabetic agents (e.g. insulin and oral
antidiabetic agents)</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Thiazides may
alter glucose tolerance. Dose adjustment of the antidiabetic medicinal product
may be necessary (see section&nbsp;4.4). Metformin should be used with caution
because of the risk of lactic acidosis induced by possible functional renal
failure linked to hydrochlorothiazide.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Anticholinergic agents and other medicinal
products affecting gastric motility</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The
bioavailability of thiazide-type diuretics may be increased by anticholinergic
agents (e.g. atropine, biperiden), apparently due to a decrease in
gastrointestinal motility and the stomach emptying rate. Conversely, it is
anticipated that prokinetic substances such as cisapride may decrease the
bioavailability of thiazide-type diuretics.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Medicinal products used in the treatment of
gout</span></i></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Dose
adjustment of uricosuric </span>medicinal products<i> </i><span lang=EN-GB>may
be necessary as hydrochlorothiazide may raise the level of serum uric acid.
Increase of dose of probenecid or sulfinpyrazone may be necessary. Co<b>-</b>administration
of thiazide diuretics, including hydrochlorothiazide, may increase the
incidence of hypersensitivity reactions to allopurinol.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicinal
products that could induce torsades de pointes</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Due to the risk of hypokalaemia,
hydrochlorothiazide should be administered with caution when associated with
medicinal products that could induce <i>torsades de pointes</i>, in particular
Class Ia and Class III </span><span lang=EN-GB>antiarrhythmics</span><span
lang=EN-GB> </span><span lang=EN-GB>and some </span><span lang=EN-GB>antipsychotics.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><i><span lang=EN-GB>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicinal
products affecting serum sodium level</span></i></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>The
hyponatraemic effect of diuretics may be intensified by concomitant
administration of medicinal products such as antidepressants, antipsychotics,
antiepileptics, etc. Caution is indicated in long-term administration of these
medicinal products.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Beta blockers and diazoxide</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Concomitant use
of thiazide diuretics, including hydrochlorothiazide, with beta blockers may
increase the risk of hyperglycaemia. Thiazide diuretics, including
hydrochlorothiazide, may enhance the hyperglycaemic effect of diazoxide.</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Ion exchange resins</span></i></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Absorption
of thiazide diuretics, including hydrochlorothiazide, is decreased by
cholestyramine or colestipol. This could result in sub-therapeutic effects of
thiazide diuretics. However, staggering the dosage of hydrochlorothiazide and
resin such that hydrochlorothiazide is administered at least 4&nbsp;hours
before or 4&#8209;6&nbsp;hours after the administration of resins would
potentially minimise the interaction.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Vitamin D and calcium salts</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Administration
of thiazide diuretics, including hydrochlorothiazide, with vitamin D or with
calcium salts may potentiate the rise in serum calcium. Concomitant use of
thiazide type diuretics may lead to hypercalcaemia in patients pre-disposed for
hypercalcaemia (e.g. hyperparathyroidism, malignancy, or vitamin-D-mediated
conditions) by increasing tubular calcium reabsorption.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Non-depolarising skeletal muscle relaxants</span></i></p>

<p class=MsoNormal style='line-height:normal'>Thiazides, including
hydrochlorothiazide, potentiate the action of skeletal muscle relaxants such as
curare derivatives.</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Cytotoxic agents</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Thiazides,
including hydrochlorothiazide, may reduce the renal excretion of cytotoxic
agents (e.g. cyclophosphamide, methotrexate) and potentiate their
myelosuppressive effects.</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Digoxine or digitalis glycosides</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Thiazide-induced
hypokalaemia or hypomagnesaemia favour the onset of digitalis-induced cardiac
arrhythmias (see section&nbsp;4.4).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoDate style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Methyldopa</span></i></p>

<p class=MsoDate><span lang=EN-GB>There have been isolated reports of
haemolytic anaemia occurring with concomitant use of hydrochlorothiazide and
methyldopa.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Iodine
contrasting agents</span></i></p>

<p class=MsoNormal><span lang=EN-GB>In case of diuretic-induced dehydration,
there is an increased risk of acute renal failure, especially with high doses
of iodine products. Patients should be rehydrated before administration.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Pressor amines (e.g. noradrenaline,
adrenaline)</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Hydrochlorothiazide
may reduce the response to pressor amines such as noradrenaline. The clinical
significance of this effect is uncertain and not sufficient to preclude their
use.</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.6&nbsp;&nbsp;&nbsp;&nbsp; Fertility,
pregnancy and lactation</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Women of childbearing potential/contraception in males and
females</span></u></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Healthcare
professionals prescribing Rasitrio should counsel women of childbearing
potential about the potential risk during pregnancy. A switch to a suitable
alternative antihypertensive treatment should be carried out in advance of a
planned pregnancy since Rasitrio should not be used in women planning to become
pregnant.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Pregnancy</span></u></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>There are no
data on the use of aliskiren in pregnant women. Aliskiren was not teratogenic
in rats or rabbits (see section&nbsp;5.3). Other substances that act directly
on the renin-angiotensin-aldosterone system have been associated with serious
foetal malformations and neonatal death. As for any medicinal product that acts
directly on the renin-angiotensin-aldosterone system, aliskiren should not be
used during the first trimester of pregnancy and is contraindicated during the
second and third trimesters (see section&nbsp;4.3).</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The safety of
amlodipine in human pregnancy has not been established. Reproductive studies in
rats have shown no toxicity except for delayed date of delivery and prolonged
duration of labour at dosages 50&nbsp;times greater than the maximum
recommended dosage for humans (see section&nbsp;5.3). Use in pregnancy is only
recommended when there is no safer alternative and when the disease itself
carries greater risk for the mother and foetus.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>There is limited experience with
hydrochlorothiazide during pregnancy, especially during the first trimester.
Animal studies are insufficient.</span></p>

<p class=MsoDate><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoDate><span lang=EN-GB>Hydrochlorothiazide crosses the placenta.
Based on the pharmacological mechanism of action of hydrochlorothiazide, its
use during the second and third trimester may compromise foeto-placental
perfusion and may cause foetal and neonatal effects like icterus, disturbance
of electrolyte balance and thrombocytopenia.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Hydrochlorothiazide should not be used for
gestational oedema, gestational hypertension or pre&#8209;eclampsia due to the
risk of decreased plasma volume and placental hypoperfusion, without a
beneficial effect on the course of the disease.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Hydrochlorothiazide should not be used for
essential hypertension in pregnant women except in rare situations where no
other treatment could be used.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Rasitrio
should not be used during the first trimester of pregnancy. Rasitrio is
contraindicated during the second and third trimesters (see section&nbsp;4.3).</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>If pregnancy
is detected during therapy, Rasitrio should be discontinued accordingly as soon
as possible.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Breast-feeding</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>It is not known
whether aliskiren and/or amlodipine are excreted in human milk. Aliskiren was
secreted in the milk of lactating rats.</span></p>

<p class=MsoDate><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoDate><span lang=EN-GB>Hydrochlorothiazide is excreted in human milk
in small amounts. Thiazides in high doses causing intense diuresis can inhibit
milk production.</span></p>

<p class=MsoDate><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The use of
Rasitrio during breast-feeding is not recommended. If Rasitrio is used during
breast-feeding, doses should be kept as low as possible.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Fertility</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>There are no
clinical data on fertility with the use of Rasitrio.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Reversible
biochemical changes in the head of spermatozoa have been reported in some
patients treated by calcium channel blockers. Clinical data are insufficient
regarding the potential effect of amlodipine on fertility. In one rat study,
adverse effects were found on male fertility (see section&nbsp;5.3). The
fertility of rats was unaffected at doses of up to aliskiren 250&nbsp;mg/kg/day
and hydrochlorothiazide 4&nbsp;mg/kg/day (see section&nbsp;5.3).</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.7&nbsp;&nbsp;&nbsp;&nbsp; Effects
on ability to drive and use machines</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>No studies on the effect on the ability to drive and use machines
have been performed</span>. However, when driving vehicles or using machines it
must be borne in mind that dizziness or drowsiness may occasionally occur when
taking Rasitrio.</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Amlodipine can
have minor or moderate influence on the ability to drive and use machines. If
patients taking amlodipine suffer from dizziness, drowsiness, headache, fatigue
or nausea, the ability to react may be impaired.</span></p>

<p class=MsoDate><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.8&nbsp;&nbsp;&nbsp;&nbsp; Undesirable
effects</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Summary of the safety profile</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Aliskiren/amlodipine/hydrochlorothiazide combination</span></u></i></p>

<p style='margin:0in'><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>The safety profile of Rasitrio presented below is
based on clinical studies performed with Rasitrio and the known safety profile
of the individual components aliskiren, amlodipine and hydrochlorothiazide.
Safety information for Rasitrio in patients aged 75&nbsp;years and older is
limited.</span></p>

<p style='margin:0in'><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoCommentText style='line-height:normal'><span lang=EN-GB
style='font-size:11.0pt'>The most frequent adverse reactions observed with
Rasitrio are hypotension and dizziness. The adverse reactions previously
reported with one of the individual components of Rasitrio (aliskiren,
amlodipine and hydrochlorothiazide) and listed in the respective paragraphs on
the individual components may occur with Rasitrio.</span></p>

<p class=Default><u><span lang=EN-GB style='font-size:11.0pt;color:windowtext'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Tabulated
list of adverse reactions:</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>The adverse
reactions for aliskiren, amlodipine and hydrochlorothiazide are ranked under
heading of frequency, the most frequent first, using the following convention:
very common (&#8805;1/10); common (&#8805;1/100 to &lt;1/10); uncommon
(&#8805;1/1,000 to &lt;1/100); rare (&#8805;1/10,000 to &lt;1/1,000); very rare
(&lt;1/10,000), not known (cannot be estimated from the available data). Within
each frequency grouping, adverse reactions are presented in order of decreasing
seriousness.</span></p>

<p style='margin:0in'><u><span style='font-size:11.0pt;font-family:"Times New Roman",serif'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p style='margin:0in;page-break-after:avoid'><i><u><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Information on
Rasitrio</span></u></i></p>

<p class=CharCharCharCharChar align=left style='margin-bottom:0in;text-align:
left;line-height:normal;page-break-after:avoid'><span style='font-size:11.0pt;
font-family:"Times New Roman",serif'>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='margin-left:5.4pt;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-bottom:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
  layout-grid-mode:line'>Nervous system disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Common</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Dizziness</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
  layout-grid-mode:line'>Vascular disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Common</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Hypotension</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><b><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>General
  disorders and administration site conditions</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Common</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Peripheral
  oedema</span></p>
  </td>
 </tr>
</table>

<p class=CharCharCharCharChar align=left style='margin-bottom:0in;text-align:
left;line-height:normal'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'>Peripheral oedema is
a known, dose-dependent adverse reaction of amlodipine and has also been
reported with aliskiren therapy in post-marketing experience. The incidence of
peripheral oedema for Rasitrio in a short-term double active-controlled study
was 7.1% compared to 8.0% for aliskiren/amlodipine, 4.1% for
amlodipine/hydrochlorothiazide and 2.0% for aliskiren/hydrochlorothiazide dual
combinations.</p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>The
incidence of any adverse reactions potentially related to hypotension in a
short-term active controlled study was 4.9% with Rasitrio versus up to 3.7%
with dual combinations. In patients &#8805;65&nbsp;years the incidence was
10.2% with Rasitrio versus up to 5.4% with dual combinations.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'>&nbsp;</p>

<p style='margin:0in;page-break-after:avoid'><i><u><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Additional
information on individual components</span></u></i></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Other
adverse reactions previously reported with one of the individual components may
occur with Rasitrio even if not observed in clinical trials.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p style='margin:0in;page-break-after:avoid'><i><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Aliskiren</span></i></p>

<p style='margin:0in;page-break-after:avoid'><span lang=EN-GB style='font-size:
11.0pt;font-family:"Times New Roman",serif'>Serious adverse reactions include
anaphylactic reaction and angioedema which have been reported in post-marketing
experience and may occur rarely (less than 1&nbsp;case per
1,000&nbsp;patients). The most common adverse reaction is diarrhoea.</span></p>

<p style='margin:0in'><u><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoDate style='page-break-after:avoid'><span lang=EN-GB>Tabulated list
of adverse reactions:</span></p>

<p class=MsoNormal><span lang=EN-GB>The known aliskiren adverse reactions are
presented in the table below using the same convention as described previously
for the fixed combination.</span></p>

<p style='margin:0in;page-break-after:avoid'><u><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='margin-left:5.4pt;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-bottom:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
  layout-grid-mode:line'>Immune system disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Anaphylactic
  reactions, h</span><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
  layout-grid-mode:line'>ypersensitivity reactions</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><b><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Cardiac
  </span></b><b><span lang=DE-CH style='font-size:11.0pt;font-family:"Times New Roman",serif'>d</span></b><b><span
  lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>isorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Common</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Dizziness</span></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Uncommon</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Palpitations</span><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>, oedema
  peripheral</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><b><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Vascular
  disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Uncommon</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Hypotension</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
  layout-grid-mode:line'>Respiratory, thoracic and mediastinal disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
  layout-grid-mode:line'>Uncommon</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
  layout-grid-mode:line'>Cough</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
  layout-grid-mode:line'>Gastrointestinal disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Common</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Diarrhoea</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><b><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Hepatobiliary
  disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Not
  known</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Liver
  disorder*</span><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>,
  j</span><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>aundice</span><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>,</span><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'> </span><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>h</span><span
  lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>epatitis</span><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>, l</span><span
  lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>iver
  failure</span><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>**</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
  layout-grid-mode:line'>Skin and subcutaneous tissue disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Uncommon</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Severe
  cutaneous adverse reactions (SCARs) including Stevens Johnson syndrome, toxic
  epidermal necrolysis (TEN), oral mucosal reactions, rash, pruritus, urticaria</span></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Angioedema,
  erythema</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
  layout-grid-mode:line'>Musculoskeletal and connective tissue disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Common</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Arthralgia</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
  layout-grid-mode:line'>Renal and urinary disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Uncommon</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=FR style='font-size:11.0pt;font-family:"Times New Roman",serif'>Acute
  renal failure, renal impairment</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
  layout-grid-mode:line'>Investigations</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Common</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Hyperkalaemia</span></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Uncommon</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Liver
  enzyme increased</span></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Haemoglobin
  decreased, haematocrit decreased, blood creatinine increased</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>*Isolated cases
of liver disorder with clinical symptoms and laboratory evidence of more marked
hepatic dysfunction.</span></p>

<p style='margin:0in'><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>**Including one case of &#8216;liver failure fulminant&#8217;
reported in the post-marketing experience, for which a causal relationship with
aliskiren cannot be excluded.</span></p>

<p style='margin:0in'><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Description of
selected adverse events:</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Hypersensitivity
reactions including anaphylactic reactions and angioedema have occurred during
treatment with aliskiren.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>In controlled
clinical trials, angioedema and hypersensitivity reactions occurred rarely
during treatment with aliskiren with rates comparable to treatment with placebo
or comparators.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Cases of
angioedema or symptoms suggestive of angioedema (swelling of the face, lips,
throat and/or tongue) have also been reported in post-marketing experience. A
number of these patients had a history of angioedema or symptoms suggestive of
angioedema which in some cases was associated with the administration of other
medicinal products known to cause angioedema, including RAAS blockers (ACEIs or
ARBs).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'>In post-marketing experience,
cases of angioedema or angioedema-like reactions have been reported when
aliskiren was co-administered with ACEIs and/or ARBs.</p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Hypersensitivity
reactions including anaphylactic reactions have also been reported in
post-marketing experience (see section&nbsp;4.4).</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>In the event
of any signs suggesting a hypersensitivity reaction/angioedema (in particular
difficulties in breathing, or swallowing, rash, itching, hives or swelling of
the face, extremities, eyes, lips and/or tongue, dizziness) patients should
discontinue treatment and contact the physician (see section&nbsp;4.4).</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Arthralgia has
been reported in post-marketing experience. In some cases this occurred as part
of a hypersensitivity reaction.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In
post-marketing experience, renal dysfunction and cases of acute renal failure
have been reported in patients at risk (see section&nbsp;4.4).</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><i><span style='font-size:11.0pt;color:windowtext'>Investigations:
</span></i><span style='font-size:11.0pt;color:windowtext'>In controlled
clinical trials, clinically relevant changes in standard laboratory parameters
were uncommonly associated with the administration of aliskiren. In clinical
studies in hypertensive patients, aliskiren had no clinically important effects
on total cholesterol, high density lipoprotein cholesterol (HDL-C),
fasting triglycerides, fasting glucose or uric acid.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><i><span style='font-size:11.0pt;color:windowtext'>Haemoglobin
and haematocrit</span></i><span style='font-size:11.0pt;color:windowtext'>:
Small decreases in haemoglobin and haematocrit (mean decreases of approximately
0.05&nbsp;mmol/l and 0.16&nbsp;volume percent, respectively) were observed. No
patients discontinued therapy due to anaemia. This effect is also seen with
other medicinal products acting on the RAAS, such as ACEIs and ARBs.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><i><span style='font-size:11.0pt;color:windowtext'>Serum
potassium</span></i><span style='font-size:11.0pt;color:windowtext'>: Increases
in serum potassium have been observed with aliskiren and these may be
exacerbated by concomitant use of other agents acting on the RAAS or by NSAIDs.
Consistent with standard medical practice, periodic determination of renal
function including serum electrolytes is advised if co-administration is
considered necessary. The combination of aliskiren with ARBs or ACEIs is
contraindicated in patients with diabetes mellitus or renal impairment (GFR
&lt;60&nbsp;ml/min/</span><span style='font-size:11.0pt;color:windowtext'>1.73&nbsp;m<sup>2</sup></span><span
style='font-size:11.0pt;color:windowtext'>) and is not recommended in other
patients (see sections&nbsp;4.3, 4.4 and 5.1).</span></p>

<p style='margin:0in'><u><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><i><span lang=EN-GB>Paediatric population: </span></i><span
lang=EN-GB>Based on the limited amount of safety data available from a
pharmacokinetic study of aliskiren treatment in 39 hypertensive children 6&#8209;17&nbsp;years
of age, the frequency, type and severity of adverse reactions in children are
expected to be similar to that seen in hypertensive adults. As for other RAAS
blockers, headache is a common adverse event in children treated with
aliskiren.</span></p>

<p style='margin:0in'><u><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Amlodipine</span></i></p>

<p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
color:windowtext'>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><b><span style='font-size:
  11.0pt;color:windowtext'>Blood and lymphatic system disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Very
  rare</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Leukopenia,
  thrombocytopenia</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><b><span style='font-size:
  11.0pt;color:windowtext'>Immune system disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Very rare</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Allergic
  reactions</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><b><span style='font-size:
  11.0pt;color:windowtext'>Metabolism and nutrition disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Very rare</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Hyperglycaemia</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><b><span style='font-size:
  11.0pt;color:windowtext'>Psychiatric disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Uncommon</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Insomnia, mood changes (including anxiety), depression</span></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Rare</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Confusion</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><b><span style='font-size:
  11.0pt;color:windowtext'>Nervous system disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Common</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Somnolence, headache (especially at the beginning of treatment)</span></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Uncommon</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Tremor, dysgeusia, syncope, hypoesthesia, paraesthesia</span></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Very rare</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Hypertonia,
  peripheral neuropathy</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><b><span style='font-size:
  11.0pt;color:windowtext'>Eye disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Uncommon</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Visual
  disturbance (including diplopia)</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><b><span style='font-size:
  11.0pt;color:windowtext'>Ear and labyrinth disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Uncommon</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Tinnitus</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><b><span style='font-size:
  11.0pt;color:windowtext'>Cardiac disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Common</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Palpitations</span></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Very rare</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Myocardial
  infarction, arrhythmia (including bradycardia, ventricular tachycardia and
  atrial fibrillation)</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><b><span style='font-size:
  11.0pt;color:windowtext'>Vascular disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Common</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Flushing</span></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Very rare</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Vasculitis</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><b><span style='font-size:
  11.0pt;color:windowtext'>Respiratory, thoracic and mediastinal disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Uncommon</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Dyspnoea, rhinitis</span></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Very rare</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Cough</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><b><span style='font-size:
  11.0pt;color:windowtext'>Gastrointestinal disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Common</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Abdominal pain, nausea</span></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Uncommon</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Vomiting, dyspepsia, altered bowel habits (including
  diarrhoea and constipation), dry mouth</span></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Very rare</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Pancreatitis,
  gastritis, gingival hyperplasia</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><b><span style='font-size:
  11.0pt;color:windowtext'>Hepatobiliary disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Very rare</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Hepatitis,
  jaundice, hepatic enzymes increased (mostly consistent with cholestasis)</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><b><span style='font-size:
  11.0pt;color:windowtext'>Skin and subcutaneous tissue disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Uncommon</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Alopecia, purpura, skin decolouration, hyperhidrosis,
  pruritus, rash, exanthema</span></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Very rare</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Angioedema,
  erythema multiforme, urticaria, exfoliative dermatitis, Stevens-Johnson
  syndrome, Quincke oedema, photosensitivity</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><b><span style='font-size:
  11.0pt;color:windowtext'>Musculoskeletal and connective tissue disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;color:windowtext'>Common</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Ankle swelling</span></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Uncommon</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Arthralgia,
  myalgia, muscle cramps, back pain</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><b><span style='font-size:
  11.0pt;color:windowtext'>Renal and urinary disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Uncommon</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Micturition
  disorder, nocturia, increased urinary frequency</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><b><span style='font-size:
  11.0pt;color:windowtext'>Reproductive system and breast disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Uncommon</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Impotence,
  gynaecomastia</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><b><span style='font-size:
  11.0pt;color:windowtext'>General disorders and administration site conditions</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Common</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Oedema, fatigue</span></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Uncommon</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span lang=FR style='font-size:11.0pt;color:windowtext'>Chest
  pain, asthenia, pain, malaise</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><b><span style='font-size:
  11.0pt;color:windowtext'>Investigations</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Uncommon</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Weight
  increase, weight decrease</span></p>
  </td>
 </tr>
</table>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Exceptional
cases of extrapyramidal syndrome have been reported.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Hydrochlorothiazide</span></i></p>

<p style='margin:0in;page-break-after:avoid'><span lang=EN-GB style='font-size:
11.0pt;font-family:"Times New Roman",serif'>Hydrochlorothiazide has been
extensively prescribed for many years, frequently in higher doses than those
contained in </span><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Rasitrio</span><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>. </span><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>The
following adverse reactions have been reported in patients treated with
thiazide diuretics alone, including hydrochlorothiazide:</span></p>

<p style='margin:0in;page-break-after:avoid'><i><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></i></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='margin-left:5.4pt;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-bottom:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:
  line'>Blood and lymphatic system disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Thrombocytopenia</span><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'> sometimes
  with purpura</span></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Very rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Agranulocytosis,
  bone marrow depression, haemolytic anaemia, leucopenia</span></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Not known</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Aplastic
  anaemia</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:
  line'>Immune system disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=X-NONE style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Very rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Hypersensitivity</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:
  line'>Metabolism and nutrition disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Very common</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Hypokalaemia</span></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Common</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Hyperuricaemia,
  hypomagnesaemia, hyponatraemia</span></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Hypercalcaemia,
  hyperglycaemia, worsening of diabetic metabolic state</span></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=X-NONE style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Very rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Hypochloraemic
  alkalosis</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:
  line'>Psychiatric disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=X-NONE style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Depression,
  sleep disturbances</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:
  line'>Nervous system disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=X-NONE style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Dizziness,
  headache, paraesthesia</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:
  line'>Eye disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Visual
  impairment</span></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=X-NONE style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Not known</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Acute
  angle-closure glaucoma</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:
  line'>Cardiac disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=X-NONE style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Cardiac
  arrhythmias</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:
  line'>Vascular disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=X-NONE style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Common</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Orthostatic
  hypotension</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:
  line'>Respiratory, thoracic and mediastinal disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=X-NONE style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Very rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Respiratory
  distress (including pneumonitis and pulmonary oedema)</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:
  line'>Gastrointestinal disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Common</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Decreased
  appetite, mild nausea and vomiting</span></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Abdominal
  discomfort, constipation, diarrhoea</span></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=X-NONE style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Very rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Pancreatitis</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:
  line'>Hepatobiliary disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Intrahepatic
  cholestasis, jaundice</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:
  line'>Skin and subcutaneous tissue disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Common</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Urticaria
  and other forms of rash</span></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Photosensitivity
  reactions</span></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Very rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Cutaneous
  lupus erythematosus-like reactions, reactivation of cutaneous lupus
  erythematosus, vasculitis necrotising and toxic epidermal necrolysis</span></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Not known</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Erythema
  multiforme</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:
  line'>Musculoskeletal and connective tissue disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=X-NONE style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Not known</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Muscle
  spasm</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:
  line'>Renal and urinary disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=X-NONE style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Not known</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=FR style='font-size:11.0pt;font-family:"Times New Roman",serif'>Renal
  dysfunction, acute renal failure</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:
  line'>Reproductive system and breast disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=X-NONE style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Common</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Impotence</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:
  line'>General disorders and administration site conditions</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=X-NONE style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Not known</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Asthenia,
  pyrexia</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:
  line'>Investigations</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Very common</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Increases
  in cholesterol and triglycerides</span></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Glycosuria</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.9&nbsp;&nbsp;&nbsp;&nbsp; Overdose</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Symptoms</span></u></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>The most
likely manifestation of overdose for Rasitrio would be hypotension, related to
the antihypertensive effect of the combination of aliskiren, amlodipine and
hydrochlorothiazide.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>With
aliskiren, the most likely manifestation of overdose would be hypotension,
related to the antihypertensive effect of aliskiren.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>With
amlodipine, available data suggest that gross overdose could result in
excessive peripheral vasodilatation and possibly reflex tachycardia. </span><span
style='font-size:11.0pt;color:windowtext'>Marked and </span><span lang=EN-GB
style='font-size:11.0pt;color:windowtext'>probably </span><span
style='font-size:11.0pt;color:windowtext'>prolonged systemic hypotension</span><span
lang=EN-GB style='font-size:11.0pt;color:windowtext'> up to and</span><span
style='font-size:11.0pt;color:windowtext'> including shock with fatal outcome,
have been reported with amlodipine.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Overdose with
hydrochlorothiazide is associated with electrolyte depletion (hypokalaemia,
hypochloraemia, hyponatraemia) and dehydration resulting from excessive
diuresis. The most common signs and symptoms of overdose are nausea and
somnolence. Hypokalaemia may result in muscle spasms and/or accentuate cardiac
arrhythmias associated with the concomitant use of digitalis glycosides or
certain antiarrhythmic medicinal products.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Treatment</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If symptomatic
hypotension should occur with Rasitrio, supportive treatment should be
initiated.</span></p>

<p class=MsoNormal style='line-height:normal'><i>&nbsp;</i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Clinically
significant hypotension due to amlodipine overdose calls for active
cardiovascular support including frequent monitoring of cardiac and respiratory
function, elevation of extremities and attention to circulating fluid volume
and urine output.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>A
vasoconstrictor may be helpful in restoring vascular tone and blood pressure,
provided that there is no contraindication to its use. Intravenous calcium
gluconate may be beneficial in reversing the effects of calcium channel
blockade.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Gastric lavage
may be worthwhile in some cases. In healthy volunteers the use of charcoal up
to 2&nbsp;hours after administration of amlodipine 10&nbsp;mg has been shown to
reduce the absorption rate of amlodipine.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Since amlodipine
is highly protein-bound, dialysis is not likely to be of benefit.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In a study
conducted in patients with end stage renal disease (ESRD) receiving
haemodialysis, dialysis clearance of aliskiren was low (&lt;2% of oral
clearance). Therefore dialysis is not adequate to treat aliskiren
over-exposure.</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACOLOGICAL
PROPERTIES</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5.1&nbsp;&nbsp;&nbsp;&nbsp; Pharmacodynamic
properties</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>Pharmacotherapeutic group</span><span lang=EN-GB>:
Agents acting on the renin-angiotensin system, renin-inhibitors; ATC code
C09XA54</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Rasitrio
combines three antihypertensive active substances with complementary mechanisms
to control blood pressure in patients with essential hypertension: aliskiren
belongs to the direct renin inhibitor class, amlodipine to the calcium channel
blocker class and hydrochlorothiazide to the thiazide diuretics class. When
combined, the consolidated effects of inhibition of the renin-angiotensin-aldosterone
system, calcium channel-mediated vasodilatation and sodium chloride excretion
result in a reduction of blood pressure to a greater degree than the
corresponding dual combinations.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Aliskiren/amlodipine/hydrochlorothiazide combination</span></u></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>In
hypertensive patients, once-daily administration of Rasitrio provided
clinically meaningful reductions in both systolic and diastolic blood pressure
that were maintained over the entire 24-hour dose interval. The greater blood
pressure reduction for Rasitrio over each dual combination was seen at every
hour including the early morning hours with the 24-hour ambulatory blood
pressure monitoring.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Rasitrio
was studied in a double-blind, randomised, active-controlled study in
1,181&nbsp;patients of which 773 were classified as moderately hypertensive
(msSBP 160&#8209;180&nbsp;mmHg) and 408 as severely hypertensive (msSBP
&gt;180&nbsp;mmHg) at baseline. A large number of patients were obese (49%) and
over 14% of the total population had diabetes. During the first 4&nbsp;weeks of
double-blind treatment, patients received triple combination
aliskiren/amlodipine/hydrochlorothiazide (HCTZ) 150/5/12.5&nbsp;mg (N=308), or
dual combinations of aliskiren/HCTZ 150/12.5&nbsp;mg (N=295),
aliskiren/amlodipine 150/5&nbsp;mg (N=282) and amlodipine/HCTZ 5/12.5&nbsp;mg
(N=295). Patients were force-titrated to higher doses after 4&nbsp;weeks for an
additional 4&nbsp;weeks of double-blind treatment to aliskiren/amlodipine/HCTZ
300/10/25&nbsp;mg, aliskiren/HCTZ 300/25&nbsp;mg, aliskiren/amlodipine
300/10&nbsp;mg and amlodipine/HCTZ 10/25&nbsp;mg.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>In
this study, Rasitrio at a dose of 300/10/25&nbsp;mg produced statistically
significant mean blood pressure reductions (systolic/diastolic) from baseline
of 37.9/20.6&nbsp;mmHg compared to 31.4/18.0&nbsp;mmHg with
aliskiren/amlodipine combination (300/10&nbsp;mg), 28.0/14.3&nbsp;mmHg with
aliskiren/hydrochlorothiazide (300/25&nbsp;mg) and 30.8/17.0&nbsp;mmHg with
amlodipine/hydrochlorothiazide (10/25&nbsp;mg) in patients with moderate to
severe hypertension. In patients with severe hypertension (SBP &#8805;180&nbsp;mmHg), the reduction in blood pressure from baseline for Rasitrio and the
dual combinations respectively was 49.5/22.5&nbsp;mmHg compared to 38.1/17.6&nbsp;mmHg
with aliskiren/amlodipine combination (300/10&nbsp;mg), 33.2/14.3&nbsp;mmHg
with aliskiren/hydrochlorothiazide (300/25&nbsp;mg) and 39.9/17.8&nbsp;mmHg
with amlodipine/hydrochlorothiazide (10/25&nbsp;mg). In a subset of
588&nbsp;patients</span><span lang=EN-GB> in which patients &gt;65&nbsp;years
were scarcely represented and those aged &gt;75&nbsp;years were very scarcely
represented</span><span lang=EN-GB>, the combination of
aliskiren/amlodipine/hydrochlorothiazide (300/10/25&nbsp;mg) produced a
systolic/diastolic mean blood pressure reduction of 39.7/21.1&nbsp;mmHg from
baseline, compared to 31.3/18.74&nbsp;mmHg for aliskiren/amlodipine
(300/10&nbsp;mg), 25.5/12.5&nbsp;mmHg for aliskiren/hydrochlorothiazide
(300/25&nbsp;mg) and 29.2/16.4&nbsp;mmHg for amlodipine/hydrochlorothiazide
(10/25&nbsp;mg) (the subset constitutes patients without aberrant readings,
defined as a difference between systolic blood pressure (SBP) readings
&#8805;10&nbsp;mmHg at baseline or endpoint). The effect of Rasitrio was
observed as early as one week after initiation of therapy. The
blood-pressure-lowering effect in patients with moderate to severe hypertension
was independent of age, gender, race, body mass index and overweight-associated
disorders (metabolic syndrome and diabetes).</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Rasitrio
was associated with a significant reduction in plasma renin activity (PRA) (&#8209;34%)
from baseline while the dual combination of amlodipine with hydrochlorothiazide
increased PRA (+170%). The clinical implications of the differences in effect
on PRA are not known at the present time.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>In
a 28 to 54&nbsp;week open label safety study, efficacy was measured as
secondary endpoint and Rasitrio at a dose of 300/10/25&nbsp;mg produced mean
blood pressure reductions (systolic/diastolic) of 37.3/21.8&nbsp;mmHg over 28
to 54&nbsp;weeks of treatment. Efficacy of Rasitrio was maintained over one
year of treatment, with no evidence of loss of effect.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>In
a randomised, double blind, active controlled, 36-week study in elderly
patients whose blood pressure was not controlled with aliskiren/HCTZ
300/25&nbsp;mg (SBP &#8805;140&nbsp;mmHg), clinically meaningful further BP
reduction was seen at week&nbsp;36 endpoint for patients who received Rasitrio
at a dose of 300/10/25&nbsp;mg (from reductions in msSBP/msDBP of
15.0/8.6&nbsp;mmHg at week&nbsp;22 to reductions of 30.8/14.1&nbsp;mmHg at
week&nbsp;36 endpoint).</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Rasitrio
has been administered to more than 1,155&nbsp;patients in completed clinical
trials, including 182&nbsp;patients for one year or more. Treatment with
Rasitrio was well tolerated at doses up to 300&nbsp;mg/10&nbsp;mg/25&nbsp;mg
with an overall incidence of adverse events similar to the corresponding dual
combinations, except for symptomatic hypotension. </span><span lang=EN-GB>The
incidence of any adverse reactions potentially related to hypotension in a
short-term controlled study was 4.9% with Rasitrio versus up to 3.7% with dual
combinations. In patients &#8805;65&nbsp;years the incidence was 10.2% with
Rasitrio versus up to 5.4% with dual combinations.</span></p>

<p class=CharCharCharCharChar align=left style='margin-bottom:0in;text-align:
left;line-height:normal'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=CharCharCharCharChar align=left style='margin-bottom:0in;text-align:
left;line-height:normal'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>The
incidence of adverse events did not show any association with gender, age (with
the exception of symptomatic hypotension), body mass index, race or ethnicity.
Adverse events have generally been mild and transient in nature. Very limited
safety data are available for patients aged &gt;75&nbsp;years or patients with
major cardiovascular co-morbidities. Discontinuation of therapy due to a
clinical adverse event occurred in 3.6% of patients treated with Rasitrio
versus 2.4% in aliskiren/amlodipine, 0.7% in aliskiren/hydrochlorothiazide and
2.7% in amlodipine/hydrochlorothiazide.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Aliskiren</span></u></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Aliskiren is
an orally active, non-peptide, potent and selective direct inhibitor of human
renin.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>By inhibiting
the enzyme renin, aliskiren inhibits the RAAS at the point of activation,
blocking the conversion of angiotensinogen to angiotensin&nbsp;I and decreasing
levels of angiotensin&nbsp;I and angiotensin&nbsp;II. Whereas other medicinal
products that inhibit the RAAS (ACEI and angiotensin&nbsp;II receptor blockers
(ARB)) cause a compensatory rise in plasma renin activity (PRA), treatment with
aliskiren decreases PRA in hypertensive patients by approximately 50 to 80%.
Similar reductions were found when aliskiren was combined with other
antihypertensive medicinal products. The clinical implications of the
differences in effect on PRA are not known at the present time.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Hypertension</span></i></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>In
hypertensive patients, once-daily administration of aliskiren at doses of
150&nbsp;mg and 300&nbsp;mg provided dose-dependent reductions in both systolic
and diastolic blood pressure that were maintained over the entire 24-hour dose
interval (maintaining benefit in the early morning) with a mean peak to trough
ratio for diastolic response of up to 98% for the 300&nbsp;mg dose. 85 to 90%
of the maximal blood-pressure-lowering effect was observed after 2&nbsp;weeks.
The blood-pressure-lowering effect was sustained during long-term treatment,
and was independent of age, gender, body mass index and ethnicity. Aliskiren
has been studied in 1,864&nbsp;patients aged 65&nbsp;years or older, and in
426&nbsp;patients aged 75&nbsp;years or older.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Aliskiren
monotherapy studies have shown blood-pressure-lowering effects comparable to
other classes of antihypertensive medicinal products including selected ACEI
and ARB. Compared to a diuretic (hydrochlorothiazide, HCTZ), aliskiren
300&nbsp;mg lowered systolic/diastolic blood pressure by 17.0/12.3&nbsp;mmHg,
compared to 14.4/10.5&nbsp;mmHg for HCTZ 25&nbsp;mg after 12&nbsp;weeks of
treatment.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Combination
therapy studies are available for aliskiren added to the diuretic
hydrochlorothiazide, the calcium channel blocker amlodipine and the beta
blocker atenolol. These combinations were well tolerated. Aliskiren induced an
additive blood-pressure-lowering effect when added to hydrochlorothiazide.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>&nbsp;</p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>The
efficacy and safety of aliskiren-based therapy were compared to ramipril-based
therapy in a 9-month non-inferiority study in 901&nbsp;elderly patients
(&#8805;65&nbsp;years) with essential systolic hypertension. Aliskiren
150&nbsp;mg or 300&nbsp;mg per day or ramipril 5&nbsp;mg or 10&nbsp;mg per day
were administered for 36&nbsp;weeks with optional add-on therapy of
hydrochlorothiazide (12.5&nbsp;mg or 25&nbsp;mg) at week&nbsp;12, and
amlodipine (5&nbsp;mg or 10&nbsp;mg) at week&nbsp;22. Over the 12-week period,
aliskiren monotherapy lowered systolic/diastolic blood pressure by
14.0/5.1&nbsp;mmHg, compared to 11.6/3.6&nbsp;mmHg for ramipril, consistent
with aliskiren being non-inferior to ramipril at the dosages chosen and the
differences in systolic and diastolic blood pressure were statistically
significant. Tolerability was comparable in both treatment arms, however cough
was more often reported with the ramipril regimen than the aliskiren regimen
(14.2% vs. 4.4%), whilst diarrhoea was more common with the aliskiren regimen
than for the ramipril regimen (6.6% vs. 5.0%).</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>In an 8-week study in 754&nbsp;hypertensive geriatric patients aged
65&nbsp;years or older and geriatric patients aged 75&nbsp;years or older (30%)
aliskiren at doses of 75&nbsp;mg, 150&nbsp;mg and 300&nbsp;mg provided
statistically significant superior reduction in blood pressure (both systolic
and diastolic) when compared to placebo. No additional blood pressure lowering
effect was detected with 300&nbsp;mg aliskiren compared to 150&nbsp;mg
aliskiren. All three doses were well tolerated in both elderly and very elderly
patients.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>There has been
no evidence of first-dose hypotension and no effect on pulse rate in patients
treated in controlled clinical studies. Excessive hypotension was uncommonly
(0.1%) seen in patients with uncomplicated hypertension treated with aliskiren
alone. Hypotension was also uncommon (&lt;1%) during combination therapy with
other antihypertensive medicinal products. With cessation of treatment, blood
pressure gradually returned towards baseline levels over a period of several
weeks, with no evidence of a rebound effect for blood pressure or PRA.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>I</span>n a 36-week study involving 820&nbsp;patients with ischaemic
left ventricular dysfunction, no changes in ventricular remodelling as assessed
by left ventricular end systolic volume were detected with aliskiren compared
to placebo on top of background therapy.</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>&nbsp;</p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>The combined
rates of cardiovascular death, hospitalisation for heart failure, recurrent
heart attack, stroke and resuscitated sudden death were similar in the
aliskiren group and the placebo group. However, in patients receiving aliskiren
there was a significantly higher rate of hyperkalaemia, hypotension and kidney
dysfunction when compared to the placebo group.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Aliskiren was evaluated for cardiovascular
and/or renal benefit in a double blind placebo controlled randomised trial in
8,606&nbsp;patients with type 2 diabetes and chronic kidney disease (evidenced
by proteinuria and/or GFR &lt;60&nbsp;ml/min/</span><span lang=EN-GB>1.73&nbsp;m<sup>2</sup></span><span
lang=EN-GB>) with or without cardiovascular disease. In most patients arterial
blood pressure was well controlled at baseline. The primary endpoint was a
composite of cardiovascular and renal complications.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>In this study,
aliskiren 300&nbsp;mg was compared to placebo when added to standard of care
which included either an angiotensin converting enzyme inhibitor or an
angiotensin receptor blocker. The study was discontinued prematurely because
the participants were unlikely to benefit from aliskiren. Study results
indicated a hazard ratio for the primary endpoint of 1.11 in favour of placebo
(95% Confidence Interval: 1.00, 1.23, 2-sided p=0.05). In addition, an
increased incidence of </span><span lang=EN-GB>adverse events</span><span
lang=EN-GB> was observed with aliskiren compared to placebo </span><span
lang=EN-GB>(37.9% versus 30.2%). In particular there was an increased incidence
of</span><span lang=EN-GB> renal </span><span lang=EN-GB>dysfunction</span><span
lang=EN-GB> (14.0% versus 12.1%), hyperkalaemia (38.9% versus 28.8%),
hypotension</span><span lang=EN-GB>-related events</span><span lang=EN-GB>
(19.7% versus 16.2%) </span><span lang=EN-GB>and adjudicated stroke endpoints (3.4%
versus 2.6%). The increased incidence of stroke was greater in patients with
renal insufficiency.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Effects of
aliskiren on mortality and cardiovascular morbidity are currently unknown.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>No long-term
efficacy data for aliskiren in patients with heart failure are currently
available (see section&nbsp;4.4).</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Cardiac electrophysiology</span></i></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>No effect on
QT interval was reported in a randomised, double-blind, placebo, and
active-controlled study using standard and Holter electrocardiography.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Amlodipine</span></u></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>The
amlodipine component of Rasitrio inhibits the transmembrane entry of calcium
ions </span><span lang=EN-GB>into cardiac and vascular smooth muscle. The
mechanism of the antihypertensive action of amlodipine is due to a direct
relaxant effect on vascular smooth muscle, causing reductions in peripheral
vascular resistance and in blood pressure. Experimental data suggest that
amlodipine binds to both dihydropyridine and non-dihydropyridine binding sites.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>The
contractile processes of cardiac muscle and vascular smooth muscle are
dependent upon the movement of extracellular calcium ions into these cells
through specific ion channels.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Following
administration of therapeutic doses to patients with hypertension, amlodipine
produces vasodilatation resulting in a reduction of supine and standing blood
pressures. These decreases in blood pressure are not accompanied by a
significant change in heart rate or plasma catecholamine levels with chronic
dosing.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Plasma
concentrations correlate with effect in both young and elderly patients.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>In
hypertensive patients with normal renal function, therapeutic doses of
amlodipine resulted in a decrease in renal vascular resistance and an increase
in glomerular filtration rate and effective renal plasma flow without change in
filtration fraction or proteinuria.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>As
with other calcium channel blockers, haemodynamic measurements of cardiac
function at rest and during exercise (or pacing) in patients with normal
ventricular function treated with amlodipine have generally demonstrated a
small increase in cardiac index without significant influence on dP/dt or on
left ventricular end diastolic pressure or volume. In haemodynamic studies,
amlodipine has not been associated with a negative inotropic effect when
administered in the therapeutic dose range to intact animals and humans, even
when co-administered with beta blockers to humans.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Amlodipine does
not change sinoatrial nodal function or atrioventricular conduction in intact
animals or humans. In clinical studies in which amlodipine was administered in
combination with beta blockers to patients with either hypertension or angina,
no adverse effects on electrocardiographic parameters were observed.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoDate><span lang=EN-GB>Amlodipine has demonstrated beneficial
clinical effects in patients with chronic stable angina, vasospastic angina and
angiographically documented coronary artery disease.</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><i><span lang=EN-GB>Use in patients with heart failure</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Calcium channel blockers, including amlodipine, should be used with
caution in patients with congestive heart failure, as they may increase the
risk of future cardiovascular events and mortality.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><i><span lang=EN-GB>Use in patients with hypertension</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>A randomised
double-blind morbidity-mortality study called the Antihypertensive and
Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT) was performed
to compare newer therapies: amlodipine 2.5&#8209;10&nbsp;mg/day (calcium
channel blocker) or lisinopril 10&#8209;40&nbsp;mg/day (ACE-inhibitor) as
first-line therapies to that of the thiazide-diuretic, chlorthalidone 12.5&#8209;25&nbsp;mg/day
in mild to moderate hypertension.</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>A total of
33,357&nbsp;hypertensive patients aged 55 or older were randomised and followed
for a mean of 4.9&nbsp;years. The patients had at least one additional coronary
heart disease risk factor, including: previous myocardial infarction or stroke
(&gt;6&nbsp;months prior to enrollment) or documentation of other atherosclerotic
cardiovascular disease (overall 51.5%), type 2 diabetes (36.1%), high density
lipoprotein - cholesterol &lt;35&nbsp;mg/dl or &lt;0.906&nbsp;mmol/l (11.6%),
left ventricular hypertrophy diagnosed by electrocardiogram or echocardiography
(20.9%), current cigarette smoking (21.9%).</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>The primary
endpoint was a composite of fatal coronary heart disease or non-fatal
myocardial infarction. There was no significant difference in the primary
endpoint between amlodipine-based therapy and chlorthalidone-based therapy: risk
ratio (RR) 0.98 95% CI (0.90&#8209;1.07) p=0.65. Among secondary endpoints, the
incidence of heart failure (component of a composite combined cardiovascular
endpoint) was significantly higher in the amlodipine group as compared to the
chlorthalidone group (10.2% vs. 7.7%, RR 1.38, 95% CI [1.25&#8209;1.52]
p&lt;0.001). However, there was no significant difference in all-cause
mortality between amlodipine-based therapy and chlorthalidone-based therapy RR
0.96 95% CI [0.89&#8209;1.02] p=0.20.</p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Hydrochlorothiazide</span></u></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>The
site of action of thiazide diuretics is primarily in the renal distal
convoluted tubule. It has been shown that there is a high-affinity receptor in
the renal cortex as the primary binding site for the thiazide diuretic action
and inhibition of NaCl transport in the distal convoluted tubule. The mode of
action of thiazides is through inhibition of the Na+Cl- symporter by competing
for the Cl- site, thereby affecting electrolyte reabsorption mechanisms:
directly increasing sodium and chloride excretion to an approximately equal
extent, and indirectly by this diuretic action reducing plasma volume, with
consequent increases in plasma renin activity, aldosterone secretion and
urinary potassium loss, and a decrease in serum potassium.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Paediatric population</span></u></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>The
European Medicines Agency has waived the obligation to submit the results of
studies with Rasitrio in all subsets of the paediatric population in essential
hypertension (see section&nbsp;4.2 for information on paediatric use).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5.2&nbsp;&nbsp;&nbsp;&nbsp; Pharmacokinetic
properties</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Aliskiren/amlodipine/hydrochlorothiazide combination</span></u></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Following
oral administration of a fixed combination tablet of aliskiren, amlodipine and
hydrochlorothiazide, peak concentrations were achieved for aliskiren within 1&#8209;2&nbsp;hours,
for amlodipine within 8&nbsp;hours and for hydrochlorothiazide within 2&#8209;3&nbsp;hours.
The rate and extent of absorption of aliskiren, amlodipine and
hydrochlorothiazide following administration of a fixed combination tablet are
similar to when administered as individual dosage forms.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>The
results from a food effect study using a </span><span lang=EN-GB>standard </span><span
lang=EN-GB>high-fat meal</span><span lang=EN-GB> with the 300/10/25&nbsp;mg
fixed combination tablet showed that food </span><span lang=EN-GB>reduced the
rate and extent of absorption of aliskiren in the fixed combination tablet with
a similar magnitude of effect as for aliskiren monotherapy. Food had no effect </span><span
lang=EN-GB>on the pharmacokinetics of amlodipine or hydrochlorothiazide in the
fixed combination tablet.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Aliskiren</span></u></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Absorption</span></i></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Following oral
absorption, peak plasma concentrations of aliskiren are reached after 1&#8209;3&nbsp;hours.
The absolute bioavailability of aliskiren is approximately 2&#8209;3%. Meals
with a high fat content reduce C<sub>max</sub> by 85% and AUC by 70%. At steady
state meals with low fat content reduce C<sub>max</sub> by 76% and AUC <sub>0-tau</sub>
by 67% in hypertensive patients. Steady-state plasma concentrations are reached
within 5&#8209;7&nbsp;days following once-daily administration and steady-state
levels are approximately 2-fold greater than with the initial dose.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Distribution</span></i></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Following
intravenous administration, the mean volume of distribution at steady state is
approximately 135&nbsp;litres, indicating that aliskiren distributes
extensively into the extravascular space. Aliskiren plasma protein binding is
moderate (47&#8209;51%) and independent of the concentration.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Biotransformation and elimination</span></i></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>The mean
half-life is about 40&nbsp;hours (range 34&#8209;41&nbsp;hours). Aliskiren is
mainly eliminated as unchanged compound in the faeces (78%). Approximately 1.4%
of the total oral dose is metabolised. The enzyme responsible for this
metabolism is CYP3A4. Approximately 0.6% of the dose is recovered in urine
following oral administration. Following intravenous administration, mean
plasma clearance is approximately 9&nbsp;l/h.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Linearity</span></i></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Exposure to
aliskiren increased more than in proportion to the increase in dose. After
single dose administration in the dose range of 75 to 600&nbsp;mg, a 2-fold
increase in dose results in a ~2.3 and 2.6-fold increase in AUC and C<sub>max</sub>,
respectively. At steady state the non-linearity may be more pronounced.
Mechanisms responsible for deviation from linearity have not been identified. A
possible mechanism is saturation of transporters at the absorption site or at
the hepatobiliary clearance route.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><i><span lang=EN-GB>Paediatric
population</span></i></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>In
a pharmacokinetic study of aliskiren treatment in 39 paediatric hypertensive
patients (aged 6&#8209;17&nbsp;years) given daily doses of 2&nbsp;mg/kg or
6&nbsp;mg/kg aliskiren administered as granules (3.125&nbsp;mg/tablet),
pharmacokinetic parameters were similar to those in adults. The available data
did not suggest that age, body weight or gender have any significant effect on
aliskiren systemic exposure (see section 4.2).</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Amlodipine</span></u></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Absorption</span></i></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>After oral
administration of therapeutic doses of amlodipine alone, peak plasma
concentrations of amlodipine are reached in 6&#8209;12&nbsp;hours. Absolute
bioavailability has been </span><span style='font-size:11.0pt;color:windowtext'>estima</span><span
style='font-size:11.0pt;color:windowtext'>ted as between 64% and 80%.
Amlodipine bioavailability is unaffected by food ingestion.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Distribution</span></i></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>The volume of
distribution is approximately 21&nbsp;l/kg. <i>In vitro </i>studies with
amlodipine have shown that approximately 97.5% of circulating amlodipine is
bound to plasma proteins.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Biotransformation and elimination</span></i></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Amlodipine
is extensively (approximately 90%) metabolised in the liver to inactive
metabolites, with 10% of the parent compound and 60% of the metabolites
excreted in the urine.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Amlodipine
elimination from plasma is biphasic with a terminal elimination half-life of
approximately 30 to 50&nbsp;hours. Steady-state plasma levels are reached after
continuous administration for 7&#8209;8&nbsp;days.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Linearity</span></i></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Amlodipine
exhibits linear pharmacokinetics between </span><span lang=EN-GB>the
therapeutic dose range of </span><span lang=EN-GB>5&nbsp;mg and 10&nbsp;mg</span><span
lang=EN-GB>.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Hydrochlorothiazide</span></u></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Absorption</span></i></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>The absorption of hydrochlorothiazide, after an oral dose, is rapid
(T<sub>max</sub> about 2&nbsp;h.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>The effect of food on hydrochlorothiazide absorption, if any, has
little clinical significance. Absolute bioavailability of hydrochlorothiazide
is 70% after oral administration.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Distribution</span></i></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>The apparent volume of distribution is 4&#8209;8&nbsp;l/kg.
Circulating hydrochlorothiazide is bound to serum proteins (40&#8209;70%),
mainly serum albumin. Hydrochlorothiazide also accumulates in erythrocytes at
approximately 3&nbsp;times the level in plasma.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Biotransformation and elimination</span></i></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Hydrochlorothiazide is eliminated predominantly as unchanged
compound. Hydrochlorothiazide is eliminated from plasma with a half-life
averaging 6 to 15&nbsp;hours in the terminal elimination phase. There is no
change in the kinetics of hydrochlorothiazide on repeated dosing, and
accumulation is minimal when dosed once daily. There is more than 95% of the
absorbed dose being excreted as unchanged compound in the urine. The renal
clearance is composed of passive filtration and active secretion into the renal
tubule.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Linearity</span></i></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>The increase in mean AUC is linear and dose proportional in the
therapeutic range.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Special populations</span></u></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Rasitrio is an
effective once-a-day antihypertensive treatment in adult patients, regardless
of gender, age, body mass index and ethnicity.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Renal impairment</span></i></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Due
to its hydrochlorothiazide component, Rasitrio is contraindicated in patients
with anuria or severe renal impairment (GFR &lt;30&nbsp;ml/min/1.73&nbsp;m<sup>2</sup>)
(see section&nbsp;4.3). No adjustment of the initial dose is required in
patients with mild to moderate renal impairment (see sections&nbsp;4.4 and
4.2).</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>The
pharmacokinetics of aliskiren were evaluated in patients with varying degrees
of renal insufficiency. Relative AUC and C<sub>max</sub> of aliskiren in
subjects with renal impairment ranged between 0.8 to 2&nbsp;times the levels in
healthy subjects following single dose administration and at steady state.
These observed changes, however, did not correlate with the severity of renal
impairment. No adjustment of the initial dose of aliskiren is required in
patients with mild to moderate renal impairment (see sections&nbsp;4.2 and
4.4). Aliskiren is not recommended in patients with severe renal impairment
(glomerular filtration rate (GFR) &lt;30&nbsp;ml/min/</span><span
style='font-size:11.0pt;color:windowtext'>1.73&nbsp;m<sup>2</sup></span><span
style='font-size:11.0pt;color:windowtext'>). Concomitant use of aliskiren with
ARBs or ACEIs is contraindicated in patients with renal impairment (GFR
&lt;60&nbsp;ml/min/</span><span style='font-size:11.0pt;color:windowtext'>1.73&nbsp;m<sup>2</sup></span><span
style='font-size:11.0pt;color:windowtext'>) (see section&nbsp;4.3).</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>The
pharmacokinetics of aliskiren were evaluated</span><span lang=EN-GB> in
patients with end stage renal disease receiving haemodialysis. Administration
of a single oral dose of 300&nbsp;mg aliskiren was associated with very minor
changes in the pharmacokinetics of aliskiren (change in C<sub>max</sub> of less
than 1.2&nbsp;fold; increase in AUC of up to 1.6&nbsp;fold) compared to matched
healthy subjects. Timing of haemodialysis did not significantly alter the
pharmacokinetics of aliskiren in ESRD patients. Therefore,<b><i> </i></b>if
administration of aliskiren in ESRD patients receiving haemodialysis is
considered necessary, no dose adjustment is warranted in these patients.
However, the use of aliskiren is not recommended in patients with severe renal
impairment (see section&nbsp;4.4).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The pharmacokinetics of amlodipine are not significantly influenced
by renal impairment.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>As
expected for a compound which is cleared almost exclusively via the kidneys,
renal function has a marked effect on the kinetics of hydrochlorothiazide. In
the presence of renal impairment, mean peak plasma levels and AUC values of
hydrochlorothiazide are increased and the urinary excretion rate is reduced. In
patients with mild to moderate renal impairment, a 3-fold increase in
hydrochlorothiazide AUC has been observed. In patients with severe renal
impairment an 8-fold increase in AUC has been observed.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Hepatic impairment</span></i></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Rasitrio is
contraindicated in patients with severe hepatic impairment (see
section&nbsp;4.3).</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>The
pharmacokinetics of aliskiren were not significantly affected in patients with
mild to severe liver disease. Consequently, no adjustment of the initial dose
of aliskiren is required in patients with mild to moderate hepatic impairment.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Very limited clinical data are available regarding amlodipine
administration in patients with hepatic impairment. Patients with hepatic
insufficiency have decreased clearance of amlodipine with resulting increase in
AUC of approximately 40&#8209;60%. Therefore caution should be exercised</span><span
lang=EN-GB> in patients with hepatic impairment.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Geriatric patients</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No data are
available on systemic exposure after administration of Rasitrio in geriatric
patients. When administered alone, the AUC of aliskiren in geriatric subjects
(&gt;65&nbsp;years) is 50% higher than in young subjects. The time to reach
peak plasma concentrations of amlodipine is similar in elderly and younger
subjects. Amlodipine clearance tends to be decreased with resulting increases
in AUC and elimination half-life in geriatric patients. </span><span
lang=EN-GB>Therefore particular caution is recommended when administering
Rasitrio to patients aged 65&nbsp;years and over, and extreme caution in
patients aged 75&nbsp;years or older (see sections&nbsp;4.2, 4.4, 4.8 and 5.1).</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Limited
data suggest that the systemic clearance of hydrochlorothiazide is reduced in
both healthy and hypertensive elderly subjects compared to young healthy
volunteers. There are no specific data regarding the effect of
hydrochlorothiazide in elderly patients.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Paediatric </span></i><i><span style='font-size:11.0pt;
color:windowtext'>population (age below 18&nbsp;years)</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The pharmacokinetics of Rasitrio have not been investigated. A
population pharmacokinetic study has been conducted in 74 hypertensive children
aged from 1 to 17&nbsp;years (with 34&nbsp;patients aged 6 to 12&nbsp;years and
28&nbsp;patients aged 13 to 17&nbsp;years) receiving amlodipine between 1.25
and 20&nbsp;mg given either once or twice daily. In children 6 to 12&nbsp;years
and in adolescents 13&#8209;17&nbsp;years of age the typical oral clearance
(CL/F) was 22.5 and 27.4&nbsp;l/hr respectively in males and 16.4 and
21.3&nbsp;l/hr respectively in females. Large variability in exposure between
individuals was observed. Data reported in children below 6&nbsp;years are
limited.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5.3&nbsp;&nbsp;&nbsp;&nbsp; Preclinical
safety data</span></b></p>

<p class=Text style='margin-bottom:0in;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Aliskiren/hydrochlorothiazide and aliskiren/amlodipine</span></u></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Non-clinical
studies of the toxicology of Rasitrio alone have not been conducted as these
studies have been conducted for the individual components.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>The
toxicity profiles of the combination of aliskiren/hydrochlorothiazide and
aliskiren/amlodipine have been well characterised in preclinical studies. Both
combinations were generally well tolerated by rats. The findings from 2- and
13-week oral toxicity studies were consistent with those for the individual
components.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Aliskiren</span></u></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Carcinogenic
potential was assessed in a 2-year rat study and a 6-month transgenic mouse
study. No carcinogenic potential was detected. One colonic adenoma and one
caecal adenocarcinoma recorded in rats at the dose of 1,500&nbsp;mg/kg/day were
not statistically significant. Although aliskiren has known irritation
potential, safety margins obtained in humans at the dose of 300&nbsp;mg during
a study in healthy volunteers were considered to be appropriate at 9&#8209;11-fold
based on faecal concentrations or 6-fold based on mucosa concentrations in
comparison with 250&nbsp;mg/kg/day in the rat carcinogenicity study.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Aliskiren was
devoid of any mutagenic potential in the <i>in vitro </i>and <i>in vivo </i>mutagenicity
studies. The assays included <i>in vitro </i>assays in bacterial and mammalian
cells and <i>in vivo </i>assessments in rats.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Reproductive
toxicity studies with aliskiren did not reveal any evidence of embryofoetal
toxicity or teratogenicity at doses up to 600&nbsp;mg/kg/day in rats or
100&nbsp;mg/kg/day in rabbits. Fertility, pre-natal development and post-natal
development were unaffected in rats at doses up to 250&nbsp;mg/kg/day. The
doses in rats and rabbits provided systemic exposures of 1 to 4 and
5&nbsp;times higher, respectively, than the maximum recommended human dose
(300&nbsp;mg).</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Safety
pharmacology studies did not reveal any adverse effects on central nervous,
respiratory or cardiovascular function. Findings during repeat-dose toxicity
studies in animals were consistent with the known local irritation potential or
the expected pharmacological effects of aliskiren.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Amlodipine</span></u></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Safety
data for amlodipine are well established both clinically and non-clinically.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Reproductive
toxicology</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Reproductive
studies in rats and mice have shown delayed date of delivery, prolonged
duration of labour and decreased pup survival at dosages approximately
50&nbsp;times greater than the maximum recommended dosage for humans based on
mg/kg.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Impairment of
fertility</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>There was no
effect on the fertility of rats treated with amlodipine (males for 64&nbsp;days
and females 14&nbsp;days prior to mating) at doses up to 10&nbsp;mg/kg/day
(8&nbsp;times* the maximum recommended human dose of 10&nbsp;mg on a mg/m<sup>2</sup>
basis). In another rat study in which male rats were treated with amlodipine
besilate for 30&nbsp;days at a dose comparable with the human dose based on
mg/kg, decreased plasma follicle-stimulating hormone and testosterone were
found as well as decreases in sperm density and in the number of mature
spermatids and Sertoli cells.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Carcinogenesis,
mutagenesis</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Rats and mice
treated with amlodipine in the diet for two years, at concentrations calculated
to provide daily dosage levels of 0.5, 1.25 and 2.5&nbsp;mg/kg/day showed no
evidence of carcinogenicity. The highest dose (for mice, similar to, and for
rats twice* the maximum recommended clinical dose of 10&nbsp;mg on a mg/m<sup>2</sup>
basis) was close to the maximum tolerated dose for mice but not for rats.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Mutagenicity
studies revealed no effects related to the medicinal product at either the gene
or chromosome levels.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>*Based on
patient weight of 50&nbsp;kg</span></p>

<p class=Default><u><span lang=EN-GB style='font-size:11.0pt;color:windowtext'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Hydrochlorothiazide</span></u></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Preclinical
evaluations to support the administration of hydrochlorothiazide in humans
included <i>in vitro</i> genotoxicity assays and reproductive toxicity and
carcinogenicity studies in rodents. Extensive clinical data are available for
hydrochlorothiazide and these are reflected in the relevant sections.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Hydrochlorothiazide
had no adverse effects on the fertility of mice and rats of either sex in
studies wherein these species were exposed, via their diet, to doses of up to
100 and 4&nbsp;mg/kg,/day respectively, prior to mating and throughout
gestation. These doses of hydrochlorothiazide in mice and rats represent 19 and
1.5&nbsp;times, respectively, the maximum recommended human dose on a mg/m<sup>2</sup>
basis. (Calculations assume an oral dose of 25&nbsp;mg/day and a 60-kg
patient.)</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
PARTICULARS</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.1&nbsp;&nbsp;&nbsp;&nbsp; List
of excipients</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><u>Tablet core</u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=IT>Cellulose microcrystalline</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=IT>Crospovidone</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=IT>Povidone</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=IT>Magnesium stearate</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=IT>Silica colloidal anhydrous</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=IT>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><u><span lang=IT>Coating</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=IT>Hypromellose</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=IT>Titanium dioxide (E171)</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=ES>Macrogol</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=ES>Talc</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=ES>Iron oxide red (E172)</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Iron oxide black (E172)</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b>6.2&nbsp;&nbsp;&nbsp;&nbsp; Incompatibilities</b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Not applicable.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.3&nbsp;&nbsp;&nbsp;&nbsp; Shelf
life</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>PVC/polychlorotrifluoroethylene (PCTFE) </span>&#8211;<span
lang=EN-GB> Alu calendar blisters:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>2&nbsp;years</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>PVC/polychlorotrifluoroethylene (PCTFE) </span>&#8211; <span
lang=EN-GB>Alu blisters:</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>2&nbsp;years</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'>PA/Alu/PVC
&#8211; Alu calendar blisters:</p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>18&nbsp;months</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.4&nbsp;&nbsp;&nbsp;&nbsp; Special
precautions for storage</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'>Do not store above 30&deg;C.</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>Store in the
original package in order to protect from moisture.</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.5&nbsp;&nbsp;&nbsp;&nbsp; Nature
and contents of container</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>PVC/polychlorotrifluoroethylene (PCTFE) - Alu calendar blisters:</span></p>

<p class=MsoDate>Single pack containing 14, 28, 56, 98&nbsp;tablets</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>PVC/polychlorotrifluoroethylene (PCTFE) - Alu blisters:</span></p>

<p class=MsoDate style='page-break-after:avoid'>Single pack containing 30,
90&nbsp;tablets</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'>Unit dose
pack (perforated unit dose blister) containing 56x1&nbsp;tablet</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>Multipacks of
unit dose (perforated unit dose blister) containing 98x1&nbsp;tablet
(2&nbsp;packs of 49x1)</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=ES>PA/Alu/PVC &#8211; Alu calendar blisters:</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'>Single pack containing 14, 28, 56&nbsp;tablets</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>Multipacks
containing 98&nbsp;tablets (2&nbsp;packs of 49)</p>

<p class=MsoDate>&nbsp;</p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Not
all pack sizes may be marketed.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.6&nbsp;&nbsp;&nbsp;&nbsp; Special
precautions for disposal</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Any unused medicinal product or waste material should be disposed of
in accordance with local requirements.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION HOLDER</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'>Novartis Europharm Limited</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'>Wimblehurst Road</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'>Horsham</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'>West Sussex, RH12 5AB</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>United
Kingdom</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'>EU/1/11/730/037&#8209;048</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; DATE
OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Date of first
authorisation: </span><span lang=EN-GB>22 November 2011</span></p>

<p class=MsoDate><span lang=EN-GB>Date of latest renewal:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>10.&nbsp;&nbsp;&nbsp;&nbsp; DATE
OF REVISION OF THE TEXT</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:28.3pt;line-height:normal'><span
lang=EN-GB>Detailed information on this medicinal product is available on the
website of the European Medicines Agency http://www.ema.europa.eu</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Rasitrio 300&nbsp;mg/10&nbsp;mg/25&nbsp;mg film-coated tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; QUALITATIVE
 AND QUANTITATIVE COMPOSITION</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Each film-coated tablet contains 300&nbsp;mg aliskiren (as
hemifumarate), 10&nbsp;mg amlodipine (as besylate) and 25&nbsp;mg
hydrochlorothiazide.</span></p>

<p class=MsoDate><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For the full
list of excipients, see section&nbsp;6.1.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
<span style='text-transform:uppercase'>form</span></span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Film-coated tablet.</span></p>

<p class=MsoDate style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Brown, ovaloid convex film-coated tablet with bevelled edges, with
&#8220;VIV&#8221; debossed on one side and &#8220;NVR&#8221; on the other.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB style='text-transform:uppercase'>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Clinical
particulars</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.1&nbsp;&nbsp;&nbsp;&nbsp; Therapeutic
indications</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Rasitrio is
indicated for the treatment of essential hypertension as substitution therapy
in adult patients whose blood pressure is adequately controlled on the
combination of aliskiren, amlodipine and hydrochlorothiazide given concurrently
at the same dose level as in the combination.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.2&nbsp;&nbsp;&nbsp;&nbsp; Posology
and method of administration</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><u><span lang=EN-GB>Posology</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The recommended dose of Rasitrio is one tablet per day.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Patients
receiving aliskiren, amlodipine and hydrochlorothiazide from separate tablets
given concurrently at the same time of the day may be switched to a fixed
combination tablet of Rasitrio containing the same component doses.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The fixed dose
combination should only be used after a stable effect on the monocomponents, </span><span
lang=HU>given concurrently,<b> </b></span><span lang=EN-GB>has been established
after dose titration. Dose should be individualised and adjusted according to
the patient&#8217;s clinical response.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><u><span lang=EN-GB>Special populations</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Elderly patients aged 65&nbsp;years and over</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>There is
evidence of an increased risk of adverse events related to hypotension in
patients aged 65&nbsp;years or older treated with Rasitrio. Therefore,
particular caution should be exercised when administering Rasitrio in patients
aged 65&nbsp;years or over.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The recommended
starting dose of aliskiren in this group of patients is 150&nbsp;mg. No
clinically meaningful additional blood pressure reduction is observed by
increasing the dose to 300&nbsp;mg in the majority of elderly patients.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Elderly patients aged 75&nbsp;years and over</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Very limited data are available on the use of Rasitrio in patients
aged 75&nbsp;years or older (see section&nbsp;5.2). The use of Rasitrio in
patients aged 75&nbsp;years or older should be restricted to patients for whom
blood pressure control has been established for the free combination of aliskiren,
amlodipine and hydrochlorothiazide </span><span lang=EN-GB>given concurrently</span><span
lang=EN-GB> without accompanying safety concerns, in particular hypotension.
Extreme caution, including more frequent monitoring of blood pressure, is
recommended (see sections&nbsp;4.4, 4.8, 5.1 and 5.2)</span><span
style='font-family:"TimesNewRomanPSMT",serif'>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Renal impairment</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No adjustment of
the initial dose is required for patients with mild to moderate renal
impairment (</span><span lang=EN-GB>estimated </span><span lang=EN-GB>glomerular
filtration rate</span><span lang=EN-GB> (GFR) 89&#8209;60&nbsp;ml/min/1.73&nbsp;m<sup>2</sup>
and 59&#8209;30&nbsp;ml/min/1.73&nbsp;m<sup>2</sup>, respectively) (see
sections&nbsp;4.4 and 5.2). Due to the hydrochlorothiazide component, </span><span
lang=EN-GB>Rasitrio is contraindicated for use in patients with anuria and in
patients with severe renal impairment (GFR &lt;30&nbsp;ml/min/1.73&nbsp;m<sup>2</sup>).
The </span><span lang=EN-GB>c</span><span lang=EN-GB>oncomitant use of Rasitrio
with angiotensin II receptor blockers (ARB) or angiotensin converting enzyme
inhibitors (ACEI) is contraindicated in patients with renal impairment (GFR
&lt;60&nbsp;ml/min/</span><span lang=EN-GB>1.73&nbsp;m<sup>2</sup></span><span
lang=EN-GB>) (see sections&nbsp;4.3, 4.4 and 5.2).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Hepatic impairment</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Rasitrio is
contraindicated in patients with severe hepatic impairment. Caution</span>
should be exercised when administering Rasitrio i<span lang=EN-GB>n </span>patients
with mild to moderate hepatic impairment or patients with progressive liver
disease. No dosage recommendations have been established for amlodipine in
patients with mild to moderate hepatic impairment <span lang=EN-GB>(see sections&nbsp;4.3
and 4.4).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Paediatric population</span></i></p>

<p class=MsoNormal style='line-height:normal'>The safety and efficacy of
Rasitrio in children and adolescents below age&nbsp;18 have not been
established. No data are available.</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><u><span lang=EN-GB>Method of administration</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Oral use. The
tablets should be swallowed whole with some water. Rasitrio should be taken
with a light meal once a day, preferably at the same time each day. Grapefruit
juice should not be taken together with Rasitrio (see section&nbsp;4.5).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b>4.3&nbsp;&nbsp;&nbsp;&nbsp; Contraindications</b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Hypersensitivity to the active substances or to
any of the excipients listed in section&nbsp;6.1, to other dihydropyridine
derivatives, or to other sulphonamide-derived substances.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>History of angioedema with aliskiren.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Hereditary or idiopathic angioedema.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Second and third trimesters of pregnancy (see
section&nbsp;4.6).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Anuria.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Severe renal impairment (GFR
&lt;30&nbsp;ml/min/1.73&nbsp;m<sup>2</sup>).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Hyponatraemia, hypercalcaemia, symptomatic
hyperuricaemia and refractory hypokalaemia.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Severe hepatic impairment.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The concomitant use of aliskiren with
ciclosporin and itraconazole, two highly potent P-glycoprotein (P-gp)
inhibitors, and other potent P-gp inhibitors (e.g. quinidine), is
contraindicated (see section&nbsp;4.5).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The concomitant use of aliskiren with ARBs or
ACEIs is contraindicated in patients with diabetes mellitus or renal impairment
(GFR &lt;60&nbsp;ml/min/</span><span lang=EN-GB>1.73&nbsp;m<sup>2</sup></span><span
lang=EN-GB>) (see sections&nbsp;4.2, 4.4, 4.5 and 5.1).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Severe hypotension.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Shock (including cardiogenic shock).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Obstruction of the outflow tract of the left
ventricle (e.g. high grade aortic stenosis).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Haemodynamically unstable heart failure after
acute myocardial infarction.</span></p>

<p class=MsoNormal style='line-height:normal;vertical-align:baseline'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.4&nbsp;&nbsp;&nbsp;&nbsp; Special
warnings and precautions for use</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>General</span></u></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>In the event
of severe and persistent diarrhoea, Rasitrio therapy should be stopped (see
section&nbsp;4.8).</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>As with any
antihypertensive medicinal product, excessive reduction of blood pressure in
patients with ischaemic cardiopathy or ischaemic cardiovascular disease could
result in a myocardial infarction or stroke.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Symptomatic
hypotension occurred with higher frequency in patients with non-complicated
hypertension treated with Rasitrio than in patients treated with dual
combinations of aliskiren/amlodipine, aliskiren/hydrochlorothiazide or
amlodipine/hydrochlorothiazide.</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Hypersensitivity
reactions to hydrochlorothiazide may occur in patients, but are more likely in
patients with allergy and asthma.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Systemic
lupus erythematosus</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Thiazide
diuretics, including hydrochlorothiazide, have been reported to exacerbate or
activate systemic lupus erythematosus.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The safety and
efficacy of amlodipine in hypertensive crisis have not been established.</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Dual blockade
of the renin-angiotensin-aldosterone system (RAAS)</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Hypotension,
syncope, stroke, hyperkalaemia, and changes in renal function (including acute
renal failure) have been reported in susceptible individuals, especially if
combining medicinal products that affect this system (see section</span><span
lang=EN-GB>&nbsp;</span><span lang=EN-GB>5.1). Dual blockade of the
renin-angiotensin-aldosterone system by combining aliskiren with an angiotensin
converting enzyme inhibitor (ACEI) or an angiotensin II receptor blocker (ARB)
is therefore not recommended. Close monitoring of blood pressure, renal
function and electrolytes should be exercised if co-administration is
considered absolutely necessary.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>T</span><span
lang=EN-GB>he use of</span><span lang=EN-GB> aliskiren in combination with ARBs
or ACEIs is contraindicated in patients with diabetes mellitus or renal
impairment (GFR &lt;60&nbsp;ml/min</span><span lang=EN-GB>/1.73&nbsp;m<sup>2</sup></span><span
lang=EN-GB>) (see section&nbsp;4.3)</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Geriatric
patients aged 65&nbsp;years and over</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Particular caution should be exercised when administering Rasitrio
in patients aged 65&nbsp;years or older. Symptomatic hypotension occurred with
higher frequency in patients with non-complicated hypertension treated with
Rasitrio than in patients treated with dual combinations of
aliskiren/amlodipine, aliskiren/hydrochlorothiazide or
amlodipine/hydrochlorothiazide. Patients aged 65&nbsp;years old or over, are
more susceptible to hypotension-related adverse reactions following treatment
with Rasitrio (see sections&nbsp;4.2, 4.8, 5.1 and 5.2).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Geriatric patients aged 75&nbsp;years and over</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Very limited efficacy and safety data are available on the use of
Rasitrio in patients aged 75&nbsp;years or older. Extreme caution, </span>including
more frequent monitoring of blood pressure, is recommended<span lang=EN-GB>
(see sections&nbsp;4.2, 4.8, 5.1 and 5.2).</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Heart failure</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Calcium channel
blockers, including amlodipine, should be used with caution in patients with
congestive heart failure, as they may increase the risk of future
cardiovascular events and mortality.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>No data on
cardiovascular mortality and morbidity are available for Rasitrio in patients
with heart failure (see section&nbsp;5.1).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Aliskiren should
be used with caution in patients with heart failure treated with furosemide
(see section&nbsp;4.5).</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Risk of symptomatic hypotension</span></u></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Symptomatic
hypotension could occur after initiation of treatment with Rasitrio Rasitrio in
the following cases:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>Patients with marked volume depletion or patients with salt
depletion <span lang=EN-GB>(e.g. those receiving high doses of diuretics) </span>or</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>Combined use of aliskiren with other agents acting on the RAAS.</p>

<p class=Default><span style='font-size:11.0pt'>The volume or salt depletion
should be corrected prior to administration of Rasitrio, or the treatment
should start under close medical supervision.</span></p>

<p style='margin:0in'><u><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Electrolyte imbalance</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Treatment with
Rasitrio should only start after correction of hypokalaemia and any coexisting
hypomagnesaemia. Thiazide diuretics can precipitate new onset hypokalaemia or
exacerbate pre-existing hypokalaemia. Thiazide diuretics should be administered
with caution in patients with conditions involving enhanced potassium loss, for
example salt-losing nephropathies and prerenal (cardiogenic) impairment of
kidney function. </span><span lang=EN-GB>If hypokalaemia develops during
hydrochlorothiazide therapy Rasitrio should be discontinued until stable
correction of the potassium balance.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'>Hypokalaemia may develop with the
use of thiazide diuretics. The risk of hypokalaemia is greater in patients with
cirrhosis of the liver, patients experiencing brisk diuresis, patients with
inadequate oral electrolyte intake and patients receiving concomitant therapy
with corticosteroids or adrenocorticotropic hormone (ACTH) (see
sections&nbsp;4.5 and 4.8).</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal><span lang=EN-GB>Conversely, </span><span lang=EN-GB>increases
in serum potassium have been observed with aliskiren in post-marketing
experience and these may be exacerbated by concomitant use of other agents
acting on the RAAS or by non-steroidal anti-inflammatory drugs (NSAIDs).
Consistent with standard medical practice, periodic determination of renal
function including serum electrolytes is advised if co-administration is
considered necessary. The concomitant use of aliskiren and ACEIs or ARBs is
contraindicated in patients with diabetes mellitus or renal impairment (GFR
&lt;60&nbsp;ml/min</span><span lang=EN-GB>/1.73&nbsp;m<sup>2</sup></span><span
lang=EN-GB>) (see section</span><span lang=EN-GB>&nbsp;</span><span lang=EN-GB>4.3,
4.5 and 4.8).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoDate><span lang=EN-GB>Thiazide diuretics can precipitate new onset
hyponatraemia and hypochloroaemic alkalosis or exacerbate pre-existing
hyponatraemia. Hyponatraemia, accompanied by neurological symptoms (nausea,
progressive disorientation, apathy) has been observed. Treatment with
hydrochlorothiazide should only be started after correction of pre-existing
hyponatraemia. In case severe or rapid hyponatraemia develops during Rasitrio
therapy, the treatment should be discontinued until normalisation of natraemia.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>All patients receiving thiazide diuretics
should be periodically monitored for imbalances in electrolytes, particularly
potassium, sodium and magnesium.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Thiazides
reduce urinary calcium excretion and may cause an intermittent and slight
elevation of serum calcium in the absence of known disorders of calcium
metabolism. Rasitrio is contraindicated in patients with hypercalcaemia and
should only be used after correction of any pre-existing hypercalcaemia.
Rasitrio should be discontinued if hypercalcaemia develops during treatment.
Serum levels of calcium should be periodically monitored during treatment with
thiazides. Marked hypercalcaemia may be evidence of hidden hyperparathyroidism.
Thiazides should be discontinued before carrying out tests for parathyroid
function.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>There is no
evidence that Rasitrio would reduce or prevent diuretic-induced hyponatraemia.
Chloride deficit is generally mild and usually does not require treatment.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Renal impairment and kidney transplantation</span></u></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Thiazide
diuretics may precipitate azotaemia in patients with chronic kidney disease.
When Rasitrio is used in patients with renal impairment, periodic monitoring of
serum electrolytes including potassium, creatinine and uric acid serum levels
is recommended. No data is available in hypertensive patients with severe renal
impairment (serum creatinine &#8805;150&nbsp;&#956;mol/l or 1.70&nbsp;mg/dl in
women and &#8805;177&nbsp;&#956;mol/l or 2.00&nbsp;mg/dl in men and/or estimated
glomerular filtration rate (GFR) &lt;30&nbsp;ml/min/</span><span
style='font-size:11.0pt;color:windowtext'>1.73&nbsp;m<sup>2</sup></span><span
style='font-size:11.0pt;color:windowtext'>), history of dialysis, nephrotic
syndrome or renovascular hypertension. Rasitrio is contraindicated in
hypertensive patients with severe renal impairment (GFR &lt;30&nbsp;ml/min/</span><span
style='font-size:11.0pt;color:windowtext'>1.73&nbsp;m<sup>2</sup></span><span
style='font-size:11.0pt;color:windowtext'>) or anuria (see sections&nbsp;4.2.
and 4.3). No dose adjustment is necessary in patients with mild to moderate
renal impairment.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>As for other
medicinal products acting on the RAAS, caution should be exercised when
Rasitrio is given in the presence of conditions pre-disposing to kidney
dysfunction such as hypovolaemia (e.g. due to blood loss, severe or prolonged
diarrhoea, prolonged vomiting, etc.), heart disease, liver disease, diabetes
mellitus or kidney disease. The concomitant use of aliskiren and ACEIs or ARBs
is contraindicated in patients with renal impairment (GFR &lt;&nbsp;60&nbsp;ml/min/</span><span
style='font-size:11.0pt;color:windowtext'>1.73&nbsp;m<sup>2</sup></span><span
style='font-size:11.0pt;color:windowtext'>). Acute renal failure, reversible
upon discontinuation of treatment, has been reported in at-risk patients
receiving aliskiren in post-marketing experience. In the event that any signs
of renal failure occur, aliskiren should be promptly discontinued.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>There is no
experience regarding the administration of Rasitrio in patients who have
recently undergone kidney transplantation, therefore caution should be
exercised in these patients.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Hepatic impairment</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Rasitrio is
contraindicated in hypertensive patients with severe hepatic impairment (see
sections&nbsp;4.3 and 5.2). Caution should be exercised when administering
Rasitrio to patients with mild to moderate hepatic impairment or progressive
liver disease (see sections&nbsp;4.2 and 5.2).</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The half life of
amlodipine is prolonged and AUC values are higher in patients with impaired
liver function; dosage recommendations have not been established.</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Aortic and mitral valve stenosis, obstructive hypertrophic
cardiomyopathy</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>As with all
other vasodilators, special caution is indicated when using amlodipine in
patients suffering from aortic or mitral stenosis, or obstructive hypertrophic
cardiomyopathy.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Metabolic and endocrine effects</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Thiazide
diuretics, including hydrochlorothiazide, may alter glucose tolerance and raise
serum levels of cholesterol and triglycerides, and uric acid. In diabetic
patients dose adjustments of insulin or oral hypoglycaemic medicinal products
may be required during Rasitrio therapy. </span><span lang=EN-GB>C</span><span
lang=EN-GB>oncomitant use of Rasitrio with ARBs or ACEIs is contraindicated in
patients with diabetes mellitus (see section&nbsp;4.3).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Due to the hydrochlorothiazide component,
Rasitrio is contraindicated in symptomatic hyperuricaemia (see
section&nbsp;4.3). </span><span lang=EN-GB>Hydrochlorothiazide may raise the
serum uric acid level due to reduced clearance of uric acid and may cause or
exacerbate hyperuricaemia as well as precipitate gout in susceptible patients.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Thiazides reduce
urinary calcium excretion and may cause an intermittent and slight elevation of
serum calcium in the absence of known disorders of calcium metabolism. Rasitrio
is contraindicated in patients with hypercalcaemia and should only be used
after correction of any pre-existing hypercalcaemia. Rasitrio should be
discontinued if hypercalcaemia develops during treatment. Serum levels of
calcium should be periodically monitored during treatment with thiazides.
Marked hypercalcaemia may be evidence of hidden hyperparathyroidism. Thiazides
should be discontinued before carrying out tests for parathyroid function.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Renal artery stenosis</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No controlled
clinical data are available on the use of Rasitrio in patients with unilateral
or bilateral renal artery stenosis, or stenosis to a solitary kidney. However,
as with other medicinal products acting on the renin-angiotensin-aldosterone
system, there is an increased risk of renal insufficiency, including acute
renal failure, when patients with renal artery stenosis are treated with
aliskiren. Therefore caution should be exercised in these patients. If renal
failure occurs, treatment should be discontinued.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Anaphylactic reactions and angioedema</span></u></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Anaphylactic
reactions have been observed during treatment with aliskiren from
post-marketing experience (see section&nbsp;4.8). As with other medicinal
products acting on the renin-angiotensin-aldosterone system (RAAS), angioedema
or symptoms suggestive of angioedema (swelling of the face, lips, throat and/or
tongue) have been reported in patients treated with aliskiren.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>A number of
these patients had a history of angioedema or symptoms suggestive of angioedema,
which in some cases followed use of other medicinal products that can cause
angioedema, including RAAS blockers (angiotensin converting enzyme inhibitors
or angiotensin receptor blockers) (see section&nbsp;4.8).</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In
post-marketing experience, angioedema or angioedema-like reactions have been
reported when aliskiren was co-administered with ACEIs and/or ARBs (see
section&nbsp;4.8).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Special caution
is necessary in patients with a hypersensitivity predisposition.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Patients with
history of angioedema may be at increased risk of experiencing angioedema
during treatment with aliskiren (see sections&nbsp;4.3 and 4.8). Caution should
therefore be exercised when prescribing aliskiren to patients with a history of
angioedema, and such patients should be closely monitored during treatment (see
section&nbsp;4.8) especially at the beginning of the treatment.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>If anaphylactic reactions or</span><span
lang=EN-GB> </span><span lang=EN-GB>angioedema occur, Rasitrio should be
promptly discontinued and appropriate therapy and monitoring provided until
complete and sustained resolution of signs and symptoms has occurred. Patients
should be informed to report to the physician any signs suggestive of allergic
reactions, in particular difficulties in breathing or swallowing, swelling of
face, extremities, eyes, lips or tongue. Where there is involvement of the
tongue, glottis or larynx adrenaline should be administered. In addition,
measures necessary to maintain patent airways should be provided.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u>Photosensitivity</u></p>

<p class=MsoNormal>Cases of photosensitivity reactions have been reported with
thiazide diuretics (see section&nbsp;4.8). If photosensitivity reaction occurs
during treatment with <span lang=EN-GB>Rasitrio</span>, it is recommended to
stop the treatment. If a re-administration of the diuretic is deemed necessary,
it is recommended to protect exposed areas to the sun or to artificial UVA.</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Acute angle-closure glaucoma</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Hydrochlorothiazide, a sulphonamide, has
been associated with an idiosyncratic reaction resulting in acute transient
myopia and acute angle-closure glaucoma. Symptoms include acute onset of
decreased visual acuity or ocular pain and typically occur within hours to
weeks of treatment initiation. Untreated acute angle-closure glaucoma can lead
to permanent vision loss. The primary treatment is to discontinue
hydrochlorothiazide as rapidly as possible. Prompt medical or surgical
treatment may need to be considered if the intraocular pressure remains
uncontrolled. Risk factors for developing acute angle-closure glaucoma may
include a history of sulphonamide or penicillin allergy.</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.5&nbsp;&nbsp;&nbsp;&nbsp; Interaction
with other medicinal products and other forms of interaction</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Information on Rasitrio interactions</span></u></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>A
population pharmacokinetic analysis in patients with hypertension did not
indicate any clinically relevant changes in the </span><span lang=EN-GB>steady-state
exposure (AUC) and C<sub>max</sub> of aliskiren, amlodipine and
hydrochlorothiazide compared to the corresponding dual therapies.</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Medicinal
products affecting serum potassium levels</span></i><span lang=EN-GB>: </span><span
lang=EN-GB>The potassium-depleting effect of hydrochlorothiazide is attenuated
by the potassium-sparing effect of aliskiren. However, this effect of
hydrochlorothiazide on serum potassium would be expected to be potentiated by
other medicinal products associated with potassium loss and hypokalaemia (e.g.
other kaliuretic diuretics, corticosteroids, laxatives, adrenocoricotropic
hormone (ACTH), amphotericin, carbenoxolone, penicillin G, salicylic acid
derivatives). Conversely,</span><span lang=EN-GB> concomitant use of other
agents affecting the RAAS, of NSAIDs or of agents that increase serum potassium
levels (e.g. potassium-sparing diuretics, potassium supplements, salt
substitutes containing potassium, heparin) may lead to increases in serum
potassium. If co-medication with an agent affecting the level of serum
potassium is considered necessary, caution is advisable. The combination of
aliskiren with </span><span lang=EN-GB>ARBs or ACEIs </span><span lang=EN-GB>is
contraindicated in patients with diabetes mellitus or renal impairment (GFR
&lt;60&nbsp;ml/min/</span><span lang=EN-GB>1.73&nbsp;m<sup>2</sup></span><span
lang=EN-GB>) and is not recommended in other patients (see sections</span><span
lang=EN-GB>&nbsp;</span><span lang=EN-GB>4.3, 4.4 and 5.1)</span><span
lang=EN-GB>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Medicinal
products affected by serum potassium disturbances</span></i><span lang=EN-GB>: </span><span
lang=EN-GB>Periodic monitoring of serum potassium is recommended when Rasitrio
is administered with medicinal products affected by serum potassium
disturbances (e.g. digitalis glycosides, antiarrhythmics).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default><i><span style='font-size:11.0pt;color:windowtext'>Non-steroidal
anti-inflammatory drugs (NSAIDs), including selective cyclooxygenase-2 inhibitors
(COX-2 inhibitors)</span></i><span class=msoins0><i><span style='font-size:
11.0pt;color:windowtext'>, acetylsalicylic acid and non-selective NSAIDs</span></i></span><i><span
style='font-size:11.0pt;color:windowtext'>:</span></i><span style='font-size:
11.0pt;color:windowtext'> As with other agents acting on the renin-angiotensin
system, NSAIDs may reduce the anti-hypertensive effect of aliskiren. NSAIDs may
also weaken the diuretic and antihypertensive activity of hydrochlorothiazide.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In some patients
with compromised renal function (dehydrated patients or elderly patients)
aliskiren and hydrochlorothiazide given concomitantly with NSAIDs may result in
further deterioration of renal function, including possible acute renal
failure, which is usually reversible. Therefore the use of Rasitrio with an
NSAID requires caution, especially in elderly patients.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Information on aliskiren interactions</span></u></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Contraindicated (see section&nbsp;4.3)</span></i></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span style='font-size:11.0pt;color:windowtext'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span style='font-size:11.0pt;color:windowtext'>Dual RAAS
blockade</span></i></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>The combination
of aliskiren with ARBs or ACEIs is contraindicated in patients with diabetes
mellitus or renal impairment (GFR &lt;60&nbsp;ml/min/</span><span
style='font-size:11.0pt;color:windowtext'>1.73&nbsp;m<sup>2</sup></span><span
style='font-size:11.0pt;color:windowtext'>) and is not recommended in other
patients (see sections&nbsp;4.3, 4.4 and 5.1).</span></p>

<p class=Default><i><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></i></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span style='font-size:11.0pt;color:windowtext'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span style='font-size:11.0pt;color:windowtext'>P-glycoprotein
(P-gp) potent inhibitors</span></i></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>A single dose
drug interaction study in healthy subjects has shown that ciclosporin (200 and
600&nbsp;mg) increases C<sub>max</sub> of aliskiren 75&nbsp;mg approximately
2.5-fold and AUC approximately 5-fold. The increase may be higher with higher
aliskiren doses. </span><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>In
healthy subjects, itraconazole (100&nbsp;mg) increases AUC and C<sub>max</sub>
of aliskiren (150&nbsp;mg) by 6.5-fold and 5.8-fold, respectively. </span><span
style='font-size:11.0pt;color:windowtext'>Therefore, concomitant use of
aliskiren and P-gp potent inhibitors is contraindicated (see section&nbsp;4.3).</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i>Not
recommended (see section&nbsp;4.2)</i></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span style='font-size:11.0pt;color:windowtext'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span style='font-size:11.0pt;color:windowtext'>Grapefruit
juice</span></i></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Administration
of grapefruit juice with aliskiren resulted in a decrease in AUC and C<sub>max</sub>
of aliskiren. Co-administration with aliskiren 150&nbsp;mg resulted in a 61%
decrease in aliskiren AUC and co-administration with aliskiren 300&nbsp;mg
resulted in a 38% decrease in aliskiren AUC. This decrease is likely due to an
inhibition of </span><span style='font-size:11.0pt;color:windowtext'>organic
anion transporting polypeptide-mediated uptake of aliskiren by grapefruit juice
in the gastrointestinal tract. Therefore, because of the risk of therapeutic
failure, grapefruit juice should not be taken together with Rasitrio.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i>Caution
required with concomitant use</i></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span style='font-size:11.0pt;color:windowtext'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span style='font-size:11.0pt;color:windowtext'>P-gp
interactions</span></i></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>MDR</span><span
style='font-size:11.0pt;color:windowtext'>1/Mdr1a/1b (P-gp) was found to be the
major efflux system involved in intestinal absorption and biliary excretion of
aliskiren in preclinical studies. Rifampicin, which is an inducer of P-gp,
reduced aliskiren bioavailability by approximately 50% in a clinical study.
Other inducers of P-gp (St. John&#8217;s wort) might decrease the
bioavailability of aliskiren. Although this has not been investigated for
aliskiren, it is known that P-gp also controls tissue uptake of a variety of
substrates and P-gp inhibitors can increase the tissue-to-plasma concentration
ratios. Therefore, P-gp inhibitors may increase tissue levels more than plasma
levels. The potential for drug interactions at the P-gp site will likely depend
on the degree of inhibition of this transporter.</span></p>

<p class=Default><i><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></i></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span style='font-size:11.0pt;color:windowtext'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span style='font-size:11.0pt;color:windowtext'>Moderate P-gp
inhibitors</span></i></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Co-administration
of ketoconazole (200&nbsp;mg) or verapamil (240&nbsp;mg) with aliskiren
(300&nbsp;mg) resulted in a 76% or 97% increase in aliskiren AUC, respectively.
The change in plasma levels of aliskiren in the presence of ketoconazole or
verapamil is expected to be within the range that would be achieved if the dose
of aliskiren were doubled; aliskiren doses of up to 600&nbsp;mg, or twice the
highest recommended therapeutic dose, have been found to be well tolerated in
controlled clinical trials. Preclinical studies indicate that aliskiren and
ketoconazole co-administration enhances aliskiren gastrointestinal absorption
and decreases biliary excretion. Therefore, caution should be exercised when
aliskiren is administered with ketoconazole, verapamil or other moderate P-gp
inhibitors (clarithromycin, telithromycin, erythromycin, amiodarone).</span></p>

<p class=Default><i><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></i></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span style='font-size:11.0pt;color:windowtext'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span style='font-size:11.0pt;color:windowtext'>Medicinal
products affecting serum potassium levels</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Concomitant use
of other agents affecting the RAAS, of NSAIDs or of agents that increase serum
potassium levels (e.g. potassium-sparing diuretics, potassium supplements, salt
substitutes containing potassium, heparin) may lead to increases in serum
potassium. If co-administration with an agent affecting the level of serum
potassium is considered necessary, caution is advisable. The combination of
aliskiren with ARBs or ACEIs is contraindicated in patients with diabetes
mellitus or renal impairment (GFR &lt;60&nbsp;ml/min/</span><span lang=EN-GB>1.73&nbsp;m<sup>2</sup></span><span
lang=EN-GB>) and is not recommended in other patients (see sections&nbsp;4.3,
4.4 and 5.1).</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span style='font-size:11.0pt;color:windowtext'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span style='font-size:11.0pt;color:windowtext'>Furosemide</span></i></p>

<p class=Default><span lang=EN style='font-size:11.0pt;color:windowtext'>Oral
co-administration of aliskiren and furosemide had no effect on the
pharmacokinetics of aliskiren but reduced exposure to furosemide by 20&#8209;30%
(the </span><span style='font-size:11.0pt;color:windowtext'>effect of aliskiren
on furosemide administered intramuscularly or intravenously has not been
investigated)</span><span lang=EN style='font-size:11.0pt;color:windowtext'>.
After </span><span style='font-size:11.0pt;color:windowtext'>multiple doses of </span><span
lang=EN style='font-size:11.0pt;color:windowtext'>furosemide (60</span><span
style='font-size:11.0pt;color:windowtext'>&nbsp;</span><span lang=EN
style='font-size:11.0pt;color:windowtext'>mg/day) co-administered with
aliskiren (300&nbsp;mg/day) </span><span style='font-size:11.0pt;color:windowtext'>to
patients with heart failure</span><span lang=EN style='font-size:11.0pt;
color:windowtext'> the urinary sodium excretion and the urine volume were
reduced during the first 4&nbsp;hours by 31% and 24%, respectively, as compared
to furosemide alone. </span><span style='font-size:11.0pt;color:windowtext'>The
mean weight of patients concomitantly treated with furosemide and 300&nbsp;mg
aliskiren (84.6&nbsp;kg) was higher than the weight of patients treated with
furosemide alone (83.4&nbsp;kg)</span><span lang=EN style='font-size:11.0pt;
color:windowtext'>. Smaller changes in furosemide pharmacokinetics and efficacy
were observed with aliskiren 150</span><span style='font-size:11.0pt;
color:windowtext'>&nbsp;</span><span lang=EN style='font-size:11.0pt;
color:windowtext'>mg/day. In patients treated with both aliskiren and oral
furosemide,</span><span style='font-size:11.0pt;color:windowtext'> it is
therefore recommended that the effects of furosemide be monitored when
initiating and adjusting furosemide or aliskiren therapy to avoid changes in
extracellular fluid volume and possible situations of volume overload (see
section&nbsp;4.4).</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span style='font-size:11.0pt;color:windowtext'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span style='font-size:11.0pt;color:windowtext'>Warfarin</span></i></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>The effects of
aliskiren on warfarin pharmacokinetics have not been evaluated.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span style='font-size:11.0pt;color:windowtext'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span style='font-size:11.0pt;color:windowtext'>Food
interactions</span></i></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Meals (low or
high fat content) have been shown to reduce the absorption of aliskiren
substantially (see section&nbsp;4.2).</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i>No
interactions</i></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt'><span
style='font-size:11.0pt;color:windowtext'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt;color:windowtext'>Compounds that
have been investigated in aliskiren clinical pharmacokinetic studies include
acenocoumarol, atenolol, celecoxib, pioglitazone, allopurinol,
isosorbide-5-mononitrate and hydrochlorothiazide. No interactions have been
identified.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>Co-administration of aliskiren with either metformin
(&#8595;28%), amlodipine (&#8593;29%) or cimetidine (&#8593;19%) resulted in
between 20% and 30%<span lang=EN-GB> change in C</span><sub><span lang=EN-GB>max</span></sub><span
lang=EN-GB> or AUC of aliskiren. When administered with atorvastatin,
steady-state aliskiren AUC and C</span><sub><span lang=EN-GB>max</span></sub><span
lang=EN-GB> increased by 50%. Co-administration of aliskiren had no significant
impact on atorvastatin, metformin or amlodipine pharmacokinetics. As a result
no dose adjustment for aliskiren or these co-administered medicinal products is
necessary.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Digoxin
and verapamil bioavailability may be slightly decreased by aliskiren.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span style='font-size:11.0pt;color:windowtext'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span style='font-size:11.0pt;color:windowtext'>CYP450
interactions</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Aliskiren does
not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1 and 3A).
Aliskiren does not induce CYP3A4. Therefore aliskiren is not expected to affect
the systemic exposure of substances that inhibit, induce or are metabolised by
these enzymes. </span><span lang=EN-GB>Aliskiren is metabolised minimally by
the cytochrome P450 enzymes. Hence, interactions due to inhibition or induction
of CYP450 isoenzymes are not expected. However, CYP3A4 inhibitors often also
affect P-gp. Increased aliskiren exposure during co-administration of CYP3A4
inhibitors that also inhibit P-gp can therefore be expected (see other P-gp
references in section&nbsp;4.5).</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span style='font-size:11.0pt;color:windowtext'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span style='font-size:11.0pt;color:windowtext'>P-gp
substrates or weak inhibitors</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No relevant
interactions with atenolol, digoxin, amlodipine or cimetidine have been
observed. When administered with atorvastatin (80&nbsp;mg), steady-state
aliskiren (300&nbsp;mg) AUC and C<sub>max</sub> increased by 50%. </span><span
lang=EN-GB>In experimental animals, it has been shown that P-gp is a major
determinant of aliskiren bioavailability. Inducers of P-gp (St. John&#8217;s
wort, rifampicin) might therefore decrease the bioavailability of aliskiren.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span style='font-size:11.0pt;color:windowtext'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span style='font-size:11.0pt;color:windowtext'>Organic anion
transporting polypeptide (OATP) inhibitors</span></i></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Preclinical
studies indicate that aliskiren might be a substrate of organic anion
transporting polypeptides. Therefore, the potential exists for interactions
between OATP inhibitors and aliskiren when administered concomitantly (see
interaction with Grapefruit juice).</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Information on amlodipine interactions</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Effects of other medicinal products on amlodipine</span></u></i></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Caution required with concomitant use</span></i></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span style='font-size:11.0pt;color:windowtext'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span style='font-size:11.0pt;color:windowtext'>CYP3A4
inhibitors</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Concomitant use
of amlodipine with strong or moderate CYP3A4 inhibitors (protease inhibitors,
azole antifungals, macrolides like erythromycin or clarithromycin, verapamil or
diltiazem) may give rise to significant increase in amlodipine exposure. The
clinical translation of these pharmacokinetic variations may be more pronounced
in the elderly. Clinical monitoring and dose adjustment may thus be required.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span style='font-size:11.0pt;color:windowtext'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span style='font-size:11.0pt;color:windowtext'>CYP3A4
inducers</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>There is no data
available regarding the effect of CYP3A4 inducers on amlodipine. The
concomitant use of CYP3A4 inducers (e.g. rifampicin, <i>hypericum perforatum</i>)
may give a lower plasma concentration of amlodipine. Amlodipine should be used
with caution together with CYP3A4 inducers.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:1.5in;text-indent:-1.5in;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Grapefruit juice</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Administration
of amlodipine with grapefruit or grapefruit juice is not recommended as
bioavailability may be increased in some patients, resulting in increased blood
pressure lowering effects.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Dantrolene (infusion)</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In animals,
lethal ventricular fibrillation and cardiovascular collapse are observed in
association with hyperkalaemia after administration of verapamil and
intravenous dantrolene. Due to risk of hyperkalaemia, it is recommended that
the co-administration of calcium channel blockers such as amlodipine be avoided
in patients susceptible to malignant hyperthermia and in the management of
malignant hyperthermia.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Effects of amlodipine on other medicinal products</span></u></i></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The blood pressure lowering effects of
amlodipine add to the blood pressure lowering effects of other antihypertensive
medicinal products.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Co-administration of multiple doses of
10&nbsp;mg of amlodipine with 80&nbsp;mg simvastatin resulted in a 77% increase
in exposure to simvastatin compared to simvastatin alone. It is recommended to
limit the dose of simvastatin to 20&nbsp;mg daily in patients on amlodipine.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>No interactions</span></i></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>In clinical interaction studies, amlodipine did
not affect the pharmacokinetics of atorvastatin, digoxin, warfarin or
ciclosporin.</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Information on hydrochlorothiazide interactions</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>When
administered concurrently, the following medicinal products may interact with
thiazide diuretics:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i>Not recommended</i></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span style='font-size:11.0pt;color:windowtext'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span style='font-size:11.0pt;color:windowtext'>Lithium</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>R</span>enal
clearance of lithium is reduced by thiazides, therefore the risk of lithium
toxicity<span lang=EN-GB> may be increased with hydrochlorothiazide</span>.
Co-administration of lithium and <span lang=EN-GB>hydrochlorothiazide</span> is
not recommended. If this combination proves essential, careful monitoring of
serum lithium level is recommended during concomitant use.</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i>Caution
required with concomitant use</i></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span style='font-size:11.0pt;color:windowtext'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span style='font-size:11.0pt;color:windowtext'>Alcohol</span></i><i><span
style='color:windowtext'>, barbiturates or narcotics</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Concomitant
administration of thiazide diuretics with subtances that also have a blood
pressure lowering effect (e.g. by reducing sympathetic central nervous system
activity or direct vasodilatation) may potentiate orthostatic hypotension.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Amantadine</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Thiazides,
including hydrochlorothiazide, may increase the risk of adverse reactions
caused by amantadine.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Antidiabetic agents (e.g. insulin and oral
antidiabetic agents)</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Thiazides may
alter glucose tolerance. Dose adjustment of the antidiabetic medicinal product
may be necessary (see section&nbsp;4.4). Metformin should be used with caution
because of the risk of lactic acidosis induced by possible functional renal
failure linked to hydrochlorothiazide.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Anticholinergic agents and other medicinal
products affecting gastric motility</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The
bioavailability of thiazide-type diuretics may be increased by anticholinergic
agents (e.g. atropine, biperiden), apparently due to a decrease in
gastrointestinal motility and the stomach emptying rate. Conversely, it is
anticipated that prokinetic substances such as cisapride may decrease the
bioavailability of thiazide-type diuretics.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Medicinal products used in the treatment of
gout</span></i></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Dose
adjustment of uricosuric </span>medicinal products<i> </i><span lang=EN-GB>may
be necessary as hydrochlorothiazide may raise the level of serum uric acid.
Increase of dose of probenecid or sulfinpyrazone may be necessary. Co<b>-</b>administration
of thiazide diuretics, including hydrochlorothiazide, may increase the
incidence of hypersensitivity reactions to allopurinol.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicinal
products that could induce torsades de pointes</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Due to the risk of hypokalaemia,
hydrochlorothiazide should be administered with caution when associated with
medicinal products that could induce <i>torsades de pointes</i>, in particular
Class Ia and Class III </span><span lang=EN-GB>antiarrhythmics</span><span
lang=EN-GB> </span><span lang=EN-GB>and some </span><span lang=EN-GB>antipsychotics.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><i><span lang=EN-GB>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicinal
products affecting serum sodium level</span></i></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>The
hyponatraemic effect of diuretics may be intensified by concomitant
administration of medicinal products such as antidepressants, antipsychotics,
antiepileptics, etc. Caution is indicated in long-term administration of these
medicinal products.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Beta blockers and diazoxide</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Concomitant use
of thiazide diuretics, including hydrochlorothiazide, with beta blockers may
increase the risk of hyperglycaemia. Thiazide diuretics, including
hydrochlorothiazide, may enhance the hyperglycaemic effect of diazoxide.</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Ion exchange resins</span></i></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Absorption
of thiazide diuretics, including hydrochlorothiazide, is decreased by
cholestyramine or colestipol. This could result in sub-therapeutic effects of
thiazide diuretics. However, staggering the dosage of hydrochlorothiazide and
resin such that hydrochlorothiazide is administered at least 4&nbsp;hours
before or 4&#8209;6&nbsp;hours after the administration of resins would
potentially minimise the interaction.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Vitamin D and calcium salts</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Administration
of thiazide diuretics, including hydrochlorothiazide, with vitamin D or with
calcium salts may potentiate the rise in serum calcium. Concomitant use of
thiazide type diuretics may lead to hypercalcaemia in patients pre-disposed for
hypercalcaemia (e.g. hyperparathyroidism, malignancy, or vitamin-D-mediated
conditions) by increasing tubular calcium reabsorption.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Non-depolarising skeletal muscle relaxants</span></i></p>

<p class=MsoNormal style='line-height:normal'>Thiazides, including
hydrochlorothiazide, potentiate the action of skeletal muscle relaxants such as
curare derivatives.</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Cytotoxic agents</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Thiazides,
including hydrochlorothiazide, may reduce the renal excretion of cytotoxic
agents (e.g. cyclophosphamide, methotrexate) and potentiate their
myelosuppressive effects.</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Digoxine or digitalis glycosides</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Thiazide-induced
hypokalaemia or hypomagnesaemia favour the onset of digitalis-induced cardiac
arrhythmias (see section&nbsp;4.4).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoDate style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Methyldopa</span></i></p>

<p class=MsoDate><span lang=EN-GB>There have been isolated reports of
haemolytic anaemia occurring with concomitant use of hydrochlorothiazide and
methyldopa.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Iodine
contrasting agents</span></i></p>

<p class=MsoNormal><span lang=EN-GB>In case of diuretic-induced dehydration,
there is an increased risk of acute renal failure, especially with high doses
of iodine products. Patients should be rehydrated before administration.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><i><span lang=EN-GB>Pressor amines (e.g. noradrenaline,
adrenaline)</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Hydrochlorothiazide
may reduce the response to pressor amines such as noradrenaline. The clinical
significance of this effect is uncertain and not sufficient to preclude their
use.</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.6&nbsp;&nbsp;&nbsp;&nbsp; Fertility,
pregnancy and lactation</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Women of childbearing potential/contraception in males and
females</span></u></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Healthcare
professionals prescribing Rasitrio should counsel women of childbearing
potential about the potential risk during pregnancy. A switch to a suitable
alternative antihypertensive treatment should be carried out in advance of a
planned pregnancy since Rasitrio should not be used in women planning to become
pregnant.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Pregnancy</span></u></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>There are no
data on the use of aliskiren in pregnant women. Aliskiren was not teratogenic in
rats or rabbits (see section&nbsp;5.3). Other substances that act directly on
the renin-angiotensin-aldosterone system have been associated with serious
foetal malformations and neonatal death. As for any medicinal product that acts
directly on the renin-angiotensin-aldosterone system, aliskiren should not be
used during the first trimester of pregnancy and is contraindicated during the
second and third trimesters (see section&nbsp;4.3).</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The safety of
amlodipine in human pregnancy has not been established. Reproductive studies in
rats have shown no toxicity except for delayed date of delivery and prolonged
duration of labour at dosages 50&nbsp;times greater than the maximum
recommended dosage for humans (see section&nbsp;5.3). Use in pregnancy is only
recommended when there is no safer alternative and when the disease itself
carries greater risk for the mother and foetus.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>There is limited experience with
hydrochlorothiazide during pregnancy, especially during the first trimester.
Animal studies are insufficient.</span></p>

<p class=MsoDate><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoDate><span lang=EN-GB>Hydrochlorothiazide crosses the placenta.
Based on the pharmacological mechanism of action of hydrochlorothiazide, its
use during the second and third trimester may compromise foeto-placental
perfusion and may cause foetal and neonatal effects like icterus, disturbance
of electrolyte balance and thrombocytopenia.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Hydrochlorothiazide should not be used for
gestational oedema, gestational hypertension or pre&#8209;eclampsia due to the
risk of decreased plasma volume and placental hypoperfusion, without a
beneficial effect on the course of the disease.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Hydrochlorothiazide should not be used for
essential hypertension in pregnant women except in rare situations where no
other treatment could be used.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Rasitrio
should not be used during the first trimester of pregnancy. Rasitrio is
contraindicated during the second and third trimesters (see section&nbsp;4.3).</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>If pregnancy
is detected during therapy, Rasitrio should be discontinued accordingly as soon
as possible.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Breast-feeding</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>It is not known
whether aliskiren and/or amlodipine are excreted in human milk. Aliskiren was
secreted in the milk of lactating rats.</span></p>

<p class=MsoDate><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoDate><span lang=EN-GB>Hydrochlorothiazide is excreted in human milk
in small amounts. Thiazides in high doses causing intense diuresis can inhibit
milk production.</span></p>

<p class=MsoDate><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The use of
Rasitrio during breast-feeding is not recommended. If Rasitrio is used during
breast-feeding, doses should be kept as low as possible.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Fertility</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>There are no
clinical data on fertility with the use of Rasitrio.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Reversible
biochemical changes in the head of spermatozoa have been reported in some
patients treated by calcium channel blockers. Clinical data are insufficient
regarding the potential effect of amlodipine on fertility. In one rat study,
adverse effects were found on male fertility (see section&nbsp;5.3). The fertility
of rats was unaffected at doses of up to aliskiren 250&nbsp;mg/kg/day and
hydrochlorothiazide 4&nbsp;mg/kg/day (see section&nbsp;5.3).</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.7&nbsp;&nbsp;&nbsp;&nbsp; Effects
on ability to drive and use machines</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>No studies on the effect on the ability to drive and use machines
have been performed</span>. However, when driving vehicles or using machines it
must be borne in mind that dizziness or drowsiness may occasionally occur when
taking Rasitrio.</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Amlodipine can
have minor or moderate influence on the ability to drive and use machines. If
patients taking amlodipine suffer from dizziness, drowsiness, headache, fatigue
or nausea, the ability to react may be impaired.</span></p>

<p class=MsoDate><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.8&nbsp;&nbsp;&nbsp;&nbsp; Undesirable
effects</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Summary of the safety profile</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Aliskiren/amlodipine/hydrochlorothiazide combination</span></u></i></p>

<p style='margin:0in'><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>The safety profile of Rasitrio presented below is
based on clinical studies performed with Rasitrio and the known safety profile
of the individual components aliskiren, amlodipine and hydrochlorothiazide.
Safety information for Rasitrio in patients aged 75&nbsp;years and older is
limited.</span></p>

<p style='margin:0in'><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoCommentText style='line-height:normal'><span lang=EN-GB
style='font-size:11.0pt'>The most frequent adverse reactions observed with
Rasitrio are hypotension and dizziness. The adverse reactions previously
reported with one of the individual components of Rasitrio (aliskiren,
amlodipine and hydrochlorothiazide) and listed in the respective paragraphs on
the individual components may occur with Rasitrio.</span></p>

<p class=Default><u><span lang=EN-GB style='font-size:11.0pt;color:windowtext'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Tabulated
list of adverse reactions:</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>The adverse
reactions for aliskiren, amlodipine and hydrochlorothiazide are ranked under
heading of frequency, the most frequent first, using the following convention:
very common (&#8805;1/10); common (&#8805;1/100 to &lt;1/10); uncommon
(&#8805;1/1,000 to &lt;1/100); rare (&#8805;1/10,000 to &lt;1/1,000); very rare
(&lt;1/10,000), not known (cannot be estimated from the available data). Within
each frequency grouping, adverse reactions are presented in order of decreasing
seriousness.</span></p>

<p style='margin:0in'><u><span style='font-size:11.0pt;font-family:"Times New Roman",serif'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p style='margin:0in;page-break-after:avoid'><i><u><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Information on
Rasitrio</span></u></i></p>

<p class=CharCharCharCharChar align=left style='margin-bottom:0in;text-align:
left;line-height:normal;page-break-after:avoid'><span style='font-size:11.0pt;
font-family:"Times New Roman",serif'>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='margin-left:5.4pt;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-bottom:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
  layout-grid-mode:line'>Nervous system disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Common</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Dizziness</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
  layout-grid-mode:line'>Vascular disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Common</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Hypotension</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><b><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>General
  disorders and administration site conditions</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Common</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Peripheral
  oedema</span></p>
  </td>
 </tr>
</table>

<p class=CharCharCharCharChar align=left style='margin-bottom:0in;text-align:
left;line-height:normal'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'>Peripheral oedema is
a known, dose-dependent adverse reaction of amlodipine and has also been
reported with aliskiren therapy in post-marketing experience. The incidence of
peripheral oedema for Rasitrio in a short-term double active-controlled study
was 7.1% compared to 8.0% for aliskiren/amlodipine, 4.1% for
amlodipine/hydrochlorothiazide and 2.0% for aliskiren/hydrochlorothiazide dual
combinations.</p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>The
incidence of any adverse reactions potentially related to hypotension in a
short-term active controlled study was 4.9% with Rasitrio versus up to 3.7%
with dual combinations. In patients &#8805;65&nbsp;years the incidence was
10.2% with Rasitrio versus up to 5.4% with dual combinations.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'>&nbsp;</p>

<p style='margin:0in;page-break-after:avoid'><i><u><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Additional
information on individual components</span></u></i></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Other
adverse reactions previously reported with one of the individual components may
occur with Rasitrio even if not observed in clinical trials.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p style='margin:0in;page-break-after:avoid'><i><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Aliskiren</span></i></p>

<p style='margin:0in;page-break-after:avoid'><span lang=EN-GB style='font-size:
11.0pt;font-family:"Times New Roman",serif'>Serious adverse reactions include
anaphylactic reaction and angioedema which have been reported in post-marketing
experience and may occur rarely (less than 1&nbsp;case per
1,000&nbsp;patients). The most common adverse reaction is diarrhoea.</span></p>

<p style='margin:0in'><u><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoDate style='page-break-after:avoid'><span lang=EN-GB>Tabulated list
of adverse reactions:</span></p>

<p class=MsoNormal><span lang=EN-GB>The known aliskiren adverse reactions are
presented in the table below using the same convention as described previously
for the fixed combination.</span></p>

<p style='margin:0in;page-break-after:avoid'><u><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='margin-left:5.4pt;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-bottom:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
  layout-grid-mode:line'>Immune system disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Anaphylactic
  reactions, h</span><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
  layout-grid-mode:line'>ypersensitivity reactions</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><b><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Cardiac
  </span></b><b><span lang=DE-CH style='font-size:11.0pt;font-family:"Times New Roman",serif'>d</span></b><b><span
  lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>isorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Common</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Dizziness</span></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Uncommon</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Palpitations</span><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>, oedema
  peripheral</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><b><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Vascular
  disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Uncommon</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Hypotension</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
  layout-grid-mode:line'>Respiratory, thoracic and mediastinal disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
  layout-grid-mode:line'>Uncommon</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
  layout-grid-mode:line'>Cough</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
  layout-grid-mode:line'>Gastrointestinal disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Common</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Diarrhoea</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><b><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Hepatobiliary
  disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Not
  known</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Liver
  disorder*</span><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>,
  j</span><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>aundice</span><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>,</span><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'> </span><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>h</span><span
  lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>epatitis</span><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>, l</span><span
  lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>iver
  failure</span><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>**</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
  layout-grid-mode:line'>Skin and subcutaneous tissue disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Uncommon</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Severe
  cutaneous adverse reactions (SCARs) including Stevens Johnson syndrome, toxic
  epidermal necrolysis (TEN), oral mucosal reactions, rash, pruritus, urticaria</span></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Angioedema,
  erythema</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
  layout-grid-mode:line'>Musculoskeletal and connective tissue disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Common</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Arthralgia</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
  layout-grid-mode:line'>Renal and urinary disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Uncommon</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=FR style='font-size:11.0pt;font-family:"Times New Roman",serif'>Acute
  renal failure, renal impairment</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
  layout-grid-mode:line'>Investigations</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Common</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Hyperkalaemia</span></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Uncommon</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Liver
  enzyme increased</span></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Haemoglobin
  decreased, haematocrit decreased, blood creatinine increased</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>*Isolated cases
of liver disorder with clinical symptoms and laboratory evidence of more marked
hepatic dysfunction.</span></p>

<p style='margin:0in'><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>**Including one case of &#8216;liver failure
fulminant&#8217; reported in the post-marketing experience, for which a causal
relationship with aliskiren cannot be excluded.</span></p>

<p style='margin:0in'><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Description of
selected adverse events:</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Hypersensitivity
reactions including anaphylactic reactions and angioedema have occurred during
treatment with aliskiren.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>In controlled
clinical trials, angioedema and hypersensitivity reactions occurred rarely
during treatment with aliskiren with rates comparable to treatment with placebo
or comparators.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Cases of
angioedema or symptoms suggestive of angioedema (swelling of the face, lips,
throat and/or tongue) have also been reported in post-marketing experience. A
number of these patients had a history of angioedema or symptoms suggestive of
angioedema which in some cases was associated with the administration of other
medicinal products known to cause angioedema, including RAAS blockers (ACEIs or
ARBs).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'>In post-marketing experience,
cases of angioedema or angioedema-like reactions have been reported when
aliskiren was co-administered with ACEIs and/or ARBs.</p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Hypersensitivity
reactions including anaphylactic reactions have also been reported in
post-marketing experience (see section&nbsp;4.4).</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>In the event
of any signs suggesting a hypersensitivity reaction/angioedema (in particular
difficulties in breathing, or swallowing, rash, itching, hives or swelling of
the face, extremities, eyes, lips and/or tongue, dizziness) patients should
discontinue treatment and contact the physician (see section&nbsp;4.4).</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Arthralgia has
been reported in post-marketing experience. In some cases this occurred as part
of a hypersensitivity reaction.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In
post-marketing experience, renal dysfunction and cases of acute renal failure
have been reported in patients at risk (see section&nbsp;4.4).</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><i><span style='font-size:11.0pt;color:windowtext'>Investigations:
</span></i><span style='font-size:11.0pt;color:windowtext'>In controlled
clinical trials, clinically relevant changes in standard laboratory parameters
were uncommonly associated with the administration of aliskiren. In clinical
studies in hypertensive patients, aliskiren had no clinically important effects
on total cholesterol, high density lipoprotein cholesterol (HDL-C),
fasting triglycerides, fasting glucose or uric acid.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><i><span style='font-size:11.0pt;color:windowtext'>Haemoglobin
and haematocrit</span></i><span style='font-size:11.0pt;color:windowtext'>:
Small decreases in haemoglobin and haematocrit (mean decreases of approximately
0.05&nbsp;mmol/l and 0.16&nbsp;volume percent, respectively) were observed. No
patients discontinued therapy due to anaemia. This effect is also seen with
other medicinal products acting on the RAAS, such as ACEIs and ARBs.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><i><span style='font-size:11.0pt;color:windowtext'>Serum
potassium</span></i><span style='font-size:11.0pt;color:windowtext'>: Increases
in serum potassium have been observed with aliskiren and these may be
exacerbated by concomitant use of other agents acting on the RAAS or by NSAIDs.
Consistent with standard medical practice, periodic determination of renal
function including serum electrolytes is advised if co-administration is
considered necessary. The combination of aliskiren with ARBs or ACEIs is
contraindicated in patients with diabetes mellitus or renal impairment (GFR
&lt;60&nbsp;ml/min/</span><span style='font-size:11.0pt;color:windowtext'>1.73&nbsp;m<sup>2</sup></span><span
style='font-size:11.0pt;color:windowtext'>) and is not recommended in other
patients (see sections&nbsp;4.3, 4.4 and 5.1).</span></p>

<p style='margin:0in'><u><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><i><span lang=EN-GB>Paediatric population: </span></i><span
lang=EN-GB>Based on the limited amount of safety data available from a
pharmacokinetic study of aliskiren treatment in 39 hypertensive children 6&#8209;17&nbsp;years
of age, the frequency, type and severity of adverse reactions in children are
expected to be similar to that seen in hypertensive adults. As for other RAAS
blockers, headache is a common adverse event in children treated with
aliskiren.</span></p>

<p style='margin:0in'><u><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Amlodipine</span></i></p>

<p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
color:windowtext'>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><b><span style='font-size:
  11.0pt;color:windowtext'>Blood and lymphatic system disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Very
  rare</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Leukopenia,
  thrombocytopenia</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><b><span style='font-size:
  11.0pt;color:windowtext'>Immune system disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Very rare</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Allergic
  reactions</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><b><span style='font-size:
  11.0pt;color:windowtext'>Metabolism and nutrition disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Very rare</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Hyperglycaemia</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><b><span style='font-size:
  11.0pt;color:windowtext'>Psychiatric disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Uncommon</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Insomnia, mood changes (including anxiety), depression</span></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Rare</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Confusion</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><b><span style='font-size:
  11.0pt;color:windowtext'>Nervous system disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Common</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Somnolence, headache (especially at the beginning of
  treatment)</span></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Uncommon</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Tremor, dysgeusia, syncope, hypoesthesia, paraesthesia</span></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Very rare</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Hypertonia,
  peripheral neuropathy</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><b><span style='font-size:
  11.0pt;color:windowtext'>Eye disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Uncommon</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Visual disturbance
  (including diplopia)</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><b><span style='font-size:
  11.0pt;color:windowtext'>Ear and labyrinth disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Uncommon</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Tinnitus</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><b><span style='font-size:
  11.0pt;color:windowtext'>Cardiac disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Common</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Palpitations</span></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Very rare</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Myocardial
  infarction, arrhythmia (including bradycardia, ventricular tachycardia and
  atrial fibrillation)</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><b><span style='font-size:
  11.0pt;color:windowtext'>Vascular disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Common</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Flushing</span></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Very rare</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Vasculitis</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><b><span style='font-size:
  11.0pt;color:windowtext'>Respiratory, thoracic and mediastinal disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Uncommon</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Dyspnoea, rhinitis</span></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Very rare</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Cough</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><b><span style='font-size:
  11.0pt;color:windowtext'>Gastrointestinal disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Common</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Abdominal pain, nausea</span></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Uncommon</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Vomiting, dyspepsia, altered bowel habits (including
  diarrhoea and constipation), dry mouth</span></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Very rare</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Pancreatitis,
  gastritis, gingival hyperplasia</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><b><span style='font-size:
  11.0pt;color:windowtext'>Hepatobiliary disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Very rare</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Hepatitis,
  jaundice, hepatic enzymes increased (mostly consistent with cholestasis)</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><b><span style='font-size:
  11.0pt;color:windowtext'>Skin and subcutaneous tissue disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Uncommon</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Alopecia, purpura, skin decolouration, hyperhidrosis,
  pruritus, rash, exanthema</span></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Very rare</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Angioedema,
  erythema multiforme, urticaria, exfoliative dermatitis, Stevens-Johnson
  syndrome, Quincke oedema, photosensitivity</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><b><span style='font-size:
  11.0pt;color:windowtext'>Musculoskeletal and connective tissue disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;color:windowtext'>Common</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Ankle swelling</span></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Uncommon</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Arthralgia,
  myalgia, muscle cramps, back pain</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><b><span style='font-size:
  11.0pt;color:windowtext'>Renal and urinary disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Uncommon</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Micturition
  disorder, nocturia, increased urinary frequency</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><b><span style='font-size:
  11.0pt;color:windowtext'>Reproductive system and breast disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Uncommon</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Impotence,
  gynaecomastia</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><b><span style='font-size:
  11.0pt;color:windowtext'>General disorders and administration site conditions</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Common</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt;
  color:windowtext'>Oedema, fatigue</span></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Uncommon</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span lang=FR style='font-size:11.0pt;color:windowtext'>Chest
  pain, asthenia, pain, malaise</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=2 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default style='page-break-after:avoid'><b><span style='font-size:
  11.0pt;color:windowtext'>Investigations</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=201 valign=top style='width:150.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Uncommon</span></p>
  </td>
  <td width=418 valign=top style='width:313.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span style='font-size:11.0pt;color:windowtext'>Weight
  increase, weight decrease</span></p>
  </td>
 </tr>
</table>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Exceptional
cases of extrapyramidal syndrome have been reported.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Hydrochlorothiazide</span></i></p>

<p style='margin:0in;page-break-after:avoid'><span lang=EN-GB style='font-size:
11.0pt;font-family:"Times New Roman",serif'>Hydrochlorothiazide has been
extensively prescribed for many years, frequently in higher doses than those
contained in </span><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Rasitrio</span><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>. </span><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>The
following adverse reactions have been reported in patients treated with
thiazide diuretics alone, including hydrochlorothiazide:</span></p>

<p style='margin:0in;page-break-after:avoid'><i><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></i></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='margin-left:5.4pt;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-bottom:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:
  line'>Blood and lymphatic system disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Thrombocytopenia</span><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>
  sometimes with purpura</span></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Very rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Agranulocytosis,
  bone marrow depression, haemolytic anaemia, leucopenia</span></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Not known</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Aplastic
  anaemia</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:
  line'>Immune system disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=X-NONE style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Very rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Hypersensitivity</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:
  line'>Metabolism and nutrition disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Very common</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Hypokalaemia</span></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Common</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Hyperuricaemia,
  hypomagnesaemia, hyponatraemia</span></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Hypercalcaemia,
  hyperglycaemia, worsening of diabetic metabolic state</span></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=X-NONE style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Very rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Hypochloraemic
  alkalosis</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:
  line'>Psychiatric disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=X-NONE style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Depression,
  sleep disturbances</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:
  line'>Nervous system disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=X-NONE style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Dizziness,
  headache, paraesthesia</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:
  line'>Eye disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Visual
  impairment</span></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=X-NONE style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Not known</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Acute
  angle-closure glaucoma</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:
  line'>Cardiac disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=X-NONE style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Cardiac
  arrhythmias</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:
  line'>Vascular disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=X-NONE style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Common</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Orthostatic
  hypotension</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:
  line'>Respiratory, thoracic and mediastinal disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=X-NONE style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Very rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Respiratory
  distress (including pneumonitis and pulmonary oedema)</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:
  line'>Gastrointestinal disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Common</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Decreased
  appetite, mild nausea and vomiting</span></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Abdominal
  discomfort, constipation, diarrhoea</span></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=X-NONE style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Very rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Pancreatitis</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:
  line'>Hepatobiliary disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Intrahepatic
  cholestasis, jaundice</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:
  line'>Skin and subcutaneous tissue disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Common</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Urticaria
  and other forms of rash</span></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Photosensitivity
  reactions</span></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Very rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Cutaneous
  lupus erythematosus-like reactions, reactivation of cutaneous lupus
  erythematosus, vasculitis necrotising and toxic epidermal necrolysis</span></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Not known</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Erythema
  multiforme</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:
  line'>Musculoskeletal and connective tissue disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=X-NONE style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Not known</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Muscle
  spasm</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:
  line'>Renal and urinary disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=X-NONE style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Not known</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=FR style='font-size:11.0pt;font-family:"Times New Roman",serif'>Renal
  dysfunction, acute renal failure</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:
  line'>Reproductive system and breast disorders</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=X-NONE style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Common</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Impotence</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:
  line'>General disorders and administration site conditions</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=X-NONE style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Not known</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Asthenia,
  pyrexia</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=3 valign=top style='width:6.3in;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:
  line'>Investigations</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Very common</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Increases
  in cholesterol and triglycerides</span></p>
  </td>
 </tr>
 <tr>
  <td width=38 valign=top style='width:28.35pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=X-NONE
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Rare</span></p>
  </td>
  <td width=435 valign=top style='width:326.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Glycosuria</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.9&nbsp;&nbsp;&nbsp;&nbsp; Overdose</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Symptoms</span></u></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>The most
likely manifestation of overdose for Rasitrio would be hypotension, related to
the antihypertensive effect of the combination of aliskiren, amlodipine and
hydrochlorothiazide.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>With
aliskiren, the most likely manifestation of overdose would be hypotension,
related to the antihypertensive effect of aliskiren.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>With
amlodipine, available data suggest that gross overdose could result in
excessive peripheral vasodilatation and possibly reflex tachycardia. </span><span
style='font-size:11.0pt;color:windowtext'>Marked and </span><span lang=EN-GB
style='font-size:11.0pt;color:windowtext'>probably </span><span
style='font-size:11.0pt;color:windowtext'>prolonged systemic hypotension</span><span
lang=EN-GB style='font-size:11.0pt;color:windowtext'> up to and</span><span
style='font-size:11.0pt;color:windowtext'> including shock with fatal outcome,
have been reported with amlodipine.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Overdose with
hydrochlorothiazide is associated with electrolyte depletion (hypokalaemia,
hypochloraemia, hyponatraemia) and dehydration resulting from excessive
diuresis. The most common signs and symptoms of overdose are nausea and
somnolence. Hypokalaemia may result in muscle spasms and/or accentuate cardiac
arrhythmias associated with the concomitant use of digitalis glycosides or
certain antiarrhythmic medicinal products.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Treatment</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If symptomatic
hypotension should occur with Rasitrio, supportive treatment should be
initiated.</span></p>

<p class=MsoNormal style='line-height:normal'><i>&nbsp;</i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Clinically
significant hypotension due to amlodipine overdose calls for active
cardiovascular support including frequent monitoring of cardiac and respiratory
function, elevation of extremities and attention to circulating fluid volume
and urine output.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>A
vasoconstrictor may be helpful in restoring vascular tone and blood pressure,
provided that there is no contraindication to its use. Intravenous calcium
gluconate may be beneficial in reversing the effects of calcium channel
blockade.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Gastric lavage
may be worthwhile in some cases. In healthy volunteers the use of charcoal up
to 2&nbsp;hours after administration of amlodipine 10&nbsp;mg has been shown to
reduce the absorption rate of amlodipine.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Since amlodipine
is highly protein-bound, dialysis is not likely to be of benefit.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In a study
conducted in patients with end stage renal disease (ESRD) receiving
haemodialysis, dialysis clearance of aliskiren was low (&lt;2% of oral
clearance). Therefore dialysis is not adequate to treat aliskiren
over-exposure.</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACOLOGICAL
PROPERTIES</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5.1&nbsp;&nbsp;&nbsp;&nbsp; Pharmacodynamic
properties</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>Pharmacotherapeutic group</span><span lang=EN-GB>:
Agents acting on the renin-angiotensin system, renin-inhibitors; ATC code
C09XA54</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Rasitrio
combines three antihypertensive active substances with complementary mechanisms
to control blood pressure in patients with essential hypertension: aliskiren
belongs to the direct renin inhibitor class, amlodipine to the calcium channel
blocker class and hydrochlorothiazide to the thiazide diuretics class. When
combined, the consolidated effects of inhibition of the renin-angiotensin-aldosterone
system, calcium channel-mediated vasodilatation and sodium chloride excretion
result in a reduction of blood pressure to a greater degree than the
corresponding dual combinations.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Aliskiren/amlodipine/hydrochlorothiazide combination</span></u></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>In
hypertensive patients, once-daily administration of Rasitrio provided
clinically meaningful reductions in both systolic and diastolic blood pressure
that were maintained over the entire 24-hour dose interval. The greater blood
pressure reduction for Rasitrio over each dual combination was seen at every
hour including the early morning hours with the 24-hour ambulatory blood
pressure monitoring.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Rasitrio
was studied in a double-blind, randomised, active-controlled study in
1,181&nbsp;patients of which 773 were classified as moderately hypertensive
(msSBP 160&#8209;180&nbsp;mmHg) and 408 as severely hypertensive (msSBP
&gt;180&nbsp;mmHg) at baseline. A large number of patients were obese (49%) and
over 14% of the total population had diabetes. During the first 4&nbsp;weeks of
double-blind treatment, patients received triple combination
aliskiren/amlodipine/hydrochlorothiazide (HCTZ) 150/5/12.5&nbsp;mg (N=308), or
dual combinations of aliskiren/HCTZ 150/12.5&nbsp;mg (N=295),
aliskiren/amlodipine 150/5&nbsp;mg (N=282) and amlodipine/HCTZ 5/12.5&nbsp;mg
(N=295). Patients were force-titrated to higher doses after 4&nbsp;weeks for an
additional 4&nbsp;weeks of double-blind treatment to aliskiren/amlodipine/HCTZ
300/10/25&nbsp;mg, aliskiren/HCTZ 300/25&nbsp;mg, aliskiren/amlodipine 300/10&nbsp;mg
and amlodipine/HCTZ 10/25&nbsp;mg.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>In
this study, Rasitrio at a dose of 300/10/25&nbsp;mg produced statistically
significant mean blood pressure reductions (systolic/diastolic) from baseline
of 37.9/20.6&nbsp;mmHg compared to 31.4/18.0&nbsp;mmHg with
aliskiren/amlodipine combination (300/10&nbsp;mg), 28.0/14.3&nbsp;mmHg with
aliskiren/hydrochlorothiazide (300/25&nbsp;mg) and 30.8/17.0&nbsp;mmHg with
amlodipine/hydrochlorothiazide (10/25&nbsp;mg) in patients with moderate to
severe hypertension. In patients with severe hypertension (SBP &#8805;180&nbsp;mmHg), the reduction in blood pressure from baseline for Rasitrio and the
dual combinations respectively was 49.5/22.5&nbsp;mmHg compared to
38.1/17.6&nbsp;mmHg with aliskiren/amlodipine combination (300/10&nbsp;mg),
33.2/14.3&nbsp;mmHg with aliskiren/hydrochlorothiazide (300/25&nbsp;mg) and
39.9/17.8&nbsp;mmHg with amlodipine/hydrochlorothiazide (10/25&nbsp;mg). In a
subset of 588&nbsp;patients</span><span lang=EN-GB> in which patients
&gt;65&nbsp;years were scarcely represented and those aged &gt;75&nbsp;years
were very scarcely represented</span><span lang=EN-GB>, the combination of
aliskiren/amlodipine/hydrochlorothiazide (300/10/25&nbsp;mg) produced a
systolic/diastolic mean blood pressure reduction of 39.7/21.1&nbsp;mmHg from
baseline, compared to 31.3/18.74&nbsp;mmHg for aliskiren/amlodipine
(300/10&nbsp;mg), 25.5/12.5&nbsp;mmHg for aliskiren/hydrochlorothiazide
(300/25&nbsp;mg) and 29.2/16.4&nbsp;mmHg for amlodipine/hydrochlorothiazide
(10/25&nbsp;mg) (the subset constitutes patients without aberrant readings,
defined as a difference between systolic blood pressure (SBP) readings
&#8805;10&nbsp;mmHg at baseline or endpoint). The effect of Rasitrio was
observed as early as one week after initiation of therapy. The
blood-pressure-lowering effect in patients with moderate to severe hypertension
was independent of age, gender, race, body mass index and overweight-associated
disorders (metabolic syndrome and diabetes).</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Rasitrio
was associated with a significant reduction in plasma renin activity (PRA) (&#8209;34%)
from baseline while the dual combination of amlodipine with hydrochlorothiazide
increased PRA (+170%). The clinical implications of the differences in effect
on PRA are not known at the present time.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>In
a 28 to 54&nbsp;week open label safety study, efficacy was measured as
secondary endpoint and Rasitrio at a dose of 300/10/25&nbsp;mg produced mean
blood pressure reductions (systolic/diastolic) of 37.3/21.8&nbsp;mmHg over 28
to 54&nbsp;weeks of treatment. Efficacy of Rasitrio was maintained over one
year of treatment, with no evidence of loss of effect.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>In
a randomised, double blind, active controlled, 36-week study in elderly
patients whose blood pressure was not controlled with aliskiren/HCTZ
300/25&nbsp;mg (SBP &#8805;140&nbsp;mmHg), clinically meaningful further BP
reduction was seen at week&nbsp;36 endpoint for patients who received Rasitrio
at a dose of 300/10/25&nbsp;mg (from reductions in msSBP/msDBP of
15.0/8.6&nbsp;mmHg at week&nbsp;22 to reductions of 30.8/14.1&nbsp;mmHg at
week&nbsp;36 endpoint).</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Rasitrio
has been administered to more than 1,155&nbsp;patients in completed clinical
trials, including 182&nbsp;patients for one year or more. Treatment with
Rasitrio was well tolerated at doses up to 300&nbsp;mg/10&nbsp;mg/25&nbsp;mg
with an overall incidence of adverse events similar to the corresponding dual
combinations, except for symptomatic hypotension. </span><span lang=EN-GB>The
incidence of any adverse reactions potentially related to hypotension in a
short-term controlled study was 4.9% with Rasitrio versus up to 3.7% with dual
combinations. In patients &#8805;65&nbsp;years the incidence was 10.2% with
Rasitrio versus up to 5.4% with dual combinations.</span></p>

<p class=CharCharCharCharChar align=left style='margin-bottom:0in;text-align:
left;line-height:normal'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=CharCharCharCharChar align=left style='margin-bottom:0in;text-align:
left;line-height:normal'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>The
incidence of adverse events did not show any association with gender, age (with
the exception of symptomatic hypotension), body mass index, race or ethnicity.
Adverse events have generally been mild and transient in nature. Very limited
safety data are available for patients aged &gt;75&nbsp;years or patients with
major cardiovascular co-morbidities. Discontinuation of therapy due to a
clinical adverse event occurred in 3.6% of patients treated with Rasitrio
versus 2.4% in aliskiren/amlodipine, 0.7% in aliskiren/hydrochlorothiazide and
2.7% in amlodipine/hydrochlorothiazide.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Aliskiren</span></u></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Aliskiren is
an orally active, non-peptide, potent and selective direct inhibitor of human
renin.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>By inhibiting
the enzyme renin, aliskiren inhibits the RAAS at the point of activation,
blocking the conversion of angiotensinogen to angiotensin&nbsp;I and decreasing
levels of angiotensin&nbsp;I and angiotensin&nbsp;II. Whereas other medicinal
products that inhibit the RAAS (ACEI and angiotensin&nbsp;II receptor blockers
(ARB)) cause a compensatory rise in plasma renin activity (PRA), treatment with
aliskiren decreases PRA in hypertensive patients by approximately 50 to 80%.
Similar reductions were found when aliskiren was combined with other
antihypertensive medicinal products. The clinical implications of the
differences in effect on PRA are not known at the present time.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Hypertension</span></i></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>In
hypertensive patients, once-daily administration of aliskiren at doses of
150&nbsp;mg and 300&nbsp;mg provided dose-dependent reductions in both systolic
and diastolic blood pressure that were maintained over the entire 24-hour dose
interval (maintaining benefit in the early morning) with a mean peak to trough
ratio for diastolic response of up to 98% for the 300&nbsp;mg dose. 85 to 90%
of the maximal blood-pressure-lowering effect was observed after 2&nbsp;weeks.
The blood-pressure-lowering effect was sustained during long-term treatment,
and was independent of age, gender, body mass index and ethnicity. Aliskiren
has been studied in 1,864&nbsp;patients aged 65&nbsp;years or older, and in
426&nbsp;patients aged 75&nbsp;years or older.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Aliskiren
monotherapy studies have shown blood-pressure-lowering effects comparable to
other classes of antihypertensive medicinal products including selected ACEI
and ARB. Compared to a diuretic (hydrochlorothiazide, HCTZ), aliskiren
300&nbsp;mg lowered systolic/diastolic blood pressure by 17.0/12.3&nbsp;mmHg,
compared to 14.4/10.5&nbsp;mmHg for HCTZ 25&nbsp;mg after 12&nbsp;weeks of
treatment.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Combination
therapy studies are available for aliskiren added to the diuretic
hydrochlorothiazide, the calcium channel blocker amlodipine and the beta
blocker atenolol. These combinations were well tolerated. Aliskiren induced an
additive blood-pressure-lowering effect when added to hydrochlorothiazide.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>&nbsp;</p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>The
efficacy and safety of aliskiren-based therapy were compared to ramipril-based
therapy in a 9-month non-inferiority study in 901&nbsp;elderly patients
(&#8805;65&nbsp;years) with essential systolic hypertension. Aliskiren
150&nbsp;mg or 300&nbsp;mg per day or ramipril 5&nbsp;mg or 10&nbsp;mg per day
were administered for 36&nbsp;weeks with optional add-on therapy of
hydrochlorothiazide (12.5&nbsp;mg or 25&nbsp;mg) at week&nbsp;12, and
amlodipine (5&nbsp;mg or 10&nbsp;mg) at week&nbsp;22. Over the 12-week period,
aliskiren monotherapy lowered systolic/diastolic blood pressure by
14.0/5.1&nbsp;mmHg, compared to 11.6/3.6&nbsp;mmHg for ramipril, consistent
with aliskiren being non-inferior to ramipril at the dosages chosen and the
differences in systolic and diastolic blood pressure were statistically
significant. Tolerability was comparable in both treatment arms, however cough
was more often reported with the ramipril regimen than the aliskiren regimen
(14.2% vs. 4.4%), whilst diarrhoea was more common with the aliskiren regimen
than for the ramipril regimen (6.6% vs. 5.0%).</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>In an 8-week study in 754&nbsp;hypertensive geriatric patients aged
65&nbsp;years or older and geriatric patients aged 75&nbsp;years or older (30%)
aliskiren at doses of 75&nbsp;mg, 150&nbsp;mg and 300&nbsp;mg provided
statistically significant superior reduction in blood pressure (both systolic
and diastolic) when compared to placebo. No additional blood pressure lowering
effect was detected with 300&nbsp;mg aliskiren compared to 150&nbsp;mg
aliskiren. All three doses were well tolerated in both elderly and very elderly
patients.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>There has been
no evidence of first-dose hypotension and no effect on pulse rate in patients
treated in controlled clinical studies. Excessive hypotension was uncommonly
(0.1%) seen in patients with uncomplicated hypertension treated with aliskiren
alone. Hypotension was also uncommon (&lt;1%) during combination therapy with
other antihypertensive medicinal products. With cessation of treatment, blood
pressure gradually returned towards baseline levels over a period of several
weeks, with no evidence of a rebound effect for blood pressure or PRA.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>I</span>n a 36-week study involving 820&nbsp;patients with ischaemic
left ventricular dysfunction, no changes in ventricular remodelling as assessed
by left ventricular end systolic volume were detected with aliskiren compared
to placebo on top of background therapy.</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>&nbsp;</p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>The combined
rates of cardiovascular death, hospitalisation for heart failure, recurrent
heart attack, stroke and resuscitated sudden death were similar in the
aliskiren group and the placebo group. However, in patients receiving aliskiren
there was a significantly higher rate of hyperkalaemia, hypotension and kidney
dysfunction when compared to the placebo group.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Aliskiren was evaluated for cardiovascular
and/or renal benefit in a double blind placebo controlled randomised trial in
8,606&nbsp;patients with type 2 diabetes and chronic kidney disease (evidenced
by proteinuria and/or GFR &lt;60&nbsp;ml/min/</span><span lang=EN-GB>1.73&nbsp;m<sup>2</sup></span><span
lang=EN-GB>) with or without cardiovascular disease. In most patients arterial
blood pressure was well controlled at baseline. The primary endpoint was a
composite of cardiovascular and renal complications.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>In this study,
aliskiren 300&nbsp;mg was compared to placebo when added to standard of care
which included either an angiotensin converting enzyme inhibitor or an
angiotensin receptor blocker. The study was discontinued prematurely because
the participants were unlikely to benefit from aliskiren. Study results
indicated a hazard ratio for the primary endpoint of 1.11 in favour of placebo
(95% Confidence Interval: 1.00, 1.23, 2-sided p=0.05). In addition, an
increased incidence of </span><span lang=EN-GB>adverse events</span><span
lang=EN-GB> was observed with aliskiren compared to placebo </span><span
lang=EN-GB>(37.9% versus 30.2%). In particular there was an increased incidence
of</span><span lang=EN-GB> renal </span><span lang=EN-GB>dysfunction</span><span
lang=EN-GB> (14.0% versus 12.1%), hyperkalaemia (38.9% versus 28.8%),
hypotension</span><span lang=EN-GB>-related events</span><span lang=EN-GB>
(19.7% versus 16.2%) </span><span lang=EN-GB>and adjudicated stroke endpoints
(3.4% versus 2.6%). The increased incidence of stroke was greater in patients
with renal insufficiency.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Effects of
aliskiren on mortality and cardiovascular morbidity are currently unknown.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>No long-term
efficacy data for aliskiren in patients with heart failure are currently
available (see section&nbsp;4.4).</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Cardiac electrophysiology</span></i></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>No effect on
QT interval was reported in a randomised, double-blind, placebo, and
active-controlled study using standard and Holter electrocardiography.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Amlodipine</span></u></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>The
amlodipine component of Rasitrio inhibits the transmembrane entry of calcium
ions </span><span lang=EN-GB>into cardiac and vascular smooth muscle. The
mechanism of the antihypertensive action of amlodipine is due to a direct
relaxant effect on vascular smooth muscle, causing reductions in peripheral
vascular resistance and in blood pressure. Experimental data suggest that
amlodipine binds to both dihydropyridine and non-dihydropyridine binding sites.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>The
contractile processes of cardiac muscle and vascular smooth muscle are
dependent upon the movement of extracellular calcium ions into these cells
through specific ion channels.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Following
administration of therapeutic doses to patients with hypertension, amlodipine
produces vasodilatation resulting in a reduction of supine and standing blood
pressures. These decreases in blood pressure are not accompanied by a
significant change in heart rate or plasma catecholamine levels with chronic dosing.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Plasma
concentrations correlate with effect in both young and elderly patients.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>In
hypertensive patients with normal renal function, therapeutic doses of
amlodipine resulted in a decrease in renal vascular resistance and an increase
in glomerular filtration rate and effective renal plasma flow without change in
filtration fraction or proteinuria.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>As
with other calcium channel blockers, haemodynamic measurements of cardiac
function at rest and during exercise (or pacing) in patients with normal ventricular
function treated with amlodipine have generally demonstrated a small increase
in cardiac index without significant influence on dP/dt or on left ventricular
end diastolic pressure or volume. In haemodynamic studies, amlodipine has not
been associated with a negative inotropic effect when administered in the
therapeutic dose range to intact animals and humans, even when co-administered
with beta blockers to humans.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Amlodipine does
not change sinoatrial nodal function or atrioventricular conduction in intact
animals or humans. In clinical studies in which amlodipine was administered in
combination with beta blockers to patients with either hypertension or angina,
no adverse effects on electrocardiographic parameters were observed.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoDate><span lang=EN-GB>Amlodipine has demonstrated beneficial
clinical effects in patients with chronic stable angina, vasospastic angina and
angiographically documented coronary artery disease.</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><i><span lang=EN-GB>Use in patients with heart failure</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Calcium channel blockers, including amlodipine, should be used with
caution in patients with congestive heart failure, as they may increase the
risk of future cardiovascular events and mortality.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><i><span lang=EN-GB>Use in patients with hypertension</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>A randomised
double-blind morbidity-mortality study called the Antihypertensive and Lipid-Lowering
treatment to prevent Heart Attack Trial (ALLHAT) was performed to compare newer
therapies: amlodipine 2.5&#8209;10&nbsp;mg/day (calcium channel blocker) or
lisinopril 10&#8209;40&nbsp;mg/day (ACE-inhibitor) as first-line therapies to
that of the thiazide-diuretic, chlorthalidone 12.5&#8209;25&nbsp;mg/day in mild
to moderate hypertension.</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>A total of
33,357&nbsp;hypertensive patients aged 55 or older were randomised and followed
for a mean of 4.9&nbsp;years. The patients had at least one additional coronary
heart disease risk factor, including: previous myocardial infarction or stroke
(&gt;6&nbsp;months prior to enrollment) or documentation of other
atherosclerotic cardiovascular disease (overall 51.5%), type 2 diabetes
(36.1%), high density lipoprotein - cholesterol &lt;35&nbsp;mg/dl or &lt;0.906&nbsp;mmol/l
(11.6%), left ventricular hypertrophy diagnosed by electrocardiogram or
echocardiography (20.9%), current cigarette smoking (21.9%).</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>The primary
endpoint was a composite of fatal coronary heart disease or non-fatal
myocardial infarction. There was no significant difference in the primary
endpoint between amlodipine-based therapy and chlorthalidone-based therapy:
risk ratio (RR) 0.98 95% CI (0.90&#8209;1.07) p=0.65. Among secondary
endpoints, the incidence of heart failure (component of a composite combined
cardiovascular endpoint) was significantly higher in the amlodipine group as
compared to the chlorthalidone group (10.2% vs. 7.7%, RR 1.38, 95% CI [1.25&#8209;1.52]
p&lt;0.001). However, there was no significant difference in all-cause
mortality between amlodipine-based therapy and chlorthalidone-based therapy RR
0.96 95% CI [0.89&#8209;1.02] p=0.20.</p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Hydrochlorothiazide</span></u></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>The
site of action of thiazide diuretics is primarily in the renal distal
convoluted tubule. It has been shown that there is a high-affinity receptor in
the renal cortex as the primary binding site for the thiazide diuretic action
and inhibition of NaCl transport in the distal convoluted tubule. The mode of
action of thiazides is through inhibition of the Na+Cl- symporter by competing
for the Cl- site, thereby affecting electrolyte reabsorption mechanisms:
directly increasing sodium and chloride excretion to an approximately equal
extent, and indirectly by this diuretic action reducing plasma volume, with
consequent increases in plasma renin activity, aldosterone secretion and
urinary potassium loss, and a decrease in serum potassium.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Paediatric population</span></u></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>The
European Medicines Agency has waived the obligation to submit the results of
studies with Rasitrio in all subsets of the paediatric population in essential
hypertension (see section&nbsp;4.2 for information on paediatric use).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5.2&nbsp;&nbsp;&nbsp;&nbsp; Pharmacokinetic
properties</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Aliskiren/amlodipine/hydrochlorothiazide combination</span></u></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Following
oral administration of a fixed combination tablet of aliskiren, amlodipine and
hydrochlorothiazide, peak concentrations were achieved for aliskiren within 1&#8209;2&nbsp;hours,
for amlodipine within 8&nbsp;hours and for hydrochlorothiazide within 2&#8209;3&nbsp;hours.
The rate and extent of absorption of aliskiren, amlodipine and
hydrochlorothiazide following administration of a fixed combination tablet are
similar to when administered as individual dosage forms.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>The
results from a food effect study using a </span><span lang=EN-GB>standard </span><span
lang=EN-GB>high-fat meal</span><span lang=EN-GB> with the 300/10/25&nbsp;mg
fixed combination tablet showed that food </span><span lang=EN-GB>reduced the
rate and extent of absorption of aliskiren in the fixed combination tablet with
a similar magnitude of effect as for aliskiren monotherapy. Food had no effect </span><span
lang=EN-GB>on the pharmacokinetics of amlodipine or hydrochlorothiazide in the
fixed combination tablet.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Aliskiren</span></u></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Absorption</span></i></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Following oral
absorption, peak plasma concentrations of aliskiren are reached after 1&#8209;3&nbsp;hours.
The absolute bioavailability of aliskiren is approximately 2&#8209;3%. Meals
with a high fat content reduce C<sub>max</sub> by 85% and AUC by 70%. At steady
state meals with low fat content reduce C<sub>max</sub> by 76% and AUC <sub>0-tau</sub>
by 67% in hypertensive patients. Steady-state plasma concentrations are reached
within 5&#8209;7&nbsp;days following once-daily administration and steady-state
levels are approximately 2-fold greater than with the initial dose.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Distribution</span></i></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Following
intravenous administration, the mean volume of distribution at steady state is
approximately 135&nbsp;litres, indicating that aliskiren distributes
extensively into the extravascular space. Aliskiren plasma protein binding is
moderate (47&#8209;51%) and independent of the concentration.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Biotransformation and elimination</span></i></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>The mean
half-life is about 40&nbsp;hours (range 34&#8209;41&nbsp;hours). Aliskiren is
mainly eliminated as unchanged compound in the faeces (78%). Approximately 1.4%
of the total oral dose is metabolised. The enzyme responsible for this
metabolism is CYP3A4. Approximately 0.6% of the dose is recovered in urine
following oral administration. Following intravenous administration, mean
plasma clearance is approximately 9&nbsp;l/h.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Linearity</span></i></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Exposure to
aliskiren increased more than in proportion to the increase in dose. After
single dose administration in the dose range of 75 to 600&nbsp;mg, a 2-fold
increase in dose results in a ~2.3 and 2.6-fold increase in AUC and C<sub>max</sub>,
respectively. At steady state the non-linearity may be more pronounced.
Mechanisms responsible for deviation from linearity have not been identified. A
possible mechanism is saturation of transporters at the absorption site or at
the hepatobiliary clearance route.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><i><span lang=EN-GB>Paediatric
population</span></i></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>In
a pharmacokinetic study of aliskiren treatment in 39 paediatric hypertensive
patients (aged 6&#8209;17&nbsp;years) given daily doses of 2&nbsp;mg/kg or
6&nbsp;mg/kg aliskiren administered as granules (3.125&nbsp;mg/tablet),
pharmacokinetic parameters were similar to those in adults. The available data
did not suggest that age, body weight or gender have any significant effect on
aliskiren systemic exposure (see section 4.2).</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Amlodipine</span></u></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Absorption</span></i></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>After oral
administration of therapeutic doses of amlodipine alone, peak plasma concentrations
of amlodipine are reached in 6&#8209;12&nbsp;hours. Absolute bioavailability
has been </span><span style='font-size:11.0pt;color:windowtext'>estima</span><span
style='font-size:11.0pt;color:windowtext'>ted as between 64% and 80%.
Amlodipine bioavailability is unaffected by food ingestion.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Distribution</span></i></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>The volume of
distribution is approximately 21&nbsp;l/kg. <i>In vitro </i>studies with
amlodipine have shown that approximately 97.5% of circulating amlodipine is
bound to plasma proteins.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Biotransformation and elimination</span></i></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Amlodipine
is extensively (approximately 90%) metabolised in the liver to inactive
metabolites, with 10% of the parent compound and 60% of the metabolites
excreted in the urine.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Amlodipine
elimination from plasma is biphasic with a terminal elimination half-life of
approximately 30 to 50&nbsp;hours. Steady-state plasma levels are reached after
continuous administration for 7&#8209;8&nbsp;days.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Linearity</span></i></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Amlodipine
exhibits linear pharmacokinetics between </span><span lang=EN-GB>the
therapeutic dose range of </span><span lang=EN-GB>5&nbsp;mg and 10&nbsp;mg</span><span
lang=EN-GB>.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Hydrochlorothiazide</span></u></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Absorption</span></i></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>The absorption of hydrochlorothiazide, after an oral dose, is rapid
(T<sub>max</sub> about 2&nbsp;h.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>The effect of food on hydrochlorothiazide absorption, if any, has
little clinical significance. Absolute bioavailability of hydrochlorothiazide
is 70% after oral administration.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Distribution</span></i></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>The apparent volume of distribution is 4&#8209;8&nbsp;l/kg.
Circulating hydrochlorothiazide is bound to serum proteins (40&#8209;70%),
mainly serum albumin. Hydrochlorothiazide also accumulates in erythrocytes at
approximately 3&nbsp;times the level in plasma.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Biotransformation and elimination</span></i></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Hydrochlorothiazide is eliminated predominantly as unchanged
compound. Hydrochlorothiazide is eliminated from plasma with a half-life
averaging 6 to 15&nbsp;hours in the terminal elimination phase. There is no
change in the kinetics of hydrochlorothiazide on repeated dosing, and
accumulation is minimal when dosed once daily. There is more than 95% of the
absorbed dose being excreted as unchanged compound in the urine. The renal
clearance is composed of passive filtration and active secretion into the renal
tubule.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Linearity</span></i></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>The increase in mean AUC is linear and dose proportional in the
therapeutic range.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Special populations</span></u></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Rasitrio is an
effective once-a-day antihypertensive treatment in adult patients, regardless
of gender, age, body mass index and ethnicity.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Renal impairment</span></i></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Due
to its hydrochlorothiazide component, Rasitrio is contraindicated in patients
with anuria or severe renal impairment (GFR &lt;30&nbsp;ml/min/1.73&nbsp;m<sup>2</sup>)
(see section&nbsp;4.3). No adjustment of the initial dose is required in
patients with mild to moderate renal impairment (see sections&nbsp;4.4 and
4.2).</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>The
pharmacokinetics of aliskiren were evaluated in patients with varying degrees
of renal insufficiency. Relative AUC and C<sub>max</sub> of aliskiren in
subjects with renal impairment ranged between 0.8 to 2&nbsp;times the levels in
healthy subjects following single dose administration and at steady state.
These observed changes, however, did not correlate with the severity of renal
impairment. No adjustment of the initial dose of aliskiren is required in
patients with mild to moderate renal impairment (see sections&nbsp;4.2 and
4.4). Aliskiren is not recommended in patients with severe renal impairment
(glomerular filtration rate (GFR) &lt;30&nbsp;ml/min/</span><span
style='font-size:11.0pt;color:windowtext'>1.73&nbsp;m<sup>2</sup></span><span
style='font-size:11.0pt;color:windowtext'>). Concomitant use of aliskiren with
ARBs or ACEIs is contraindicated in patients with renal impairment (GFR
&lt;60&nbsp;ml/min/</span><span style='font-size:11.0pt;color:windowtext'>1.73&nbsp;m<sup>2</sup></span><span
style='font-size:11.0pt;color:windowtext'>) (see section&nbsp;4.3).</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>The
pharmacokinetics of aliskiren were evaluated</span><span lang=EN-GB> in
patients with end stage renal disease receiving haemodialysis. Administration
of a single oral dose of 300&nbsp;mg aliskiren was associated with very minor
changes in the pharmacokinetics of aliskiren (change in C<sub>max</sub> of less
than 1.2&nbsp;fold; increase in AUC of up to 1.6&nbsp;fold) compared to matched
healthy subjects. Timing of haemodialysis did not significantly alter the
pharmacokinetics of aliskiren in ESRD patients. Therefore,<b><i> </i></b>if
administration of aliskiren in ESRD patients receiving haemodialysis is
considered necessary, no dose adjustment is warranted in these patients.
However, the use of aliskiren is not recommended in patients with severe renal
impairment (see section&nbsp;4.4).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The pharmacokinetics of amlodipine are not significantly influenced
by renal impairment.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>As
expected for a compound which is cleared almost exclusively via the kidneys,
renal function has a marked effect on the kinetics of hydrochlorothiazide. In
the presence of renal impairment, mean peak plasma levels and AUC values of
hydrochlorothiazide are increased and the urinary excretion rate is reduced. In
patients with mild to moderate renal impairment, a 3-fold increase in
hydrochlorothiazide AUC has been observed. In patients with severe renal
impairment an 8-fold increase in AUC has been observed.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Hepatic impairment</span></i></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Rasitrio is
contraindicated in patients with severe hepatic impairment (see
section&nbsp;4.3).</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>The
pharmacokinetics of aliskiren were not significantly affected in patients with
mild to severe liver disease. Consequently, no adjustment of the initial dose
of aliskiren is required in patients with mild to moderate hepatic impairment.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Very limited clinical data are available regarding amlodipine
administration in patients with hepatic impairment. Patients with hepatic
insufficiency have decreased clearance of amlodipine with resulting increase in
AUC of approximately 40&#8209;60%. Therefore caution should be exercised</span><span
lang=EN-GB> in patients with hepatic impairment.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Geriatric patients</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No data are
available on systemic exposure after administration of Rasitrio in geriatric
patients. When administered alone, the AUC of aliskiren in geriatric subjects
(&gt;65&nbsp;years) is 50% higher than in young subjects. The time to reach
peak plasma concentrations of amlodipine is similar in elderly and younger
subjects. Amlodipine clearance tends to be decreased with resulting increases
in AUC and elimination half-life in geriatric patients. </span><span
lang=EN-GB>Therefore particular caution is recommended when administering
Rasitrio to patients aged 65&nbsp;years and over, and extreme caution in
patients aged 75&nbsp;years or older (see sections&nbsp;4.2, 4.4, 4.8 and 5.1).</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Limited
data suggest that the systemic clearance of hydrochlorothiazide is reduced in
both healthy and hypertensive elderly subjects compared to young healthy
volunteers. There are no specific data regarding the effect of
hydrochlorothiazide in elderly patients.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=Default style='page-break-after:avoid'><i><span style='font-size:11.0pt;
color:windowtext'>Paediatric </span></i><i><span style='font-size:11.0pt;
color:windowtext'>population (age below 18&nbsp;years)</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The pharmacokinetics of Rasitrio have not been investigated. A population
pharmacokinetic study has been conducted in 74 hypertensive children aged from
1 to 17&nbsp;years (with 34&nbsp;patients aged 6 to 12&nbsp;years and
28&nbsp;patients aged 13 to 17&nbsp;years) receiving amlodipine between 1.25
and 20&nbsp;mg given either once or twice daily. In children 6 to 12&nbsp;years
and in adolescents 13&#8209;17&nbsp;years of age the typical oral clearance
(CL/F) was 22.5 and 27.4&nbsp;l/hr respectively in males and 16.4 and
21.3&nbsp;l/hr respectively in females. Large variability in exposure between
individuals was observed. Data reported in children below 6&nbsp;years are
limited.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5.3&nbsp;&nbsp;&nbsp;&nbsp; Preclinical
safety data</span></b></p>

<p class=Text style='margin-bottom:0in;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Aliskiren/hydrochlorothiazide and aliskiren/amlodipine</span></u></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Non-clinical
studies of the toxicology of Rasitrio alone have not been conducted as these
studies have been conducted for the individual components.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>The
toxicity profiles of the combination of aliskiren/hydrochlorothiazide and
aliskiren/amlodipine have been well characterised in preclinical studies. Both
combinations were generally well tolerated by rats. The findings from 2- and
13-week oral toxicity studies were consistent with those for the individual
components.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Aliskiren</span></u></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Carcinogenic
potential was assessed in a 2-year rat study and a 6-month transgenic mouse
study. No carcinogenic potential was detected. One colonic adenoma and one
caecal adenocarcinoma recorded in rats at the dose of 1,500&nbsp;mg/kg/day were
not statistically significant. Although aliskiren has known irritation
potential, safety margins obtained in humans at the dose of 300&nbsp;mg during
a study in healthy volunteers were considered to be appropriate at 9&#8209;11-fold
based on faecal concentrations or 6-fold based on mucosa concentrations in
comparison with 250&nbsp;mg/kg/day in the rat carcinogenicity study.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Aliskiren was
devoid of any mutagenic potential in the <i>in vitro </i>and <i>in vivo </i>mutagenicity
studies. The assays included <i>in vitro </i>assays in bacterial and mammalian
cells and <i>in vivo </i>assessments in rats.</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Reproductive
toxicity studies with aliskiren did not reveal any evidence of embryofoetal
toxicity or teratogenicity at doses up to 600&nbsp;mg/kg/day in rats or
100&nbsp;mg/kg/day in rabbits. Fertility, pre-natal development and post-natal
development were unaffected in rats at doses up to 250&nbsp;mg/kg/day. The
doses in rats and rabbits provided systemic exposures of 1 to 4 and 5&nbsp;times
higher, respectively, than the maximum recommended human dose (300&nbsp;mg).</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt;color:windowtext'>Safety
pharmacology studies did not reveal any adverse effects on central nervous,
respiratory or cardiovascular function. Findings during repeat-dose toxicity
studies in animals were consistent with the known local irritation potential or
the expected pharmacological effects of aliskiren.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Amlodipine</span></u></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Safety
data for amlodipine are well established both clinically and non-clinically.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Reproductive
toxicology</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Reproductive
studies in rats and mice have shown delayed date of delivery, prolonged
duration of labour and decreased pup survival at dosages approximately
50&nbsp;times greater than the maximum recommended dosage for humans based on
mg/kg.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Impairment of
fertility</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>There was no
effect on the fertility of rats treated with amlodipine (males for 64&nbsp;days
and females 14&nbsp;days prior to mating) at doses up to 10&nbsp;mg/kg/day
(8&nbsp;times* the maximum recommended human dose of 10&nbsp;mg on a mg/m<sup>2</sup>
basis). In another rat study in which male rats were treated with amlodipine
besilate for 30&nbsp;days at a dose comparable with the human dose based on
mg/kg, decreased plasma follicle-stimulating hormone and testosterone were
found as well as decreases in sperm density and in the number of mature
spermatids and Sertoli cells.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Carcinogenesis,
mutagenesis</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Rats and mice
treated with amlodipine in the diet for two years, at concentrations calculated
to provide daily dosage levels of 0.5, 1.25 and 2.5&nbsp;mg/kg/day showed no
evidence of carcinogenicity. The highest dose (for mice, similar to, and for
rats twice* the maximum recommended clinical dose of 10&nbsp;mg on a mg/m<sup>2</sup>
basis) was close to the maximum tolerated dose for mice but not for rats.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Mutagenicity
studies revealed no effects related to the medicinal product at either the gene
or chromosome levels.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>*Based on
patient weight of 50&nbsp;kg</span></p>

<p class=Default><u><span lang=EN-GB style='font-size:11.0pt;color:windowtext'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt;
color:windowtext'>Hydrochlorothiazide</span></u></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Preclinical
evaluations to support the administration of hydrochlorothiazide in humans
included <i>in vitro</i> genotoxicity assays and reproductive toxicity and
carcinogenicity studies in rodents. Extensive clinical data are available for
hydrochlorothiazide and these are reflected in the relevant sections.</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Hydrochlorothiazide
had no adverse effects on the fertility of mice and rats of either sex in
studies wherein these species were exposed, via their diet, to doses of up to
100 and 4&nbsp;mg/kg,/day respectively, prior to mating and throughout
gestation. These doses of hydrochlorothiazide in mice and rats represent 19 and
1.5&nbsp;times, respectively, the maximum recommended human dose on a mg/m<sup>2</sup>
basis. (Calculations assume an oral dose of 25&nbsp;mg/day and a 60-kg
patient.)</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
PARTICULARS</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.1&nbsp;&nbsp;&nbsp;&nbsp; List
of excipients</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Tablet core</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=IT>Cellulose microcrystalline</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=IT>Crospovidone</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=IT>Povidone</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=IT>Magnesium stearate</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=IT>Silica colloidal anhydrous</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=IT>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=IT>Coating</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=IT>Hypromellose</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=IT>Titanium dioxide (E171)</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=ES>Macrogol</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=ES>Talc</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=ES>Iron oxide red (E172)</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Iron oxide black (E172)</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>Iron oxide
yellow (E172)</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b>6.2&nbsp;&nbsp;&nbsp;&nbsp; Incompatibilities</b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Not applicable.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.3&nbsp;&nbsp;&nbsp;&nbsp; Shelf
life</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>PVC/polychlorotrifluoroethylene (PCTFE) </span>&#8211;<span
lang=EN-GB> Alu calendar blisters:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>2&nbsp;years</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>PVC/polychlorotrifluoroethylene (PCTFE) </span>&#8211; <span
lang=EN-GB>Alu blisters:</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>2&nbsp;years</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'>PA/Alu/PVC
&#8211; Alu calendar blisters:</p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>18&nbsp;months</span></p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.4&nbsp;&nbsp;&nbsp;&nbsp; Special
precautions for storage</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'>Do not store above 30&deg;C.</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>Store in the
original package in order to protect from moisture.</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.5&nbsp;&nbsp;&nbsp;&nbsp; Nature
and contents of container</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>PVC/polychlorotrifluoroethylene (PCTFE) - Alu calendar blisters:</span></p>

<p class=MsoDate>Single pack containing 14, 28, 56, 98&nbsp;tablets</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>PVC/polychlorotrifluoroethylene (PCTFE) - Alu blisters:</span></p>

<p class=MsoDate style='page-break-after:avoid'>Single pack containing 30,
90&nbsp;tablets</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'>Unit dose
pack (perforated unit dose blister) containing 56x1&nbsp;tablet</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>Multipacks of
unit dose (perforated unit dose blister) containing 98x1&nbsp;tablet
(2&nbsp;packs of 49x1)</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=ES>PA/Alu/PVC &#8211; Alu calendar blisters:</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'>Single pack containing 14, 28, 56&nbsp;tablets</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>Multipacks
containing 98&nbsp;tablets (2&nbsp;packs of 49)</p>

<p class=MsoDate>&nbsp;</p>

<p class=Text style='margin-bottom:0in;line-height:normal'><span lang=EN-GB>Not
all pack sizes may be marketed.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.6&nbsp;&nbsp;&nbsp;&nbsp; Special
precautions for disposal</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Any unused medicinal product or waste material should be disposed of
in accordance with local requirements.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION HOLDER</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'>Novartis Europharm Limited</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'>Wimblehurst Road</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'>Horsham</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'>West Sussex, RH12 5AB</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>United
Kingdom</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'>EU/1/11/730/049&#8209;060</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; DATE
OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Date of first
authorisation: </span><span lang=EN-GB>22 November 2011</span></p>

<p class=MsoDate><span lang=EN-GB>Date of latest renewal:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>10.&nbsp;&nbsp;&nbsp;&nbsp; DATE
OF REVISION OF THE TEXT</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:28.3pt;line-height:normal'><span
lang=EN-GB>Detailed information on this medicinal product is available on the
website of the European Medicines Agency http://www.ema.europa.eu</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>ANNEX II</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-align:justify;line-height:
normal'><b><span lang=EN-GB>A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MANUFACTURER
RESPONSIBLE FOR BATCH RELEASE</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=NormalAgency style='margin-left:85.05pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
text-transform:uppercase'>B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Conditions or
restrictions regarding supply and use</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=NormalAgency style='margin-left:85.05pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
text-transform:uppercase'>C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other conditions and
requirements of the Marketing Authorisation</span></b></p>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif;text-transform:uppercase'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-28.35pt'><b><span
lang=EN-GB>D.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <span style='text-transform:uppercase'>conditions
or restrictions with regard to the safe and effective use of the medicinal
product</span></span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Verdana",sans-serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=BodytextAgency style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal'><b><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>A.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>MANUFACTURER
RESPONSIBLE FOR BATCH RELEASE</span></b></p>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=NormalAgency><u><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>Name and address of the manufacturer responsible for
batch release</span></u></p>

<p class=NormalAgency><span lang=IT style='font-size:11.0pt;font-family:"Times New Roman",serif'>Novartis
Farma S.p.A.</span></p>

<p class=NormalAgency><span lang=IT style='font-size:11.0pt;font-family:"Times New Roman",serif'>Via
Provinciale Schito 131</span></p>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>IT-80058 Torre Annunziata</span></p>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>Italy</span></p>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=NormalAgency style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
text-transform:uppercase'>B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Conditions or
restrictions regarding supply and use</span></b></p>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=NormalAgency><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Medicinal
product subject to medical prescription.</span></p>

<p class=NormalAgency><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=NormalAgency><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=NormalAgency style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
text-transform:uppercase'>C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other conditions and
requirements of the Marketing Authorisation</span></b></p>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b>Periodic Safety Update Reports</b></p>

<p class=MsoNormal style='margin-right:-.05pt'>The <span lang=EN-GB>marketing
authorisation holder</span> shall submit periodic safety update reports for
this product in accordance with the requirements set out in the list of Union
reference dates (EURD list) provided for under Article 107c(7) of Directive
2001/83/EC and published on the European medicines web-portal.</p>

<p class=MsoNormal style='margin-right:-.05pt'>&nbsp;</p>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=NormalAgency style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
text-transform:uppercase'>D.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Conditions or
restrictions with regard to the safe and effective use of the medicinal product</span></b></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:justify;text-indent:
-28.35pt;vertical-align:baseline'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Risk Management Plan</span></b><b><span
lang=EN-GB> (RMP)</span></b></p>

<p class=MsoNormal style='margin-right:-.05pt'><span lang=EN-GB>The MAH shall
perform the required pharmacovigilance activities and interventions detailed in
the agreed RMP presented in Module&nbsp;1.8.2 of the Marketing Authorisation
and any agreed subsequent updates of the RMP.</span></p>

<p class=MsoNormal style='margin-right:-.05pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt'><span lang=EN-GB>An updated RMP
should be submitted:</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>At the request of the </span><span lang=EN-GB>European
Medicines Agency;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Whenever </span><span lang=EN-GB>the risk
management system is modified, especially as the result of </span><span
lang=EN-GB>new information being received that may lead to a </span><span
lang=EN-GB>significant change to the benefit/risk profile or as the result </span><span
lang=EN-GB>of an important (pharmacovigilance or risk minimisation) milestone
being reached.</span></p>

<p class=MsoNormal style='margin-right:-.05pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt'><span lang=EN-GB>If the
submission of a PSUR and the update of a RMP coincide, they can be submitted at
the same time.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:.5in;margin-bottom:.0001pt;text-indent:-.5in'><span lang=EN-GB
style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>O<span style='color:black'>bligation </span></span></b><b><span
lang=EN-GB>to conduct post-authorisation measures</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><span
lang=EN-GB>The MAH shall complete, within the stated timeframe, the below
measures:</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="98%"
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width="80%" valign=top style='width:80.44%;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><b><span
  lang=EN-GB>Description</span></b></p>
  </td>
  <td width="19%" valign=top style='width:19.56%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><b><span
  lang=EN-GB>Due date</span></b></p>
  </td>
 </tr>
 <tr>
  <td width="80%" valign=top style='width:80.44%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=TabletextrowsAgency style='line-height:normal'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>The MAH shall
  submit the final study report of the ALTITUDE study, including the 1-year
  safety extension phase covering the results of the active treatment phase
  relevant to the two different cut-off dates.</span></p>
  </td>
  <td width="19%" valign=top style='width:19.56%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TabletextrowsAgency style='line-height:normal'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>31 October 2013</span></p>
  </td>
 </tr>
</table>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>ANNEX III</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>LABELLING AND PACKAGE LEAFLET</span></b></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>A. LABELLING</span></b></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>CARTON OF SINGLE PACK/CARTON OF UNIT PACK (perforated unit dose
blister)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Rasitrio 150&nbsp;mg/5&nbsp;mg/12.5&nbsp;mg film-coated tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Aliskiren/amlodipine/hydrochlorothiazide</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each tablet
contains 150&nbsp;mg aliskiren (as aliskiren hemifumarate), 5&nbsp;mg amlodipine
(as amlodipine besylate) and 12.5&nbsp;mg hydrochlorothiazide.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:#D9D9D9'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#D9D9D9'>Film-coated tablets</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>14&nbsp;tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#D9D9D9'>28&nbsp;tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#D9D9D9'>30&nbsp;tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#D9D9D9'>56&nbsp;tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#D9D9D9'>90&nbsp;tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#D9D9D9'>98&nbsp;tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Read the package
leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Oral use</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep out of the
sight and reach of children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER
SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'>Do not store above 30&deg;C.</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'>Store in the original package in order to protect from moisture and
light.</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>10.&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>11.&nbsp;&nbsp;&nbsp;&nbsp; NAME AND
ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=Smalltext120 style='page-break-after:avoid'><span style='font-size:
11.0pt'>Novartis Europharm Limited</span></p>

<p class=Smalltext120 style='page-break-after:avoid'><span style='font-size:
11.0pt'>Wimblehurst Road</span></p>

<p class=Smalltext120 style='page-break-after:avoid'><span style='font-size:
11.0pt'>Horsham</span></p>

<p class=Smalltext120 style='page-break-after:avoid'><span style='font-size:
11.0pt'>West Sussex, RH12 5AB</span></p>

<p class=Smalltext120><span style='font-size:11.0pt'>United Kingdom</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>12.&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'>&nbsp;</p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=621
 style='width:466.1pt;border-collapse:collapse'>
 <tr>
  <td width=158 valign=top style='width:1.65in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>EU/1/11/730/001</p>
  </td>
  <td width=463 valign=top style='width:347.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=FR style='color:black;background:#D9D9D9'>14&nbsp;tablets (PVC/PCTFE blisters)</span></p>
  </td>
 </tr>
 <tr>
  <td width=158 valign=top style='width:1.65in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=FR style='color:black;background:#D9D9D9'>EU/1/11/730/009</span></p>
  </td>
  <td width=463 valign=top style='width:347.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=FR style='color:black;background:#D9D9D9'>14&nbsp;tablets (PA/Alu/PVC blisters)</span></p>
  </td>
 </tr>
 <tr>
  <td width=158 valign=top style='width:1.65in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=FR style='color:black;background:#D9D9D9'>EU/1/11/730/002</span></p>
  </td>
  <td width=463 valign=top style='width:347.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=FR style='color:black;background:#D9D9D9'>28&nbsp;tablets (PVC/PCTFE blisters)</span></p>
  </td>
 </tr>
 <tr>
  <td width=158 valign=top style='width:1.65in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=FR style='color:black;background:#D9D9D9'>EU/1/11/730/010</span></p>
  </td>
  <td width=463 valign=top style='width:347.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=FR style='color:black;background:#D9D9D9'>28&nbsp;tablets (PA/Alu/PVC blisters)</span></p>
  </td>
 </tr>
 <tr>
  <td width=158 valign=top style='width:1.65in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  style='color:black;background:#D9D9D9'>EU/1/11/730/003</span></p>
  </td>
  <td width=463 valign=top style='width:347.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  style='color:black;background:#D9D9D9'>30</span><span lang=EN-GB
  style='color:black;background:#D9D9D9'>&nbsp;tablets (</span><span lang=FR
  style='color:black;background:#D9D9D9'>PVC/PCTFE </span><span lang=EN-GB
  style='color:black;background:#D9D9D9'>blisters)</span></p>
  </td>
 </tr>
 <tr>
  <td width=158 valign=top style='width:1.65in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  style='color:black;background:#D9D9D9'>EU/1/11/730/004</span></p>
  </td>
  <td width=463 valign=top style='width:347.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  style='color:black;background:#D9D9D9'>56</span><span lang=EN-GB
  style='color:black;background:#D9D9D9'>&nbsp;tablets (</span><span lang=FR
  style='color:black;background:#D9D9D9'>PVC/PCTFE </span><span lang=EN-GB
  style='color:black;background:#D9D9D9'>blisters)</span></p>
  </td>
 </tr>
 <tr>
  <td width=158 valign=top style='width:1.65in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  style='color:black;background:#D9D9D9'>EU/1/11/730/011</span></p>
  </td>
  <td width=463 valign=top style='width:347.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=FR style='color:black;background:#D9D9D9'>56&nbsp;tablets (PA/Alu/PVC blisters)</span></p>
  </td>
 </tr>
 <tr>
  <td width=158 valign=top style='width:1.65in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  style='color:black;background:#D9D9D9'>EU/1/11/730/007</span></p>
  </td>
  <td width=463 valign=top style='width:347.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  style='color:black;background:#D9D9D9'>56</span><span lang=EN-GB
  style='color:black;background:#D9D9D9'>&nbsp;tablets (</span><span lang=FR
  style='color:black;background:#D9D9D9'>PVC/PCTFE </span><span lang=EN-GB
  style='color:black;background:#D9D9D9'>single-unit-dose blisters)</span></p>
  </td>
 </tr>
 <tr>
  <td width=158 valign=top style='width:1.65in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  style='color:black;background:#D9D9D9'>EU/1/11/730/005</span></p>
  </td>
  <td width=463 valign=top style='width:347.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  style='color:black;background:#D9D9D9'>90</span><span lang=EN-GB
  style='color:black;background:#D9D9D9'>&nbsp;tablets (</span><span lang=FR
  style='color:black;background:#D9D9D9'>PVC/PCTFE </span><span lang=EN-GB
  style='color:black;background:#D9D9D9'>blisters)</span></p>
  </td>
 </tr>
 <tr>
  <td width=158 valign=top style='width:1.65in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span style='color:black;
  background:#D9D9D9'>EU/1/11/730/006</span></p>
  </td>
  <td width=463 valign=top style='width:347.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span style='color:black;
  background:#D9D9D9'>98</span><span lang=EN-GB style='color:black;background:
  #D9D9D9'>&nbsp;tablets (</span><span lang=FR style='color:black;background:
  #D9D9D9'>PVC/PCTFE </span><span lang=EN-GB style='color:black;background:
  #D9D9D9'>blisters)</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>13.&nbsp;&nbsp;&nbsp;&nbsp; BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>14.&nbsp;&nbsp;&nbsp;&nbsp; GENERAL CLASSIFICATION
FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Medicinal
product subject to medical prescription.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>15.&nbsp;&nbsp;&nbsp;&nbsp; INSTRUCTIONS
ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>16.&nbsp;&nbsp;&nbsp;&nbsp; INFORMATION
IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Rasitrio
150&nbsp;mg/5&nbsp;mg/12.5&nbsp;mg</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>INTERMEDIATE CARTON OF MULTIPACK OF 98 (2&nbsp;packs of 49&nbsp;film-coated
tablets) </span></b><span lang=EN-GB>-<b> WITHOUT BLUE BOX</b></span></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Rasitrio 150&nbsp;mg/5&nbsp;mg/12.5&nbsp;mg film-coated tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Aliskiren/amlodipine/hydrochlorothiazide</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each tablet
contains 150&nbsp;mg aliskiren (as aliskiren hemifumarate), 5&nbsp;mg
amlodipine (as amlodipine besylate) and 12.5&nbsp;mg hydrochlorothiazide.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#D9D9D9'>Film-coated tablets</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Component of a multipack comprising 2&nbsp;packs, each containing
49&nbsp;tablets.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black;background:#D9D9D9'>Component of a multipack
comprising 2&nbsp;packs, each containing 49x1&nbsp;tablet.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Not to be sold
separately.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Oral use</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep out of the
sight and reach of children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER
SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
style='background:#D9D9D9'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'>Do not store above 30&deg;C.</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'>Store in the original package in order to protect from moisture and
light.</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>10.&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>11.&nbsp;&nbsp;&nbsp;&nbsp; NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Novartis Europharm Limited</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Wimblehurst Road</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Horsham</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>West Sussex, RH12 5AB</span></p>

<p class=Smalltext120><span style='font-size:11.0pt'>United Kingdom</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>12.&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=621
 style='width:466.1pt;border-collapse:collapse'>
 <tr>
  <td width=158 valign=top style='width:1.65in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>EU/1/11/730/012</span></p>
  </td>
  <td width=463 valign=top style='width:347.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=DE-CH
  style='color:black;background:#D9D9D9'>98&nbsp;tablets (2x49, PA/Alu/PVC
  blisters)</span></p>
  </td>
 </tr>
 <tr>
  <td width=158 valign=top style='width:1.65in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  style='color:black;background:#D9D9D9'>EU/1/11/730/008</span></p>
  </td>
  <td width=463 valign=top style='width:347.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  style='color:black;background:#D9D9D9'>98&nbsp;tablets (2x49x1, PVC/PCTFE
  single-unit-dose blisters)</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>13.&nbsp;&nbsp;&nbsp;&nbsp; BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>14.&nbsp;&nbsp;&nbsp;&nbsp; GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Medicinal
product subject to medical prescription.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>15.&nbsp;&nbsp;&nbsp;&nbsp; INSTRUCTIONS
ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>16.&nbsp;&nbsp;&nbsp;&nbsp; INFORMATION
IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Rasitrio
150&nbsp;mg/5&nbsp;mg/12.5&nbsp;mg</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>OUTER CARTON OF MULTIPACK OF 98 (2 packs of 49 film-coated tablets)
- WITH BLUE BOX</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Rasitrio 150&nbsp;mg/5&nbsp;mg/12.5&nbsp;mg film-coated tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Aliskiren/amlodipine/hydrochlorothiazide</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each tablet
contains 150&nbsp;mg aliskiren (as aliskiren hemifumarate), 5&nbsp;mg
amlodipine (as amlodipine besylate) and 12.5&nbsp;mg hydrochlorothiazide.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'>Multipack
containing 98 (2<span lang=EN-GB>&nbsp;</span>packs of 49) tablets.</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#D9D9D9'>Multipack containing 98 (2&nbsp;packs of
49x1) tablets.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Oral use</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep out of the
sight and reach of children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER
SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'>Do not store above 30&deg;C.</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'>Store in the original package in order to protect from moisture and
light.</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>10.&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>11.&nbsp;&nbsp;&nbsp;&nbsp; NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Novartis Europharm Limited</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Wimblehurst Road</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Horsham</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>West Sussex, RH12 5AB</span></p>

<p class=Smalltext120><span style='font-size:11.0pt'>United Kingdom</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>12.&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=621
 style='width:466.1pt;border-collapse:collapse'>
 <tr>
  <td width=158 valign=top style='width:1.65in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>EU/1/11/730/012</span></p>
  </td>
  <td width=463 valign=top style='width:347.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=DE-CH
  style='color:black;background:#D9D9D9'>98&nbsp;tablets (2x49, PA/Alu/PVC
  blisters)</span></p>
  </td>
 </tr>
 <tr>
  <td width=158 valign=top style='width:1.65in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  style='color:black;background:#D9D9D9'>EU/1/11/730/008</span></p>
  </td>
  <td width=463 valign=top style='width:347.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  style='color:black;background:#D9D9D9'>98&nbsp;tablets (2x49x1, PVC/PCTFE single-unit-dose
  blisters)</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>13.&nbsp;&nbsp;&nbsp;&nbsp; BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>14.&nbsp;&nbsp;&nbsp;&nbsp; GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Medicinal
product subject to medical prescription.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>15.&nbsp;&nbsp;&nbsp;&nbsp; INSTRUCTIONS
ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>16.&nbsp;&nbsp;&nbsp;&nbsp; INFORMATION
IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Rasitrio
150&nbsp;mg/5&nbsp;mg/12.5&nbsp;mg</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr style='height:39.25pt'>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:39.25pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><b><span lang=EN-GB>MINIMUM
  PARTICULARS TO APPEAR ON BLISTERS OR STRIPS</span></b></p>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><b><span lang=EN-GB>BLISTERS (PVC/PCTFE
  OR PA/Alu/PVC)</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
  OF THE MEDICINAL PRODUCT</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Rasitrio 150&nbsp;mg/5&nbsp;mg/12.5&nbsp;mg film-coated tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Aliskiren/amlodipine/hydrochlorothiazide</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
  OF THE MARKETING AUTHORISATION HOLDER</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Novartis
Europharm Limited</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
  DATE</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; BATCH
  NUMBER</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr style='height:39.25pt'>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:39.25pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><b><span lang=EN-GB>MINIMUM
  PARTICULARS TO APPEAR ON BLISTERS OR STRIPS</span></b></p>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><b><span lang=EN-GB>BLISTERS
  (CALENDAR) (PVC/PCTFE OR PA/Alu/PVC)</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
  OF THE MEDICINAL PRODUCT</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Rasitrio 150&nbsp;mg/5&nbsp;mg/12.5&nbsp;mg film-coated tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Aliskiren/amlodipine/hydrochlorothiazide</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
  OF THE MARKETING AUTHORISATION HOLDER</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Novartis
Europharm Limited</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
  DATE</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; BATCH
  NUMBER</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Monday</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tuesday</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Wednesday</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Thursday</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Friday</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Saturday</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sunday</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>CARTON OF SINGLE PACK/CARTON OF UNIT PACK (perforated unit dose
blister)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Rasitrio
300&nbsp;mg/5&nbsp;mg/12.5&nbsp;mg film-coated tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Aliskiren/amlodipine/hydrochlorothiazide</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each tablet
contains 300&nbsp;mg aliskiren (as aliskiren hemifumarate), 5&nbsp;mg
amlodipine (as amlodipine besylate) and 12.5&nbsp;mg hydrochlorothiazide.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:#D9D9D9'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#D9D9D9'>Film-coated tablets</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>14&nbsp;tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#D9D9D9'>28&nbsp;tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#D9D9D9'>30&nbsp;tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#D9D9D9'>56&nbsp;tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#D9D9D9'>90&nbsp;tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#D9D9D9'>98&nbsp;tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Read the package
leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Oral use</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep out of the
sight and reach of children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER
SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'>Do not store above 30&deg;C.</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>Store in the
original package in order to protect from moisture.</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>10.&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>11.&nbsp;&nbsp;&nbsp;&nbsp; NAME AND
ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=Smalltext120 style='page-break-after:avoid'><span style='font-size:
11.0pt'>Novartis Europharm Limited</span></p>

<p class=Smalltext120 style='page-break-after:avoid'><span style='font-size:
11.0pt'>Wimblehurst Road</span></p>

<p class=Smalltext120 style='page-break-after:avoid'><span style='font-size:
11.0pt'>Horsham</span></p>

<p class=Smalltext120 style='page-break-after:avoid'><span style='font-size:
11.0pt'>West Sussex, RH12 5AB</span></p>

<p class=Smalltext120><span style='font-size:11.0pt'>United Kingdom</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>12.&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'>&nbsp;</p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=621
 style='width:466.1pt;border-collapse:collapse'>
 <tr>
  <td width=158 valign=top style='width:1.65in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>EU/1/11/730/013</p>
  </td>
  <td width=463 valign=top style='width:347.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=FR style='color:black;background:#D9D9D9'>14&nbsp;tablets (PVC/PCTFE
  blisters)</span></p>
  </td>
 </tr>
 <tr>
  <td width=158 valign=top style='width:1.65in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=FR style='color:black;background:#D9D9D9'>EU/1/11/730/021</span></p>
  </td>
  <td width=463 valign=top style='width:347.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=FR style='color:black;background:#D9D9D9'>14&nbsp;tablets (PA/Alu/PVC
  blisters)</span></p>
  </td>
 </tr>
 <tr>
  <td width=158 valign=top style='width:1.65in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=FR style='color:black;background:#D9D9D9'>EU/1/11/730/014</span></p>
  </td>
  <td width=463 valign=top style='width:347.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=FR style='color:black;background:#D9D9D9'>28&nbsp;tablets (PVC/PCTFE
  blisters)</span></p>
  </td>
 </tr>
 <tr>
  <td width=158 valign=top style='width:1.65in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=FR style='color:black;background:#D9D9D9'>EU/1/11/730/022</span></p>
  </td>
  <td width=463 valign=top style='width:347.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=FR style='color:black;background:#D9D9D9'>28&nbsp;tablets (PA/Alu/PVC
  blisters)</span></p>
  </td>
 </tr>
 <tr>
  <td width=158 valign=top style='width:1.65in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  style='color:black;background:#D9D9D9'>EU/1/11/730/015</span></p>
  </td>
  <td width=463 valign=top style='width:347.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  style='color:black;background:#D9D9D9'>30</span><span lang=EN-GB
  style='color:black;background:#D9D9D9'>&nbsp;tablets (</span><span lang=FR
  style='color:black;background:#D9D9D9'>PVC/PCTFE </span><span lang=EN-GB
  style='color:black;background:#D9D9D9'>blisters)</span></p>
  </td>
 </tr>
 <tr>
  <td width=158 valign=top style='width:1.65in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  style='color:black;background:#D9D9D9'>EU/1/11/730/016</span></p>
  </td>
  <td width=463 valign=top style='width:347.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  style='color:black;background:#D9D9D9'>56</span><span lang=EN-GB
  style='color:black;background:#D9D9D9'>&nbsp;tablets (</span><span lang=FR
  style='color:black;background:#D9D9D9'>PVC/PCTFE </span><span lang=EN-GB
  style='color:black;background:#D9D9D9'>blisters)</span></p>
  </td>
 </tr>
 <tr>
  <td width=158 valign=top style='width:1.65in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  style='color:black;background:#D9D9D9'>EU/1/11/730/023</span></p>
  </td>
  <td width=463 valign=top style='width:347.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=FR style='color:black;background:#D9D9D9'>56&nbsp;tablets (PA/Alu/PVC
  blisters)</span></p>
  </td>
 </tr>
 <tr>
  <td width=158 valign=top style='width:1.65in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  style='color:black;background:#D9D9D9'>EU/1/11/730/019</span></p>
  </td>
  <td width=463 valign=top style='width:347.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  style='color:black;background:#D9D9D9'>56</span><span lang=EN-GB
  style='color:black;background:#D9D9D9'>&nbsp;tablets (</span><span lang=FR
  style='color:black;background:#D9D9D9'>PVC/PCTFE </span><span lang=EN-GB
  style='color:black;background:#D9D9D9'>single-unit-dose blisters)</span></p>
  </td>
 </tr>
 <tr>
  <td width=158 valign=top style='width:1.65in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  style='color:black;background:#D9D9D9'>EU/1/11/730/017</span></p>
  </td>
  <td width=463 valign=top style='width:347.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  style='color:black;background:#D9D9D9'>90</span><span lang=EN-GB
  style='color:black;background:#D9D9D9'>&nbsp;tablets (</span><span lang=FR
  style='color:black;background:#D9D9D9'>PVC/PCTFE </span><span lang=EN-GB
  style='color:black;background:#D9D9D9'>blisters)</span></p>
  </td>
 </tr>
 <tr>
  <td width=158 valign=top style='width:1.65in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span style='color:black;
  background:#D9D9D9'>EU/1/11/730/018</span></p>
  </td>
  <td width=463 valign=top style='width:347.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span style='color:black;
  background:#D9D9D9'>98</span><span lang=EN-GB style='color:black;background:
  #D9D9D9'>&nbsp;tablets (</span><span lang=FR style='color:black;background:
  #D9D9D9'>PVC/PCTFE </span><span lang=EN-GB style='color:black;background:
  #D9D9D9'>blisters)</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>13.&nbsp;&nbsp;&nbsp;&nbsp; BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>14.&nbsp;&nbsp;&nbsp;&nbsp; GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Medicinal
product subject to medical prescription.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>15.&nbsp;&nbsp;&nbsp;&nbsp; INSTRUCTIONS
ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>16.&nbsp;&nbsp;&nbsp;&nbsp; INFORMATION
IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Rasitrio
300&nbsp;mg/5&nbsp;mg/12.5&nbsp;mg</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>INTERMEDIATE CARTON OF MULTIPACK OF 98 (2&nbsp;packs of
49&nbsp;film-coated tablets) </span></b><span lang=EN-GB>-<b> WITHOUT BLUE BOX</b></span></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Rasitrio
300&nbsp;mg/5&nbsp;mg/12.5&nbsp;mg film-coated tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Aliskiren/amlodipine/hydrochlorothiazide</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each tablet
contains 300&nbsp;mg aliskiren (as aliskiren hemifumarate), 5&nbsp;mg
amlodipine (as amlodipine besylate) and 12.5&nbsp;mg hydrochlorothiazide.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#D9D9D9'>Film-coated tablets</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Component of a multipack comprising 2&nbsp;packs, each containing
49&nbsp;tablets.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black;background:#D9D9D9'>Component of a multipack
comprising 2&nbsp;packs, each containing 49x1&nbsp;tablet.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Not to be sold
separately.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Oral use</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep out of the
sight and reach of children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER
SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
style='background:#D9D9D9'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'>Do not store above 30&deg;C.</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>Store in the
original package in order to protect from moisture.</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>10.&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>11.&nbsp;&nbsp;&nbsp;&nbsp; NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Novartis Europharm Limited</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Wimblehurst Road</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Horsham</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>West Sussex, RH12 5AB</span></p>

<p class=Smalltext120><span style='font-size:11.0pt'>United Kingdom</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>12.&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=621
 style='width:466.1pt;border-collapse:collapse'>
 <tr>
  <td width=158 valign=top style='width:1.65in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>EU/1/11/730/024</span></p>
  </td>
  <td width=463 valign=top style='width:347.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=DE-CH
  style='color:black;background:#D9D9D9'>98&nbsp;tablets (2x49, PA/Alu/PVC
  blisters)</span></p>
  </td>
 </tr>
 <tr>
  <td width=158 valign=top style='width:1.65in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  style='color:black;background:#D9D9D9'>EU/1/11/730/020</span></p>
  </td>
  <td width=463 valign=top style='width:347.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  style='color:black;background:#D9D9D9'>98&nbsp;tablets (2x49x1, PVC/PCTFE
  single-unit-dose blisters)</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>13.&nbsp;&nbsp;&nbsp;&nbsp; BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>14.&nbsp;&nbsp;&nbsp;&nbsp; GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Medicinal
product subject to medical prescription.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>15.&nbsp;&nbsp;&nbsp;&nbsp; INSTRUCTIONS
ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>16.&nbsp;&nbsp;&nbsp;&nbsp; INFORMATION
IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Rasitrio
300&nbsp;mg/5&nbsp;mg/12.5&nbsp;mg</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>OUTER CARTON OF MULTIPACK OF 98 (2 packs of 49 film-coated tablets)
- WITH BLUE BOX</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Rasitrio
300&nbsp;mg/5&nbsp;mg/12.5&nbsp;mg film-coated tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Aliskiren/amlodipine/hydrochlorothiazide</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each tablet
contains 300&nbsp;mg aliskiren (as aliskiren hemifumarate), 5&nbsp;mg
amlodipine (as amlodipine besylate) and 12.5&nbsp;mg hydrochlorothiazide.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'>Multipack
containing 98 (2<span lang=EN-GB>&nbsp;</span>packs of 49) tablets.</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#D9D9D9'>Multipack containing 98 (2&nbsp;packs of
49x1) tablets.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Oral use</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep out of the
sight and reach of children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER
SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'>Do not store above 30&deg;C.</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>Store in the
original package in order to protect from moisture.</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>10.&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>11.&nbsp;&nbsp;&nbsp;&nbsp; NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Novartis Europharm Limited</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Wimblehurst Road</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Horsham</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>West Sussex, RH12 5AB</span></p>

<p class=Smalltext120><span style='font-size:11.0pt'>United Kingdom</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>12.&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=621
 style='width:466.1pt;border-collapse:collapse'>
 <tr>
  <td width=158 valign=top style='width:1.65in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>EU/1/11/730/024</span></p>
  </td>
  <td width=463 valign=top style='width:347.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=DE-CH
  style='color:black;background:#D9D9D9'>98&nbsp;tablets (2x49, PA/Alu/PVC
  blisters)</span></p>
  </td>
 </tr>
 <tr>
  <td width=158 valign=top style='width:1.65in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  style='color:black;background:#D9D9D9'>EU/1/11/730/020</span></p>
  </td>
  <td width=463 valign=top style='width:347.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  style='color:black;background:#D9D9D9'>98&nbsp;tablets (2x49x1, PVC/PCTFE
  single-unit-dose blisters)</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>13.&nbsp;&nbsp;&nbsp;&nbsp; BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>14.&nbsp;&nbsp;&nbsp;&nbsp; GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Medicinal
product subject to medical prescription.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>15.&nbsp;&nbsp;&nbsp;&nbsp; INSTRUCTIONS
ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>16.&nbsp;&nbsp;&nbsp;&nbsp; INFORMATION
IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Rasitrio
300&nbsp;mg/5&nbsp;mg/12.5&nbsp;mg</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr style='height:39.25pt'>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:39.25pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><b><span lang=EN-GB>MINIMUM
  PARTICULARS TO APPEAR ON BLISTERS OR STRIPS</span></b></p>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><b><span lang=EN-GB>BLISTERS
  (PVC/PCTFE OR PA/Alu/PVC)</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
  OF THE MEDICINAL PRODUCT</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Rasitrio
300&nbsp;mg/5&nbsp;mg/12.5&nbsp;mg film-coated tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Aliskiren/amlodipine/hydrochlorothiazide</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
  OF THE MARKETING AUTHORISATION HOLDER</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Novartis
Europharm Limited</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
  DATE</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; BATCH
  NUMBER</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr style='height:39.25pt'>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:39.25pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><b><span lang=EN-GB>MINIMUM
  PARTICULARS TO APPEAR ON BLISTERS OR STRIPS</span></b></p>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><b><span lang=EN-GB>BLISTERS
  (CALENDAR) (PVC/PCTFE OR PA/Alu/PVC)</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
  OF THE MEDICINAL PRODUCT</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Rasitrio
300&nbsp;mg/5&nbsp;mg/12.5&nbsp;mg film-coated tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Aliskiren/amlodipine/hydrochlorothiazide</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
  OF THE MARKETING AUTHORISATION HOLDER</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Novartis
Europharm Limited</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
  DATE</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; BATCH
  NUMBER</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Monday</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tuesday</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Wednesday</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Thursday</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Friday</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Saturday</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sunday</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>CARTON OF SINGLE PACK/CARTON OF UNIT PACK (perforated unit dose
blister)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Rasitrio
300&nbsp;mg/5&nbsp;mg/25&nbsp;mg film-coated tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Aliskiren/amlodipine/hydrochlorothiazide</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each tablet
contains 300&nbsp;mg aliskiren (as aliskiren hemifumarate), 5&nbsp;mg
amlodipine (as amlodipine besylate) and 25&nbsp;mg hydrochlorothiazide.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:#D9D9D9'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#D9D9D9'>Film-coated tablets</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>14&nbsp;tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#D9D9D9'>28&nbsp;tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#D9D9D9'>30&nbsp;tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#D9D9D9'>56&nbsp;tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#D9D9D9'>90&nbsp;tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#D9D9D9'>98&nbsp;tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Read the package
leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Oral use</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep out of the
sight and reach of children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER
SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'>Do not store above 30&deg;C.</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>Store in the
original package in order to protect from moisture.</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>10.&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>11.&nbsp;&nbsp;&nbsp;&nbsp; NAME AND
ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=Smalltext120 style='page-break-after:avoid'><span style='font-size:
11.0pt'>Novartis Europharm Limited</span></p>

<p class=Smalltext120 style='page-break-after:avoid'><span style='font-size:
11.0pt'>Wimblehurst Road</span></p>

<p class=Smalltext120 style='page-break-after:avoid'><span style='font-size:
11.0pt'>Horsham</span></p>

<p class=Smalltext120 style='page-break-after:avoid'><span style='font-size:
11.0pt'>West Sussex, RH12 5AB</span></p>

<p class=Smalltext120><span style='font-size:11.0pt'>United Kingdom</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>12.&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'>&nbsp;</p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=621
 style='width:466.1pt;border-collapse:collapse'>
 <tr>
  <td width=158 valign=top style='width:1.65in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>EU/1/11/730/025</p>
  </td>
  <td width=463 valign=top style='width:347.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=FR style='color:black;background:#D9D9D9'>14&nbsp;tablets (PVC/PCTFE
  blisters)</span></p>
  </td>
 </tr>
 <tr>
  <td width=158 valign=top style='width:1.65in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=FR style='color:black;background:#D9D9D9'>EU/1/11/730/033</span></p>
  </td>
  <td width=463 valign=top style='width:347.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=FR style='color:black;background:#D9D9D9'>14&nbsp;tablets (PA/Alu/PVC
  blisters)</span></p>
  </td>
 </tr>
 <tr>
  <td width=158 valign=top style='width:1.65in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=FR style='color:black;background:#D9D9D9'>EU/1/11/730/026</span></p>
  </td>
  <td width=463 valign=top style='width:347.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=FR style='color:black;background:#D9D9D9'>28&nbsp;tablets (PVC/PCTFE
  blisters)</span></p>
  </td>
 </tr>
 <tr>
  <td width=158 valign=top style='width:1.65in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=FR style='color:black;background:#D9D9D9'>EU/1/11/730/034</span></p>
  </td>
  <td width=463 valign=top style='width:347.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=FR style='color:black;background:#D9D9D9'>28&nbsp;tablets (PA/Alu/PVC
  blisters)</span></p>
  </td>
 </tr>
 <tr>
  <td width=158 valign=top style='width:1.65in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  style='color:black;background:#D9D9D9'>EU/1/11/730/027</span></p>
  </td>
  <td width=463 valign=top style='width:347.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  style='color:black;background:#D9D9D9'>30</span><span lang=EN-GB
  style='color:black;background:#D9D9D9'>&nbsp;tablets (</span><span lang=FR
  style='color:black;background:#D9D9D9'>PVC/PCTFE </span><span lang=EN-GB
  style='color:black;background:#D9D9D9'>blisters)</span></p>
  </td>
 </tr>
 <tr>
  <td width=158 valign=top style='width:1.65in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  style='color:black;background:#D9D9D9'>EU/1/11/730/028</span></p>
  </td>
  <td width=463 valign=top style='width:347.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  style='color:black;background:#D9D9D9'>56</span><span lang=EN-GB
  style='color:black;background:#D9D9D9'>&nbsp;tablets (</span><span lang=FR
  style='color:black;background:#D9D9D9'>PVC/PCTFE </span><span lang=EN-GB
  style='color:black;background:#D9D9D9'>blisters)</span></p>
  </td>
 </tr>
 <tr>
  <td width=158 valign=top style='width:1.65in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  style='color:black;background:#D9D9D9'>EU/1/11/730/035</span></p>
  </td>
  <td width=463 valign=top style='width:347.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=FR style='color:black;background:#D9D9D9'>56&nbsp;tablets (PA/Alu/PVC
  blisters)</span></p>
  </td>
 </tr>
 <tr>
  <td width=158 valign=top style='width:1.65in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  style='color:black;background:#D9D9D9'>EU/1/11/730/031</span></p>
  </td>
  <td width=463 valign=top style='width:347.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  style='color:black;background:#D9D9D9'>56</span><span lang=EN-GB
  style='color:black;background:#D9D9D9'>&nbsp;tablets (</span><span lang=FR
  style='color:black;background:#D9D9D9'>PVC/PCTFE </span><span lang=EN-GB
  style='color:black;background:#D9D9D9'>single-unit-dose blisters)</span></p>
  </td>
 </tr>
 <tr>
  <td width=158 valign=top style='width:1.65in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  style='color:black;background:#D9D9D9'>EU/1/11/730/029</span></p>
  </td>
  <td width=463 valign=top style='width:347.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  style='color:black;background:#D9D9D9'>90</span><span lang=EN-GB
  style='color:black;background:#D9D9D9'>&nbsp;tablets (</span><span lang=FR
  style='color:black;background:#D9D9D9'>PVC/PCTFE </span><span lang=EN-GB
  style='color:black;background:#D9D9D9'>blisters)</span></p>
  </td>
 </tr>
 <tr>
  <td width=158 valign=top style='width:1.65in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span style='color:black;
  background:#D9D9D9'>EU/1/11/730/030</span></p>
  </td>
  <td width=463 valign=top style='width:347.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span style='color:black;
  background:#D9D9D9'>98</span><span lang=EN-GB style='color:black;background:
  #D9D9D9'>&nbsp;tablets (</span><span lang=FR style='color:black;background:
  #D9D9D9'>PVC/PCTFE </span><span lang=EN-GB style='color:black;background:
  #D9D9D9'>blisters)</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>13.&nbsp;&nbsp;&nbsp;&nbsp; BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>14.&nbsp;&nbsp;&nbsp;&nbsp; GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Medicinal
product subject to medical prescription.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>15.&nbsp;&nbsp;&nbsp;&nbsp; INSTRUCTIONS
ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>16.&nbsp;&nbsp;&nbsp;&nbsp; INFORMATION
IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Rasitrio
300&nbsp;mg/5&nbsp;mg/25&nbsp;mg</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>INTERMEDIATE CARTON OF MULTIPACK OF 98 (2&nbsp;packs of
49&nbsp;film-coated tablets) </span></b><span lang=EN-GB>-<b> WITHOUT BLUE BOX</b></span></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Rasitrio
300&nbsp;mg/5&nbsp;mg/25&nbsp;mg film-coated tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Aliskiren/amlodipine/hydrochlorothiazide</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each tablet
contains 300&nbsp;mg aliskiren (as aliskiren hemifumarate), 5&nbsp;mg
amlodipine (as amlodipine besylate) and 25&nbsp;mg hydrochlorothiazide.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#D9D9D9'>Film-coated tablets</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Component of a multipack comprising 2&nbsp;packs, each containing
49&nbsp;tablets.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black;background:#D9D9D9'>Component of a multipack
comprising 2&nbsp;packs, each containing 49x1&nbsp;tablet.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Not to be sold
separately.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Oral use</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep out of the
sight and reach of children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER
SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
style='background:#D9D9D9'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'>Do not store above 30&deg;C.</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>Store in the
original package in order to protect from moisture.</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>10.&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>11.&nbsp;&nbsp;&nbsp;&nbsp; NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Novartis Europharm Limited</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Wimblehurst Road</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Horsham</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>West Sussex, RH12 5AB</span></p>

<p class=Smalltext120><span style='font-size:11.0pt'>United Kingdom</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>12.&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=621
 style='width:466.1pt;border-collapse:collapse'>
 <tr>
  <td width=158 valign=top style='width:1.65in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>EU/1/11/730/036</span></p>
  </td>
  <td width=463 valign=top style='width:347.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=DE-CH
  style='color:black;background:#D9D9D9'>98&nbsp;tablets (2x49, PA/Alu/PVC
  blisters)</span></p>
  </td>
 </tr>
 <tr>
  <td width=158 valign=top style='width:1.65in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  style='color:black;background:#D9D9D9'>EU/1/11/730/032</span></p>
  </td>
  <td width=463 valign=top style='width:347.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  style='color:black;background:#D9D9D9'>98&nbsp;tablets (2x49x1, PVC/PCTFE
  single-unit-dose blisters)</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>13.&nbsp;&nbsp;&nbsp;&nbsp; BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>14.&nbsp;&nbsp;&nbsp;&nbsp; GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Medicinal
product subject to medical prescription.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>15.&nbsp;&nbsp;&nbsp;&nbsp; INSTRUCTIONS
ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>16.&nbsp;&nbsp;&nbsp;&nbsp; INFORMATION
IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Rasitrio
300&nbsp;mg/5&nbsp;mg/25&nbsp;mg</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>OUTER CARTON OF MULTIPACK OF 98 (2 packs of 49 film-coated tablets)
- WITH BLUE BOX</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Rasitrio
300&nbsp;mg/5&nbsp;mg/25&nbsp;mg film-coated tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Aliskiren/amlodipine/hydrochlorothiazide</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each tablet
contains 300&nbsp;mg aliskiren (as aliskiren hemifumarate), 5&nbsp;mg
amlodipine (as amlodipine besylate) and 25&nbsp;mg hydrochlorothiazide.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'>Multipack
containing 98 (2<span lang=EN-GB>&nbsp;</span>packs of 49) tablets.</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#D9D9D9'>Multipack containing 98 (2&nbsp;packs of
49x1) tablets.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Oral use</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep out of the
sight and reach of children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER
SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'>Do not store above 30&deg;C.</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>Store in the
original package in order to protect from moisture.</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>10.&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>11.&nbsp;&nbsp;&nbsp;&nbsp; NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Novartis Europharm Limited</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Wimblehurst Road</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Horsham</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>West Sussex, RH12 5AB</span></p>

<p class=Smalltext120><span style='font-size:11.0pt'>United Kingdom</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>12.&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=621
 style='width:466.1pt;border-collapse:collapse'>
 <tr>
  <td width=158 valign=top style='width:1.65in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>EU/1/11/730/036</span></p>
  </td>
  <td width=463 valign=top style='width:347.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=DE-CH
  style='color:black;background:#D9D9D9'>98&nbsp;tablets (2x49, PA/Alu/PVC
  blisters)</span></p>
  </td>
 </tr>
 <tr>
  <td width=158 valign=top style='width:1.65in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  style='color:black;background:#D9D9D9'>EU/1/11/730/032</span></p>
  </td>
  <td width=463 valign=top style='width:347.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  style='color:black;background:#D9D9D9'>98&nbsp;tablets (2x49x1, PVC/PCTFE
  single-unit-dose blisters)</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>13.&nbsp;&nbsp;&nbsp;&nbsp; BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>14.&nbsp;&nbsp;&nbsp;&nbsp; GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Medicinal
product subject to medical prescription.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>15.&nbsp;&nbsp;&nbsp;&nbsp; INSTRUCTIONS
ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>16.&nbsp;&nbsp;&nbsp;&nbsp; INFORMATION
IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Rasitrio
300&nbsp;mg/5&nbsp;mg/25&nbsp;mg</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr style='height:39.25pt'>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:39.25pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><b><span lang=EN-GB>MINIMUM
  PARTICULARS TO APPEAR ON BLISTERS OR STRIPS</span></b></p>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><b><span lang=EN-GB>BLISTERS
  (PVC/PCTFE OR PA/Alu/PVC)</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
  OF THE MEDICINAL PRODUCT</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Rasitrio
300&nbsp;mg/5&nbsp;mg/25&nbsp;mg film-coated tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Aliskiren/amlodipine/hydrochlorothiazide</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
  OF THE MARKETING AUTHORISATION HOLDER</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Novartis
Europharm Limited</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
  DATE</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; BATCH
  NUMBER</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr style='height:39.25pt'>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:39.25pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><b><span lang=EN-GB>MINIMUM
  PARTICULARS TO APPEAR ON BLISTERS OR STRIPS</span></b></p>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><b><span lang=EN-GB>BLISTERS
  (CALENDAR) (PVC/PCTFE OR PA/Alu/PVC)</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
  OF THE MEDICINAL PRODUCT</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Rasitrio
300&nbsp;mg/5&nbsp;mg/25&nbsp;mg film-coated tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Aliskiren/amlodipine/hydrochlorothiazide</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
  OF THE MARKETING AUTHORISATION HOLDER</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Novartis
Europharm Limited</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
  DATE</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; BATCH
  NUMBER</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Monday</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tuesday</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Wednesday</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Thursday</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Friday</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Saturday</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sunday</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>CARTON OF SINGLE PACK/CARTON OF UNIT PACK (perforated unit dose
blister)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Rasitrio
300&nbsp;mg/10&nbsp;mg/12.5&nbsp;mg film-coated tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Aliskiren/amlodipine/hydrochlorothiazide</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each tablet
contains 300&nbsp;mg aliskiren (as aliskiren hemifumarate), 10&nbsp;mg
amlodipine (as amlodipine besylate) and 12.5&nbsp;mg hydrochlorothiazide.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:#D9D9D9'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#D9D9D9'>Film-coated tablets</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>14&nbsp;tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#D9D9D9'>28&nbsp;tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#D9D9D9'>30&nbsp;tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#D9D9D9'>56&nbsp;tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#D9D9D9'>90&nbsp;tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#D9D9D9'>98&nbsp;tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Read the package
leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Oral use</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep out of the
sight and reach of children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER
SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'>Do not store above 30&deg;C.</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>Store in the
original package in order to protect from moisture.</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>10.&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>11.&nbsp;&nbsp;&nbsp;&nbsp; NAME AND
ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=Smalltext120 style='page-break-after:avoid'><span style='font-size:
11.0pt'>Novartis Europharm Limited</span></p>

<p class=Smalltext120 style='page-break-after:avoid'><span style='font-size:
11.0pt'>Wimblehurst Road</span></p>

<p class=Smalltext120 style='page-break-after:avoid'><span style='font-size:
11.0pt'>Horsham</span></p>

<p class=Smalltext120 style='page-break-after:avoid'><span style='font-size:
11.0pt'>West Sussex, RH12 5AB</span></p>

<p class=Smalltext120><span style='font-size:11.0pt'>United Kingdom</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>12.&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'>&nbsp;</p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=621
 style='width:466.1pt;border-collapse:collapse'>
 <tr>
  <td width=158 valign=top style='width:1.65in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>EU/1/11/730/037</p>
  </td>
  <td width=463 valign=top style='width:347.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=FR style='color:black;background:#D9D9D9'>14&nbsp;tablets (PVC/PCTFE
  blisters)</span></p>
  </td>
 </tr>
 <tr>
  <td width=158 valign=top style='width:1.65in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=FR style='color:black;background:#D9D9D9'>EU/1/11/730/045</span></p>
  </td>
  <td width=463 valign=top style='width:347.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=FR style='color:black;background:#D9D9D9'>14&nbsp;tablets (PA/Alu/PVC
  blisters)</span></p>
  </td>
 </tr>
 <tr>
  <td width=158 valign=top style='width:1.65in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=FR style='color:black;background:#D9D9D9'>EU/1/11/730/038</span></p>
  </td>
  <td width=463 valign=top style='width:347.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=FR style='color:black;background:#D9D9D9'>28&nbsp;tablets (PVC/PCTFE
  blisters)</span></p>
  </td>
 </tr>
 <tr>
  <td width=158 valign=top style='width:1.65in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=FR style='color:black;background:#D9D9D9'>EU/1/11/730/046</span></p>
  </td>
  <td width=463 valign=top style='width:347.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=FR style='color:black;background:#D9D9D9'>28&nbsp;tablets (PA/Alu/PVC
  blisters)</span></p>
  </td>
 </tr>
 <tr>
  <td width=158 valign=top style='width:1.65in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  style='color:black;background:#D9D9D9'>EU/1/11/730/039</span></p>
  </td>
  <td width=463 valign=top style='width:347.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  style='color:black;background:#D9D9D9'>30</span><span lang=EN-GB
  style='color:black;background:#D9D9D9'>&nbsp;tablets (</span><span lang=FR
  style='color:black;background:#D9D9D9'>PVC/PCTFE </span><span lang=EN-GB
  style='color:black;background:#D9D9D9'>blisters)</span></p>
  </td>
 </tr>
 <tr>
  <td width=158 valign=top style='width:1.65in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  style='color:black;background:#D9D9D9'>EU/1/11/730/040</span></p>
  </td>
  <td width=463 valign=top style='width:347.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  style='color:black;background:#D9D9D9'>56</span><span lang=EN-GB
  style='color:black;background:#D9D9D9'>&nbsp;tablets (</span><span lang=FR
  style='color:black;background:#D9D9D9'>PVC/PCTFE </span><span lang=EN-GB
  style='color:black;background:#D9D9D9'>blisters)</span></p>
  </td>
 </tr>
 <tr>
  <td width=158 valign=top style='width:1.65in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  style='color:black;background:#D9D9D9'>EU/1/11/730/047</span></p>
  </td>
  <td width=463 valign=top style='width:347.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=FR style='color:black;background:#D9D9D9'>56&nbsp;tablets (PA/Alu/PVC
  blisters)</span></p>
  </td>
 </tr>
 <tr>
  <td width=158 valign=top style='width:1.65in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  style='color:black;background:#D9D9D9'>EU/1/11/730/043</span></p>
  </td>
  <td width=463 valign=top style='width:347.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  style='color:black;background:#D9D9D9'>56</span><span lang=EN-GB
  style='color:black;background:#D9D9D9'>&nbsp;tablets (</span><span lang=FR
  style='color:black;background:#D9D9D9'>PVC/PCTFE </span><span lang=EN-GB
  style='color:black;background:#D9D9D9'>single-unit-dose blisters)</span></p>
  </td>
 </tr>
 <tr>
  <td width=158 valign=top style='width:1.65in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  style='color:black;background:#D9D9D9'>EU/1/11/730/041</span></p>
  </td>
  <td width=463 valign=top style='width:347.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  style='color:black;background:#D9D9D9'>90</span><span lang=EN-GB
  style='color:black;background:#D9D9D9'>&nbsp;tablets (</span><span lang=FR
  style='color:black;background:#D9D9D9'>PVC/PCTFE </span><span lang=EN-GB
  style='color:black;background:#D9D9D9'>blisters)</span></p>
  </td>
 </tr>
 <tr>
  <td width=158 valign=top style='width:1.65in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span style='color:black;
  background:#D9D9D9'>EU/1/11/730/042</span></p>
  </td>
  <td width=463 valign=top style='width:347.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span style='color:black;
  background:#D9D9D9'>98</span><span lang=EN-GB style='color:black;background:
  #D9D9D9'>&nbsp;tablets (</span><span lang=FR style='color:black;background:
  #D9D9D9'>PVC/PCTFE </span><span lang=EN-GB style='color:black;background:
  #D9D9D9'>blisters)</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>13.&nbsp;&nbsp;&nbsp;&nbsp; BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>14.&nbsp;&nbsp;&nbsp;&nbsp; GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Medicinal
product subject to medical prescription.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>15.&nbsp;&nbsp;&nbsp;&nbsp; INSTRUCTIONS
ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>16.&nbsp;&nbsp;&nbsp;&nbsp; INFORMATION
IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Rasitrio
300&nbsp;mg/10&nbsp;mg/12.5&nbsp;mg</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>INTERMEDIATE CARTON OF MULTIPACK OF 98 (2&nbsp;packs of
49&nbsp;film-coated tablets) </span></b><span lang=EN-GB>-<b> WITHOUT BLUE BOX</b></span></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Rasitrio
300&nbsp;mg/10&nbsp;mg/12.5&nbsp;mg film-coated tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Aliskiren/amlodipine/hydrochlorothiazide</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each tablet
contains 300&nbsp;mg aliskiren (as aliskiren hemifumarate), 10&nbsp;mg
amlodipine (as amlodipine besylate) and 12.5&nbsp;mg hydrochlorothiazide.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#D9D9D9'>Film-coated tablets</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Component of a multipack comprising 2&nbsp;packs, each containing
49&nbsp;tablets.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black;background:#D9D9D9'>Component of a multipack
comprising 2&nbsp;packs, each containing 49x1&nbsp;tablet.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Not to be sold
separately.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Oral use</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep out of the
sight and reach of children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER
SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
style='background:#D9D9D9'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'>Do not store above 30&deg;C.</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>Store in the
original package in order to protect from moisture.</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>10.&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>11.&nbsp;&nbsp;&nbsp;&nbsp; NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Novartis Europharm Limited</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Wimblehurst Road</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Horsham</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>West Sussex, RH12 5AB</span></p>

<p class=Smalltext120><span style='font-size:11.0pt'>United Kingdom</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>12.&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=621
 style='width:466.1pt;border-collapse:collapse'>
 <tr>
  <td width=158 valign=top style='width:1.65in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>EU/1/11/730/048</span></p>
  </td>
  <td width=463 valign=top style='width:347.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=DE-CH
  style='color:black;background:#D9D9D9'>98&nbsp;tablets (2x49, PA/Alu/PVC
  blisters)</span></p>
  </td>
 </tr>
 <tr>
  <td width=158 valign=top style='width:1.65in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  style='color:black;background:#D9D9D9'>EU/1/11/730/044</span></p>
  </td>
  <td width=463 valign=top style='width:347.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  style='color:black;background:#D9D9D9'>98&nbsp;tablets (2x49x1, PVC/PCTFE
  single-unit-dose blisters)</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>13.&nbsp;&nbsp;&nbsp;&nbsp; BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>14.&nbsp;&nbsp;&nbsp;&nbsp; GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Medicinal
product subject to medical prescription.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>15.&nbsp;&nbsp;&nbsp;&nbsp; INSTRUCTIONS
ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>16.&nbsp;&nbsp;&nbsp;&nbsp; INFORMATION
IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Rasitrio
300&nbsp;mg/10&nbsp;mg/12.5&nbsp;mg</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>OUTER CARTON OF MULTIPACK OF 98 (2 packs of 49 film-coated tablets)
- WITH BLUE BOX</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Rasitrio
300&nbsp;mg/10&nbsp;mg/12.5&nbsp;mg film-coated tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Aliskiren/amlodipine/hydrochlorothiazide</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each tablet
contains 300&nbsp;mg aliskiren (as aliskiren hemifumarate), 10&nbsp;mg
amlodipine (as amlodipine besylate) and 12.5&nbsp;mg hydrochlorothiazide.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'>Multipack
containing 98 (2<span lang=EN-GB>&nbsp;</span>packs of 49) tablets.</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#D9D9D9'>Multipack containing 98 (2&nbsp;packs of
49x1) tablets.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Oral use</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep out of the
sight and reach of children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER
SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'>Do not store above 30&deg;C.</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>Store in the
original package in order to protect from moisture.</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>10.&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>11.&nbsp;&nbsp;&nbsp;&nbsp; NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Novartis Europharm Limited</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Wimblehurst Road</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Horsham</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>West Sussex, RH12 5AB</span></p>

<p class=Smalltext120><span style='font-size:11.0pt'>United Kingdom</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>12.&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=621
 style='width:466.1pt;border-collapse:collapse'>
 <tr>
  <td width=158 valign=top style='width:1.65in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>EU/1/11/730/048</span></p>
  </td>
  <td width=463 valign=top style='width:347.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=DE-CH
  style='color:black;background:#D9D9D9'>98&nbsp;tablets (2x49, PA/Alu/PVC
  blisters)</span></p>
  </td>
 </tr>
 <tr>
  <td width=158 valign=top style='width:1.65in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  style='color:black;background:#D9D9D9'>EU/1/11/730/044</span></p>
  </td>
  <td width=463 valign=top style='width:347.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  style='color:black;background:#D9D9D9'>98&nbsp;tablets (2x49x1, PVC/PCTFE
  single-unit-dose blisters)</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>13.&nbsp;&nbsp;&nbsp;&nbsp; BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>14.&nbsp;&nbsp;&nbsp;&nbsp; GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Medicinal
product subject to medical prescription.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>15.&nbsp;&nbsp;&nbsp;&nbsp; INSTRUCTIONS
ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>16.&nbsp;&nbsp;&nbsp;&nbsp; INFORMATION
IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Rasitrio
300&nbsp;mg/10&nbsp;mg/12.5&nbsp;mg</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr style='height:39.25pt'>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:39.25pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><b><span lang=EN-GB>MINIMUM
  PARTICULARS TO APPEAR ON BLISTERS OR STRIPS</span></b></p>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><b><span lang=EN-GB>BLISTERS
  (PVC/PCTFE OR PA/Alu/PVC)</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
  OF THE MEDICINAL PRODUCT</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Rasitrio
300&nbsp;mg/10&nbsp;mg/12.5&nbsp;mg film-coated tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Aliskiren/amlodipine/hydrochlorothiazide</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
  OF THE MARKETING AUTHORISATION HOLDER</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Novartis
Europharm Limited</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
  DATE</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; BATCH
  NUMBER</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr style='height:39.25pt'>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:39.25pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><b><span lang=EN-GB>MINIMUM
  PARTICULARS TO APPEAR ON BLISTERS OR STRIPS</span></b></p>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><b><span lang=EN-GB>BLISTERS
  (CALENDAR) (PVC/PCTFE OR PA/Alu/PVC)</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
  OF THE MEDICINAL PRODUCT</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Rasitrio
300&nbsp;mg/10&nbsp;mg/12.5&nbsp;mg film-coated tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Aliskiren/amlodipine/hydrochlorothiazide</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
  OF THE MARKETING AUTHORISATION HOLDER</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Novartis
Europharm Limited</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
  DATE</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; BATCH
  NUMBER</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Monday</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tuesday</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Wednesday</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Thursday</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Friday</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Saturday</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sunday</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>CARTON OF SINGLE PACK/CARTON OF UNIT PACK (perforated unit dose
blister)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Rasitrio
300&nbsp;mg/10&nbsp;mg/25&nbsp;mg film-coated tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Aliskiren/amlodipine/hydrochlorothiazide</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each tablet
contains 300&nbsp;mg aliskiren (as aliskiren hemifumarate), 10&nbsp;mg
amlodipine (as amlodipine besylate) and 25&nbsp;mg hydrochlorothiazide.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:#D9D9D9'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#D9D9D9'>Film-coated tablets</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>14&nbsp;tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#D9D9D9'>28&nbsp;tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#D9D9D9'>30&nbsp;tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#D9D9D9'>56&nbsp;tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#D9D9D9'>90&nbsp;tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#D9D9D9'>98&nbsp;tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Read the package
leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Oral use</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep out of the
sight and reach of children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER
SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'>Do not store above 30&deg;C.</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>Store in the
original package in order to protect from moisture.</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>10.&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>11.&nbsp;&nbsp;&nbsp;&nbsp; NAME AND
ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=Smalltext120 style='page-break-after:avoid'><span style='font-size:
11.0pt'>Novartis Europharm Limited</span></p>

<p class=Smalltext120 style='page-break-after:avoid'><span style='font-size:
11.0pt'>Wimblehurst Road</span></p>

<p class=Smalltext120 style='page-break-after:avoid'><span style='font-size:
11.0pt'>Horsham</span></p>

<p class=Smalltext120 style='page-break-after:avoid'><span style='font-size:
11.0pt'>West Sussex, RH12 5AB</span></p>

<p class=Smalltext120><span style='font-size:11.0pt'>United Kingdom</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>12.&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'>&nbsp;</p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=621
 style='width:466.1pt;border-collapse:collapse'>
 <tr>
  <td width=158 valign=top style='width:1.65in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>EU/1/11/730/049</p>
  </td>
  <td width=463 valign=top style='width:347.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=FR style='color:black;background:#D9D9D9'>14&nbsp;tablets (PVC/PCTFE
  blisters)</span></p>
  </td>
 </tr>
 <tr>
  <td width=158 valign=top style='width:1.65in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=FR style='color:black;background:#D9D9D9'>EU/1/11/730/057</span></p>
  </td>
  <td width=463 valign=top style='width:347.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=FR style='color:black;background:#D9D9D9'>14&nbsp;tablets (PA/Alu/PVC
  blisters)</span></p>
  </td>
 </tr>
 <tr>
  <td width=158 valign=top style='width:1.65in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=FR style='color:black;background:#D9D9D9'>EU/1/11/730/050</span></p>
  </td>
  <td width=463 valign=top style='width:347.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=FR style='color:black;background:#D9D9D9'>28&nbsp;tablets (PVC/PCTFE
  blisters)</span></p>
  </td>
 </tr>
 <tr>
  <td width=158 valign=top style='width:1.65in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=FR style='color:black;background:#D9D9D9'>EU/1/11/730/058</span></p>
  </td>
  <td width=463 valign=top style='width:347.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=FR style='color:black;background:#D9D9D9'>28&nbsp;tablets (PA/Alu/PVC
  blisters)</span></p>
  </td>
 </tr>
 <tr>
  <td width=158 valign=top style='width:1.65in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  style='color:black;background:#D9D9D9'>EU/1/11/730/051</span></p>
  </td>
  <td width=463 valign=top style='width:347.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  style='color:black;background:#D9D9D9'>30</span><span lang=EN-GB
  style='color:black;background:#D9D9D9'>&nbsp;tablets (</span><span lang=FR
  style='color:black;background:#D9D9D9'>PVC/PCTFE </span><span lang=EN-GB
  style='color:black;background:#D9D9D9'>blisters)</span></p>
  </td>
 </tr>
 <tr>
  <td width=158 valign=top style='width:1.65in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  style='color:black;background:#D9D9D9'>EU/1/11/730/052</span></p>
  </td>
  <td width=463 valign=top style='width:347.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  style='color:black;background:#D9D9D9'>56</span><span lang=EN-GB
  style='color:black;background:#D9D9D9'>&nbsp;tablets (</span><span lang=FR
  style='color:black;background:#D9D9D9'>PVC/PCTFE </span><span lang=EN-GB
  style='color:black;background:#D9D9D9'>blisters)</span></p>
  </td>
 </tr>
 <tr>
  <td width=158 valign=top style='width:1.65in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  style='color:black;background:#D9D9D9'>EU/1/11/730/059</span></p>
  </td>
  <td width=463 valign=top style='width:347.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=FR style='color:black;background:#D9D9D9'>56&nbsp;tablets (PA/Alu/PVC
  blisters)</span></p>
  </td>
 </tr>
 <tr>
  <td width=158 valign=top style='width:1.65in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  style='color:black;background:#D9D9D9'>EU/1/11/730/055</span></p>
  </td>
  <td width=463 valign=top style='width:347.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  style='color:black;background:#D9D9D9'>56</span><span lang=EN-GB
  style='color:black;background:#D9D9D9'>&nbsp;tablets (</span><span lang=FR
  style='color:black;background:#D9D9D9'>PVC/PCTFE </span><span lang=EN-GB
  style='color:black;background:#D9D9D9'>single-unit-dose blisters)</span></p>
  </td>
 </tr>
 <tr>
  <td width=158 valign=top style='width:1.65in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  style='color:black;background:#D9D9D9'>EU/1/11/730/053</span></p>
  </td>
  <td width=463 valign=top style='width:347.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  style='color:black;background:#D9D9D9'>90</span><span lang=EN-GB
  style='color:black;background:#D9D9D9'>&nbsp;tablets (</span><span lang=FR
  style='color:black;background:#D9D9D9'>PVC/PCTFE </span><span lang=EN-GB
  style='color:black;background:#D9D9D9'>blisters)</span></p>
  </td>
 </tr>
 <tr>
  <td width=158 valign=top style='width:1.65in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span style='color:black;
  background:#D9D9D9'>EU/1/11/730/054</span></p>
  </td>
  <td width=463 valign=top style='width:347.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span style='color:black;
  background:#D9D9D9'>98</span><span lang=EN-GB style='color:black;background:
  #D9D9D9'>&nbsp;tablets (</span><span lang=FR style='color:black;background:
  #D9D9D9'>PVC/PCTFE </span><span lang=EN-GB style='color:black;background:
  #D9D9D9'>blisters)</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>13.&nbsp;&nbsp;&nbsp;&nbsp; BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>14.&nbsp;&nbsp;&nbsp;&nbsp; GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Medicinal
product subject to medical prescription.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>15.&nbsp;&nbsp;&nbsp;&nbsp; INSTRUCTIONS
ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>16.&nbsp;&nbsp;&nbsp;&nbsp; INFORMATION
IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Rasitrio
300&nbsp;mg/10&nbsp;mg/25&nbsp;mg</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>INTERMEDIATE CARTON OF MULTIPACK OF 98 (2&nbsp;packs of
49&nbsp;film-coated tablets) </span></b><span lang=EN-GB>-<b> WITHOUT BLUE BOX</b></span></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Rasitrio
300&nbsp;mg/10&nbsp;mg/25&nbsp;mg film-coated tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Aliskiren/amlodipine/hydrochlorothiazide</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each tablet
contains 300&nbsp;mg aliskiren (as aliskiren hemifumarate), 10&nbsp;mg
amlodipine (as amlodipine besylate) and 25&nbsp;mg hydrochlorothiazide.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#D9D9D9'>Film-coated tablets</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Component of a multipack comprising 2&nbsp;packs, each containing
49&nbsp;tablets.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black;background:#D9D9D9'>Component of a multipack
comprising 2&nbsp;packs, each containing 49x1&nbsp;tablet.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Not to be sold
separately.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Oral use</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep out of the
sight and reach of children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER
SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
style='background:#D9D9D9'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'>Do not store above 30&deg;C.</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>Store in the
original package in order to protect from moisture.</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>10.&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>11.&nbsp;&nbsp;&nbsp;&nbsp; NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Novartis Europharm Limited</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Wimblehurst Road</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Horsham</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>West Sussex, RH12 5AB</span></p>

<p class=Smalltext120><span style='font-size:11.0pt'>United Kingdom</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>12.&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=621
 style='width:466.1pt;border-collapse:collapse'>
 <tr>
  <td width=158 valign=top style='width:1.65in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>EU/1/11/730/060</span></p>
  </td>
  <td width=463 valign=top style='width:347.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=DE-CH
  style='color:black;background:#D9D9D9'>98&nbsp;tablets (2x49, PA/Alu/PVC
  blisters)</span></p>
  </td>
 </tr>
 <tr>
  <td width=158 valign=top style='width:1.65in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  style='color:black;background:#D9D9D9'>EU/1/11/730/056</span></p>
  </td>
  <td width=463 valign=top style='width:347.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  style='color:black;background:#D9D9D9'>98&nbsp;tablets (2x49x1, PVC/PCTFE
  single-unit-dose blisters)</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>13.&nbsp;&nbsp;&nbsp;&nbsp; BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>14.&nbsp;&nbsp;&nbsp;&nbsp; GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Medicinal
product subject to medical prescription.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>15.&nbsp;&nbsp;&nbsp;&nbsp; INSTRUCTIONS
ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>16.&nbsp;&nbsp;&nbsp;&nbsp; INFORMATION
IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Rasitrio
300&nbsp;mg/10&nbsp;mg/25&nbsp;mg</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>OUTER CARTON OF MULTIPACK OF 98 (2 packs of 49 film-coated tablets)
- WITH BLUE BOX</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Rasitrio 300&nbsp;mg/10&nbsp;mg/25&nbsp;mg
film-coated tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Aliskiren/amlodipine/hydrochlorothiazide</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each tablet
contains 300&nbsp;mg aliskiren (as aliskiren hemifumarate), 10&nbsp;mg
amlodipine (as amlodipine besylate) and 25&nbsp;mg hydrochlorothiazide.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'>Multipack
containing 98 (2<span lang=EN-GB>&nbsp;</span>packs of 49) tablets.</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#D9D9D9'>Multipack containing 98 (2&nbsp;packs of
49x1) tablets.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Oral use</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep out of the
sight and reach of children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER
SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'>Do not store above 30&deg;C.</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>Store in the
original package in order to protect from moisture.</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>10.&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>11.&nbsp;&nbsp;&nbsp;&nbsp; NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Novartis Europharm Limited</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Wimblehurst Road</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Horsham</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>West Sussex, RH12 5AB</span></p>

<p class=Smalltext120><span style='font-size:11.0pt'>United Kingdom</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>12.&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=621
 style='width:466.1pt;border-collapse:collapse'>
 <tr>
  <td width=158 valign=top style='width:1.65in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>EU/1/11/730/060</span></p>
  </td>
  <td width=463 valign=top style='width:347.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=DE-CH
  style='color:black;background:#D9D9D9'>98&nbsp;tablets (2x49, PA/Alu/PVC
  blisters)</span></p>
  </td>
 </tr>
 <tr>
  <td width=158 valign=top style='width:1.65in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  style='color:black;background:#D9D9D9'>EU/1/11/730/056</span></p>
  </td>
  <td width=463 valign=top style='width:347.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  style='color:black;background:#D9D9D9'>98&nbsp;tablets (2x49x1, PVC/PCTFE
  single-unit-dose blisters)</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>13.&nbsp;&nbsp;&nbsp;&nbsp; BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>14.&nbsp;&nbsp;&nbsp;&nbsp; GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Medicinal
product subject to medical prescription.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>15.&nbsp;&nbsp;&nbsp;&nbsp; INSTRUCTIONS
ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>16.&nbsp;&nbsp;&nbsp;&nbsp; INFORMATION
IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Rasitrio
300&nbsp;mg/10&nbsp;mg/25&nbsp;mg</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr style='height:39.25pt'>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:39.25pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><b><span lang=EN-GB>MINIMUM
  PARTICULARS TO APPEAR ON BLISTERS OR STRIPS</span></b></p>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><b><span lang=EN-GB>BLISTERS
  (PVC/PCTFE OR PA/Alu/PVC)</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
  OF THE MEDICINAL PRODUCT</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Rasitrio
300&nbsp;mg/10&nbsp;mg/25&nbsp;mg film-coated tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Aliskiren/amlodipine/hydrochlorothiazide</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
  OF THE MARKETING AUTHORISATION HOLDER</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Novartis Europharm
Limited</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
  DATE</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; BATCH
  NUMBER</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr style='height:39.25pt'>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:39.25pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><b><span lang=EN-GB>MINIMUM
  PARTICULARS TO APPEAR ON BLISTERS OR STRIPS</span></b></p>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><b><span lang=EN-GB>BLISTERS
  (CALENDAR) (PVC/PCTFE OR PA/Alu/PVC)</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
  OF THE MEDICINAL PRODUCT</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Rasitrio
300&nbsp;mg/10&nbsp;mg/25&nbsp;mg film-coated tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Aliskiren/amlodipine/hydrochlorothiazide</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
  OF THE MARKETING AUTHORISATION HOLDER</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Novartis
Europharm Limited</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
  DATE</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; BATCH
  NUMBER</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Monday</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tuesday</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Wednesday</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Thursday</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Friday</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Saturday</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sunday</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>B. PACKAGE LEAFLET</span></b></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>Package leaflet: information for the user</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
text-autospace:none'><span lang=EN-GB>Rasitrio
150&nbsp;mg/5&nbsp;mg/12.5&nbsp;mg film-coated tablets</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>Aliskiren/amlodipine/hydrochlorothiazide</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Read all of this leaflet carefully before you start taking this
medicine because it contains important information for you.</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Keep this leaflet. You may need to read it
again.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you have any further questions, ask your
doctor or pharmacist.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>This medicine has been prescribed for you only.
Do not pass it on to others. It may harm them, even if their signs of illness
are the same as yours.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you get any side effects, talk to your doctor
or pharmacist. This includes any possible side effects not listed in this
leaflet.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>What is in this leaflet</span></b></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What Rasitrio is and what it
is used for</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What you need to know before
you take Rasitrio</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How to take Rasitrio</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Possible side effects</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How to store Rasitrio</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contents of the pack and
other information</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What Rasitrio is and what it
is used for</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>What Rasitrio is</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Rasitrio contains three active substances, called aliskiren,
amlodipine and hydrochlorothiazide. All of these substances help to control
high blood pressure (hypertension).</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span style='font-size:11.0pt;
font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>Aliskiren is a substance that
belongs to a group of medicines called renin inhibitors. These reduce the
amount of angiotensin&nbsp;II the body can make. Angiotensin&nbsp;II causes
blood vessels to tighten, which raises blood pressure. Lowering the amount of
angiotensin&nbsp;II allows the blood vessels to relax; this lowers blood
pressure.</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span style='font-size:11.0pt;
font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>Amlodipine belongs to a group of
medicines known as calcium channel blockers, which help to control high blood
pressure. Amlodipine causes blood vessels to dilate and relax; this lowers
blood pressure.</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span style='font-size:11.0pt;
font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>Hydrochlorothiazide belongs to a
group of medicines called thiazide diuretics. Hydrochlorothiazide increases
urine output, which also lowers blood pressure.</span></p>

<p class=Listlevel1 style='margin:0in;text-indent:0in'><span style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>High blood pressure increases the workload of the heart and
arteries. If this continues for a long time, it can damage the blood vessels of
the brain, heart and kidneys, and may result in a stroke, heart failure, heart
attack or kidney failure. Lowering the blood pressure to a normal level reduces
the risk of developing these disorders.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>What Rasitrio is used for</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Rasitrio is used
to treat high blood pressure </span><span lang=EN-GB>in adult patients </span>who
have their blood pressure already controlled by aliskiren, amlodipine and
hydrochlorothiazide taken as separate medicines given at the same time. These
patients may thus benefit from taking one tablet containing all three
substances<span lang=EN-GB>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What you need
to know before you take Rasitrio</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Do not take Rasitrio</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you are allergic to aliskiren, to amlodipine,
to other dihydropyridine-derived medicines (known as calcium channel blockers),
to hydrochlorothiazide, to sulphonamide-derived medicines (medicines used to
treat chest or urinary infections) or to any of the other ingredients of this
medicine (listed in section 6). If you think you may be allergic, do not take Rasitrio
and ask your doctor for advice.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have experienced the following forms of angioedema
(difficulties in breathing or swallowing, or swelling of the face, hands and
feet, eyes, lips and/or tongue):</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:56.7pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:normal;
vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>angioedema when taking aliskiren,</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:56.7pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:normal;
vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>hereditary angioedema,</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:56.7pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:normal;
vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>angioedema without any known cause.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you are more than 3&nbsp;months pregnant. (It
is also better to avoid Rasitrio in early pregnancy &#8211; see Pregnancy
section).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have serious liver problems.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span><span lang=EN-GB>if you have serious kidney problems.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span><span lang=EN-GB>if you have problems to produce urine (anuria).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span>if the level of potassium in your blood is too low despite treatment.</p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span>if the level of sodium in your blood is too low.</p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span>if the level of calcium in your blood is too high.</p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span>if you have gout (uric acid crystals in the joints).</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;vertical-align:baseline'><span lang=EN-GB>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you are taking any of the following
medicines:</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;vertical-align:baseline'><span lang=EN-GB>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>ciclosporin (a medicine used in transplantation
to prevent organ rejection or for other conditions, e.g. rheumatoid arthritis
or atopic dermatitis),</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;vertical-align:baseline'><span lang=EN-GB>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>itraconazole (a medicine used to treat fungal
infections),</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>quinidine (a medicine used to correct heart
rhythm).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;vertical-align:baseline'><span lang=EN-GB>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have diabetes mellitus or impaired kidney
function and you are treated with either of the following classes of medicines
used to treat high blood pressure:</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;vertical-align:baseline'><span lang=EN-GB>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>an &#8220;angiotensin converting enzyme
inhibitor&#8221; such as enalapril, lisinopril, ramipril etc.</span></p>

<p class=MsoNormal style='margin-left:28.35pt'>or</p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;vertical-align:baseline'><span lang=EN-GB>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>an &#8220;angiotensin II receptor blocker&#8221;
such as valsartan, telmisartan, irbesartan etc.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have a very low blood pressure.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you are suffering from shock, including
cardiogenic shock.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have a narrowing of the aortic heart
valve (aortic stenosis).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;vertical-align:baseline'><span lang=EN-GB>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have heart failure after an acute heart
attack.</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>If any of the
above applies to you, do not take Rasitrio</span></b><span lang=EN-GB> <b>and
talk to your doctor.</b></span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Warnings and precautions</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Talk to your doctor before taking Rasitrio:</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you are suffering from vomiting or diarrhoea
or if you are taking a diuretic (a medicine to increase the amount of urine you
produce).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have already experienced angioedema
(difficulties in breathing, or swallowing, or swelling of the face, hands and
feet, eyes, lips and/or tongue). If this happens, stop taking Rasitrio and
contact your doctor.</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you suffer from heart problems.</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you are on a low-salt diet.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if your urine flow has decreased markedly for 24&nbsp;hours
or more and/or if you have serious kidney problems (e.g. require dialysis),
including if you have had a kidney transplant or a narrowing or blockage of the
arteries that supply blood to your kidney.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have impaired kidney function, your
doctor will carefully consider whether Rasitrio is suitable for you and may
wish to monitor you carefully.</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you suffer from liver problems (impaired
liver function).</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have diabetes (high level of sugar in
your blood).</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have a high level of cholesterol or
triglycerides in your blood.</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you suffer from a disease called lupus
erythematosus (also called &#8220;lupus&#8221; or &#8220;SLE&#8221;).</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you suffer from allergy or asthma.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you are taking either of the following
classes of medicines used to treat high blood pressure:</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;vertical-align:baseline'><span lang=EN-GB>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>an &#8220;angiotensin converting enzyme
inhibitor&#8221; such as enalapril, lisinopril, ramipril etc.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;line-height:normal'>or</p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;vertical-align:baseline'><span lang=EN-GB>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>an &#8220;angiotensin II receptor blocker&#8221;
such as valsartan, telmisartan, irbesartan etc.</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you are 65&nbsp;years of age or older</span><span
lang=EN-GB> (see section Elderly (age 65&nbsp;years or older) below).</span></p>

<p class=MsoNormal style='margin-left:26.95pt;text-indent:-26.95pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have signs and symptoms such as abnormal
thirst, dry mouth, general weakness, drowsiness, restlessness, muscle pain or
cramps, weakness, low blood pressure, reduced urine output, nausea, vomiting,
or an abnormally fast heart beat which may indicate an excessive effect of
hydrochlorothiazide (contained in Rasitrio).</span></p>

<p class=MsoDate style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you experience skin reactions such as rash
after sun exposure.</span></p>

<p class=MsoDate style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you experience a decrease in vision or eye
pain. These could be symptoms of an increase of pressure in your eye and can
happen within hours to weeks of taking Rasitrio. This can lead to permanent
vision impairment, if not treated.</span></p>

<p class=MsoNormal style='margin-left:26.95pt;text-indent:-26.95pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have renal artery stenosis (narrowing of
the blood vessels to one or both kidneys).</span></p>

<p class=MsoNormal style='margin-left:26.95pt;text-indent:-26.95pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have serious congestive heart failure (a
type of heart disease where the heart cannot pump enough blood around the body.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>You must tell your doctor if you think you
are (or might become) pregnant. Rasitrio is not recommended in early pregnancy,
and must not be taken if you are more than 3&nbsp;months pregnant, as it may
cause serious harm to your baby if used at that stage (see Pregnancy section).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Children and adolescents</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The use of Rasitrio
in children and adolescents up to 18&nbsp;years of age is not recommended.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Elderly</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>You should tell your doctor if you are 65&nbsp;years of age or older
because you may be more susceptible to side effects related to low blood
pressure (see section 4 on possible side effects). Your doctor will carefully
consider whether Rasitrio is suitable for you. If you are 75&nbsp;years of age
or older, your doctor may wish to monitor your blood pressure more frequently.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>In the majority of </span><span lang=EN-GB>patients aged
65&nbsp;years or older</span><span lang=EN-GB>, the 300&nbsp;mg dose of
aliskiren shows no additional benefit in reducing blood pressure compared to
the </span><span lang=EN-GB>150&nbsp;mg dose.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Other medicines and Rasitrio</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Tell your doctor or pharmacist if you are taking, have recently
taken or might take any other medicines.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Do not take Rasitrio and talk to your doctor if you are taking any
of the following medicines:</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>ciclosporin (a medicine used in transplantation
to prevent organ rejection and also in other conditions, e.g. rheumatoid
arthritis or atopic dermatitis).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>itraconazole (a medicine used to treat fungal
infections).</span></p>

<p class=MsoListParagraph style='margin-top:0in;margin-right:-.1pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>quinidine (a medicine used to correct heart
rhythm).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>one of the following classes of medicines used
to treat high blood pressure if you have diabetes mellitus or impaired kidney
function:</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;vertical-align:baseline'><span lang=EN-GB>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>an &#8220;angiotensin converting enzyme inhibitor&#8221;
such as enalapril, lisinopril, ramipril etc.</span></p>

<p class=MsoNormal style='text-indent:28.35pt'>or</p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;vertical-align:baseline'><span lang=EN-GB>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>an &#8220;angiotensin II receptor blocker&#8221;
such as valsartan, telmisartan, irbesartan etc.</span></p>

<p class=MsoListParagraph style='margin-top:0in;margin-right:-.1pt;margin-bottom:
0in;margin-left:0in;margin-bottom:.0001pt;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><b><span lang=EN-GB>Tell your doctor if you are using the following
medicines:</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>medicines or substances that increase the amount
of potassium in your blood. These include potassium supplements or salt
substitutes containing potassium, potassium-sparing medicines and heparin.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>medicines that may reduce the amount of
potassium in your blood, such as diuretics (water tablets), corticosteroids, laxatives,
carbenoxolone, amphotericin or penicillin G.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>medicines to reduce blood pressure, including
methyldopa.</span></p>

<p class=MsoDate style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>medicines to increase blood pressure, such as
noradrenaline or adrenaline.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>medicines that may induce &#8220;<i>torsades de
pointes</i>&#8221; (irregular heart beat), such as antiarrhythmics (medicines
used to treat heart problems) and some antipsychotics.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>ketonazole, a medicine used to treat fungal
infections.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>verapamil, a medicine used to lower high blood
pressure, to correct heart rhythm or to treat angina pectoris.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span>clarithromycin, telithromycin, erythromycin which are antibiotics used
to treat infections.</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span>amiodarone, a medicine used to treat abnormal heart rhythms.</p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>atorvastatin, a medicine used to treat high
cholesterol.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>furosemide, a medicine belonging to the type
known as diuretics, which is used to increase the amount of urine you produce
and is also used to treat a certain kind of heart problem (heart failure) or
oedema (swelling).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>medicines that may reduce the amount of sodium
in your blood, such as antidepressants, antipsychotics, antiepileptics
(carbamazepine).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>rifampicin, </span>a medicine used to prevent or
treat infections.</p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>St. John&#8217;s wort <i>(hypericum perforatum)</i>,
</span>a herbal medicine used to elevate mood<span lang=EN-GB>.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>pain killers such as non-steroidal
anti-inflammatory agents (NSAIDs), including selective cyclooxygenase-2
inhibitors (Cox-2 inhibitors) (used especially in the patients over 65&nbsp;years
old).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span>diltiazem, a medicine used to treat heart problems.</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span>ritonavir, a medicine used to treat viral infection.</p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>lithium (a medicine used to treat some types of
depression).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>some laxatives.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>medicines for the treatment of gout, such as
allopurinol.</span></p>

<p class=MsoDate style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>digoxin or other digitalis glycosides (medicines
used to treat heart problems).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>vitamin D and calcium salts.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>one of the following classes of medicines used
to treat high blood pressure:</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:10.35pt;margin-bottom:.0001pt;text-indent:.25in'><span lang=EN-GB>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; an
&#8220;angiotensin converting enzyme inhibitor&#8221; such as enalapril,
lisinopril, ramipril etc.</span></p>

<p class=MsoNormal style='text-indent:28.35pt'>or</p>

<p class=MsoNormal style='text-indent:28.35pt'>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <span
lang=EN-GB>an &#8220;angiotensin II receptor blocker&#8221; such as valsartan, telmisartan,
irbesartan etc.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>medicines used to control heart rhythm.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>medicines for the treatment of diabetes (oral
agents such as metformin or insulins).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>medicines that may increase blood sugar level,
such as beta blockers and diazoxide.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>steroids.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>cytotoxic medicines (used to treat cancer),</span><span
lang=EN-GB> such as methotrexate or cyclophosphamide</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>arthritis medicines.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>medicines used to treat oesophageal ulceration
and inflammation (e.g. carbenoxolone).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>muscle relaxants </span><span lang=EN-GB>(medicines
to relax the muscles which are used during operations).</span></p>

<p class=MsoDate style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>amantadine (a medicine used to treat
Parkinson&#8217;s disease, also used to treat or prevent certain illnesses
caused by viruses).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>anticholinergic </span><span
class=MsoCommentReference><span lang=EN-GB>agents</span></span><span
lang=EN-GB> (medicines used to treat a variety of disorders such as
gastrointestinal cramps, urinary bladder spasm, asthma, motion sickness,
muscular spasms, Parkinson&#8217;s disease and as an aid to anaesthesia).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>cholestyramine, colestipol or other resins
(substances used mainly to treat high levels of lipids in the blood).</span></p>

<p class=MsoDate style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>alcohol, sleeping pills and anaesthetics
(medicines allowing patients to undergo surgery and other procedures).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>iodine contrast media (agents used for imaging
examinations).</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Your doctor may need to change your dose and/or take other
precautions if you are taking one of the following medicines:</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB style='font-family:"Arial",sans-serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>furosemide, a medicine belonging to the type
known as diuretics, which is used to increase the amount of urine you produce
and is also used to treat a certain kind of heart problem (heart failure) or
oedema (swelling).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB style='font-family:"Arial",sans-serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>some medicines used to treat infections, such as
ketoconazole, amphotericin or penicillin G.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Rasitrio with food and drink</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>You should take this medicine with a light meal once a day,
preferably at the same time each day. You should not take this medicine with
grapefruit juice.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Due to hydrochlorothiazide contained in Rasitrio, if you drink
alcohol while on treatment with this medicine, you may have an increased
feeling of dizziness on standing up, especially when getting up from a sitting
position.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Pregnancy</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not take this
medicine if you are pregnant (see section Do not take Rasitrio). If you become
pregnant while taking this medicine stop taking it immediately and talk to your
doctor. If you think you may be pregnant or are planning to have a baby, ask
your doctor or pharmacist for advice before taking this medicine. Your doctor
will normally advise you to stop taking Rasitrio before you become pregnant and
will advise you to take another medicine instead of Rasitrio. Rasitrio is not
recommended in early pregnancy, and must not be taken when more than
3&nbsp;months pregnant, as it may cause serious harm to your baby if it is used
after the third month of pregnancy.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Breast-feeding</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tell your doctor
if you are breast-feeding or about to start breast-feeding.</span> Rasitrio is
not recommended for mothers who are breast-feeding, and your doctor may choose
another treatment for you if you wish to breast-feed.</p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Driving and using machines</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>This medicine
<span lang=EN-GB>may make you feel dizzy and drowsy. If you experience this
symptom, do not drive or use tools or machines.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>&nbsp;</p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How to take Rasitrio</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Always take this medicine exactly as your doctor has told you and do
not exceed the recommended dose. Check with your doctor or pharmacist if you
are not sure.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The usual dose of Rasitrio is one tablet a day.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>Method of administration</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Swallow the tablet whole with some water. You should take this
medicine with a light meal once a day, preferably at the same time each day. You
should not take this medicine together with grapefruit juice.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>If you take more Rasitrio than you should</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If you have
accidentally taken too many Rasitrio tablets, talk to a doctor immediately. You
may require medical attention.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>If you forget to take Rasitrio</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>If you forget to take a dose of this medicine, take it as soon as
you remember and then take the next dose at its usual time. If it is almost
time for your next dose you should simply take the next tablet at the usual
time. <b>Do not </b>take a double dose (two tablets at once) to make up for a
forgotten tablet.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Do not stop taking this medicine</span></b><span lang=EN-GB>, even
if you are feeling well (unless your doctor tells you to do so).</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>People who have high blood pressure often do not notice any signs of
the problem. Many may feel quite normal. It is very important that you take
this medicine exactly as your doctor tells you to get the best results and
reduce the risk of side effects. Keep your appointments with the doctor even if
you are feeling well.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>If you have any further questions on the use of this medicine, ask
your doctor or pharmacist.</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Possible
side effects</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>Like all medicines, this medicine can cause side effects, although
not everybody gets them.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.4pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>Side effects reported for Rasitrio are:</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>Common</span></b><span lang=EN-GB> <i>(may affect up
to 1 in 10&nbsp;people)</i></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>dizziness</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>low blood pressure</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>swelling of hands, ankles and feet (peripheral
oedema).</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><b><span
lang=EN-GB>Tell your doctor immediately if you experience the following at the
beginning of your treatment:</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Fainting and/or
light-headedness linked to low blood pressure could occur at the beginning of
treatment with Rasitrio. </span><span lang=EN-GB>Patients 65&nbsp;years of age
or older are more susceptible to side effects related to low blood pressure. In
clinical trials low blood pressure occurred more frequently in patients taking
Rasitrio than those taking only dual combinations of aliskiren/amlodipine,
aliskiren/hydrochlorothiazide or amlodipine/hydrochlorothiazide (see section 2).</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The following, possibly serious, side effects have been reported
with medicines containing aliskiren, amlodipine or hydrochlorothiazide alone.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><u><span lang=EN-GB>Aliskiren</span></u></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Some side effects can be serious (frequency not known):</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>A few patients have experienced these serious side effects </span><i><span
lang=EN-GB>(</span></i><i><span lang=EN-GB>may affect up to 1 in
1,000&nbsp;people</span></i><i><span lang=EN-GB>)</span></i><span lang=EN-GB>. <b>If
any of the following occur,</b> <b>tell your doctor straight away:</b></span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Severe allergic reaction with symptoms such as
rash, itching, swelling of face or lips or tongue, difficulty breathing,
dizziness.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Nausea, loss of appetite, dark coloured urine or
yellowing of skin and eyes (signs of liver disorder).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB>Possible side effects</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>Common </span></b><i><span lang=EN-GB>(may affect up to 1 in
10&nbsp;people)</span></i></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>diarrhoea</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>joint pain (arthralgia)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>high level of potassium in the blood</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>dizziness.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>Uncommon</span></b><span lang=EN-GB> <i>(may affect up to 1 in 100</i></span><i><span
lang=EN-GB>&nbsp;people</span></i><i><span lang=EN-GB>)</span></i></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>skin rash (this may also be a sign of allergic
reactions or angioedema &#8211; see &#8220;Rare&#8221; side effects below)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>kidney problems including acute renal failure
(severely decreased urine output)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>swelling of hands, ankles or feet (peripheral
oedema)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>severe skin reactions (toxic epidermal
necrolysis and/or oral mucosal reactions &#8211; red skin, blistering of the
lips, eyes or mouth, skin peeling, fever)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>low blood pressure</span><span lang=EN-GB> </span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>palpitations</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>cough</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>itching, itchy rash (urticaria)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>increased liver enzymes.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>Rare</span></b><span lang=EN-GB> <i>(may affect up to 1 in
1,000&nbsp;people)</i></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>severe allergic reaction (anaphylactic reaction)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>allergic reactions (hypersensitivity)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>angioedema (the symptoms of which can include
difficulties in breathing or swallowing, rash, itching, hives or swelling of
the face, hands and feet, eyes, lips and/or tongue, dizziness)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>increased level of creatinine in the blood</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>red skin (erythema).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><u><span lang=EN-GB>Amlodipine</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>In patients taking amlodipine alone, the following have
been reported:</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;vertical-align:
baseline'><b><span lang=EN-GB>Common</span></b><span lang=EN-GB> </span><i><span
lang=EN-GB>(may affect up to 1 in 10&nbsp;people)</span></i></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>sleepiness</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>dizziness</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>headache (especially at the beginning of
treatment)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>hot flushes</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>abdominal pain</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>nausea</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>ankle swelling</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>swelling</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>tiredness</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>palpitations (awareness of your heart beat).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;vertical-align:
baseline'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;vertical-align:
baseline'><b><span lang=EN-GB>Uncommon</span></b><span lang=EN-GB> <i>(may affect
up to 1 in 100&nbsp;people)</i></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>insomnia</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>mood changes (including anxiety)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>depression</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>trembling</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>disturbed sense of taste</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>sudden, temporary loss of consciousness</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>decreased skin sensitivity</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>tingling or numbness</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>vision disorder (including double vision)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>ringing noise in ears</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>low blood pressure</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>breathlessness</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>runny nose</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>vomiting</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>stomach discomfort after meal</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>altered bowel habits (including diarrhoea and
constipation)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>dry mouth</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>hair loss</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>purple skin patches</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>skin discolouration</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>excessive sweating</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>itching; rash</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>generalised rash</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>joint pain</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>muscle pain</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>muscle cramps</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>back pain</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>urination disorders</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>urination at night</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>frequent urination</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>impotence</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>breast enlargement in men</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>chest pain</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>weakness</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>pain</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>feeling unwell</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>weight increase</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>weight decrease.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;vertical-align:
baseline'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;vertical-align:
baseline'><b><span lang=EN-GB>Rare </span></b><i><span lang=EN-GB>(may affect up
to 1 in 1,000&nbsp;people)</span></i></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>confusion.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>Very rare</span></b><span lang=EN-GB> <i>(may affect up to 1 in
10,000&nbsp;people)</i></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>low level of white blood cells and blood
platelets</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>allergic reaction with symptoms such as rash,
itching, hives, difficulty breathing or swallowing, dizziness</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>high level of sugar in the blood</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>increased muscle stiffness and inability to
stretch</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>sensation of numbness or tingling with sensation
of burning in fingers and toes</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>heart attack</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>irregular heart beat</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>inflammation of blood vessels</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>cough</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>severe upper stomach pain</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>inflammation of the gastric lining</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>bleeding, tender or enlarged gums</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>inflammation of the liver</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>liver disorder which can occur together with
yellow skin and eyes, or dark-coloured urine</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>abnormal liver function test</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>angioedema (difficulties in breathing, or
swallowing, or swelling of the face, hands and feet, eyes, lips and/or tongue)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>skin reaction with skin reddening and peeling,
blistering of lips, eyes or mouth; dry skin, rash, itchy rash</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>skin rash with flaking or peeling; rash, red
skin, blistering of the lips, eyes or mouth, skin peeling, fever</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>swelling mainly of the face and throat</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>increased sensitivity of the skin to sun.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><u><span lang=EN-GB>Hydrochlorothiazide</span></u></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>In patients
taking hydrochlorothiazide alone, the following have been reported, however the
frequency cannot be estimated from the available data:</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
lang=EN-GB>Very common</span></b><span lang=EN-GB> <i>(may affect more than 1
in 10&nbsp;people)</i></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;text-autospace:none'><span lang=EN-GB
style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>low level of potassium in the blood</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;text-autospace:none'><span lang=EN-GB
style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>increase of lipids in the blood.</span></p>

<p class=MsoDate><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoDate><b><span lang=EN-GB>Common</span></b><span lang=EN-GB> <i>(may
affect up to 1 in 10&nbsp;people)</i></span></p>

<p class=MsoDate style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>high level of uric acid in the blood</span></p>

<p class=MsoDate style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>low level of magnesium in the blood</span></p>

<p class=MsoDate style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>low level of sodium in the blood</span></p>

<p class=MsoDate style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>dizziness, fainting on standing up</span></p>

<p class=MsoDate style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>reduced appetite</span></p>

<p class=MsoDate style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>nausea and vomiting</span></p>

<p class=MsoDate style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>itchy rash and other types of rash</span></p>

<p class=MsoDate style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>inability to achieve or maintain erection.</span></p>

<p class=MsoNormal style='text-autospace:none'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
lang=EN-GB>Rare</span></b><span lang=EN-GB> <i>(may affect up to 1 in
1,000&nbsp;people)</i></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;text-autospace:none'><span lang=EN-GB
style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>low level of blood platelets (sometimes with
bleeding or bruising underneath the skin)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>high level of calcium in the blood</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>high level of sugar in the blood</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>worsening of the diabetic metabolic state</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>sad mood (depression)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>sleep disturbances</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>dizziness</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>headache</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>tingling or numbness</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>vision disorder</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>irregular heart beat</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>abdominal discomfort</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>constipation</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>diarrhoea</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>liver disorders which can occur together with
yellow skin and eyes</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>increased sensitivity of skin to the sun</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>sugar in the urine.</span></p>

<p class=MsoNormal style='text-autospace:none'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
lang=EN-GB>Very rare</span></b><span lang=EN-GB> <i>(may affect up to 1&nbsp;in
10,000&nbsp;people)</i></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;text-autospace:none'><span lang=EN-GB
style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>fever, sore throat or mouth ulcers, more
frequent infections (lack or low level of white blood cells)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>pale skin, tiredness, breathlessness,
dark-coloured urine (haemolytic anaemia)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>rash, itching, hives, difficulty breathing or
swallowing, dizziness (hypersensitivity reactions)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>confusion, tiredness, muscle twitching and
spasm, rapid breathing (hypochloraemic alkalosis)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>difficulty breathing with fever, coughing,
wheezing, breathlessness (respiratory distress including pneumonitis and
pulmonary oedema)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>severe upper stomach pain (pancreatitis)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>facial rash, joint pain, muscle disorder, fever
(lupus erythematosus)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>inflammation of blood vessels with symptoms such
as<i> </i>rash, purplish-red spots, fever (vasculitis)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>severe skin disease that causes rash, red skin,
blistering of the lips, eyes or mouth, skin peeling, fever (toxic epidermal
necrolysis).</span></p>

<p class=MsoNormal style='text-autospace:none'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>Not known</span></b><span
lang=EN-GB> <i>(frequency cannot be estimated from the available data)</i></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>weakness</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>bruising and frequent infections (aplastic
anaemia)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>decrease in vision or pain in your eyes due to
high pressure (possible signs of acute-angle closure glaucoma)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>severe skin disease that causes rash, red skin,
blistering of the lips, eyes or mouth, skin peeling, fever (erythema
multiforme)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>muscle spasm</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>severely decreased urine output (possible signs
of renal disorder or renal failure), weakness (asthenia)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>fever.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>If any of these affect you severely, tell your doctor. You may need
to stop Rasitrio.</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>If you get any side effects, </span><span lang=EN-GB>talk to your
doctor or pharmacist.</span><span lang=EN-GB> This includes any possible side
effects not listed in this leaflet</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How
to store Rasitrio</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Keep this medicine out of the sight and reach of children.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Do not use this medicine after the expiry date which is stated on
the carton and blister after &#8220;EXP&#8221;. The expiry date refers to the
last day of that month.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not store
above 30&deg;C.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Store Rasitrio
tablets in the original package in order to protect from moisture and light.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not throw
away any medicines via wastewater or household waste. Ask your pharmacist how
to throw away medicines you no longer use. These measures will help protect the
environment.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contents of the pack and
other information</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>What </span></b><b><span lang=EN-GB>Rasitrio contains</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Each Rasitrio 150&nbsp;mg/5&nbsp;mg/12.5&nbsp;mg
film-coated tablet contains 150&nbsp;mg aliskiren (as hemifumarate), 5&nbsp;mg
amlodipine (as besylate) and 12.5&nbsp;mg hydrochlorothiazide. The other
ingredients are </span><span lang=EN-GB>cellulose microcrystalline, crospovidone,
povidone, magnesium stearate, silica colloidal anhydrous, hypromellose,
titanium dioxide (E171), macrogol, talc, iron oxide red (E172), iron oxide
black (E172).</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>What Rasitrio looks like and contents of the pack</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Rasitrio 150&nbsp;mg/5&nbsp;mg/12.5&nbsp;mg
film-coated tablets are violet white, oval tablets, with &#8220;YIY&#8221;
debossed on one side and &#8220;NVR&#8221; on the other.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>Rasitrio </span>is available in packs containing 14,
28, 56, 98&nbsp;tablets in calendar blisters.</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'>It is also
available in multi-packs of <span lang=EN-GB>98&nbsp;tablets (2&nbsp;packs of
49) in calendar blisters.</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>Rasitrio </span>is available in packs containing<span
lang=EN-GB> 30 or 90&nbsp;tablets in blisters.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Rasitrio is available in packs containing 56x1&nbsp;tablet in
perforated unit dose blister.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>It is also available in multi-packs of 98x1&nbsp;tablet
(2&nbsp;packs of 49x1) in perforated unit dose blister.</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Not all pack sizes may be available in your country.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Marketing Authorisation Holder</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'>Novartis Europharm Limited</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'>Wimblehurst Road</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'>Horsham</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'>West Sussex, RH12 5AB</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>United
Kingdom</p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Manufacturer</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Novartis Farma S.p.A.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=IT>Via Provinciale Schito 131</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=IT>I-80058 Torre Annunziata/NA</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Italy</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>For any information about this medicine, please contact the local
representative of the Marketing Authorisation Holder:</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'>&nbsp;</p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=624
 style='margin-left:-1.7pt;border-collapse:collapse'>
 <tr>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=FR-BE>Belgi&euml;/Belgique/Belgien</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR-BE>Novartis
  Pharma N.V.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR-BE>T&eacute;l/Tel:
  +32 2 246 16 11</span></p>
  <p class=MsoNormal style='margin-right:1.7pt;line-height:normal'><span
  lang=FR>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=LT>Lietuva</span></b></p>
  <p class=MsoNormal style='margin-right:-22.45pt;line-height:normal'><span
  lang=LT>Novartis Pharma Services Inc.</span></p>
  <p class=MsoNormal style='margin-right:-22.45pt;line-height:normal'><span
  lang=LT>Tel: +370 5 269 16 50</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=IT>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR>Novartis Pharma
  Services Inc.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&#1058;&#1077;&#1083;.:
  +359 2 489 98 28</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=NO-BOK>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=DE-CH>Luxembourg/Luxemburg</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE-CH>Novartis
  Pharma N.V.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR-BE>T&eacute;l/Tel:
  +32 2 246 16 11</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=NO-BOK>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=NO-BOK>&#268;esk&aacute;
  republika</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=NO-BOK>Novartis
  s.r.o.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE-CH>Tel: +420 225
  775 111</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE-CH>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=HU>Magyarorsz&aacute;g</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=HU>Novartis
  Hung&aacute;ria Kft. Pharma</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=HU>Tel.: +36 1 457
  65 00</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b>Danmark</b></p>
  <p class=MsoNormal style='line-height:normal'>Novartis Healthcare A/S</p>
  <p class=MsoNormal style='line-height:normal'>Tlf: +45 39 16 84 00</p>
  <p class=MsoNormal style='line-height:normal'>&nbsp;</p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=MT>Malta</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=MT>Novartis Pharma
  Services Inc.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=MT>Tel: +</span>356 <span
  lang=EN-GB>2122 2872</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=DE>Deutschland</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE>Novartis Pharma
  GmbH</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE>Tel: +49 911 273
  0</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=NL>Nederland</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=NL>Novartis Pharma
  B.V.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=NL>Tel: +31 26 37 82
  111</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=ET>Eesti</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=ET>Novartis Pharma
  Services Inc.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=ET>Tel: +372 </span><span
  lang=EN-GB>66 30 810</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=ET>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=NO-BOK>Norge</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=NO-BOK>Novartis
  Norge AS</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=NO-BOK>Tlf: +47 23
  05 20 00</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EL>&#917;&#955;&#955;&#940;&#948;&#945;</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=ET>Novartis (Hellas)
  A.E.B.E.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EL>&#932;&#951;&#955;</span><span
  lang=ET>: +30 210 281 17 12</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=ET>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=DE-AT>&Ouml;sterreich</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE-AT>Novartis
  Pharma GmbH</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE-AT>Tel: +43 1 86
  6570</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=ES>Espa&ntilde;a</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=ES>Novartis
  Farmac&eacute;utica, S.A.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=ES>Tel: +34 93 306
  42 00</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=ES>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoHeading7 align=left style='text-align:left;line-height:normal;
  page-break-after:auto'><b><span lang=PL style='font-style:normal'>Polska</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=PL>Novartis Poland
  Sp. z o.o.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=PL>Tel.: +48 22 375
  4888</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=FR>France</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR>Novartis Pharma
  S.A.S.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR>T&eacute;l: +33 1
  55 47 66 00</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=FR>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=PT>Portugal</span></b></p>
  <p class=Text style='margin-bottom:0in;line-height:normal'><span lang=PT-BR>Novartis
  Farma - Produtos Farmac&ecirc;uticos, S.A.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=PT>Tel: +351 21 000
  8600</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Hrvatska</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Novartis Hrvatska d.o.o.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel. +385 1 6274 220</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=IT>Rom&acirc;nia</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=IT>Novartis Pharma
  Services Romania SRL</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=IT>Tel: +40 21 31299
  01</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Ireland</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Novartis
  Ireland Limited</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: +353 1
  260 12 55</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=SL>Slovenija</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=SL>Novartis Pharma
  Services Inc.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=SL>Tel: +386 1 300
  75 50</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=IS>&Iacute;sland</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=IS>Vistor hf.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=IT>S</span><span
  lang=CS>&iacute;</span><span lang=IT>mi</span><span lang=IS>: +354 535 7000</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=IT>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=SK>Slovensk&aacute;
  republika</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=SK>Novartis Slovakia
  s.r.o.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=SK>Tel: +421 2 5542
  5439</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=SK>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=PT-BR>Italia</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=PT-BR>Novartis Farma
  S.p.A.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=IT>Tel: +39 02 96 54
  1</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=SV>Suomi/Finland</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=SV>Novartis Finland
  Oy</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=SV>Puh/Tel: </span><span
  lang=DE-CH>+358 (0)10 6133 200</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=SV>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EL>&#922;&#973;&#960;&#961;&#959;&#962;</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR>Novartis Pharma
  Services Inc.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EL>&#932;&#951;&#955;:
  +357 22 690 690</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EL>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=SV>Sverige</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=SV>Novartis Sverige
  AB</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=SV>Tel: +46 8 732 32
  00</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=FI>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=LV>Latvija</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=LV>Novartis Pharma
  Services Inc.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=LV>Tel: +371 67 887
  070</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EL>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>United
  Kingdom</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Novartis</span><span
  lang=EN-GB> </span><span lang=EN-GB>Pharmaceuticals UK Ltd.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: +44 1276
  698370</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=SV>&nbsp;</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>This leaflet
was last revised in</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Other sources
of information</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Detailed
information on this medicine is available on the European Medicines Agency
website: </span><span lang=EN-GB>http://www.ema.europa.eu</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>Package leaflet: information for the user</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>Rasitrio 300&nbsp;mg/5&nbsp;mg/12.5&nbsp;mg film-coated tablets</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>Aliskiren/amlodipine/hydrochlorothiazide</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Read all of this leaflet carefully before you start taking this
medicine because it contains important information for you.</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Keep this leaflet. You may need to read it
again.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you have any further questions, ask your
doctor or pharmacist.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>This medicine has been prescribed for you only.
Do not pass it on to others. It may harm them, even if their signs of illness
are the same as yours.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you get any side effects, talk to your doctor
or pharmacist. This includes any possible side effects not listed in this
leaflet.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>What is in this leaflet</span></b></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What Rasitrio is and what it
is used for</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What you need to know before
you take Rasitrio</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How to take Rasitrio</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Possible side effects</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How to store Rasitrio</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contents of the pack and
other information</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What Rasitrio is and what it
is used for</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>What Rasitrio is</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Rasitrio contains three active substances, called aliskiren,
amlodipine and hydrochlorothiazide. All of these substances help to control
high blood pressure (hypertension).</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span style='font-size:11.0pt;
font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>Aliskiren is a substance that
belongs to a group of medicines called renin inhibitors. These reduce the
amount of angiotensin&nbsp;II the body can make. Angiotensin&nbsp;II causes
blood vessels to tighten, which raises blood pressure. Lowering the amount of
angiotensin&nbsp;II allows the blood vessels to relax; this lowers blood pressure.</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span style='font-size:11.0pt;
font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>Amlodipine belongs to a group of
medicines known as calcium channel blockers, which help to control high blood
pressure. Amlodipine causes blood vessels to dilate and relax; this lowers
blood pressure.</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span style='font-size:11.0pt;
font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>Hydrochlorothiazide belongs to a
group of medicines called thiazide diuretics. Hydrochlorothiazide increases
urine output, which also lowers blood pressure.</span></p>

<p class=Listlevel1 style='margin:0in;text-indent:0in'><span style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>High blood pressure increases the workload of the heart and
arteries. If this continues for a long time, it can damage the blood vessels of
the brain, heart and kidneys, and may result in a stroke, heart failure, heart
attack or kidney failure. Lowering the blood pressure to a normal level reduces
the risk of developing these disorders.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>What Rasitrio is used for</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Rasitrio is used
to treat high blood pressure </span><span lang=EN-GB>in adult patients </span>who
have their blood pressure already controlled by aliskiren, amlodipine and
hydrochlorothiazide taken as separate medicines given at the same time. These
patients may thus benefit from taking one tablet containing all three
substances<span lang=EN-GB>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What you need
to know before you take Rasitrio</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Do not take Rasitrio</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you are allergic to aliskiren, to amlodipine,
to other dihydropyridine-derived medicines (known as calcium channel blockers),
to hydrochlorothiazide, to sulphonamide-derived medicines (medicines used to
treat chest or urinary infections) or to any of the other ingredients of this
medicine (listed in section 6). If you think you may be allergic, do not take
Rasitrio and ask your doctor for advice.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have experienced the following forms of
angioedema (difficulties in breathing or swallowing, or swelling of the face,
hands and feet, eyes, lips and/or tongue):</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:56.7pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:normal;
vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>angioedema when taking aliskiren,</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:56.7pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:normal;
vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>hereditary angioedema,</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:56.7pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:normal;
vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>angioedema without any known cause.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you are more than 3&nbsp;months pregnant. (It
is also better to avoid Rasitrio in early pregnancy &#8211; see Pregnancy
section).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have serious liver problems.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span><span lang=EN-GB>if you have serious kidney problems.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span><span lang=EN-GB>if you have problems to produce urine (anuria).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span>if the level of potassium in your blood is too low despite treatment.</p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span>if the level of sodium in your blood is too low.</p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span>if the level of calcium in your blood is too high.</p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span>if you have gout (uric acid crystals in the joints).</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;vertical-align:baseline'><span lang=EN-GB>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you are taking any of the following
medicines:</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;vertical-align:baseline'><span lang=EN-GB>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>ciclosporin (a medicine used in transplantation
to prevent organ rejection or for other conditions, e.g. rheumatoid arthritis
or atopic dermatitis),</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;vertical-align:baseline'><span lang=EN-GB>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>itraconazole (a medicine used to treat fungal
infections),</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>quinidine (a medicine used to correct heart
rhythm).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;vertical-align:baseline'><span lang=EN-GB>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have diabetes mellitus or impaired kidney
function and you are treated with either of the following classes of medicines
used to treat high blood pressure:</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;vertical-align:baseline'><span lang=EN-GB>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>an &#8220;angiotensin converting enzyme
inhibitor&#8221; such as enalapril, lisinopril, ramipril etc.</span></p>

<p class=MsoNormal style='margin-left:28.35pt'>or</p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;vertical-align:baseline'><span lang=EN-GB>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>an &#8220;angiotensin II receptor blocker&#8221;
such as valsartan, telmisartan, irbesartan etc.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have a very low blood pressure.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you are suffering from shock, including
cardiogenic shock.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have a narrowing of the aortic heart
valve (aortic stenosis).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;vertical-align:baseline'><span lang=EN-GB>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have heart failure after an acute heart
attack.</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>If any of the
above applies to you, do not take Rasitrio</span></b><span lang=EN-GB> <b>and
talk to your doctor.</b></span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Warnings and precautions</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Talk to your doctor before taking Rasitrio:</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you are suffering from vomiting or diarrhoea
or if you are taking a diuretic (a medicine to increase the amount of urine you
produce).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have already experienced angioedema
(difficulties in breathing, or swallowing, or swelling of the face, hands and
feet, eyes, lips and/or tongue). If this happens, stop taking Rasitrio and contact
your doctor.</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you suffer from heart problems.</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you are on a low-salt diet.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if your urine flow has decreased markedly for
24&nbsp;hours or more and/or if you have serious kidney problems (e.g. require
dialysis), including if you have had a kidney transplant or a narrowing or
blockage of the arteries that supply blood to your kidney.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have impaired kidney function, your
doctor will carefully consider whether Rasitrio is suitable for you and may
wish to monitor you carefully.</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you suffer from liver problems (impaired
liver function).</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have diabetes (high level of sugar in
your blood).</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have a high level of cholesterol or
triglycerides in your blood.</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you suffer from a disease called lupus
erythematosus (also called &#8220;lupus&#8221; or &#8220;SLE&#8221;).</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you suffer from allergy or asthma.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you are taking either of the following
classes of medicines used to treat high blood pressure:</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;vertical-align:baseline'><span lang=EN-GB>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>an &#8220;angiotensin converting enzyme
inhibitor&#8221; such as enalapril, lisinopril, ramipril etc.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;line-height:normal'>or</p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;vertical-align:baseline'><span lang=EN-GB>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>an &#8220;angiotensin II receptor blocker&#8221;
such as valsartan, telmisartan, irbesartan etc.</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you are 65&nbsp;years of age or older</span><span
lang=EN-GB> (see section Elderly (age 65&nbsp;years or older) below).</span></p>

<p class=MsoNormal style='margin-left:26.95pt;text-indent:-26.95pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have signs and symptoms such as abnormal
thirst, dry mouth, general weakness, drowsiness, restlessness, muscle pain or
cramps, weakness, low blood pressure, reduced urine output, nausea, vomiting,
or an abnormally fast heart beat which may indicate an excessive effect of
hydrochlorothiazide (contained in Rasitrio).</span></p>

<p class=MsoDate style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you experience skin reactions such as rash
after sun exposure.</span></p>

<p class=MsoDate style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you experience a decrease in vision or eye
pain. These could be symptoms of an increase of pressure in your eye and can
happen within hours to weeks of taking Rasitrio. This can lead to permanent
vision impairment, if not treated.</span></p>

<p class=MsoNormal style='margin-left:26.95pt;text-indent:-26.95pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have renal artery stenosis (narrowing of
the blood vessels to one or both kidneys).</span></p>

<p class=MsoNormal style='margin-left:26.95pt;text-indent:-26.95pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have serious congestive heart failure (a
type of heart disease where the heart cannot pump enough blood around the body.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>You must tell your doctor if you think you
are (or might become) pregnant. Rasitrio is not recommended in early pregnancy,
and must not be taken if you are more than 3&nbsp;months pregnant, as it may
cause serious harm to your baby if used at that stage (see Pregnancy section).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Children and adolescents</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The use of Rasitrio
in children and adolescents up to 18&nbsp;years of age is not recommended.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Elderly</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>You should tell your doctor if you are 65&nbsp;years of age or older
because you may be more susceptible to side effects related to low blood
pressure (see section 4 on possible side effects). Your doctor will carefully
consider whether Rasitrio is suitable for you. If you are 75&nbsp;years of age
or older, your doctor may wish to monitor your blood pressure more frequently.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>In the majority of </span><span lang=EN-GB>patients aged
65&nbsp;years or older</span><span lang=EN-GB>, the 300&nbsp;mg dose of
aliskiren shows no additional benefit in reducing blood pressure compared to
the </span><span lang=EN-GB>150&nbsp;mg dose.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Other medicines and Rasitrio</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Tell your doctor or pharmacist if you are taking, have recently
taken or might take any other medicines.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Do not take Rasitrio and talk to your doctor if you are taking any
of the following medicines:</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>ciclosporin (a medicine used in transplantation
to prevent organ rejection and also in other conditions, e.g. rheumatoid
arthritis or atopic dermatitis).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>itraconazole (a medicine used to treat fungal
infections).</span></p>

<p class=MsoListParagraph style='margin-top:0in;margin-right:-.1pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>quinidine (a medicine used to correct heart
rhythm).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>one of the following classes of medicines used
to treat high blood pressure if you have diabetes mellitus or impaired kidney
function:</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;vertical-align:baseline'><span lang=EN-GB>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>an &#8220;angiotensin converting enzyme
inhibitor&#8221; such as enalapril, lisinopril, ramipril etc.</span></p>

<p class=MsoNormal style='text-indent:28.35pt'>or</p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;vertical-align:baseline'><span lang=EN-GB>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>an &#8220;angiotensin II receptor blocker&#8221;
such as valsartan, telmisartan, irbesartan etc.</span></p>

<p class=MsoListParagraph style='margin-top:0in;margin-right:-.1pt;margin-bottom:
0in;margin-left:0in;margin-bottom:.0001pt;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><b><span lang=EN-GB>Tell your doctor if you are using the following
medicines:</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>medicines or substances that increase the amount
of potassium in your blood. These include potassium supplements or salt
substitutes containing potassium, potassium-sparing medicines and heparin.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>medicines that may reduce the amount of
potassium in your blood, such as diuretics (water tablets), corticosteroids,
laxatives, carbenoxolone, amphotericin or penicillin G.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>medicines to reduce blood pressure, including
methyldopa.</span></p>

<p class=MsoDate style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>medicines to increase blood pressure, such as
noradrenaline or adrenaline.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>medicines that may induce &#8220;<i>torsades de
pointes</i>&#8221; (irregular heart beat), such as antiarrhythmics (medicines
used to treat heart problems) and some antipsychotics.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>ketonazole, a medicine used to treat fungal
infections.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>verapamil, a medicine used to lower high blood
pressure, to correct heart rhythm or to treat angina pectoris.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span>clarithromycin, telithromycin, erythromycin which are antibiotics used
to treat infections.</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span>amiodarone, a medicine used to treat abnormal heart rhythms.</p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>atorvastatin, a medicine used to treat high
cholesterol.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>furosemide, a medicine belonging to the type
known as diuretics, which is used to increase the amount of urine you produce
and is also used to treat a certain kind of heart problem (heart failure) or
oedema (swelling).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>medicines that may reduce the amount of sodium
in your blood, such as antidepressants, antipsychotics, antiepileptics
(carbamazepine).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>rifampicin, </span>a medicine used to prevent or
treat infections.</p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>St. John&#8217;s wort <i>(hypericum perforatum)</i>,
</span>a herbal medicine used to elevate mood<span lang=EN-GB>.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>pain killers such as non-steroidal
anti-inflammatory agents (NSAIDs), including selective cyclooxygenase-2
inhibitors (Cox-2 inhibitors) (used especially in the patients over
65&nbsp;years old).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span>diltiazem, a medicine used to treat heart problems.</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span>ritonavir, a medicine used to treat viral infection.</p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>lithium (a medicine used to treat some types of
depression).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>some laxatives.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>medicines for the treatment of gout, such as
allopurinol.</span></p>

<p class=MsoDate style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>digoxin or other digitalis glycosides (medicines
used to treat heart problems).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>vitamin D and calcium salts.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>one of the following classes of medicines used
to treat high blood pressure:</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:10.35pt;margin-bottom:.0001pt;text-indent:.25in'><span lang=EN-GB>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; an
&#8220;angiotensin converting enzyme inhibitor&#8221; such as enalapril,
lisinopril, ramipril etc.</span></p>

<p class=MsoNormal style='text-indent:28.35pt'>or</p>

<p class=MsoNormal style='text-indent:28.35pt'>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <span
lang=EN-GB>an &#8220;angiotensin II receptor blocker&#8221; such as valsartan,
telmisartan, irbesartan etc.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>medicines used to control heart rhythm.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>medicines for the treatment of diabetes (oral
agents such as metformin or insulins).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>medicines that may increase blood sugar level,
such as beta blockers and diazoxide.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>steroids.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>cytotoxic medicines (used to treat cancer),</span><span
lang=EN-GB> such as methotrexate or cyclophosphamide</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>arthritis medicines.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>medicines used to treat oesophageal ulceration
and inflammation (e.g. carbenoxolone).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>muscle relaxants </span><span lang=EN-GB>(medicines
to relax the muscles which are used during operations).</span></p>

<p class=MsoDate style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>amantadine (a medicine used to treat
Parkinson&#8217;s disease, also used to treat or prevent certain illnesses
caused by viruses).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>anticholinergic </span><span
class=MsoCommentReference><span lang=EN-GB>agents</span></span><span
lang=EN-GB> (medicines used to treat a variety of disorders such as
gastrointestinal cramps, urinary bladder spasm, asthma, motion sickness,
muscular spasms, Parkinson&#8217;s disease and as an aid to anaesthesia).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>cholestyramine, colestipol or other resins
(substances used mainly to treat high levels of lipids in the blood).</span></p>

<p class=MsoDate style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>alcohol, sleeping pills and anaesthetics
(medicines allowing patients to undergo surgery and other procedures).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>iodine contrast media (agents used for imaging
examinations).</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Your doctor may need to change your dose and/or take other
precautions if you are taking one of the following medicines:</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB style='font-family:"Arial",sans-serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>furosemide, a medicine belonging to the type
known as diuretics, which is used to increase the amount of urine you produce
and is also used to treat a certain kind of heart problem (heart failure) or
oedema (swelling).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB style='font-family:"Arial",sans-serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>some medicines used to treat infections, such as
ketoconazole, amphotericin or penicillin G.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Rasitrio with food and drink</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>You should take this medicine with a light meal once a day,
preferably at the same time each day. You should not take this medicine with
grapefruit juice.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Due to hydrochlorothiazide contained in Rasitrio, if you drink
alcohol while on treatment with this medicine, you may have an increased
feeling of dizziness on standing up, especially when getting up from a sitting
position.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Pregnancy</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not take this
medicine if you are pregnant (see section Do not take Rasitrio). If you become
pregnant while taking this medicine stop taking it immediately and talk to your
doctor. If you think you may be pregnant or are planning to have a baby, ask
your doctor or pharmacist for advice before taking this medicine. Your doctor
will normally advise you to stop taking Rasitrio before you become pregnant and
will advise you to take another medicine instead of Rasitrio. Rasitrio is not
recommended in early pregnancy, and must not be taken when more than
3&nbsp;months pregnant, as it may cause serious harm to your baby if it is used
after the third month of pregnancy.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Breast-feeding</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tell your doctor
if you are breast-feeding or about to start breast-feeding.</span> Rasitrio is
not recommended for mothers who are breast-feeding, and your doctor may choose
another treatment for you if you wish to breast-feed.</p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Driving and using machines</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>This medicine
<span lang=EN-GB>may make you feel dizzy and drowsy. If you experience this
symptom, do not drive or use tools or machines.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>&nbsp;</p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How to take Rasitrio</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Always take this medicine exactly as your doctor has told you and do
not exceed the recommended dose. Check with your doctor or pharmacist if you
are not sure.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The usual dose of Rasitrio is one tablet a day.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>Method of administration</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Swallow the tablet whole with some water. You should take this
medicine with a light meal once a day, preferably at the same time each day.
You should not take this medicine together with grapefruit juice.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>If you take more Rasitrio than you should</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If you have
accidentally taken too many Rasitrio tablets, talk to a doctor immediately. You
may require medical attention.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>If you forget to take Rasitrio</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>If you forget to take a dose of this medicine, take it as soon as
you remember and then take the next dose at its usual time. If it is almost
time for your next dose you should simply take the next tablet at the usual
time. <b>Do not </b>take a double dose (two tablets at once) to make up for a
forgotten tablet.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Do not stop taking this medicine</span></b><span lang=EN-GB>, even
if you are feeling well (unless your doctor tells you to do so).</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>People who have high blood pressure often do not notice any signs of
the problem. Many may feel quite normal. It is very important that you take
this medicine exactly as your doctor tells you to get the best results and
reduce the risk of side effects. Keep your appointments with the doctor even if
you are feeling well.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>If you have any further questions on the use of this medicine, ask
your doctor or pharmacist.</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Possible
side effects</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>Like all medicines, this medicine can cause side effects, although
not everybody gets them.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.4pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>Side effects reported for Rasitrio are:</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>Common</span></b><span lang=EN-GB> <i>(may affect
up to 1 in 10&nbsp;people)</i></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>dizziness</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>low blood pressure</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>swelling of hands, ankles and feet (peripheral
oedema).</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><b><span
lang=EN-GB>Tell your doctor immediately if you experience the following at the
beginning of your treatment:</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Fainting and/or
light-headedness linked to low blood pressure could occur at the beginning of
treatment with Rasitrio. </span><span lang=EN-GB>Patients 65&nbsp;years of age
or older are more susceptible to side effects related to low blood pressure. In
clinical trials low blood pressure occurred more frequently in patients taking
Rasitrio than those taking only dual combinations of aliskiren/amlodipine,
aliskiren/hydrochlorothiazide or amlodipine/hydrochlorothiazide (see section 2).</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The following, possibly serious, side effects have been reported
with medicines containing aliskiren, amlodipine or hydrochlorothiazide alone.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><u><span lang=EN-GB>Aliskiren</span></u></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Some side effects can be serious (frequency not known):</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>A few patients have experienced these serious side effects </span><i><span
lang=EN-GB>(</span></i><i><span lang=EN-GB>may affect up to 1 in
1,000&nbsp;people</span></i><i><span lang=EN-GB>)</span></i><span lang=EN-GB>. <b>If
any of the following occur,</b> <b>tell your doctor straight away:</b></span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Severe allergic reaction with symptoms such as
rash, itching, swelling of face or lips or tongue, difficulty breathing,
dizziness.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Nausea, loss of appetite, dark coloured urine or
yellowing of skin and eyes (signs of liver disorder).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB>Possible side effects</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>Common </span></b><i><span lang=EN-GB>(may affect up to 1 in
10&nbsp;people)</span></i></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>diarrhoea</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>joint pain (arthralgia)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>high level of potassium in the blood</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>dizziness.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>Uncommon</span></b><span lang=EN-GB> <i>(may affect up to 1 in 100</i></span><i><span
lang=EN-GB>&nbsp;people</span></i><i><span lang=EN-GB>)</span></i></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>skin rash (this may also be a sign of allergic
reactions or angioedema &#8211; see &#8220;Rare&#8221; side effects below)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>kidney problems including acute renal failure
(severely decreased urine output)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>swelling of hands, ankles or feet (peripheral
oedema)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>severe skin reactions (toxic epidermal
necrolysis and/or oral mucosal reactions &#8211; red skin, blistering of the
lips, eyes or mouth, skin peeling, fever)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>low blood pressure</span><span lang=EN-GB> </span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>palpitations</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>cough</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>itching, itchy rash (urticaria)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>increased liver enzymes.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>Rare</span></b><span lang=EN-GB> <i>(may affect up to 1 in
1,000&nbsp;people)</i></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>severe allergic reaction (anaphylactic reaction)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>allergic reactions (hypersensitivity)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>angioedema (the symptoms of which can include
difficulties in breathing or swallowing, rash, itching, hives or swelling of
the face, hands and feet, eyes, lips and/or tongue, dizziness)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>increased level of creatinine in the blood</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>red skin (erythema).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><u><span lang=EN-GB>Amlodipine</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>In patients taking amlodipine alone, the following have
been reported:</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;vertical-align:
baseline'><b><span lang=EN-GB>Common</span></b><span lang=EN-GB> </span><i><span
lang=EN-GB>(may affect up to 1 in 10&nbsp;people)</span></i></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>sleepiness</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>dizziness</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>headache (especially at the beginning of
treatment)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>hot flushes</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>abdominal pain</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>nausea</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>ankle swelling</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>swelling</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>tiredness</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>palpitations (awareness of your heart beat).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;vertical-align:
baseline'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;vertical-align:
baseline'><b><span lang=EN-GB>Uncommon</span></b><span lang=EN-GB> <i>(may
affect up to 1 in 100&nbsp;people)</i></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>insomnia</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>mood changes (including anxiety)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>depression</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>trembling</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>disturbed sense of taste</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>sudden, temporary loss of consciousness</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>decreased skin sensitivity</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>tingling or numbness</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>vision disorder (including double vision)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>ringing noise in ears</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>low blood pressure</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>breathlessness</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>runny nose</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>vomiting</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>stomach discomfort after meal</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>altered bowel habits (including diarrhoea and
constipation)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>dry mouth</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>hair loss</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>purple skin patches</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>skin discolouration</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>excessive sweating</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>itching; rash</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>generalised rash</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>joint pain</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>muscle pain</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>muscle cramps</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>back pain</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>urination disorders</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>urination at night</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>frequent urination</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>impotence</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>breast enlargement in men</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>chest pain</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>weakness</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>pain</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>feeling unwell</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>weight increase</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>weight decrease.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;vertical-align:
baseline'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;vertical-align:
baseline'><b><span lang=EN-GB>Rare </span></b><i><span lang=EN-GB>(may affect
up to 1 in 1,000&nbsp;people)</span></i></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>confusion.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>Very rare</span></b><span lang=EN-GB> <i>(may affect up to 1 in
10,000&nbsp;people)</i></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>low level of white blood cells and blood
platelets</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>allergic reaction with symptoms such as rash,
itching, hives, difficulty breathing or swallowing, dizziness</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>high level of sugar in the blood</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>increased muscle stiffness and inability to
stretch</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>sensation of numbness or tingling with sensation
of burning in fingers and toes</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>heart attack</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>irregular heart beat</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>inflammation of blood vessels</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>cough</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>severe upper stomach pain</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>inflammation of the gastric lining</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>bleeding, tender or enlarged gums</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>inflammation of the liver</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>liver disorder which can occur together with
yellow skin and eyes, or dark-coloured urine</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>abnormal liver function test</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>angioedema (difficulties in breathing, or
swallowing, or swelling of the face, hands and feet, eyes, lips and/or tongue)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>skin reaction with skin reddening and peeling,
blistering of lips, eyes or mouth; dry skin, rash, itchy rash</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>skin rash with flaking or peeling; rash, red
skin, blistering of the lips, eyes or mouth, skin peeling, fever</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>swelling mainly of the face and throat</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>increased sensitivity of the skin to sun.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><u><span lang=EN-GB>Hydrochlorothiazide</span></u></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>In patients
taking hydrochlorothiazide alone, the following have been reported, however the
frequency cannot be estimated from the available data:</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
lang=EN-GB>Very common</span></b><span lang=EN-GB> <i>(may affect more than 1
in 10&nbsp;people)</i></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;text-autospace:none'><span lang=EN-GB
style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>low level of potassium in the blood</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;text-autospace:none'><span lang=EN-GB
style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>increase of lipids in the blood.</span></p>

<p class=MsoDate><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoDate><b><span lang=EN-GB>Common</span></b><span lang=EN-GB> <i>(may
affect up to 1 in 10&nbsp;people)</i></span></p>

<p class=MsoDate style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>high level of uric acid in the blood</span></p>

<p class=MsoDate style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>low level of magnesium in the blood</span></p>

<p class=MsoDate style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>low level of sodium in the blood</span></p>

<p class=MsoDate style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>dizziness, fainting on standing up</span></p>

<p class=MsoDate style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>reduced appetite</span></p>

<p class=MsoDate style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>nausea and vomiting</span></p>

<p class=MsoDate style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>itchy rash and other types of rash</span></p>

<p class=MsoDate style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>inability to achieve or maintain erection.</span></p>

<p class=MsoNormal style='text-autospace:none'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
lang=EN-GB>Rare</span></b><span lang=EN-GB> <i>(may affect up to 1 in
1,000&nbsp;people)</i></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;text-autospace:none'><span lang=EN-GB
style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>low level of blood platelets (sometimes with
bleeding or bruising underneath the skin)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>high level of calcium in the blood</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>high level of sugar in the blood</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>worsening of the diabetic metabolic state</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>sad mood (depression)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>sleep disturbances</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>dizziness</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>headache</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>tingling or numbness</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>vision disorder</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>irregular heart beat</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>abdominal discomfort</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>constipation</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>diarrhoea</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>liver disorders which can occur together with
yellow skin and eyes</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>increased sensitivity of skin to the sun</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>sugar in the urine.</span></p>

<p class=MsoNormal style='text-autospace:none'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
lang=EN-GB>Very rare</span></b><span lang=EN-GB> <i>(may affect up to 1&nbsp;in
10,000&nbsp;people)</i></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;text-autospace:none'><span lang=EN-GB
style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>fever, sore throat or mouth ulcers, more
frequent infections (lack or low level of white blood cells)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>pale skin, tiredness, breathlessness,
dark-coloured urine (haemolytic anaemia)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>rash, itching, hives, difficulty breathing or
swallowing, dizziness (hypersensitivity reactions)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>confusion, tiredness, muscle twitching and
spasm, rapid breathing (hypochloraemic alkalosis)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>difficulty breathing with fever, coughing,
wheezing, breathlessness (respiratory distress including pneumonitis and
pulmonary oedema)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>severe upper stomach pain (pancreatitis)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>facial rash, joint pain, muscle disorder, fever
(lupus erythematosus)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>inflammation of blood vessels with symptoms such
as<i> </i>rash, purplish-red spots, fever (vasculitis)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>severe skin disease that causes rash, red skin,
blistering of the lips, eyes or mouth, skin peeling, fever (toxic epidermal
necrolysis).</span></p>

<p class=MsoNormal style='text-autospace:none'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>Not known</span></b><span
lang=EN-GB> <i>(frequency cannot be estimated from the available data)</i></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>weakness</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>bruising and frequent infections (aplastic
anaemia)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>decrease in vision or pain in your eyes due to
high pressure (possible signs of acute-angle closure glaucoma)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>severe skin disease that causes rash, red skin,
blistering of the lips, eyes or mouth, skin peeling, fever (erythema
multiforme)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>muscle spasm</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>severely decreased urine output (possible signs
of renal disorder or renal failure), weakness (asthenia)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>fever.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>If any of these affect you severely, tell your doctor. You may need
to stop Rasitrio.</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>If you get any side effects, </span><span lang=EN-GB>talk to your
doctor or pharmacist.</span><span lang=EN-GB> This includes any possible side
effects not listed in this leaflet</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How
to store Rasitrio</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Keep this medicine out of the sight and reach of children.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Do not use this medicine after the expiry date which is stated on
the carton and blister after &#8220;EXP&#8221;. The expiry date refers to the
last day of that month.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not store
above 30&deg;C.</span></p>

<p class=MsoNormal style='line-height:normal'>Store Rasitrio tablets in the
original package in order to protect from moisture.</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not throw
away any medicines via wastewater or household waste. Ask your pharmacist how
to throw away medicines you no longer use. These measures will help protect the
environment.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contents of the pack and
other information</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>What </span></b><b><span lang=EN-GB>Rasitrio contains</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Each </span><span lang=EN-GB>Rasitrio 300&nbsp;mg/5&nbsp;mg/12.5&nbsp;mg
film-coated tablet contains 300&nbsp;mg aliskiren (as hemifumarate), 5&nbsp;mg
amlodipine (as besylate) and 12.5&nbsp;mg hydrochlorothiazide. The other
ingredients are cellulose microcrystalline, crospovidone, povidone, magnesium
stearate, silica colloidal anhydrous, hypromellose, titanium dioxide (E171),
macrogol, talc, iron oxide red (E172), iron oxide black (E172).</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>What Rasitrio looks like and contents of the pack</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Rasitrio 300&nbsp;mg/5&nbsp;mg/12.5&nbsp;mg
film-coated tablets are light pink, oval tablets, with &#8220;LIL&#8221;
debossed on one side and &#8220;NVR&#8221; on the other.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>Rasitrio </span>is available in packs containing 14,
28, 56, 98&nbsp;tablets in calendar blisters.</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'>It is also
available in multi-packs of <span lang=EN-GB>98&nbsp;tablets (2&nbsp;packs of
49) in calendar blisters.</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>Rasitrio </span>is available in packs containing<span
lang=EN-GB> 30 or 90&nbsp;tablets in blisters.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Rasitrio is available in packs containing 56x1&nbsp;tablet in
perforated unit dose blister.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>It is also available in multi-packs of 98x1&nbsp;tablet (2&nbsp;packs
of 49x1) in perforated unit dose blister.</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Not all pack sizes may be available in your country.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Marketing Authorisation Holder</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'>Novartis Europharm Limited</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'>Wimblehurst Road</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'>Horsham</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'>West Sussex, RH12 5AB</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>United
Kingdom</p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Manufacturer</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Novartis Farma S.p.A.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=IT>Via Provinciale Schito 131</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=IT>I-80058 Torre Annunziata/NA</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Italy</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>For any information about this medicine, please contact the local
representative of the Marketing Authorisation Holder:</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'>&nbsp;</p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=624
 style='margin-left:-1.7pt;border-collapse:collapse'>
 <tr>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=FR-BE>Belgi&euml;/Belgique/Belgien</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR-BE>Novartis
  Pharma N.V.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR-BE>T&eacute;l/Tel:
  +32 2 246 16 11</span></p>
  <p class=MsoNormal style='margin-right:1.7pt;line-height:normal'><span
  lang=FR>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=LT>Lietuva</span></b></p>
  <p class=MsoNormal style='margin-right:-22.45pt;line-height:normal'><span
  lang=LT>Novartis Pharma Services Inc.</span></p>
  <p class=MsoNormal style='margin-right:-22.45pt;line-height:normal'><span
  lang=LT>Tel: +370 5 269 16 50</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=IT>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR>Novartis Pharma
  Services Inc.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&#1058;&#1077;&#1083;.:
  +359 2 489 98 28</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=NO-BOK>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=DE-CH>Luxembourg/Luxemburg</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE-CH>Novartis
  Pharma N.V.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR-BE>T&eacute;l/Tel:
  +32 2 246 16 11</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=NO-BOK>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=NO-BOK>&#268;esk&aacute;
  republika</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=NO-BOK>Novartis
  s.r.o.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE-CH>Tel: +420 225
  775 111</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE-CH>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=HU>Magyarorsz&aacute;g</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=HU>Novartis
  Hung&aacute;ria Kft. Pharma</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=HU>Tel.: +36 1 457
  65 00</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b>Danmark</b></p>
  <p class=MsoNormal style='line-height:normal'>Novartis Healthcare A/S</p>
  <p class=MsoNormal style='line-height:normal'>Tlf: +45 39 16 84 00</p>
  <p class=MsoNormal style='line-height:normal'>&nbsp;</p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=MT>Malta</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=MT>Novartis Pharma
  Services Inc.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=MT>Tel: +</span>356 <span
  lang=EN-GB>2122 2872</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=DE>Deutschland</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE>Novartis Pharma
  GmbH</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE>Tel: +49 911 273
  0</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=NL>Nederland</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=NL>Novartis Pharma
  B.V.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=NL>Tel: +31 26 37 82
  111</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=ET>Eesti</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=ET>Novartis Pharma
  Services Inc.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=ET>Tel: +372 </span><span
  lang=EN-GB>66 30 810</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=ET>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=NO-BOK>Norge</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=NO-BOK>Novartis
  Norge AS</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=NO-BOK>Tlf: +47 23
  05 20 00</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EL>&#917;&#955;&#955;&#940;&#948;&#945;</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=ET>Novartis (Hellas)
  A.E.B.E.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EL>&#932;&#951;&#955;</span><span
  lang=ET>: +30 210 281 17 12</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=ET>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=DE-AT>&Ouml;sterreich</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE-AT>Novartis
  Pharma GmbH</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE-AT>Tel: +43 1 86
  6570</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=ES>Espa&ntilde;a</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=ES>Novartis Farmac&eacute;utica,
  S.A.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=ES>Tel: +34 93 306
  42 00</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=ES>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoHeading7 align=left style='text-align:left;line-height:normal;
  page-break-after:auto'><b><span lang=PL style='font-style:normal'>Polska</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=PL>Novartis Poland
  Sp. z o.o.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=PL>Tel.: +48 22 375
  4888</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=FR>France</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR>Novartis Pharma
  S.A.S.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR>T&eacute;l: +33 1
  55 47 66 00</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=FR>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=PT>Portugal</span></b></p>
  <p class=Text style='margin-bottom:0in;line-height:normal'><span lang=PT-BR>Novartis
  Farma - Produtos Farmac&ecirc;uticos, S.A.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=PT>Tel: +351 21 000
  8600</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Hrvatska</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Novartis Hrvatska d.o.o.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel. +385 1 6274 220</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=IT>Rom&acirc;nia</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=IT>Novartis Pharma
  Services Romania SRL</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=IT>Tel: +40 21 31299
  01</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Ireland</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Novartis
  Ireland Limited</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: +353 1
  260 12 55</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=SL>Slovenija</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=SL>Novartis Pharma
  Services Inc.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=SL>Tel: +386 1 300
  75 50</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=IS>&Iacute;sland</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=IS>Vistor hf.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=IT>S</span><span
  lang=CS>&iacute;</span><span lang=IT>mi</span><span lang=IS>: +354 535 7000</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=IT>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=SK>Slovensk&aacute;
  republika</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=SK>Novartis Slovakia
  s.r.o.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=SK>Tel: +421 2 5542
  5439</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=SK>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=PT-BR>Italia</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=PT-BR>Novartis Farma
  S.p.A.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=IT>Tel: +39 02 96 54
  1</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=SV>Suomi/Finland</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=SV>Novartis Finland
  Oy</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=SV>Puh/Tel: </span><span
  lang=DE-CH>+358 (0)10 6133 200</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=SV>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EL>&#922;&#973;&#960;&#961;&#959;&#962;</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR>Novartis Pharma
  Services Inc.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EL>&#932;&#951;&#955;:
  +357 22 690 690</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EL>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=SV>Sverige</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=SV>Novartis Sverige
  AB</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=SV>Tel: +46 8 732 32
  00</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=FI>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=LV>Latvija</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=LV>Novartis Pharma
  Services Inc.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=LV>Tel: +371 67 887
  070</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EL>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>United
  Kingdom</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Novartis</span><span
  lang=EN-GB> </span><span lang=EN-GB>Pharmaceuticals UK Ltd.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: +44 1276
  698370</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=SV>&nbsp;</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>This leaflet
was last revised in</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Other sources
of information</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Detailed
information on this medicine is available on the European Medicines Agency
website: </span><span lang=EN-GB>http://www.ema.europa.eu</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>Package leaflet: information for the user</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
text-autospace:none'><span lang=EN-GB>Rasitrio 300&nbsp;mg/5&nbsp;mg/25&nbsp;mg
film-coated tablets</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>Aliskiren/amlodipine/hydrochlorothiazide</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Read all of this leaflet carefully before you start taking this
medicine because it contains important information for you.</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Keep this leaflet. You may need to read it
again.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you have any further questions, ask your
doctor or pharmacist.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>This medicine has been prescribed for you only.
Do not pass it on to others. It may harm them, even if their signs of illness
are the same as yours.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you get any side effects, talk to your doctor
or pharmacist. This includes any possible side effects not listed in this
leaflet.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>What is in this leaflet</span></b></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What Rasitrio is and what it
is used for</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What you need to know before
you take Rasitrio</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How to take Rasitrio</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Possible side effects</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How to store Rasitrio</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contents of the pack and
other information</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What Rasitrio is and what it
is used for</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>What Rasitrio is</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Rasitrio contains three active substances, called aliskiren,
amlodipine and hydrochlorothiazide. All of these substances help to control
high blood pressure (hypertension).</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span style='font-size:11.0pt;
font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>Aliskiren is a substance that
belongs to a group of medicines called renin inhibitors. These reduce the
amount of angiotensin&nbsp;II the body can make. Angiotensin&nbsp;II causes
blood vessels to tighten, which raises blood pressure. Lowering the amount of
angiotensin&nbsp;II allows the blood vessels to relax; this lowers blood
pressure.</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span style='font-size:11.0pt;
font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>Amlodipine belongs to a group of
medicines known as calcium channel blockers, which help to control high blood
pressure. Amlodipine causes blood vessels to dilate and relax; this lowers
blood pressure.</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span style='font-size:11.0pt;
font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>Hydrochlorothiazide belongs to a
group of medicines called thiazide diuretics. Hydrochlorothiazide increases
urine output, which also lowers blood pressure.</span></p>

<p class=Listlevel1 style='margin:0in;text-indent:0in'><span style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>High blood pressure increases the workload of the heart and
arteries. If this continues for a long time, it can damage the blood vessels of
the brain, heart and kidneys, and may result in a stroke, heart failure, heart
attack or kidney failure. Lowering the blood pressure to a normal level reduces
the risk of developing these disorders.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>What Rasitrio is used for</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Rasitrio is used
to treat high blood pressure </span><span lang=EN-GB>in adult patients </span>who
have their blood pressure already controlled by aliskiren, amlodipine and
hydrochlorothiazide taken as separate medicines given at the same time. These
patients may thus benefit from taking one tablet containing all three
substances<span lang=EN-GB>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What you need
to know before you take Rasitrio</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Do not take Rasitrio</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you are allergic to aliskiren, to amlodipine,
to other dihydropyridine-derived medicines (known as calcium channel blockers),
to hydrochlorothiazide, to sulphonamide-derived medicines (medicines used to
treat chest or urinary infections) or to any of the other ingredients of this
medicine (listed in section 6). If you think you may be allergic, do not take
Rasitrio and ask your doctor for advice.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have experienced the following forms of
angioedema (difficulties in breathing or swallowing, or swelling of the face,
hands and feet, eyes, lips and/or tongue):</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:56.7pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:normal;
vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>angioedema when taking aliskiren,</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:56.7pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:normal;
vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>hereditary angioedema,</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:56.7pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:normal;
vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>angioedema without any known cause.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you are more than 3&nbsp;months pregnant. (It
is also better to avoid Rasitrio in early pregnancy &#8211; see Pregnancy
section).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have serious liver problems.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span><span lang=EN-GB>if you have serious kidney problems.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span><span lang=EN-GB>if you have problems to produce urine (anuria).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span>if the level of potassium in your blood is too low despite treatment.</p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span>if the level of sodium in your blood is too low.</p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span>if the level of calcium in your blood is too high.</p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span>if you have gout (uric acid crystals in the joints).</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;vertical-align:baseline'><span lang=EN-GB>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you are taking any of the following
medicines:</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;vertical-align:baseline'><span lang=EN-GB>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>ciclosporin (a medicine used in transplantation
to prevent organ rejection or for other conditions, e.g. rheumatoid arthritis
or atopic dermatitis),</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;vertical-align:baseline'><span lang=EN-GB>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>itraconazole (a medicine used to treat fungal
infections),</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>quinidine (a medicine used to correct heart
rhythm).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;vertical-align:baseline'><span lang=EN-GB>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have diabetes mellitus or impaired kidney
function and you are treated with either of the following classes of medicines
used to treat high blood pressure:</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;vertical-align:baseline'><span lang=EN-GB>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>an &#8220;angiotensin converting enzyme
inhibitor&#8221; such as enalapril, lisinopril, ramipril etc.</span></p>

<p class=MsoNormal style='margin-left:28.35pt'>or</p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;vertical-align:baseline'><span lang=EN-GB>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>an &#8220;angiotensin II receptor blocker&#8221;
such as valsartan, telmisartan, irbesartan etc.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have a very low blood pressure.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you are suffering from shock, including
cardiogenic shock.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have a narrowing of the aortic heart
valve (aortic stenosis).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;vertical-align:baseline'><span lang=EN-GB>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have heart failure after an acute heart
attack.</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>If any of the
above applies to you, do not take Rasitrio</span></b><span lang=EN-GB> <b>and
talk to your doctor.</b></span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Warnings and precautions</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Talk to your doctor before taking Rasitrio:</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you are suffering from vomiting or diarrhoea
or if you are taking a diuretic (a medicine to increase the amount of urine you
produce).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have already experienced angioedema
(difficulties in breathing, or swallowing, or swelling of the face, hands and
feet, eyes, lips and/or tongue). If this happens, stop taking Rasitrio and
contact your doctor.</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you suffer from heart problems.</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you are on a low-salt diet.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if your urine flow has decreased markedly for
24&nbsp;hours or more and/or if you have serious kidney problems (e.g. require
dialysis), including if you have had a kidney transplant or a narrowing or
blockage of the arteries that supply blood to your kidney.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have impaired kidney function, your
doctor will carefully consider whether Rasitrio is suitable for you and may
wish to monitor you carefully.</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you suffer from liver problems (impaired
liver function).</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have diabetes (high level of sugar in
your blood).</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have a high level of cholesterol or
triglycerides in your blood.</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you suffer from a disease called lupus
erythematosus (also called &#8220;lupus&#8221; or &#8220;SLE&#8221;).</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you suffer from allergy or asthma.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you are taking either of the following
classes of medicines used to treat high blood pressure:</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;vertical-align:baseline'><span lang=EN-GB>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>an &#8220;angiotensin converting enzyme
inhibitor&#8221; such as enalapril, lisinopril, ramipril etc.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;line-height:normal'>or</p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;vertical-align:baseline'><span lang=EN-GB>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>an &#8220;angiotensin II receptor blocker&#8221;
such as valsartan, telmisartan, irbesartan etc.</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you are 65&nbsp;years of age or older</span><span
lang=EN-GB> (see section Elderly (age 65&nbsp;years or older) below).</span></p>

<p class=MsoNormal style='margin-left:26.95pt;text-indent:-26.95pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have signs and symptoms such as abnormal
thirst, dry mouth, general weakness, drowsiness, restlessness, muscle pain or
cramps, weakness, low blood pressure, reduced urine output, nausea, vomiting,
or an abnormally fast heart beat which may indicate an excessive effect of
hydrochlorothiazide (contained in Rasitrio).</span></p>

<p class=MsoDate style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you experience skin reactions such as rash
after sun exposure.</span></p>

<p class=MsoDate style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you experience a decrease in vision or eye
pain. These could be symptoms of an increase of pressure in your eye and can
happen within hours to weeks of taking Rasitrio. This can lead to permanent
vision impairment, if not treated.</span></p>

<p class=MsoNormal style='margin-left:26.95pt;text-indent:-26.95pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have renal artery stenosis (narrowing of
the blood vessels to one or both kidneys).</span></p>

<p class=MsoNormal style='margin-left:26.95pt;text-indent:-26.95pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have serious congestive heart failure (a
type of heart disease where the heart cannot pump enough blood around the body.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>You must tell your doctor if you think you
are (or might become) pregnant. Rasitrio is not recommended in early pregnancy,
and must not be taken if you are more than 3&nbsp;months pregnant, as it may
cause serious harm to your baby if used at that stage (see Pregnancy section).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Children and adolescents</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The use of Rasitrio
in children and adolescents up to 18&nbsp;years of age is not recommended.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Elderly</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>You should tell your doctor if you are 65&nbsp;years of age or older
because you may be more susceptible to side effects related to low blood
pressure (see section 4 on possible side effects). Your doctor will carefully
consider whether Rasitrio is suitable for you. If you are 75&nbsp;years of age
or older, your doctor may wish to monitor your blood pressure more frequently.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>In the majority of </span><span lang=EN-GB>patients aged
65&nbsp;years or older</span><span lang=EN-GB>, the 300&nbsp;mg dose of
aliskiren shows no additional benefit in reducing blood pressure compared to
the </span><span lang=EN-GB>150&nbsp;mg dose.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Other medicines and Rasitrio</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Tell your doctor or pharmacist if you are taking, have recently taken
or might take any other medicines.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Do not take Rasitrio and talk to your doctor if you are taking any
of the following medicines:</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>ciclosporin (a medicine used in transplantation
to prevent organ rejection and also in other conditions, e.g. rheumatoid arthritis
or atopic dermatitis).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>itraconazole (a medicine used to treat fungal
infections).</span></p>

<p class=MsoListParagraph style='margin-top:0in;margin-right:-.1pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>quinidine (a medicine used to correct heart
rhythm).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>one of the following classes of medicines used
to treat high blood pressure if you have diabetes mellitus or impaired kidney
function:</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;vertical-align:baseline'><span lang=EN-GB>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>an &#8220;angiotensin converting enzyme
inhibitor&#8221; such as enalapril, lisinopril, ramipril etc.</span></p>

<p class=MsoNormal style='text-indent:28.35pt'>or</p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;vertical-align:baseline'><span lang=EN-GB>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>an &#8220;angiotensin II receptor blocker&#8221;
such as valsartan, telmisartan, irbesartan etc.</span></p>

<p class=MsoListParagraph style='margin-top:0in;margin-right:-.1pt;margin-bottom:
0in;margin-left:0in;margin-bottom:.0001pt;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><b><span lang=EN-GB>Tell your doctor if you are using the following
medicines:</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>medicines or substances that increase the amount
of potassium in your blood. These include potassium supplements or salt
substitutes containing potassium, potassium-sparing medicines and heparin.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>medicines that may reduce the amount of
potassium in your blood, such as diuretics (water tablets), corticosteroids,
laxatives, carbenoxolone, amphotericin or penicillin G.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>medicines to reduce blood pressure, including
methyldopa.</span></p>

<p class=MsoDate style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>medicines to increase blood pressure, such as
noradrenaline or adrenaline.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>medicines that may induce &#8220;<i>torsades de
pointes</i>&#8221; (irregular heart beat), such as antiarrhythmics (medicines
used to treat heart problems) and some antipsychotics.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>ketonazole, a medicine used to treat fungal
infections.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>verapamil, a medicine used to lower high blood
pressure, to correct heart rhythm or to treat angina pectoris.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span>clarithromycin, telithromycin, erythromycin which are antibiotics used
to treat infections.</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span>amiodarone, a medicine used to treat abnormal heart rhythms.</p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>atorvastatin, a medicine used to treat high
cholesterol.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>furosemide, a medicine belonging to the type
known as diuretics, which is used to increase the amount of urine you produce
and is also used to treat a certain kind of heart problem (heart failure) or
oedema (swelling).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>medicines that may reduce the amount of sodium
in your blood, such as antidepressants, antipsychotics, antiepileptics
(carbamazepine).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>rifampicin, </span>a medicine used to prevent or
treat infections.</p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>St. John&#8217;s wort <i>(hypericum perforatum)</i>,
</span>a herbal medicine used to elevate mood<span lang=EN-GB>.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>pain killers such as non-steroidal
anti-inflammatory agents (NSAIDs), including selective cyclooxygenase-2
inhibitors (Cox-2 inhibitors) (used especially in the patients over
65&nbsp;years old).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span>diltiazem, a medicine used to treat heart problems.</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span>ritonavir, a medicine used to treat viral infection.</p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>lithium (a medicine used to treat some types of
depression).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>some laxatives.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>medicines for the treatment of gout, such as
allopurinol.</span></p>

<p class=MsoDate style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>digoxin or other digitalis glycosides (medicines
used to treat heart problems).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>vitamin D and calcium salts.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>one of the following classes of medicines used
to treat high blood pressure:</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:10.35pt;margin-bottom:.0001pt;text-indent:.25in'><span lang=EN-GB>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; an
&#8220;angiotensin converting enzyme inhibitor&#8221; such as enalapril,
lisinopril, ramipril etc.</span></p>

<p class=MsoNormal style='text-indent:28.35pt'>or</p>

<p class=MsoNormal style='text-indent:28.35pt'>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <span
lang=EN-GB>an &#8220;angiotensin II receptor blocker&#8221; such as valsartan,
telmisartan, irbesartan etc.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>medicines used to control heart rhythm.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>medicines for the treatment of diabetes (oral
agents such as metformin or insulins).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>medicines that may increase blood sugar level,
such as beta blockers and diazoxide.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>steroids.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>cytotoxic medicines (used to treat cancer),</span><span
lang=EN-GB> such as methotrexate or cyclophosphamide</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>arthritis medicines.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>medicines used to treat oesophageal ulceration
and inflammation (e.g. carbenoxolone).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>muscle relaxants </span><span lang=EN-GB>(medicines
to relax the muscles which are used during operations).</span></p>

<p class=MsoDate style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>amantadine (a medicine used to treat
Parkinson&#8217;s disease, also used to treat or prevent certain illnesses
caused by viruses).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>anticholinergic </span><span
class=MsoCommentReference><span lang=EN-GB>agents</span></span><span
lang=EN-GB> (medicines used to treat a variety of disorders such as
gastrointestinal cramps, urinary bladder spasm, asthma, motion sickness,
muscular spasms, Parkinson&#8217;s disease and as an aid to anaesthesia).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>cholestyramine, colestipol or other resins
(substances used mainly to treat high levels of lipids in the blood).</span></p>

<p class=MsoDate style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>alcohol, sleeping pills and anaesthetics
(medicines allowing patients to undergo surgery and other procedures).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>iodine contrast media (agents used for imaging
examinations).</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Your doctor may need to change your dose and/or take other
precautions if you are taking one of the following medicines:</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB style='font-family:"Arial",sans-serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>furosemide, a medicine belonging to the type
known as diuretics, which is used to increase the amount of urine you produce
and is also used to treat a certain kind of heart problem (heart failure) or
oedema (swelling).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB style='font-family:"Arial",sans-serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>some medicines used to treat infections, such as
ketoconazole, amphotericin or penicillin G.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Rasitrio with food and drink</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>You should take this medicine with a light meal once a day,
preferably at the same time each day. You should not take this medicine with
grapefruit juice.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Due to hydrochlorothiazide contained in Rasitrio, if you drink
alcohol while on treatment with this medicine, you may have an increased
feeling of dizziness on standing up, especially when getting up from a sitting
position.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Pregnancy</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not take this
medicine if you are pregnant (see section Do not take Rasitrio). If you become
pregnant while taking this medicine stop taking it immediately and talk to your
doctor. If you think you may be pregnant or are planning to have a baby, ask
your doctor or pharmacist for advice before taking this medicine. Your doctor
will normally advise you to stop taking Rasitrio before you become pregnant and
will advise you to take another medicine instead of Rasitrio. Rasitrio is not
recommended in early pregnancy, and must not be taken when more than
3&nbsp;months pregnant, as it may cause serious harm to your baby if it is used
after the third month of pregnancy.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Breast-feeding</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tell your doctor
if you are breast-feeding or about to start breast-feeding.</span> Rasitrio is
not recommended for mothers who are breast-feeding, and your doctor may choose
another treatment for you if you wish to breast-feed.</p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Driving and using machines</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>This medicine
<span lang=EN-GB>may make you feel dizzy and drowsy. If you experience this
symptom, do not drive or use tools or machines.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>&nbsp;</p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How to take Rasitrio</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Always take this medicine exactly as your doctor has told you and do
not exceed the recommended dose. Check with your doctor or pharmacist if you
are not sure.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The usual dose of Rasitrio is one tablet a day.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>Method of administration</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Swallow the tablet whole with some water. You should take this
medicine with a light meal once a day, preferably at the same time each day.
You should not take this medicine together with grapefruit juice.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>If you take more Rasitrio than you should</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If you have
accidentally taken too many Rasitrio tablets, talk to a doctor immediately. You
may require medical attention.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>If you forget to take Rasitrio</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>If you forget to take a dose of this medicine, take it as soon as
you remember and then take the next dose at its usual time. If it is almost
time for your next dose you should simply take the next tablet at the usual
time. <b>Do not </b>take a double dose (two tablets at once) to make up for a
forgotten tablet.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Do not stop taking this medicine</span></b><span lang=EN-GB>, even
if you are feeling well (unless your doctor tells you to do so).</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>People who have high blood pressure often do not notice any signs of
the problem. Many may feel quite normal. It is very important that you take
this medicine exactly as your doctor tells you to get the best results and
reduce the risk of side effects. Keep your appointments with the doctor even if
you are feeling well.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>If you have any further questions on the use of this medicine, ask
your doctor or pharmacist.</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Possible
side effects</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>Like all medicines, this medicine can cause side effects, although
not everybody gets them.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.4pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>Side effects reported for Rasitrio are:</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>Common</span></b><span lang=EN-GB> <i>(may affect
up to 1 in 10&nbsp;people)</i></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>dizziness</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>low blood pressure</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>swelling of hands, ankles and feet (peripheral
oedema).</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><b><span
lang=EN-GB>Tell your doctor immediately if you experience the following at the
beginning of your treatment:</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Fainting and/or
light-headedness linked to low blood pressure could occur at the beginning of
treatment with Rasitrio. </span><span lang=EN-GB>Patients 65&nbsp;years of age
or older are more susceptible to side effects related to low blood pressure. In
clinical trials low blood pressure occurred more frequently in patients taking
Rasitrio than those taking only dual combinations of aliskiren/amlodipine,
aliskiren/hydrochlorothiazide or amlodipine/hydrochlorothiazide (see section 2).</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The following, possibly serious, side effects have been reported
with medicines containing aliskiren, amlodipine or hydrochlorothiazide alone.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><u><span lang=EN-GB>Aliskiren</span></u></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Some side effects can be serious (frequency not known):</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>A few patients have experienced these serious side effects </span><i><span
lang=EN-GB>(</span></i><i><span lang=EN-GB>may affect up to 1 in
1,000&nbsp;people</span></i><i><span lang=EN-GB>)</span></i><span lang=EN-GB>. <b>If
any of the following occur,</b> <b>tell your doctor straight away:</b></span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Severe allergic reaction with symptoms such as
rash, itching, swelling of face or lips or tongue, difficulty breathing,
dizziness.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Nausea, loss of appetite, dark coloured urine or
yellowing of skin and eyes (signs of liver disorder).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB>Possible side effects</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>Common </span></b><i><span lang=EN-GB>(may affect up to 1 in
10&nbsp;people)</span></i></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>diarrhoea</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>joint pain (arthralgia)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>high level of potassium in the blood</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>dizziness.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>Uncommon</span></b><span lang=EN-GB> <i>(may affect up to 1 in 100</i></span><i><span
lang=EN-GB>&nbsp;people</span></i><i><span lang=EN-GB>)</span></i></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>skin rash (this may also be a sign of allergic
reactions or angioedema &#8211; see &#8220;Rare&#8221; side effects below)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>kidney problems including acute renal failure
(severely decreased urine output)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>swelling of hands, ankles or feet (peripheral
oedema)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>severe skin reactions (toxic epidermal
necrolysis and/or oral mucosal reactions &#8211; red skin, blistering of the
lips, eyes or mouth, skin peeling, fever)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>low blood pressure</span><span lang=EN-GB> </span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>palpitations</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>cough</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>itching, itchy rash (urticaria)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>increased liver enzymes.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>Rare</span></b><span lang=EN-GB> <i>(may affect up to 1 in
1,000&nbsp;people)</i></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>severe allergic reaction (anaphylactic reaction)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>allergic reactions (hypersensitivity)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>angioedema (the symptoms of which can include
difficulties in breathing or swallowing, rash, itching, hives or swelling of
the face, hands and feet, eyes, lips and/or tongue, dizziness)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>increased level of creatinine in the blood</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>red skin (erythema).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><u><span lang=EN-GB>Amlodipine</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>In patients taking amlodipine alone, the following have
been reported:</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;vertical-align:
baseline'><b><span lang=EN-GB>Common</span></b><span lang=EN-GB> </span><i><span
lang=EN-GB>(may affect up to 1 in 10&nbsp;people)</span></i></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>sleepiness</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>dizziness</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>headache (especially at the beginning of
treatment)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>hot flushes</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>abdominal pain</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>nausea</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>ankle swelling</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>swelling</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>tiredness</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>palpitations (awareness of your heart beat).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;vertical-align:
baseline'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;vertical-align:
baseline'><b><span lang=EN-GB>Uncommon</span></b><span lang=EN-GB> <i>(may
affect up to 1 in 100&nbsp;people)</i></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>insomnia</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>mood changes (including anxiety)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>depression</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>trembling</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>disturbed sense of taste</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>sudden, temporary loss of consciousness</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>decreased skin sensitivity</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>tingling or numbness</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>vision disorder (including double vision)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>ringing noise in ears</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>low blood pressure</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>breathlessness</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>runny nose</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>vomiting</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>stomach discomfort after meal</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>altered bowel habits (including diarrhoea and
constipation)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>dry mouth</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>hair loss</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>purple skin patches</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>skin discolouration</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>excessive sweating</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>itching; rash</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>generalised rash</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>joint pain</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>muscle pain</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>muscle cramps</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>back pain</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>urination disorders</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>urination at night</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>frequent urination</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>impotence</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>breast enlargement in men</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>chest pain</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>weakness</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>pain</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>feeling unwell</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>weight increase</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>weight decrease.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;vertical-align:
baseline'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;vertical-align:
baseline'><b><span lang=EN-GB>Rare </span></b><i><span lang=EN-GB>(may affect
up to 1 in 1,000&nbsp;people)</span></i></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>confusion.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>Very rare</span></b><span lang=EN-GB> <i>(may affect up to 1 in
10,000&nbsp;people)</i></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>low level of white blood cells and blood
platelets</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>allergic reaction with symptoms such as rash,
itching, hives, difficulty breathing or swallowing, dizziness</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>high level of sugar in the blood</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>increased muscle stiffness and inability to
stretch</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>sensation of numbness or tingling with sensation
of burning in fingers and toes</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>heart attack</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>irregular heart beat</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>inflammation of blood vessels</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>cough</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>severe upper stomach pain</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>inflammation of the gastric lining</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>bleeding, tender or enlarged gums</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>inflammation of the liver</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>liver disorder which can occur together with
yellow skin and eyes, or dark-coloured urine</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>abnormal liver function test</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>angioedema (difficulties in breathing, or
swallowing, or swelling of the face, hands and feet, eyes, lips and/or tongue)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>skin reaction with skin reddening and peeling,
blistering of lips, eyes or mouth; dry skin, rash, itchy rash</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>skin rash with flaking or peeling; rash, red
skin, blistering of the lips, eyes or mouth, skin peeling, fever</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>swelling mainly of the face and throat</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>increased sensitivity of the skin to sun.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><u><span lang=EN-GB>Hydrochlorothiazide</span></u></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>In patients
taking hydrochlorothiazide alone, the following have been reported, however the
frequency cannot be estimated from the available data:</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
lang=EN-GB>Very common</span></b><span lang=EN-GB> <i>(may affect more than 1
in 10&nbsp;people)</i></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;text-autospace:none'><span lang=EN-GB
style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>low level of potassium in the blood</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;text-autospace:none'><span lang=EN-GB
style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>increase of lipids in the blood.</span></p>

<p class=MsoDate><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoDate><b><span lang=EN-GB>Common</span></b><span lang=EN-GB> <i>(may
affect up to 1 in 10&nbsp;people)</i></span></p>

<p class=MsoDate style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>high level of uric acid in the blood</span></p>

<p class=MsoDate style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>low level of magnesium in the blood</span></p>

<p class=MsoDate style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>low level of sodium in the blood</span></p>

<p class=MsoDate style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>dizziness, fainting on standing up</span></p>

<p class=MsoDate style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>reduced appetite</span></p>

<p class=MsoDate style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>nausea and vomiting</span></p>

<p class=MsoDate style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>itchy rash and other types of rash</span></p>

<p class=MsoDate style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>inability to achieve or maintain erection.</span></p>

<p class=MsoNormal style='text-autospace:none'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
lang=EN-GB>Rare</span></b><span lang=EN-GB> <i>(may affect up to 1 in
1,000&nbsp;people)</i></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;text-autospace:none'><span lang=EN-GB
style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>low level of blood platelets (sometimes with
bleeding or bruising underneath the skin)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>high level of calcium in the blood</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>high level of sugar in the blood</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>worsening of the diabetic metabolic state</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>sad mood (depression)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>sleep disturbances</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>dizziness</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>headache</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>tingling or numbness</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>vision disorder</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>irregular heart beat</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>abdominal discomfort</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>constipation</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>diarrhoea</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>liver disorders which can occur together with
yellow skin and eyes</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>increased sensitivity of skin to the sun</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>sugar in the urine.</span></p>

<p class=MsoNormal style='text-autospace:none'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
lang=EN-GB>Very rare</span></b><span lang=EN-GB> <i>(may affect up to 1&nbsp;in
10,000&nbsp;people)</i></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;text-autospace:none'><span lang=EN-GB
style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>fever, sore throat or mouth ulcers, more
frequent infections (lack or low level of white blood cells)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>pale skin, tiredness, breathlessness,
dark-coloured urine (haemolytic anaemia)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>rash, itching, hives, difficulty breathing or
swallowing, dizziness (hypersensitivity reactions)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>confusion, tiredness, muscle twitching and
spasm, rapid breathing (hypochloraemic alkalosis)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>difficulty breathing with fever, coughing,
wheezing, breathlessness (respiratory distress including pneumonitis and
pulmonary oedema)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>severe upper stomach pain (pancreatitis)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>facial rash, joint pain, muscle disorder, fever
(lupus erythematosus)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>inflammation of blood vessels with symptoms such
as<i> </i>rash, purplish-red spots, fever (vasculitis)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>severe skin disease that causes rash, red skin,
blistering of the lips, eyes or mouth, skin peeling, fever (toxic epidermal
necrolysis).</span></p>

<p class=MsoNormal style='text-autospace:none'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>Not known</span></b><span
lang=EN-GB> <i>(frequency cannot be estimated from the available data)</i></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>weakness</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>bruising and frequent infections (aplastic
anaemia)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>decrease in vision or pain in your eyes due to
high pressure (possible signs of acute-angle closure glaucoma)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>severe skin disease that causes rash, red skin,
blistering of the lips, eyes or mouth, skin peeling, fever (erythema
multiforme)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>muscle spasm</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>severely decreased urine output (possible signs
of renal disorder or renal failure), weakness (asthenia)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>fever.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>If any of these affect you severely, tell your doctor. You may need
to stop Rasitrio.</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>If you get any side effects, </span><span lang=EN-GB>talk to your
doctor or pharmacist.</span><span lang=EN-GB> This includes any possible side
effects not listed in this leaflet</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How
to store Rasitrio</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Keep this medicine out of the sight and reach of children.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Do not use this medicine after the expiry date which is stated on
the carton and blister after &#8220;EXP&#8221;. The expiry date refers to the
last day of that month.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not store
above 30&deg;C.</span></p>

<p class=MsoNormal style='line-height:normal'>Store Rasitrio tablets in the
original package in order to protect from moisture.</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not throw
away any medicines via wastewater or household waste. Ask your pharmacist how
to throw away medicines you no longer use. These measures will help protect the
environment.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contents of the pack and
other information</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>What </span></b><b><span lang=EN-GB>Rasitrio contains</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Each </span><span lang=EN-GB>Rasitrio 300&nbsp;mg/5&nbsp;mg/25&nbsp;mg
film-coated tablet contains 300&nbsp;mg aliskiren (as hemifumarate), 5&nbsp;mg
amlodipine (as besylate) and 25&nbsp;mg hydrochlorothiazide. The other ingredients
are cellulose microcrystalline, crospovidone, povidone, magnesium stearate,
silica colloidal anhydrous, hypromellose, titanium dioxide (E171), macrogol,
talc, iron oxide black (E172), iron oxide red (E172), iron oxide yellow (E172).</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>What Rasitrio looks like and contents of the pack</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Rasitrio 300&nbsp;mg/5&nbsp;mg/25&nbsp;mg
film-coated tablets are pale orange-brown, oval tablets, with &#8220;OIO&#8221;
debossed on one side and &#8220;NVR&#8221; on the other.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>Rasitrio </span>is available in packs containing 14,
28, 56, 98&nbsp;tablets in calendar blisters.</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'>It is also
available in multi-packs of <span lang=EN-GB>98&nbsp;tablets (2&nbsp;packs of
49) in calendar blisters.</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>Rasitrio </span>is available in packs containing<span
lang=EN-GB> 30 or 90&nbsp;tablets in blisters.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Rasitrio is available in packs containing 56x1&nbsp;tablet in
perforated unit dose blister.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>It is also available in multi-packs of 98x1&nbsp;tablet
(2&nbsp;packs of 49x1) in perforated unit dose blister.</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Not all pack sizes may be available in your country.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Marketing Authorisation Holder</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'>Novartis Europharm Limited</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'>Wimblehurst Road</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'>Horsham</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'>West Sussex, RH12 5AB</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>United
Kingdom</p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Manufacturer</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Novartis Farma S.p.A.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=IT>Via Provinciale Schito 131</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=IT>I-80058 Torre Annunziata/NA</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Italy</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>For any information about this medicine, please contact the local
representative of the Marketing Authorisation Holder:</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'>&nbsp;</p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=624
 style='margin-left:-1.7pt;border-collapse:collapse'>
 <tr>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=FR-BE>Belgi&euml;/Belgique/Belgien</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR-BE>Novartis
  Pharma N.V.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR-BE>T&eacute;l/Tel:
  +32 2 246 16 11</span></p>
  <p class=MsoNormal style='margin-right:1.7pt;line-height:normal'><span
  lang=FR>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=LT>Lietuva</span></b></p>
  <p class=MsoNormal style='margin-right:-22.45pt;line-height:normal'><span
  lang=LT>Novartis Pharma Services Inc.</span></p>
  <p class=MsoNormal style='margin-right:-22.45pt;line-height:normal'><span
  lang=LT>Tel: +370 5 269 16 50</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=IT>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR>Novartis Pharma
  Services Inc.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&#1058;&#1077;&#1083;.:
  +359 2 489 98 28</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=NO-BOK>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=DE-CH>Luxembourg/Luxemburg</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE-CH>Novartis
  Pharma N.V.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR-BE>T&eacute;l/Tel:
  +32 2 246 16 11</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=NO-BOK>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=NO-BOK>&#268;esk&aacute;
  republika</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=NO-BOK>Novartis
  s.r.o.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE-CH>Tel: +420 225
  775 111</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE-CH>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=HU>Magyarorsz&aacute;g</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=HU>Novartis
  Hung&aacute;ria Kft. Pharma</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=HU>Tel.: +36 1 457
  65 00</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b>Danmark</b></p>
  <p class=MsoNormal style='line-height:normal'>Novartis Healthcare A/S</p>
  <p class=MsoNormal style='line-height:normal'>Tlf: +45 39 16 84 00</p>
  <p class=MsoNormal style='line-height:normal'>&nbsp;</p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=MT>Malta</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=MT>Novartis Pharma
  Services Inc.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=MT>Tel: +</span>356 <span
  lang=EN-GB>2122 2872</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=DE>Deutschland</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE>Novartis Pharma
  GmbH</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE>Tel: +49 911 273
  0</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=NL>Nederland</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=NL>Novartis Pharma
  B.V.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=NL>Tel: +31 26 37 82
  111</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=ET>Eesti</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=ET>Novartis Pharma
  Services Inc.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=ET>Tel: +372 </span><span
  lang=EN-GB>66 30 810</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=ET>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=NO-BOK>Norge</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=NO-BOK>Novartis
  Norge AS</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=NO-BOK>Tlf: +47 23
  05 20 00</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EL>&#917;&#955;&#955;&#940;&#948;&#945;</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=ET>Novartis (Hellas)
  A.E.B.E.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EL>&#932;&#951;&#955;</span><span
  lang=ET>: +30 210 281 17 12</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=ET>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=DE-AT>&Ouml;sterreich</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE-AT>Novartis
  Pharma GmbH</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE-AT>Tel: +43 1 86
  6570</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=ES>Espa&ntilde;a</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=ES>Novartis
  Farmac&eacute;utica, S.A.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=ES>Tel: +34 93 306
  42 00</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=ES>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoHeading7 align=left style='text-align:left;line-height:normal;
  page-break-after:auto'><b><span lang=PL style='font-style:normal'>Polska</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=PL>Novartis Poland
  Sp. z o.o.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=PL>Tel.: +48 22 375
  4888</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=FR>France</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR>Novartis Pharma
  S.A.S.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR>T&eacute;l: +33 1
  55 47 66 00</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=FR>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=PT>Portugal</span></b></p>
  <p class=Text style='margin-bottom:0in;line-height:normal'><span lang=PT-BR>Novartis
  Farma - Produtos Farmac&ecirc;uticos, S.A.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=PT>Tel: +351 21 000
  8600</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Hrvatska</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Novartis Hrvatska d.o.o.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel. +385 1 6274 220</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=IT>Rom&acirc;nia</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=IT>Novartis Pharma
  Services Romania SRL</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=IT>Tel: +40 21 31299
  01</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Ireland</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Novartis
  Ireland Limited</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: +353 1
  260 12 55</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=SL>Slovenija</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=SL>Novartis Pharma
  Services Inc.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=SL>Tel: +386 1 300
  75 50</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=IS>&Iacute;sland</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=IS>Vistor hf.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=IT>S</span><span
  lang=CS>&iacute;</span><span lang=IT>mi</span><span lang=IS>: +354 535 7000</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=IT>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=SK>Slovensk&aacute;
  republika</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=SK>Novartis Slovakia
  s.r.o.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=SK>Tel: +421 2 5542
  5439</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=SK>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=PT-BR>Italia</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=PT-BR>Novartis Farma
  S.p.A.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=IT>Tel: +39 02 96 54
  1</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=SV>Suomi/Finland</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=SV>Novartis Finland
  Oy</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=SV>Puh/Tel: </span><span
  lang=DE-CH>+358 (0)10 6133 200</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=SV>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EL>&#922;&#973;&#960;&#961;&#959;&#962;</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR>Novartis Pharma Services
  Inc.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EL>&#932;&#951;&#955;:
  +357 22 690 690</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EL>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=SV>Sverige</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=SV>Novartis Sverige
  AB</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=SV>Tel: +46 8 732 32
  00</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=FI>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=LV>Latvija</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=LV>Novartis Pharma
  Services Inc.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=LV>Tel: +371 67 887
  070</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EL>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>United
  Kingdom</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Novartis</span><span
  lang=EN-GB> </span><span lang=EN-GB>Pharmaceuticals UK Ltd.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: +44 1276
  698370</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=SV>&nbsp;</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>This leaflet
was last revised in</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Other sources
of information</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Detailed
information on this medicine is available on the European Medicines Agency
website: </span><span lang=EN-GB>http://www.ema.europa.eu</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>Package leaflet: information for the user</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
text-autospace:none'><span lang=EN-GB>Rasitrio
300&nbsp;mg/10&nbsp;mg/12.5&nbsp;mg film-coated tablets</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>Aliskiren/amlodipine/hydrochlorothiazide</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Read all of this leaflet carefully before you start taking this
medicine because it contains important information for you.</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Keep this leaflet. You may need to read it
again.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you have any further questions, ask your
doctor or pharmacist.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>This medicine has been prescribed for you only.
Do not pass it on to others. It may harm them, even if their signs of illness
are the same as yours.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you get any side effects, talk to your doctor
or pharmacist. This includes any possible side effects not listed in this
leaflet.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>What is in this leaflet</span></b></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What Rasitrio is and what it
is used for</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What you need to know before
you take Rasitrio</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How to take Rasitrio</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Possible side effects</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How to store Rasitrio</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contents of the pack and other
information</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What Rasitrio is and what it
is used for</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>What Rasitrio is</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Rasitrio contains three active substances, called aliskiren,
amlodipine and hydrochlorothiazide. All of these substances help to control
high blood pressure (hypertension).</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span style='font-size:11.0pt;
font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>Aliskiren is a substance that
belongs to a group of medicines called renin inhibitors. These reduce the
amount of angiotensin&nbsp;II the body can make. Angiotensin&nbsp;II causes
blood vessels to tighten, which raises blood pressure. Lowering the amount of
angiotensin&nbsp;II allows the blood vessels to relax; this lowers blood
pressure.</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span style='font-size:11.0pt;
font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>Amlodipine belongs to a group of
medicines known as calcium channel blockers, which help to control high blood
pressure. Amlodipine causes blood vessels to dilate and relax; this lowers blood
pressure.</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span style='font-size:11.0pt;
font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>Hydrochlorothiazide belongs to a
group of medicines called thiazide diuretics. Hydrochlorothiazide increases
urine output, which also lowers blood pressure.</span></p>

<p class=Listlevel1 style='margin:0in;text-indent:0in'><span style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>High blood pressure increases the workload of the heart and
arteries. If this continues for a long time, it can damage the blood vessels of
the brain, heart and kidneys, and may result in a stroke, heart failure, heart
attack or kidney failure. Lowering the blood pressure to a normal level reduces
the risk of developing these disorders.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>What Rasitrio is used for</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Rasitrio is used
to treat high blood pressure </span><span lang=EN-GB>in adult patients </span>who
have their blood pressure already controlled by aliskiren, amlodipine and
hydrochlorothiazide taken as separate medicines given at the same time. These
patients may thus benefit from taking one tablet containing all three
substances<span lang=EN-GB>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What you need
to know before you take Rasitrio</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Do not take Rasitrio</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you are allergic to aliskiren, to amlodipine,
to other dihydropyridine-derived medicines (known as calcium channel blockers),
to hydrochlorothiazide, to sulphonamide-derived medicines (medicines used to
treat chest or urinary infections) or to any of the other ingredients of this
medicine (listed in section 6). If you think you may be allergic, do not take Rasitrio
and ask your doctor for advice.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have experienced the following forms of
angioedema (difficulties in breathing or swallowing, or swelling of the face,
hands and feet, eyes, lips and/or tongue):</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:56.7pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:normal;
vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>angioedema when taking aliskiren,</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:56.7pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:normal;
vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>hereditary angioedema,</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:56.7pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:normal;
vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>angioedema without any known cause.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you are more than 3&nbsp;months pregnant. (It
is also better to avoid Rasitrio in early pregnancy &#8211; see Pregnancy
section).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have serious liver problems.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span><span lang=EN-GB>if you have serious kidney problems.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span><span lang=EN-GB>if you have problems to produce urine (anuria).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span>if the level of potassium in your blood is too low despite treatment.</p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span>if the level of sodium in your blood is too low.</p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span>if the level of calcium in your blood is too high.</p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span>if you have gout (uric acid crystals in the joints).</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;vertical-align:baseline'><span lang=EN-GB>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you are taking any of the following
medicines:</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;vertical-align:baseline'><span lang=EN-GB>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>ciclosporin (a medicine used in transplantation
to prevent organ rejection or for other conditions, e.g. rheumatoid arthritis
or atopic dermatitis),</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;vertical-align:baseline'><span lang=EN-GB>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>itraconazole (a medicine used to treat fungal
infections),</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>quinidine (a medicine used to correct heart
rhythm).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;vertical-align:baseline'><span lang=EN-GB>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have diabetes mellitus or impaired kidney
function and you are treated with either of the following classes of medicines
used to treat high blood pressure:</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;vertical-align:baseline'><span lang=EN-GB>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>an &#8220;angiotensin converting enzyme inhibitor&#8221;
such as enalapril, lisinopril, ramipril etc.</span></p>

<p class=MsoNormal style='margin-left:28.35pt'>or</p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;vertical-align:baseline'><span lang=EN-GB>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>an &#8220;angiotensin II receptor blocker&#8221;
such as valsartan, telmisartan, irbesartan etc.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have a very low blood pressure.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you are suffering from shock, including
cardiogenic shock.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have a narrowing of the aortic heart
valve (aortic stenosis).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;vertical-align:baseline'><span lang=EN-GB>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have heart failure after an acute heart
attack.</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>If any of the
above applies to you, do not take Rasitrio</span></b><span lang=EN-GB> <b>and
talk to your doctor.</b></span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Warnings and precautions</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Talk to your doctor before taking Rasitrio:</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you are suffering from vomiting or diarrhoea
or if you are taking a diuretic (a medicine to increase the amount of urine you
produce).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have already experienced angioedema
(difficulties in breathing, or swallowing, or swelling of the face, hands and
feet, eyes, lips and/or tongue). If this happens, stop taking Rasitrio and
contact your doctor.</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you suffer from heart problems.</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you are on a low-salt diet.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if your urine flow has decreased markedly for
24&nbsp;hours or more and/or if you have serious kidney problems (e.g. require
dialysis), including if you have had a kidney transplant or a narrowing or
blockage of the arteries that supply blood to your kidney.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have impaired kidney function, your
doctor will carefully consider whether Rasitrio is suitable for you and may
wish to monitor you carefully.</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you suffer from liver problems (impaired
liver function).</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have diabetes (high level of sugar in
your blood).</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have a high level of cholesterol or
triglycerides in your blood.</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you suffer from a disease called lupus
erythematosus (also called &#8220;lupus&#8221; or &#8220;SLE&#8221;).</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you suffer from allergy or asthma.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you are taking either of the following
classes of medicines used to treat high blood pressure:</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;vertical-align:baseline'><span lang=EN-GB>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>an &#8220;angiotensin converting enzyme inhibitor&#8221;
such as enalapril, lisinopril, ramipril etc.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;line-height:normal'>or</p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;vertical-align:baseline'><span lang=EN-GB>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>an &#8220;angiotensin II receptor blocker&#8221;
such as valsartan, telmisartan, irbesartan etc.</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you are 65&nbsp;years of age or older</span><span
lang=EN-GB> (see section Elderly (age 65&nbsp;years or older) below).</span></p>

<p class=MsoNormal style='margin-left:26.95pt;text-indent:-26.95pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have signs and symptoms such as abnormal
thirst, dry mouth, general weakness, drowsiness, restlessness, muscle pain or
cramps, weakness, low blood pressure, reduced urine output, nausea, vomiting,
or an abnormally fast heart beat which may indicate an excessive effect of hydrochlorothiazide
(contained in Rasitrio).</span></p>

<p class=MsoDate style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you experience skin reactions such as rash
after sun exposure.</span></p>

<p class=MsoDate style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you experience a decrease in vision or eye
pain. These could be symptoms of an increase of pressure in your eye and can
happen within hours to weeks of taking Rasitrio. This can lead to permanent
vision impairment, if not treated.</span></p>

<p class=MsoNormal style='margin-left:26.95pt;text-indent:-26.95pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have renal artery stenosis (narrowing of
the blood vessels to one or both kidneys).</span></p>

<p class=MsoNormal style='margin-left:26.95pt;text-indent:-26.95pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have serious congestive heart failure (a
type of heart disease where the heart cannot pump enough blood around the body.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>You must tell your doctor if you think you
are (or might become) pregnant. Rasitrio is not recommended in early pregnancy,
and must not be taken if you are more than 3&nbsp;months pregnant, as it may
cause serious harm to your baby if used at that stage (see Pregnancy section).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Children and adolescents</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The use of Rasitrio
in children and adolescents up to 18&nbsp;years of age is not recommended.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Elderly</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>You should tell your doctor if you are 65&nbsp;years of age or older
because you may be more susceptible to side effects related to low blood
pressure (see section 4 on possible side effects). Your doctor will carefully
consider whether Rasitrio is suitable for you. If you are 75&nbsp;years of age
or older, your doctor may wish to monitor your blood pressure more frequently.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>In the majority of </span><span lang=EN-GB>patients aged
65&nbsp;years or older</span><span lang=EN-GB>, the 300&nbsp;mg dose of
aliskiren shows no additional benefit in reducing blood pressure compared to
the </span><span lang=EN-GB>150&nbsp;mg dose.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Other medicines and Rasitrio</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Tell your doctor or pharmacist if you are taking, have recently
taken or might take any other medicines.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Do not take Rasitrio and talk to your doctor if you are taking any
of the following medicines:</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>ciclosporin (a medicine used in transplantation
to prevent organ rejection and also in other conditions, e.g. rheumatoid
arthritis or atopic dermatitis).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>itraconazole (a medicine used to treat fungal
infections).</span></p>

<p class=MsoListParagraph style='margin-top:0in;margin-right:-.1pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>quinidine (a medicine used to correct heart
rhythm).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>one of the following classes of medicines used
to treat high blood pressure if you have diabetes mellitus or impaired kidney
function:</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;vertical-align:baseline'><span lang=EN-GB>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>an &#8220;angiotensin converting enzyme
inhibitor&#8221; such as enalapril, lisinopril, ramipril etc.</span></p>

<p class=MsoNormal style='text-indent:28.35pt'>or</p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;vertical-align:baseline'><span lang=EN-GB>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>an &#8220;angiotensin II receptor blocker&#8221;
such as valsartan, telmisartan, irbesartan etc.</span></p>

<p class=MsoListParagraph style='margin-top:0in;margin-right:-.1pt;margin-bottom:
0in;margin-left:0in;margin-bottom:.0001pt;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><b><span lang=EN-GB>Tell your doctor if you are using the following
medicines:</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>medicines or substances that increase the amount
of potassium in your blood. These include potassium supplements or salt
substitutes containing potassium, potassium-sparing medicines and heparin.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>medicines that may reduce the amount of
potassium in your blood, such as diuretics (water tablets), corticosteroids,
laxatives, carbenoxolone, amphotericin or penicillin G.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>medicines to reduce blood pressure, including
methyldopa.</span></p>

<p class=MsoDate style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>medicines to increase blood pressure, such as
noradrenaline or adrenaline.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>medicines that may induce &#8220;<i>torsades de
pointes</i>&#8221; (irregular heart beat), such as antiarrhythmics (medicines
used to treat heart problems) and some antipsychotics.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>ketonazole, a medicine used to treat fungal infections.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>verapamil, a medicine used to lower high blood
pressure, to correct heart rhythm or to treat angina pectoris.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span>clarithromycin, telithromycin, erythromycin which are antibiotics used
to treat infections.</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span>amiodarone, a medicine used to treat abnormal heart rhythms.</p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>atorvastatin, a medicine used to treat high
cholesterol.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>furosemide, a medicine belonging to the type
known as diuretics, which is used to increase the amount of urine you produce
and is also used to treat a certain kind of heart problem (heart failure) or
oedema (swelling).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>medicines that may reduce the amount of sodium
in your blood, such as antidepressants, antipsychotics, antiepileptics
(carbamazepine).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>rifampicin, </span>a medicine used to prevent or
treat infections.</p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>St. John&#8217;s wort <i>(hypericum perforatum)</i>,
</span>a herbal medicine used to elevate mood<span lang=EN-GB>.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>pain killers such as non-steroidal
anti-inflammatory agents (NSAIDs), including selective cyclooxygenase-2
inhibitors (Cox-2 inhibitors) (used especially in the patients over
65&nbsp;years old).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span>diltiazem, a medicine used to treat heart problems.</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span>ritonavir, a medicine used to treat viral infection.</p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>lithium (a medicine used to treat some types of
depression).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>some laxatives.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>medicines for the treatment of gout, such as
allopurinol.</span></p>

<p class=MsoDate style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>digoxin or other digitalis glycosides (medicines
used to treat heart problems).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>vitamin D and calcium salts.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>one of the following classes of medicines used
to treat high blood pressure:</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:10.35pt;margin-bottom:.0001pt;text-indent:.25in'><span lang=EN-GB>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; an
&#8220;angiotensin converting enzyme inhibitor&#8221; such as enalapril,
lisinopril, ramipril etc.</span></p>

<p class=MsoNormal style='text-indent:28.35pt'>or</p>

<p class=MsoNormal style='text-indent:28.35pt'>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <span
lang=EN-GB>an &#8220;angiotensin II receptor blocker&#8221; such as valsartan,
telmisartan, irbesartan etc.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>medicines used to control heart rhythm.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>medicines for the treatment of diabetes (oral
agents such as metformin or insulins).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>medicines that may increase blood sugar level,
such as beta blockers and diazoxide.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>steroids.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>cytotoxic medicines (used to treat cancer),</span><span
lang=EN-GB> such as methotrexate or cyclophosphamide</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>arthritis medicines.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>medicines used to treat oesophageal ulceration
and inflammation (e.g. carbenoxolone).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>muscle relaxants </span><span lang=EN-GB>(medicines
to relax the muscles which are used during operations).</span></p>

<p class=MsoDate style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>amantadine (a medicine used to treat
Parkinson&#8217;s disease, also used to treat or prevent certain illnesses
caused by viruses).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>anticholinergic </span><span
class=MsoCommentReference><span lang=EN-GB>agents</span></span><span
lang=EN-GB> (medicines used to treat a variety of disorders such as
gastrointestinal cramps, urinary bladder spasm, asthma, motion sickness,
muscular spasms, Parkinson&#8217;s disease and as an aid to anaesthesia).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>cholestyramine, colestipol or other resins
(substances used mainly to treat high levels of lipids in the blood).</span></p>

<p class=MsoDate style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>alcohol, sleeping pills and anaesthetics
(medicines allowing patients to undergo surgery and other procedures).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>iodine contrast media (agents used for imaging
examinations).</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Your doctor may need to change your dose and/or take other precautions
if you are taking one of the following medicines:</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB style='font-family:"Arial",sans-serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>furosemide, a medicine belonging to the type
known as diuretics, which is used to increase the amount of urine you produce
and is also used to treat a certain kind of heart problem (heart failure) or
oedema (swelling).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB style='font-family:"Arial",sans-serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>some medicines used to treat infections, such as
ketoconazole, amphotericin or penicillin G.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Rasitrio with food and drink</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>You should take this medicine with a light meal once a day,
preferably at the same time each day. You should not take this medicine with
grapefruit juice.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Due to hydrochlorothiazide contained in Rasitrio, if you drink
alcohol while on treatment with this medicine, you may have an increased
feeling of dizziness on standing up, especially when getting up from a sitting
position.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Pregnancy</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not take this
medicine if you are pregnant (see section Do not take Rasitrio). If you become
pregnant while taking this medicine stop taking it immediately and talk to your
doctor. If you think you may be pregnant or are planning to have a baby, ask
your doctor or pharmacist for advice before taking this medicine. Your doctor
will normally advise you to stop taking Rasitrio before you become pregnant and
will advise you to take another medicine instead of Rasitrio. Rasitrio is not
recommended in early pregnancy, and must not be taken when more than
3&nbsp;months pregnant, as it may cause serious harm to your baby if it is used
after the third month of pregnancy.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Breast-feeding</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tell your doctor
if you are breast-feeding or about to start breast-feeding.</span> Rasitrio is
not recommended for mothers who are breast-feeding, and your doctor may choose
another treatment for you if you wish to breast-feed.</p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Driving and using machines</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>This medicine
<span lang=EN-GB>may make you feel dizzy and drowsy. If you experience this
symptom, do not drive or use tools or machines.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>&nbsp;</p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How to take Rasitrio</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Always take this medicine exactly as your doctor has told you and do
not exceed the recommended dose. Check with your doctor or pharmacist if you
are not sure.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The usual dose of Rasitrio is one tablet a day.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>Method of administration</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Swallow the tablet whole with some water. You should take this
medicine with a light meal once a day, preferably at the same time each day.
You should not take this medicine together with grapefruit juice.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>If you take more Rasitrio than you should</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If you have
accidentally taken too many Rasitrio tablets, talk to a doctor immediately. You
may require medical attention.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>If you forget to take Rasitrio</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>If you forget to take a dose of this medicine, take it as soon as
you remember and then take the next dose at its usual time. If it is almost
time for your next dose you should simply take the next tablet at the usual
time. <b>Do not </b>take a double dose (two tablets at once) to make up for a
forgotten tablet.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Do not stop taking this medicine</span></b><span lang=EN-GB>, even
if you are feeling well (unless your doctor tells you to do so).</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>People who have high blood pressure often do not notice any signs of
the problem. Many may feel quite normal. It is very important that you take this
medicine exactly as your doctor tells you to get the best results and reduce
the risk of side effects. Keep your appointments with the doctor even if you
are feeling well.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>If you have any further questions on the use of this medicine, ask
your doctor or pharmacist.</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Possible
side effects</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>Like all medicines, this medicine can cause side effects, although
not everybody gets them.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.4pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>Side effects reported for Rasitrio are:</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>Common</span></b><span lang=EN-GB> <i>(may affect
up to 1 in 10&nbsp;people)</i></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>dizziness</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>low blood pressure</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>swelling of hands, ankles and feet (peripheral
oedema).</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><b><span
lang=EN-GB>Tell your doctor immediately if you experience the following at the
beginning of your treatment:</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Fainting and/or
light-headedness linked to low blood pressure could occur at the beginning of
treatment with Rasitrio. </span><span lang=EN-GB>Patients 65&nbsp;years of age
or older are more susceptible to side effects related to low blood pressure. In
clinical trials low blood pressure occurred more frequently in patients taking
Rasitrio than those taking only dual combinations of aliskiren/amlodipine,
aliskiren/hydrochlorothiazide or amlodipine/hydrochlorothiazide (see section 2).</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The following, possibly serious, side effects have been reported
with medicines containing aliskiren, amlodipine or hydrochlorothiazide alone.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><u><span lang=EN-GB>Aliskiren</span></u></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Some side effects can be serious (frequency not known):</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>A few patients have experienced these serious side effects </span><i><span
lang=EN-GB>(</span></i><i><span lang=EN-GB>may affect up to 1 in
1,000&nbsp;people</span></i><i><span lang=EN-GB>)</span></i><span lang=EN-GB>. <b>If
any of the following occur,</b> <b>tell your doctor straight away:</b></span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Severe allergic reaction with symptoms such as
rash, itching, swelling of face or lips or tongue, difficulty breathing,
dizziness.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Nausea, loss of appetite, dark coloured urine or
yellowing of skin and eyes (signs of liver disorder).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB>Possible side effects</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>Common </span></b><i><span lang=EN-GB>(may affect up to 1 in
10&nbsp;people)</span></i></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>diarrhoea</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>joint pain (arthralgia)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>high level of potassium in the blood</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>dizziness.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>Uncommon</span></b><span lang=EN-GB> <i>(may affect up to 1 in 100</i></span><i><span
lang=EN-GB>&nbsp;people</span></i><i><span lang=EN-GB>)</span></i></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>skin rash (this may also be a sign of allergic
reactions or angioedema &#8211; see &#8220;Rare&#8221; side effects below)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>kidney problems including acute renal failure
(severely decreased urine output)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>swelling of hands, ankles or feet (peripheral
oedema)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>severe skin reactions (toxic epidermal
necrolysis and/or oral mucosal reactions &#8211; red skin, blistering of the
lips, eyes or mouth, skin peeling, fever)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>low blood pressure</span><span lang=EN-GB> </span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>palpitations</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>cough</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>itching, itchy rash (urticaria)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>increased liver enzymes.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>Rare</span></b><span lang=EN-GB> <i>(may affect up to 1 in
1,000&nbsp;people)</i></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>severe allergic reaction (anaphylactic reaction)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>allergic reactions (hypersensitivity)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>angioedema (the symptoms of which can include
difficulties in breathing or swallowing, rash, itching, hives or swelling of
the face, hands and feet, eyes, lips and/or tongue, dizziness)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>increased level of creatinine in the blood</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>red skin (erythema).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><u><span lang=EN-GB>Amlodipine</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>In patients taking amlodipine alone, the following have
been reported:</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;vertical-align:
baseline'><b><span lang=EN-GB>Common</span></b><span lang=EN-GB> </span><i><span
lang=EN-GB>(may affect up to 1 in 10&nbsp;people)</span></i></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>sleepiness</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>dizziness</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>headache (especially at the beginning of
treatment)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>hot flushes</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>abdominal pain</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>nausea</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>ankle swelling</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>swelling</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>tiredness</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>palpitations (awareness of your heart beat).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;vertical-align:
baseline'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;vertical-align:
baseline'><b><span lang=EN-GB>Uncommon</span></b><span lang=EN-GB> <i>(may
affect up to 1 in 100&nbsp;people)</i></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>insomnia</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>mood changes (including anxiety)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>depression</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>trembling</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>disturbed sense of taste</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>sudden, temporary loss of consciousness</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>decreased skin sensitivity</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>tingling or numbness</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>vision disorder (including double vision)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>ringing noise in ears</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>low blood pressure</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>breathlessness</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>runny nose</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>vomiting</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>stomach discomfort after meal</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>altered bowel habits (including diarrhoea and
constipation)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>dry mouth</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>hair loss</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>purple skin patches</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>skin discolouration</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>excessive sweating</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>itching; rash</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>generalised rash</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>joint pain</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>muscle pain</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>muscle cramps</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>back pain</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>urination disorders</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>urination at night</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>frequent urination</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>impotence</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>breast enlargement in men</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>chest pain</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>weakness</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>pain</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>feeling unwell</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>weight increase</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>weight decrease.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;vertical-align:
baseline'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;vertical-align:
baseline'><b><span lang=EN-GB>Rare </span></b><i><span lang=EN-GB>(may affect
up to 1 in 1,000&nbsp;people)</span></i></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>confusion.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>Very rare</span></b><span lang=EN-GB> <i>(may affect up to 1 in
10,000&nbsp;people)</i></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>low level of white blood cells and blood
platelets</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>allergic reaction with symptoms such as rash,
itching, hives, difficulty breathing or swallowing, dizziness</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>high level of sugar in the blood</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>increased muscle stiffness and inability to
stretch</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>sensation of numbness or tingling with sensation
of burning in fingers and toes</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>heart attack</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>irregular heart beat</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>inflammation of blood vessels</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>cough</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>severe upper stomach pain</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>inflammation of the gastric lining</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>bleeding, tender or enlarged gums</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>inflammation of the liver</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>liver disorder which can occur together with
yellow skin and eyes, or dark-coloured urine</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>abnormal liver function test</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>angioedema (difficulties in breathing, or
swallowing, or swelling of the face, hands and feet, eyes, lips and/or tongue)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>skin reaction with skin reddening and peeling,
blistering of lips, eyes or mouth; dry skin, rash, itchy rash</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>skin rash with flaking or peeling; rash, red
skin, blistering of the lips, eyes or mouth, skin peeling, fever</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>swelling mainly of the face and throat</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>increased sensitivity of the skin to sun.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><u><span lang=EN-GB>Hydrochlorothiazide</span></u></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>In patients
taking hydrochlorothiazide alone, the following have been reported, however the
frequency cannot be estimated from the available data:</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
lang=EN-GB>Very common</span></b><span lang=EN-GB> <i>(may affect more than 1
in 10&nbsp;people)</i></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;text-autospace:none'><span lang=EN-GB
style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>low level of potassium in the blood</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;text-autospace:none'><span lang=EN-GB
style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>increase of lipids in the blood.</span></p>

<p class=MsoDate><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoDate><b><span lang=EN-GB>Common</span></b><span lang=EN-GB> <i>(may
affect up to 1 in 10&nbsp;people)</i></span></p>

<p class=MsoDate style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>high level of uric acid in the blood</span></p>

<p class=MsoDate style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>low level of magnesium in the blood</span></p>

<p class=MsoDate style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>low level of sodium in the blood</span></p>

<p class=MsoDate style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>dizziness, fainting on standing up</span></p>

<p class=MsoDate style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>reduced appetite</span></p>

<p class=MsoDate style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>nausea and vomiting</span></p>

<p class=MsoDate style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>itchy rash and other types of rash</span></p>

<p class=MsoDate style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>inability to achieve or maintain erection.</span></p>

<p class=MsoNormal style='text-autospace:none'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
lang=EN-GB>Rare</span></b><span lang=EN-GB> <i>(may affect up to 1 in
1,000&nbsp;people)</i></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;text-autospace:none'><span lang=EN-GB
style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>low level of blood platelets (sometimes with
bleeding or bruising underneath the skin)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>high level of calcium in the blood</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>high level of sugar in the blood</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>worsening of the diabetic metabolic state</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>sad mood (depression)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>sleep disturbances</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>dizziness</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>headache</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>tingling or numbness</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>vision disorder</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>irregular heart beat</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>abdominal discomfort</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>constipation</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>diarrhoea</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>liver disorders which can occur together with
yellow skin and eyes</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>increased sensitivity of skin to the sun</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>sugar in the urine.</span></p>

<p class=MsoNormal style='text-autospace:none'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
lang=EN-GB>Very rare</span></b><span lang=EN-GB> <i>(may affect up to 1&nbsp;in
10,000&nbsp;people)</i></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;text-autospace:none'><span lang=EN-GB
style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>fever, sore throat or mouth ulcers, more
frequent infections (lack or low level of white blood cells)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>pale skin, tiredness, breathlessness,
dark-coloured urine (haemolytic anaemia)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>rash, itching, hives, difficulty breathing or
swallowing, dizziness (hypersensitivity reactions)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>confusion, tiredness, muscle twitching and
spasm, rapid breathing (hypochloraemic alkalosis)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>difficulty breathing with fever, coughing,
wheezing, breathlessness (respiratory distress including pneumonitis and pulmonary
oedema)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>severe upper stomach pain (pancreatitis)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>facial rash, joint pain, muscle disorder, fever
(lupus erythematosus)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>inflammation of blood vessels with symptoms such
as<i> </i>rash, purplish-red spots, fever (vasculitis)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>severe skin disease that causes rash, red skin,
blistering of the lips, eyes or mouth, skin peeling, fever (toxic epidermal
necrolysis).</span></p>

<p class=MsoNormal style='text-autospace:none'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>Not known</span></b><span
lang=EN-GB> <i>(frequency cannot be estimated from the available data)</i></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>weakness</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>bruising and frequent infections (aplastic
anaemia)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>decrease in vision or pain in your eyes due to
high pressure (possible signs of acute-angle closure glaucoma)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>severe skin disease that causes rash, red skin,
blistering of the lips, eyes or mouth, skin peeling, fever (erythema
multiforme)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>muscle spasm</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>severely decreased urine output (possible signs
of renal disorder or renal failure), weakness (asthenia)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>fever.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>If any of these affect you severely, tell your doctor. You may need
to stop Rasitrio.</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>If you get any side effects, </span><span lang=EN-GB>talk to your
doctor or pharmacist.</span><span lang=EN-GB> This includes any possible side
effects not listed in this leaflet</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How
to store Rasitrio</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Keep this medicine out of the sight and reach of children.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Do not use this medicine after the expiry date which is stated on
the carton and blister after &#8220;EXP&#8221;. The expiry date refers to the
last day of that month.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not store
above 30&deg;C.</span></p>

<p class=MsoNormal style='line-height:normal'>Store Rasitrio tablets in the
original package in order to protect from moisture.</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not throw
away any medicines via wastewater or household waste. Ask your pharmacist how
to throw away medicines you no longer use. These measures will help protect the
environment.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contents of the pack and
other information</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>What </span></b><b><span lang=EN-GB>Rasitrio contains</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Each </span><span lang=EN-GB>Rasitrio 300&nbsp;mg/10&nbsp;mg/12.5&nbsp;mg
film-coated tablet contains 300&nbsp;mg aliskiren (as hemifumarate), 10&nbsp;mg
amlodipine (as besylate) and 12.5&nbsp;mg hydrochlorothiazide. The other
ingredients are cellulose microcrystalline, crospovidone, povidone, magnesium
stearate, silica colloidal anhydrous, hypromellose, titanium dioxide (E171),
macrogol, talc, iron oxide red (E172), iron oxide black (E172).</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>What Rasitrio looks like and contents of the pack</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Rasitrio 300&nbsp;mg/10&nbsp;mg/12.5&nbsp;mg
film-coated tablets are light red, oval tablets, with &#8220;UIU&#8221;
debossed on one side and &#8220;NVR&#8221; on the other.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>Rasitrio </span>is available in packs containing 14,
28, 56, 98&nbsp;tablets in calendar blisters.</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'>It is also
available in multi-packs of <span lang=EN-GB>98&nbsp;tablets (2&nbsp;packs of
49) in calendar blisters.</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>Rasitrio </span>is available in packs containing<span
lang=EN-GB> 30 or 90&nbsp;tablets in blisters.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Rasitrio is available in packs containing 56x1&nbsp;tablet in perforated
unit dose blister.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>It is also available in multi-packs of 98x1&nbsp;tablet
(2&nbsp;packs of 49x1) in perforated unit dose blister.</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Not all pack sizes may be available in your country.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Marketing Authorisation Holder</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'>Novartis Europharm Limited</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'>Wimblehurst Road</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'>Horsham</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'>West Sussex, RH12 5AB</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>United
Kingdom</p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Manufacturer</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Novartis Farma S.p.A.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=IT>Via Provinciale Schito 131</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=IT>I-80058 Torre Annunziata/NA</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Italy</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>For any information about this medicine, please contact the local
representative of the Marketing Authorisation Holder:</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'>&nbsp;</p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=624
 style='margin-left:-1.7pt;border-collapse:collapse'>
 <tr>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=FR-BE>Belgi&euml;/Belgique/Belgien</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR-BE>Novartis
  Pharma N.V.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR-BE>T&eacute;l/Tel:
  +32 2 246 16 11</span></p>
  <p class=MsoNormal style='margin-right:1.7pt;line-height:normal'><span
  lang=FR>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=LT>Lietuva</span></b></p>
  <p class=MsoNormal style='margin-right:-22.45pt;line-height:normal'><span
  lang=LT>Novartis Pharma Services Inc.</span></p>
  <p class=MsoNormal style='margin-right:-22.45pt;line-height:normal'><span
  lang=LT>Tel: +370 5 269 16 50</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=IT>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR>Novartis Pharma
  Services Inc.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&#1058;&#1077;&#1083;.:
  +359 2 489 98 28</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=NO-BOK>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=DE-CH>Luxembourg/Luxemburg</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE-CH>Novartis
  Pharma N.V.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR-BE>T&eacute;l/Tel:
  +32 2 246 16 11</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=NO-BOK>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=NO-BOK>&#268;esk&aacute;
  republika</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=NO-BOK>Novartis
  s.r.o.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE-CH>Tel: +420 225
  775 111</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE-CH>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=HU>Magyarorsz&aacute;g</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=HU>Novartis
  Hung&aacute;ria Kft. Pharma</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=HU>Tel.: +36 1 457
  65 00</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b>Danmark</b></p>
  <p class=MsoNormal style='line-height:normal'>Novartis Healthcare A/S</p>
  <p class=MsoNormal style='line-height:normal'>Tlf: +45 39 16 84 00</p>
  <p class=MsoNormal style='line-height:normal'>&nbsp;</p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=MT>Malta</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=MT>Novartis Pharma
  Services Inc.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=MT>Tel: +</span>356 <span
  lang=EN-GB>2122 2872</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=DE>Deutschland</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE>Novartis Pharma
  GmbH</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE>Tel: +49 911 273
  0</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=NL>Nederland</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=NL>Novartis Pharma
  B.V.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=NL>Tel: +31 26 37 82
  111</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=ET>Eesti</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=ET>Novartis Pharma
  Services Inc.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=ET>Tel: +372 </span><span
  lang=EN-GB>66 30 810</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=ET>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=NO-BOK>Norge</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=NO-BOK>Novartis
  Norge AS</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=NO-BOK>Tlf: +47 23
  05 20 00</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EL>&#917;&#955;&#955;&#940;&#948;&#945;</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=ET>Novartis (Hellas)
  A.E.B.E.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EL>&#932;&#951;&#955;</span><span
  lang=ET>: +30 210 281 17 12</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=ET>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=DE-AT>&Ouml;sterreich</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE-AT>Novartis
  Pharma GmbH</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE-AT>Tel: +43 1 86
  6570</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=ES>Espa&ntilde;a</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=ES>Novartis
  Farmac&eacute;utica, S.A.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=ES>Tel: +34 93 306
  42 00</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=ES>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoHeading7 align=left style='text-align:left;line-height:normal;
  page-break-after:auto'><b><span lang=PL style='font-style:normal'>Polska</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=PL>Novartis Poland
  Sp. z o.o.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=PL>Tel.: +48 22 375
  4888</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=FR>France</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR>Novartis Pharma
  S.A.S.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR>T&eacute;l: +33 1
  55 47 66 00</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=FR>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=PT>Portugal</span></b></p>
  <p class=Text style='margin-bottom:0in;line-height:normal'><span lang=PT-BR>Novartis
  Farma - Produtos Farmac&ecirc;uticos, S.A.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=PT>Tel: +351 21 000
  8600</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Hrvatska</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Novartis Hrvatska d.o.o.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel. +385 1 6274 220</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=IT>Rom&acirc;nia</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=IT>Novartis Pharma
  Services Romania SRL</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=IT>Tel: +40 21 31299
  01</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Ireland</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Novartis
  Ireland Limited</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: +353 1
  260 12 55</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=SL>Slovenija</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=SL>Novartis Pharma
  Services Inc.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=SL>Tel: +386 1 300
  75 50</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=IS>&Iacute;sland</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=IS>Vistor hf.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=IT>S</span><span
  lang=CS>&iacute;</span><span lang=IT>mi</span><span lang=IS>: +354 535 7000</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=IT>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=SK>Slovensk&aacute;
  republika</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=SK>Novartis Slovakia
  s.r.o.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=SK>Tel: +421 2 5542
  5439</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=SK>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=PT-BR>Italia</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=PT-BR>Novartis Farma
  S.p.A.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=IT>Tel: +39 02 96 54
  1</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=SV>Suomi/Finland</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=SV>Novartis Finland
  Oy</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=SV>Puh/Tel: </span><span
  lang=DE-CH>+358 (0)10 6133 200</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=SV>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EL>&#922;&#973;&#960;&#961;&#959;&#962;</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR>Novartis Pharma
  Services Inc.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EL>&#932;&#951;&#955;:
  +357 22 690 690</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EL>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=SV>Sverige</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=SV>Novartis Sverige
  AB</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=SV>Tel: +46 8 732 32
  00</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=FI>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=LV>Latvija</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=LV>Novartis Pharma
  Services Inc.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=LV>Tel: +371 67 887
  070</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EL>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>United
  Kingdom</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Novartis</span><span
  lang=EN-GB> </span><span lang=EN-GB>Pharmaceuticals UK Ltd.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: +44 1276
  698370</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=SV>&nbsp;</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>This leaflet
was last revised in</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Other sources
of information</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Detailed
information on this medicine is available on the European Medicines Agency
website: </span><span lang=EN-GB>http://www.ema.europa.eu</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>Package leaflet: information for the user</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
text-autospace:none'><span lang=EN-GB>Rasitrio
300&nbsp;mg/10&nbsp;mg/25&nbsp;mg film-coated tablets</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>Aliskiren/amlodipine/hydrochlorothiazide</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Read all of this leaflet carefully before you start taking this
medicine because it contains important information for you.</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Keep this leaflet. You may need to read it
again.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you have any further questions, ask your
doctor or pharmacist.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>This medicine has been prescribed for you only.
Do not pass it on to others. It may harm them, even if their signs of illness
are the same as yours.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you get any side effects, talk to your doctor
or pharmacist. This includes any possible side effects not listed in this
leaflet.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>What is in this leaflet</span></b></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What Rasitrio is and what it
is used for</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What you need to know before
you take Rasitrio</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How to take Rasitrio</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Possible side effects</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How to store Rasitrio</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contents of the pack and
other information</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What Rasitrio is and what it
is used for</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>What Rasitrio is</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Rasitrio contains three active substances, called aliskiren,
amlodipine and hydrochlorothiazide. All of these substances help to control
high blood pressure (hypertension).</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span style='font-size:11.0pt;
font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>Aliskiren is a substance that
belongs to a group of medicines called renin inhibitors. These reduce the
amount of angiotensin&nbsp;II the body can make. Angiotensin&nbsp;II causes
blood vessels to tighten, which raises blood pressure. Lowering the amount of
angiotensin&nbsp;II allows the blood vessels to relax; this lowers blood
pressure.</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span style='font-size:11.0pt;
font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>Amlodipine belongs to a group of
medicines known as calcium channel blockers, which help to control high blood
pressure. Amlodipine causes blood vessels to dilate and relax; this lowers
blood pressure.</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span style='font-size:11.0pt;
font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>Hydrochlorothiazide belongs to a
group of medicines called thiazide diuretics. Hydrochlorothiazide increases
urine output, which also lowers blood pressure.</span></p>

<p class=Listlevel1 style='margin:0in;text-indent:0in'><span style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>High blood pressure increases the workload of the heart and
arteries. If this continues for a long time, it can damage the blood vessels of
the brain, heart and kidneys, and may result in a stroke, heart failure, heart
attack or kidney failure. Lowering the blood pressure to a normal level reduces
the risk of developing these disorders.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>What Rasitrio is used for</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Rasitrio is used
to treat high blood pressure </span><span lang=EN-GB>in adult patients </span>who
have their blood pressure already controlled by aliskiren, amlodipine and
hydrochlorothiazide taken as separate medicines given at the same time. These
patients may thus benefit from taking one tablet containing all three
substances<span lang=EN-GB>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What you need
to know before you take Rasitrio</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Do not take Rasitrio</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you are allergic to aliskiren, to amlodipine,
to other dihydropyridine-derived medicines (known as calcium channel blockers),
to hydrochlorothiazide, to sulphonamide-derived medicines (medicines used to
treat chest or urinary infections) or to any of the other ingredients of this
medicine (listed in section 6). If you think you may be allergic, do not take
Rasitrio and ask your doctor for advice.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have experienced the following forms of
angioedema (difficulties in breathing or swallowing, or swelling of the face,
hands and feet, eyes, lips and/or tongue):</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:56.7pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:normal;
vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>angioedema when taking aliskiren,</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:56.7pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:normal;
vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>hereditary angioedema,</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:56.7pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:normal;
vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>angioedema without any known cause.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you are more than 3&nbsp;months pregnant. (It
is also better to avoid Rasitrio in early pregnancy &#8211; see Pregnancy
section).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have serious liver problems.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span><span lang=EN-GB>if you have serious kidney problems.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span><span lang=EN-GB>if you have problems to produce urine (anuria).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span>if the level of potassium in your blood is too low despite treatment.</p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span>if the level of sodium in your blood is too low.</p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span>if the level of calcium in your blood is too high.</p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span>if you have gout (uric acid crystals in the joints).</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;vertical-align:baseline'><span lang=EN-GB>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you are taking any of the following
medicines:</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;vertical-align:baseline'><span lang=EN-GB>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>ciclosporin (a medicine used in transplantation
to prevent organ rejection or for other conditions, e.g. rheumatoid arthritis
or atopic dermatitis),</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;vertical-align:baseline'><span lang=EN-GB>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>itraconazole (a medicine used to treat fungal
infections),</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>quinidine (a medicine used to correct heart
rhythm).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;vertical-align:baseline'><span lang=EN-GB>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have diabetes mellitus or impaired kidney
function and you are treated with either of the following classes of medicines
used to treat high blood pressure:</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;vertical-align:baseline'><span lang=EN-GB>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>an &#8220;angiotensin converting enzyme
inhibitor&#8221; such as enalapril, lisinopril, ramipril etc.</span></p>

<p class=MsoNormal style='margin-left:28.35pt'>or</p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;vertical-align:baseline'><span lang=EN-GB>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>an &#8220;angiotensin II receptor blocker&#8221;
such as valsartan, telmisartan, irbesartan etc.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have a very low blood pressure.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you are suffering from shock, including
cardiogenic shock.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have a narrowing of the aortic heart
valve (aortic stenosis).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;vertical-align:baseline'><span lang=EN-GB>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have heart failure after an acute heart
attack.</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>If any of the
above applies to you, do not take Rasitrio</span></b><span lang=EN-GB> <b>and
talk to your doctor.</b></span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Warnings and precautions</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Talk to your doctor before taking Rasitrio:</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you are suffering from vomiting or diarrhoea
or if you are taking a diuretic (a medicine to increase the amount of urine you
produce).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have already experienced angioedema
(difficulties in breathing, or swallowing, or swelling of the face, hands and
feet, eyes, lips and/or tongue). If this happens, stop taking Rasitrio and
contact your doctor.</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you suffer from heart problems.</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you are on a low-salt diet.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if your urine flow has decreased markedly for
24&nbsp;hours or more and/or if you have serious kidney problems (e.g. require
dialysis), including if you have had a kidney transplant or a narrowing or
blockage of the arteries that supply blood to your kidney.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have impaired kidney function, your
doctor will carefully consider whether Rasitrio is suitable for you and may
wish to monitor you carefully.</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you suffer from liver problems (impaired
liver function).</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have diabetes (high level of sugar in
your blood).</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have a high level of cholesterol or
triglycerides in your blood.</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you suffer from a disease called lupus
erythematosus (also called &#8220;lupus&#8221; or &#8220;SLE&#8221;).</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you suffer from allergy or asthma.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you are taking either of the following
classes of medicines used to treat high blood pressure:</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;vertical-align:baseline'><span lang=EN-GB>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>an &#8220;angiotensin converting enzyme
inhibitor&#8221; such as enalapril, lisinopril, ramipril etc.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;line-height:normal'>or</p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;vertical-align:baseline'><span lang=EN-GB>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>an &#8220;angiotensin II receptor blocker&#8221;
such as valsartan, telmisartan, irbesartan etc.</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you are 65&nbsp;years of age or older</span><span
lang=EN-GB> (see section Elderly (age 65&nbsp;years or older) below).</span></p>

<p class=MsoNormal style='margin-left:26.95pt;text-indent:-26.95pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have signs and symptoms such as abnormal
thirst, dry mouth, general weakness, drowsiness, restlessness, muscle pain or
cramps, weakness, low blood pressure, reduced urine output, nausea, vomiting,
or an abnormally fast heart beat which may indicate an excessive effect of
hydrochlorothiazide (contained in Rasitrio).</span></p>

<p class=MsoDate style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you experience skin reactions such as rash
after sun exposure.</span></p>

<p class=MsoDate style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you experience a decrease in vision or eye
pain. These could be symptoms of an increase of pressure in your eye and can
happen within hours to weeks of taking Rasitrio. This can lead to permanent
vision impairment, if not treated.</span></p>

<p class=MsoNormal style='margin-left:26.95pt;text-indent:-26.95pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have renal artery stenosis (narrowing of
the blood vessels to one or both kidneys).</span></p>

<p class=MsoNormal style='margin-left:26.95pt;text-indent:-26.95pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have serious congestive heart failure (a
type of heart disease where the heart cannot pump enough blood around the body.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>You must tell your doctor if you think you
are (or might become) pregnant. Rasitrio is not recommended in early pregnancy,
and must not be taken if you are more than 3&nbsp;months pregnant, as it may
cause serious harm to your baby if used at that stage (see Pregnancy section).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Children and adolescents</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The use of Rasitrio
in children and adolescents up to 18&nbsp;years of age is not recommended.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Elderly</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>You should tell your doctor if you are 65&nbsp;years of age or older
because you may be more susceptible to side effects related to low blood
pressure (see section 4 on possible side effects). Your doctor will carefully
consider whether Rasitrio is suitable for you. If you are 75&nbsp;years of age
or older, your doctor may wish to monitor your blood pressure more frequently.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>In the majority of </span><span lang=EN-GB>patients aged
65&nbsp;years or older</span><span lang=EN-GB>, the 300&nbsp;mg dose of
aliskiren shows no additional benefit in reducing blood pressure compared to
the </span><span lang=EN-GB>150&nbsp;mg dose.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Other medicines and Rasitrio</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Tell your doctor or pharmacist if you are taking, have recently
taken or might take any other medicines.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Do not take Rasitrio and talk to your doctor if you are taking any
of the following medicines:</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>ciclosporin (a medicine used in transplantation
to prevent organ rejection and also in other conditions, e.g. rheumatoid
arthritis or atopic dermatitis).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>itraconazole (a medicine used to treat fungal
infections).</span></p>

<p class=MsoListParagraph style='margin-top:0in;margin-right:-.1pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>quinidine (a medicine used to correct heart
rhythm).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>one of the following classes of medicines used
to treat high blood pressure if you have diabetes mellitus or impaired kidney
function:</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;vertical-align:baseline'><span lang=EN-GB>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>an &#8220;angiotensin converting enzyme
inhibitor&#8221; such as enalapril, lisinopril, ramipril etc.</span></p>

<p class=MsoNormal style='text-indent:28.35pt'>or</p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;vertical-align:baseline'><span lang=EN-GB>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>an &#8220;angiotensin II receptor blocker&#8221;
such as valsartan, telmisartan, irbesartan etc.</span></p>

<p class=MsoListParagraph style='margin-top:0in;margin-right:-.1pt;margin-bottom:
0in;margin-left:0in;margin-bottom:.0001pt;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><b><span lang=EN-GB>Tell your doctor if you are using the following
medicines:</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>medicines or substances that increase the amount
of potassium in your blood. These include potassium supplements or salt
substitutes containing potassium, potassium-sparing medicines and heparin.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>medicines that may reduce the amount of
potassium in your blood, such as diuretics (water tablets), corticosteroids,
laxatives, carbenoxolone, amphotericin or penicillin G.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>medicines to reduce blood pressure, including
methyldopa.</span></p>

<p class=MsoDate style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>medicines to increase blood pressure, such as
noradrenaline or adrenaline.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>medicines that may induce &#8220;<i>torsades de
pointes</i>&#8221; (irregular heart beat), such as antiarrhythmics (medicines
used to treat heart problems) and some antipsychotics.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>ketonazole, a medicine used to treat fungal
infections.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>verapamil, a medicine used to lower high blood
pressure, to correct heart rhythm or to treat angina pectoris.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span>clarithromycin, telithromycin, erythromycin which are antibiotics used
to treat infections.</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span>amiodarone, a medicine used to treat abnormal heart rhythms.</p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>atorvastatin, a medicine used to treat high
cholesterol.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>furosemide, a medicine belonging to the type
known as diuretics, which is used to increase the amount of urine you produce
and is also used to treat a certain kind of heart problem (heart failure) or
oedema (swelling).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>medicines that may reduce the amount of sodium
in your blood, such as antidepressants, antipsychotics, antiepileptics
(carbamazepine).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>rifampicin, </span>a medicine used to prevent or
treat infections.</p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>St. John&#8217;s wort <i>(hypericum perforatum)</i>,
</span>a herbal medicine used to elevate mood<span lang=EN-GB>.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>pain killers such as non-steroidal
anti-inflammatory agents (NSAIDs), including selective cyclooxygenase-2
inhibitors (Cox-2 inhibitors) (used especially in the patients over
65&nbsp;years old).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span>diltiazem, a medicine used to treat heart problems.</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span>ritonavir, a medicine used to treat viral infection.</p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>lithium (a medicine used to treat some types of
depression).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>some laxatives.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>medicines for the treatment of gout, such as
allopurinol.</span></p>

<p class=MsoDate style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>digoxin or other digitalis glycosides (medicines
used to treat heart problems).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>vitamin D and calcium salts.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>one of the following classes of medicines used
to treat high blood pressure:</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:10.35pt;margin-bottom:.0001pt;text-indent:.25in'><span lang=EN-GB>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; an
&#8220;angiotensin converting enzyme inhibitor&#8221; such as enalapril, lisinopril,
ramipril etc.</span></p>

<p class=MsoNormal style='text-indent:28.35pt'>or</p>

<p class=MsoNormal style='text-indent:28.35pt'>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <span
lang=EN-GB>an &#8220;angiotensin II receptor blocker&#8221; such as valsartan,
telmisartan, irbesartan etc.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>medicines used to control heart rhythm.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>medicines for the treatment of diabetes (oral
agents such as metformin or insulins).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>medicines that may increase blood sugar level,
such as beta blockers and diazoxide.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>steroids.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>cytotoxic medicines (used to treat cancer),</span><span
lang=EN-GB> such as methotrexate or cyclophosphamide</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>arthritis medicines.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>medicines used to treat oesophageal ulceration
and inflammation (e.g. carbenoxolone).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>muscle relaxants </span><span lang=EN-GB>(medicines
to relax the muscles which are used during operations).</span></p>

<p class=MsoDate style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>amantadine (a medicine used to treat
Parkinson&#8217;s disease, also used to treat or prevent certain illnesses
caused by viruses).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>anticholinergic </span><span
class=MsoCommentReference><span lang=EN-GB>agents</span></span><span
lang=EN-GB> (medicines used to treat a variety of disorders such as
gastrointestinal cramps, urinary bladder spasm, asthma, motion sickness,
muscular spasms, Parkinson&#8217;s disease and as an aid to anaesthesia).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>cholestyramine, colestipol or other resins
(substances used mainly to treat high levels of lipids in the blood).</span></p>

<p class=MsoDate style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>alcohol, sleeping pills and anaesthetics
(medicines allowing patients to undergo surgery and other procedures).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>iodine contrast media (agents used for imaging
examinations).</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Your doctor may need to change your dose and/or take other
precautions if you are taking one of the following medicines:</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB style='font-family:"Arial",sans-serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>furosemide, a medicine belonging to the type
known as diuretics, which is used to increase the amount of urine you produce
and is also used to treat a certain kind of heart problem (heart failure) or
oedema (swelling).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;vertical-align:baseline'><span lang=EN-GB style='font-family:"Arial",sans-serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>some medicines used to treat infections, such as
ketoconazole, amphotericin or penicillin G.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Rasitrio with food and drink</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>You should take this medicine with a light meal once a day,
preferably at the same time each day. You should not take this medicine with
grapefruit juice.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Due to hydrochlorothiazide contained in Rasitrio, if you drink
alcohol while on treatment with this medicine, you may have an increased
feeling of dizziness on standing up, especially when getting up from a sitting
position.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Pregnancy</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not take this
medicine if you are pregnant (see section Do not take Rasitrio). If you become
pregnant while taking this medicine stop taking it immediately and talk to your
doctor. If you think you may be pregnant or are planning to have a baby, ask
your doctor or pharmacist for advice before taking this medicine. Your doctor
will normally advise you to stop taking Rasitrio before you become pregnant and
will advise you to take another medicine instead of Rasitrio. Rasitrio is not
recommended in early pregnancy, and must not be taken when more than
3&nbsp;months pregnant, as it may cause serious harm to your baby if it is used
after the third month of pregnancy.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Breast-feeding</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tell your doctor
if you are breast-feeding or about to start breast-feeding.</span> Rasitrio is
not recommended for mothers who are breast-feeding, and your doctor may choose
another treatment for you if you wish to breast-feed.</p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Driving and using machines</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>This medicine
<span lang=EN-GB>may make you feel dizzy and drowsy. If you experience this
symptom, do not drive or use tools or machines.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>&nbsp;</p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How to take Rasitrio</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Always take this medicine exactly as your doctor has told you and do
not exceed the recommended dose. Check with your doctor or pharmacist if you
are not sure.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The usual dose of Rasitrio is one tablet a day.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>Method of administration</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Swallow the tablet whole with some water. You should take this
medicine with a light meal once a day, preferably at the same time each day.
You should not take this medicine together with grapefruit juice.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>If you take more Rasitrio than you should</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If you have
accidentally taken too many Rasitrio tablets, talk to a doctor immediately. You
may require medical attention.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>If you forget to take Rasitrio</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>If you forget to take a dose of this medicine, take it as soon as
you remember and then take the next dose at its usual time. If it is almost
time for your next dose you should simply take the next tablet at the usual
time. <b>Do not </b>take a double dose (two tablets at once) to make up for a
forgotten tablet.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Do not stop taking this medicine</span></b><span lang=EN-GB>, even
if you are feeling well (unless your doctor tells you to do so).</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>People who have high blood pressure often do not notice any signs of
the problem. Many may feel quite normal. It is very important that you take
this medicine exactly as your doctor tells you to get the best results and
reduce the risk of side effects. Keep your appointments with the doctor even if
you are feeling well.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>If you have any further questions on the use of this medicine, ask
your doctor or pharmacist.</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Possible
side effects</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>Like all medicines, this medicine can cause side effects, although
not everybody gets them.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.4pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>Side effects reported for Rasitrio are:</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>Common</span></b><span lang=EN-GB> <i>(may affect
up to 1 in 10&nbsp;people)</i></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>dizziness</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>low blood pressure</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>swelling of hands, ankles and feet (peripheral
oedema).</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><b><span
lang=EN-GB>Tell your doctor immediately if you experience the following at the
beginning of your treatment:</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Fainting and/or
light-headedness linked to low blood pressure could occur at the beginning of
treatment with Rasitrio. </span><span lang=EN-GB>Patients 65&nbsp;years of age
or older are more susceptible to side effects related to low blood pressure. In
clinical trials low blood pressure occurred more frequently in patients taking
Rasitrio than those taking only dual combinations of aliskiren/amlodipine,
aliskiren/hydrochlorothiazide or amlodipine/hydrochlorothiazide (see section 2).</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The following, possibly serious, side effects have been reported
with medicines containing aliskiren, amlodipine or hydrochlorothiazide alone.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><u><span lang=EN-GB>Aliskiren</span></u></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Some side effects can be serious (frequency not known):</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>A few patients have experienced these serious side effects </span><i><span
lang=EN-GB>(</span></i><i><span lang=EN-GB>may affect up to 1 in
1,000&nbsp;people</span></i><i><span lang=EN-GB>)</span></i><span lang=EN-GB>. <b>If
any of the following occur,</b> <b>tell your doctor straight away:</b></span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Severe allergic reaction with symptoms such as
rash, itching, swelling of face or lips or tongue, difficulty breathing,
dizziness.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Nausea, loss of appetite, dark coloured urine or
yellowing of skin and eyes (signs of liver disorder).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB>Possible side effects</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>Common </span></b><i><span lang=EN-GB>(may affect up to 1 in
10&nbsp;people)</span></i></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>diarrhoea</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>joint pain (arthralgia)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>high level of potassium in the blood</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>dizziness.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>Uncommon</span></b><span lang=EN-GB> <i>(may affect up to 1 in 100</i></span><i><span
lang=EN-GB>&nbsp;people</span></i><i><span lang=EN-GB>)</span></i></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>skin rash (this may also be a sign of allergic
reactions or angioedema &#8211; see &#8220;Rare&#8221; side effects below)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>kidney problems including acute renal failure
(severely decreased urine output)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>swelling of hands, ankles or feet (peripheral
oedema)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>severe skin reactions (toxic epidermal
necrolysis and/or oral mucosal reactions &#8211; red skin, blistering of the
lips, eyes or mouth, skin peeling, fever)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>low blood pressure</span><span lang=EN-GB> </span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>palpitations</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>cough</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>itching, itchy rash (urticaria)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>increased liver enzymes.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>Rare</span></b><span lang=EN-GB> <i>(may affect up to 1 in
1,000&nbsp;people)</i></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>severe allergic reaction (anaphylactic reaction)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>allergic reactions (hypersensitivity)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>angioedema (the symptoms of which can include
difficulties in breathing or swallowing, rash, itching, hives or swelling of
the face, hands and feet, eyes, lips and/or tongue, dizziness)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>increased level of creatinine in the blood</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>red skin (erythema).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><u><span lang=EN-GB>Amlodipine</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>In patients taking amlodipine alone, the following have
been reported:</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;vertical-align:
baseline'><b><span lang=EN-GB>Common</span></b><span lang=EN-GB> </span><i><span
lang=EN-GB>(may affect up to 1 in 10&nbsp;people)</span></i></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>sleepiness</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>dizziness</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>headache (especially at the beginning of
treatment)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>hot flushes</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>abdominal pain</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>nausea</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>ankle swelling</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>swelling</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>tiredness</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>palpitations (awareness of your heart beat).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;vertical-align:
baseline'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;vertical-align:
baseline'><b><span lang=EN-GB>Uncommon</span></b><span lang=EN-GB> <i>(may
affect up to 1 in 100&nbsp;people)</i></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>insomnia</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>mood changes (including anxiety)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>depression</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>trembling</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>disturbed sense of taste</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>sudden, temporary loss of consciousness</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>decreased skin sensitivity</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>tingling or numbness</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>vision disorder (including double vision)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>ringing noise in ears</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>low blood pressure</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>breathlessness</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>runny nose</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>vomiting</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>stomach discomfort after meal</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>altered bowel habits (including diarrhoea and
constipation)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>dry mouth</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>hair loss</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>purple skin patches</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>skin discolouration</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>excessive sweating</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>itching; rash</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>generalised rash</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>joint pain</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>muscle pain</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>muscle cramps</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>back pain</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>urination disorders</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>urination at night</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>frequent urination</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>impotence</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>breast enlargement in men</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>chest pain</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>weakness</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>pain</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>feeling unwell</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>weight increase</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>weight decrease.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;vertical-align:
baseline'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;vertical-align:
baseline'><b><span lang=EN-GB>Rare </span></b><i><span lang=EN-GB>(may affect
up to 1 in 1,000&nbsp;people)</span></i></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>confusion.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>Very rare</span></b><span lang=EN-GB> <i>(may affect up to 1 in
10,000&nbsp;people)</i></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>low level of white blood cells and blood
platelets</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>allergic reaction with symptoms such as rash,
itching, hives, difficulty breathing or swallowing, dizziness</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>high level of sugar in the blood</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>increased muscle stiffness and inability to
stretch</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>sensation of numbness or tingling with sensation
of burning in fingers and toes</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>heart attack</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>irregular heart beat</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>inflammation of blood vessels</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>cough</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>severe upper stomach pain</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>inflammation of the gastric lining</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>bleeding, tender or enlarged gums</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>inflammation of the liver</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>liver disorder which can occur together with
yellow skin and eyes, or dark-coloured urine</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>abnormal liver function test</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>angioedema (difficulties in breathing, or
swallowing, or swelling of the face, hands and feet, eyes, lips and/or tongue)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>skin reaction with skin reddening and peeling,
blistering of lips, eyes or mouth; dry skin, rash, itchy rash</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>skin rash with flaking or peeling; rash, red
skin, blistering of the lips, eyes or mouth, skin peeling, fever</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>swelling mainly of the face and throat</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>increased sensitivity of the skin to sun.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><u><span lang=EN-GB>Hydrochlorothiazide</span></u></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>In patients
taking hydrochlorothiazide alone, the following have been reported, however the
frequency cannot be estimated from the available data:</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
lang=EN-GB>Very common</span></b><span lang=EN-GB> <i>(may affect more than 1
in 10&nbsp;people)</i></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;text-autospace:none'><span lang=EN-GB
style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>low level of potassium in the blood</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;text-autospace:none'><span lang=EN-GB
style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>increase of lipids in the blood.</span></p>

<p class=MsoDate><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoDate><b><span lang=EN-GB>Common</span></b><span lang=EN-GB> <i>(may
affect up to 1 in 10&nbsp;people)</i></span></p>

<p class=MsoDate style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>high level of uric acid in the blood</span></p>

<p class=MsoDate style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>low level of magnesium in the blood</span></p>

<p class=MsoDate style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>low level of sodium in the blood</span></p>

<p class=MsoDate style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>dizziness, fainting on standing up</span></p>

<p class=MsoDate style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>reduced appetite</span></p>

<p class=MsoDate style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>nausea and vomiting</span></p>

<p class=MsoDate style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>itchy rash and other types of rash</span></p>

<p class=MsoDate style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>inability to achieve or maintain erection.</span></p>

<p class=MsoNormal style='text-autospace:none'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
lang=EN-GB>Rare</span></b><span lang=EN-GB> <i>(may affect up to 1 in
1,000&nbsp;people)</i></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;text-autospace:none'><span lang=EN-GB
style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>low level of blood platelets (sometimes with
bleeding or bruising underneath the skin)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>high level of calcium in the blood</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>high level of sugar in the blood</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>worsening of the diabetic metabolic state</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>sad mood (depression)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>sleep disturbances</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>dizziness</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>headache</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>tingling or numbness</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>vision disorder</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>irregular heart beat</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>abdominal discomfort</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>constipation</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>diarrhoea</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>liver disorders which can occur together with
yellow skin and eyes</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>increased sensitivity of skin to the sun</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>sugar in the urine.</span></p>

<p class=MsoNormal style='text-autospace:none'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
lang=EN-GB>Very rare</span></b><span lang=EN-GB> <i>(may affect up to 1&nbsp;in
10,000&nbsp;people)</i></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;text-autospace:none'><span lang=EN-GB
style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>fever, sore throat or mouth ulcers, more
frequent infections (lack or low level of white blood cells)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>pale skin, tiredness, breathlessness,
dark-coloured urine (haemolytic anaemia)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>rash, itching, hives, difficulty breathing or
swallowing, dizziness (hypersensitivity reactions)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>confusion, tiredness, muscle twitching and
spasm, rapid breathing (hypochloraemic alkalosis)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>difficulty breathing with fever, coughing,
wheezing, breathlessness (respiratory distress including pneumonitis and
pulmonary oedema)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>severe upper stomach pain (pancreatitis)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>facial rash, joint pain, muscle disorder, fever
(lupus erythematosus)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>inflammation of blood vessels with symptoms such
as<i> </i>rash, purplish-red spots, fever (vasculitis)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>severe skin disease that causes rash, red skin,
blistering of the lips, eyes or mouth, skin peeling, fever (toxic epidermal
necrolysis).</span></p>

<p class=MsoNormal style='text-autospace:none'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>Not known</span></b><span
lang=EN-GB> <i>(frequency cannot be estimated from the available data)</i></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>weakness</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>bruising and frequent infections (aplastic
anaemia)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>decrease in vision or pain in your eyes due to
high pressure (possible signs of acute-angle closure glaucoma)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>severe skin disease that causes rash, red skin,
blistering of the lips, eyes or mouth, skin peeling, fever (erythema
multiforme)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>muscle spasm</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>severely decreased urine output (possible signs
of renal disorder or renal failure), weakness (asthenia)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>fever.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>If any of these affect you severely, tell your doctor. You may need
to stop Rasitrio.</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>If you get any side effects, </span><span lang=EN-GB>talk to your
doctor or pharmacist.</span><span lang=EN-GB> This includes any possible side
effects not listed in this leaflet</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How
to store Rasitrio</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Keep this medicine out of the sight and reach of children.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Do not use this medicine after the expiry date which is stated on
the carton and blister after &#8220;EXP&#8221;. The expiry date refers to the
last day of that month.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not store
above 30&deg;C.</span></p>

<p class=MsoNormal style='line-height:normal'>Store Rasitrio tablets in the
original package in order to protect from moisture.</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not throw
away any medicines via wastewater or household waste. Ask your pharmacist how
to throw away medicines you no longer use. These measures will help protect the
environment.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contents of the pack and
other information</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>What </span></b><b><span lang=EN-GB>Rasitrio contains</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none;vertical-align:baseline'><span lang=EN-GB>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Each </span><span lang=EN-GB>Rasitrio 300&nbsp;mg/10&nbsp;mg/25&nbsp;mg
film-coated tablet contains 300&nbsp;mg aliskiren (as hemifumarate), 10&nbsp;mg
amlodipine<b> </b>(as<b> </b>besylate) and 25&nbsp;mg hydrochlorothiazide. The
other ingredients are cellulose microcrystalline, crospovidone, povidone,
magnesium stearate, silica colloidal anhydrous, hypromellose, titanium dioxide
(E171), macrogol, talc, iron oxide black (E172), iron oxide red (E172), iron
oxide yellow (E172).</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>What Rasitrio looks like and contents of the pack</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none;vertical-align:baseline'><span lang=EN-GB>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Rasitrio 300&nbsp;mg/10&nbsp;mg/25&nbsp;mg
film-coated tablets are brown, oval tablets, with &#8220;VIV&#8221; debossed on
one side and &#8220;NVR&#8221; on the other.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>Rasitrio </span>is available in packs containing 14,
28, 56, 98&nbsp;tablets in calendar blisters.</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'>It is also
available in multi-packs of <span lang=EN-GB>98&nbsp;tablets (2&nbsp;packs of
49) in calendar blisters.</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>Rasitrio </span>is available in packs containing<span
lang=EN-GB> 30 or 90&nbsp;tablets in blisters.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Rasitrio is available in packs containing 56x1&nbsp;tablet in
perforated unit dose blister.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>It is also available in multi-packs of 98x1&nbsp;tablet
(2&nbsp;packs of 49x1) in perforated unit dose blister.</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Not all pack sizes may be available in your country.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Marketing Authorisation Holder</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'>Novartis Europharm Limited</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'>Wimblehurst Road</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'>Horsham</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'>West Sussex, RH12 5AB</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>United
Kingdom</p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Manufacturer</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Novartis Farma S.p.A.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=IT>Via Provinciale Schito 131</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=IT>I-80058 Torre Annunziata/NA</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Italy</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>For any information about this medicine, please contact the local
representative of the Marketing Authorisation Holder:</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'>&nbsp;</p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=624
 style='margin-left:-1.7pt;border-collapse:collapse'>
 <tr>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=FR-BE>Belgi&euml;/Belgique/Belgien</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR-BE>Novartis
  Pharma N.V.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR-BE>T&eacute;l/Tel:
  +32 2 246 16 11</span></p>
  <p class=MsoNormal style='margin-right:1.7pt;line-height:normal'><span
  lang=FR>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=LT>Lietuva</span></b></p>
  <p class=MsoNormal style='margin-right:-22.45pt;line-height:normal'><span
  lang=LT>Novartis Pharma Services Inc.</span></p>
  <p class=MsoNormal style='margin-right:-22.45pt;line-height:normal'><span
  lang=LT>Tel: +370 5 269 16 50</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=IT>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR>Novartis Pharma
  Services Inc.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&#1058;&#1077;&#1083;.:
  +359 2 489 98 28</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=NO-BOK>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=DE-CH>Luxembourg/Luxemburg</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE-CH>Novartis
  Pharma N.V.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR-BE>T&eacute;l/Tel:
  +32 2 246 16 11</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=NO-BOK>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=NO-BOK>&#268;esk&aacute;
  republika</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=NO-BOK>Novartis
  s.r.o.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE-CH>Tel: +420 225
  775 111</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE-CH>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=HU>Magyarorsz&aacute;g</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=HU>Novartis
  Hung&aacute;ria Kft. Pharma</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=HU>Tel.: +36 1 457
  65 00</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b>Danmark</b></p>
  <p class=MsoNormal style='line-height:normal'>Novartis Healthcare A/S</p>
  <p class=MsoNormal style='line-height:normal'>Tlf: +45 39 16 84 00</p>
  <p class=MsoNormal style='line-height:normal'>&nbsp;</p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=MT>Malta</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=MT>Novartis Pharma
  Services Inc.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=MT>Tel: +</span>356 <span
  lang=EN-GB>2122 2872</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=DE>Deutschland</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE>Novartis Pharma
  GmbH</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE>Tel: +49 911 273
  0</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=NL>Nederland</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=NL>Novartis Pharma
  B.V.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=NL>Tel: +31 26 37 82
  111</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=ET>Eesti</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=ET>Novartis Pharma
  Services Inc.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=ET>Tel: +372 </span><span
  lang=EN-GB>66 30 810</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=ET>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=NO-BOK>Norge</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=NO-BOK>Novartis
  Norge AS</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=NO-BOK>Tlf: +47 23
  05 20 00</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EL>&#917;&#955;&#955;&#940;&#948;&#945;</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=ET>Novartis (Hellas)
  A.E.B.E.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EL>&#932;&#951;&#955;</span><span
  lang=ET>: +30 210 281 17 12</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=ET>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=DE-AT>&Ouml;sterreich</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE-AT>Novartis
  Pharma GmbH</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE-AT>Tel: +43 1 86
  6570</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=ES>Espa&ntilde;a</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=ES>Novartis
  Farmac&eacute;utica, S.A.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=ES>Tel: +34 93 306
  42 00</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=ES>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoHeading7 align=left style='text-align:left;line-height:normal;
  page-break-after:auto'><b><span lang=PL style='font-style:normal'>Polska</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=PL>Novartis Poland
  Sp. z o.o.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=PL>Tel.: +48 22 375
  4888</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=FR>France</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR>Novartis Pharma
  S.A.S.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR>T&eacute;l: +33 1
  55 47 66 00</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=FR>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=PT>Portugal</span></b></p>
  <p class=Text style='margin-bottom:0in;line-height:normal'><span lang=PT-BR>Novartis
  Farma - Produtos Farmac&ecirc;uticos, S.A.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=PT>Tel: +351 21 000
  8600</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Hrvatska</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Novartis Hrvatska d.o.o.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel. +385 1 6274 220</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=IT>Rom&acirc;nia</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=IT>Novartis Pharma
  Services Romania SRL</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=IT>Tel: +40 21 31299
  01</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Ireland</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Novartis
  Ireland Limited</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: +353 1
  260 12 55</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=SL>Slovenija</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=SL>Novartis Pharma
  Services Inc.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=SL>Tel: +386 1 300
  75 50</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=IS>&Iacute;sland</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=IS>Vistor hf.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=IT>S</span><span
  lang=CS>&iacute;</span><span lang=IT>mi</span><span lang=IS>: +354 535 7000</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=IT>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=SK>Slovensk&aacute;
  republika</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=SK>Novartis Slovakia
  s.r.o.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=SK>Tel: +421 2 5542
  5439</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=SK>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=PT-BR>Italia</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=PT-BR>Novartis Farma
  S.p.A.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=IT>Tel: +39 02 96 54
  1</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=SV>Suomi/Finland</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=SV>Novartis Finland
  Oy</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=SV>Puh/Tel: </span><span
  lang=DE-CH>+358 (0)10 6133 200</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=SV>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EL>&#922;&#973;&#960;&#961;&#959;&#962;</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR>Novartis Pharma
  Services Inc.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EL>&#932;&#951;&#955;:
  +357 22 690 690</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EL>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=SV>Sverige</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=SV>Novartis Sverige
  AB</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=SV>Tel: +46 8 732 32
  00</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=FI>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=LV>Latvija</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=LV>Novartis Pharma
  Services Inc.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=LV>Tel: +371 67 887
  070</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EL>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>United
  Kingdom</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Novartis</span><span
  lang=EN-GB> </span><span lang=EN-GB>Pharmaceuticals UK Ltd.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: +44 1276
  698370</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=SV>&nbsp;</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>This leaflet
was last revised in</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Other sources
of information</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Detailed
information on this medicine is available on the European Medicines Agency
website: </span><span lang=EN-GB>http://www.ema.europa.eu</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

</div>

</body>

</html>
